[{"article": "1 Yiou et al.\nPHOENIX, Oct. 19, 2017 /PRNewswire/ -- Creative Medical Technology Holdings (OTCQB \u2013 CELZ) announced today completion of the safety data analysis on 20 patients with pharmacologically-resistant erectile dysfunction treated with the Company's patented CaverStem\u2122 procedure.\nThe trial, sponsored by Creative Medical Technology Holdings, was conducted at the University of California Los Angeles Harbor Hospital/LA Biomed under Institutional Review Board (IRB) approval.\n\"Having published the first peer-reviewed paper on this procedure back in 2013 together with internationally renowned urologists and stem cell experts3, it is very exciting for me to watch this translate from bench to bedside.\"\n\"Based on establishment of safety of the CaverStem\u2122 procedure in a formal university-based clinical trial, and independent confirmation of efficacy in an European clinical trial1, we have launched commercialization for the CaverStem\u2122 procedure,\" said Timothy Warbington, President and Chief Executive Officer of Creative Medical Technology Holdings.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Despite the fact that the news release insinuated that a clinical trial had been completed and that a new treatment for ED will be out in 2 months, the language of the release itself was quite constrained. There were none of the common sensational phrases like \u201cbreakthrough\u201d or \u201cmiracle\u201d or \u201cnovel treatment.\u201d In language choice, the news release was satisfactory. Though the release implies benefit of this treatment, nothing actually states this is the case.", "answer": 1}, {"article": "In particular, it measures rhythmic patterns known as theta and beta waves.\nAnd one chapter of the book is devoted to neurofeedback.\nAnd that research appears to be on the way.\nBut it will take better research to figure out whether neurofeedback can live up to that promise, Rabiner says.\nBut, there's growing evidence that it can help.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story does not appear to be based on a news release.", "answer": 1}, {"article": "At that point, a valve designed to open on its own, allowsthe balloon to empty and be excreted naturally from the body,eliminating the need for endoscopy or another procedure.\nimmediate pastpresident of the ASMBS and vice-chair, UC Irvine Department ofSurgery and chief of gastrointestinal surgery, who was not involvedin the study said the device is not a permanent solution to weightloss, but has the potential to help those individuals who areoverweight or have obesity and are not candidates for bariatricsurgery.\nThe Agency for Healthcare Research andQuality (AHRQ) reported significant improvements in the safety ofmetabolic/bariatric surgery due in large part to improvedlaparoscopic techniques.\nAllurionTechnologies, the manufacturer of the device called Elipse\uf0d4, whichis not yet commercially available, is studyingwhat it says is the \u201cfirst procedureless gastric balloon\u201d inpatients with a body mass index (BMI) of 27 or more.\nNewswise \u2014 Anew gastric balloon that can be swallowed like a pill and then filledwhile in the stomach, helped patients lose more than 37 percent oftheir excess weight over four months, according to new researchpresented here at ObesityWeek 2015, the largest international eventfocused on the basic science, clinical application and prevention andtreatment of obesity.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "At just 34 patients, and with the results unpublished, the study is just too small to be making claims like this: \u201cOur findings demonstrate that Elipse provides individuals and their caregivers with a safe, effective, and non-invasive weight loss intervention that does not require surgery,endoscopy, or anesthesia.\u201d", "answer": 0}, {"article": "Aside from hair transplants, which can cost about $10,000 each and do not always look natural, the only current hope for complete replacement is hair cloning, the act of producing entirely new hair from the DNA of an existing one, which researchers have been attempting, unsuccessfully, for years.\n\u201cWe keep on moving back that time, but I think there\u2019s absolutely no doubt that it\u2019s going to be done.\u201d\n\nHe believes hair cloning will be commercially available within 10 years.\nThough the claim was met with some skepticism by other clinicians, the idea that ACell\u2019s powder, which has been approved by the government, could facilitate new hair growth has breathed new life into the race to clone hair.\napproved a new hair-loss remedy (Propecia, in 1997), so it is understandable that anticipation for a new one might be running high.\nBut the fact is that many men \u2014 and women \u2014 simply do not accept baldness easily.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story went well beyond any news release. In fact, unlike other stories we have seen about emerging cosmetic therapies, this story may not be a big hit with the product\u2019s manufacturer. The man in the\u00a0lead anecdote, for example, says that he\u00a0has stopped\u00a0using the product because it is\u00a0too expensive.", "answer": 1}, {"article": "A new study confirms that long-acting forms of contraception such as intrauterine devices and implants are better than birth control pills and patches at preventing pregnancies, giving doctors new ammunition to recommend these methods.\n\nThe study, to be published Thursday in the New England Journal of Medicine, involved about 7,500 women in a project promoting long-acting birth control to reduce unintended pregnancies. There are an estimated three million unplanned pregnancies a year in the U.S., often because of incorrect or...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The report does not appear to rely on a press release.", "answer": 1}, {"article": "ET.\nAlthough the results provide evidence that PDE5 inhibitors may benefit heart health, the retrospective study design makes it impossible to ascertain direct cause and effect, Andersson noted.\n\"This type of erectile dysfunction treatment is beneficial in terms of prognosis, and having an active sex life seems to be a marker for a decreased risk of death.\"\n\"From the perspective of a doctor, if a patient asks about erectile dysfunction drugs after a heart attack and has no contraindications for PDE5 inhibitors, based on these results you can feel safe about prescribing it.\"\nThis study received funding from the Stockholm County Council and the Swedish Heart and Lung Foundation.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release provides the reader with a reasonable review of the research results.", "answer": 1}, {"article": "Bipolar disorder effects around 1 percent of the population worldwide and sufferers can experience moods that swing from one extreme to another, and have periods of depression and mania lasting several weeks or longer.\nScientists say the drug, ebselen, may be a swift answer to long-sought after better medications for patients with the manic depressive disorder, since it is already known to be safe.\n\u201cEbselen is an experimental drug that has been tested in people for other conditions, and does not have problematic side effects like lithium does,\u201d said Grant Churchill of the department of pharmacology at Britain\u2019s Oxford University.\n\u201cNow we urgently need to see if it works like lithium in people.\u201d\n\nSome 60 years after it was first discovered, lithium - a mood stabiliser that can protect against both depression and mania, and reduce the risk of suicide - remains the most effective long-term treatment.\nBut it is very toxic - at only twice the right dose it could kill a patient, Churchill said - and its adverse side-effects mean many people stop taking the drug and relapse into episodes of mania and depression.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does not appear that the story relied on a press release.", "answer": 1}, {"article": "UCLA's Bhat noted another limitation in the study: \"These are all genetic cataracts.\nThat's one of the most difficult steps to learn as a surgeon.\nMost patients don't even want to wait.\nShe also had questions about how the procedure was done with such a tiny incision.\nIf it takes months to get to an outcome, it's not superior to the lens technologies we have now.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Given the multitude of independent sources, this story doesn\u2019t appear to rely on a news release.", "answer": 1}, {"article": "(Sunlight stimulates production of vitamin D for people in sunnier climes.)\nThis practice isn't totally harmless.\n\"Large trials of other widely used supplements have sometimes found benefits,\" Manson wrote, \"but in other cases--such as with high doses of beta carotene, vitamin E and selenium--have disproven some health claims for these supplements and identified health risks that may not have otherwise been detected.\"\n\"I think there's been a disconnect between the observational studies and the randomized clinical trials to date,\" Manson said.\nThe results are expected in late 2017 or early 2018.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to draw from a news release.", "answer": 1}, {"article": "Stephen Buckley, head of information at the mental health charity Mind, said: \u201cWe welcome research which adds to our understanding of treatments and medications that may work for people experiencing mental health problems.\nThe Royal College of Psychiatrists said that, if it worked, the test could prove to be a key moment in the quest for the holy grail of biological psychiatry.\n\u201cThis study provides a clinically suitable approach for personalising antidepressants therapy.\nIf the test proves effective it is hoped that by measuring patients\u2019 level of blood inflammation it would identify which of them would benefit from receiving antidepressants soon after their diagnosis to stop their condition worsening.\n\u201cSuch a finding and a test to back it up would be critical to advancing our understanding of the biological causes of depression.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story draws heavily on a news release from King\u2019s College London without attribution. However, it barely satisfies our criteria by offering comments from two outside sources, the Royal College of Psychiatrists and mental health charity Mind.", "answer": 1}, {"article": "A growing body of evidence suggests that weight-loss surgery is more effective than diet and exercise at getting rid of Type 2 diabetes.\n\nA small but rigorous randomized trial published Wednesday in JAMA Surgery provides the latest evidence showing the superiority of bariatric surgery over lifestyle changes in resolving the chronic condition involving high blood sugar.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article quotes a variety of sources who were not involved with the research, so we can be sure it went beyond any news release.", "answer": 1}, {"article": "Other immunotherapy approaches are in the pipeline, along with fancier versions of drugs to block the hormones that feed prostate cancer.\nAnd it's clear that experts are still scratching their heads about just how Provenge works.\nBut, after all, Provenge is just the first cancer immunotherapy on the market.\nThat's better than the only other approved treatment for such advanced cancers.\nThe primary mystery is how Provenge extends life, since it doesn't shrink prostate tumors, as far as anyone can tell.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear this story didn\u2019t rely on a news release.", "answer": 1}, {"article": "\"We can get that whole process of what a meal does without actually having the meal,\" he said.\nThat makes it much safer than, say, systemic stimulants that also rev up the heart and other parts of the body and cause strong side effects, according to the research.\nOther researchers are working on similar approaches, he said, but this drug, so far, passes harmlessly out of the intestine after doing its work.\nExperts rightfully caution against relying on miracle diet drugs, but a new study offers a novel approach that bears watching.\nFor now, the new approach has been demonstrated only in mice, according to the research, published Monday in the journal Nature Medicine.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The quotes in the story are not the same as the ones in a news release issued by the Salk Institute, so it appears an interview was done. However, it should also be noted that in some ways the news release was more cautious than this story about the drug and its potential use in treating obesity. For example, the story says the research shows the drug is \u201cmuch safer\u201d than systemic stimulants, whereas the release says the researchers \u201chypothesize\u201d that the drug is \u201clikely safer in humans\u201d than similar drugs.\nSee http://www.salk.edu/news/pressrelease_details.php?press_id=2068", "answer": 1}, {"article": "Vitamin D is found in certain foods and beverages such as fortified milk and cereals, and fatty fish such as salmon.\nThe study involved more than 35,000 female nurses whose mothers answered questions about their diet habits during pregnancy.\nAmong the nurses studied, 199 developed MS over the 16-year study period.\nThe disease most often strikes adults after age 20, but it can develop in children.\nGrowing evidence has suggested that vitamin D, found in fortified milk, may lower one\u2019s risk of MS. Now, researchers with the Harvard School of Public Health in Boston have shown that it\u2019s possible this protective benefit could begin while a baby is developing in the womb.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The information in this piece was taken directly from the American Academy of Neurology\u2019s news release.\u00a0\u00a0 There is no sign of any independent reporting. ", "answer": 0}, {"article": "Glenn Jaffe, M.D., a professor in the Department of Ophthalmology at Duke University School of Medicine, said adalimumab works to treat uveitis by targeting a protein that is thought to promote inflammation.\nJaffe said the study focused on time to treatment failure because delaying or preventing inflammation is the key to successful treatment.\n\u201cPatients may have many unwanted side effects when taking steroids long-term, as many uveitis patients do,\u201d Jaffe said.\nDr. Jaffe served as a consultant for AbbVie, and other study authors also report financial relationships with the company.\nAbbVie, the pharmaceutical company that manufactures and markets adalimumab as Humira, sponsored the study.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We didn\u2019t see anything that\u2019s cause for alarm.", "answer": 1}, {"article": "The American Congress of Obstetricians and Gynecologists, for example, recommends that regular screenings begin at age 40, while the American Cancer Society calls for women to start yearly screening at age 45 and then move to screening every two years starting at age 55.\nSeveral groups that lobbied for congressional action said in a statement last month that the task force recommendations conflict with those of other organizations.\nThe congressional action, which was included in the recently enacted spending law, has drawn criticism from some experts.\nThe task force first suggested in 2009 that breast cancer screening begin at 50 instead of 40, touching off enormous criticism.\nThe task force's final recommendation is likely to be controversial because some other groups say the screening should start earlier.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story clearly includes original reporting and goes beyond what would be found in a news release.", "answer": 1}, {"article": "People with hypertension have traditionally been advised to stay away from alcohol because excessive drinking can increase blood pressure.\nThe forthcoming study on men doesn't include an MRI component needed for a more complete comparison.\nBOTTOM LINE: Having one or two drinks a day may be beneficial for men with high blood pressure, but studies like these shouldn't be used to justify excessive drinking.\nMRI measurements of brain activity in the subjects suggested that the difference was related to a surge in negative emotions.\nBOTTOM LINE: Exposure to negative stereotypes can actually cause people to perform more poorly.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no way to know if the story relied on a press release as the sole source of information.", "answer": 2}, {"article": "The panel suggests that heart patients be screened by first asking two standard questions: In the past two weeks, have you had little interest or pleasure in doing things?\nPsychiatrist Michelle Riba said the statement\u2019s emphasis on frequent screening is important.\n\u201cSome physicians are qualified to treat it \u2014 others may be more comfortable referring the problem to a qualified mental health professional,\u201d Froelicher said.\n\u201cWhat you want to see in a particular patient is how they do over time,\u201d said Riba, past president of the American Psychiatric Association, which has endorsed the heart association\u2019s recommendations.\n\u201cA lot of patients with depression don\u2019t follow up on it,\u201d said Dr. Mary Whooley, a professor of medicine at the University of California, San Francisco, who was not on the panel.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story quotes multiple experts, the reader can assume the story did not rely on a press release as the sole source of information.", "answer": 1}, {"article": "Tuberculosis is a chronic bacterial infection that's spread through the air and usually infects the lungs, although other organs of the body can be involved.\nFurther trials of the new test are planned, the researchers said.\nBut Siegel said such testing, which has been in use for more than a century, isn't always accurate.\nA report on the researchers' work was published in the Sept. 2 issue of the New England Journal of Medicine.\nThe test, known as the \"Xpert MTB/RIF\" test for Mycobacterium tuberculosis and resistance to rifampin (RIF), appears to be more than 97 percent accurate and is even able to diagnose drug-resistant TB, researchers said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Although the story does quote from a news release, it\u00a0appropriately notes the source of\u00a0the information. And since it includes an interview\u00a0with an\u00a0independent expert, we can be sure the story wasn\u2019t based entirely on a\u00a0release. \u00a0\u00a0", "answer": 1}, {"article": "Most Australian adults have been infected with the herpes zoster virus and are at risk of shingles, even if they do not remember having chicken pox.\nLead researcher Professor Tony Cunningham from the Westmead Institute for Medical Research said the study shows that the vaccine stimulates production of a specific immune memory cell (CD4 T cells), generating a strong and sustained protection against the virus.\nThis is 12 times higher than other less effective shingles vaccines.\nA new study has shown how the body's immune system responds to the new shingles vaccine, Shingrix, making it more than 90% effective at protecting against the virus.\nWe are seeing results comparable to those of childhood vaccinations.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There\u2019s no unjustifiable language.\nHowever, the news release would have been stronger if it had given data to back up this statement:\n\u201cThis is quite remarkable because there are no other vaccines that perform nearly so well for people in their 70s and their 80s. We are seeing results comparable to those of childhood vaccinations.\u201d", "answer": 1}, {"article": "Laurie Fenton, president of the Lung Cancer Alliance, an advocacy group headquartered in Washington, said: \"We think this is a breakthrough for lung cancer.\nOthers, including researchers and policymakers in the government, say it is a question that will not be settled for five or six years, when other studies are complete.\nOf that group, 85 percent had small tumors that had not spread.\nOnly 15 percent of people with the disease survive five years from the time it is diagnosed.\nWhat it will take to prove that CAT scans are either useful or a waste of time and money is a matter of great controversy.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story quotes multiple independent sources, the reader can assume the story did not rely on a press release as the sole source of information.", "answer": 1}, {"article": "They included sharing news about friends or relatives or plans for the day as a way to involve their spouse in day-to-day events; waiting patiently and keeping eye contact while spouses searched for words; and finding alternate ways to communicate \u2014 for example, singing songs together when attempts to engage the spouse in certain topics failed.\nFuture research might focus on interventions that could help diffuse these frustrations, the paper noted.\nThe couples, who were recruited from a day program for people with memory disorders and their spouses, were receiving coaching in communication, with caregivers learning to listen, to avoid arguing, to not treat their spouse like a child.\nThe caregiving spouses seemed to value their partners\u2019 efforts to communicate as much as or more than the actual content of their conversations.\n\u201cAt the same time, people with Alzheimer\u2019s do have moments of clarity or show affection when it\u2019s unexpected.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes quotes from an interview with the lead researcher at Florida Atlantic University, and those quotes are different from the ones included in a news release issued by the university. So while we\u2019re sure that the story went beyond the news release, the story does appear to lean on that release more than we\u2019d ideally like to see. The single source named in the release is the same single source in the story. Some of the verbiage in the story seems to be a paraphrasing of verbiage in the release, and the points raised in the story seem to mirror those in the release. The story does enough to meet our standard here, but it would have been easy enough to flesh out the coverage significantly with additional sources and information.", "answer": 1}, {"article": "These plaques, which are caused by blood cholesterol, build up over time and cause arteries to narrow, leading to heart disease as the heart works harder to pump blood through the body.\nThe findings appear in the July 7 issue of Annals of Internal Medicine.\nPeople with many calcium deposits can improve their long-term prospects by eating right, exercising, and taking medication to treat heart risk factors such as high blood pressure, elevated blood cholesterol and type 2 diabetes, Shaw said.\n\"The best use is in patients who have no symptoms, but the value of the test is not well known.\"\nCalcium deposits develop as a response to plaque formation along the artery walls, Shaw said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes an independent expert and has quotes not included in the Emory University news release about this study.\n\u00a0", "answer": 1}, {"article": "Learning skills for positive emotions result in less HIV in blood and less anti-depressant use\n\u2022 Positive emotions are possible even with stress of chronic health problems\n\u2022 Men using positive emotion skills learned to cope with their stress, while control group went on anti-depressants\n\nCHICAGO --- When individuals recently diagnosed with HIV were coached to practice skills to help them experience positive emotions, the result was less HIV in their blood and lower antidepressant use, reports a new Northwestern Medicine study.\nThe HIV study is part of a larger body of positive affect research being conducted by Moskowitz.\nThis is believed to be the first test of a positive emotion intervention in people newly diagnosed with HIV.\nThe positive emotion intervention also improved mental health.\nBased on the study results, the intervention is promising for people in the initial stages of adjustment to any serious chronic illness.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We find the word \u201camazing\u201d used to describe the results as too much of an exaggeration for a study that in its peer reviewed journal format is called \u201cmodest\u201d for results. The best that the study showed was a fair to poor difference between the two groups of patients studied.  ", "answer": 0}, {"article": "Metabolic syndrome is characterized by obesity, hypertension and other cardiac risk factors.\nFunding for the study was provided by Wakunaga of America Co., Ltd., the producer of Kyolic Aged Garlic Extract.\nOther LA BioMed researchers who participated in the study were: Suguru Matsumoto, Rine Nakanishi, Dong Li, Anas Alani, Panteha Rezaeian, Jeby Abraham, Michael A. Fahmy, Christopher Dailing, Ferdinand Flores and Sajad Hamal.\nFollowing evaluation, the participants were given either a placebo or a dose of 2,400 milligrams of Aged Garlic Extract every day.\nThe study involved 55 patients, aged 40 to 75 years, who had been diagnosed with metabolic syndrome.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "This release does not use any unjustifiable language.", "answer": 1}, {"article": "\"We always assume there's luxury,\" Wright said.\nInstead, the cause is multiple system atrophy, a neurodegenerative disease.\nThough other symptoms will show up eventually and help in diagnosing the patient, in the meantime, the patient will be receiving the wrong medicines.\nHowever, the test cannot distinguish between the different atypical disorders, which doctors must rely on symptoms to diagnose.\nSpecialists and sub-specialists are available only in big cities, Wright said, and access to a simple blood test would enable a correct diagnosis in a primary care office.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "Adults don\u2019t have much brown fat, but a new study suggests that hormones produced by the heart just might help them make more.\n\u201cThese hormones are involved in fluid regulation, but we showed in this study that they also play a role in breaking down fat,\u201d she says.\nIf studies show the same thing in humans, the heart hormone may hold the key to an effective weight loss treatment, says researcher Sheila Collins, PhD, of Sanford-Burnham Medical Research Institute in Orlando, Fla.\nThe study appears online in the Journal of Clinical Investigation.\nFeb. 6, 2012 -- You may have heard about brown fat -- a unique type of fat that acts like a furnace in the body to burn calories instead of storing them as excess weight.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Since it includes an independent perspective, we can be sure the story was not based entirely on a press release.", "answer": 1}, {"article": "And Owens says that people with medical conditions like ulcers, kidney problems, liver problems or bleeding disorders are more vulnerable, as are people who take blood-thinning drugs and NSAIDs.\nAnd while many medical groups recommend daily aspirin to lower heart disease risk, not all federal agencies agree.\nThese new recommendations aren't final, and are open to public comment.\nIf people don't have a significantly increased risk of having a heart attack or stroke over the next decade, Nissen says, they may be \"causing more harm than benefit.\"\nThe Food and Drug Administration actually issued a warning against routinely taking aspirin to prevent heart disease in people without significantly high risk.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We think it\u2019s clear that the story is not based solely on a news release.", "answer": 1}, {"article": "A recent study has found evidence suggesting text messages could reduce one\u2019s odds of a second heart attack.\n\nA six-month clinical trial in Australia found that patients recovering from a heart attack were more likely to maintain lower blood pressure, less body fat and lower cholesterol levels than a control group when the patients received text messages asking and giving suggestions about their health routines. Patients receiving the texts also were more likely to be active and to quit smoking than the patients in the control...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We weren\u2019t able to locate a news release, but the inclusion of an independent source in the story is a reliable indicator that the story didn\u2019t rely on\u00a0one.", "answer": 1}, {"article": "The page you are looking for has either moved or is not available (error 404).\n\nPlease return to the homepage or use the search box above to see if the page is available in a new location.\n\nIf you think this message is in error or need assistance, please email the webmaster.", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We didn\u2019t observe any unjustifiable language in the release\u2019s description of the study.", "answer": 1}, {"article": "He contended that kratom does not act on the brain's opioid receptors the way prescription painkillers and heroin do. But back in 2016, the Journal of the American Chemical Society reported that kratom indeed works this way. Last month, an FDA study found that 22 of the 25 of the most prevalent compounds in kratom do bind to opioid receptors, and so should be considered an opioid. The study also said most deaths did occur in people who used kratom in addition to other drugs, though in one case, only kratom was detected.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story clearly goes beyond any news release that might have been issued.", "answer": 1}, {"article": "But most of the success so far has been with blood cancers like lymphomas and leukemias.\nIf the patient had not received the CAR T therapy, he likely would only have survived a few weeks after his cancer recurred, says Badie.\nBased on this man\u2019s case, his team is hoping to now inject not just the tumor site but also the ventricular space in the brain, since that may help control spread of the cancer.\nBadie says it\u2019s not obvious why, but his analysis showed that these tumors did not contain much of the protein targeted by the CAR T cells that were injected.\nThis is the first time that immune cells have been injected into these brain regions, because introducing anything into the ventricles can cause dangerous and possibly deadly inflammation.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not provide much beyond the news release, but\u00a0did not appear to rely on it, as the story\u2019s tone is not nearly as miracle-mongering as the news release.", "answer": 1}, {"article": "Autism is a complex brain disorder characterized by difficulties in social interaction and communication, ranging from mild to profound impairment.\nThe new scanning method \u2014 which picks up on structural changes in the brain\u2019s grey matter \u2014 could be ready for general use in a couple of years.\nThe accuracy of the scan in predicting autism was so high that the results were strongly significant, despite the small number of patients involved.\nExperts not involved in the research applauded the research but cautioned further study was still needed.\n\u201cAlthough this method is not ready for normal diagnostic situations, any step to easier diagnosis is welcome,\u201d said Terry Brugha, professor of psychiatry at the University of Leicester.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Since this story included two expert interviews, we can be sure it didn\u2019t rely on a news release", "answer": 1}, {"article": "Between 12% and 20% of women in the 35 countries in the Organisation for Economic Co-operation and Development suffer from perinatal depression, and 20-35% in poorer countries.\nThe study found that women who had least social support such as those who were not living with or near their mother or mother-in-law, benefited most from the therapy intervention, both in the short and long term.\n\u201cThis is an important study for the impact on mothers with depression but there are global implications for the treatment of all human beings suffering from depression.\nCognitive behavioural therapy has significant positive effects on a mother\u2019s mental health, income, employment and parenting skills even seven years after the birth of the child, according to the first study of its kind.\nThe international research project into the impact of depression on pregnant mothers and their babies, led by Professor Sonia Bhalotra from the Institute for Social and Economic Research at the University of Essex, could have major implications for public policy.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We couldn\u2019t find a news release per se, so we\u2019ll rate this N/A. But we did find this media briefing. The story includes quotes not found in the briefing.", "answer": 2}, {"article": "Your office thermostat is set for men's comfort.\nBased on other studies in the past that seemed to allude to marijuana use and later development of psychotic symptoms such as delusions or hallucinations, the researchers had thought they might find some associations to disease or other health conditions.\nUpdate: The study's findings generated significant controversy along with requests for supplemental analysis, according to the editors of the Psychology of Addictive Behaviors.\nA study published by the American Psychological Association in the journal Psychology of Addictive Behaviors this week should alleviate some of the worst fears.\nThe researchers found no links to physical or mental health issues -- including depression, psychotic symptoms or asthma -- in any group, even those with very high use.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The quotes from researcher Bechtold\u00a0are identical to those in an American Psychological Association news release.\nThe story euphemistically refers to these comments appearing in \u201ca statement.\u201d \u00a0Let\u2019s call it what it is: \u00a0a news release or press release written by public relations people.\nLifting quotes and then not seeking independent perspectives are a double whammy.", "answer": 0}, {"article": "Researchers believe electrical pulses can act like a sort of pacemaker in the brain, heading off the chaotic \"electrical storms\" that cause epileptic seizures.\nThe device alone reduced that to about one seizure a year.\nAnd she hasn't had any seizures since she added low doses of a medication more than 18 months ago.\nAnd the trigeminal nerve stimulator is not the first time researchers have used electrical pulses to prevent seizures.\nThe device causes \"a slight tingling sensation\" on her skin, she says.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "Susan Pisano, a spokeswoman for the Association of Health Insurance Plans, the largest trade group, said insurers would wait for guidance from the FDA, but adds, \"If the FDA pulls back its approval for this particular indication, it would trigger a review of plan policies.\nBut here's the catch: Avastin costs more than $8,000 a month.\nBut some physicians, including Perez, say the issue is getting harder to ignore.\nBy e-mail, she adds, \"How do you put a dollar value on that?\"\nWe need some oversight body to say whether something is effective.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This piece does not rely on a press release. ", "answer": 1}, {"article": "The condition, in which a person\u2019s body clock does not automatically set to the 24-hour day, affects a majority of blind people.\n\u201cThese results also highlight the importance of chronic therapy in treating Non-24,\u201d CEO Mihael Polymeropoulos said in a statement on Wednesday.\nThe drug is being tested for \u2018non-24-hour disorder\u2019 that has no approved treatment.\nVanda on December 18 said the drug performed better than a placebo in the first of the four planned late-stage trials on the drug.\nThe study, named Reset, was a 20-patient trial designed to test the maintenance effect of a 20 mg dose of the drug, tasimelteon.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This quote comes straight out of a company news release:\n\u201cThese results also highlight the importance of chronic therapy in treating Non-24,\u201d CEO Mihael Polymeropoulos said in a statement on Wednesday.\nAnd, given that there is no other source cited, it appears that the story relied largely on that news release.", "answer": 0}, {"article": "A diet that includes tomatoes could lower the chance of having a stroke.\n\nA new study shows that men who had the highest levels of lycopene\u2014an antioxidant found in tomatoes\u2014had fewer strokes than men who had the lowest level of lycopene in their blood. Overall, the risk of strokes was reduced by 55%.\n\nThe study, based in Finland, will be published...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There\u2019s no evidence that this story relied on a press release.", "answer": 1}, {"article": "Joslin has one of the largest diabetes training programs in the world, educating 150 M.D.\nThe results, published by the Journal of the American Medical Association, demonstrate the first major therapy advance for the condition in nearly 40 years.\nThe DRCR.net enrolled 305 participants (394 eyes) with PDR in one or both eyes at 55 clinical sites across the country.\nSlightly more than half (53 percent) of eyes in the laser group received Lucentis injections to treat DME.\nAbout 6 percent of eyes in the Lucentis group received laser therapy, mostly for issues other than DME.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release does a good job of avoiding hype and explaining what was a complex study.", "answer": 1}, {"article": "\u201cOurs is probably a bottom estimate,\u201d Dr. Cahill said.\nHe added that the study also confirmed how quickly physicians had adopted the proteins both for approved and unapproved uses.\nWhile use of the products in such operations has since fallen, one expert said the new report should convince doctors to stop using them in anterior cervical fusions, as the procedure is known.\nIn a statement, she said the trial would help address how the procedure, if approved by federal regulators, \u201cshould be appropriately managed to minimize complications.\u201d\n\nSome experts have speculated that the adverse effects were dose-related.\nThe products\u2019 use in cervical fusion procedures is a small component of their total sales, which reached an estimated $760.3 million in 2008, with Medtronic\u2019s share the larger one, according to Millennium Research Group, a consulting firm in Toronto.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\nThe story includes quotes three experts that appear to be from interviews.", "answer": 1}, {"article": "Sunlight's ultraviolet (UV) rays can damage the DNA in skin cells, increasing the risk for skin cancer.\nBut she said more reserach is needed to see if everyone benefits from it.\nA new study could change the way doctors treat patients at high risk for skin cancer.\nDoctors involved in the study are excited by their findings on vitamin B3 nicotinamide.\nIt doesn't involve any high-priced new pharmaceuticals -- the key may be an over-the-counter vitamin supplement that costs less than $10 a month.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Since two outside experts are quoted, we can be sure the story didn\u2019t rely excessively on a news release.", "answer": 1}, {"article": "The Ache: In cold and flu season, pathogens spread when people are crammed into close quarters, such as airplanes and cars.\n\nThe Claim: Personal air purifiers worn around the neck clean the air in the wearer\u2019s breathing zone of viruses and bacteria as well as allergens, say companies that sell them.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story features original reporting, so we can be sure it\u2019s not based on a news release.\n\u00a0", "answer": 1}, {"article": "The findings, presented on Sunday at a meeting of the American Academy of Allergy, Asthma and Immunology in Washington, suggest that a treatment for peanut allergy may be developed in two or three years, said Dr. Wesley Burks, the chief of the division of pediatric allergy and immunology at Duke University Medical Center, who helped conduct the research.\nA medically supervised daily dose of peanuts may help children with peanut allergies greatly increase their tolerance to the food, according to two new studies that raise the possibility of a cure for this potentially life-threatening condition.\nNearly half of the 150 deaths attributed to food allergies each year in the United States are caused by peanut allergies, according to Duke University.\nWhile drugs can be used to treat an allergic reaction, there are no approved treatments for food allergies.\nAbout 3.3 million people are allergic to peanuts or tree nuts.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The New York Times article states, \"'[N]early half of the 150 deaths attributed to food allergies in the United States each year are caused by peanut allergies,\u2019 according to Duke University.\" \nA Duke University press release includes this same sentence, with the exception of the words \"in the United States.\"\nThis is a minor matter, hardly evidence that the NYT reporter is rewriting a handout. But it\u2019s unsettling nonetheless.\u00a0 ", "answer": 1}, {"article": "Who and When: More than 140,000 U.S. women who had DCIS between 1998 and 2014; this study compared lumpectomy plus radiation vs. lumpectomy alone, lumpectomy vs. mastectomy, and lumpectomy plus radiation vs. mastectomy\n\nWhat (Study Measures and Outcomes): Use of radiation and/or extent of surgery (exposures); breast cancer mortality rates within 15 years (outcomes)\n\nHow (Study Design): This was an observational study.\nRelated Material: The invited commentary, \"Systemic Effects of Radiotherapy in Ductal Carcinoma In Situ,\" by Mira Goldberg, M.D., and Timothy J. Whelan, B.M., B.Ch., of McMaster University, Ontario, Canada, also is available on the For The Media website.\nEvery article is free online from the day of publication.\nThe absolute risk reduction was 0.27 percent, making it necessary to treat 370 women to save one life.\nTo Learn More: The full study is available on the For The Media website.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We found no unjustifiable language.", "answer": 1}, {"article": "Condoms, the most common non-hormonal method of contraception, have an efficacy rate of 82 percent.\nAmphora was found to have an 86 percent efficacy rate in avoiding pregnancies and no serious side-effects were observed in the study, which evaluated about 1,400 healthy women belonging to the age group 18-35 years, Evofem said.\nThe company plans to resubmit the marketing application for Amphora in the second quarter next year and if approved, plans to launch the product in January 2020.\n\u201cOur research and current understanding of women suggests the time is now for there to be a new non-hormonal category in contraception,\u201d Chief Executive Saundra Pelletier said on a conference call with analysts.\n\u201cThese results pave the way for Amphora\u2019s disruption of the contraception market as a novel, highly effective, non-hormonal and woman-controlled method that finally answers women\u2019s long-awaited desire to avoid hormones,\u201d Roth Capital Partners analyst Yasmeen Rahimi said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story appears to go beyond the company news release.", "answer": 1}, {"article": "A tiny but promising study suggests that a medicine used for immune disorders may offer long-term benefits to Alzheimer's patients\u2014a result likely to spur demand for the treatment even though it is in limited supply and isn't approved for the memory-debilitating disease.\n\nThe treatment, intravenous immunoglobulin therapy, or IVIG, is made from the blood plasma of healthy young adults. Since 2004 it had shown early promise for Alzheimer's, which afflicts some five million Americans.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not rely on a news release.", "answer": 1}, {"article": "\"I hear a lot of moms say, 'I'm disappointed I had to have a C-section.'\nBut for many women, being told they need a C-section is unpleasant news.\nSometimes the situation is truly life-threatening.\nAnd there were a bunch of little adjustments, such as moving the EKG monitors from their usual location on top of the mother's chest to her side.\nBy late evening she was told she'd need a C-section to deliver her son, Avery.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not seem to be based on any press releases. The quotes and sources used show signs of original reporting.", "answer": 1}, {"article": "Currently, people who do not have HIV but are at substantial risk of getting it--because they have multiple sexual partners, for example, or an HIV-infected partner--can receive antiviral medications to prevent disease, a strategy called pre-exposure prophylaxis (PrEP).\nThis is why researchers continue to look for other ways to control the virus--and broadly neutralizing antibodies could prove to be part of an alternate treatment strategy.\nAlthough these patients were found to have some resistant virus in their blood, further research in the lab showed that those viruses were still sensitive to other broadly neutralizing antibodies, including 3BNC117, that target different parts of the pathogen.\nThe purpose was to determine whether the antibody was safe and whether it had antiviral activity in humans.\nIn an effort to accomplish this, the investigators are looking into modified variants of the antibodies with prolonged activity, so that they would need to be given less often in the PrEP setting.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t include overtly sensational language. But some of the claims, such as \u201cthe most potent of its kind so far\u201d and \u201cshowing early promise,\u201d may not be wholly justified by the research so far. The author quotes contain some statements that go beyond the results as well.", "answer": 1}, {"article": "Acupuncture, a popular form of alternative medicine, involves inserting ultra-thin needles into the skin.\nThe question is whether the acupuncture reduced the hot flashes or a placebo effect played a role, said Freedland, who's familiar with the study findings.\n\"We are now designing a randomized clinical trial to further evaluate acupuncture after prostate cancer treatment,\" Ashamalla added.\nIt's also possible, he said, that the symptoms went away on their own, which commonly happens to men on hormone therapy.\nMONDAY, April 25, 2011 (HealthDay News) -- Acupuncture might help reduce the hot flashes that frequently affect prostate cancer patients while they're on hormone therapy, a small study suggests.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Mixed bag.\nThe story admits it drew its lead researcher quotes from a news release.\nBut it turned to an independent expert for analysis.\u00a0 Because that independent expert injected some questions about the limitations of the research, we\u2019ll award this a barely satisfactory grade.\nBut why wasn\u2019t the lead author himself interviewed?", "answer": 1}, {"article": "A new study raised questions about the benefits of a relatively common procedure for heart patients\u2014implanting tiny devices that prop open clogged arteries to relieve chest pain.\n\nThe 200-patient study conducted by U.K. researchers found that patients with stable chest pain, or angina, who received stent devices experienced no significant improvement in exercise time on a treadmill, compared with similar patients who received no stents during sham procedures.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story goes well beyond what is contained in the news release from the host institution, Imperial College.", "answer": 1}, {"article": "\"Most people, especially athletes, when they had hip symptoms, usually they just got diagnosed as a chronic groin pull,\" said J.W.\nAnd they've found that it can be fixed using arthroscopic surgery, which uses narrow instruments inserted through smaller incisions than traditional surgery.\nBut those experiencing hip pain or stiffness have had more-limited options.\nThis is a marked uptick from a decade ago, when Ochiai said the single course in hip arthroscopy was nearly canceled due to lack of interest.\nDoctors say FAI is not something a patient is born with; rather, it develops in adolescence, for unknown reasons.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\n \nThe story cites two sources and does not appear to rely solely or largely on a news release.", "answer": 1}, {"article": "A new study shows that computer technology known as machine learning is up to 93 percent accurate in correctly classifying a suicidal person and 85 percent accurate in identifying a person who is suicidal, has a mental illness but is not suicidal, or neither.\nThey then used machine learning algorithms to classify the patients into one of the three groups.\nThe researchers extracted and analyzed verbal and non-verbal language from the data.\nThe results showed that machine learning algorithms can tell the differences between the groups with up to 93 percent accuracy.\nDr. Pestian and his colleagues enrolled 379 patients in the study between Oct. 2013 and March 2015 from emergency departments and inpatient and outpatient centers at three sites.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Nothing in this release raised a red flag for us.", "answer": 1}, {"article": "Fish like salmon, herring and sardine are a common source of EPA-DHA, while ALA is found in vegetables including soybeans, flax seeds and walnuts.\nDaan Kromhout of Wageningen University, who led the study, told the European Society of Cardiology the lack of efficacy might reflect the good background drug treatment patients were receiving, with 85 percent on cholesterol-lowering statins, as well as blood pressure and blood-thinning tablets.\nDiabetes patients also showed a possible benefit.\n\u201cThe results indicate that more investigation is required into the efficacy of vegetable omega 3, but do not question the current authoritative dietary recommendations and advices for omega 3 intakes on which our products are based,\u201d the company said in a statement.\nUnilever, whose margarine brands that contain omega-3 include Flora and I Can\u2019t Believe It\u2019s Not Butter, said the lack of benefit seen with EPA and DHA was surprising, considering the weight of evidence published to date.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear the story didn\u2019t rely solely or largely on a news release. ", "answer": 1}, {"article": "CT scanning uses X-rays and computers to produce a clearer image than traditional X-ray techniques, but CT also uses higher radiation doses to generate those images.\nThat\u2019s consistent with the findings of the National Lung Screening Trial in the U.S., which in November released data \u2014 published online in the New England Journal of Medicine last week \u2014 showing that 20 percent fewer middle-aged heavy smokers died of lung cancer when they were screened annually with a CT scan compared to a standard, less detailed chest X-ray.\n\u201cWe now have a technology that can detect (lung cancer) early enough to make some impact,\u201d Berg said.\nMoreover, they warn that while regular screening might help doctors catch cancer earlier, it also comes with a high price tag and added risks to patients.\nAnd screening comes with an inherent risk of false-positives \u2014 scans which suggest a lung cancer that turns out not to be there.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear the story didn\u2019t simply rely on a news release.", "answer": 1}, {"article": "Scientists have found an unexpected use for virtual reality headsets: to help pinpoint people who may later develop Alzheimer\u2019s disease.\n\u201cThe aim of the study is very simple: can we detect changes in brain function before people are aware that they have them?\u201d\n\nResearchers recently pinpointed the significance of a tiny area of the brain known as the entorhinal cortex, which acts as a hub in a widespread brain network that controls navigation.\nThis now appears to be the first part of the brain that succumbs to Alzheimer\u2019s.\nNot all will be destined to be affected by the disease, however.\nThe goal of the work is to help people as they develop the disease.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We couldn\u2019t find a related news release, so we\u2019ll rate this N/A.", "answer": 2}, {"article": "If nothing else, \"The Business of Being Born,\" with its indelible image of a naked, exhilarated Ricki Lake cooing \"Hi there!\"\nWolf and other natural-birth advocates say we need a better idea of what normal birth looks like, as movies and TV usually depict the process as painful and bloody.\nBut the image that viewers may find most shocking is that of a baby being cut out of a woman's abdomen via Caesarean.\nThis, according to Lake, the executive producer of the film, and Abby Epstein, the film's director, is the right reaction: one of their messages is that C-sections should only be performed when needed to guarantee the well-being of the mother and infant, and should not be a first choice for healthy mothers.\nDoctors such as Stark say we need a better sense of what goes on while the baby is still in utero.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story quotes multiple sources, the reader can assume that the story did not rely on a press release as the sole source of information.", "answer": 1}, {"article": "\"She had a persistent boil on her buttocks,\" he explained.\nFor biochemist Peter Molan, honey's ancient power to heal is not a matter of faith.\nThe most promising research, he and many other scientists say, focuses instead on bioactive honey's potency as a topical application.\n(And there's wide agreement among medical professionals that people should not test the treatment themselves by slathering their cuts and burns with honey from the pantry shelf.)\nRose Cooper, a microbiologist and honey expert at the University of Wales Institute at Cardiff, remains cautiously optimistic that the increased use of honey dressings will help better information to emerge.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story quotes multiple researchers, the reader can assume the story did not rely on a press release as the sole source of information.", "answer": 1}, {"article": "WASHINGTON\u2014People with mild Alzheimer\u2019s disease who started taking an experimental Eli Lilly & Co. drug earlier in the course of their disease fared better than patients who started later in a clinical trial.\n\nThe outcome may bolster the company\u2019s case that the drug, solanezumab, can slow the decline of memory and function in mild Alzheimer\u2019s patients, despite prior studies with negative results. But the new data aren\u2019t final proof of the drug\u2019s benefit\u2014a separate, continuing study due to end in late 2016 is designed to...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "While it seems clear that the story was driven by news releases from both manufacturers, the reporters clearly offered background that went beyond the news release material.", "answer": 1}, {"article": "\"It's automatically responsive to our body function, producing stimulation when needed,\" says Wang.\nThat means the device only stimulates the vagus nerve when the stomach moves.\n\"One potential advantage of the new device over existing vagus nerve stimulators is that it does not require external battery charging, which is a significant advantage when you consider the inconvenience that patients experience when having to charge a battery multiple times a week for an hour or so.\"\nUnlike gastric bypass, which permanently alters the capacity of the stomach, the effects of the new devices also are reversible.\nThat ongoing maintenance can be a big barrier to use, says Luke Funk, a surgery professor in UW-Madison's Division of Minimally Invasive, Foregut and Bariatric Surgery.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "By definition, researchers do not know whether an experimental device is better or worse than existing devices or other alternatives, so the release should not have included quotes that jump to conclusions, such as, \u201cOur expectation is that the device will be more effective and convenient to use than other technologies\u201d or that the stomach-motion trigger is superior to the control method of the existing vagus nerve stimulator, since the methods have not been compared.", "answer": 0}, {"article": "\"There is another drug, called rituximab, that's been in early trials for MS for years.\nThe investigators further noted that even eight months after treatment launch, no serious adverse effects were directly attributable to the new drug.\nTo test the drug, Kappos and his team recruited patients aged 18 to 55 seeking MS treatment in 79 centers in 20 countries.\nAnd I see no major advantage of this drug versus that older drug.\nAfter 24 weeks, some of the doses were adjusted.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The addition of the Mayo expert\u2019s perspective shows that the story did not rely solely on a news release.", "answer": 1}, {"article": "Another is that aducanumab seems to enhance the ability of existing immune cells in the brain to devour toxins, including amyloid.\nBut there are reasons to think aducanumab may succeed where other drugs have failed.\nThose efforts have failed to produce a single approved drug so far.\nThe publication in Nature on Wednesday provides details about those early reports.\nAnd the researchers did.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes original reporting and clearly goes beyond any news release.", "answer": 1}, {"article": "Also some fancier CT studies, involving multiple \"slices\" through the body in a single examination, can be replaced by simpler CT tests, conventional X-rays or tests such as ultrasound or MRI that don't involve radiation.\nTo cut down on unnecessarily high radiation doses, Thrall says, the College of Radiology is also developing an \"alarm\" system that will alert hospitals when their CT scan exceeds an acceptable dose.\n\"I think we need to pause and think about whether the extra information [from CT scans] really helps us make a diagnosis,\" Smith-Bindman says.\nHe says at his institution, the Massachusetts General Hospital, doctors who order a CT scan or other imaging study must list the reason.\nThat will require hospitals to feed dose data to a central computer run by the radiology group.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story quotes multiple experts, the reader can assume the story did not rely on a press release as the sole source of information.", "answer": 1}, {"article": "Researchers have found strong evidence that adenotonsillectomy \u2014 the surgery to remove the tonsils and adenoids \u2014 can help relieve childhood behavioral or attention problems, including attention-deficit hyperactivity disorder, or A.D.H.D.\nFinally, a child psychiatrist determined which children's difficulties merited the diagnosis of attention-deficit hyperactivity disorder.\nAbout half of the patients undergo the procedure to control chronic throat or ear infections.\nAll the children spent one night in a sleep laboratory to record their sleep and breathing patterns.\nAccording to the paper, which was published yesterday in Pediatrics, it has been known that children with sleep disorders often have behavior problems.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t judge if the story relied on text from a press release.", "answer": 2}, {"article": "Strawberries have the potential to prevent esophageal cancer, according to a preliminary study released Wednesday.\n\nResearchers, led by Ohio State University, were able to show that freeze-dried strawberries slowed the growth of dysplastic, or precancerous, lesions in about 30 people who consumed the fruit for six months.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Not applicable.\u00a0 We can\u2019t be sure of the extent to which the story may have relied on a news release.\u00a0 We do know this:", "answer": 2}, {"article": "Botox is now being used by men, some of whom did not even run for President. The number of men in the U.S. who paid to get a series of tiny injections in their face nearly tripled from 2001 to 2007--to 300,000, or about 7% of the total Botoxed population. And despite the recession, those numbers aren't going down yet; one of the many things the laid-off cannot afford is to look their age.\n\nMen usually get Botox to remove those two vertical lines between their eyebrows that make them look angry and confused and thus, one could argue, masculine. They...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There does not appear to be a press release related to this story. ", "answer": 2}, {"article": ".\nOn that basis, the authors recommend that techniques such as the Boston modification of Robertson technique should be preferred by surgeons seeking to avoid pseudoptosis.\n\"This study is one of the largest breast anthropometry (measurement) studies ever performed,\" says Lau.\nThe paper, The Sternum-Nipple Distance is Double the Nipple-Inframammary Fold Distance in Macromastia, is published Ahead-of-Print online in the Annals of Plastic Surgery.\nOther advantages of the Boston modification of Robertson technique include decreased operative time and elimination of the \"triple point,\" the most common site of postoperative incision rupture.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t rely on sensational language. However, the headline \u201cTechnique improves breast reduction outcomes,\u201d and the comments of Dr. Lau, (\u201c..we offer an improved technique that preserves more of the critical breast anatomy. This study provides an anatomical foundation for why our technique may yield better, longer-lasting results\u201d and\u00a0\u201cThese results help us provide the best breast reduction outcomes to our patients\u201d) seem to provide an overly optimistic interpretation of the study results.", "answer": 1}, {"article": "They were divided in groups of 10.\nResearchers said that the lab results identify a class of existing drugs that are likely to treat Alzheimer\u2019s by blocking a particular part of the immune response.\nResearchers, who conducted the study on mice, found that mefenamic acid \u2014 a common Non-Steroidal Anti Inflammatory Drug (NSAID) used to relieve menstrual pain \u2014 can completely reverse memory loss and brain inflammation that are hallmark changes of Alzheimer\u2019s, which currently affects over five million Americans.\nFor the study, researchers used 20 transgenic mice that develop symptoms of Alzheimer\u2019s disease.\nThe research was conducted when mice had developed memory problems.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story has no independent sources, and uses language from\u00a0the news release nearly verbatim in multiple places. For example:\nNews release:\u00a0Memory loss was completely reversed back to the levels seen in mice without the disease.\nStory:\u00a0Researchers observed that memory loss was fully reversed to the levels seen in mice without Alzheimer\u2019s.", "answer": 0}, {"article": "Serotonin imbalances have also been linked to depression.\nStudy results were also endorsed in 11 accompanying editorials from leading experts in psychiatry, addiction, and palliative care.\nAll patients in the study \u2014 mostly women age 22 to 75 who are or were patients at the Perlmutter Cancer Center of NYU Langone \u2014 had either advanced breast, gastrointestinal, or blood cancers and had been diagnosed as suffering from serious psychological distress related to their disease.\nStudy participants, he says, experienced no serious negative effects, such as hospitalization or more serious mental health conditions.\n\u201cOur results represent the strongest evidence to date of a clinical benefit from psilocybin therapy, with the potential to transform care for patients with cancer-related psychological distress,\u201d says study lead investigator Stephen Ross, MD, director of substance abuse services in the Department of Psychiatry at NYU Langone.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "This one was actually a close call, particularly because of one line in the release. In the third paragraph, the release states that \u201cStudy results were also endorsed in 11 accompanying editorials from leading experts in psychiatry, addiction, and palliative care.\u201d Cautious optimism may be a more accurate description of some of those editorials. However, much depends on how one chooses to interpret the word \u201cendorse.\u201d Given that all of the editorials acknowledge the work, and that is a reasonable interpretation of the word \u201cendorse,\u201d we\u2019ll give it a pass. However, given that \u201cendorse\u201d can also be read as actively supporting or promoting something, we wish they had chosen different language.", "answer": 1}, {"article": "The apolipoprotein gene is inherited from each parent and when a patient inherits the ApoE4 variant from one parent they have a three times greater risk of developing Alzheimer's disease, whereas a patient who inherits ApoE4 from both parents is eight-to-12 times more likely to develop the disease.\nIn addition to this study, researchers will present the latest in Alzheimer's disease at the AACC Annual Scientific Meeting & Clinical Lab Expo, including:\n\u2022 New research explores using the level of angiotensin-converting enzyme (ACE) in the brain and spinal cord as a biomarker for neurodegenerative diseases, including Parkinson's disease and AD.\n\"This fast, accurate testing will allow doctors and patients to make more informed choices earlier to potentially slow the possible progress of Alzheimer's.\"\n\"This type of testing is important in our quest to understand and diagnose Alzheimer's and empower patients to understand risks, consider medication, and even make early lifestyle changes.\"\n\"Higher FT4 or TSH Below the Normal Range are Associated with an Increased Risk of Dementia: a Meta-analysis of 10 Studies\" (A-180)\n\nSession Information \n\nRegistration for the AACC Annual Scientific Meeting is free for members of the media.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "No problem here.", "answer": 1}, {"article": "Patients taking briakinumab had more serious infections and more cancers than those taking methotrexate.\nGordon was not involved in the current study, but he has been involved in research of the drug and has been a paid consultant and investigator for Abbott.\n\"Many of us were disappointed it was withdrawn because there would be a subset of patients who wouldn't respond to anything else and it would have been nice to have for them.\"\nThe study is published in the New England Journal of Medicine.\nBut as successful as the drug appears to be for some patients, it may come with a significant risk.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely solely on a news release.", "answer": 1}, {"article": "Insurance coverage varies, and doctors often only offer this testing to women at higher risk because of things like advanced maternal age.\nStudies have shown that the new fetal DNA tests do a better job, says Norton.\nSeitz, in Alabama, thought it was a bonus that getting this new blood test would tell her if she was having a boy or a girl.\nThe results she did get from the fetal DNA test were reassuring.\n\"Approximately 1 in 700 pregnancies there's an extra X or extra Y,\" she says, noting that these are mild conditions that would normally go undetected, unless a woman had an invasive test like an amnio.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release. The reporter clearly spoke to several expert sources.", "answer": 1}, {"article": "Glover acknowledges that \"it's not a perfect solution.\nThere are more than a few caveats when it comes to the treatment regimen.\nThough the immunotherapy treatment is simply a matter of gradually increasing your tolerance to peanuts, you could have a severe reaction at home.\nStill, if it had taken twice the amount of time, she would have done it: \"It's peace of mind.\"\nGenerally, we would take it after dinner.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story goes well beyond the information provided in a news release.  ", "answer": 1}, {"article": "Shingles is a viral disease produced by the chicken pox virus, a common childhood disease, and is characterized by pain and a blistering rash along the nerves that have housed the dormant virus.\nEveryone in the study, published in the Journal of the American Medical Association, was at least 60 years old, and the researchers didn\u2019t include anybody for whom the live vaccine is not recommended.\nDespite the FDA\u2019s approval, the vaccine has not caught on as much as some had hoped.\nThe vaccine has been tested, but never under real-world conditions in regular doctors\u2019 offices.\nBut researchers cautioned that because they did not follow patients over the longer term, they didn\u2019t know how effective the vaccine is years later.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\nThe story does not appear to rely on a news release.", "answer": 1}, {"article": "Arthritis pain is caused by bones rubbing together after protective cartilage is damaged or worn away.\nAfter years of cortisone treatments and therapy, wrist replacement became a last resort.\nAfter replacement surgery and months of physical therapy, patients can lift no more than 15 or 20 pounds, he said.\nMore than a dozen bones lie beneath the skin and muscles of the hand and wrist, compared with two or three for those larger joints.\n\"Some of the newer implant designs save a lot of the bone stock,\" said Collins, who performs about 10 wrist replacements a year.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Two weeks before this story was published, the Texas Medical Center issued a press release about wrist replacement surgery, covering much of the same information in the Houston Chronicle article. The Medical Center is named in the second sentence of the article, and the story\u2019s expert source is the same surgeon that is quoted in the press release. The story fulfills every public relations department\u2019s dream, and does not stray far from the hospital\u2019s and surgeon\u2019s story line. But we can't be sure if the story relied solely or largely on the press release.\u00a0", "answer": 2}, {"article": "The hormone is released by the body in times of starvation to protect lean muscle mass and trigger the body to start burning fat stores.\nThat\u2019s the finding of a new study from doctors in Utah who looked at the relationship between periodic fasting and cardiovascular disease.\n\u201cWe were able to replicate the findings and show that people who fast routinely have a lower prevalence of coronary disease.\u2019\u2019\n\nThe downside of the study is that it didn\u2019t ask for specific details on the type and duration of fasting among the patients.\nHe said the group was planning additional research into the potential health effects of regular fasting.\nBecause about 90 percent of the patients were Mormons, a faith that encourages its members to fast for one day a month, the doctors expected to find a relatively high rate of regular fasting among the study participants.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story appears to have included an interview with the researcher, so we think it\u2019s unlikely that it relied solely on a news release.", "answer": 1}, {"article": ".\nCherian noted that the study does not prove that the DASH diet leads to a reduced risk of depression; it only shows an association.\n\"Future studies are now needed to confirm these results and to determine the best nutritional components of the DASH diet to prevent depression later in life and to best help people keep their brains healthy,\" said Cherian.\nRegister now for the 2018 AAN Annual Meeting Press Room in Los Angeles, April 21-27, 2018\n\nThe study was supported by the National Institute on Aging.\nThe odds of becoming depressed over time was 11 percent lower among the top group of DASH adherers versus the lowest group.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "This is a tricky one. The release does one thing that we don\u2019t like \u2014 and it does that thing more than once. The headline says \u201cDiet\u2026may also reduce risk of depression\u201d (emphasis added). The first sentence says \u201cPeople\u2026may have lower rates of depression\u2026\u201d (emphasis added). In either instance, the release could just as easily have said \u201cmay not.\u201d It begs the question of why the news release was issued at this point. However, we want to applaud two things the release does do. First, the release explicitly states that \u201cthe study does not prove that the DASH diet leads to a reduced risk of depression; it only shows an association.\u201d That is such an important point to make, and we think that is great. Second, the release also quotes one of the researchers as saying \u201cFuture studies are now needed to confirm these results and to determine the best nutritional components of the DASH diet to prevent depression later in life and to best help people keep their brains healthy.\u201d Again, this is an important point and we are very glad to see it addressed. All in all, we give it a satisfactory rating here.", "answer": 1}, {"article": "We're sorry, but Newspapers.com doesn't work properly without JavaScript enabled. You will need to enable Javascript by changing your browser settings. Learn how to enable it.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article does not draw language or facts from the company\u2019s press release.\nHowever, the article does report the drug\u2019s potential but uNPRoven uses against MRSA and metastatic melanoma, both of which are claimed by the company\u2019s president in a press release issued the day before the article appeared.\u00a0 Because only the president of the company is cited in the story, this feels like press release influence. \u00a0 ", "answer": 0}, {"article": "\"I know that I can just sort of be on my sits bones, instead of a funny arch with my stomach pushed out or my back arched in some strange way,\" says Rodriguez\n\nJosephine Gray is Rodriguez's teacher and is a certified instructor in Alexander Technique.\nThose who had six Alexander lessons showed some improvement.\nAfter a year, those who had massage were no better off.\nBut finding a remedy for back pain can be a lot like a guessing game.\nIf that's the case, Little says he'll have to go back to the drawing board.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article did not appear to rely on a press release.\n\u00a0\n", "answer": 1}, {"article": "Previous studies have connected high levels of inflammatory markers in the blood to bone loss and to fractures in older women and men, which prompted Orchard and her colleagues to wonder what they'd find if they took one more step back - to the dietary choices that contribute to inflammation in the body.\nThe study, led by Tonya Orchard, an assistant professor of human nutrition at The Ohio State University, appears in the Journal of Bone and Mineral Research.\nBecause the study was observational, it's not possible to definitively link dietary patterns and bone health and fracture outcomes.\nVedat Yildiz of Ohio State's Center for Biostatistics also worked on the study, which was supported by the National Heart, Lung and Blood Institute and the U.S. Department of Health and Human Services.\nThe researchers used bone-mineral-density data from a subset of 10,290 women.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There is no unjustifiable language in the release.", "answer": 1}, {"article": "It\u2019s of phenomenal significance in that regard,\u201d he told Reuters.\nExperts described the study results as phenomenal and said the device, developed by German researchers, could eventually change the lives of up to 200,000 people worldwide who suffer from blindness due to a degenerative eye disease called retinitis pigmentosa.\nRobert Maclaren, a professor of Ophthalmology at Britain\u2019s Oxford University and a consultant retinal surgeon at the Oxford Eye Hospital, who was not involved in this trial, said he was \u201cvery excited\u201d by Zrenner\u2019s results.\nZrenner said further trials of the implant should be completed in two to three years and if those proved successful the device could be on the market and available for thousands of patients in about five years\u2019 time.\nThe implant device, which sits completely within the eye, is a tiny plate, measuring just 3 mm squared and a 10th of a millimeter thick, which has around 1,500 tiny light sensors connected to amplifiers and electrodes.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on\u00a0a news release, and, in fact, this news release from the University of Tubingen contains more interesting information about the study than the story.", "answer": 1}, {"article": "The average age of children in the study was 7.\nIt wasn't clear if this impairment would show up in a test of the sniff response, however.\nThe findings suggest that a sniff test could be quite useful in the clinic, although the researchers emphasize that their test is in no way ready for that yet.\nThey also want to find out how early in life such a test might be used.\nThe findings suggest that non-verbal tests related to smell might serve as useful early indicators of ASD, the researchers say.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release did not over-sell the findings, and was very careful to point out the work that needs to be done before a clinical test can be put into widespread use.", "answer": 1}, {"article": "Details of the cases are documented in the paper \"Artemisia annua dried leaf tablets treated malaria resistant to ACT and i.v.\nIn effect, the dried leaves constitute a robust natural combination therapy, one whose benefits far surpass those of ACT and other combination drugs.\nThis supply chain helped produce the tablets used to treat the 18 patients in the Democratic Republic of Congo.\nThe 18 patients, ranging in age from 14 months to 60 years, did not respond to the standard ACT treatment, and all lapsed into severe malaria, defined by symptoms that can include loss of consciousness, respiratory distress, convulsions, and pulmonary edema.\n(Weathers noted more than 100 other drug-resistant patients also have been successfully treated with DLA tablets.)\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release uses the word \u201ccure\u201d in the headline and text without giving clear evidence that this is a universal cure for drug-resistant malaria. The release doesn\u2019t tell us how long patients were followed after treatment, and we don\u2019t know if they relapsed months or years later.", "answer": 0}, {"article": "Journal of Child and Adolescent Psychopharmacology.\nBoth findings reaffirm the potential that mindfulness therapy could bring to the table.\n\"These integrative approaches expand traditional treatments and offer new strategies for coping with psychological distress,\u201d said the study\u2019s co-author Sian Cotton, director of the UC's Center for Integrative Health and Wellness, in a statement.\nAfter the 12-week experiment, Cotton and his colleagues found mindfulness therapy increased neural activity in a part of the brain that plays in a role in processing cognitive and emotion information known as the cingulate.\nThe therapy was also able to increase brain activity in the insula, a part of the brain that helps monitor how the body feels psychologically.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story gets a Satisfactory grade here but fails in spirit. It draws extensively from a University of Cincinnati news release. However, because it acknowledges the source of the quotes used and doesn\u2019t appear to plagiarize any other content from the release, it technically meets the standard for this criterion.", "answer": 1}, {"article": "\"So they will be able to make a very personal decision without anyone realizing it,\" he said.\nIf larger clinical trials confirm the results, the test could become standard practice, Patsalis said.\nIt also can identify Down syndrome in the 11th week of pregnancy, early enough for a woman to end her pregnancy if she chooses, Patsalis said.\nDr. Brian Skotko, clinical fellow in genetics at Children's Hospital Boston and a spokesman for the National Down Syndrome Society, said this study has widespread implications for the incidence of Down syndrome.\nThe new test eliminates the risk of miscarriage, Patsalis said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not rely solely on a news release.", "answer": 1}, {"article": "Uridine, which is produced by the liver and kidneys, is also found in some foods as a part of RNA, which helps make protein in the body.\nTo be effective, all three compounds must be given together, the researchers said.\nWhether Souvenaid will slow the progression of Alzheimer's isn't known.\nTo show the drink's effect on the brain, patients underwent electroencephalography (EEG) throughout the trial.\nThere is, however, a longer trial going on that might answer that question, Wurtman said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not rely solely on a news release.", "answer": 1}, {"article": "Specific means that the test is unlikely to be positive if cancer isn\u2019t really present.\nThe two tests together appeared to generate both sensitive and specific results.\nThe company that developed the test, Gen-Probe, helped to pay for the study, and several authors said they had a personal financial interest in the technology.\nSensitive means it\u2019s unlikely that the test would miss a case of cancer.\nNow that the researchers have validated the test, further studies in larger, more diverse populations will be important to understand how it is best used.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story does not appear to rely solely on a news release.", "answer": 1}, {"article": "But researchers controlled for these and many other factors, and found that compared with women who ate no walnuts, those who consumed 8 ounces of walnuts or more a month reduced their risk for Type 2 diabetes by 24 percent.\nWalnuts may have some unique benefits.\u201d\n\nThe study was supported with grants from the National Institutes of Health and the California Walnut Commission.\nThey found 5,930 cases of Type 2 diabetes.\nEating walnuts may reduce the risk for Type 2 diabetes in women, a large new study concludes.\nThe scientists, writing in the April issue of The Journal of Nutrition, used dietary and health data on 138,000 women participating in a large continuing study of women\u2019s health.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Not applicable because we\u2019re unsure.\u00a0 There was so little information provided in the story, it is not clear how much independent reporting took place.", "answer": 2}, {"article": "Men who only father daughters appear to be at greater risk of developing prostate cancer, according to a study published last week in the Journal of the National Cancer Institute.\nThe study found that hypochondriacs who got cognitive behavior therapy, which encourages people to challenge the validity of their disabling beliefs, also improved -- as much as those given the drug.\nThe study was published this month in the American Journal of Psychiatry by researchers at Leiden University in the Netherlands and other Dutch centers.\nResearchers suggested that a combination of this talk therapy and medication might be especially effective.\nIn the first controlled study that compared a group of hypochondriacs given the drug with a group that got psychological talk therapy and another group that received sugar pills, the medication significantly reduced people's fears about imaginary illnesses.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can't judge if the story relied solely or largely on a news release.\u00a0 No one is quoted.\u00a0 It appears to be drawn directly from an article in the American Journal of Psychiatry and may have been spawned by a news release.\u00a0\u00a0 ", "answer": 2}, {"article": ".\nDuring this time, the couples were instructed to use other non-hormonal birth control methods.\nThe contraceptive method was effective in nearly 96 percent of continuing users.\nOnly four pregnancies occurred among the men's partners during the efficacy phase of the study.\nHealthcare professionals gave the men two injections every eight weeks.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release does not engage in sensational language.", "answer": 1}, {"article": "Pulse pressure is the difference between systolic and diastolic (bottom number) in blood pressure readings.\nThe researchers conclude that mangos may be a heart-healthy fruit that may help play a role in reducing the risk of cardiovascular disease.\n\"This is the first study to demonstrate positive vascular effects of mango intake in humans,\" said lead researcher Robert Hackman, with the UC Davis Department of Nutrition.\nAdditionally, some of the participants showed favorable changes in the production of breath methane, an indication of the potential influence on gut fermentation.\nYet once mango was consumed, systolic blood pressure was significantly lower two hours after mango intake compared to baseline values.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The headline states that \u201cmangoes helped improve cardiovascular\u2026health in women.\u201d But the release doesn\u2019t support that. The release tells us that healthy women who ate mango had reduced systolic blood pressure two hours after eating mango. It doesn\u2019t tell us how much of a reduction there was. It doesn\u2019t tell us whether the same result might occur with a different type of food. And it\u2019s not clear that reducing the blood pressure of women who had healthy blood pressure is necessarily an improvement of cardiovascular health.", "answer": 0}, {"article": "Eating more fiber during adolescence was linked to a 16 percent lower risk of breast cancer overall, and a 24 percent lower risk of breast cancer before menopause.\nEating more fruits and vegetables was especially beneficial, the researchers said.\n\"The results of this study emphasize the role of an early life high-fiber diet on prevention of breast cancer in later life.\n\"Having the recommended 25 to 30 grams of fiber daily would decrease the risk by 30 percent and potentially even greater with higher fiber intake,\" Farvid said.\nDr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital, in New York, told CBS News, \"It lends support to the fact that we need to encourage people to start healthy habits earlier on.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story definitely incorporated original reporting.", "answer": 1}, {"article": "Since 1998, the Food and Drug Administration has required that breakfast cereals, breads, rice, pasta and other grain products made with enriched flour come fortified with folic acid.\nBut there's one notable exception to this success story \u2014 Hispanic women \u2014 and researchers think the reason may lie in a staple of their diet: tortillas.\n\"The FDA is concerned that the breakdown of folic acid in corn masa flour could yield a substance that raises concerns about safety.\"\n\"The story of folic acid is one of the great public health stories of \u2014 ever,\" says Dr. R.J. Berry, who works with the Division of Birth Defects and Developmental Disabilities of the Centers for Disease Control and Prevention in Atlanta.\nSo why does the FDA currently ban dosing corn masa flour with folic acid?\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story quotes multiple sources and does not rely on a news release.", "answer": 1}, {"article": ".\nThe association has strict policies to prevent these relationships from influencing the science content.\nThe association makes no representation or warranty as to their accuracy or reliability.\nThe Dallas-based association officially launched in 1998 as a division of the American Heart Association.\nThe current results demonstrate the importance of prompt imaging and treatment of patients with clot-caused stroke, even in those who wake up having experienced a stroke or who for other reasons are not identified in the first few hours after the onset of symptoms.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "No unjustifiable language was used; the language of the news release was appropriately cautious and reinforced multiple times that even small delays in treatment could contribute to more brain damage.", "answer": 1}, {"article": "score of 0.9 or higher at the age of 50.\ntesting is not helpful for men with 10 years or less of life expectancy.\nThey still have a very low individual risk of dying from prostate cancer, judging from the new data.\nA man with a higher score may want to do more frequent testing.\nStill, the absolute risks for men with elevated scores were lower than might be expected.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\u00a0Does not appear to relay solely on a news release.", "answer": 1}, {"article": "The research team, led by Cleveland Clinic's Eric Klein, M.D., conducted a multicenter prospective study of 261 men scheduled for prostate biopsy at five academic and community centers in the U.S. enrolled between August 2015 and December 2016.\n\"Despite criticism, PSA has transformed the landscape of early detection, screening, and management of prostate cancer in the last few decades,\" said Dr. Klein, chair of Cleveland Clinic's Glickman Urological & Kidney Institute.\nThe IsoPSA test was developed by Cleveland Diagnostics, a company co-founded by Cleveland Clinic, in which it has financial interest.\nDr. Klein has no personal financial interest in the company.\nDr. Stovsky has a leadership position (Chief Medical Officer) and investment interest in Cleveland Diagnostics, Inc.\n\nCleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release does not include unjustifiable, sensational language.", "answer": 1}, {"article": "\"But I will say that I don't know of any study looking at acupuncture and vision.\nNeither treatment prompted significant side effects, the authors said.\nDr. Richard Bensinger, a Seattle-based ophthalmologist and spokesman for the American Academy of Ophthalmology, said that the finding is \"certainly suggestive and worth following up.\"\nThere are studies based on symptomatic things such as pain, and I think there's pretty good evidence that it does have benefit in that respect.\nBut for vision therapy this is the first I've heard of it, and I don't know that anyone has ever tried this before.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story was not based on a news release.", "answer": 1}, {"article": "\"They say, 'Oh my God, this has changed my life.\nIn their editorial, Woloshine and Schwartz said Sprout and others put pressure on FDA to approve the drug.\nShe said she and her colleagues included the results of the unpublished studies because sometimes negative studies of a drug don't get published.\nStreicher, an associate professor of clinical obstetrics and gynecology at the Northwestern University Feinberg School of Medicine, said the study drew \"erroneous conclusions.\"\nDr. Loes Jasper, one of the authors of the Dutch analysis, said she and her colleagues removed the results from that study and still found that Addyi's affects were minimal.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Other than Dr. Lauren Streicher and the patient Jodi Cole who seem to keep appearing and reappearing in other stories on this study, there is no evidence of being overly-reliant on a press release.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/29/national/w155455S59.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not appear to rely solely or largely on a press release.", "answer": 1}, {"article": "\"There was no significant difference,\" Boden said.\nThe findings underscore the danger of rushing to adopt a procedure before careful studies have been conducted to fully determine its benefits, Boden and others said.\nAlthough about one-third of patients who initially got medical treatment later turned to angioplasty, the findings show how much medical treatment of heart disease has improved, Boden said.\n\"This study was limited to a fairly select group of patients with very stable symptoms.\"\nThose concerns had led doctors to curtail their use of the newer devices, and the new findings are expected to have a similar effect on angioplasty overall.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Since several sources were used, it is safe to assume that this story did not rely solely or largely on a news release.\u00a0 ", "answer": 1}, {"article": "\"With my technique, there is a much more limited scar and it limits the scarring in the fold of the breast, which is usually the most uncomfortable. By the third day, most women are up and around and doing most of their activities.\"", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There does not appear to be a press release linked to this story. ", "answer": 2}, {"article": "As with each of our next generation OTC drug products, we intend to license HSRx 2121 to a leading marketing entity that has the resources and expertise to maximize sales, here and abroad,\" Parise said.\nThe HSRx product demonstrated superior treatment performance throughout the entire clinical study.\nEach product is subjected to independently conducted clinical trials against a current market-leading product to demonstrate its ability to deliver superior treatment outcomes with reduced side effects.\nTUCSON, Ariz., Nov. 18, 2015 /PRNewswire/ -- In a clinical trial conducted for HSRx Group, an Arizona-based biopharmaceutical company, the OTC acne treatment product HSRx 2121 significantly outperformed a market-leading product in reducing acne count, redness and severity.\nHSRx Group has developed a portfolio of next generation OTC drug products for many categories of common health conditions.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "It is inappropriate and unjustifiable to include acne \u201camong the 10 most prevalent human infectious diseases\u201d when threats like HIV/AIDS, tuberculosis, influenza, Ebola are deadly, unlike acne, and in a whole other class of disease.\nThe strong claims made without providing data on the comparison product are completely unjustified.\n\u201cThe HSRx product demonstrated superior treatment performance throughout the entire clinical study.\u201d\nWe also get hyped statements about NASA acne warnings, and we\u2019re troubled by the highlighted outcome being the profit potential and NOT patient-oriented outcomes (and reduction in suffering).", "answer": 0}, {"article": "\"It is very big.\nVeridex launched the first commercial test using circulating tumor cell technology in 2004, the company said.\nCapturing and counting those cells can provide information to patients and doctors about prognoses with certain types of metastatic cancers, the statement said.\nResearchers hope the test will be used by oncologists as a diagnostic tool aimed at discovering as early as possible if a cancer has spread, as well as by researchers in coming up with new drug therapies.\nToner said you are likely to find just one circulating tumor cell in 5 to 10 billion blood cells.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\nThis story is merely a condensed version of a news release. Some quotes appear to be lifted directly from the news release. \n\u201cVeridex, LLC Announces Collaboration to Develop Next-Generation Circulating Tumor Cell (CTC) Technology with Massachusetts General Hospital\u201d http://www.jnj.com/connect/news/all/Veridex-LLC-Announces-Collaboration-to-Develop-Next-Generation-Circulating-Tumor-Cell-Technology-with-Massachusetts-General-Hospital", "answer": 0}, {"article": "People getting the combination of immunotherapy and chemotherapy were 51% less likely to die after 10.5 months than people receiving chemotherapy alone.\nNearly 300 people were randomly assigned to receive either the combination of the immune-based drugs or the traditional chemotherapy treatment.\nDoctors can also determine if a person\u2019s lung cancer is genetically vulnerable to the checkpoint inhibitor drugs tested in the current study.\nThe studies involve a group of immune-based cancer drugs called checkpoint inhibitors, which are designed to rip away the molecular cloak behind which cancer cells hide from the immune system.\nBased on their success in treating skin cancers, scientists are now studying this group of drugs in a number of other cancers, including tumors in the lung.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story doesn\u2019t appear to rely on a news release.", "answer": 1}, {"article": "Too much insulin can cause low blood sugar (hypoglycemia), which can be life-threatening, while too little causes the serious damage of diabetes such as kidney, vision and circulation problems.\nHowever, teenagers did not see a benefit, probably because they were less likely to wear the device, Tamborlane said.\nAll patients felt self-conscious wearing the device, Ritholz noted.\nPeople who used the device more than six days per week saw improvement, regardless of age, he added.\nThese results were similar to findings in children where the system extended the amount of time spent at target blood sugar levels, he added.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story does not appear to rely overly on the ADA press release. However, we see no evidence of any sources used outside the cited teleconference, which seems like a press briefing. Because of our uncertainty about how much independently vetted reporting took place, we\u2019ll rate this not applicable. ", "answer": 2}, {"article": "Floaters become more common with age, and although some people simply get used to them, others are bothered by them or their vision is impaired.\nThe new research was led by Dr. Chirag Shah and Dr. Jeffrey Heier of Ophthalmic Consultants of Boston.\nA limitation of the study was its small size and short follow-up period, the researchers said.\nHowever, Shah and Heier said there are few published studies on the laser treatment's effectiveness in treating floaters.\nThere were no differences between the two groups in harmful side effects, according to the study, which was published July 20 in JAMA Ophthalmology.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no indication that this story relies on the news release.", "answer": 1}, {"article": "A new generation of treatments for severe eczema is on the horizon, which doctors say could help millions more patients gain relief from chronic outbreaks of the oozing, itchy and sometimes debilitating rashes that come with the disease.\n\nAt least two new eczema medicines could be approved by the U.S. Food and Drug Administration in 2017, and a half-dozen more drugs are being tested in clinical trials.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "An existing release from Regeneron takes a deep dive into the Phase 3 trials;\u00a0the story does not.", "answer": 1}, {"article": "Hair changes about as fast as grass grows, which is to say it\u2019s extraordinarily slow and not visible to anyone checking impatiently in the mirror every day.\nFor now, Maryanne Senna, a dermatologist and the director of the Hair Academic Innovative Research Unit at Massachusetts General Hospital in Boston, said the best she can tell patients who ask \u2014 and a lot of them do \u2014 is that Harklinikken won\u2019t do any harm.\nClients must also use the company\u2019s shampoo, conditioner and styling products, forsaking all others \u2014 a psychological as well as a financial buy-in, Dr. Senna said.\nThat\u2019s the most Mr. Skjoth will say about it.\nOne is how much emphasis the company places on compliance, the major stumbling block in the efficacy of any treatment, said Dr. Senna, an author of studies on the subject.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "Prostate cancer remains the second leading cause of cancer death among men in the U.S., with nearly 30,000 deaths annually.\nThe study showed that 12 months after the draft guidelines were published diagnoses of new low risk cancers had fallen by 37.9%, and continued to fall more rapidly than other disease risk strata, suggesting that, in this regard, the USPSTF recommendation had its intended effect,.\nThe uncertain benefit of PSA based screening, combined with the complications associated with treatment, led the USPSTF to conclude in October 2011 that the harms of PSA based screening outweighed the benefits, leading it to recommend against regular screening.\n\"While some of the effects of this guideline may be beneficial in terms of reducing harms of over diagnosis and overtreatment, the reduction in intermediate and high risk cancer diagnoses raises concern for delayed diagnoses of important cancers associated with inferior cancer outcomes,\" noted Dr. Barocas.\nThis study helped quantify the potential benefits (reduced harms of over diagnosis and overtreatment of low risk disease and disease found in elderly men) and potential harms (missed opportunities to diagnose important cancers in men who may benefit from treatment).\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The headline is arguably unjustified, but since we\u2019ve already dinged the release for that infraction above, we\u2019ll award a Satisfactory here since we see nothing else that\u2019s egregious.", "answer": 1}, {"article": "About 35 million Americans have migraines, according to the American Headache Society, and about 20% to 30% of these patients have headaches that are preceded by visual or other sensory warning signs.\nDrugs commonly used in the treatment of severe headaches are generally not considered effective in the aura phase of migraine attacks, and many patients want to treat their migraines without using drugs, neurologist and headache specialist Richard B. Lipton, MD, tells WebMD.\nCompared to patients who got sham treatments, more patients treated with the experimental device, known as single-pulse transcranial magnetic stimulation (sTMS), were pain-free two hours later.\n\"Some people don't tolerate the drug treatments very well and others just want to avoid them.\"\nLipton directs the Montefiore Headache Center at the Albert Einstein College of Medicine in the Bronx.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does not appear that the story relied soley on a news release.", "answer": 1}, {"article": "Men whose prostate cancer comes back after surgery are more likely to survive if, along with the usual radiation, they also take drugs to block male hormones.\n\nThe finding, published Wednesday in The New England Journal of Medicine, comes from a long-running study that experts say will help clarify treatment for many patients.\n\nAfter surgery to remove the prostate, more than 30 percent of men have a recurrence, and until now there has not been clear evidence about the best way to stop the disease from killing them. Most are given radiation, but prescribing drugs to counter the effects of male hormones has been inconsistent.\n\nThe study, paid for by the National Cancer Institute, showed that among men who received radiation and hormonal treatment, 76.3 percent were still alive after 12 years, compared to 71.3 percent who had radiation alone.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is obvious original reporting in the story.", "answer": 1}, {"article": "Commenting on the next stage of the research, she said: \u201cIn the larger phase II trial we\u2019ve recruited 140 women with relapsed ovarian cancer across the U.K. to standard chemotherapy (paclitaxel) or paclitaxel in combination with vistusertib.\nDr. Dean A. Fennell, professor and consultant in thoracic medical oncology at the University of Leicester, who was not involved in the study, told Newsweek the study presents an \u201cexciting result.\u201d\n\nHe was particularly surprised by the magnitude of the response triggered by vistusertib combined with paclitaxel, which is closely related to standard chemotherapy.\nCombined with paclitaxel chemotherapy, the scientists were able to block cancer cells from harnessing p-S6K.\nThat is why the patients\u2019 tumors shrunk, the study suggests.\nIt built on previous research by the ICR that showed ovarian cancer cells resistant to treatment generally have higher levels of a molecule called p-S6K, which aids the growth of the disease.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story drew from but did not rely on an enthusiastic ICR news release, which said the drug combination had \u201cexciting\u201d results.", "answer": 1}, {"article": "Glioblastoma is the most common and aggressive malignant brain tumor in adults.\nThe Duke researchers have started a follow-up study combining the treatment with a chemotherapy drug to try to improve the results.\nThe treatment can cause a dangerous swelling in the brain that can lead to seizures and other complications, the researchers found.\nMuch more follow-up research is needed to better assess and hopefully improve the treatment's effectiveness, the researchers say.\nTwo patients have survived more than six years, Bigner says.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story drew from a Duke news release but refrained from adopting the news release\u2019s assertion that the poliovirus \u201csignificantly improved long-term survival for patients with recurrent glioblastoma.\u201d", "answer": 1}, {"article": "\"I say, 'Go for it!'\nForeman wrote a column about her surgery.\nThat, he says, will be the next big advance in sinus treatment.\nBut surgery rarely cures them.\nBut she didn't hurt very much.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It is clear that this story didn\u2019t rely on a news release.", "answer": 1}, {"article": "To learn more, visit njhealth.org.\nResearchers hope that using the bacteria-infused cream will offer a long-term solution where other treatments fall short.\nExperts say there is more research to be done, but that the goal of the trial is to discover the best combination of bacteria to clear eczema from the skin and then make it available to patients as a prescription cream.\nA new clinical trial is testing a natural treatment that researchers hope will provide a long-term solution for those dealing with the dry, itchy and painful skin that comes with chronic eczema.\nWhile it may seem counterintuitive to treat bacteria with more bacteria, experts say this approach seeks to restore the natural microbial balance of healthy skin.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t rely on sensational terms so we\u2019ll give it a Satisfactory.\nThe unwarranted claims, such as alluding to a possible \u201clong-term solution\u201d for eczema without providing any evidence, are addressed under other criteria.", "answer": 1}, {"article": "GLYX-13 targets parts of the brain linked to learning and memory.\nThe clinical trial included about 120 patients, Moskal said.\nA new trial that makes use of the drug in pill form is slated to get under way next year, Moskal noted.\nThe study received funding from the U.S. National Institutes of Health among others.\nThe drug was so well received by patients that many who were in the trial have called asking to be in any further trials, Moskal said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Although the story uses similar wording and information from the Northwestern press release, there is evidence of original reporting, shown by the independent comment by Dr. Bryan Bruno.", "answer": 1}, {"article": "A California company has developed a genetic test that can predict whether patients treated for early-stage colon cancer are likely to suffer a recurrence of the disease, the third leading cause of cancer deaths in the U.S.\n\nThe results of the test, based on an analysis of seven different genes found in colon-cancer tumors, yield a score that tells whether patients are at low, intermediate or high risk of having the disease come back after it is removed through surgery.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to draw excessively from the company\u2019s press release. ", "answer": 1}, {"article": "For nine months, the developing fetus is attached to its mother by the umbilical cord.\nAndersson's study marks the first time researchers have followed children to see whether the clamping makes a difference later in life.\nBut those doctors overestimated the benefit to the mother and didn't look at the impact their change had on the babies, said Heike Rabe, a researcher at Brighton and Sussex Medical School and University Hospitals, in the United Kingdom, who wrote an editorial accompanying the study.\nNow, research suggests there may be benefits to keeping mom and baby attached a few minutes longer.\nIron deficiency occurs in about one in six American babies, and it's more common among those clamped quickly, said Ola Andersson, a neonatologist and pediatrician at Uppsala University in Sweden, who led a study published today in JAMA Pediatrics.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story quotes an additional source and did not rely on a news release.", "answer": 1}, {"article": "Another difference is that Zostavax contains a live, weakened virus, making it unsuitable for people with poor immunity, whereas Shingrix contains a nonliving virus particle and may eventually be approved for those with compromised immunity, who are especially susceptible to a severe case of shingles.\nIf you\u2019re lucky you may detect the onset of shingles before the rash appears.\nI should tell you that the new vaccine is not exactly a walk in the park.\nMy only reaction beyond local soreness was an acid stomach for a day or two.\nYears ago when I went to bed with what had been a daylong gnawing irritation on one side of my back, I awakened in the middle of the night with the thought, \u201cI have shingles.\u201d First thing in the morning I got a prescription for the antiviral drug acyclovir, which halted progress of the disease.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to be based on a news release.\n\u00a0", "answer": 1}, {"article": "There are two common surgical approaches for a total hip replacement: anterior, which involves entering surgically through the front of the hip, and posterior, or entering surgically through the side or buttocks.\nA big attraction for her was the possibility of going home right after the surgery.\nAnd to be quite honest, if the pain is controlled and the patient is healthy and medically completely stable there is no reason for them to be in the hospital.\nThose who have risk factors must plan on staying overnight in the hospital, not going right home.\nShe had heard a lot of positive feedback from people who had undergone hip replacement surgery at her hospital.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes original interviews and other reporting.", "answer": 1}, {"article": "In the randomized studies, 44 men started on 12.5 mg of oral enclomiphene citrate daily, with 25 men being up-titrated to 25 mg; 42 men received a topical 1.62 percent AndroGel; and 41 men received a placebo.\nOver five months, patients had 10 clinic visits with one overnight stay.\nThe findings, which are published in BJU International, could change the way men are treated for low testosterone.\nWiley is a global provider of knowledge and knowledge-enabled services that improve outcomes in areas of research, professional practice and education.\nThe Company's website can be accessed at http://www.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There was no overtly sensational language used in this news release.", "answer": 1}, {"article": "Researchers have two main theories on why light therapy works.\nThe researchers said enough clinical evidence now supports mental health professionals recommending light therapy as a treatment for depression.\nAlthough the light therapy helped many patients, it provided the most benefit to those who were also taking the antidepressant.\nAbout 60 percent of those using light therapy with the antidepressant reported feeling almost back to normal, Lam said.\nThe research, published Wednesday in JAMA Psychiatry, is significant because major depression is one of the most common mental health disorders in the United States and one of the leading causes of disability worldwide.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because an independent source is quoted, we can be reasonably certain that this story went beyond any news release.", "answer": 1}, {"article": "Try to eat a pound of vegetables each day, half of which are cooked and the other half eaten raw, as well as half a pound of raw fruit.\nBut while certain common foods \u2014 like raw onions, garlic, citrus juices, coffee and chocolate \u2014 are likely to cause reflux in most people with the condition, Dr. Aviv and other experts emphasize that everyone is different, and trial and error is the most effective way to determine an individual\u2019s trigger foods and drinks.\nLosing weight is one of the best ways to find relief without having to rely on medication.\nHe said they should be taken 30 to 60 minutes before eating breakfast or dinner (or both), but not used as an \u201cantidote\u201d to consuming acidic foods.\nIf adopting the above measures fails to fully control acid reflux, taking a proton pump inhibitor may also be needed.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to be based on a news release.", "answer": 1}, {"article": "June 28, 2010 -- Cholesterol-lowering statin drugs appear to reduce the risk for prostate cancer recurrence in patients who have had a surgical procedure called radical prostatectomy.\nBut the fact that the fewest recurrences were seen in men who took the highest statin doses is compelling, says senior investigator Stephen J. Freedland, MD, of the Duke Prostate Center.\n\u201cStatin users may see their doctors more often and may be more health conscious in general, and it has been suggested that this could explain the observed reduction in risk,\u201d Freedland tells WebMD.\nThose who took the highest doses saw their recurrence risk drop by half.\nThe research does not prove that taking cholesterol-lowering drugs directly slows the growth and progression of prostate cancer.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does read a lot like the news release. But it\u2019s clear the interviews were fresh, and at least one outside source was consulted. http://www.cancer.duke.edu/modules/news/article.php?storyid=257", "answer": 1}, {"article": "\"They have a lot of promise and are potentially very important,\" said Katherine Hamilton, a headache specialist at Penn Medicine. The drugs, which are injected under the skin, offer hope for patients who have not responded to other treatments, but Hamilton said that what is \"potentially even more clinically relevant is they have a lower side-effect profile\" than other medications commonly used for migraine. She added, though, that it remains to be seen how patients who take them for long periods will fare. As new drugs, their long-term impact is not yet known.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not appear to rely on a news release.", "answer": 1}, {"article": "Traditional heart catheterization through a vein in the neck can take 20 minutes or longer.\nBut because it's self-contained, the catheter theoretically should provide little margin for contamination that can lead to infection.\nHe recently procured a bank loan agreement and is hoping the award recognition and hospitals' willingness to try the catheter will attract a venture capitalist.\nHe plans to bear the cost of any prostheses the veterans need to work on the catheters.\nReavill plans to hire 13 to 20 disabled vets to get the production off the ground \u2014 with the goal of hiring up to 18,000 if the device goes national.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because other sources were quoted, it does not appear that the story relied solely on a news release.\n\u00a0", "answer": 1}, {"article": "The results of the Women's Health Initiative (WHI)--the largest, most scientifically rigorous study of older women's medical issues ever conducted--continue to startle researchers, confuse the public and frustrate headline writers. Case in point: last week's report that taking estrogen for seven years does not increase the risk of breast cancer for many women. There is a lot of good news in that finding, as well as some important caveats.\n\nIn many ways, the story began four years ago when researchers halted a different part of the WHI--one that looked at the long-term health effects of taking the hormone combination estrogen and progestin...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does not appear that the story relied solely or largely on a news release. ", "answer": 1}, {"article": "Diabetes, high cholesterol, high blood pressure, stroke and being overweight jeopardize vascular health.\nBy detecting Alzheimer's disease long before symptoms emerge, Dr. Nagele hopes those with disease-related autoantibody biomarkers will be encouraged to make beneficial lifestyle changes that may help to slow development of the disease.\n\"I can't think of a single patient who wouldn't take steps to prevent the progression of Alzheimer's if they could directly affect their prognosis.\"\nWhile the cause of Alzheimer's remains elusive, it is clear that maintaining a healthy blood-brain barrier is a critical preventative measure.\nDr. Nagele's work focuses on utilizing autoantibodies as blood-based biomarkers to accurately detect the presence of myriad diseases and pinpoint the stage to which a disease has progressed.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We find it unacceptable to drop in this completely-unsupported-by-any-evidence line in the middle of the news release:\n\u201cThe blood test developed by Dr. Nagele has also shown promise in detecting other diseases, including Parkinsons\u2019s, multiple sclerosis and breast cancer.\u201d", "answer": 0}, {"article": "That 1.7 percent difference is not considered statistically significant.\nAbbott Laboratories' newly approved Absorb stent comes with one important caveat: it hasn't yet been shown to be safer than older metal implants.\nThe new stent is designed to gradually dissolve over three years.\nDoctors who studied Absorb said it may take several years before its advantages become clear.\nOther complications with the new device include allergic reactions, infections and internal bleeding.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story\u2019s emphasis on the lack of long-term safety data is a strong departure from the information provided in the Abbott Labs press release.", "answer": 1}, {"article": "\"People say, 'What's the harm in screening?'\nBut they drew strong criticism from others who are convinced that routine screening is necessary.\nIt did find enough new data to recommend for the first time against screening for older men.\nThe recommendations come at a time when doctors are increasingly questioning whether many tests, drugs and procedures are being overused, unnecessarily driving up health-care costs and exposing patients to the risks of unneeded treatment.\nThe new review of the scientific literature found no evidence to alter that assessment for younger men.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not \u00a0rely exclusively on a press release as it includes numerous quotes from a variety of experts with differing view points.", "answer": 1}, {"article": "You've probably heard about it \u2014 maybe you even remember seeing it once \u2014 but you're not really sure what it is or even where to find it.\n\nThe female condom (FC2), or internal condom, is a non-hormonal barrier method of birth control. But instead of going on a penis, it goes in a vagina, which is why it's also sometimes referred to as an internal condom. For more information, BuzzFeed Health spoke with two experts who could demystify this lesser-known contraceptive:\n\n* Dr. Harry Fisch, clinical professor of urology and reproductive medicine at Weill Cornell Medical College, and chief corporate officer of Veru Healthcare, which distributes FC2\n\n* Dr. Lauren Streicher, associate clinical professor of obstetrics and gynecology at Northwestern University\u2019s Feinberg School of Medicine", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story contains fresh interview material from scientists and does not rely on a news release.", "answer": 1}, {"article": "The California Walnut Commission offices are located at 101 Parkshore Dr., Ste.\nAs this study was conducted on animals, results cannot yet be implied for humans.\nThis is the first study that evaluates whether walnut consumption can cause changes to micro-ribonucleic acids (miRNA), the nucleotides that are involved in altering gene expression.\nTumor growth rate was also significantly slower in the walnut group compared to the control group.\nThe CWC is mainly involved in health research and export market development activities.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "While we aren\u2019t happy with the headline, we think this release squeaks by because the main text is accurate and we applaud the first sentence clearly labeling it an \u201canimal study.\u201d\nThe release clearly avoids any sensationalized verbiage, a feat to be lauded in cases like this when an inference of a simple activity \u2014 like eating nuts \u2014 might lead a reader to jump to wrong conclusions.", "answer": 1}, {"article": "Fish-oil supplements don't appear to help pregnant women prevent post-partum depression or boost the baby's brain development as previously believed, according to a large trial published Tuesday in the Journal of the American Medical Association.\n\nThe 2,400-woman, randomized study complicates the advice for pregnant women. It adds to a body of mixed research on some potential benefits of the popular omega-3 fatty acid known as DHA, or docosahexaenoic acid. DHA, which can move from the mother to the baby during pregnancy, accumulates...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely on a news release. ", "answer": 1}, {"article": "A number of new multiple-sclerosis medications are beginning to hit the market that promise to make it easier for patients to control flare-ups of the disease and slow its progression.\n\nThe drugs, designed to be taken orally, represent a new generation of treatment for MS. Currently, people with the disease can choose from a range of drugs that are administered by injection.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "No, the story quotes four people and does not appear to rely on a release.", "answer": 1}, {"article": "Researchers say this allows patients to re-examine traumatic memories.\nHe struggled to sleep.\nA handful of medications meant to help left him feeling like a zombie, and he gave them up.\nHe was contemplating suicide when he tried MDMA.\n\u201cThe MDMA alone or the therapy alone don\u2019t appear to be as effective,\u201d Dr. Mithoefer said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not rely on the news release.", "answer": 1}, {"article": "When I began training last year for my first marathon, my running partner Dave Freedholm, an experienced amateur distance runner, impressed on me the need to vigilantly avoid dehydration. His drink of choice was Accelerade. Like Gatorade, the original sports drink, it's packed with sugars and sodium to provide energy and replace the electrolytes depleted in sweat. But it also contains protein, which he said would help my muscles repair themselves more quickly after the punishing training runs he took me on.\n\nSure enough, I never felt much pain until after the marathon itself, and even then I recovered within a couple of days...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no way to know if the story relied on a press release as the sole source of information.", "answer": 2}, {"article": "\"Now they tell me, 'You never say 'What?'\nThe implant is permanent.\nEven with one implant, Merlo called the results \"surreal.\"\nOften, it meant only being able to do one thing at a time, explained the mother of three young children.\nSince her teens, Lesa Merlo, of Hinsdale, had learned to compensate as her hearing declined.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not use the exact wording from a Loyola University Health System news release, but the content and language are similar. Same patient. Out of 40 patients implanted at Loyola, why did the story use the same patient as the one profiled in the news release? There was no new information or sources in the story than what appeared in the news release.\u00a0 For that reason, we rule this unsatisfactory.", "answer": 0}, {"article": "Acupuncture designed to treat depression appears to improve symptoms in pregnant women, suggesting it as an alternative to antidepressant medication during pregnancy, a study found.\n\nThe study, published Monday in the journal Obstetrics & Gynecology, is the largest to date examining the effectiveness of acupuncture to treat depression in pregnant women. It was funded by a grant from the government's Agency for Healthcare Research and Quality. \"Acupuncture that we have tested works for pregnant, depressed women,\"...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no way to know if the story relied on a press release as the sole source of information.", "answer": 2}, {"article": "\"In most cases, a recall doesn't mean you have cancer,\" says Hubbard, a biostatistician at the Group Health Research Institute in Seattle.\nAfter 10 years of annual screening, more than half of women will be called back at least once for another mammogram.\nThe study wasn't really designed to answer the question of which screening regimen is best, study researcher Rebecca Hubbard, PhD, says.\nThe task force says the decision to start regular, biennial mammograms before age 50 should be an individual choice based on each patient's situation.\nThose false-positives may cause inconvenience and anxiety, and biopsies can cause pain and scarring, the researchers note.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There\u2019s no evidence that the story relied solely on a news release.", "answer": 1}, {"article": "\"In 2012, scientists took that particular frog and wanted to know why is it, why do these frogs keep milk fresh?\nThe urumin peptide could be a novel treatment since it targets the hemagglutinin, unlike current drugs on the market which target other parts of the virus, resulting in less impact, Jacob said.\n\"In this paper we screened 32 peptides, and the surprise was that four out of 32 had activity against the virus,\" Jacob said.\nIf those studies prove to be successful, human testing could be next.\n\"A majority of the peptides were antibacterial and some of them kill the things that make milk go bad.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The reporter for\u00a0the story has clearly gone into enterprise mode here, soliciting information from other sources and investing in substantial explanation of the peptide\u2019s modus operandi.", "answer": 1}, {"article": "\"This may simply indicate that some of the causes for preterm birth may not pre-exist before the pregnancy,\" Graves said.\nThe test may cost $150 to $250, Graves said.\nThe test wasn't as effective at 24 weeks of gestation.\nPhysicians will \"be able to use a simple blood test and then know that this woman is at increased risk or reduced risk of a preterm birth,\" said Graves, whose laboratory performed the research in the study.\nEven if the test is found to indicate that a birth will be premature, physicians would have limited options.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely solely on a news release.", "answer": 1}, {"article": "\u201cWe believe we can modify this test and make it much easier and simple... (and then) we can have something ready to be introduced into the clinic,\u201d he told Reuters in Nicosia.\nSince amniocentesis carries a small risk of spontaneous miscarriage \u2014 Patsalis put it at around one or two percent \u2014 scientists have been looking for new less invasive ways to test for Down\u2019s and other potential genetic problems.\n\u201cSuch a non-invasive approach will avoid the risk of miscarriages of normal pregnancies caused by current, more invasive procedures,\u201d the scientists wrote in their paper.\nIn a study in the Nature Medicine journal researchers from Cyprus said a trial on 40 pregnancies using the test, which involves analyzing the woman\u2019s blood to detect DNA differences between the mother and the fetus, showed it accurately predicted which fetuses were at risk of developing the syndrome.\nPhilippos Patsalis, medical director of the Cyprus Institute of Neurology and Genetics, who led the study, said the results were \u201cvery exciting\u201d and the test now needed to be trialed in a larger study of about 1,000 pregnancies, but could lead to changes in clinical practice within two years.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Not applicable because we can\u2019t judge the extent to which the story relied on a news release.\u00a0 We do know it quoted only one of the researchers.", "answer": 2}, {"article": "For further information, please contact:\nThe previously unrecognized PMS/PMDD benefit of PS Plus came about when 2,000 volunteers received and consumed Lipogen's PS Plus for brain health and stress management.\n\"Realizing the significance of this discovery, it encouraged us to further explore a product line for women's health utilizing Lipogen's proprietary phospholipid ingredients.\"\nOur patented solution is made of natural ingredients, is GMO-free, and can save significant health costs over medication alternatives, all with no reported side-effects.\"\n\"We also have begun an ongoing, double-blind, randomized, placebo-controlled clinical trial with daacro GmbH, Trier, Germany, to learn more how Lipogen's formulation can help alleviate PMS and PMDD symptoms.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The claims made were not supported by the evidence provided. Some of the unsupported or misleading claims:\n\u201cRealizing the significance of this discovery\u201d\n\u201cStrong results\u201d\n\u201cCan save significant health costs over medication alternatives\u201d\n\u201cNo reported side-effects\u201d\n\u201cLipogen guarantees its customers ingredient systems that are supported by the highest level of scientific data.\u201d What are these \u201cingredient systems\u201d and why didn\u2019t they include the \u201chighest level of scientific data?\u201d", "answer": 0}, {"article": "She said: \"My first thought on diagnosis was that I wanted to survive, I gave little thought to long term or late effects of treatment.\nIt is crucial that we tackle what is becoming an increasingly common form of cancer through research studies like this.\nThe results will be crucial to future large scale trials looking at optimum care for anal cancer patients.\nBy identifying a unique phenomenon, these results will be taken into account by future work and ultimately could lead to better diagnosis of tumour stage and thus better treatment.\nOur research team has done a wonderful job highlighting an important and as yet unrecognised issue in the staging of cases of anal cancer.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Some of the language, including the headline and quotes, is overblown and unattributed. There is no \u201cbreakthrough in treatment\u201d inherent in the study or the findings. And calling a finding a \u201cunique phenomenon\u201d without telling readers what, exactly, is the evidence for the phenomenon is unfortunate.", "answer": 0}, {"article": "Tissue plasminogen activator, known as tPA, can dramatically reverse stroke symptoms in those whose strokes are caused by blood clots and blockages, which account for an estimated 85 percent of all strokes.\nThe study, reported online Nov. 2 and in the December issue of the journal Radiology, reinforces results from similar research, Oppenheim said.\nDr. Wally Ghurabi, emergency department director at Santa Monica-UCLA Medical Center, said a group of ongoing studies there include a similar focus on MRIs and stroke.\n\"These results will be useful for centers that offer 24-hour access to acute stroke patients.\nOppenheim said the next step would be clinical trials to validate whether MRIs serve as a \"surrogate clock\" for stroke onset.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely solely or largely on a news release.", "answer": 1}, {"article": "An experimental Johnson & Johnson drug substantially reduced the severity of the inflammatory skin disorder psoriasis, according to a new study.\n\nJ&J is developing ustekinumab as part of a new category of drugs that targets proteins known as interleukins. In addition to psoriasis, J&J is studying the compound's potential to treat Crohn's disease, a gastrointestinal ailment.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s unclear if the story relied solely or largely on a news release, although only non-peer-reviewed company-sponsored research was discussed. ", "answer": 2}, {"article": "Digital tomosynthesis (DBT), or 3D mammography, does slightly better, detecting approximately 25 percent more cancers, or roughly 5 cancers in 1,000 women screened.\nTo put this in perspective, the cancer detection rate of mammography is roughly 4 cancers in 1,000 women who have a mammogram.\nBased on the results from Penn's study, the AB-MR may be a better option.\nThe School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2016 fiscal year.\nIn addition to Weinstein, additional authors include Mitchell D. Schnall, Elizabeth S. McDonald, Alice Chong, and Emily F. Conant.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release didn\u2019t appear to use unjustifiable language.", "answer": 1}, {"article": "Cirrhosis - the most severe stage, occurring after years of inflammation, where the liver shrinks and becomes scarred and lumpy; this damage is permanent and can lead to liver failure (where the liver stops working properly) and liver cancer\n\nIt can take years for fibrosis or cirrhosis to develop and the presence of this scarring predicts those people with the worse prognosis.\nWe currently have to rely on liver biopsy to measure fibrosis at its early stages - by examining a piece of the liver under the microscope.\nThis research was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre.\nIt's important to make lifestyle changes to prevent the disease from getting worse.\nIt is the first time an epigenetic signature in blood has been discovered which is diagnostic of the severity of fibrosis for people with Non-alcoholic Fatty Liver Disease (NAFLD).\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "\u201c\u2026this could be a replacement for a liver biopsy.\u201d That line is just under the headline, and it\u2019s an overreach. It could just as easily have said that this may not be a replacement for a liver biopsy \u2014 particularly given that the study looked at only 26 patients. Here\u2019s the thing: this research is really interesting. It could stand on its own, with all of the relevant qualifiers, and still be fascinating. It highlights some interesting things about how the human body works, how it responds to disease, and how researchers can monitor those changes to understand what\u2019s happening in our bodies. The release didn\u2019t need to go over top, but it did.\nA couple other examples of unjustifiable language:\n\u201cThis scientific breakthrough has great promise because the majority of patients show no symptoms,\u201d according to a quoted researcher. In the preceding paragraphs the test under development is described as \u201cproof of principle research,\u201d and \u201cthis first stage of research,\u201d and it\u2019s noted that the test is now being confirmed in a larger group of patients. We cry foul on the use of \u201cbreakthrough\u201d for this preliminary work.\n\u201c\u2026[G]reat promise because the majority of patients show no symptoms.\u201d We don\u2019t know that asymptomatic patients will benefit from early detection.", "answer": 0}, {"article": "DOI: 10.1016/j.ophtha.2016.01.036.\nThe research is also the first to show that diet and lifestyle may play a greater role than genetics in cataract development and severity.\nNewswise \u2014 SAN FRANCISCO \u2013 A diet rich in vitamin C could cut risk of cataract progression by a third, suggests a study being published online today in Ophthalmology, the journal of the American Academy of Ophthalmology.\nThese results make the study the first to suggest that genetic factors may be less important in progression of cataract than previously thought.\nHow vitamin C inhibits cataract progression may have to do with its strength as an antioxidant.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release includes an unsupported claim in the headline, \u201cEating Foods High in Vitamin C Cuts Risk of Cataract Progression by a Third.\u201d This is an observational study \u2014 a type of research that can\u2019t determine cause and effect. And so the active verb used here \u201ccuts risk\u201d is not appropriate to describe the results.\nWith that being said, this does not rise to the kind of flagrant language that we flag under this criterion.", "answer": 1}, {"article": "A serious mood disorder that affects as many as 1 in 7 women after childbirth, postpartum depression can lead to panic attacks, inconsolable sadness, and deep feelings of inadequacy.\nOne of the drug\u2019s most promising features: It appears to work quickly \u2014 some women in the study started experiencing relief after 24 hours.\nThe company has not submitted study data to federal regulators and isn\u2019t at this point seeking approval of the drug, known as SAGE-547, for postpartum depression.\nThe early results are \u201cpromising and exciting,\u201d said Dr. Allison Baker, a psychiatrist at Massachusetts General Hospital\u2019s Center for Women\u2019s Mental Health, but \u201cwe need to see replication of this data over a much wider range in terms of numbers.\u201d\n\nThe study is small and has not been peer-reviewed; Sage disclosed the results in a press release.\nSage\u2019s drug is designed to change the traffic patterns in the brain.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story clearly states that the study results were put out in a company news release. The story includes a quote from a company conference call, in addition to the numbers from the news release. However, the reliance on company sources undermines the value of the story.", "answer": 1}, {"article": "You\u2019re shepherding a fixed amount of resources across a large population and trying to do it according to some sort of evidence-based system.\u201d\n\nKaiser Health News is an editorially independent program of the Henry J. Kaiser Family Foundation, a nonprofit, nonpartisan health policy research and communication organization not affiliated with Kaiser Permanente.\nThat 19-member panel voted 10 to 5 last year that studies of the treatment showed it to be as good as or better than usual care for depression.\nWhile rTMS has ardent supporters, its effectiveness is still debated, and there is little evidence showing how long the results last.\nFive percent of the patients in the sham group became symptom-free.\nThe fee is generally about $10,000, but officials say they work with patients who can't afford that.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story is not based on a press release.", "answer": 1}, {"article": "According to the Centers for Disease Control and Prevention (CDC), birth defects caused by genetic disorders affect one in every 33 births in the United States.\nExperts say the couples are not the only people who benefit from these tests.\nA diagnosis before pregnancy may sound like a designer baby, but doctors say that\u2019s not the case.\nSpecialists now have a way to test the parents-to-be that may not only increase their chances of getting pregnant but also reduce the risk of them passing on certain genetic diseases.\nThese results have helped eliminate pre-term birth and hospitalizations for pre-term labor, and patients and families have better outcomes, he added.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "With comments from interviews with two sources, the story does appear to go beyond any news release. But the lack of any apparent news hook, and the fact that both quoted sources offer the services discussed in the story at their clinic, make us suspicious that impetus for this story is promotional rather than informational.", "answer": 1}, {"article": "Bone-health experts are making a new push to reduce rates of osteoporosis, with a particular focus on controlling the bone-wasting disease in men.\n\nAn important goal is to get greater numbers of men to be tested for osteoporosis when they come to a hospital or clinic with a fracture to the wrist, vertebrae or other bones that wasn\u2019t from a major accident or trauma. Doctors call this a fragility fracture\u2014one that results from a decrease in bone density.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story does not rely on any press release.[SJA: agree]", "answer": 1}, {"article": ".\nPublished early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings may help resolve controversies over soy's potential link to breast cancer outcomes.\n\"Because of this disparity, it remains unknown whether isoflavone consumption should be encouraged or avoided for breast cancer patients.\"\nTherefore, we can recommend women to consume soy foods because of soy's many health benefits,\" he wrote.\nOur findings suggest that survival may be better in patients with a higher consumption of isoflavones,\" said senior author Esther John, PhD, of the Cancer Prevention Institute of California.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release includes a comment from a related editorial that should be out-of-bounds for an observational study:\n\u201cWe now have evidence that soy foods not only prevent breast cancer but also benefit women who have breast cancer. Therefore, we can recommend women to consume soy foods because of soy\u2019s many health benefits,\u201d he wrote.", "answer": 0}, {"article": "Exercise, and in particular strength-training routines that develop muscles of the trunk and core, can help reduce pain and improve function, though many people avoid them for fear of doing further harm.\nThose in the third group served as \u201cself-care\u201d controls and received a book containing advice on back exercises and ways to reduce pain.\nDr. Sherman recommended taking an intensive stretching class, then establishing a routine at home.\n\u201cMore participants in the yoga and stretching groups were very satisfied with their overall care for back pain.\u201d\n\nDr. Sherman said that like many other therapies for low back pain, yoga probably would not work for everyone.\n\u201cThe smaller studies which hinted that yoga might be helpful all had problems one way or another.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article did not rely on a news release. Group Health in Seattle did release a lengthy press release on this study. But the New York Times article did not appear to use it.\n\n\n\n ", "answer": 1}, {"article": "Co-authors with Sharma, who presented the data at ASCO, are Petri Bono, Helsinki University Hospital, Helsinki, Finland; Joseph Kim, Yale Cancer Center; Pavlina Spiliopoulou, Beatson, West of Scotland Cancer Centre, Glasgow; Emiliano Calvo, Centro Integral Oncol\u00f3gico Clara Campal, Madrid,Spain; Rathi Pillai, Emory Winship Cancer Institute, Atlanta; Patrick Ott, Dana Farber Cancer Institute, Boston; Filippo DeBraud, Istituto Nazionale dei Tumori, Milan, Italy; Michael Morse, Duke University Medical Center, Durham, N.C.; Dung Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore; Dirk Jaeger, Heidelberg University Hospital, Heidelberg, Germany; Emily Chan, Vanderbilt University, Nashville, Tenn.; Chris Harbison, Chen-Sheng Lin, Marina Tschaika, Alex Azrilevich, of Bristol-Myers Squibb, and Jonathan Rosenberg of Memorial Sloan Kettering Cancer Center.\nThe U.S. FDA approved atezolizumab, which blocks PD-L1, for these patients.\nThis Phase I/II clinical trial treated 78 patients: five (6.4 percent) had complete responses, 14 (18 percent) had partial responses, in which tumor burden shrinks by at least 30 percent, and 22 (28.2 percent) had stable disease.\nLong-term follow up shows 22 percent of those treated with the drug survive 10 years or longer.\nOverall survival will be analyzed in conjunction with the Phase II portion of this clinical trial, which provides nivolumab or a combination of nivolumab plus the immune checkpoint inhibitor ipilimumab.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The headline says \u201cNivolumab immunotherapy helps patients with advanced bladder cancer.\u201d It would have been much more accurate to say \u201cNivolumab immunotherapy helps some patients with advanced bladder cancer\u201d \u2014 many patients saw no benefit at all. The release also says that nivolumab is \u201creally well-tolerated\u201d \u2014 but goes on to note that more than 20 percent of patients had severe, life-threatening or disabling side effects. Perhaps what they meant to say was that nivolumab is \u201creally well-tolerated compared to other treatment options.\u201d But we can only go by the language that is actually used in the release, and it reached just a bit too far.", "answer": 0}, {"article": "Prostate cancer is the second most common cancer in men worldwide and kills 254,000 men a year.\nThe ICR-led study is aiming to find out whether screening men who have genetic variants that increase their prostate cancer risk could lead to earlier diagnosis.\nThe findings suggest that by narrowing the focus of prostate cancer screening to those whose genes put them at most risk, doctors would catch more cancers early as well as reducing the potential for costly and damaging overdiagnosis.\nThe study found that the predictive value of screening these men \u2014 expressed as the number of cancers detected relative to the number of tissue samples taken \u2014 was 48 percent, far higher than the 24 percent achieved in population-wide screening.\nA study in the United States last year found that routine prostate cancer screening had resulted in more than a million being diagnosed with tumors who might otherwise have suffered no ill effects from them.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Most of the information in the story about the study appears to come from this press release, including the sole quote:\u00a0\"Although these are early results, it appears that PSA screening is reasonably accurate at predicting potentially aggressive prostate cancer among men at higher risk of the disease due to a genetic predisposition. This study provides support for continued screening in men with genetic mutations.\" While the story does add some great context about screenings and previous studies, it is hard to overlook this dependence on a press release.", "answer": 0}, {"article": "Former NASA astronaut Mark Kelly announced that he is running for John McCain's Senate seat in Arizona in the 2020 election.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story was not based unduly on any news release that we could identify.", "answer": 1}, {"article": "\"I feel like I can accomplish what I want to accomplish.\nWhile the results are striking, this technology is not a guarantee of complete resolution of depressive symptoms or medication side effects.\nIt's unclear how many patients have had to stop or chosen to stop treatment for depression due to side effects.\nFinally, her psychiatrist, suspicious that her body might process medication differently than most, recommended a genetic test to see why Ellis wasn\u2019t responding to the prescriptions.\n\u201cOnce the genetic testing became available it provided Sarah with more than just physical relief,\" says Dr. Matthew B. Stanley of the Avera Medical Group in Sioux Falls, South Dakota.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to be based entirely on a news release;\u00a0there does appear to be enough original reporting to rate the story Satisfactory on this criterion.", "answer": 1}, {"article": "Colorectal cancer is the third most common cancer in men and women, and strikes 1.2 million people each year.\nThis is not the first study to suggest Celebrex and similar drugs \u2014 known as COX-2 inhibitors - may reduce the risk of developing colon cancer, he said, but people need to balance that potential benefit with the higher risk of cardiovascular complications.\nThe study, published in the American Journal of Gastroenterology, received financial support from Pfizer, which sells Celebrex.\nApproximately half of the people who started the study agreed to continue.\n\u201cThe findings in this study don\u2019t necessarily make that decision any easier,\u201d said Dr. Andrew Chan of Massachusetts General Hospital and Harvard Medical School, who did not participate in the research.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There was enough original reporting for us to be certain that this was not based on a press release.", "answer": 1}, {"article": "To compare the effects of linagliptin to glimepiride (the most commonly used sulphonylurea), the researchers conducted a double-blind study over the course of two years.\nThe researchers pointed out that most patients are prescribed a class of drugs called sulphonylureas to supplement metformin.\nResearchers in Germany noted that the new drug, linagliptin (Tradjenta), is intended for use in patients that do not fare well with metformin, the most common first-line drug used to treat the disease.\nOne expert said patients and doctors may still have to balance the superiority of linagliptin against its higher cost in comparison to older drugs.\nAnd since hypoglycemia \"can have substantial negative clinical consequences\" in terms of risk for death, illness, mental function and poor quality of life, preventing it is crucial, study co-author Baptist Gallwitz, of Tubingen University Hospital, said in a news release.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does cite the Lancet press release as a source.\u00a0 We don\u2019t understand why a major news organization would have to do this.\u00a0 But since an independent source was quoted, we\u2019ll give the story the benefit of the doubt on this criterion.", "answer": 1}, {"article": "In addition to Chang, other authors on the all-MD Anderson study include: Stephen Hahn, M.D., Ritsuko Komaki, M.D., Pamela K. Allen, Ph.D., Zhongxing Liao, M.D., Steven H. Lin, M.D., Ph.D., Daniel Gomez, M.D., James Welsh, M.D., Melenda Jeter M.D., James Cox, M.D., Michael O'Reilly, M.D., Ming Li, M.D.\nOf note, said Chang, no patients developed the most severe, or grade five, toxicities, as seen in patients who receive standard of care.\nIn contrast, the historical OS rate with standard of care concurrent chemotherapy and traditional radiation was 16 months at the time when the study was designed.\nWhile the study's survival, recurrence rates and toxic effects are still favorable when compared to rates associated with the most advanced traditional photon radiation therapy, intensity modulated radiation therapy (IMRT), technology to diagnose and stage the disease, as well all treatment modalities have significantly improved.\nToxic effects of treatment in both the acute and late settings also were analyzed.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There is no unjustifiable language in the release. However, the headline could have been improved. It states, \u201cConcurrent chemotherapy, proton therapy improves survival in patients with advanced lung cancer.\u201d The first line of the release then clarifies this, \u201cFor patients with advanced, inoperable stage 3 lung cancer, concurrent chemotherapy and the specialized radiation treatment, proton therapy, offers improved survival compared to historical data for standard of care.\u201d ", "answer": 1}, {"article": "Chemotherapy kills off cells, healthy ones as well as cancercous ones.\n\u201cAt the 1.67 percent high-risk threshold,\u201d Georgetown\u2019s Lin says, \u201cevery woman age 62 and older would be [considered] high-risk.\u201d That might lead to a situation in which millions of women would be encouraged, unnecessarily,to consider this therapy, along with its potential harmful effects.\nBut there are conflicting views on who meets that \u201chigh risk\u201d definition\n\nChemoprevention should not be confused with chemotherapy.\nSerious side effects is one reason.\nIn part this may be because many doctors are not even discussing this option with their patients.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is good reporting from interviews with a variety of researchers and no reliance on a press release.", "answer": 1}, {"article": "In those procedures, doctors either extract a small amount of the fluid that surrounds the fetus (amniocentesis) or they take a sample of the placenta (chorionic villus sampling).\nWhile it\u2019s available over the Internet, she said her team had only looked at hospital-based test performance.\n\u201cBut it should only be used by families that are at risk for sex-linked diseases.\u201d\n\nBianchi said she owns stock in Verinata Health, a company that is developing cell-free fetal DNA tests for Down syndrome, although that company had no role in the new study.\n\u201cIf parents are using it to determine gender and then terminate the pregnancy based on that, that could be a problem,\u201d she told Reuters Health.\nBianchi said one study had estimated the blood test costs about 255 pounds in the UK (about $413), all included.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely solely on a news release.", "answer": 1}, {"article": "Magnetic resonance imaging measured cortical thickness and resting-state functional connectivity (rsFC) before training, after training and three months post-training.\nThe findings, published in Brain and Behavior, further suggest that changes in cortical thickness and neural network connectivity may prove an effective way to quantitatively measure treatment efficacy, an ability that has not existed until now.\nThe knowledge-based training group learned information about the structure and function of the brain as well as the effects of sleep and exercise on brain performance.\nOver an eight-week period, the strategy-based training group learned strategies to improve attention and reasoning.\nBuilding upon previous research, the study challenges the widely held belief that recovery from a TBI is limited to two years after an injury.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The releases employs a balanced tone.", "answer": 1}, {"article": "TMS works by producing an electrical current that can pass through the skull and into the target area of the brain.\nBased on the results, George and his team say, it would be necessary to treat 12 depressed patients with TMS in order to have one patient recover.\nIn a second phase of the study, all patients were given the real TMS treatment.\n\u201cIt looks as if from this trial you at least need to try three weeks and maybe even six weeks before you would give up.\u201d\n\nPatients who got better were prescribed venlafaxine - marketed as Effexor \u2014 and a small dose of lithium, noted George, a combination that\u2019s been shown to help people stay well after their depression has remitted.\nGeorge said he and his colleagues would like to study whether giving people TMS intermittently instead of putting them on antidepressants would produce equally durable effects.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story doesn\u2019t appear to have lifted any copy directly from an NIH news release about the study. Since it included only one expert source who was\u00a0also\u00a0the lead investigator on the study, however,\u00a0we can\u2019t say for sure how much the story relied on the release. We\u2019ll call it not applicable.", "answer": 2}, {"article": "Editor's note: Tune in as Dr. Sanjay Gupta explores the signs, tests and lifestyle changes that could make cardiac problems a thing of the past on \"The Last Heart Attack,\" Saturday, August 27, 8 and 11 p.m.\nThe study was published Tuesday in the Journal of the American Medical Association.\nLead author Dr. David Jenkins, Canada research chair in nutrition and metabolism at the University of Toronto and St. Michael's Hospital, had previously shown the effectiveness of a cholesterol-lowering diet when all the meals were provided to participants.\nEven so, the results were dramatic.\nBoth groups lost about four pounds over the six months.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story has a quote that is taken from a phone interview, which tells us the story wasn\u2019t entirely based on a news release.", "answer": 1}, {"article": "L-Nutra, to sell products that serve this purpose, which may be seen as a conflict of interest.\nHe also believes the benefits are down to improved efficiency on a cellular level.\nThis activation, or reduction, of pathways is why the components of the diet, such a proteins, must also be controlled.\nLongo has since founded his own nutrition company.\nTo him, diet underpins longevity.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes quotes from a source not involved in the study, so it appears the story went beyond relying solely on a news release.", "answer": 1}, {"article": "I wouldn\u2019t wish it on my worst enemy, but I have to go through with it.\u201d\n\nDr. Lowy explored the entire cavity from the diaphragm to the pelvis.\nMr. S. left the hospital eight days later, happy to have undergone the treatment.\nThe procedure took six hours.\n\u201cIt\u2019s maximally invasive,\u201d said Dr. Sugarbaker, who often removes the \u201cspare parts\u201d \u2014 organs a patient can live without, like the spleen, the gall bladder, the ovaries and the uterus.\nSo he signed up for surgery and Hipec with Dr. Lowy.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story benefited from independent reporting.", "answer": 1}, {"article": "With Cognivue, patients sit before a video screen that shows a series of images, such as a group of dots, that move around and fluctuate in clarity.\nThe device would be available only for use by medical professionals as part of a more comprehensive assessment of cognitive function.\nIt is not intended to be a standalone diagnostic tool, and its effectiveness for people with less than 12 years of education is not proven.\nDuffy said his tool holds promise as a relatively inexpensive and easy way to test people\u2019s memory and ability to think.\nThe test, which has been around since 1975, offers only a broad indication of cognitive abilities and fails to pick up borderline problems, she said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that this story does not rely solely on a news release.", "answer": 1}, {"article": "Prostate cancer becomes more common as men age \u2014 autopsies of elderly men find that most had prostate cancer, whether they knew it or not.\nStill, he said the new test could help patients if it was used with caution.\nThe next step was to ask whether those variants really could predict who had prostate cancer.\nBut some said that if the test leads to more screening, it is not necessarily a good thing.\n\u201cWe are just feeding off of this cancer phobia.\u201d\n\nWhat is needed, and what the new test does not provide, is a way to decide which cancers are dangerous and which are not, Dr. Isaacs said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story included interview material with several respected clinicians active in this field. ", "answer": 1}, {"article": "\"Adoption of the clinical chemistry score algorithm would standardize reporting of high-sensitivity cardiac troponin test results, how the tests are interpreted in the normal range, and represent an option less susceptible to both analytical and preanalytical errors.\nThe authors suggest the score can be useful for standardizing diagnoses and improving safety.\nIn this international study, researchers from Canada, Australia, New Zealand and Germany combined common laboratory blood tests available at many hospitals around the world to create a single laboratory score, or clinical chemistry score, to diagnose heart attack.\nAn international team of researchers has developed a simple laboratory score that is safer and faster at diagnosing patients who visit the emergency department with heart attack symptoms.\nThe score, published in CMAJ (Canadian Medical Association Journal), can also identify patients at risk of subsequent heart issues after discharge.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The text and quotes seem appropriate to the research.", "answer": 1}, {"article": "Aug. 9, 2010 -- Researchers have identified a protein \"signature\" in the spinal fluid of patients with Alzheimer's disease, which could represent an important advance in its diagnosis.\nIn one study, this protein signature was also seen in spinal fluid samples from all patients with mild cognitive impairment who progressed to Alzheimer's disease within five years.\nThe signature was found in the cerebrospinal fluid (CSF) of 90% of people with a diagnosis of Alzheimer's disease and 72% of people with mild cognitive impairment (MCI) -- a disorder that often progresses to Alzheimer's.\nLow levels of the amyloid protein amyloid-beta 1-42, along with high levels of total tau and elevated phospho tau 181 (P-tau 181), identified Alzheimer's disease in three independent study groups, Hugo Vanderstichele, PhD, of the Belgian biotech company Innogenetics, tells WebMD.\n\"Using this approach, which was totally independent of diagnosis, we were able to identify patients with Alzheimer's disease,\" Vanderstichele says.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story does not appear to be based on a news release.", "answer": 1}, {"article": "Paul J.D.\nWhiteside, a doctoral candidate in the MU Division of Food Systems and Bioengineering, devised a system that will not only improve the process, but will be safer for both clinicians and patients.\nThe techniques developed by the interdisciplinary team can be used by dermatologists and will reduce safety concerns in laser dermatology by improving laser transmission through surface layers of the skin.\nUsing various amplitudes and pulses, the instruments they developed were tested on the samples and showed great promise for the clinical setting.\nWhiteside presented his technique to clinicians on April 9, 2017, at the annual conference of American Society for Laser Medicine and Surgery (ASLMS).\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release is peppered with claims and quotes that are not supported by evidence. The headline claims that removal of birthmarks, port-wine stains and tattoos could be \u201crevolutionized,\u201d but the experiment did not include any testing of effectiveness on such skin markings. Claims of improved safety are also not supported by any data. Again, the experiment mentioned in the release, which was presented at a recent conference, reported results only on the optical transmission properties of pig skin samples; nothing about safety or clinical effectiveness.", "answer": 0}, {"article": "Impaired insulin sensitivity is one risk factor for type 2 diabetes, which is associated with age and obesity and happens when the body can\u2019t properly convert blood sugar into energy.\n\u201cIt gives us some hope that if there is no way to extend sleep during the week, people should try very hard to protect their sleep when they do get an opportunity to sleep in and sleep as much as possible to pay back the sleep debt,\u201d said lead study author Josaine Broussard of the University of Colorado Boulder.\nAnd it doesn\u2019t prove that catching up on sleep will prevent diabetes.\n\u201cBy catching up on sleep on the weekends, people are reducing average extent and severity of the effects of sleep deprivation,\u201d Gangwisch added by email.\nBut then, when they let the men get extra sleep for the next two nights, their blood tests returned to normal, countering the effect of the short-term sleep deprivation.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Since the story includes commentary from an independent expert, we can be sure it didn\u2019t rely excessively on a news release.", "answer": 1}, {"article": "\n\u2022 Detailed Results of Phase 2 Trial Presented at the American College of Gastroenterology 2016 Annual Scientific Meeting\n\u2022 93.3% of Patients Treated Using the Lead Formulation of Novel Prep Achieved a Colonoscopy Rating of Excellent or Good, Compared to 85.7% of Those Using Standard Prep Products in Colonoscopist-blinded Trial\n\u2022 More 'Patient-friendly,' Palatable Prep Could Help Increase Patient Acceptance of Colonoscopies for Colorectal Cancer Screening\n\nNewton, MA (October 17, 2016) - Detailed results from a Phase 2 study of a novel colonoscopy prep (ECP) under development by ColonaryConcepts, LLC show the investigational treatment to be at least as effective and safe as two currently available colonoscopy prep formulations, while offering a much higher level of patient satisfaction and preference than standard preps.\nThere were no serious adverse events across any of the treatment groups.\nFifty-one patients were treated with ECP and 14 with active comparators.\n\"Results from this study show that this innovative investigational product performed as well as or better at colon cleansing than two currently available colonoscopy prep formulations.\n\"We are very pleased with the efficacy and safety results of this study, which clearly support advancing this product to a Phase 3 trial,\" said Corey A. Siegel, M.D., M.S., a co-founder of ColonaryConcepts, and Director of the Inflammatory Bowel Disease Center at the Dartmouth-Hitchcock Medical Center and Associate Professor of Medicine at The Geisel School of Medicine at Dartmouth.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t include any sensational or unjustified language.", "answer": 1}, {"article": "Separate strands of material become stronger when they link up.\n\u201cCreating a material that behaves like skin is very difficult,\u201d added Dr. Barbara Gilchrest, a dermatologist at the Massachusetts General Hospital who worked on the study.\nThere are hundreds of skin products that do this now, but this one sticks better and doesn\u2019t pucker the skin, the team reports.\nThe stuff can just be peeled off, or taken off with makeup remover, the researchers said.\nThe cream\u2019s effects are detailed in a scientific report in the journal Nature Materials, but as part of the school\u2019s close association with the companies, it\u2019s being patented and produced at almost the same time.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story used several quotes from the news release without acknowledging that. For example, this quote appeared in the story and in the news release:\n\u201cIt has to have the right optical properties, otherwise it won\u2019t look good, and it has to have the right mechanical properties, otherwise it won\u2019t have the right strength and it won\u2019t perform correctly,\u201d Langer said.\nAs did this one:\n\u201cCreating a material that behaves like skin is very difficult,\u201d says Barbara Gilchrest, a dermatologist at MGH and an author of the paper. \u201cMany people have tried to do this, and the materials that have been available up until this have not had the properties of being flexible, comfortable, nonirritating, and able to conform to the movement of the skin and return to its original shape.\u201d", "answer": 0}, {"article": "The Claim: Red palm oil, a deep orange fat pressed from the palm tree fruit, is a superfood\u2014packed with healthy antioxidants and good for the heart, say companies who sell it.\n\nThe Verdict: The colorful oil is rich in tocotrienols, nutrients in the vitamin E family, and carotenoids, which the body converts into vitamin A. Several studies suggest possible benefits in stroke and liver disease from vitamin extracts made from the oil, but so far there isn\u2019t proof that consuming the oil can ward off disease, scientists say.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes multiple sources. It is clearly not based on a news release.", "answer": 1}, {"article": "The 12 poses, by their English names, were tree, triangle, warrior II, side-angle, twisted triangle, locust, bridge, supine hand-to-foot I, supine hand-to-foot II, straight-legged twist, bent-knee twist and corpse pose.\nBut all told, the team concluded, the results may lend support to Dr. Fishman\u2019s long-held belief that yoga can help reverse bone loss.\nThe daily regimen, once learned, took 12 minutes to complete.\nIn addition, \u201cYoga is good for range of motion, strength, coordination and reduced anxiety,\u201d he said, \u201call of which contribute to the ability to stay upright and not fall.\nA decade after the start of the study, bone density measurements were again taken and emailed to the researchers; many participants also had repeat X-rays done.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no evidence of reliance on a news release", "answer": 1}, {"article": "\"There are many gaps in the evidence,\" Reiss said.\nStill, Dr. Paul Wright, chair of neurology at North Shore University Hospital in Manhasset, N.Y., said the research \"is still in its infancy but very promising.\"\nExperts agreed that the findings held promise, but much more research will be needed.\n\"Saliva is easily obtained, safe and affordable, and has promising potential for predicting and tracking cognitive decline, but we're in the very early stages of this work and much more research is needed,\" study author Shraddha Sapkota, a neuroscience graduate student at the University of Alberta in Canada, said in a news release from the Alzheimer's Association.\nFor that reason, \"larger studies are needed to corroborate and validate their findings,\" Wright said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story does not rely solely on a news release.", "answer": 1}, {"article": ".\nOur study shows that age alone should not preclude referral for TAVR in patients age 90 years and older.\"\nHowever, with the advent of TAVR technology, we can now offer these extreme elderly patients a treatment option that otherwise would have been high-risk or prohibitive.\"\n\"Historically, extreme elderly patients can be at a very high risk for open surgery,\" said Dr. Thourani.\nAs part of the PARTNER-I trial, Vinod H. Thourani, MD, from Emory University in Atlanta, and colleagues from 12 other institutions in the United States found that transcatheter aortic valve replacement (TAVR) is a safe and effective way to treat aortic stenosis in nonagenarians who qualify for the surgical technique.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "In medical care, and certainly in surgical care, doctors and patients need to make informed decisions that balance risks and potential benefits. If there is a strong likelihood that a procedure will significantly enhance a patient\u2019s quality of life, a patient may opt to pursue a procedure regardless of potential risks. But that cannot be assumed. And therein lies the problem with this release. If one includes the headline, the release uses the words \u201csafe\u201d and \u201ceffective\u201d three times each by the time the reader has reached the third paragraph. However, any mention of potential harms associated with the procedures doesn\u2019t come until the reader reaches paragraphs eight and nine. The word \u201csafe\u201d can easily be construed as meaning \u201cfree from risk\u201d \u2014 and that\u2019s clearly not the case here.\nSince we\u2019ve already called attention to this problem above under the Harms criterion, we\u2019ll give the story a pass here. We\u2019d add that including information about the outcomes if nothing is done would be helpful in highlighting that the risks of this procedure may be worth it. But fundamentally, the individual undergoing this procedure is taking a short-term risk to improve symptoms and prolong life. For some individuals this risk may be worth taking, but others may be willing to accept their current state. It is notable that three-year mortality was around 50% among these patients \u2014 so while it may have relatively low short-term risks, it is not postponing death, often from other issues in this aged population.", "answer": 1}, {"article": "Breast cancer strikes more than 180,000 women each year in the United States and kills more than 40,000, making it the most common form of cancer after skin cancer and second leading cancer killer among women.\nThe test comes as concern has been rising about the proliferation of genetic tests.\nWhile welcomed by some patient advocates and doctors, the $1,625 test raises concerns among others.\nThe test by Decode Genetics of Reykjavik, Iceland, a respected pioneer in genetic research, promises to determine a woman's risk through a simple blood sample or cheek swab.\nAn FDA spokeswoman said the agency had just become aware of the new test and could not say whether it would take any action, though she noted that in August the agency sent a letter expressing concern to another company marketing a questionable genetic test for ovarian cancer.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on the Decode Genetics press release. There is independent reporting and a balanced review of this new genetic test. ", "answer": 1}, {"article": "\u201cIf it weren\u2019t for the trial I wouldn\u2019t be here,\u201d she said.\nTo be sure, more than half of patients with metastatic melanoma would not be helped all that much by either drug.\nThe effect was so marked that the trial was stopped early for ethical reasons, so that patients in the control group could be offered the new drug.\nThe new trial of this drug, by contrast, involved patients who were getting treated for the first time.\nThe drug is expected to be approved by the Food and Drug Administration within a few months.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely on a news release.", "answer": 1}, {"article": "Research has shown that giving statins to patients who already have Alzheimer's does not seem to help.\nAnd despite this study, there is not enough evidence to prescribe statins for the brain.\nThose who were taking a cholesterol-lowering statin such as Lipitor, had a surprising result.\nSince cholesterol is part of the tell-tale plaques on the brains of Alzheimer's patients, it made sense to think that statins might help.\n\"But statins as prevention for Alzheimers is not indicated at this time.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There were two press releases issues with this study, one by the journal and one by the University of Michigan. \nThe segment does not draw excessively on either. ", "answer": 1}, {"article": "Software engineer Ben Wallace underwent subchondroplasty in November to help shore up a damaged hip.\nThe best candidates for the procedure are patients who still have some cartilage protecting their joint, but have somehow \"overloaded\" and injured the bone, causing swelling and pain, Hepinstall said.\nThose with full-blown bone-on-bone arthritis or joint pain caused by damage to the cartilage and ligaments will get little to no relief from the procedure, Vasileff said.\nIt is much less invasive than a knee or hip replacement, and typically is performed on an outpatient basis, Vasileff said.\n\"I figured I'm going to have a fake hip in there at the age of 30, which was very depressing,\" Wallace explained.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story included sources not affiliated with the news release.", "answer": 1}, {"article": "Multiple neurological disorders, including Parkinson\u2019s disease and dementia with Lewy bodies, involve the abnormal clumping of a protein called alpha-synuclein into brain deposits called Lewy bodies.\nThe research findings were published in Acta Neuropathologica Communications.\nThis research was supported in part by NIH funding awards ZIA AI001086-08, AGO5131, and PHS P30-AG010133.\nScientists from the University of California San Diego, University of Verona in Italy, Indiana University School of Medicine, Indianapolis, and the Case Western Reserve University School of Medicine, Cleveland, collaborated on the project.\nImportantly, test results were available within two days, compared to related assays that require up to 13 days.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There\u2019s no unjustifiable language.", "answer": 1}, {"article": "Vitamin D is called the \"sunshine vitamin\" because human bodies produce it when the sun's ultraviolet rays strike the skin.\nHowever, colon cancer patients shouldn't try to boost vitamin D levels beyond the normal range, one expert said.\nBut vitamin D also influences cellular function in ways that could be beneficial in treating cancer, Ng said.\n\"These findings are interesting, and show that vitamin D may have a role in improving outcomes in cancer care.\"\nThe report, scheduled for presentation this week at the Gastrointestinal Cancers Symposium in San Francisco, adds more weight to suspicions that vitamin D might be a valuable cancer-fighting supplement.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There was a news release issued by the researchers\u2019 \u00a0institution, but the story had different quotes obviously gleaned from interviews. The story clearly went well beyond the news release.", "answer": 1}, {"article": "Before Young, the combination had been tried on patients with recurrent solid tumors such as non-small cell lung cancer, melanoma, renal cell carcinoma and many other cancer types.\nIt\u2019s quite a dramatic response.\u201d\n\nSo dramatic, in fact, that Yuan refers to Young as her \u201cmiracle patient.\u201d\n\n\u201cThis in some ways is pretty unprecedented.\n\u201cIt\u2019s such a promising early response.\n\u201cSix weeks into her treatment, the skin lesions were gone, her itchiness went away.\nIt was of tremendous magnitude in the last [blood] draw.\u201d\n\nThe next step will be to take bone and CT scans to see if the cancer is disappearing internally as well as externally, which Young will receive in a couple of weeks.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Liberal use of words and phrases like \u201cpotentially revolutionary,\u201d \u201cmiracle,\u201d \u201cpretty unprecedented\u201d and \u201cshocking\u201d to describe the treatment response are all unjustifiable and misleading. The results are only for one patient \u2014 who had not yet completed the full treatment at the time this release was issued \u2014 and there\u2019s been only very short term clinical followup.", "answer": 0}, {"article": "Almost everyone suffering from back pain says something like, \"I want to feel better, I want to play golf again, or I want to be able to play baseball with my grandkids,\" anesthesiologist and lead author Steve P. Cohen tells Shots.\nPatients don't care much about the finer points of diagnostic accuracy.\nDoctors may not change their approach anytime soon, however.\nThe study's suggestion on how to manage back pain also runs counter to current guidelines from major medical groups.\nBut some pain experts defend the value of the diagnostic tests.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Not applicable.\u00a0 We can\u2019t be sure if the story relied on a news release, but we know it relied at least partially on a Reuters story.\u00a0 Should this warrant an unsatisfactory score here?\u00a0 Maybe. ", "answer": 2}, {"article": "UCSF Benioff Children's Hospital Oakland (formerly Children's Hospital & Research Center Oakland) is a premier, not-for-profit medical center for children in Northern California, and is the only hospital in the East Bay 100% devoted to pediatrics.\nIn addition to King, the study's other authors are Sarah J Zyba, Swapna V Shenvi, David W Killilea, Tai C Holland, Elijah Kim, Adrian Moy, Barbara Sutherland, Virginia Gildengorin, and Mark K Shigenaga, conducting the research at CHORI's Nutrition and Metabolism Center.\nIt plays a vital role in maintaining optimal childhood growth, and in ensuring a healthy immune system.\nThis was a novel approach, different from the commonly used method of looking at zinc in the blood or using stunting and morbidity for assessing zinc status.\nCHORI is at the forefront of translating research into interventions for treating and preventing human diseases.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release does not include unjustifiable, sensational language.", "answer": 1}, {"article": "D.C.I.S.\nMore important, the difference between the numbers of side effects was not statistically significant, meaning that it could have occurred by chance and that the drugs could be similar or even the same.\nTo Dr. Norton, the most important conclusion to be drawn from the study is that more research on breast cancer prevention is needed.\nBut Dr. Leslie Ford, an associate director for clinical research at the cancer institute, said that the differences could not be ignored because they came so near to being significant.\nGiven that there are shades of gray and room for debate about these findings, some critics questioned the way they were made public.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story quotes multiple sources from different backgrounds, the reader can be reassured that the story does not rely solely on a press release as a source of information.", "answer": 1}, {"article": "March 31, 2010 -- A widely prescribed drug used to shrink enlarged prostates appears to reduce the incidence of prostate cancer in men with an increased risk for the disease.\nScheduled biopsies were performed two and four years after they entered the trial.\nBut none had evidence of cancer when biopsies were performed within six months of entering the trial.\nWhile the studies suggest a role for Avodart and Proscar in the prevention of prostate cancer, experts tell WebMD that important questions remain about using the drugs for this purpose.\nStudy researcher Gerald L. Andriole, MD, says a significant proportion of men screened for prostate cancer fall into this clinically ambiguous category of having elevated PSAs and negative biopsies.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story quotes experts other than simply the study investigators, the reader can assume the story did not rely on a press release as the sole source of information.", "answer": 1}, {"article": "Their metabolism slows down, they expend fewer calories when they exercise because their muscles become much more efficient, and their thyroid hormone and adrenaline levels drop.\nWhen they took leptin, their calorie burning increased to pre-diet levels.\nThen, for five weeks, they were given twice-daily injections with enough leptin to restore the levels they had before losing the weight.\nWould the subjects still show the metabolic changes of starvation?\nAnd the leptin study suggests that the weight loss solution may eventually be a pill that tricks the brain into thinking that no weight has been lost.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "", "answer": 2}, {"article": "Traditionally, patients with leukemia, lymphoma and myeloma have first tried to find an adult bone marrow donor either from a close relative or from a national bone marrow registry.\nBut Tirpak's physician, Dr. Mary Laughlin, turned to something deemed medical waste until recently: umbilical cord blood.\nAnd patients still must endure months of recovery.\nWell worth it, say Mumford and Tirpak, who received her stem cell injection two years ago.\nUntil recently, Tirpak would have faced a death sentence without a bone marrow transplant.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely solely on a news release.", "answer": 1}, {"article": "Error code 404. Something went\n\nwrong and we can't seem to find\n\nthe page you're looking for.\n\n Report a broken link.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "Watson says we don't know for sure, but it's possible the body begins to adapt to those changes, which is why the weight loss is reversed over time.\nFriedman kept the weight off for almost 10 years.\nAnd research conducted over the past decade suggests it works.\nThat's when she opted for bariatric surgery.\nSo Friedman opted for a less invasive procedure to make her stomach smaller again.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes an independent expert comment and does not appear to rely solely or mainly on a press release.", "answer": 1}, {"article": "In a study published in the Sept. 28 issue of the journal Menopause, scientists reported that about half the women in the study reduced the frequency of hot flashes, while half did not.\nOf the 170 women who received acupuncture, a small group of women (11.9 percent) had an 85 percent reduction in hot flashes by the eighth week of the study, Avis said.\nForty-seven percent of the study group reported a 47 percent reduction over this same time frame.\nWomen who had a reduction in their hot flashes saw a benefit beginning after about three to four weeks of weekly treatments.\u201d\n\nThe National Institutes of Health-funded study was designed to examine different patterns of responses to acupuncture.\n\u201cWomen will know pretty quickly if acupuncture will work for them.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "In its opening sentence, the release refers to hot flashes as \u201cthe bane of existence\u201d for many women going through menopause. This is the sort of hyperbole that the \u201cunjustifiable language\u201d criterion was designed to address. Can it affect quality of life? Absolutely. Should it be presented as a life-destroying b\u00eate noire? No.", "answer": 0}, {"article": "Source: Australian Bureau of Statistics, 2016, National Health Survey: First results, 2014-15, ABS cat.\n\u201cThis study shows that the new MedDairy works better than a generic low-fat diet, ensuring better health outcomes for people at risk of cardiovascular disease.\u201d\n\nImportantly, the MedDairy diet also meets additional calcium requirements recommended by Australia\u2019s national health bodies.\nNewswise \u2014 Thousands of people can take heart as new research from the University of South Australia shows a dairy-enhanced Mediterranean diet will significantly increase health outcomes for those at risk of cardiovascular disease \u2013 and it\u2019s even more effective than a low-fat diet.\nSimilarly, the Mediterranean diet (MedDiet) has been shown to deliver significant health benefits.\n\u201cThe new MedDairy diet allows for three to four servings with dairy, which means Australians can more sustainably meet their recommended daily nutrient intakes while also maintaining the significant health benefits offered through the MedDiet.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release begins by stating that a dairy-supplemented Mediterranean diet \u201cwill significantly increase health outcomes for those at risk of cardiovascular disease \u2013 and it\u2019s even more effective than a low-fat diet.\u201d However, a definitive statement like this should not be made based on a single randomized trial with a small sample. (And without an explanation of what \u201csignificantly\u201d actually amounts to.) \u00a0More appropriate language would be that a dairy-supplemented Mediterranean diet may improve the risk of heart disease.", "answer": 0}, {"article": "Varicose veins are one of the more unsightly signs of aging. But new, less-invasive treatments are making it easier to remove them painlessly, bypassing a difficult surgical procedure that was often the only option in the past.\n\nAs many as 25% of women and 15% of men suffer from varicose veins; over the age of 50, one out of two people are affected. Heredity plays a part, but obesity, prolonged standing on the job and hormone therapy increase the risks. Sometimes, varicose veins have no signs or symptoms and require no treatment,...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a news release.", "answer": 1}, {"article": "A new method for performing a \u201cvirtual\u201d colonoscopy that requires less unpleasant preparation was shown in a new study to accurately detect larger precancerous polyps\u2014and was a better experience for patients.\n\nThe second-leading cause of cancer deaths in the U.S., colon cancer can be prevented if precancerous polyps\u2014known as adenomas\u2014are found and removed during a colonoscopy\u2026.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a press release.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070225/5laser.htm was not found on this server.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story included several independent perspectives, so it is reasonable to assume that it did not rely solely or largely on a news release.", "answer": 1}, {"article": "Eat as you dare.\nNow here\u2019s the interesting part: eating more foods thought to be less healthy \u2014 those typical of Western diets \u2014did not link to an increase in heart attacks, strokes, or deaths.\nA new study of over 15,000 people in 39 countries explored the benefits of this diet for one special group: those already diagnosed with heart disease.\nSurprisingly, the results suggest it might be possible they can have their cake and eat it, too.\nThat said, Stewart notes his study has limitations, including a lack of strict guidelines about portion size and no measure of total calories.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We saw quite a few repeated phrases from the news release here and the story. It appears it did rely very heavily on the release, especially considering there wasn\u2019t an outside source commenting on the study, nor direct quotes.\n\u00a0", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061105/13healy.htm was not found on this server.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no way to know if the story relied on a press release.", "answer": 2}, {"article": "After adjusting for age, diabetes, hypertension and other factors, men who took a daily aspirin or another Nsaid reduced their risk of moderate or severe urinary symptoms by 27 percent, and their risk of an enlarged prostate by 49 percent.\nDr. Lieber acknowledged that the study was observational and not a placebo-controlled trial.\nThe study, published online by The American Journal of Epidemiology, had limited data on dosage, but scientists believe that even low doses of anti-inflammatory drugs reduce the risk of urological problems.\n\u201cSo this is a possible fringe benefit.\u201d\n\nResearchers studied 2,447 men over 12 years, examining them every other year.\n\u201cAt least half the patients I see are taking a daily aspirin for other health reasons,\u201d said Dr. Michael M. Lieber, an author of the study and a Mayo Clinic urologist.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if the story relied largely on a news release, although it is troubling that only one source \u2013 the lead investigator \u2013 is quoted. ", "answer": 2}, {"article": "Flavonoids have been found to relax blood vessels and thereby improve blood flow, inhibit platelets from sticking together in the blood, and have a beneficial antioxidant effect. What still is not known is whether regularly eating dark chocolate, especially with its high sugar and fat content, eventually will lead to an unhealthy weight gain that would erase the beneficial effects of the flavonoids found in the cocoa.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The report includes some information that was widely available in press releases, but also additional information that goes beyond the press releases.", "answer": 1}, {"article": "Dental caries (tooth decay) is caused by bacteria on the tooth surface feeding on carbohydrates, then making acids as waste.\nThe findings, which support earlier research demonstrating positive results of the assessment and treatment method in a university setting, have the potential to transform dental care for high-risk patients at a lower cost to both patients and dental clinics and practices.\nThose in the control group also reduced their risk to a lesser degree, simply by using over-the-counter products that also protect teeth and affect the bacteria.\"\nThe authors said now that this has been shown to be effective in a non-academic clinical setting, there also is potential for insurance companies to reimburse CAMBRA and other preventive therapies for adults, thereby lowering patient costs while increasing profits for dental practices.\nFrom this assessment, the dentist utilizes behavioral approaches and chemical treatments to optimize protective factors.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There is no unjustifiable language.", "answer": 1}, {"article": "\"For black tea lovers, there may be a new reason to keep drinking it,\" she said.\nThe new study also concluded that both green tea and black tea have different effects on liver metabolism.\nThe new findings show that black tea polyphenols, which are too large to be absorbed in the small intestine, stimulate the growth of gut bacterium and the formation of short-chain fatty acids, a type of bacterial metabolites that has been shown to alter the energy metabolism in the liver.\nThe findings build on a 2015 UCLA study that demonstrated that both green tea and black tea helped prevent obesity in mice that consumed a high-fat, high-sugar diet.\nDr. Zhaoping Li, director of the UCLA Center for Human Nutrition, chief of the UCLA Division of Clinical Nutrition and the study's senior author, said the findings suggest that the health benefits of both green tea and black tea go beyond their antioxidant benefits, and that both teas have a strong impact on the gut microbiome.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "It\u2019s never justifiable to imply a human effect based entirely on mouse research. Moreover, the release further suggests that it\u2019s already been proven that green tea induces weight loss \u2014 something that certainly has not been conclusively established.\n\u00a0", "answer": 0}, {"article": "Even the issues of how much vitamin D adults should take and whether calcium supplements help keep bones strong have been matters of debate.\nAlso missing, Nelson said, are randomized studies that would indicate how often patients should be screened.\nA preliminary report in July packed a surprise: No direct evidence was found that testing patients for low bone density helped avoid broken bones.\nStill, this group stressed the risk was very small, resulting in 2 cases of throat cancer in 1,000 people ages 60 to 79, compared with the normal rate of 1 per 1,000.\nHer task force recommended that an international registry be created for tracking such cases to help researchers better pinpoint which patients might be at risk.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article did not appear to rely on a news release. ", "answer": 1}, {"article": "An enzyme is a protein that performs a chemical reaction.\nSome experts identified limitations to the research.\nBut this could take a few years to develop.\nA new study, however, offers some potential for hope.\nThe re-engineered enzyme, named KumaMax, appears to be highly effective, at least in a test tube.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There\u2019s enough original reporting that we can be sure this isn\u2019t based on a press release.", "answer": 1}, {"article": "\"In some cancers, a part of the TRK gene has become attached to another gene, which is called a fusion.\nThe larotrectinib research was supported by Loxo Oncology Inc., the National Institutes of Health, the Cancer Prevention and Research Institute of Texas, the National Center for Advancing Translational Sciences, and Alex's Lemonade Stand Foundation.\nDr. Laetsch will be the national leader for that clinical trial in children.\nLarotrectinib is the first cancer drug to receive FDA breakthrough therapy designation for patients with a specific fusion of two genes in the cancer cell, no matter what cancer type.\nEqually important, the response was long-lasting for most patients.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "This release emphasizes the possibility of a very helpful new cancer drug, but it\u2019s irresponsible to refer to results from a phase 1 safety trial as having an \u201cunprecedented\u201d response and \u201camazing.\u201d It\u2019s misleading to trumpet effectiveness on a very small sample that was not intended to evaluate effectiveness. It\u2019s still too early to say the treatment works.", "answer": 0}, {"article": "We could not find the requested page.\n\nPlease visit our home page to explore our services.", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release does not use sensational language.\nHowever, we did want to highlight this quote, which was problematic:\n\u201cThe success of the Q-score in predicting melanoma is a marked improvement over competing technologies,\u201d says Daniel Gareau, first author of the report and instructor in clinical investigation in the Krueger laboratory.\u201d\nWe think that it is a bit premature to be this definitive. \u00a0A recent review of competing technologies suggests that confocal scanning laser microscopy has a sensitivity of 88-98% and a specificity of 83-99%.", "answer": 1}, {"article": "Acute myeloid leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow.\nThe trial met its primary endpoint demonstrating a statistically significant improvement in overall survival.\nFurthermore, approximately half of those patients are considered suitable for intensive treatment.\nVYXEOS was also granted Fast Track designation for the treatment of elderly patients with secondary AML.\n\"The successful outcome of this Phase 3 trial represents an important advance for AML patients, their families and clinicians,\" said Scott Jackson, Chief Executive Officer of Celator Pharmaceuticals.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Some exaggerated language was used by those describing the implications of the study, including a prediction that the drug will become \u201ca new standard of care\u201d even prior to regulatory approval, and calling the findings \u201ca\u00a0major step forward,\u201d \u00a0\u201can important advance,\u201d and a \u201cmajor milestone,\u201d for the company making it.", "answer": 0}, {"article": "\u2022 Retrograde menstrual flow: During a period, when a woman is shedding her uterine lining, some of that tissue can flow through her fallopian tubes and into her pelvis, which researchers think may cause endometriosis.\nSo it\u2019s no surprise it takes between three and 11 years after the onset of symptoms to diagnose endometriosis.\nAn endometriosis pain treatment was just approved by the Food and Drug Administration, and it\u2019s expected to arrive at pharmacies as soon as August.\nIn the trials, women who took the drug had greater bone loss than did those who received placebo, and this wasn\u2019t entirely surprising.\nThe pill, called elagolix (brand name Orilissa), from the drugmaker AbbVie, is the first FDA-approved oral treatment in more than a decade for the moderate to severe pain that comes with endometriosis.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Abbvie, the company that funded the Stage 3 clinical trials of elagolix (brand name: Orilissa) and will now market the drug, made available an extensive news release on its web site. The Vox story contains a good bit of enterprise reporting and produced a story that is far more clear than the company\u2019s effort.", "answer": 1}, {"article": "By the time most lung cancers are diagnosed -- which usually involves an invasive examination of the lungs -- patients already have advanced malignancies.\nMaybe one day, screening could be done using an even simpler nasal or sputum test, the researchers said.\nThe minimally invasive procedure involves using a small brush to collect a smattering of cells from the windpipe (a bronchoscopy), explained study co-author Andrea Bild, an assistant professor of pharmacology and toxicology at the University of Utah in Salt Lake City.\nCurrently, there is no good way to detect lung cancer -- the number one cancer killer -- in its early stages when it's most treatable.\nOnly 15 percent of patients are still alive at five years, said Nana-Sinkam.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "One independent expert quoted, so apparently did not rely on a news release. ", "answer": 1}, {"article": "Stay in touch on Linkedin, on Twitter @EpicSciences or on Facebook.com/EpicSciences.\nThis independent, multicenter, blinded study is one of the first studies to validate that a liquid biopsy test can predict therapeutic response and demonstrate a survival benefit.\nThis is the second blinded, multi-center clinical utility validation study utilizing the nuclear-localized AR-V7 test.\nThrough a blood draw, the test detects AR-V7 protein in the nucleus of circulating tumor cells utilizing Epic Sciences' No Cell Left Behind\u00ae platform to accurately identify patients who are resistant to androgen receptor (AR)-targeted therapies and who should instead switch to chemotherapy.\nThe PROPHECY study investigated the AR-V7 test in patients receiving ARSi therapy and demonstrated that patients who tested positive had worse survival by all measures and had no clinical benefit from ARSi therapy.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Given the lack of statistically significant results, it was premature for this news release to state that the blood test \u201cpredicts treatment response and survival\u201d for patients with metastatic prostate cancer. The statement that the test could be \u201cas valuable to a patient\u2019s outcome as a blockbuster cancer drug\u201d also seemed exaggerated.\nIt would have been appropriate to note that only by studying the test as part of the treatment program itself can we be certain that it led to improved outcomes.\n", "answer": 0}, {"article": "WASHINGTON -- A new study shows patients taking the anticlotting drug Plavix along with a type of drug used to block stomach acid have an increased risk of a subsequent hospitalization for heart trouble.\n\nThe study, which is being published in this week's Journal of the American Medical Association, adds to other recent studies that suggest proton pump inhibitors like Aciphex, Nexium, Prevacid and Protonix reduce the effectiveness of Plavix, which is marketed by Bristol-Myers Squibb Co. and Sanofi-Aventis SA.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There\u2019s no evidence that the story relied solely or largely on a news release.\n\u00a0", "answer": 1}, {"article": "Complications can include fluid buildup around the heart, called cardiac tamponade, which makes it difficult for the heart to pump blood.\nHe said, \"Relief of symptoms in patients with atrial fibrillation can be challenging.\"\nAblation was successful in 74 percent of patients, Arbelo said.\nAtrial arrhythmias in the first three months after ablation were classified as early recurrences and not considered as failures, Arbelo said.\n\"Of concern is that complication rates are still higher than desirable for this procedure, and there was suboptimal use of stroke-preventing anticoagulation [anti-clotting] therapy after the procedure,\" added Fonarow, who was not involved with the study.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because there is commentary from independent researchers, the story does not appear to rely on the news release.\n\u00a0", "answer": 1}, {"article": "\"This can potentially decrease having to go back to the operating room and with no real effect on your [cosmetic] outcome,\" said study leader Dr. Susan Boolbol, chief of breast surgery at Beth Israel Medical Center, in New York City.\nIn June, the radiation-free device won the blessing of a U.S. Food and Drug Administration advisory panel.\nLooking at the volume of tissue excised, the researchers said not much more tissue was removed when the device was used compared to tissue removed in the initial and subsequent surgeries among the control-group patients, Boolbol said.\nThe expected cost of the MarginProbe in the United States, if approved, is not yet known, said Michael Graffeo, a spokesman for its maker, Dune Medical Devices.\nThe patients were followed for two months to see if they needed a repeat surgery.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "No evidence that the story relied on a news release.", "answer": 1}, {"article": "While some previous research has found acupuncture for lazy eye effective, the researchers couldn't find a study that directly compared acupuncture with conventional treatments such as patching.\n''Acupuncture could potentially become an alternative treatment to occlusion [patching] therapy for ambylopia [lazy eye], the researchers write.\nThey assigned 43 children to the acupuncture group, and they received five treatments a week.\nAnother 45 children wore a patch over their normal eye for two hours daily, a typical regimen, and were also asked to do an hour of near-vision activity a day.\nThe study, conducted in China, is published in the Archives of Ophthalmology.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Since the story\u00a0quotes two experts not affiliated with study, we can be sure it wasn\u2019t\u00a0based on a news release.", "answer": 1}, {"article": "But it\u2019s not proof,\u201d Broderick said.\nWhy endovascular treatment wasn\u2019t better is a mystery that the researchers are struggling to explain.\nThe results of the clinical trials, presented this week at a meeting in Hawaii, shocked and surprised stroke physicians.\nThe other half of the patients got standard treatment, which didn\u2019t include the procedure.\nRemoving the clot wasn\u2019t better than standard care in either group \u2014 those with a lot or a little brain tissue to lose.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely on a news release.", "answer": 1}, {"article": "At the end of the day I don't know that this will be the best technology out there, but it is a step forward to allow continued innovation in this area,\" Foreman said.\nAnother concern was that doctors could misinterpret the device's feedback, particularly error messages when a mole cannot be scanned.\nThe agency also worried about its use by general doctors not accustomed to identifying suspicious skin moles.\nRegulators said this week that they ultimately approved the device after Mela Sciences agreed to limit its use to board-certified dermatologists who undergo a specialized training course.\nThe hope is to find more melanomas sooner.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a news release.", "answer": 1}, {"article": "Dr. David E. Neal, a professor of surgical oncology at the University of Cambridge in the U.K. and author of an accompanying editorial, believes that, \"PSA testing detects prostate cancer early in its natural history when it causes no symptoms.\nThis study adds to previous evidence that PSA testing and screening for prostate cancer saves lives, he said.\nStill, the PSA test remains \"a blunt instrument,\" when it comes to determining the aggressiveness of a particular tumor, Neal said.\nMoreover, the risk of over-diagnosis was less than previously thought, with just 12 men needed to be diagnosed to save one life.\nOf the men in the screened group diagnosed with prostate cancer, nearly 79 percent were diagnosed because they took part in the study, the researchers noted.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\u00a0The story does not appear to rely on a news release.", "answer": 1}, {"article": "More and more, physicians are hearing about and understanding the benefits of MRI technology for prostate care, which has also been helpful in preventing overdiagnosis and overtreatment.\nThat\u2019s one of our strengths.\u201d\n\nYu has seen how MRI technology has changed prostate patients\u2019 care.\nThese are tumors that would have never developed into a life-threatening cancer, but might lead a doctor and patient to treat it unnecessarily.\nMuch like someone would have an MRI to investigate the cause of back pain, the technology gives doctors eyes on what is happening in prostate tissue.\nOver the course of two years, Harder, 60, an MRI technologist, would have three TRUS biopsies.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We address examples of unjustifiable language in the quality of evidence and disease-mongering sections. There are other troublesome statements, such as that a urologist at another institution \u201cwas ready to throw in the towel\u201d after a patient\u2019s three inconclusive biopsies, which makes that clinician sound either uncaring or incompetent.\nThe statement: \u201cOther patients who continue to hit a brick wall with negative results from TRUS biopsies yet persistently high PSA levels may not be as fortunate.\u201d This implies that not trying hard enough may prove fatal for patients \u2014 something that is not true in terms of available evidence.", "answer": 1}, {"article": "The resource you are looking for might have been removed, had its name changed, or is temporarily unavailable.", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Easy, fun, competitive (?), will help anyone look good and feel great \u2013 all without data or any supporting information other than two anecdotes, at least one of which is heavily conflicted.", "answer": 0}, {"article": "Pacemakers zap the heart with low levels of electricity when the heartbeat becomes too fast, too slow or too irregular.\nStill, he said, the new device will probably be more expensive than other pacemakers, and may pose special risks of its own.\nIt's only been implanted in a few dozen people who were studied for a matter of months, limiting information about its long-term use and safety.\nStill, a new company-funded study shows that \"this is now a possibility\" that could reduce infections and the severity of pacemaker surgery, said study author Dr. Vivek Reddy, director of the Cardiac Arrhythmia Service at Mount Sinai Hospital in New York City.\nHe expects the pacemaker \"will likely be utilized for some select patients\" after more testing.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There was enough independent reporting to suggest that the story did not rely on a news release.", "answer": 1}, {"article": "Dr Joanna Bowtell, head of Sport and Health Sciences at the University of Exeter, said: \"Our cognitive function tends to decline as we get older, but previous research has shown that cognitive function is better preserved in healthy older adults with a diet rich in plant-based foods.\nIn the study, healthy people aged 65-77 who drank concentrated blueberry juice every day showed improvements in cognitive function, blood flow to the brain and activation of the brain while carrying out cognitive tests.\n\"In this study we have shown that with just 12 weeks of consuming 30ml of concentrated blueberry juice every day, brain blood flow, brain activation and some aspects of working memory were improved in this group of healthy older adults.\"\nCompared to the placebo group, those who took the blueberry supplement showed significant increases in brain activity in brain areas related to the tests.\nThe new paper, \"Enhanced task-related brain activation and resting perfusion in healthy older adults after chronic blueberry supplementation\", is published in the journal Applied Physiology, Nutrition and Metabolism.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We think the headline is not justified by the evidence presented.\n\u201cBlueberry concentrate improves brain function in older people.\u201d\nThe statement makes it sound as if this single study of 12 people proves a functional improvement that is permanent, and that is not proven by the limited 12-week study. We also question whether the markers that were used \u2014 blood flow and brain activity during tests \u2014 can be reliably linked to a permanent change in the individual\u2019s cognitive ability.", "answer": 0}, {"article": "According to Kramer, \"This randomized study concludes that [aspirin's] use is not only effective for reducing the incidence of preeclampsia at term, but also preterm.\nAbout 1,600 women completed the double-blind, placebo-controlled study.\nThe reduction in risk was even greater for early deliveries.\nThere were no serious side effects for expectant mothers, or adverse events for the babies related to aspirin use during pregnancy, the researchers noted.\nNicolaides said the aspirin may help improve blood flow from the mother to the placenta.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story does not appear to rely on a news release.", "answer": 1}, {"article": "Guadecitabine works to reverse a so-called epigenetic change in cancer cells known as methylation, which may alter genetic activity in cells in a way that can block the action of tumor-suppressing genes, pushing cells to become cancerous and resistant to therapy.\nThe clinical trial included 22 patients with metastatic colorectal cancer who had been treated previously with irinotecan and whose disease was progressing.\nThe study also showed signs that guadecitabine reduced methylation among the cancer cells.\nThere was one death during the study, possibly resulting from febrile neutropenia caused by the treatment.\nThe drug combination is being tested in an ongoing phase II clinical trial (NCT01896856) in a larger group of metastatic colorectal cancer patients at multiple institutions to determine the effectiveness of the dual therapy compared with chemotherapy regimens that do not include guadecitabine, says Azad.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The bulk of the release is very good in this regard, but the first thing readers see is the headline. That doesn\u2019t mean the headline is more important, but it does mean that the headline is subject to additional scrutiny. And the headline here reaches too far. Here\u2019s the headline: \u201cExperimental drug guadecitabine found safe in patients with colorectal cancer.\u201d Here\u2019s an excerpt from lower down in the release: \u201c16 patients experienced neutropenia, a low count of the infection-fighting white blood cells called neutrophils; five patients with neutropenia had fevers; three patients became anemic; and two patients developed thrombocytopenia, a lowered count of blood-clotting platelets. Other side effects included diarrhea (three patients), fatigue (two patients) and dehydration (two patients). There was one death during the study, possibly resulting from febrile neutropenia caused by the treatment.\u201d The word \u201csafe\u201d is relative when discussing chemotherapy treatment, but when most readers see something described as \u201csafe\u201d they assume that means it won\u2019t harm them. For that reason, it\u2019s a stretch to apply the word \u201csafe\u201d to any treatment in which a sample size of 22 patients is associated with this many adverse outcomes, and may have contributed to a death.", "answer": 0}, {"article": "An experimental Alzheimer\u2019s drug showed positive results and raised hopes anew that pharmaceutical companies were moving closer to a medicine that could finally disrupt the disease\u2019s memory-robbing course, though a string of failures shadow the efforts.\n\nAlzheimer\u2019s has proved an especially tough drug target. Approved therapies only relieve symptoms temporarily, and one experimental treatment after another promising to stymie the neurodegeneration has ultimately failed to work. Some pharmaceutical companies, after costly failures,...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story didn\u2019t rely on the companies\u2019 news release.", "answer": 1}, {"article": "Rather than estrogen, DMAU uses a male hormone like testosterone.\n\u201cDespite having low levels of circulating testosterone, very few subjects reported symptoms consistent with testosterone deficiency or excess,\u201d Page said.\nResearchers analyzed the men\u2019s hormones and cholesterol with blood tests at the start and end of the study.\nThe \u201cundecanoate\u201d in DMAU, however, is a long-chain fatty acid that can slow the drug\u2019s journey out of the body, Page said.\nResearchers have developed a prototype male pill that appears to be safe in a month-long trial.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This gets a satisfactory rating, but barely. The bulk of the story appears to be drawn from a news release. However, the story also includes information not found in the release, but which can be found in the online study abstract.", "answer": 1}, {"article": "If a woman's doctor tells her she does not need radiation after a mastectomy, the woman should be told why and she should ask if the radiation oncologist weighed in on the decision.\nThe guidelines don't offer a single formula for which patients need radiation therapy, Edge noted.\nThe new guidelines help clarify what used to be a gray area, Andrews explained.\nAndrews said that one take-home message for patients is to expect the surgeon to have consulted with the radiation oncologist and others on her team.\nDoctors need to weigh the risks and benefits, Edge added.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Since the story includes input from an independent source, it clearly goes beyond what is found in any release related to the new guidelines.", "answer": 1}, {"article": "\"These are very basic facts, concerning simply who lived and died,\" he noted.\nRemote monitoring via telephone lines and online physician access is available for all ICD and CRT-D devices, the authors noted, and enrollment in such programs is typically free with a cardiologist's recommendation.\nThe same is true for 88 percent of CRT-D patients, they noted.\nThe study team also found that patients whose implants were monitored remotely, on a continual basis, by a health facility network were about half as likely to die as patients who only had intermittent in-person assessments.\nThe study authors noted that the observation is somewhat surprising, given that some of the patients not enrolled in structured studies have already experienced a cardiac event and are therefore prescribed such devices to prevent a recurrence.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Not applicable because we can\u2019t be sure of the extent to which the story relied on a news release.\nWe do know, because the story acknowledged this, that the quote from the study co-author came from a news release.\u00a0 Why?\nThe release, it should be noted, actually provides more and better information than the news story.", "answer": 2}, {"article": "Coronary angioplasty is a procedure in which arteries are opened to increase blood flow to the heart.\nOf the study\u2019s patient population receiving PCI, 9 percent received the procedure in which doctors used wrist access.\n\u201cWe have unequivocal evidence and data that show better outcomes when we access the heart\u2019s coronary arteries and perform angioplasty through a blood vessel in the wrist rather than through the femoral artery in the groin,\u201d said first author Amit P. Amin, MD, an assistant professor of medicine.\nThe researchers estimated that shifting standard practice by 30 percent to the wrist approach, along with same-day discharge, could save the United States $300 million per year.\n\u201cWe have seen that it is very safe to send these patients home the same day,\u201d said Amin, who treats patients at Barnes-Jewish Hospital.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The first author of the research report is quoted as describing\u00a0the evidence of this study as \u201cunequivocal,\u201d which is a bit strong, but the language in the rest of the release is straightforward.", "answer": 1}, {"article": "Radiotracers work by injecting a small amount of a compound tagged with a radionuclide into patients.\nTwo prostate cancer experts said the tool, if borne out in patients, could prove very useful.\nHe noted that, as of now, doctors typically rely on results of the PSA blood test and/or standard diagnostic scans to help guide treatment decisions.\nThe researchers pointed out traditional bone scans are unable to differentiate between malignant and nonmalignant lesions.\nHowever, Goluboff also noted that research from animal-based studies does not always pan out in humans and \"further, larger studies are of course required to confirm these findings.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There were two independent experts quoted, but the only quote from the researcher came from a conference news release. That\u2019s not good journalistic practice, and is another sign of the rush to publish \u2013 even before the data were presented at the conference.", "answer": 0}, {"article": "Several studies have found that dark chocolate, with its heart-healthy flavonols, can lower blood pressure and improve cholesterol.\nReid and his team constructed a mathematical model to predict the long-term health effects of eating dark chocolate daily in high-risk people.\nThey did not study actual people eating actual chocolate.\nThe study is published in the journal BMJ.\nHowever, Reid believes theirs is the first study to model the long-term effects of eating dark chocolate in reducing cardiovascular risk.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely solely on a news release.", "answer": 1}, {"article": "Nancy U. Lin and Harold J. Burstein, of the Dana-Farber Cancer Institute and Harvard Medical School in Boston, said: \"EMBRACE provides much needed, high-level evidence for chemotherapy use in patients with heavily pretreated breast cancer.\n\"This global phase 3 study establishes a potential new standard treatment for women with heavily pretreated metastatic breast cancer, for whom there was previously no chemotherapy treatment with proven survival benefit,\" the authors wrote.\nThe study, known as the EMBRACE trial, was funded by Eisai Inc., which markets eribulin.\nThe study included 508 women who were given eribulin and 254 women who received treatment of the physician's choice, which was defined as: any single-agent chemotherapy, hormonal or biological treatment approved for cancer treatment; radiotherapy; or symptomatic treatment alone.\nDr. Javier Cortes, of the Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology in Barcelona, Spain, and colleagues published the findings in the March 3 online edition of The Lancet.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article did not rely solely on a news release.", "answer": 1}, {"article": "\"I would say that hearing better kind of completes your personality, and I think Ethan became a complete personality once his hearing came online.\u201d\n\nAfter witnessing Priddy's miraculous results, Naberhaus was inspired to shrug off his image as the hard-of-hearing teacher and get a cochlear implant.\nBut Priddy adapted quickly to his second implant and can now talk on the telephone all he wants.\nEventually, he decided to get another cochlear implant in his left ear.\nHe was nervous about this because, being left-handed, he favors his left ear and was worried that he wouldn't be able to do one of his favorite pastimes: talking on the telephone.\nWhen Priddy's implant was turned on six weeks later, he couldn't decipher the sounds he was hearing, but he was definitely hearing them.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely solely or largely on a news release.", "answer": 1}, {"article": "But on Oct. 23, the F.D.A.\nHe said the drug should be distributed so that hospitals could have it in stock.\nOf the 32 patients who received the drug that way, 29 were still alive, BioCryst said in late October.\nSome doctors said they were satisfied with the existing system.\nAnecdotes like Ms. Gurno\u2019s aside, the efficacy of peramivir is still in question, according to the government.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\nThe story does not appear to rely on a news release.", "answer": 1}, {"article": "The Ache: Common cholesterol-lowering drugs called statins can have unpleasant side effects, including muscle aches and weakness.\n\nThe Claim: An extract from a bitter, fragrant citrus fruit called bergamot, commonly known as a flavoring in Earl Grey tea, can lower cholesterol with minimal side effects, some scientists say. It also boosts good cholesterol, reduces fatty deposits in the liver and lowers blood sugar, they add.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story shows evidence of data gathering including speaking to experts and reviewing the literature. We can be sure that this story wasn\u2019t based mainly on a news release.", "answer": 1}, {"article": "Thousands of heart-failure patients die each year because they aren't able to get a transplanted organ. Now, many medical experts are touting the benefits of a new mechanical pump that gives a patient's own heart a new lease on life.\n\nPatients surgically implanted with the new pump, known as a left-ventricular assist device, or LVAD, had a survival rate of 58% after two years, according to a recent study. That's not as good as a heart transplant, which offers a survival rate of about 70% after 10 years. But it surpasses the...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no evidence that this story relied on a news release.", "answer": 1}, {"article": "Primary pulmonary hypertension (PPH), a rare fatal lung disease, has been reported in patients who had taken a combination of phentermine and fenfluramine or dexfenfluramine for weight loss.\nDosage should be individualized to obtain an adequate response with the lowest effective dose.\nThe limited usefulness of agents of this drug class (anorectics), including Lomaira, should be measured against possible risk factors inherent in their use.\nPhentermine has the potential to be abused.\nThese are not all of the potential side effects of phentermine.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We see no unjustifiable language being used in this release.", "answer": 1}, {"article": "\"Whereas the typical developing kid will have an explosion of their language ability starting at about 12 months in both comprehension and production, kids in autism delay don't start comprehending or producing until later, and they don't ever have that kind of explosion.\nBefore bringing it to clinics, researchers need to make sure this test isn't detecting other developmental delays such as dyslexia, he noted.\nAbout 50 percent of kids with autism never develop language,\" she noted.\nRight now, experts have little to go by in detecting autism other than carefully monitoring the regular developmental milestones in children, Young said.\n\"This provides more evidence for abnormal connectivity in the brain.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Since independent sources are quoted, it does not appear that the story relied solely on a press release.", "answer": 1}, {"article": "Nearly 800,000 Americans suffer a stroke every year, with about a sixth of them dying of it and many more left disabled.\n\u201cGiven the observational design of the study, findings from this study cannot prove that it\u2019s chocolate that lowers the risk of stroke,\u201d Susanna Larsson from Karolinska Institutet in Stockholm told Reuters Health in an email.\nThe results add to a growing body of evidence linking cocoa consumption to heart health, but they aren\u2019t a free pass to gorge on chocolate.\nNEW YORK (Reuters Health) - A sweet tooth isn\u2019t necessarily bad for your health\u2014 at least not when it comes to chocolate, hints a new study.\nOver the next decade, there were 1,549 strokes, and the more chocolate women ate, the lower their risk.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes comments attributed to a direct email from one of the study authors, so\u00a0we can confirm our overall impression that this story wasn\u2019t based\u00a0on a\u00a0press release.", "answer": 1}, {"article": "Angioplasty remains the top treatment for people having a heart attack or hospitalized with worsening symptoms.\nNeither treatment proved better for any subgroups like smokers, diabetics, or older or sicker people.\nAlso, the clogs treated with angioplasty are not the really dangerous kind.\nHalf of these low-risk patients received stents and medication.\nTo the surprise of the researchers, both groups fared about the same: approximately 19 percent had a heart attack or died within seven years, adds LaPook.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story quotes the lead author of the study and one physician who is not related to the study, the reader can assume the story did not rely on a press release as the sole source of information.", "answer": 1}, {"article": "[4] Quotes direct from author and cannot be found in text of Article.\nThe score, which uses measures that can be obtained by simple questionnaires without any need for physical examination, such as self-rated health and usual walking speed, could be used by individuals to improve awareness of their health status, and by doctors to identify high-risk individuals for further treatment, say the authors.\nThey used a statistical survival model to assess the probability that 655 specific demographic, lifestyle, and health measurements could predict death from any cause and six specific causes, in men and women separately.\nThe performance of the score was validated in 35810 participants enrolled at two Scottish centres which were not used to develop the score, and was found to have around 80% accuracy in men and women (table 2).\nThe resource has been open to bona fide health researchers for 18 months.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "One of the investigators refers to the study\u2019s development of a prediction score from self-report data as \u201cexciting,\u201d but most of the quotes, while positive, also convey useful information, including qualifiers.", "answer": 1}, {"article": "HIV infects the body by corrupting T cells that are mobilized by the immune system when the virus enters a person's body.\n\"By delivering the medication exactly where it's needed, we hoped to increase the chances of inducing immune quiescence.\"\nThe article recently appeared in the Journal of Controlled Release.\nThe tool, a vaginal implant, decreases the number of cells that the HIV virus can target in a woman's genital tract.\nWhen the T cells stay resting, it's referred to as being immune quiescent.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Alluding to potential impacts on women or people four times in the first few paragraphs, but not mentioning the research utilized an animal model until the penultimate paragraph, is quite misleading and unjustified.\nWe\u2019d suggest changing the headline to: \u201cUniversity of Waterloo develops a new way to fight HIV transmission in rabbit study.\u201d", "answer": 0}, {"article": "Then the researchers, led by Dr. Frank Hu of the Harvard T.H.\nThat is, each year, coffee would be keeping 1 person in 1,000 from dying.\nA co-author of the 2013 study linking heavy coffee drinking to higher mortality called the new one \u201cvery good,\u201d especially since it controlled for the deadly effects of smoking, which the earlier one did not.\nIf you do want to infer causation from this latest study, know that drinking coffee reduced the absolute mortality risk from 6.8 deaths a year per 1,000 people to, at best, 5.8.\nThat eliminated the stereotypical coffee-swilling, cigarette-sucking types.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The STAT story was well researched, offering links that could form a small \u201cbibliography\u201d of relevant studies and using an outside commentator to put the new findings in perspective.", "answer": 1}, {"article": "And I've seen patients who have gotten up in the middle of the night and they trip and fall on the tubing,\" he explained.\nAs for improving infection control in intensive care units, Huang said, \"further analysis may help us understand why this intervention didn't work.\"\nDr. Susan Huang, a professor of infectious disease at the University of California, Irvine, wrote an editorial accompanying the study.\nBut there was no drop in infections or catheter use in intensive care units (ICUs), the study findings showed.\nRoughly 250,000 such infections occur in hospitals each year in the United States, costing about $250 million, the researchers pointed out.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story included original quotes, presumably from an interview with Dr. Sanjay Saint. While it does extensively quote a NEJM editorial, those views help put the study and its limitations \u2014 e.g. no effect on ICUs, where reducing UTIs could do the most to save lives and reduce suffering \u2014 into plain view.", "answer": 1}, {"article": "It involves extracting white blood cells called T cells \u2014 the foot soldiers of the immune system \u2014 from a patient\u2019s blood, freezing them and sending them to Novartis\u2019s sprawling manufacturing plant in Morris Plains, N.J.\nAnd childhood leukemia is just the start for a field that has attracted intense interest in academia and industry.\nThe pediatric trial opened the following spring with Emily.\nThe article that appeared in the New England Journal of Medicine in August 2011 created a \u201cfirestorm,\u201d June said \u2014 one that brought them new resources.\nMany of them took part in the clinical trial, and all have gotten extensive training by Grupp and others.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story goes well beyond any news release.", "answer": 1}, {"article": "Two studies published Tuesday lend support to controversial new cholesterol guidelines that could vastly increase the number of Americans advised to take cholesterol-lowering drugs called statins.\nThe new studies are not large clinical trials that will definitively settle the matter of whether to expand drug treatment to millions more people in hopes of preventing cardiovascular disease, the leading killer of Americans.\nBut they could help dispel some of the criticism of the new guidelines and strengthen the position of those who contend treatment should be extended to more people.\nThe other suggests that treating people based on the new guidelines would be cost-effective, even with the tremendously increased use of statins.\n\u201cThere is no longer any question as to whether to offer treatment with statins for patients for primary prevention, and there should now be fewer questions about how to treat and in whom,\u201d said an editorial that accompanied the publication of the studies in JAMA, a journal of the American Medical Association.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because it contains comments from independent experts, we can be sure the story did not rely excessively on any news release.", "answer": 1}, {"article": "\"Compared to childhood vaccines, people would [probably] think 55% is not too impressive, because many childhood vaccines are in the range of 80% to 90% [effective],\" says researcher Hung Fu Tseng, PhD, MPH, a research scientist at Kaiser Permanente Southern California.\nAnother new study, published in the American Journal of Preventive Medicine, finds that by 2008, less than 7% of U.S. adults aged 60 and older had gotten the vaccine, which has been available just since 2006.\nCalled Zostavax, the shingles vaccine is made by Merck.\nThe new study is published in the Journal of the American Medical Association.\nAbout a million episodes of shingles, sometimes debilitating, occur in the U.S. annually, Tseng says.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\nThe story does not appear to rely on a news release.", "answer": 1}, {"article": "CHICAGO\u2014Using whole-brain radiation to treat cancer that has spread to the brain is a treatment that for many patients is worse than the disease, a new study suggests.\n\nResearchers said the technique, when used after a more precise radiotherapy to kill the cancer, resulted in more memory loss and other cognitive deficits than treating with radiotherapy alone. While the more aggressive treatment was better at preventing recurrence of tumors in the brain, it didn\u2019t extend survival.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does have some similarities to a release from the American Society of Clinical Oncology, but that may be because the reporter was watching the same panel that the release was covering. The story certainly incorporates information not included in the release.", "answer": 1}, {"article": "Thanks to members Drs.\nWith this knowledge, the American Medical Society for Sports Medicine (AMSSM) has released a new scientific statement that provides guidance for physicians and healthcare professionals who provide care for those patients with knee osteoarthritis.\nThis is different than studies recently published that say the average response differs.\u201d The full report, published ahead of print in the Clinical Journal of Sport Medicince (CJSM) and will appear in the (British Journal of Sports Medicine) BJSM, entitled, AMSSM Scientific Statement Concerning Viscosupplementation Injections for Knee Osteoarthritis Importance for Individual Patient Outcomes, includes the following notable AMSSM recommendations and one suggestion:\n\u2022 AMSSM RECOMMENDS viscosupplementation injections for Kellgren and Lawrence (KL) grade II-III knee osteoarthritis in those patients above the age of 60 based on HIGH quality evidence demonstrating benefit using OMERACT-OARSI Responder Rating but the evidence should be downgraded due to indirectness for those under 60 years of age.\nNewswise \u2014 LEAWOOD, KS \u2014 Osteoarthritis (OA) is one of the leading causes of disability in adults in the United States and knee OA specifically is ranked within the top 10 non-communicable diseases for global disability-adjusted life years.\nUsing a network meta-analysis we are able to compare the multiple studies done on viscosupplementation and have found that people are more likely to show clinical improvement with viscosupplementation over placebo (saline) and intra-articular steroids.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We think the phrase \u201chigh quality evidence\u201d was unjustified language in this release because there was no evidence provided. It\u2019s nearly unheard of for a medical association to offer practice \u201cguidance\u201d or a specific treatment recommendation that changes practice without providing copious data to back up that recommendation.", "answer": 0}, {"article": "Saturated fat has been thought to promote cardiovascular diseases by raising the \"bad\" LDL cholesterol in the blood.\nEven the participants who increased their energy intake during the study showed substantial reductions in fat stores and disease risk.\n\"Participants on the very-high-fat diet also had substantial improvements in several important cardiometabolic risk factors, such as ectopic fat storage, blood pressure, blood lipids (triglycerides), insulin and blood sugar.\"\n\"Future studies should examine which people or patients may need to limit their intake of saturated fat,\" assistant professor Simon Nitter Dankel points out, who led the study together with the director of the laboratory clinics, professor Gunnar Mellgren, at Haukeland university hospital in Bergen, Norway.\nThe researchers found strikingly similar health effects of diets based on either lowly processed carbohydrates or fats.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Unjustifiable language is present in the release, beginning with the headline \u2014\u00a0 \u201cSaturated fat could be good for you.\u201d This tiny study provides little if any evidence for that claim, and the statement contradicts substantial amounts of conflicting research. Moreover, the release later says that a high saturated fat diet \u201cdid not increase the calculated risk of cardiovascular diseases\u201d \u2014 it doesn\u2019t say that it \u201clowered\u201d risk. So it seems that the best one could conclude, even in a generous interpretation, is that \u201csaturated fat might not be bad for you.\u201d", "answer": 0}, {"article": "For most people, \"the lower your blood pressure, the better you are.\nVolunteers for the study ate just over six grams of dark chocolate daily for almost five months \u2014 one square from a German chocolate bar called Ritter Sport, equal to about 1\u00bd Hershey's Kisses.\nTests suggested that steady exposure to dark chocolate prompted chemical changes that helped dilate blood vessels and regulate blood pressure, the researchers said.\nSvetsky cautioned that weight gain from eating large amounts of dark chocolate would counteract any benefits on blood pressure.\nThe study appears in Wednesday's Journal of the American Medical Association.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not appear to rely solely or largely on a press release. ", "answer": 1}, {"article": "The company, which says gammaCore is already available in the European Union, expects to start selling it later this year in the U.S.\n\nVagus nerve stimulation is used to treat a range if disorders, including epilepsy, depression and overeating.\nRelated: New Migraine Drugs Would Treat Pain Before it Starts\n\nSilberstein helped test the device, which users press against the neck.\nThe device is a vagus nerve stimulator and it\u2019s not entirely clear how it works.\nBoth approaches are limited \u2014 it\u2019s not safe to use the injection more than twice a day \u2014 and inconvenient.\nThe Food and Drug Administration approved a device on Tuesday meant to treat cluster headaches \u2014 a rare form of headache that affects mostly men.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story relied significantly on the company\u2019s news release and would have been strengthened by\u00a0either directly vetting the claims or seeking an independent expert source to help with that.\nThe only quotes in the story came from a company statement.", "answer": 0}, {"article": "As the ovaries curb production of the hormones estrogen and progesterone in the years leading up to menopause and afterward, women can experience symptoms ranging from irregular periods and vaginal dryness to mood swings and insomnia.\nWith additional years of follow-up, it also appears that the increased heart attack risk associated with HRT in the initial results from the WHI trials is limited to older women, McNeil added.\nFor women who started hormones in their 60s or 70s, however, there wasn\u2019t a meaningful difference in death rates according to whether they got the treatment or a placebo during the initial years of the study.\n\u201cWomen seeking treatment for distressing hot flashes, night sweats or other menopausal symptoms may find the mortality results reassuring,\u201d said lead study author Dr. JoAnn Manson of Brigham and Women\u2019s Hospital and Harvard Medical School in Boston.\nAfter 18 years, including both the treatment period and a decade or more of follow-up, women\u2019s age when they joined the study no longer appeared to significantly influence death rates.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes original reporting and does not rely solely on the news release.", "answer": 1}, {"article": "\u201cThis is hugely significant.\n\u201cThis study breaks new ground in uncovering how some breast cancers continue to survive without oestrogen and suggests that women could benefit from adding statins to standard anti-hormone treatments.\nOur study also demonstrates that statins could be a valuable addition to breast cancer treatment, and that this warrants investigation in clinical trials.\u201d\n\nThe research has not yet been tested in humans.\nCholesterol production by the tumour will not be the only reason why ER-positive breast cancers recur, but campaigners are excited by the possibilities for a treatment if further research corroborates these findings.\n\u201cThis early study raises an interesting question of whether cholesterol-reducing treatment, such as statins, could help lower the chances of breast cancer returning for some women who have developed a resistance to hormone therapy,\u201d said Jane Murphy, clinical nurse specialist.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "While the story does include unique quotes not found in the news release, it also uses quotes directly from the news release without attribution, such as this one:\n\u201cDuring the course of treatment, ER-positive breast cancers that are \u2018fed\u2019 by oestrogen often become resistant to standard hormone therapy. Our research has demonstrated that these cancer cells can use a cholesterol molecule to mimic oestrogen so that they continue to grow without it.\n\u201cThis is hugely significant. Testing the patient\u2019s tumour for 25-HC or the enzymes that make it may allow us to predict which patients are likely to develop resistance hormone therapy, and tailor their treatment accordingly.\n\u201cOur study also demonstrates that statins could be a valuable addition to breast cancer treatment, and that this warrants investigation in clinical trials.\u201d\nAnd this quote:\n\u201cThis is a really crucial discovery. Far too many women have to deal with the potentially devastating consequences of their breast cancer coming back and this research presents an important opportunity to improve the effectiveness of today\u2019s most commonly used treatments.\n\u201cThis study breaks new ground in uncovering how some breast cancers continue to survive without oestrogen and suggests that women could benefit from adding statins to standard anti-hormone treatments.\n\u201cBut this is early research and greater clinical evidence is now needed to understand the potential risks and benefits of this approach.\u201d", "answer": 0}, {"article": "We are actively seeking the best-suited licensees having resources and marketing expertise to maximize sales for each of our products in the U.S. and globally.\"\nEach HSRx OTC drug product is proven in independently conducted clinical studies to provide superior treatment outcomes.\nAt 72 hours, OsteoRx\u2122 results were nearly five and a half times better.\nThe clinical studies support powerful marketing claims.\nAfter 48 hours, the average pain reduction for OsteoRx\u2122 users was nearly three times greater than for patients using the competing brand.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The headline is unjustifiable. It refers to a \u201cclinical research study\u201d which is never identified or referenced.\nDue to the absence of the clinical study, the claims of pain relief and increased range of motion are also unjustifiable.", "answer": 0}, {"article": "But she added, \u201cThe community hopes that if telaprevir is approved by the F.D.A.\nBut analysts expect the drug to cost tens of thousands of dollars for a course of treatment.\nThat shorter time line, plus a higher chance of success, could entice more people to be treated, experts say.\nThat is seen as essentially a cure.\nBut experts hope that eventually several of the pills now in development could be used together, much as AIDS is treated, doing away with the need for interferon.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Not applicable because we can\u2019t be sure of the extent to which a news release impacted this story.\u00a0 But we also can\u2019t figure out what the source is of the information provided unless it\u2019s the company. \u00a0", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2009/11/02/financial/f035110S68.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure of the extent to which the story was influenced by a news release.\u00a0 We do know that no independent source was quoted.", "answer": 2}, {"article": "Atrial fibrillation (also called AFib or AF) is a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications.\nAbout half of those patients will develop AF after surgery.\nThe association has strict policies to prevent these relationships from influencing the science content.\nThe injections were made in the four major fat pads surrounding the heart.\nThe results must be replicated in larger studies before Botox injections are routinely used to prevent AF after bypass surgery, researchers said.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release does not use unjustifiable language. Instead, the language is very measured and appropriate.", "answer": 1}, {"article": "CT (computed tomography), sometimes called CAT (computed axial tomography), is performed by computerized machines that scan patients with X-rays to create three-dimensional cross-sectional images of organs and other parts of the body, providing far greater detail than standard single X-rays.\nBecause it would take decades to follow a large number of patients who have undergone CT scans to determine the exact risks posed by the exams, there are no direct data demonstrating the danger.\nA child's risk may run as high as one case of cancer for every 500 scans, experts say.\nWhile there are scant hard data about how often CT scans are done needlessly, several experts estimated that perhaps one-third could be eliminated.\nSome say part of the blame lies with physicians who have financial interests in imaging facilities.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story quotes multiple experts, the reader can assume that the story does not rely on a press release as the sole source of information.", "answer": 1}, {"article": "Hysterectomy is the surgical removal of the uterus.\nWhat's happening now is that the vast majority, about 70 percent, are done the old-fashioned way, with a large surgical incision, lots of pain, and a six-to-eight-week recovery.\nThe surgery she's upset about may be archaic - but it's very common.\n\"You would want them to have the least invasive procedure possible.\"\nShe thinks hundreds of thousands of them are getting the wrong operation every year.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no way to know if the story relied on a press release as the sole source of information. However, we have some suspicions. Does funding of the National Women\u2019s Health Resource Center report\u00a0by Ethicon, inc. (a manufacturer of surgical equipment), released at the Congress of Minimally Invasive GYnecologists, have anything to do with this focus? If the concern is too many abdominal hysterectomies, the focus should be on all the alternatives to it \u2014 medication, progestin IUD, and especially vaginal hysterectomy.\u00a0 ", "answer": 2}, {"article": "Philip Gehrman, a Penn clinical psychologist who was senior author, said the study proves that rapid treatment of depression is possible. But more research is needed to figure out why sleep deprivation works. His team is now conducting its own study. He's not hoping to use sleep deprivation as a treatment but thinks that pinpointing what it does to the brain will help doctors develop other, more sustained treatments.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on the news release, and demonstrates independent reporting by adding details and quotes that were not part of the release.\n\u00a0", "answer": 1}, {"article": "Ralph Sacco and Tatjana Rundek of the University of Miami in an accompanying editorial.\nThe study was also noteworthy because, over the long haul, patients did a particularly good job of taking the medications they were given.\nOutcomes in this study were at least 50 percent lower than those reported in previous studies,\u201d Sacco and Rundek write.\n\u201cAlthough this was not a randomized trial and there was no comparison group to assess whether specialized units performed better than nonspecialized (stroke) units, these (newly-reported) risks are substantially lower than expected.\nOne year after symptoms, the stroke rate was 5.1 percent.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because of the inclusion of independent sources, this story doesn\u2019t appear to rely on a news release.", "answer": 1}, {"article": "The report concluded that both are necessary for bone health but that as for preventing cancer, heart disease, diabetes and autoiummune disorders, the evidence was \u201cinconsistent, inconclusive as to causality, and insufficient to inform nutritional requirements.\u201d Even so, the committee recommended that children and adults up to age 70 get 600 IU of vitamin D daily \u2014 from food and, if necessary, supplements \u2014 and that adults age 71 and older get 800 IU.\nThe one thing the research leaders are certain of is that the public\u2019s faith in vitamin D as a modern panacea has far outpaced what the scientific evidence proves.\nIn fact, the physician has wagered a few good bottles of champagne that none of three large randomized trials now underway will find proof of positive effects.\nThat\u2019s why there are no official recommendations yet from any medical organizations.\nUnfortunately, the lessons of history have shown repeatedly that many of these supplements that appeared to be very promising did not pan out in more rigorous testing.\u201d\n\nManson should know.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story clearly goes beyond any news release.", "answer": 1}, {"article": "We are excited to announce that FibromyalgiaTreating.com is now part of RedOrbit.com. All of the same great people, writers and editors but now with more firepower. We now have access to an enormous amount of additional research information from doctors and scientists. We can now extend to other conditions that may be part of your everyday lives and help you on a broad level if that is what you need. We are here for you and now, better than ever so sit back and enjoy the new Fibromyalgia Treating by RedOrbit!", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely solely on a press release for information, and there is independent reporting and sources cited not affiliated with the recently published data on CAD. ", "answer": 1}, {"article": "If necessary, he suggests finding an indoor place to move, whether it's the gym, a staircase or a shopping mall.\nFortunately, new research shows there is a simple antidote: 30 minutes of exercise a day, year-round.\n\"Just 30 minutes a day of walking, riding a bike, doing yoga -- anything active, really -- can result in significant reduction of asthma symptoms.\"\nCould a prescription for exercise be the result of this study Bacon is hopeful.\nIt's something to keep in mind during winter months, when fitness levels tend to drop along with the temperature, and cold air provides another trigger for asthma symptoms.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "This point was also touched upon in the \u201cQuality of Evidence\u201d section. We feel some of the wording used in the news release could have been toned down, such as \u201csimple antidote,\u201d \u201coverwhelmingly clear,\u201d \u201csignificant reduction\u201d and a \u201cwhopping 245.\u201d The release also incorrectly implied causality rather than association with its choice of words \u2014 e.g. \u201crelieves symptoms\u201d in the headline. We would recommend more neutral and even cautionary language when reporting the findings of a study with significant limitations such as this one.", "answer": 0}, {"article": "Dana Greene, a nutritionist in Boston, regularly tells her patients to consume more fruits and vegetables, including berries.\nThe study included nearly 94,000 young and middle-aged women who took part in the Nurses' Health Study II.\nDuring the study period, 405 participants had heart attacks.\nWhat does a heart attack look like in women?\nThe study was funded by the U.S. National Institutes of Health and the U.K. Biotechnology and Biological Sciences Research Council.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The lede of the HealthDay story is almost identical to the press release, and the story uses similar language as the release.\u00a0However, there is evidence of original reporting with the two independent sources.\u00a0 Barely satisfactory.", "answer": 1}, {"article": "\"We need people to swim against the stream.\nThe new device was about that accurate at differentiating between severe and less severe heart failure patients.\nThe device has gas sensors that detect various odorous molecules in sweat.\nThe goal of the project is to develop a simple, accurate, noninvasive, and reproducible method for early identification of chronic heart failure, he tells WebMD.\nThe researchers are now testing more than 1,000 patients and trying to identify the odorous molecules unique to heart failure patients, Kechagias says.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a news release.", "answer": 1}, {"article": "\"Blueberries are one of the more potent foods in terms of protecting the brain,\" Morris said.\nThe MIND diet recommends limiting yourself to no more than five of these treats per week.\nNow here are the five food groups it says you should avoid to reduce your risk of developing dementia...\n\nYou already know they're not so good for your waistline, and it turns out pastries and other sweets could have a negative effect on brain health as well.\nThe MIND diet recommends eating berries at least twice a week.\nBerries are the only fruit specifically recommended in the MIND diet.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "A news release by Rush University is available online. The story includes enough information beyond the press release that we are satisfied that it did not rely too heavily on it.", "answer": 1}, {"article": "The amygdala and hypothalamus are regions of the brain that control several memory and emotional functions.\nThe double-blind, placebo-controlled study involved 40 adults between the ages of 50 and 90 years who had mild memory complaints.\nThe research, published online Jan. 19 in the American Journal of Geriatric Psychiatry, examined the effects of an easily absorbed curcumin supplement on memory performance in people without dementia, as well as curcumin\u2019s potential impact on the microscopic plaques and tangles in the brains of people with Alzheimer\u2019s disease.\nThe people who took curcumin experienced significant improvements in their memory and attention abilities, while the subjects who received placebo did not, Small said.\nTheravalues Corp. provided the curcumin and placebos for the trial, as well as funds for laboratory testing and for Small\u2019s travel to present preliminary findings at the 2017 Alzheimer\u2019s Association International Conference.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release\u2019s first sentence says that people should consume more Indian food for health benefits, but the study measured the effects of \u201can easily absorbed curcumin supplement\u201d \u2014 not traditional Indian meals.", "answer": 0}, {"article": "\u2022 Measure baseline omega-3 intake or status of study participants to determine the extent to which it confounds results.\n\"The 6 percent reduced risk among RCTs, coupled with an 18 percent risk reduction in prospective cohort studies -- which tend to include more real-life dietary scenarios over longer periods -- tell a compelling story about the importance of EPA and DHA omega-3s for cardiovascular health.\"\n\"It's also important that the observed risk reductions were even stronger in patient populations with elevated triglycerides and LDL cholesterol levels, two risk factors that affect more than one quarter of the American population.\"\n\"There are important public health implications related to reducing the risk of coronary heart disease, and therefore we are encouraged by the results of this comprehensive analysis,\" said Dr. Harry Rice, Vice President of Regulatory and Scientific Affairs for the Global Organization for EPA and DHA Omega-3s (GOED), which funded the study.\n\"The results confirm that increasing omega-3s is a healthy lifestyle intervention that can contribute towards reductions in CHD risk,\" added Adam Ismail, Executive Director of GOED.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "A few points here. First, the release states that increasing their consumption of omega-3s is a \u201cchange that most consumers need to make.\u201d That\u2019s over-reach, and that alone would give the release an unsatisfactory rating here.\nBut there\u2019s one other note that we\u2019ll make here, since it doesn\u2019t really fit anywhere else: at no point does the news release tell readers what EPA and DHA stand for. Nor does it explain what they are, or even what omega-3 fatty acids are, much less how they may be beneficial for heart health. If you\u2019re going to use terms that are not common knowledge \u2014 such as \u201cDHA omega-3s\u201d \u2014 please give your readers some idea of what you\u2019re talking about.", "answer": 0}, {"article": "\"The idea is when you get the treatment and it is successful and the pain gets better then you can start cutting down the on the medication, and see how low you can go\" said Dr. Richard Cruciani.\nSince then, the technique has been refined.\nThis new approach places them right on the scalp.\nCould this could work for all kinds of pain?\nFor years, his only relief was a cocktail of prescribed medications.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The segment does not appear to be influenced by the press release. ", "answer": 1}, {"article": "\u201cIt\u2019s not going to be a panacea,\u201d says Thomas.\nThe compound, created by chemists at the Scripps Research Institute, works in a way that\u2019s similar to other vaccines.\nImportantly, this vaccine is designed to work against only heroin, not other opioids.\nAll four monkeys responded to the vaccine, but the two that were receiving it a second time had a stronger response, hinting that their immune systems were already primed with the \u201cmemory\u201d of the compound.\nHere, the Scripps investigators, working with researchers at Virginia Commonwealth University, tested the vaccine on four rhesus monkeys.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story closely resembles the news release from the Scripps Institute in substance and in the use of quotes from the researchers.\u00a0However, because an outside source was quoted, it doesn\u2019t rely solely on the news release.", "answer": 1}, {"article": ".\nThis new radionuclide drug shows strong binding to the protein PSMA and is readily and safely taken up by malignant PSMA-positive tumors.\nPSMA-617 could represent a watershed moment for prostate cancer theranostics.\nPositive response to therapy was verified via combined PET and computed tomography (PET/CT), a hybrid imaging system that shows both functional and structural aspects of the body.\nThis phase was followed by a first-in-human clinical trial of both imaging and therapy in a single person.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There is too much frothy language in this release based on a study that involved only one patient. For example:\nWe also wish the release had defined the word \u201ctheranostics,\u201d which would have made it easier for readers to tell if this is, indeed, a \u201cwatershed moment\u201d in that field.", "answer": 0}, {"article": "In addition, people can obtain folic acid from breads, cereals and other grain products enriched with folic acid, as well as folic acid supplements.\nHowever, there is no scientific evidence that taking folate supplements will be beneficial, Armstrong noted.\nNone of the other factors they examined accounted for their finding, Nilsson's team noted.\nIn fact, folate deficiencies may be involved in the development of autism, he added.\n\"We know that, in young children, folate deficiencies are associated with poorer neurocognitive function and neurocognitive development,\" he noted.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not appear to rely solely on a news release.", "answer": 1}, {"article": "\u2022 The percentage of days with full asthma control were virtually the same for acetaminophen and ibuprofen: 85.8 and 86.8 percent, respectively.\nWhile the study was modest in size, it was powered to detect any clinically significant differences, more so than past retrospective studies, Phipatanakul notes.\nThe study enrolled 300 children 1 to 5 years old with mild persistent asthma.\n(The asthma therapies were given in varying order as part of a concurrent randomized trial, making this, in effect, a \"trial within a trial.\")\nOf the original 300 children, 226 (75 percent) completed the study.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release from Boston Children\u2019s Hospital does not use unjustifiable, sensational language.", "answer": 1}, {"article": "New vertebral fractures occurred less frequently in the active treatment groups vs placebo: in 0.58 percent (n = 4) of participants in the abaloparatide group; in 0.84 percent (n = 6) of participants in the teriparatide group; and in 4.22 percent (n = 30) of those in the placebo group.\n\u201cFurther research is needed to understand the clinical importance of risk difference, the risks and benefits of abaloparatide treatment, and the efficacy of abaloparatide vs other osteoporosis treatments,\u201d the authors write.\n: This study was funded by Radius Health.\nOverall, there were no differences in serious adverse events between the treatment groups.\nAdditional therapies are needed for prevention of osteoporotic fractures.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There is no unjustifiable language in the release.", "answer": 1}, {"article": "Anderson Cancer Center.\nThat is due in part to the lack of any easy way to detect the cancer in its earliest stages.\nIf such a test were developed, it would likely be used first to test patients at high risk for pancreatic cancer.\nThe new finding could lead to a blood test that would allow doctors to screen for pancreatic cancer much more effectively.\nLevels of the protein were markedly lower after surgical removal of a patient's tumors.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story quotes just one source, the chair of MD Anderson\u2019s Cancer Biology department (the institution that issued a news release for the study), and those quotes can be found in the news release, we believe the story relied too heavily on the release.", "answer": 0}, {"article": "Sonata uses a probe that is inserted through the cervix into the uterus. The probe not only allows the doctor to see the fibroid using ultrasound, but it also has a radio-frequency device at the tip. The doctor hits a foot pedal to send energy through the probe to heat the fibroid, shrinking it over time. The body absorbs the dead tissue, so it does not have to be surgically removed.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to be based on a news release.", "answer": 1}, {"article": "Researchers are developing decision aids to guide physicians and consumers beginning to struggle with lung cancer screening.\nBut it is worth remembering that however effective it is, screening can\u2019t ward off disease.\nThe post-surgical death rate in the national trial was just 1 percent, but that involved major medical centers with specialized radiologists and surgeons \u2014 the ideal setting.\nSo those required \u201cshared decision-making visits\u201d with doctors will involve lots of very individual questions and judgments.\nResearchers call it \u201ccompeting mortality.\u201d Finding lung cancer is a hollow victory if patients endure testing and treatment, then die of another illness before the cancer would have killed them.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We see no evidence that this analytical narrative relied on a news release.", "answer": 1}, {"article": "\"Whether the vaccine is going to look anything like this one I don't know.\nThe results were barely significant on statistical grounds, perplexing for scientific reasons and unanticipated by most researchers.\nIt is unlikely -- but not impossible -- that any country would consider it effective enough to be used as a public health measure against HIV.\nNevertheless, the first positive result for an AIDS vaccine after two decades of experimentation is being called a milestone.\nOther researchers were less sanguine about the study but did not want to be quoted by name as being skeptical when only a few details of the results have been released.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It is abundantly clear that this story did not rely on a news release, but, rather, was based on enterprise journalism with context and with a historical perspective.\u00a0 ", "answer": 1}, {"article": "Mitochondria are the organelles within the body\u2019s cells that generate energy.\nWhether much lower doses would benefit athletic performance is not clear, Dr. Evans said.\nThat is the process that he says is reversed by resveratrol and, he hopes, by the more powerful sirtuin-activator drugs that his company is developing, though many years of clinical trials will still be needed to demonstrate whether they work and are safe to use.\nOne manufacturer of such capsules is Longevinex, whose president, Bill Sardi, said today that demand for the product had increased by a factor of 2400 since Nov. 1.\nDr. Ronald M. Evans, a leading expert on the hormonal control of metabolism at the Salk Institute, said that the report by Dr. Auwerx\u2019s team had \u201cshown very convincingly that resveratrol improves mitochondrial function\u201d and fends off metabolic disease.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not appear to rely on a press release.", "answer": 1}, {"article": "It will enable us to have more potent countermeasures to jet lag than continuous light, which is the current prescribed light therapy treatment,\" Zeitzer said.\nZeitzer's latest study, published Monday in the Journal of Clinical Investigation , could make treatment easier by providing light exposure during sleep, before the trip, without changing or interrupting your routine.\nThe treatment \"exploits biology in the eye\" to speed up the brain's adjustment to time changes, he said.\nThis time around, researchers tried to further optimize the process.\nParticipants were able to sleep through the flashes of light without waking.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Despite its reliance on one source, it doesn\u2019t appear as if the article is overly indebted to a PR news release. The article contains quotes from the study co-author that are different than those found in the release.", "answer": 1}, {"article": "Pernilla Wittung-Stafshede stresses the importance of finding ways to combat these neurological conditions in the future:\n\n\"These diseases come with age, and people are living longer and longer.\nNow, new research from Chalmers has shown that the protein parvalbumin, which is very common in many fish species, may be contributing to this effect.\n\"It will be very interesting to study how parvalbumin distributes within human tissues in more depth.\nWith the parvalbumin protein so highly abundant in certain fish species, increasing the amount of fish in our diet might be a simple way to fight off Parkinson's disease.\nMore About: Fish and Better Neurological Health\n\nThe link between higher consumption of fish and better long-term health for the brain has been long established.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There are glimpses of cautious language in this news release such as:\n\u201cIt will be interesting\u00a0 to study how parvalbumin distributes within human tissues in more depth.\u201d\n\u201cThe team is careful to note that no definite links (between higher fish consumption) can be established at this point.\u201d\nBut this is drowned out by unjustified phrasing (italicized) like this:\n\u201cAmyloids are not necessarily a bad thing, but can be responsible for various diseases.\u201d\n\u201cincreasing the amount of fish in our diet might be a simple way to fight off Parkinson\u2019s disease.\u201d\n\u201cOther neurodegenerative diseases, including Alzheimer\u2019s, ALS, and Huntington\u2019s disease are also caused by certain amyloid structures interfering in the brain.\u201d\nFinally, the evidence here is in fish. Not humans. And even if it was in humans the language used in this news release would still be unjustified.", "answer": 0}, {"article": "\u201cNow we know that electrical impulses to the olfactory bulb can provide a sense of smell \u2014 and that\u2019s encouraging.\u201d\n\nIn addition to Dr. Holbrook, authors on the International Forum of Allergy & Rhinology study include co-first author Sidharth V. Puram, MD, PhD, of Washington University School of Medicine, Reiner B.\nReporting online today in International Forum of Allergy & Rhinology, the research team describes their results, which provide a proof of concept for efforts to develop implant technology to return the sense of smell to those who have lost it.\nThere are currently no proven therapies for these cases.\nThis breakthrough in human patients opens the door for a \u201ccochlear implant for the nose\u201d to be developed \u2014 though the study authors caution that the concept of an olfactory stimulator is more challenging than existing technologies.\nEye and Ear has pioneered new treatments for blindness, deafness and diseases of the head and neck.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The use of the word \u201cbreakthrough\u201d is out of place in a summary of proof of concept work.", "answer": 0}, {"article": "Children with ADHD have trouble paying attention, focusing and can be hyperactive.\nNineteen of those children had a relapse in symptoms on the challenge test.\nAnd, she added, that clinical practice shouldn't be changed based on the results of one study.\nMost of the children were boys.\nThe researchers selected foods that were considered both low- and high-IgG foods.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story didn\u2019t rely on a news release.", "answer": 1}, {"article": "New Jersey and Ohio were the first to participate statewide in the program.\nShe said the program was eye-opening for how much information she learned about how to prevent sudden unexpected infant death.\nThe boxes are a new idea for many Americans.\nThe boxes aren\u2019t the only option for safe sleeping, of course, but health officials say they\u2019re a useful part of a broader safe-sleep education program.\nThe boxes provide a clutter-free sleep space that has been shown to reduce accidental and unexpected deaths, she said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story doesn\u2019t appear to be based solely on a news release.", "answer": 1}, {"article": "MRI has long been known as an effective breast cancer screening modality that offers better sensitivity than mammography and ultrasound.\nHowever, with breast cancer remaining a major cause of cancer death in women, there is good reason to pursue the search for improved screening methods, according to the study's lead author, Christiane Kuhl, M.D., chair of the Department of Radiology at RWTH Aachen University in Aachen, Germany.\nThe new study showed that, consistent with previous research, breast MRI can depict these rapidly growing cancers with high reliability.\nAccording to Dr. Kuhl, the results suggest that MRI can serve as a useful supplemental screening tool for women at average risk, especially those with dense mammographic tissue, and that MRI is superior to supplemental ultrasound for this purpose.\nThe results also highlight the ability of MRI in the detection of more aggressive types of cancer.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t rely on sensational language.\nHowever, we find the opening\u00a0sentence of the news release to be, if not unjustifiable, potentially misleading:\n\u201cMRI screening improves early diagnosis of breast cancer in all women-not only those at high risk-according to a new study from Germany published online in the journal Radiology.\u201d\nTo our eyes, there is nothing in the study that supports this claim applied to\u00a0all women. The cohort examined in this prospective observational study are characterized by women with average risk of breast cancer.", "answer": 1}, {"article": "The California Walnut Commission offices are located at 101 Parkshore Dr., Ste.\nCo-authors with Dr. Falk are Liana C. Del Gobbo, PhD, Robin Feldman, MBA, Kara Lewis, PhD, and Dariush Mozaffarian, MD, PhD.\nOf 1,301 articles surveyed, 61 trials met eligibility criteria for this systematic review and meta-analysis, totaling 2,582 unique participants.\nThis study was supported in part by funds from The International Tree Nut Council Nutrition Research and Education Foundation.\nCWC is an equal opportunity employer and provider.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release uses a measured, professional tone and no unjustifiable language.", "answer": 1}, {"article": "Whitcomb, whose research on the determinants of fertility and pregnancy outcomes usually involves studying biomarkers at the molecular level, adds, \"Lifestyle is definitely relevant to these outcomes because it can have an effect at the molecular level.\nFurther study is necessary to clarify possible mechanisms through which walking and vigorous activity might affect time-to-pregnancy.\"\nModerate activity, sitting and other activity categories were not associated with fecundability overall or in BMI-stratified analyses, they add.\nWhitcomb says, \"We don't know what to make of the finding that high intensity physical activity may have different biological effects than walking, but our study doesn't offer enough detail to get at why vigorous activity would work differently than other levels.\"\nThe researchers also note that the overall generalizability of this work is limited because the study population may not be representative of the general population with regard to fecundability, and exercise habits may differ in women with prior miscarriage compared to those without.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "In general, this news release does a very good job of using cautious language. However, it should have avoided the cause-and-effect language implied by the use of the words \u201cmay aid\u201d in the headline, particularly since this was a secondary analysis of earlier research into side effects of aspirin use during pregnancy, not a randomized controlled trial of walking during pregnancy. The latter type of study might have warranted the more causal language.\nWe did appreciate the inclusion of the final sentence:\nFurther study is necessary to clarify possible mechanisms through which walking and vigorous activity might affect time-to-pregnancy.\n\u00a0", "answer": 1}, {"article": "Kymriah is a leukemia treatment made by pharmaceutical giant Novartis.\nThe drug will be available in the United States in early spring, with an estimated 1,000 to 2,000 people in the US standing to benefit from this treatment, according to Spark.\nIn the phase 3 clinical trial, 27 out of 29 participants -- 93% -- who received the gene therapy demonstrated a gain in functional vision as assessed by a mobility test performed in a maze, according to the company.\nOne-time-only treatments for rare genetic disorders are still unique, he noted.\nThe company also stated that its proposal to the Centers for Medicare and Medicaid Services, the government program that covers about 100 million Americans, would allow installment payments for the drug.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story contained information not available in the Spark Therapeutics news\u00a0release.", "answer": 1}, {"article": "Myo-inositol is also found in fruits, beans, grains and nuts, although Bild said the finding does not necessarily explain why people who eat more of these foods have a lower risk of cancer in general.\nAnd, they said, a natural supplement derived from food that is being tested to prevent lung cancer appears to halt the precancerous changes.\nAnd the second group was taking the natural supplement, myo-inositol, to try to prevent lung cancer.\nSpira and Bild put together results from two ongoing trials of smokers.\nBut another experiment got the researchers more excited.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "       \n \nThis piece did not rely solely on a news release. \n ", "answer": 1}, {"article": "\u201cIt is important to know that Noctiva is not approved for all causes of night-time urination, so patients should discuss their symptoms with their health care provider who can determine the underlying cause of the night-time urination and whether Noctiva is right for them.\u201d\n\nNocturia (wakening at night to urinate) is a symptom that can be caused by a wide variety of conditions, such as congestive heart failure, poorly controlled diabetes mellitus, medications, or diseases of the bladder or prostate.\nNoctiva is being approved with a boxed warning and a Medication Guide because it can cause low sodium levels in the blood (hyponatremia).\nNoctiva should not be used in children.\nNoctiva is the first FDA-approved treatment for this condition.\nNoctiva is also not recommended for the treatment of nocturia in pregnant women.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There\u2019s no sensationalizing here.", "answer": 1}, {"article": "Macular edema can arise during any stage of diabetic retinopathy and is the most common cause of diabetes-related vision loss.\nSubsequently, injections were resumed if DME worsened.\nLaser treatment alone was the standard treatment for DME until widespread adoption of anti-VEGF drugs a few years ago.\nAdditionally, laser treatment was given if DME persisted without continual improvement after six months of injections.\nOf these, about 750,000 have DME.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "No unjustifiable language here.", "answer": 1}, {"article": "Article reference: Thomas L. Jang, Neal Patel, Izak Faiena, Kushan Radadia, Dirk F. Moore, Sammy E. Elsamra, Eric A.\nAnother interesting finding from the research was that slightly more than half of men diagnosed with the disease did not receive combination therapies for their prostate cancer.\n\"This important study demonstrates that many men with high-risk prostate cancer derive a survival advantage through a multi-modality approach to their disease.\n\"Our study suggests that removing the prostate followed by adjuvant radiotherapy is associated with greater overall survival in men with prostate cancer.\"\nThey found that 10 years after treatment, 89 percent of the prostate removal plus radiation group was still alive.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release refrains from unjustifiable language except by overselling the findings in the lead, saying researchers \u201chave shown that more patients live longer if treated with the combination of prostate removal plus radiation therapy.\u201d That language implies that those treatments caused patients to live longer even though the study was not capable of showing a cause-and-effect relationship. But since we\u2019ve already addressed that issue elsewhere in the review, we\u2019ll award a satisfactory rating here to avoid docking points twice for the same concern.\nBetter language was contained in this quote from the researchers: \u201cOur study suggests that removing the prostate followed by adjuvant radiotherapy is associated with greater overall survival in men with prostate cancer.\u201d", "answer": 1}, {"article": "Healthy dietary patterns were generally higher in fruits, vegetables, fish, legumes, cereals, whole grains, and fiber, and they were lower in red meat, salt, and refined sugars.\nAll content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects.\nThe findings appear in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN).\nThe article, entitled \u201cHealthy Dietary Patterns, Mortality and End-Stage Kidney Disease in CKD: A Meta-Analysis of Cohort Studies,\u201d will appear online at http://cjasn.asnjournals.org/ on December 8, 2016, doi: 10.2215/CJN.\nThis content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There is no unjustifiable language in the release.", "answer": 1}, {"article": "\"My reaction was, 'Well, you smoked for 30 years.\nLike many patients his age, he didn't expect there would be any effective treatment.\nAnd, after five years, almost 9 out of 10 patients were alive and cancer free.\nHe was senior author of a study published in the Journal of Clinical Oncology in October.\nThis was the case for Morton Pollner, who is one of Adusumilli's patients.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article does not appear to rely on a news release.", "answer": 1}, {"article": "Microcapsules loaded with stem cell-derived insulin-producing cells retrieved after they had been transplanted into a mouse.\nThose drugs are not ideal, because they carry a risk of infection or cancer.\nBut experts say the findings provide hope for future treatments for people.\n\u201cThe main issue with type 1 diabetes is a loss of beta cells,\u201d said ViaCyte CEO Paul Laikind, \u201cbut there\u2019s also good data out there to suggest dysfunction in other regulatory cell types.\u201d\n\nThe team behind the studies published Monday, meanwhile, is working on tests now in monkey models.\nVegas said that if the primate studies are successful, the next step will be developing a therapy to be used in people.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a news release.", "answer": 1}, {"article": "His doctor prescribed a C.P.A.P.\nBut not everyone finds that Provent alleviates their apnea.\nIn those people, Provent typically doesn\u2019t work.\n\u201cMy symptoms subsided dramatically.\u201d\n\nProvent works like a traditional C.P.A.P.\nIt is also more expensive, and it doesn\u2019t work for every patient.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a press release.", "answer": 1}, {"article": "Tiny channels collect perspiration and route it to different compartments where it interacts with chemicals that change color to reflect sweat loss, the perspiration\u2019s acidity level, and concentrations of chloride, glucose and lactate.\nThe experimental gadget goes well beyond activity monitors like the Fitbit.\nWhile Wednesday\u2019s studies used an early version that analyzed sweat just once during the exercise, he\u2019s now testing a design capable of multiple measurements over time.\nThe skin-like sweat patch adds a capability called microfluidics, capturing and analyzing tiny amounts of body fluid.\nRogers\u2019 sweat patches are designed for one-time use over a few hours.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "Newswise \u2014 RESEARCH TRIANGLE PARK, NC\u2014 Major depressive disorder affects more than 32 million Americans, and their first stop for treatment is often their primary care provider.\nHowever, the evidence shows that cognitive behavioral therapy can be just as effective, providing important information for patients and their physicians to consider when choosing among available treatment options.\"\nThe research from the RTI International-University of Chapel Hill Evidence-based Practice Center was published today in the British Medical Journal.\nThe authors focused specifically on comparing second generation antidepressants, such as Wellbutrin, Lexapro and Prozac with cognitive behavioral therapy, which includes several in-person or phone sessions with a therapist to examine how actions and thoughts can impact depression.\n\"Our findings indicate that both options should be considered effective initial treatment strategies.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t use unjustifiable language. Some of the language is muddied in that it doesn\u2019t spell out the difference between major depressive disorder and other types of depression.", "answer": 1}, {"article": "Legumes, beans, whole grains and some seeds have it, as do uncooked potatoes and unripe bananas.\nIt\u2019s too soon to tell if resistant starch can help people weight.\nMost intriguing and surprising of all is that so many leftovers contain resistant starch.\nEven if you heat them up again, they retain their new resistant starches.\nBut that\u2019s not the case with resistant starches, so named because they resist digestion.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "In its statement, the panel said that \"for some adults ages 76 to 85, the benefits of screening are smaller, and the potential for harm greater.\nHowever, the U.S. Preventive Services Task Force stopped short of saying any one screening method was better than another.\nPeople with disorders or medical histories that raise their odds for colon cancer may need more rigorous screening, the USPSTF said.\nThis year about 134,000 people in the country will be diagnosed with the disease, and about 49,000 will die from it., the panel said\n\nThe USPSTF is an independent, volunteer panel of experts that makes recommendations about the effectiveness of specific preventive health services.\nAll of the recommendations are specific to symptom-free people 50 years of age or older with an average risk colorectal cancer, the panel stressed.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes comments from an independent physician, which is enough to squeak by as Satisfactory on this rating. However, it should be noted that all of the comments from the USPSTF came from a news release. Although the story clearly attributes the source of the USPSTF comments, which is good, ideally there would also have been at least some original commentary\u00a0directly from task force members, providing unique\u00a0insights not found in the news release.", "answer": 1}, {"article": "For more on omega-3 fatty acids, visit the National Institutes of Health.\nNone of the low-dose supplements seemed to stave off such events in most of the patients.\nAll had experienced a heart attack at some point in the decade leading up to the study, and all were taking blood pressure medications, anti-clotting drugs and statins.\nThe amount of supplementation added to the various margarines was deemed to be \"low-dose.\"\nIn the study, researchers focused on a group of more than 4,800 Dutch heart attack patients between the ages of 60 and 80, slightly more than three-quarters of whom were men.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "No evidence that the story relied solely or largely on a news release. ", "answer": 1}, {"article": "Doctors in Seattle cured a late-stage cancer patient after tinkering with his body's defenses against infection, leading to cautious optimism about treating late-stage melanoma, a deadly skin cancer.\n\nThe surprising result, published in this week's issue of the New England Journal of Medicine, is the latest hopeful finding from the 30-year-old field of \"adoptive immunotherapy,\" which theorizes that the body can be taught to fight off its own cancers.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\nIt does not appear that the story relied solely or largely on a news release. \n", "answer": 1}, {"article": "Women aged 70 to 75 had the greatest risk reduction, reducing the risk of dying from breast cancer by 84 percent.\nThe study appears online Dec. 6 in the journal Cancer Epidemiology, Biomarkers & Prevention.\nThe greater risk reduction in women aged 70 to 75, Otto said, is probably a result of the long-term good effects of screening participation in the earlier target age group, 50 to 69, before the upper age limit for screening was extended in the Netherlands from 69 to 75.\nThe routine screening also lowered the chances of being diagnosed with an advanced cancer, she said.\nThe study, however, has some limitations, Bernik noted.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This article clearly states it is based on a publication in the journal Cancer Epidemiology, Biomarkers and Prevention Dec. 6,2011.", "answer": 1}, {"article": "The majority of smokers who successfully switch to vaping say they have fewer respiratory infections, according to a study led by Queen Mary University of London\n\nThe majority of smokers who successfully switch to vaping say they have fewer respiratory infections, according to a study led by Queen Mary University of London (QMUL).\n\"The study needs to be interpreted with caution because it is based on self-reported data, and further studies using objective measures are needed.\nThe main limitation of the study is that the reports are subjective.\nThis misinformation includes a misreported study on rats that claimed that vaping may increase vulnerability to infections.\nFuture studies should assess respiratory symptoms objectively and on unselected samples of vapers.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release does not use unjustifiable language.", "answer": 1}, {"article": "They found that Chinese women who ate the most soy were also less likely to die of lung cancer, the No.\nOf the 444 patients with lung cancer, 318 died during the three years of follow-up, the researchers wrote.\nIt wouldn\u2019t be difficult to eat enough soy to be protected, Patel noted.\n\u201cThis finding, along with our previous observation of an approximately 40 percent reduction in risk of incident lung cancer associated with high intake of soy food, provides further support for the role of soy food intake in lung cancer development and prognosis,\u201d the researchers wrote.\n\u201cThe high soy level patients were eating what the FDA has said is heart-healthy, or 25 grams of soy a day,\u2019 she said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not seem to have relied inappropriately on this press release. Plus there was an independent expert comment.", "answer": 1}, {"article": "\u201cBut there\u2019s never before been data saying how harmful stopping shortly before surgery can be.\nThe scientists had no data on how long patients had been taking statins, but only on when they stopped.\n\u201cWe already knew that people on statins before surgery had a decreased risk of death,\u201d said a co-author, Dr. Yi Deng, an assistant professor of anesthesiology at Baylor College of Medicine.\nResearchers looked at 3,021 heart surgery patients, most of whom were taking cholesterol-lowering statins.\nAfter controlling for many preoperative health and behavioral characteristics, they found that compared with other patients, those who took statins on the day of surgery had a 48 percent reduced risk of dying in the next 30 days.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This is a barely passing satisfactory because there is a quote from one of the researchers, presumably from an interview, that is not found in the news release.\nOtherwise this story contains no information that can\u2019t be found in the release.", "answer": 1}, {"article": "An electromagnetic wave then agitates water molecules in the surrounding tumor tissue, producing friction and heat that eventually destroy the tumor.\nU.S. researchers say the technique certainly shows promise.\nThe findings were presented here at the annual meeting of the Radiological Society of North America.\nThe procedure, which costs about $2,000, takes about an hour, and the patient is typically kept overnight in the hospital for observation.\nIn a preliminary study, the technique, called microwave ablation, eliminated lung tumors in 19 of 28 patients.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does not appear that the story relied solely on a press release.", "answer": 1}, {"article": "\u201cIt was a little humiliating, to be honest,\u201d she said of the testing.\nAll the while, the scientists monitored a handful of \u201chot spots\u201d in the brain which, previous work had shown, were strongly related to memory encoding.\n\u201cThe average enhancement effect was about 12 to 13 percent,\u201d Dr. Kahana said.\nBefore the stimulation tests, the team determined the precise settings for each patient\u2019s high- and low-functioning states.\nShe agreed to the memory testing for the study.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "No quotes or even framing seem to have been copied from a news\u00a0release\u00a0posted by the University of Pennsylvania.", "answer": 1}, {"article": ".\n\"PPF could be easily translated to the clinic as an adjuvant therapy in combination with standard of care treatment for GBM patients.\"\nHowever, this security system is so effective at protecting the brain that it prevents many life-saving drugs -- all but some small molecules -- from being able to treat cancer and other diseases of the brain.\nMedian survival for newly diagnosed GBM patients is only 14.6 months.\nSince then, the Foundation has contributed more than $50 million to research in gliomas within the United States and Canada, with the goal of better diagnostics and treatments that offer long-term survival and a high quality of life for patients with brain tumors.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Calling this lab test \u201ca significant breakthrough\u201d misleads readers. Quotes and text throughout the release refer to potential benefits to patients even though this test was done in cell cultures. The actual effects in patients with glioblastoma multiforme are unknown.", "answer": 0}, {"article": "This page either does not exist or is currently unavailable.\n\nFrom here you can either hit the \"back\" button on your browser to return to the previous page, or visit the ABCNews.com Home Page. You can also search for something on our site below.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "", "answer": 1}, {"article": "He says:\n\n\"When I was diagnosed with early prostate cancer, I had the option of active surveillance but I didn't want to wait until it got worse so when I was offered a place on the trial I signed up straight away.\nWith such an approach we should be able to achieve a significantly higher remission rate than in the trial and send nearly all low-risk localised prostate cancers into remission.\nThe VTP treatment is currently being reviewed by the European Medicines Agency (EMA), so it is likely to be a number of years before it can be offered to patients more widely.\nThe chances of cancer progressing to a more dangerous stage were three times lower for patients on VTP, and the treatment doubled the average time to progression from 14 months to 28 months.\n\"New procedures are generally associated with a learning curve, but the lack of complications in the trial suggests that the treatment protocol is safe, efficient and relatively easy to scale up.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "A researcher\u2019s statement that VTP represents a \u201ca huge leap forward for prostate cancer treatment\u201d is overblown. Further, we don\u2019t like that same researcher\u2019s flawed comparison of VTP with advances in breast cancer treatment:\nIn 1975 almost everyone with breast cancer was given a radical mastectomy, but since then treatments have steadily improved and we now rarely need to remove the whole breast. In prostate cancer we are still commonly removing or irradiating the whole prostate, so the success of this new tissue-preserving treatment is welcome news indeed.\nIt remains to be seen whether VTP will \u201csteadily improve\u201d treatment for prostate cancer.\nWe also take issue with this data-free speculation from a researcher:\nWe can now pinpoint prostate cancers using MRI scans and targeted biopsies, allowing a much more targeted approach to diagnosis and treatment. This means we could accurately identify men who would benefit from VTP and deliver treatment more precisely to the tumour. With such an approach we should be able to achieve a significantly higher remission rate than in the trial and send nearly all low-risk localised prostate cancers into remission. We also hope that VTP will be effective against other types of cancer \u2013 the treatment was developed for prostate cancer because of the urgent need for new therapies, but it should be translatable to other solid cancers including breast and liver cancer.\nWe submit that the \u201curgent need\u201d is to find\u00a0tumor markers that better identify low-risk patients who do not need any treatment at all.", "answer": 0}, {"article": "Feb. 3, 2011 -- Children with attention deficit hyperactivity disorder (ADHD) should be offered a special ADHD diet to see if eliminating certain foods might reduce their symptoms, Dutch researchers say.\nIn five weeks of trying the diet, Pelsser says, parents will know if their child is responding or not; if not, they can move on to other treatments.\nThe diet studied, known as the restricted elimination diet (RED), can work, the researchers say, because they believe ADHD symptoms in some children might be affected by eating specific foods.\nU.S. experts had some caveats, saying that the results of the study, which included 100 children, should be repeated in other populations to see if the findings hold up.\nIn the study, published in The Lancet, 78% of children who stuck with the diet did respond by having fewer symptoms.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story didn\u2019t rely on a news release.", "answer": 1}, {"article": "MEMPHIS, Tenn., Oct. 26, 2015 /PRNewswire/ -- Imagine.\nWe are confident that the ICE3 trial can prove certain women can be successfully treated less aggressively than in the past.\nFollowing numerous limited studies, a growing number of women are now being treated with the technique as part of a groundbreaking clinical trial involving leading breast cancer specialists across the country.\nPotentially, it will usher in a new and gentler pathway for the treatment of a disease that affects one in every eight women annually.\nThe ongoing refinement of the technology makes treatment more precise and extremely reliable.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The introduction is pretty dramatic \u2014 \u201cImagine. A nick of the skin, a flash of cold\u2026\u201d \u2014 but the release crosses the line with its language about the disfiguring nature of surgery. It says women achieve \u201cexcellent cosmetic results\u201d with cryoablation and that they are \u201cextremely relieved to avoid painful, disfiguring surgery and long recovery times.\u201d According to the release, it seems that the only alternative to cryoablation is disfiguring mastectomy, but there are other intermediate surgical options (lumpectomy) that minimize scarring and post-mastectomy reconstruction is available. The release should have been more tempered in its description of surgical outcomes.", "answer": 0}, {"article": "Carl Alexander, a spokesman from the charity Cancer Research UK, said: \u201cThis study is an exciting example of how research can find clues in our genes to help us uncover those more likely to develop the disease.\nIf it is found to be effective, it could be an important tool for physicians.\nRosalind Eeles, an author of the study at the U.K.-based Institute of Cancer Research (ICR) who specializes in finding genetic variants that increase the risk of prostate cancer, told The Guardian the team is \u201cexcited by the test\u201d because it can be used by doctors to offer patients targeted screenings.\nThe new method is being trialed on 300 men in doctors' offices across London, and is due to be expanded to 5,000 next year, according to BBC News.\nBy testing a man\u2019s DNA, researchers can look for genes linked to the disease, which one in seven men in the Western world will be diagnosed with in their lifetime.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not rely on a news release, but drew heavily from reporting by two other news organizations.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061008/16organ.htm was not found on this server.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because several different sources are used in the story, it appears that it did not rely solely or largely on a news release. ", "answer": 1}, {"article": "The F.D.A.\nThat, said Dr. Leon of Columbia, who was the trial\u2019s principal investigator, was remarkable.\nThe result was a requirement that a hospital should be doing at least 50 surgical aortic valve replacements a year to have access to the technology.\nFormer skeptics like Dr. Cohn now recommend the procedure for high-risk patients.\nMore recent 2015 data from Medtronic indicates that its valve is better than surgery for high-risk patients, resulting in fewer deaths, at least in the first two years.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article certainly goes well beyond any news release.", "answer": 1}, {"article": "\"If you are an Asian kid, you've had these placed on you since time immemorial,\" he said.\n\"It's a very clever way of getting the medications right where they need to be.\"\nPain patches have a number of benefits, Rosenquist and Dombrowski said, not the least of which is convenience.\nBut the patches, marketed under the brand name Salonpas, are nothing new.\nThe patches also deliver their medicine directly to the site of a person's pain.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a news release.", "answer": 1}, {"article": "BioZorb has received 510(k) clearance from the U.S. Food and Drug Administration.\nThe study also noted that the device provides a helpful guide for post-treatment mammograms and other long-term follow-up to check for any cancer recurrence in these patients.\nBy providing better targeting, they said, the marker could also play a role in facilitating the use of external beam partial breast irradiation.\nThe article reports that the device provides clear visualization of the surgical site where the tumor was removed, thereby improving communication between the surgeon and radiation oncologist.\nThe authors said use of the marker facilitated their shift toward these shorter courses of radiotherapy.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t employ unjustifiable language.", "answer": 1}, {"article": "Differences in mean changes in swallowing at radiotherapy week 4 (\u221215 in the CRT group and \u221225 in the radiotherapy alone group, P = .02), loss of appetite at radiotherapy week 4 (\u221211 in the CRT group and \u221218 in the radiotherapy alone group, P = .03), nausea at week 8 after radiotherapy (\u22127.3 in the CRT group and 0.3 in the radiotherapy alone group, P = .04), coughing at radiotherapy week 4 (7.4 in the CRT group and \u22125.6 in the radiotherapy alone group, P = .02) and at week 8 after radiotherapy (\u22123.2 in the CRT group and 1.1 in the radiotherapy alone group, P = .04), constipation at month 8 (2.6 in the CRT group and \u221219 in the radiotherapy alone group, P < .001), and cognitive functioning at month 12 (\u22127.0 in the CRT group and 4.6 in the radiotherapy alone group, P = .04) were not seen at the other time points.\nThe use of concomitant cisplatin and radiotherapy resulted in a statistically significant improvement in laryngeal preservation compared with radiotherapy alone, with a hazard ratio of 0.46.\nThe 2.2% and 11.1% absolute improvements in the rates of laryngeal preservation, at 2 and 3 years, respectively, favored CRT compared with radiotherapy alone (Figure 2).\nSurvival was also slightly improved for patients who received CRT compared with radiotherapy alone (HR, 0.87; 95% CI, 0.60-1.27) (Table 2).\nA pharmacologic profile was also performed weekly on patients receiving cetuximab infusion (CRT group).\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release uses fairly cautious language throughout. However, two statements that contradict each other earned this an unsatisfactory:\n\u201cThe higher rate of laryngeal preservation that was achieved with the use of CRT compared with radiotherapy alone was encouraging,\u201d\n\u201cThis study was not powered to assess organ preservation.\u201d", "answer": 1}, {"article": "Too much LDL cholesterol circulating in the blood can lead to the thickening of artery walls, making them less flexible and therefore impairing their function and increasing the risk of heart disease.\nAll of those subjects were also receiving treatment with the statin Lipitor.\nEarlier studies had shown this effect in primates, but this new study, published Wednesday in the New England Journal of Medicine, provides the first clinical trial data for testing the drug on humans.\nIn this phase one clinical trial, which is designed to determine if a drug is safe, researchers found that using a monoclonal antibody (lab-produced protein) called REGN727, was not only safe, but effectively blocked PCSK9 and therefore signficantly reduced bad cholesterol in healthy patients as well as those also taking the popular cholesterol-lowering drug Lipitor.\nThe cost of this drug will also play a role in determining which patients might use it, Fong and Young say.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We don\u2019t think the story relied solely or largely on a news release.", "answer": 1}, {"article": "Dr. Scolnick has not seen the results of the Novartis trial, but was told of them and concluded that if the drugs work in fragile X, \u201cthere\u2019s nothing to say that they won\u2019t work in some cases of broader autism-spectrum disorders.\u201d\n\nThe roots for the Novartis results began in 1982 when Stephen T. Warren, then a graduate student in genetics at Michigan State University, was looking for a job and something to research.\nSure enough, mice, fish and fruit flies that through genetic engineering were made to have fragile X seemed to become normal when given Dr. Bear\u2019s compound.\nThe results of the trial were something of a jumble until Novartis scientists noticed that patients who had a particular, undisclosed biological trait improved far more than others.\nThey found that if Dr. Bear reverse-engineered his compounds, they seemed to slow brain transmissions.\nWhen a doctor finally thought to do a fragile X test, Ms. Clapp and her husband, Dr. Michael Tranfaglia \u2014 both Harvard graduates with post-graduate degrees \u2014 researched the disease and came to two conclusions: fragile X was potentially treatable; and only about five researchers in the world were working toward a cure.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that this story wasn\u2019t based on\u00a0a press release.\u00a0 But do we need to create a cateogry for stories based largely on non-published disclosures in conversations with pharma execs? ", "answer": 1}, {"article": "A surgically implanted electrical device that stimulates the sacral nerve can calm an overactive bladder, according to a company that sells it. Physicians say sacral neural stimulation works well for many patients, but a test period with an external device is recommended first.\n\nMillions of Americans suffer from \"urge incontinence,\" accidents caused by a strong, sudden need to get to the bathroom, or overly frequent urination, defined as eight or more times a day. Quality of life is affected, as sufferers must...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story quoted many experts, the reader can assume the story did not rely on a press release as the sole source of information.", "answer": 1}, {"article": "Researchers compared data on 6,684 women and girls taking spironolactone to 31,614 who were prescribed antibiotics.\nDavid J. Margolis, MD, PhD, a professor of Dermatology, was the study's senior author.\nThe School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $405 million awarded in the 2017 fiscal year.\nIt affects 85 percent of people under the age of 18, but it also regularly impacts adults.\nThe prescription change is a proxy for ineffectiveness, since switching is often the result of treatment failure due to lack of efficacy, side effects, cost, or other factors.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There was no sensational language employed in the release.", "answer": 1}, {"article": "Jan. 18, 2011 -- Low doses of the antidepressant Lexapro (escitalopram) cooled off hot flashes better than placebo in about 200 menopausal women, according to a new study.\nIn the study, Freeman found the antidepressant reduced both the number and severity of hot flashes compared to placebo.\nPrevious studies of other antidepressants have yielded mixed results, according to Freeman.\nThe findings are published in TheJournal of the American Medical Association.\nThe new study findings suggest Lexapro can provide an option for women reluctant to take hormone therapy.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story included\u00a0interviews with one of the study researchers and an independent source.\u00a0It did not rely excessively on a press release.", "answer": 1}, {"article": "Doctors diagnose Alzheimer\u2019s by excluding other causes of memory loss, such as stroke, tumors and heavy drinking.\nAnd they may also help identify early signs of the disease in healthy people, the team reported in the Archives of Neurology.\nThe study is the latest to show that measuring disease-related proteins in spinal fluid is useful in diagnosing Alzheimer\u2019s disease.\nThey were also able to detect 100 percent of people with memory impairments who would progress to Alzheimer\u2019s disease within five years.\nAnd they detected Alzheimer\u2019s proteins in 36 percent of people with normal brain function.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Not applicable because we can\u2019t be sure of the extent to which the story may have relied on a news release.\u00a0 No quotes from an interview were included \u2013 only a quote from the journal article.\u00a0 ", "answer": 2}, {"article": "Concussion is a major public health concern, often resulting in significant acute symptoms and in some individuals, long-term neurological dysfunction.\nThis new method, fully funded by the Children's Health Foundation and conducted by the Western Concussion Study Group, is unique in that previous attempts have looked unsuccessfully for a single highly accurate protein biomarker that can distinguish concussed from non-concussed adolescent patients.\nIn the new study, researchers have demonstrated that a blood test can now accurately diagnose a concussion using a form of blood profiling known as metabolomics.\n\"With further research, we anticipate that our blood test will also aid clinicians in predicting concussion outcome, as well as aid rehabilitation after concussion.\"\nLONDON, ON - Scientists from Children's Health Research Institute, a program of Lawson Health Research Institute, and Western University have developed a new blood test that identifies with greater than 90 per cent certainty whether or not an adolescent athlete has suffered a concussion.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Using the term \u2018game-changing\u2019 in the title is unjustified. Few technologies (especially one tested in only 19 individuals) can be called game-changing. This is a very preliminary result, and while encouraging, it in no way provides evidence that this is a game changer. It may be, but that can be said of many tests and treatments in early development that later do not pan out.", "answer": 0}, {"article": "I was absolutely terrified because I saw my mom go through it, and I saw how much pain she was in,\" Barletta says.\nThat's still the standard procedure for the 50,000 Americans who are operated on each year for this problem.\nLaPook notes that it will be a few more years before this procedure is widely available.\n\"I was so happy that I was OK, that I had escaped the open heart,\" Barletta says.\nWhen Barletta's valve problem got worse two years ago, she faced the same operation.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can't be sure if the story relied solely or largely on a news release. ", "answer": 2}, {"article": "on Sept. 2.\n\u201cA peripheral T-cell lymphoma patient,\u201d he said, \u201cat first blush will see this therapy as a very good thing.\u201d\n\nAllos, which is still unprofitable, has lost $350 million since its founding in 1992 and failed to win approval of a previous drug.\nMr. Schimmer\u2019s note was entitled \u201cFolotyn Prices High, Reiterate Outperform.\u201d He estimated annual sales of the drug in the United States reaching about $300 million by 2014.\nIn a note to clients in October, Joshua Schimmer, an analyst at Leerink Swann, estimated that a typical treatment would last 3.5 months and cost $126,000, or about $36,000 a month.\nThat median expenditure now, he said, is $87,000 for a little over a year of treatments.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story quotes mutliple experts, the reader can assume the story did not rely on a press release as the sole source of information.", "answer": 1}, {"article": "+ Loss of fat was associated with faster walking speed, while loss of muscle was associated with reduced knee strength.\nCo-authors on this paper included W. Jack Rejeski and Anthony Marsh, co-principal investigators of the CLIP-II study, and Jessica Sheedy, Beverly Nesbit and Jill Gaukstern, all of the Wake Forest University Department of Health and Exercise Science; and Walter Ambrosius, Michael Walkup, Jonathan Burdette and Barbara Nicklas of the Wake Forest School of Medicine.\nLosing weight is generally recommended for those with obesity, but preserving muscle - while losing fat - is particularly important for older adults in order to maximize functional benefit, Beavers said.\nLoss of lean mass could have important consequences given the high risk of physical disability among the growing population of older adults.\nIn this 18-month study of 249 adults in their 60s who were overweight or obese, restricting calories plus resistance training in the form of weight-machine workouts resulted in less muscle loss, but significant fat loss, when compared to weight loss plus walking or weight loss alone.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "No unjustifiable or sensational language. With one exception, the release used \u201cpeople first\u201d language consistently when referring to obesity, a chronic disease. It referred to \u201cadults with obesity\u201d rather than \u201cobese people.\u201d\nThe phrase, \u201cIn this 18-month study of 249 adults in their 60s who were overweight or obese,\u201d might have been written as \u201cadults in their 60s with overweight or obesity.\u201d", "answer": 1}, {"article": "Also, scar tissue often builds up around intravenous wires, a process that can make removing and replacing them difficult or dangerous.\nBut Dr. Bardy estimated that the device could work in about 25 percent of patients who now get a defibrillator.\nHundreds of patients who received the model have had to undergo new operations to replace it.\nDr. Bardy said the cost of the new device is about the same as a standard defibrillator.\nIn the study published Wednesday, Dr. Bardy and others reported that the new device had undergone several successful initial trials, including one in which it was used for a year in about 60 patients.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\nThe story does not appear to rely on a news release.", "answer": 1}, {"article": "Schafer Cardiovascular Research Fund, the Johns Hopkins Magic That Matters Research Fund for Cardiovascular Research, grants from the National Center for Advancing Translational Sciences (UL1-TR-000040 and UL1-TR-001079), and contracts from the National Heart, Lung, and Blood Institute (HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169).\nIn the study, published on Jan. 10 in Circulation, the researchers say these calcium scores allow physicians to go beyond the traditionally calculated risk factors to determine which blood pressure treatment strategy may be most appropriate for a particular patient.\nThus, even though their calculated heart disease risk is relatively low and their blood pressure is below traditional cutoffs for treatment, the researchers say people in this category with calcium over 100 are high risk and may benefit from more aggressive blood pressure treatment.\nPreviously, the appropriate blood pressure treatment for these patients used risk calculations and some guesswork, potentially leaving many vulnerable to heart disease or taking drugs they don't need.\nThe researchers say this demonstrates that calcium scores may only be useful in guiding more personalized blood pressure treatment for patients with mild high blood pressure -- the gray zone -- not those with high blood pressure.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "This is a close call. Overall the tone of this news release is measured. However, the sub-headline jumps the gun when it states the CAC score \u201cgives risk assessment to prevent over- or undertreatment of blood pressure.\u201d The score may be able to help guide treatment decisions when the path is unclear, but as the body of the news release mentions, a randomized trial is needed to find out whether there\u2019s a clinical benefit.\u00a0 \nAlso, we\u2019re wondering whether the term \u201cpersonalized treatment\u201d is overused. In the past it\u2019s typically referred to treatment approaches directed by genetic variables. But in this case, the term has been expanded to cover variables in calcium buildup, with no known genetic component.\nThe release also states: \u201cthe researchers say these calcium scores allow physicians to go beyond the traditionally calculated risk factors to determine which blood pressure treatment strategy may be most appropriate for a particular patient.\u201d \u00a0At best, this provides the rationale for conducing a study to determine whether blood pressure treatment is appropriate\u2013it cannot address the issue of which strategy.", "answer": 0}, {"article": "\"I'm single, I'm bouncing around, and I'd like the opportunity to have a family, so I just figured, 'Why not?'\nNow, technology is dangling the possibility that women can stop that clock, at least for a while.\nThe bigger challenge, Sher and others say, is reaching out to younger women \u2014 getting them to take action before it's too late.\nAll told, costs can easily exceed $40,000, money Montoro doesn't have.\nStill, Widra would like a larger-scale, longer-term track record.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story obviously required in-person reporting of a group meeting of women worried about fertility. However, it could have been improved with phone calls to a wider diversity of medical researchers.", "answer": 1}, {"article": "\"Parents often say that their biggest concern is, 'When is my child going to be back to normal again?'\nA reliable lab test would help ensure that children who have a head injury don't go back to school, or to the soccer field, before their brain has healed, Bhomia says.\nBut saliva may not be the best place to measure microRNAs, Bhomia says.\nMany of the injuries are related to sports.\nHicks and a team of researchers have been looking for an objective test that might help.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There are quotes in the story that indicate original reporting was done.", "answer": 1}, {"article": "Melanoma is one of the most common forms of cancer and the most serious type of skin cancer.\nThe study was published on August 5th in the Journal of the American Academy of Dermatology.\nThe research team retrospectively analyzed more than 100 cases of atypical moles.\nThe study was supported in part by a grant from the National Institutes of Health.\n\u200b\u200b\u200b\u200bCalifornia Skin Institute \u2014 A recently developed test for assessing suspicious moles for melanoma is more accurate than standard analyses, according to Dr. Rossitza Lazova, a former Yale investigator.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release does not use sensational language.", "answer": 1}, {"article": "Blood tests for iron deficiency without anemia have been developed but they are more costly and difficult to obtain in the doctor's office compared to hemoglobin testing for anemia.\nMurray-Kolb and Paul also worked on the study in The Journal of Pediatrics, along with Eric W. Schaefer, a biostatistician in the Department of Public Health Sciences.\nYet, the researchers' risk assessment questionnaire was equally poor.\nSekhar and colleagues hoped to determine risk factors for iron deficiency without anemia that could pinpoint which women could benefit most from this more costly testing.\nAs part of the survey, female participants had blood testing for iron deficiency as well as hemoglobin testing to identify anemia.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The headline, \u201cEarlier blood testing for iron deficiency, anemia recommended for young women\u201d\u00a0is unjustified and is not supported by the study findings.", "answer": 0}, {"article": "Plaque psoriasis is an autoimmune condition that causes cells to build up on the surface of the skin, forming thick red patches and flaky silver-white scales.\nThe drug also comes with a more serious warning, as well.\nIn order to prescribe it, doctors must be certified with the program and must counsel patients about this risk.\nThe drug\u2019s recommended dosage schedule is an injection once a week for the first three weeks, followed by an injection every other week.\nHe adds that the data on Siliq suggests that it is not only effective in treating psoriasis, but that many patients experience improvement in anxiety and depression, as well.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story included comments from an independent source.", "answer": 1}, {"article": "Heart disease is the leading cause of death among women, yet breast cancer is often the most feared.\n\"This information is available on every mammogram, with no additional cost or radiation exposure, and our research suggests breast arterial calcification is as good as the standard risk factor-based estimate for predicting risk,\" Hecht said.\nBecause the study involved women who received both mammography and CT scan for clinical indications, these women may have been more likely than the average woman to have coexisting conditions, although Hecht said these were unrelated to heart disease.\nThis study is being published simultaneously online in JACC: Cardiovascular Imaging.\nMammograms were reviewed by a second radiologist who was blinded to the CAC results.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release does not cross our line on unjustifiable language. While some statements seem to imply that women will immediately benefit from the additional assessment of their mammograms, they are tempered with some cautionary language such as \u201cthese findings warrant further evaluation and validation in larger studies.\u201d", "answer": 1}, {"article": "Among its raft of recommendations, the consensus statement says that:\n\u2022 Should aim to play for 150 minutes/week, or do less, but couple golf with other physical activity, and walk the course rather than ride a golf cart\n\u2022 Do warm-up/strengthening exercises to cut the risk of injury and use sun-cream and wear collared shirts/blouses to minimise the risk of skin cancer\n\u2022 Build on existing initiatives to promote inclusivity and develop environments and price structures that will be attractive to everyone\n\u2022 Develop a culture that will inspire more women and girls to play golf\n\u2022 Make every effort to promote equality and diversity, and boost accessibility\n\u2022 Promote sustainability through wildlife conservation and by restricting the use of water, energy, and pesticides\n\u2022 Provide additional facilities at clubs, such as a gym, walking routes, cr\u00e8ches and improve the focus on health and safety, with the provision of healthy foods, defibrillators, and speed limiters on golf carts, for example\n\u2022 Promote the benefits of regular physical activity, including golf, for people of all ages, genders, and income brackets\n\u2022 Work with industry and national associations to boost take up of the sport, particularly in groups where physical activity levels are low\n\u2022 Work with industry and regulatory bodies to get golf included in the Paralympics\n\n\"These outputs, if widely shared and adopted, will contribute to an improved understanding of golf and health, and aid these groups in making evidence-informed decisions and to improve health and wellbeing,\" the consensus statement concludes.\nMore people might be keen to take it up if golf were promoted as an enjoyable, lifelong outdoors activity that affords a sense of community and competitive challenge while providing some 'me time' as well as helping to fulfil recommended exercise quotas, says the statement.\nThe sport needs to be more inclusive and welcoming of people from all walks of life and ethnic backgrounds, and any such initiatives should be supported, it says.\nAnd it can boost older people's strength and balance.\nThe sport is also associated with good mental health and improving the overall health of those with disabilities.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Given there is no study here, and the basis of the health claims is nothing more than a subjective consensus statement of experts (some with major conflicts of interest), we find the headline and health recommendations of this news release to be unjustified and overreaching.", "answer": 0}, {"article": "However, nearly 46 percent of low-risk women aged 50 to 59 were screened, as were 59 percent of low-risk women aged 60 to 64.\nOver seven years, more than 42 percent of eligible women aged 65 to 74 were not screened, Amarath's team found, nor were nearly 57 percent of those older than 75.\nHowever, the study also found that those risk factors -- a small body frame, a history of fractures, or taking medications that could thin bones -- had only a slight effect on a woman's decision to get her bones tested.\nThe study was published online May 19 in the Journal of General Internal Medicine.\n\"DXA screening was underused in women at increased fracture risk, including women aged 65 years and older.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story draws liberally from a news release\u00a0about the study,\u00a0which is also the source of all of the story\u2019s quotes. Although the story alerts readers to this fact, which is good practice, it doesn\u2019t provide any other evidence of original reporting \u2014 so we\u2019ll have to award a Not Satisfactory grade here.", "answer": 0}, {"article": "In addition, we saw that several smaller brain areas actually started to grow in response to training,\" says Ulrik Dalgas.\nThe researchers behind the study are still unable to explain why training has a positive effect on the brain in people with multiple sclerosis.\nA bigger and more in-depth on-going study will help to clarify this, and may also lead to improved treatment options, says Ulrik Dalgas.\nThe study shows that resistance training has a number of positive effects on the brain, which go beyond what can be achieved through effective disease specific medication.\nHowever, he stresses that the aim is not to replace medication with physical training.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release does not include unjustifiable, sensational language.", "answer": 1}, {"article": "Anderson Cancer Center in Houston.\nThe goal of the vaccine, Hale said, is to educate the body to respond to that HER2-based peptide, so it will recognize the cancer when it recurs and attack it.\nNumerous vaccines to prevent breast cancer recurrence are currently under study, he noted.\nThe study is a phase 2 study, meant to evaluate the vaccine's effectiveness and any side effects.\nThat is a good thing, Hale said, because \"an increase in these cells has been found to be associated with [cancer] recurrence.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article does not appear to be based solely on a press release.", "answer": 1}, {"article": "Last year, 2.3 million young Europeans (aged 15 to 34) used cocaine, and the US National Institute on Drug Abuse estimates that 1.4 million Americans suffer from cocaine addiction1.\nAs far as we know, this work represents the first clinical report indicating that rTMS treatment results in significant reduction in cocaine use.\nIt is also important to emphasize that, in this study patients were seeking treatment for their cocaine addiction in a hospital setting: the group studied, albeit small, was a \"real world\" sample.\nIt is important that this is taken forward to a larger trial.\nThe study indicated the safety of rTMS in patients with cocaine addiction.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "This release does not seem to use any language that appears unjustifiable.", "answer": 1}, {"article": "Letters being mailed to study participants advise them to discuss with their doctors whether they should have additional scans or not.\nMany smokers already had sought out spiral CTs, even though the American Cancer Society hasn't recommended the test - citing a lack of clear evidence that they work - and most insurance doesn't cover the $300 to $400 cost.\nThe massive National Lung Screening Trial enrolled 53,000 current or former smokers to try to settle the debate.\nNor is it clear if the study results are applicable to all smokers.\nIt found 20 percent fewer deaths from lung cancer among those screened with spiral CTs than among those given chest X-rays, the NCI said Thursday, a difference significant enough that it ended the study early.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\n\nThe only direct quote in the story is from a news release issued by the National Cancer Institute.\n(http://www.cancer.gov/newscenter/pressreleases/NLSTresultsRelease)\nIt is not clear what other sources may have been consulted.", "answer": 2}, {"article": "Bochner and his colleagues Drs.\nAnne Marie Singh and Melanie Dispenza are now testing how successful the drug is at targeting allergies to food, such as tree nuts and peanuts.\nHe knew that the generally well-tolerated cancer drug was successful in blocking a protein inside a cell called Bruton's Tyrosine Kinase (BTK).\n\"It almost completely knocked out the patients' skin test and blood cell allergic reactivity,\" said senior author Dr. Bruce Bochner, the Samuel M. Feinberg Professor of Medicine at Northwestern University Feinberg School of Medicine.\nA rather unlikely pairing - cancer and allergies - Bochner thought to test if a cancer drug could prevent allergic reactions by collaborating with Feinberg's oncology department.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "As noted above, the release is replete with speculation about possible benefits that have yet to be tested. It likened the drug to \u201cthe holy grail of food allergy treatment\u201d even though food allergies weren\u2019t part of the study.\nThe headline also strikes us as irresponsible and misleading: \u201cNew cancer drug can prevent reactions to common airborne allergens.\u201d", "answer": 0}, {"article": "Niki Munk, an assistant professor of health sciences in the School of Health and Rehabilitation Sciences at Indiana University-Purdue University Indianapolis and one of the co-first authors of the study, said that the study's findings are important, given the large number of people who suffer low back pain in the U.S.\n\nLow back pain leads all disorders in years lost to disability in the U.S.\nAdditional investigation is needed to replicate the results of the initial study and to conduct a cost-benefit analysis of massage therapy, Munk said.\nWhile the study results are promising, much more work needs to be done, Munk said: \"The fact of the matter is that chronic lower back pain is very complex and often requires a maintenance-type approach versus a short-term intervention option.\"\nMore than 50 percent of those who participated in the study experienced clinically meaningful improvements in their low back pain with disability, according to Munk.\nIn this study, patients were referred by a physician to a massage therapist.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t include any unjustifiable language. But the headline and opening of the release tend to give the study more credit than is due. It\u2019s in the closing paragraphs that the release notes that the study results need to be replicated and that a cost-benefit analysis should be done to learn the effectiveness of this treatment.", "answer": 1}, {"article": "Celgene\u2019s drug Abraxane prolonged the lives of patients with advanced pancreatic cancer by almost two months in a clinical trial, researchers reported Tuesday, signifying an advance in treating a notoriously difficult disease but not as big a leap as some doctors and investors had hoped.\n\n\u201cIt was not the breakthrough we were anticipating,\u201d said Dr. Andrea Wang-Gillam, an assistant professor and pancreatic cancer specialist at Washington University in St. Louis, who was not involved in the trial.\n\nStill, Dr. Wang-Gillam and others said any progress was welcome against metastatic pancreatic cancer, which has defied most treatments, with patients tending to live only about six months after diagnosis.\n\nPancreatic cancer is the fourth most common cause of cancer death, with 38,000 Americans expected to die this year, almost as many deaths as from breast cancer, according to the American Cancer Society. Yet there are only 45,000 new cases of pancreatic cancer a year compared with more than 230,000 new breast cancer cases.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely solely or largely on a news release, although it did report on data released by the manufacturer in advance of presentation at a scientific meeting.\u00a0 But the addition of independent perspectives shows how much original reporting was done.", "answer": 1}, {"article": "Rectal cancer affects some 2,000 men and women in Sweden every year.\nThe study now presented in The Lancet Oncology is based on the claim that the adverse effects of rectal cancer treatment can be reduced by administering more but lower doses of radiation for a longer time, or by increasing the interval between radiotherapy and surgery.\n\"The results of the study will give rise to improved therapeutic strategies, fewer complications with a sustained low incidence of local recurrence, and better survival rates for rectal cancer patients,\" says Professor Martling.\nIt also showed that there is no difference between long-course and short-course radiotherapy other than that the former considerably lengthens the time for treatment.\nThe results of the study show that patients with delayed surgery develop fewer complications with equally good oncological outcomes.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t rely on sensational language to describe the study results.\nThe headline calling this a \u201cnew therapy\u201d might strike some readers as slightly misleading. However, the release explains that the researchers launched a 14-year study of the three protocols in the late 1990s, a few years after preoperative radiotherapy was first introduced for rectal cancer \u2014 partly owing to foundational research by the Swedish institute.\nSince the Karolinska Institutet has been a world leader in rectal cancer research and treatment, its horn-tooting statement \u2014 \u201cThanks to our results, radiotherapy is recommended to many rectal cancer patients.\u201d \u2014 appears justified.", "answer": 1}, {"article": "Researchers at Italy's Institute of Neuroscience injected rats and mice with botulinum neurotoxin A in doses comparable to those used in people.\nYes, there was some evidence the toxin slipped into the bloodstream or the lymph system, but Botox in the bloodstream cannot enter the brain, says its manufacturer.\nNot surprisingly, these \"preclinical tests\" (that is, those performed before testing on humans) were especially rigorous for botulinum.\nBotox's manufacturer, Allergan, thinks those older studies are more credible.\nThose unapproved uses are another concern of the agency.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not appear to rely on a press release.\u00a0", "answer": 1}, {"article": "The U.S. National Institute of Allergy and Infectious Diseases has more on sinusitis.\nThis second finding is probably explained by the fact that people going for second or further surgeries were probably sicker to begin with, Josephson said.\n\"These were patients who have chronic sinusitis so, by definition, they have at least three months of symptoms and they have evidence of an ongoing inflammation or infection of their nose and sinuses on either a CT scan or an examination of the nose and sinuses,\" Smith said.\nNone of which is to say that patients shouldn't try medical therapies first, he added.\n\"Certainly this reinforces our belief that sinus surgery increases the quality of life of patients, and I see that clinically as well as scientifically,\" added Dr. Jordan S. Josephson, a sinus and allergy specialist at Lenox Hill Hospital in New York City.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure of the extent to which the story relied on a news release, so we grade this criterion Not Applicable. ", "answer": 2}, {"article": "For example, the U.S. Preventive Services Task Force, a federal expert panel, currently doesn\u2019t recommend routine cholesterol screening in any children.\n\u201cUnfortunately, there is no evidence that starting a ten-year-old on cholesterol-lowering drugs will prevent heart disease 40 years later,\u201d said Dr. Michael L. LeFevre, a member of the task force.\n\u201cIt is therefore prudent to implement universal screening in the pediatric population independent of family history,\u201d the researchers conclude.\nYet among the kids without heart disease in their family, the percentage of children who might benefit from treatment was closer to two percent than to one, meaning that family history didn\u2019t seem to make a difference.\nHe said statin treatment in children was still controversial, and that no long-term safety data existed.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story does not appear to be based on a news release.", "answer": 1}, {"article": "Individuals with panic chronically hyperventilate, even when not experiencing a panic attack.\nTheir first product, Freespira, is an FDA-cleared treatment for individuals suffering from panic disorder, panic attacks and other symptoms of panic.\nNinety percent of patients in this study experienced a significant improvement in PTSD symptoms at two months and six months post-treatment.\nThe peer-reviewed published multi-center Freespira clinical trial, presented by Dr. Tolin, demonstrated that 71% of patients were panic attack free immediately after treatment and 79% of patients were panic attack free 12 months post-treatment.\nEarly data from a fifth study reported on Freespira treatment for patients with Post-Traumatic Stress Disorder (PTSD).\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The headline word \u201celiminates\u201d seems unjustifiable. We aren\u2019t given enough information about numbers of patients studied, or the long-term follow up that would justify that word.", "answer": 0}, {"article": "One of the most frustrating aspects of brain injuries is that they can be difficult to diagnose; emergency rooms can sometimes miss subtle symptoms, leading to improper treatment and potentially catastrophic consequences. Now, researchers are close to identifying so-called biomarkers that may soon make it possible to pinpoint brain injuries with a simple blood test.\n\nPresence of these biomarkers\u2014proteins produced by an injured brain\u2014could end up determining the future treatment of the estimated 1.4 million athletes, car-crash...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We don\u2019t see evidence that the article relies on a news release.", "answer": 1}, {"article": "And finally, this is a very real world study.\u201d\n\nThe study was received well by the audience.\nOne of the caveats of the study was that participants were highly motivated people looking for ways to cope with and decrease their blood pressure.\nThese tools were carefully chosen to increase in knowledge about and motivation to maintain a heart-healthy lifestyle.\nParticipants were also largely white and well-educated, with most having a postsecondary education, so the results of the study might not be generalize well to other groups.\nThe study is very useful in telling and confirming that we should talk to the patients, no matter how we do it,\u201d said Bernard Wong, a cardiologist based in Hong Kong.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes information not found in the\u00a0news release.", "answer": 1}, {"article": "But don't rush out to adopt a furry friend just yet.\nWhat's more, Kozyrskyj's study suggested that the presence of pets in the house reduced the likelihood of the transmission of vaginal GBS (group B Strep) during birth, which causes pneumonia in newborns and is prevented by giving mothers antibiotics during delivery.\n\"The abundance of these two bacteria were increased twofold when there was a pet in the house,\" said Kozyrskyj, adding that the pet exposure was shown to affect the gut microbiome indirectly--from dog to mother to unborn baby--during pregnancy as well as during the first three months of the baby's life.\nIt's far too early to predict how this finding will play out in the future, but Kozyrskyj doesn't rule out the concept of a \"dog in a pill\" as a preventive tool for allergies and obesity.\nThe latest findings from Kozyrskyj and her team's work on fecal samples collected from infants registered in the Canadian Healthy Infant Longitudinal Development study build on two decades of research that show children who grow up with dogs have lower rates of asthma.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There were some statements that bordered on unjustified terms, but nothing that rose to the level of sensationalism. For example, when the release referred to the \u201cimmunity-boosting exchange\u201d that happens with various forms of childbirth we wondered: Where\u2019s the evidence that these exposures \u2018boost\u2019 immunity? Is there such evidence?\nAnd while the comment, \u201c\u2026Kozyrskyj doesn\u2019t rule out the concept of a \u201cdog in a pill\u201d as a preventive tool for allergies and obesity,\u201d is clever and catchy, it doesn\u2019t have any basis in reality from this research which is still very much in the theory stage.", "answer": 1}, {"article": "However, Owens said, \u201cit\u2019s hard to do all of that in your head.\nThe problem with the old-fashioned way, he told Reuters Health in an email, is that there are many pieces of information about a patient to consider.\nBut the new study looked at a more sophisticated way of estimating individual patients\u2019 needs.\nA researcher not involved in the work said it was a \u201cnice study\u201d that is a first step toward showing that tailored guidelines could have benefits.\nAbout one-quarter of surveyed doctors said they had \u201cbasic\u201d electronic medical record systems in their offices.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely solely on a news release.", "answer": 1}, {"article": "There are many factors that cause obesity but there is a growing weight of evidence that shows obesity is not just caused by a behavioural disorder, such as a lack of self-control, but that many overweight people are physically addicted to foods rich in fat and sugar.\nThere is mounting evidence to show that there is a substantial number of obese people who are food addicts because they have an inability to control their impulsive actions and this drug has shown it can give them more control, which will help overweight people lose weight and so improve their health.\n\"It has been shown to reduce impulsiveness in a variety of disorders such as alcohol dependence, schizophrenia and ADHD.\n\"The drug improves self-control, which is a key factor in determining obesity, so our hypothesis is that this drug should help in treating the disease.\"\nFood addicts suffer from the same neurobiological conditions so we believe it will help food addicts as well and our initial tests have backed up that theory.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We\u2019ll give the release the benefit of the doubt here since we\u2019ve already addressed some language issues elsewhere in the review. However, the general premise of the release \u2014 that a single dose of a drug might curb obesity \u2014 is stretching credulity.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Women who take bone drugs for several years have a slightly increased chance of suffering an unusual type of thigh fracture, according to a large Canadian study.\nThe findings add to earlier concern over the medicines, called bisphosphonates, whose U.S. labels have been required since October to include a warning about the thighbone fracture risk.\nAnd the actual risk of having one of the unusual fractures was low, said Laura Y. Park-Wyllie, of St. Michael\u2019s Hospital in Toronto, who worked on the new study.\nAfter taking bone drugs for five years, about one in 1,000 women went on to suffer a thigh fracture over the next year.\nBut some experts worry that negative media coverage might have led to more fractures and possibly deaths by dissuading patients from taking the drugs.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely solely or largely on a news release.", "answer": 1}, {"article": "\u201cThe person has to be wanting to quit smoking,\u201d he said.\nIn response, Laser Therapeutics is designing another study to address those comments, he said.\nTherefore, quitting leads to a quick drop in endorphin levels, he said.\nUsing acupuncture methods to treat addictions such as smoking is not new, White said, but there is still no clear evidence that treatment with needles has any therapeutic effects either.\nBut the government organization had only dealt with drugs - not new technology - for smoking cessation, which has slowed down the process, Camera said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no news release. In fact, the story is a direct response to inflated claims made about laser therapy.", "answer": 1}, {"article": "Examining more than 500,000 Facebook posts from both groups, researchers determined which words, post lengths, frequency of posting and timing of posts were most associated with a depression diagnosis. They found people with depression used the words \"I, my, and me,\" as well as such words as \"hurt, tired, and hospital,\" more often than others in the months preceding their diagnosis. Using indicators such as these, they built a computer model that could predict which people would receive a depression diagnosis with comparable accuracy to commonly used clinical surveys.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story goes well beyond the news release issued by the University of Pennsylvania.", "answer": 1}, {"article": "Doctors usually try to start people off with lifestyle treatment, such as weight loss, drinking less caffeine and alcohol, and avoiding lifting heavy objects.\nThe women in the study had to suffer at least six episodes of incontinence over three days.\nIncontinence may sound funny, but it\u2019s no joke, the researchers said.\nThe team studied women with severe incontinence who could not be helped with drugs or other treatments.\nIt\u2019s good news for women with severe urge incontinence, who can choose between treatments based on preference, said Dr. Cindy Amundsen of Duke University, who led the study.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We didn\u2019t catch any overtly copy/pasted quotes or language that made its way into the story from the\u00a0Duke University news release.", "answer": 1}, {"article": "About CVS Health \n\nCVS Health (NYSE: CVS) is a pharmacy innovation company helping people on their path to better health.\n\"Our research shows that home infusion care is a promising model that is both cost- and clinically-effective and is overwhelmingly preferred by patients when intravenous therapy is required.\"\n\"In fact, our patients report high satisfaction with our Coram home infusion services, citing convenience and comfort as key elements that improved their overall experience.\"\nResearchers compared measures of quality, safety, clinical outcomes, quality of life and costs of home infusion services to those provided in medical settings.\nDespite this, clinical outcomes and quality of care have not previously been systematically evaluated.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t rely on any unreasonable or unjustified language. However, we do not think the news release proves the words used in the headline that say \u201cHome Infusion Care Improves Patient Outcomes and Quality of Life While Reducing Overall Costs.\u201d\nBased on a literature review, which does not randomize people into apples-to-apples comparison, you cannot claim to show better outcomes. The release does not offer any quantified benefits to support medical outcomes and doesn\u2019t provide quantified information about quality of life improvement. The fact that patients prefer home infusion to travel to a clinic is not by itself a proof that their lives have been improved. As we wrote in the benefits section above \u2014 we are not given numbers to prove by what amount patients prefer home infusion.", "answer": 1}, {"article": "Publicity in recent years about emotional, cognitive, and memory problems in aging football and hockey players who suffered multiple concussions during their careers has raised the anxiety level around the topic. A lawsuit by thousands of NFL players who claim the league did not keep them well enough informed about the long-term risks of concussion - dementia is one of them - is based in Philadelphia and has raised even higher the profile of what doctors call mild traumatic brain injury.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story clearly does not rely on a press release.", "answer": 1}, {"article": "For instance, yoga may influence brain chemicals known as neurotransmitters (boosting levels of feel-good agents like serotonin), lower inflammation, reduce oxidative stress and produce a healthier balance of lipids and growth factors \u2014 just as other forms of exercise do.\nBut while the research is promising, yoga likely won\u2019t be a panacea for mental illness.\nSome of the studies included in the analysis even suggested that yoga might affect the body in ways similar to antidepressants and psychotherapy.\nThe researchers say there\u2019s enough evidence to warrant a larger study on the effects of yoga on mental health, and it should be considered as part of treatment for more disorders.\n\u201cMost individuals already know that yoga produces some kind of a calming effect.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes an interview with one of the study authors, and doesn\u2019t pull any material directly from this press release. (But it also cites a Huffington Post article \u2013 odd to do so.) We\u2019ll call it good enough for a satisfactory.", "answer": 1}, {"article": "Lauren Dunn is a medical producer for NBC News; Linda Carroll is a contributor for NBCNews.com\nWithout the glasses, she can\u2019t read anything.\nAlso, Hamilton notes, the implants aren\u2019t a \u201cbe all end all.\nIt\u2019s functioning in your day-to-day life.\u201d\n\nEkstadt has the privilege of being the first person in the nation to get the Raindrop outside of a clinical trial.\nBoth of the new implants, Raindrop and KAMRA, go into only one eye.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.\n\u00a0", "answer": 1}, {"article": "Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:\n\n\"If we're going to drive further improvements in survival from cancer, it's essential that we find ways of prolonging life in people whose cancers have evolved and become resistant to treatment.\nWe hope our results lead to the adoption of this drug combination in breast cancer, where it delays the need to start chemotherapy by an average of nine months.\nThe new research, published today (Thursday) in The Lancet Oncology, shows that even women with specific genetic changes conveying resistance to hormone therapy can benefit from the new drug combination.\nThe trial was funded by Pfizer.\nThis trial is an exciting example of one of the most promising approaches to overcoming drug resistance, by combining drugs with different mechanisms of action to block off cancer's escape routes.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release uses appropriate language\u00a0throughout.", "answer": 1}, {"article": "Side effects including shaking, headaches, vomiting and swollen gums\u2014as well as unwanted hair growth.\nAn existing drug used to treat a common bone disorder could hold the key to the cure for baldness, according to a new study.\nThe research team, led by Dr. Nathan Hawkshaw at the University of Manchester, in the U.K., investigated whether CsA could provide some clues for treating baldness.\n\u201cIt is also important to realize that this is being proposed as a treatment for hair loss, not a cure as such.\u201d\n\nThis piece has been updated with a comment from the British Association of Dermatologists.\n\u201cFor individuals with hair loss, treatments can be very hit and miss, there isn\u2019t one which is universally effective.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story didn\u2019t rely solely on a news release. (It did cite it, though.)", "answer": 1}, {"article": "EEGs measure brain electrical activity through electrodes attached to the scalp.\nEEGs are also relatively inexpensive, painless and safe, Bosl said.\nWe know early intervention is extremely important.\nAnd unlike MRIs, they require no sedation, so testing could be put to widespread use, he said.\n\"If it can eventually be shown that this technique can reliably identify which children will indeed develop autism, then we will have a valuable tool for early detection,\" Ewen said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "No evidence that the story relied on a news release.", "answer": 1}, {"article": "As a leading institution funded by the National Cancer Institute, Mayo Clinic Cancer Center conducts basic, clinical and population science research, translating discoveries into improved methods for prevention, diagnosis, prognosis and therapy.\nDr. McBane noted that cancer and cancer treatment can be associated with kidney injury, which can limit the drug's use further.\nHowever, it was unclear whether these drugs could be used safely in cancer patients until now.\n\"As a class, these drugs have a number of advantages, including oral delivery, lack of interactions with foods or other medications, and the lack of a need for monitoring drug levels.\"\nHe says these qualities make this class of drug much easier to use than the traditional blood thinners.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "No sensational language was used.", "answer": 1}, {"article": "\"Sadly,\" they write, \"we are left in a conundrum.\nBut this isn't the first study to call into question the benefits of mammography and whether women are too often the victims of overdiagnosis.\nAnd yet, a new study published in JAMA Internal Medicine has found something that may seem counterintuitive: More breast cancer screening didn't actually save lives.\nWe also need to remember that in medicine, more often than not, we generally overestimate the benefits and underestimate the harms.\nYou can see this clearly in the chart below: The number of diagnosed breast cancers rose with more screening, yet the number of deaths from breast cancer 10 years later remained stubbornly stable.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story brings in context from an accompanying editorial, risk communication tools, independent guidelines, and other studies of overdiagnosis. It clearly went beyond any news release.", "answer": 1}, {"article": "In addition, some people have implanted defibrillators or pacemakers.\nCimaglermin, however, may be such a drug, she said.\nPeople with heart failure often take a combination of drugs, Lenihan said.\nEvery drug currently used to treat heart failure has to be given daily or several times a day to get it to work, Bishopric said.\n\"These findings need to be replicated in larger trials, and you have to be able to predict whether improved heart function from cimaglermin will help people live longer and feel better,\" she noted.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story doesn\u2019t appear to have relied on a news release.", "answer": 1}, {"article": "Co-authors are Erin Van Blarigan, ScD, of the departments of Urology, and Epidemiology and Biostatistics at UCSF; Howard Sesso, ScD, MPH; Edward Giovannucci, MD, ScD; Meir Stampfer, MD, DrPH, and Julie Batista, ScD, all of Harvard T.H.\nThis study was supported by grants from the Prostate Cancer Foundation and the National Institutes of Health.\nIn the study, published today, Nov. 17, 2015, in the Journal of the National Cancer Institute, the researchers analyzed data from two U.S. studies: the Health Professionals Follow-Up Study that tracked more than 42,000 males ages 40 to 75, from 1986 to 2010; and a second, the Physicians' Health Study that followed more than 20,000 males ages 40 to 84, from 1982 to 2010.\nTo gage the effects of lifestyle habits, the researchers developed a score based on the results of the health professionals survey, then applied it to the physicians' study.\nWhile there were fewer cases and less detailed data collected in the physicians' study, the score was similar in both populations, indicating the potential benefit of healthy lifestyle habits in warding off lethal prostate cancer, said the authors.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Apart from the cause-and-effect statements addressed above, there is no unjustifiable language used here.", "answer": 1}, {"article": "Georgetown University Medical Center (GUMC) is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through MedStar Health).\nThe authors report having no personal financial interests related to the study.\nThe lead author on the study, Sarah Oppeneer Nomura, PhD, of Georgetown Lombardi, said that while further research is needed in larger study populations and with more detailed dietary data, this project addresses an important gap in research on the possible role of lifestyle factors, such as dietary habits, in relation to side effects of treatments.\nWhether the reduction in symptoms accounts for longtime use of soy and cruciferous vegetables needs further investigation, says the study's senior author, Judy Huei-yu Wang, PhD, of Georgetown Lombardi's Cancer Prevention and Control Program.\nWASHINGTON -- Consuming soy foods (such as soy milk, tofu and edamame) and cruciferous vegetables (such as cabbages, kale, collard greens, bok choy, Brussels sprouts, and broccoli) may be associated with a reduction in common side effects of breast cancer treatment in breast cancer survivors, say a team of scientists led by Georgetown Lombardi Comprehensive Cancer Center.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The authors didn\u2019t use unjustifiable language and did mention that more research is needed to confirm their study findings.", "answer": 1}, {"article": "The page you are looking for has moved. Please go to the main EurekAlert! homepage to locate the section you are interested in and reset your bookmarks.\n\nFor further assistance, please contact webmaster@eurekalert.org.", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "No data are included to back up the provocative headline. Stating that daily ibuprofen can \u201cprevent\u201d or \u201cward off\u201d Alzheimer\u2019s disease is unjustified.\nFurthermore, quoting the lead author as calling this unproven therapy a \u201cgame changer\u201d and \u201ctrue breakthrough\u201d \u2014 or that \u201cAD can eventually be eliminated\u201d \u2014\u00a0 is hyperbolic.", "answer": 0}, {"article": "They did so to offer support, but also to spread awareness, because they say too often life and death for someone having a cardiac arrest comes down to chance. If a bystander performs CPR while medics are on their way, survival rates more than double, doctors say.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There\u2019s enough original reporting here that we can be sure the story didn\u2019t rely excessively on a news release.", "answer": 1}, {"article": "Watching her patients undergo bone marrow transplant ?\nOf the 12 AML patients who received this experimental T-cell therapy after a transplant put their disease in remission, all are still in remission after a median follow-up of more than two years.\nBecause it was the first study of this particular approach, the researchers focused on a high-risk group -- AML patients undergoing bone marrow transplant who had certain genetic or disease characteristics that decrease the chance of long-term transplant success -- \"a hard population of patients,\" Chapuis said, many of whom \"were horribly sick.\"\nThis is the team's first trial of this strategy, which was initially developed in the lab of Dr. Phil Greenberg, one of the study's leaders and the head of Fred Hutch's Program in Immunology.\nIn the experimental T-cell therapy tested in this trial, certain T cells from each patient's transplant donor were genetically engineered to produce receptors that allowed the T cells to recognize, very specifically, a target molecule called WT1.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t rely on sensationalism to describe the findings. However, researchers are quoted as saying the experimental treatment \u201cmight actually be helping patients who have a high risk of relapsing to not relapse down the line.\u201d Then again, the reverse may be true and it might not be.\nWhile leukemia relapse is unwelcome, it cannot be known from this trial whether lower relapse rates mean longer or better lives for patients. Highlighting this sort of intermediate (or surrogate) endpoint distracts attention from the things that really matter to patients: the length and quality of their lives.", "answer": 1}, {"article": "For people hoping to shed some pounds, changing the type of protein in the diet, rather than the amount of it, is an idea the researchers think deserves more study as a weight loss strategy.\nThe research was funded by the American Egg Board, and will be presented at the19th European Congress on Obesity in Lyon, France.\n\"This study shows that diets with higher protein quality may enhance satiety, leading to better compliance and success of a weight loss diet,\" researcher Nikhil Dhurandhar, PhD, says in a news release.\nMay 11, 2012 -- Starting your day off with an egg may help curb your appetite better than cereal, new research suggests.\nScientists suspect that egg protein may be better at making people feel full longer compared to the protein found in wheat.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story identifies one of the quotes as coming from a press release, but it actually seems to have come from the study abstract itself.\u00a0 In either case, that\u2019s not best journalistic practice.", "answer": 0}, {"article": "\u201cThis wakes up the immune system and says, \u2018Hey!\n\u201cAfter that, there were no side effects.\u201d\n\nSuch muted side effects point to a major benefit of this new approach, doctors and patients said.\nJohn O\u2019Donnell, a retired math teacher in Piscataway, N.J., was one of those who tried the combination therapy, but ultimately responded only to Imlygic.\nApproved by the Food and Drug Administration on Tuesday for treating advanced-stage melanoma, the virus \u2014 called Imlygic, which was developed in part in a Massachusetts lab \u2014 is a modified version of the herpes virus that both attacks the cancer and sparks the immune system into action against tumors.\n\u201cThis is huge for the whole field, and for cancer patients,\u201d said John Bell, a senior scientist at the Ottawa Hospital Research Institute in Canada.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Amgen issued a news release on the same day as the Boston Globe/Stat story was published; there is enough original reporting that we can be sure the story went beyond this or any other news release.", "answer": 1}, {"article": "CHICAGO -- Many patients treated with Byetta, a diabetes drug by Amylin Pharmaceuticals Inc. and Eli Lilly & Co., were able to maintain good blood-sugar control and also lose weight after three years on the drug, according to a study.\n\nThe study, described at the American Diabetes Association's annual meeting here, examines clinical data from the longest trial involving Byetta presented to date.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if the story relied solely or largely on a news release, but we do know it quoted only the principal investigator of the study. ", "answer": 2}, {"article": "Patients with untreatable angina who received the injections of CD34+ stem cells in key areas of the heart had significantly fewer chest pain episodes and significantly better performance on exercise tests than patients who got placebo injections.\nResults from a pivotal study of the treatment were reported today in the American Heart Association (AHA) journal Circulation Research.\nThe patients received 10 such injections during a single catheterization procedure.\nPatients were given a drug for several days to increase the number of CD34+ stem cells in the blood.\nThe approach also showed promise in a 2007 pilot study involving fewer than 30 patients.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Although a news release from the American Heart Association is cited as one source for the story, we do not see evidence that the story relied solely or largely on that or any news release.", "answer": 1}, {"article": "The main campus also includes University Hospitals Rainbow Babies & Children's Hospital, ranked among the top children's hospitals in the nation; University Hospitals MacDonald Women's Hospital, Ohio's only hospital for women; and University Hospitals Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center.\nPrevious survey research completed by Dr. Kingsberg and others has shown that while 32 million women may be experiencing symptomatic VVA and suffering from related impacts on sexual function, interpersonal relationships, self-esteem and overall quality of life, only 7 percent are currently using a prescription therapy to alleviate symptoms.\nThe survey, which included 731 respondents with a 96 percent response rate, sought to quantify participants' satisfaction with the application method and overall treatment delivery system.\nThough they may suffer from physical and emotional pain as a result of VVA, women may not feel comfortable discussing these symptoms with a healthcare professional, may not recognize the symptoms as treatable, may not fully understand the treatment options available, or if they did receive treatment, found the current prescription treatment options inconvenient, messy, or uncomfortable to use.\n\"These survey results show that something as simple as a change to a more elegant delivery system that is easier to use and not messy might empower more post-menopausal women to seek prescription treatment for VVA, and perhaps help them stay with the application guidelines for longer,\" said study first author Sheryl Kingsberg, PhD, Division Chief, OB/GYN Behavioral Medicine, UH Cleveland Medical Center; Professor of Obstetrics and Gynecology and Psychiatry, Case Western Reserve University School of Medicine; and first author of the survey analysis.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "As noted, other than perhaps overestimating the percentage of women affected by VVA, especially by painful sexual intercourse, the news release was relatively low key. It quotes Dr. Kingston, the study\u2019s first author, as saying that health professionals \u201cstill have to find better ways to educate the millions of women suffering with VVA about the symptoms, however, so that more of them know it is common, decide to discuss treatment with their healthcare professional, and seek symptom relief with appropriate treatment.\u201d Given that health sources generally seem to agree that VVA is common, reduces quality of life for post-menopausal women and remains under-treated, that statement does not seem terribly out of line.", "answer": 1}, {"article": "By Amy Norton NEW YORK (Reuters Health) - People with multiple sclerosis have long said that smoking marijuana helps ease their painful muscle cramping.\n\u201cSpasticity is a big problem for many people with MS, and the current medications don\u2019t necessarily work for everyone,\u201d said LaRocca, who was not involved in the new study.\nBoth LaRocca and Corey-Bloom said there were limitations to the current study.\nBut it\u2019s not clear if that would have any long-term consequences, Corey-Bloom said.\n\u201cI think this study shows that yes, (marijuana) may help with spasticity, but at a cost,\u201d said Corey-Bloom, of the University of California, San Diego.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely solely on a news release.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - In a new study of middle-aged New Jersey men, taking cholesterol-lowering drugs was linked to a lower chance of dying from prostate cancer.\nThe findings don\u2019t prove that the drugs, called statins, ward off aggressive cancer.\nBut they jibe with previous studies suggesting that getting cholesterol levels under control might help reduce the risk of life-threatening disease, researchers said.\nMarcella\u2019s team didn\u2019t have the data to figure out if taking a statin for longer, or starting one earlier, was more beneficial than more limited use of the drugs.\n\u201cIf a person\u2019s on the fence about taking a statin medication for their heart, this is another potential benefit they may have by taking one of these,\u201d he told Reuters Health.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely on a news release.", "answer": 1}, {"article": "Another company, TrovaGene, has developed a DNA test using urine, which, according to Gabriele Cerrone, TrovaGene\u2019s co-founder and director, is 95 percent accurate at predicting boys at seven weeks, and 88 percent accurate at predicting girls.\nThe study \u201chas wide-reaching implications,\u201d said Dr. Louise Wilkins-Haug, director for maternal-fetal medicine and reproductive genetics at Brigham and Women\u2019s Hospital in Boston, who was not involved in the research.\nLawyers for Acu-Gen could not be reached for comment.\nMost tests that were highly accurate were conducted on a mother\u2019s blood, not urine.\nRebecca Griffin, a founder of the biggest seller, Intelligender, said two independent studies found it 90 percent accurate at 10 weeks.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not rely on a release.", "answer": 1}, {"article": "For more on chemotherapy, visit the American Cancer Society.\nSpecifically, nearly 70 percent of those in the fish oil group either kept their pre-chemo muscle mass or gained muscle.\nWhat's more, blood analyses revealed that those in the fish oil group who had the biggest bump in bloodstream EPA concentrations also had the greatest muscle mass gains.\nThe finding is based on a small study involving just 40 lung cancer patients.\n\"But I would caution that the amount of pure concentrated fish oil supplement the people in this study were given is a lot,\" she added.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Mixed bag but we must give an unsatisfactory score because the story lifted researcher quotes from a news release and apparently didn\u2019t interview any of the researchers.\nGranted, the story sought an independent perspective, but the entire story was apparently based on a news release, not on any independent interviewing of the research team.", "answer": 0}, {"article": "Vasopressin, an anti-diuretic, reduces urine production.\nIn the United States there's no approved drug to treat the problem, the study authors said.\nThat uninterrupted sleep period extended to more than four hours, Kaminetsky said.\nThis suggests that the anti-inflammatory impact of routine exercise may minimize nocturia, he said.\nDesmopressin spray prompted \"a significant decrease\" in the frequency of nightly bathroom trips compared with the untreated group, Kaminetsky said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "With knee-replacement surgery on the rise, more patients with two bad knees are opting for a controversial procedure that replaces both at the same time.\n\nSimultaneous bilateral knee replacement, as the surgery is known, is a subject of debate among orthopedic surgeons, with conflicting evidence about the risks and benefits. Proponents say it eliminates the need for a second hospital stay and grueling rehabilitation period, reduces time spent under anesthesia and costs less.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to be tied to a news release. And, given the number of patients and doctors interviewed, the story goes well beyond what would be included in a news release anyway.", "answer": 1}, {"article": "Professor Babaeva said: \"Our findings suggest that the decreased rheumatoid arthritis disease activity with the combination of anticytokines translates into decreased cardiovascular risk.\nProfessor Babaeva's previous research showed that treatment with anticytokine drugs can decrease the activity of rheumatoid arthritis.\nThe current study investigated the impact of the combination of drugs on cardiovascular events.\nThe effect was more apparent and developed earlier when patients were treated with a combination of anti-TNF\u03b1 and anti-IFN?, both at extra-low doses.\nWe recommend this new approach for preventing cardiovascular events in patients with moderate disease activity who are not receiving the standard biologics and who do not have severe complications.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There are no obvious examples of the use of unjustifiable descriptors. However, the first paragraph seems to suggest that it is well-known that these drugs will reduce rheumatoid and cardiovascular disease. The implication is that these have been well-proven, but we think that\u2019s still an open question. ", "answer": 1}, {"article": "Co-authors include: Drs.\nThis study was funded by a Canadian Institutes of Health Research (CIHR) team grant in Pediatric Emergency Medicine.\n\"The low rate of serious adverse events and significant interventions supports the safety of procedural sedation in the hands of emergency department physicians,\" said Dr. Bhatt.\n\"Although sedation-related serious adverse events occur infrequently, recognition and early intervention is necessary to ensure patient safety,\" said Dr. Maala Bhatt, lead author, director of pediatric emergency research at CHEO, and assistant professor at the University of Ottawa.\n\"We've been able to identify sedation medications and practices associated with the best clinical outcomes, which is practice-changing.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t rely on sensational language.\u00a0 We think the release may have strayed into unjustifiable territory by suggesting the study findings may be \u201cpractice-changing.\u201d That remains to be seen but we\u2019ll give the release the benefit of the doubt on this claim.", "answer": 1}, {"article": "[Seriously, why does anyone under 18 still have access to a tanning bed?]\nThat said, the agency warned Wednesday that the new drug can cause serious side effects, including trouble swallowing or nerve damage to the jaw that can result in an uneven smile or muscle weakness in the face.\nThe FDA warned, however, that the treatment also has the potential to kill other types of cells, such as skin cells, if injected improperly.\nPatients can receive as many as 50 injections of the drug in a single treatment, the agency said, with up to six treatments administered no less than a month apart.\nKeith Leonard, chief executive of Kythera, the California-based firm that developed Kybella, said at a conference last month that he believes the new treatment \"can drive a very large market and leave very satisfied patients.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story leans heavily on the FDA news release, and the additional context it provides comes from past statements by company stakeholders and a salesy survey about consumer demand for cosmetic procedures. Not quite good enough for a Satisfactory rating.", "answer": 0}, {"article": "Dr. Matthew Brams, M.D., Clinical Assistant Professor at Baylor College of Medicine and principal investigator for study 305, added: \"The study of SHP465 in children and adolescents is an essential next step to progressing the clinical program.\nAll forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement.\n\"These results represent an important step toward a new treatment option for patients with ADHD.\nReaders are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.\nIn the event such risks or uncertainties materialize, Shire's results could be materially adversely affected.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There does not appear to be any unjustifiable claim being made here.", "answer": 1}, {"article": "The U.S. Centers for Disease Control and Prevention has more on flu.\nThe disinfecting success of initial experiments still need to be confirmed, said lead research David Brenner.\nHowever, Brenner and his colleagues wondered if a much narrower spectrum of ultraviolet light, far-UVC, might be a safer option.\nTwo flu experts were encouraged by the findings.\nIt could offer a new, inexpensive way to eliminate airborne flu viruses in indoor public spaces such as hospitals, doctors' offices, schools, airports and aircraft, said the team from Columbia University Medical Center in New York City.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story discloses that the quotes from the lead researcher are taken from the news release. The inclusion of two more sources means the story just squeaks by on this rating.", "answer": 0}, {"article": "Feb. 10, 2011 (Los Angeles) -- Giving clot-busting drugs to people with mild strokes could prevent more than 2,000 of them from becoming disabled each year, researchers say.\nIn fact, one in three people who suffer a mild stroke are disabled three months later, Khatri says.\nBut people with mild strokes are typically denied tPA because the studies that established its effectiveness excluded mild cases, says Pooja Khatri, MD, of the University of Cincinnati.\nIt's been assumed that people with mild strokes \"generally [do] well and the risk of tPA treatment, which includes a slight but significant risk of life-threatening bleeding in the brain, would not be worth the benefit,\" she says.\nMild strokes -- characterized by such symptoms as clumsiness in the hand, weakness of an extremity, some slurred speech, temporary loss of vision, and/or dizziness -- account for more than half of strokes in the U.S.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does not appear that the story relied solely on a news release.", "answer": 1}, {"article": "It is known as BMS-790052.\nIn fact, no fewer than 90 studies are currently underway examining different HCV-targeting drugs.\nA unique thing about the NS5A-targeting drug, according to Meanwell, is that laboratory studies show it to be effective against all HCV genotypes.\nBut the study provides the first clinical evidence that targeting the HCV protein NS5A may be an effective strategy for curing patients who are chronically infected with the HCV virus, says Nicholas A. Meanwell, PhD, who is executive director of chemistry with Bristol-Myers Squibb.\nThe research is so early that the drug hasn't been named.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure whether this story relied on a news release.\u00a0 ", "answer": 2}, {"article": "Estrogen stimulates the growth of ER+ tumors.\nThe investigation was funded by the American College of Surgeons Oncology Group and led by Dr. Julie A. Margenthaler, an assistant professor of surgery and a breast surgeon at the Siteman Cancer Center at Washington University in St. Louis.\nThe observation was based on a national study launched at 118 hospitals across the United States.\nThe most common form of breast cancer, ER+ accounts for about three-quarters of all breast cancer cases in the United States, the authors noted.\nThe findings are scheduled to be presented June 7 at the American Society of Clinical Oncology annual meeting, in Chicago.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story\u00a0is based exclusively on a press release. \u00a0", "answer": 0}, {"article": "Staying sexually active\u2014and considering sexuality an important part of life\u2014may be linked to higher cognitive functioning as people age, according to a study in the March issue of the American Journal of Geriatric Psychiatry.\n\nOlder men and women who were satisfied with their sexual relationships and considered sexuality an essential component of aging performed better on tests of cognitive function than those who felt sexuality and intimacy were unimportant, the research showed.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We couldn\u2019t locate a news release for this study, but there isn\u2019t enough original reporting to assure us that the story didn\u2019t rely on a news release. Therefore, we\u2019ll rate it Not Applicable.", "answer": 2}, {"article": "For more about healthy eating, visit the U.S. Centers for Disease Control and Prevention.\nDr. Sonia Anand, a professor of medicine and epidemiology at McMaster University in Hamilton, Canada, praised the study, saying it's \"reasonable\" to link changes in diet to death rates in this way.\nChan School of Public Health in Boston, cautioned that it's not time to declare victory in the battle against unhealthy eating.\nThe findings paint a surprising picture of American health.\nBut other research has pinpointed a decline in death rates in this century, Wang said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Health Affairs did publish a brief summary \u201cnews release\u201d on its website, but the article clearly went beyond the release to report the story.", "answer": 1}, {"article": "\u201cIt\u2019s not one size fits all.\u201d\n\nBut national guidelines still recommend that adults over age 65 follow the same guidelines as younger people: to get at least 150 minutes of moderate-to-vigorous physical activity per week.\nActivities like these account for more than 55% of older adults\u2019 daily activity, says LaCroix, so the fact that they were protective in this study is very good news.\nLaCroix says her new study refutes that research and shows that older adults can still benefit at levels below the moderate-to-vigorous guidelines.\nQuestionnaires used in self-reported studies don\u2019t do a good job of encompassing all the ways people get physical activity throughout the day, she says, which may have skewed previous study results.\nThe researchers hope their work sparks more discussion about how people\u2014especially older ones\u2014think about exercise and their goals for being active.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This is borderline. The story maps very closely to the news release. However, the story appears to incorporate quotes from study author Andrea LaCroix that are not found in the news release.", "answer": 1}, {"article": "Vegetables particularly high in alpha-carotene include yellow-orange vegetables, such as carrots, sweet potatoes, pumpkin, and winter squash, and dark green vegetables, such as broccoli, green beans, green peas, spinach, turnip greens, collards, and lettuce.\nResearchers wanted to see if other carotenoids may also play a role in reducing the risk of disease.\nThe study shows that eating foods rich in antioxidants, like vegetables and fruits, fights disease and may prolong life.\nNov. 22, 2010 -- Eat your veggies and you may live longer, a study suggests.\n\"These findings support increasing fruit and vegetable consumption as a means of preventing premature death,\" write researcher Chaoyang Li, MD, PhD, of the CDC and colleagues in the Archives of Internal Medicine.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\n\nThe story appears to be based on a news release from the Archives of Internal Medicine.\u00a0 Entire sentences in the story appear to be lifted wholesale from the following news release. \n\u201cHigh Alpha-Carotene Levels Associated With Longer Life\u201d\nhttp://pubs.ama-assn.org/media/2010a/1122.dtl#1", "answer": 0}, {"article": "Dry mouth was much more common in those who took the medicine; urinary infections and incomplete emptying of the bladder were more common in those given Botox.\nNow a placebo-controlled study has found that the treatments are equally useful in reducing the frequency of episodes of incontinence, but vary in side effects and long-term effectiveness.\nThe scientists, writing online on Oct. 4 in The New England Journal of Medicine, found that both treatments significantly reduced incontinence episodes.\n\u201cThese are both effective treatments,\u201d said the lead author, Dr. Anthony G. Visco, an associate professor of obstetrics and gynecology at Duke.\nThe medicine has to be taken daily, while Botox is given in a single injection that is effective for about 6 to 12 months.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a press release.", "answer": 1}, {"article": "What if doctors had a pill that prevents breast cancer and nobody wanted to take it? That has pretty much been the situation with tamoxifen, an estrogen-like drug that was proved in 1998 to cut in half the chance of developing breast cancer if taken for five years by women with increased risk of the malignancy. The trouble is, tamoxifen also triggers menopausal symptoms like hot flashes and slightly increases the chances that a woman will develop blood clots and uterine cancer. As a result, women haven't been too eager to take the medication--nor have many doctors been all that enthusiastic...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not appear to be directly from a press release and there is a link for more information on study at NCI website. Breast cancer experts not affiliated with the NCI trial provide perspective in interpreting the results. ", "answer": 1}, {"article": "\"It appears that women who reported taking prenatal vitamins starting three months prior to conception and through the first month after conception seem to have a reduced chance their child will develop autism ,\" says study researcher Irva Hertz-Picciotto, PhD, professor of epidemiology and environmental health at the MIND Institute and Department of Public Health, University of California, Davis.\nExactly why the prenatal vitamins may protect against autism is not clear, she says.\nThe risk rose if the mothers or the children had a high-risk gene form.\nAll were enrolled in the CHARGE study (CHildhood Autism Risks from Genetics and Environment) from 2003 to 2009.\nThe research needs to be duplicated, Hertz-Picciotto tells WebMD.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story quotes an independent researcher and doesn\u2019t seem to rely excessively on\u00a0any news release.", "answer": 1}, {"article": "During transcranial magnetic stimulation (TMS), a doctor places a large magnetic coil against the patient\u2019s scalp, which creates electric currents to stimulate nerve cells.\nThere were no improvements seen in test scores of those who got the other treatment.\nThis is often not enough to make a meaningful improvement.\nThis therapy may restore balance between the two sides of the brain.\nTen out of 20 people who faced this problem following a stroke received the magnet therapy daily for two weeks.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story was not based solely or largely on a press release.", "answer": 1}, {"article": "Human monoclonal antibodies are naturally occurring human antibodies that are genetically altered in a laboratory, cloned in large numbers and introduced into the patient to target disease sites.\nThe study was published online Nov. 5 in the Journal of the American Medical Association, to coincide with a planned presentation at the American Heart Association's annual meeting in Los Angeles.\nThe 12-week, phase 2 clinical trial was conducted at 33 international sites and included adults who suffered muscle problems when taking statins, a class of cholesterol-lowering drugs that includes Crestor and Lipitor.\nThe patients who received AMG145 had 41 percent to 63 percent reductions in \"bad\" (LDL) cholesterol and did not experience significant muscle-related side effects, said study leader Dr. David Sullivan, of the Royal Prince Alfred Hospital in Australia, and colleagues.\n\"For those patients with elevated LDL who are intolerant to statins, this provides a viable option,\" said Dr. Suzanne Steinbaum, a preventive cardiologist at Lenox Hill Hospital in New York City.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely largely on a news release.", "answer": 1}, {"article": "During the DaTscan test, an imaging drug is injected into a patient's bloodstream and the patient undergoes a single-photon emission computed tomography, or SPECT, scan.\nIn cases where a diagnosis isn't necessarily clear-cut, the DaTscan offers important advances in patient care and treatment, said Dr. Michael Rezak, director of the Movement Disorders Center at Central DuPage Hospital, where the scan is offered.\n\"DaTscan is used in difficult-to-diagnose cases and must be used in conjunction with a clinical evaluation and a patient's response to medications,\" Rezak said.\nSince June, 25 men and women of all ages have been tested with DaTscan at Central DuPage, Rezak said.\nBefore the test, Ramas, of West Chicago, experienced two years of uncertainty about his health as several specialists tried to pinpoint the cause of his joint and tendon pain, fatigue, stiffness in his legs and lack of bladder control.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\nThe story does not appear to rely on a news release. However, it does not tell readers much information beyond what they would get from reading just the hospital news releases touting this test.\n", "answer": 1}, {"article": "Digital rectal exams can tell a specialist that the prostate is getting bigger, but that happens with normal aging as well as with cancer.\nThe test had a sensitivity of 49 percent, meaning it correctly identified 49 percent of cancers.\n\u201cIf the PCA3 is abnormal, above about 35, you have got an 80 percent chance of having cancer,\u201d Crawford said.\nThe Progensa test looks for a genetic material called PCA3.\nA study last year estimated that more than 1 million men in the United States alone had been needlessly treated for prostate tumors that likely would never have killed them.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\u00a0Not applicable.\u00a0 We can\u2019t be sure of the extent to which a news release may have influenced this story. ", "answer": 2}, {"article": "Women who took hormones had an average of 24 fewer hot flashes per month, while those who took soy had 12 per month fewer.\nAnd not every woman needs treatment, notes Bachmann, who was not involved in the study.\nWomen with severe or frequent hot flashes or whose hot flashes keep them up at night, should consider treatment, she said.\nThat means that if women do take hormones, Bachmann told Reuters Health, it should be the lowest dose and for the shortest possible period of time.\nThe study did not look at whether eating soy in food has the same effect on hot flashes as supplements, Bolanos-Diaz said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely solely on a news release.", "answer": 1}, {"article": "46 babies had a brother or sister with known autism, which means they themselves are at an increased risk for the neurodevelopmental disorder that affects about one in 110 children according to the Centers for Disease Control and Prevention.\nWiznitzer \u2013 a pediatric neurologist at Rainbow Babies & Children's Hospital in Cleveland, Ohio \u2013 notes that what the study can't tell us is what the differences in brain activity between the two groups of babies actually mean.\nHe, too, is hopeful that further research will provide more concrete information.\nHe said that, judging by the differences in brain activity, he and his colleagues could detect which babies were in the high-risk group.\nHe hopes to expand the number of babies in his study to 200.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story didn\u2019t rely on a news release.", "answer": 1}, {"article": "This type of drug development program, which enrolled patients with different tumors but a common gene mutation, wouldn\u2019t have been possible a decade ago because we knew a lot less about such cancer mutations,\" said Dr. Gottlieb.\nIts approval reflects advances in the use of biomarkers to guide drug development and the more targeted delivery of medicine.\"\n\"Using our breakthrough therapy designation and accelerated approval processes, we support innovation in precision oncology drug development and the evolution of more targeted and effective treatments for cancer patients,\" the FDA stated.\n\"This new site-agnostic oncology therapy isn\u2019t specific to a cancer arising in a particular body organ, such as breast or colon cancer.\nVitrakvi will run further tests of the drug's safety and effectiveness.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story appears to be entirely based on an FDA news release.", "answer": 0}, {"article": "A flu drug \u2014 shown to reduce the duration of symptoms \u2014 could upend treatment in U.S.\n\nNext winter, there may be a new drug for people who contract influenza \u2014 one that appears to be able to shut down infection quickly and, unlike anything else on the market, can be taken as a single dose.\n\nThe Food and Drug Administration on Tuesday said that it would give the drug, baloxavir marboxil, a priority review, and approval has the potential to upend the way influenza is treated.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The catalyst for the story was a news release issued by Genentech about the FDA granting priority review of baloxavir marboxil, but the story does not use direct quotes from the news release.", "answer": 1}, {"article": "FDA approves first drug aimed at women with inherited breast cancer\n\nU.S. regulators have approved the first drug aimed at women with advanced breast cancer caused by an inherited flawed gene.\n\nThe Food and Drug Administration on Friday approved AstraZeneca PLC\u2019s Lynparza for patients with inherited BRCA gene mutations who have undergone chemotherapy.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "While the story does not mimic a news release word-for-word, it relies heavily on two news releases, from AstraZeneca and the FDA. Both of the quotes in the story are from these news releases, for example.", "answer": 0}, {"article": "Todd McAllister of Cytograft Tissue Engineering in California and colleagues implanted lab-grown blood vessels into 10 patients with advanced kidney disease in Argentina and Poland from 2004 to 2007.\nThe study was was paid for by Cytograft Tissue Engineering.\nAll of the vessels were implanted into patients' upper arms, to connect them to dialysis machines.\nIn 2007, the scientists published preliminary findings for another 4 patients in the New England Journal of Medicine.\nIn the five remaining patients, the vessels worked for at least 6 to 20 months after they were implanted.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story included original quotes from a researcher and journal commentator, as well an independent source.", "answer": 1}, {"article": "Dementia affects about 50 million people worldwide, with 10 million new cases occurring every year.\nFocusing LIPUS treatment on a region in the brain called the hippocampus, which is involved in memory, has also been found to improve dementia in mice, but the details of how it does this need to be more fully investigated.\nThe research, conducted by scientists at Tohoku University in Japan, suggests that this type of therapy may also benefit humans.\nThe mice with a condition simulating Alzheimer's disease in humans received 11 LIPUS treatments over a period of three months.\nThe researchers conclude that their study, recently published in the journal Brain Stimulation, provides the first experimental evidence that whole-brain LIPUS therapy markedly improves cognitive dysfunctions without serious side effects by enhancing specific cells related to dementia's pathology.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We found this quote from the lead author partly unjustifiable: \u201cThe LIPUS therapy is a non-invasive physiotherapy that could apply to high-risk elderly patients without the need for surgery or anaesthesia, and could be used repeatedly.\u201d The quote is caveated \u2014 i.e. \u201ccould apply\u201d \u2014 but it\u2019s still a major leap to connect early results from animal-model research to a real-world treatment, especially the suggestion that it won\u2019t harm anyone and remain effective with repetition (something the study doesn\u2019t really address, as the treatment is front-loaded three times within five days). Also, most medical research\u00a0doesn\u2019t pan out; treatments often fail to work in clinical trials involving humans, or the potential harms detected tend to outweigh the possible benefits.\nA more responsible quote would have noted that a human treatment is the ultimate hope, but that much more research remains to show that it works in humans and that it\u2019s safe when repeated, either in mice or humans.", "answer": 0}, {"article": "This news-agency article is no longer available on nytimes.com.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story discusses a number of different apps and quotes sources from a variety of institutions.", "answer": 1}, {"article": "\"People were saying, 'I had absolutely zero symptoms.\nIt could be that the whipworm larvae weren't prepared correctly.\nBack in Berkeley, Velasquez-Manoff thought he might one of the lucky ones.\nHe talked to many people who were using an unlikely tool to treat their problems: parasitic worms that live in your gut \u2014 permanently.\nHe says the benefits of the worms definitely didn't outweigh the bad side effects.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There\u2019s no evidence that the story relied on a news release.\n\u00a0", "answer": 1}, {"article": "For example, Kramer says, what if a man got a PSA test when his prostate cancer was in the very earliest stages of metastatic disease?\nMessing says this misses the point of his study, which appears in the online July 30 issue of the journal Cancer.\nThe new study seems to make a powerful argument in favor of PSA testing.\nBut it's not that simple, says Barnett Kramer, MD, MPH, associate director for disease prevention at the National Institutes of Health.\nBut he would not yet have symptoms or detectable metastatic disease, so he'd be diagnosed with earlier-stage disease.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not rely on a press release.", "answer": 1}, {"article": "For more details and to read the full study, please visit the For The Media website.\nA limitation of the study was its small sample size and short follow-up period.\n\u201cGreater confidence in these outcomes may result from larger confirmatory studies of longer duration,\u201d the authors write.\nSeveral measures of quality of life also improved compared with those in the sham laser group, including general vision and independence.\nA total of 19 patients (53 percent) in the YAG laser group reported significantly or completely improved symptoms vs 0 individuals in the sham group.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release is factual and straightforward. Its primary problem is one of omission. It doesn\u2019t note that that data on the effectiveness of this procedure are still limited and that most individuals with eye floaters will not need it.", "answer": 1}, {"article": "Most head and neck cancers are linked to alcohol consumption and to smoking.\nInterestingly, the protective effect of coffee was not diminished in drinkers and smokers.\nThough there weren't enough data on decaf drinkers to draw conclusions, drinking tea -- even massive quantities -- was not protective.\nThat's probably not what University of Milan researchers Carlotta Galeone, ScD, PhD, and colleagues thought they'd find when they analyzed nine studies comparing 5,139 people with head and neck cancer to 9,028 people without cancer.\nBut whether these substances actually protect against cancer in humans is a question for future studies.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if the story relied on a news release.\u00a0 We do know that no independent source was quoted.\u00a0 ", "answer": 2}, {"article": "Older adults who take college courses may increase their cognitive capacity and possibly reduce their risk for developing Alzheimer's disease or other forms of dementia, according to new research published by the American Psychological Association.\nThis study is the first to examine similar positive effects from college courses taken by older adults, said Lenehan, of the University of Tasmania.\nThe participants' age, gender, feelings of well-being or level of social connectedness didn't affect the findings.\n\"The study findings are exciting because they demonstrate that it's never too late to take action to maximize the cognitive capacity of your brain,\" said lead researcher Megan Lenehan, PhD.\nThe participants who took college classes volunteered for the study so they probably had a greater interest in continuing education that the general senior population, the journal article noted.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Apart from the overly optimistic title and some inappropriate use of active verbs (already noted above), the release provides information in a clear and a reasonable fashion without the use of hyperbole.", "answer": 1}, {"article": "During Pap tests, cells are swabbed or scraped from the cervix for examination under a microscope to find cancer or possible pre-cancerous changes.\nThe report, in the Annals of Internal Medicine, sums up a research review done for the U.S. Preventive Services Task Force (USPSTF), an expert medical panel supported by the federal government.\nYou\u2019re trying to make a tradeoff between sensitivity and specificity.\u201d\n\nSince cervical cancer screening is repeated over time, what\u2019s needed is evidence of the longer-term effects of different tests, according to Whitlock.\nBut many women still do not get regular Pap screening, Whitlock pointed out.\nThe tests also had the same \u201cspecificity,\u201d which can be used to measure how often a screening test produces false-positive results.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes reporting beyond any release.", "answer": 1}, {"article": "At the end of the study, the group of volunteers who had used the dapivirine ring had 27% fewer HIV infections than a control group who had a placebo ring with no drug, the study found.\nBut it\u2019s now known that, when taken properly, Truvada cuts new cases of HIV by at least 92%.\nOne of the new studies, published today in the New England Journal of Medicine, tested the ring in more than 2,600 women in four countries \u2014 Malawi, SouthAfrica, Uganda, and Zimbabwe \u2014 over nearly two years.\n\u201cThat individual control of prevention is so powerful.\u201d\n\nThe dapivirine ring has been in development for more than a decade, and the the new studies are the first to show that it prevents HIV transmission.\nLike birth control, the more types of HIV prevention, the better, experts say.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Since the article uses quotes not found in a news release on the studies, we are confident the story does not rely solely on a PR release.", "answer": 1}, {"article": "Hupin D, Roche F, Gremeaux, et al.\nThese differences in risk were statistically significant.\nDr Hupin emphasised that the widespread acceptance of this message would encourage more elderly people to include even \"low doses\" of physical activity in their usual daily activities, without experiencing high levels of fatigue or of pain.\nBased on the results, Dr Hupin said that a revision of the recommendations for physical activity in the elderly may thus be warranted and beneficial - low dose physical activity can significantly reduce mortality.\nAs a simple rule for the elderly Dr Hupin recommended that at least 15 minutes of physical activity for five days a week would be a suitable first target for the elderly.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release uses neutral, unbiased language that edges on jargony. Most lay people would not understand the terms \u201ccohort,\u201d \u201cMET-h values\u201d or \u201cmeta- analysis.\u201d\nAlthough these terms could have more simply explained, we feel the absence of sensational language merits a satisfactory rating here.", "answer": 1}, {"article": "\"The development of osteoporosis drugs by pharmaceutical companies has focused heavily on blocking CatK in recent years,\" said Dieter Br\u00f6mme, a professor in the faculty of dentistry and a Canada Research Chair in Proteases and Disease.\nThe study builds on previous research by Br\u00f6mme and his team that looked at the effectiveness of red sage, known as Danshen in Chinese and used to treat bone ailments, in stopping the activity of CatK in limited ways.\nAn herb widely used in traditional Chinese medicine might hold the key to a new osteoporosis therapy that could prevent bone loss without causing side effects.\nThe treatment could also potentially be used to treat a variety of other bone and cartilage diseases such as arthritis and certain bone cancers.\nThey found that it prevented bone loss and increased the bone mineral density of the mice treated with the compound by 35 per cent, when compared with the control group.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "To call this a \u201ctreatment\u201d as this news release and its headline does is premature.", "answer": 0}, {"article": "In macular edema, fluid from those damaged vessels leaks into the macula, the part of the retina that is responsible for the straight-ahead vision important for driving, recognizing faces and reading.\nAbout 1 percent of those getting Lucentis injections suffered an inflammation of the eye from an infection.\nThe steroid treatment did not improve eyesight more than laser therapy alone and caused side effects.\nHe said treatment with Lucentis in the clinical trial virtually eliminated those incidents.\nResults of the trial were published online on Tuesday by the journal Ophthalmology.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\u00a0Does not appear to rely on a press release.", "answer": 1}, {"article": "With advanced heart failure, a leading cause of hospitalizations, blood-pumping ability is diminished as the heart\u2019s left ventricle becomes enlarged and weakened.\nVericel last month reported that the study succeeded.\nHowever, the treatment failed to improve secondary goals of the trial, such as heart-pumping efficiency and six-minute walking distance, and Vericel shares fell more than 31 percent by afternoon trading on Monday.\n\u201cIt\u2019s a little baffling that you\u2019re keeping patients alive, but not having any effect on those secondary endpoints,\u201d said Needham & Co analyst Chad Messer.\n\u201cFor patients, this is a really hopeful thing.\u201d\n\nHenry, who presented the data at the ACC meeting, stressed the need for larger trials to prove the benefit of ixmyelocel-T\n\nFor the treatment, bone marrow is taken from the patient and enhanced over two weeks to increase two types of cells associated with healing.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story contains original commentary, and so it does not appear to rely on a news release.", "answer": 1}, {"article": "People who were given the 60 mg doses saw a nearly 16 percent reduction in the amount of amyloid, and those given the 200 mg doses saw a 36 percent reduction.\nThere are approximately one dozen therapies, including vaccines, for Alzheimer's disease that are currently in the pipeline, Lyden noted.\nThe need for a drug to delay the onset or slow progression of Alzheimer's disease can't be underestimated, Aggrawal said.\nThat said, these experimental drugs carry the potential for serious side effects, including causing the immune system to go haywire.\n\"This is problematic in that use of these treatments may carry a very high risk for neurologic complications, thus necessitating heightened monitoring, and diminishing its applicability as a treatment for a larger patient population such as the Alzheimer's disease population,\" she said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely solely on a news release.", "answer": 1}, {"article": "The found the chronic poor sleepers became sick more often: those who slept for five hours or less each night were 4.5 times more likely to catch the cold than people who slept seven hours or more.\nThe study is unique because it used objective measures to show that poor sleep habits make people more vulnerable to a cold virus, says Badr, who was not involved in the research.\nThe study provides more evidence of the link between healthy sleeping habits \u2014 which experts say means at least seven hours of sleep each night \u2014 and overall good health.\nFurthermore, the researchers actually gave the subjects the virus, assuring that everyone was exposed to the same bug.\nIn fact, sleep was more important than any other factor, including age, stress or income level, in predicting who would get sick after being exposure to the cold virus, the researchers say.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not rely overly on this\u00a0news release.", "answer": 1}, {"article": "Actinic keratoses are typically red, scaly skin lesions that can over time develop into a type of skin cancer.\n\u201cThe shorter application period is what makes ingenol mebutate a breakthrough in the treatment of actinic keratosis,\u201d researcher Mark Lebwohl, MD, says in a news release.\nThe new study was funded by Picato manufacturer LEO Pharma.\nBecause the new gel is only used for a few days, any irritation is usually short-lived.\nOther available topical treatments must be used for several weeks, and often irritate the skin.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The quote mentioned above comes from a news release and there is nothing in the story that does not appear in very similar wording in the news release.", "answer": 0}, {"article": "Folic acid is naturally present in green, leafy vegetables and legumes.\nO\u2019Connor, of the University of Toronto and the Hospital for Sick Children in Ontario, Canada, called the findings \u201cpretty significant.\u201d\n\nStill, she said, you can\u2019t be sure if the kids who performed better had a better diet in general or if some other hidden factor could explain the results.\nThe researchers looked at 386 15-year-olds who were finishing up ninth grade.\n\u201cThere is very little deficiency of folic acid in North America,\u201d Deborah O\u2019Connor, a nutrition researcher who was not involved in the study, told Reuters Health.\nThe differences remained even after the researchers accounted for gender, smoking, the mothers\u2019 education and which schools the kids went to.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story did not appear to rely solely on a news release.", "answer": 1}, {"article": "PSA is a protein produced by cells of the prostate gland.\nHigh levels of PSA can be a marker for prostate cancer, although it's far from a perfect screening tool, experts say.\nThe National Cancer Institute has more on the PSA test.\nAnd many prostate cancers are just that -- of little risk to men during their lifetimes, Brawley said.\nAs for PSA velocity, the ACS doesn't have a position on what PSA velocity warrants a biopsy.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not appear to rely solely on a news release.", "answer": 1}, {"article": "Collaborating with Dr. Pisco were Marisa Duarte, M.D., Tiago Bilhim, M.D., Ph.D., Jorge Branco, M.D., Ph.D., Fernando Cirurgi\u00e3o, M.D., Marcela Forjaz, M.D., L\u00facia Fernandes, M.D., Jos\u00e9 Pereira, M.D., Nuno Costa, M.D., Joana B. M. Pisco, M.D., and Ant\u00f3nio G. Oliveira, M.D., Ph.D.\n\nRadiology is edited by Herbert Y. Kressel, M.D., Harvard Medical School, Boston, Mass., and owned and published by the Radiological Society of North America, Inc. (http://pubs. )\nThe procedures had a clinical success rate of approximately 79 percent for fibroid-related symptoms.\nDr. Pisco suggested that UFE may become the first-line treatment for women with fibroids who wish to conceive, particularly for those with numerous or very large fibroids.\nHowever, myomectomy is not always possible or effective and can result in major complications including hysterectomy, according to study co-author Jo\u00e3o Martins Pisco, M.D., Ph.D., from the Department of Interventional Radiology at Saint Louis Hospital in Lisbon, Portugal.\nDespite its less invasive nature, UFE has yet to be fully embraced in the medical community as a fertility-preserving treatment for women with symptomatic fibroids due to concerns that the procedure may cause inadequate blood flow to the endometrium, or lining of the uterus, and the ovaries.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There is no evidence of unjustifiable language.", "answer": 1}, {"article": "Computed tomography coronary angiography (CTCA), is a high-resolution X-ray of the heart that can be used to diagnose the reason for angina, or chest pain, symptoms and clarify what other treatments might be needed.\nAlthough getting CTCA is associated with a lower likelihood of having a heart attack later on, its effects on symptoms and quality of life may vary, the researchers note in the journal Heart.\n\u201cAlthough CTCA removes diagnostic uncertainty and halves the rate of subsequent heart attacks, quality of life can be negatively impacted in those who are worried about their health and are found to have nonobstructive coronary artery disease,\u201d Newby said.\nWhen the CTCA results revealed something less than a blockage, so-called nonobstructive disease, as the cause for the patient\u2019s chest pain, patients\u2019 quality of life got worse in the following weeks and months.\nThis reflects the fact that the cause of the symptoms had been unknown before and in addition they now have heart artery disease that needs treatment, Newby said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes interview quotes from two sources and does not appear to rely on a news release. No news release about this study was found online.", "answer": 1}, {"article": "Obstructive sleep apnea (OSA) is marked by interruptions in breathing while asleep; it is common among children with enlarged tonsils or adenoids.\n\"The children in this study wet the bed due to sleep-related problems.\"\n\"Children with sleep apnea and bedwetting should see an otolaryngologist first.\"\n\"But not every child with sleep apnea will wet the bed, and not every bedwetter will have sleep apnea.\"\nThere are many other causes of bedwetting, Lakshmanan said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a news release.", "answer": 1}, {"article": "\u201cWe are not quite there yet, but it may become a real possibility for finding out real information without having to risk a pregnancy.\u201d\n\nFor example, \u201cIf this comes back negative, you don\u2019t need an amniocentesis, but if it comes back positive, we would probably still do an amniocentesis to confirm the results,\u201d she says.\nIt is not a diagnostic test for Down syndrome, she says.\n\u201cThis test looks very promising, but it is also very expensive,\u201d\n\nWhile there are risks attached to amniocentesis and CVS screens, these are minimized when the test is performed by a skilled obstetrician, she says.\nJoyce Fox, MD, the chief of medical genetics at Cohen Children's Medical Center in New Hyde Park, N.Y., definitely sees a role for a test such as the one described in the new study.\n\u201cFor women who are concerned about losing a pregnancy as a result of an invasive test, this is an excellent addition to our armamentarium of screening,\u201d she says.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a news release.", "answer": 1}, {"article": "Doppler ultrasound, done in the third trimester, is an established way to monitor high-risk pregnancies \u2014 those complicated by problems like poor fetal growth or health conditions in the mother, such as high blood pressure and heart and kidney diseases.\nAnother question, Alfirevic said, is whether ultrasounds of blood vessels other than the umbilical artery might improve pregnancy outcomes.\nIn general, he and his colleagues found, the trials included in the review, which were mainly done in the 1990s, had their shortcomings.\nResearch, according to Alfirevic, has moved on to other questions, including how to best manage abnormal findings from a Doppler scan.\n\u201cThere is no evidence to suggest that it should be done in low-risk women,\u201d Alfirevic said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story does not appear to rely solely on a news release. It says the lead researcher was interviewed.", "answer": 1}, {"article": "But an electrolyte imbalance caused by dehydration, influenza or other health problems that deplete the system of potassium, magnesium and other minerals also can cause cardiac arrest.\nThat's most likely what happened to Mr. Beck, whose heart arteries were clear.\nWithout the procedure, Dr. Granato said, the discussion about Mr. Beck would require a more serious tone.\nMr. Beck said he didn't regain full consciousness for nine days.\nBut putting the therapy into practice in many hospitals has been slow.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no evidence that this story relied solely or largely on a news release.\u00a0 ", "answer": 1}, {"article": "An experimental drug designed by Roche Holding AG's Genentech unit against a new cancer target yielded encouraging results against two rare tumors, researchers said, potentially opening up a new front in the battle against the disease.\n\nIn a small study, the drug, known as GDC-0449, shrank tumors in 18 of 33 patients, or 55%, with an advanced form of a skin cancer called basal cell carcinoma. In addition, the drug had a dramatic, though temporary, effect on a 26-year-old patient who had undergone multiple surgeries, chemotherapy...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There does not appear to be a press release associated with this story. ", "answer": 2}, {"article": "Animal studies have suggested that omega-3 fatty acids may have anti-cancer effects, but the results from human epidemiological studies have been inconclusive.\nThe analysis appears online in The American Journal of Clinical Nutrition.\n\u201cThis is more evidence to suggest that omega-3s are beneficial and may have anti-inflammatory action helpful in reducing cancer risk,\u201d said the lead author, Dr. Harvey J. Murff, an associate professor of medicine at Vanderbilt.\nAfter controlling for age, race, body mass index, smoking and other factors, the researchers found that women in the highest fifth for omega-3 consumption \u2014 those who consumed three or more servings of fish a week \u2014 were 33 percent less likely than women in the lowest fifth to have adenomatous polyps, a type likely to become cancerous.\nAll patients were interviewed about diet, health habits and medical history.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does not appear that the story relied on a news release.\u00a0 We couldn\u2019t find one from the Journal.\u00a0 And the news release from Vanderbilt was actually far more complete than the NY Times story.", "answer": 1}, {"article": "A variation of a drug commonly given to cancer patients with bone damage appears to be an effective tool for preventing repeat hip fractures in elderly patients, according to a study in the New England Journal of Medicine.\n\nThe study results, which were to be presented yesterday in Hawaii, have potentially big implications because hip fractures are a common and debilitating injury for older people. Most of the 300,000 hip fractures each year in the U.S. are related to osteoporosis in older people, as well as falls, according...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not appear to rely on a press release.", "answer": 1}, {"article": "Surgeons sometimes fly blind when operating on hard-to-reach anatomical parts or hard-to-see conditions. For visual references inside the brain or body, they often rely on images and scans taken before an operation.\n\nA growing number of hospitals are equipping operating suites with magnetic resonance imaging, CT scanners and other technology that enables surgeons to scan a patient in real time, without having to move them from the operating table.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to draw from a news release.", "answer": 1}, {"article": "HDL cholesterol is not fully understood, but essentially sucks cholesterol out of cells, to be flushed from the body through the liver.\nThe study was sponsored by Merck, the drug\u2019s manufacturer.\nPeople who can\u2019t control cholesterol with diet, exercise and statin drugs could soon have a new option.\nThe first patients will be enrolled in April, according to Dr. Rory Collins of Oxford University, where the research will be overseen.\nLee Davies, a Merck spokesman, said the company is not likely to seek FDA approval until those results are in, most likely in 2015.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\nThe story does not appear to rely on a news release.", "answer": 1}, {"article": "The U.S. National Institute of Neurological Disorders and Stroke has more about autism.\nTwo experts agreed that early intervention is key.\n\"Children with autism typically receive treatment beginning at 3 to 4 years old,\" he explained.\nThe goal of the therapy -- delivered over five months while the infants were ages 7 to 10 months -- was to improve the infant's attention, communication, early language development, and social engagement.\nHe was cautiously optimistic about the promise of the video feedback approach.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story reaches out to three experts, so we are confident it\u2019s not based solely on a news release.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070715/23knee.htm was not found on this server.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It is unclear whether the article relied solely or largely on a press release. It is clear that it presented only the rosy perspective of one surgeon at one hospital.\u00a0\u00a0 ", "answer": 2}, {"article": "\"Emergency departments are going to have to think twice about a test like that,\" says Michael Shannon, senior physician in emergency medicine at Children's Hospital Boston.\nA new cold and flu test can precisely diagnose a dozen winter ailments and reduce unneeded use of antibiotics, says the company that sells it.\nPhysicians say the test is accurate and the most comprehensive available, but some say its long processing time limits usefulness in emergency rooms.\nThe test is expected to be used mainly in hospitals and emergency rooms, but doctors can send the swab to a local lab.\nAnd patients will have to wait at least six to seven hours -- maybe a day or two depending on staffing at the hospital laboratory.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because an independent source was quoted, it appears the story did not rely solely or largely on a news release.", "answer": 1}, {"article": "In a three-year study of more than 1,300 people with knee osteoarthritis, digital X-rays revealed substantially less loss of cartilage in the joint space in those who took strontium ranelate every day compared with people who took a placebo daily.\nNearly one in 100 people have evidence of knee osteoarthritis on an X-ray.\nThe wearing away of cartilage leads to pain and other symptoms.\nIn people with osteoarthritis, the cartilage in a joint wears away in some areas.\nStudy head Jean-Yves Reginster, MD, PhD, presented the findings today at the American College of Rheumatology (ACR) Annual Meeting in Washington, D.C.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It doesn\u2019t look like the story relied inappropriately on this press release. ", "answer": 1}, {"article": "It defines low birthweight as being when a baby is born weighing less than 5 pounds, 8 ounces.\nRelated: Too Many Babies Die on Their First Day\n\nCharpak\u2019s team found the babies randomly assigned to get this treatment were 39 percent more likely to live into adulthood.\nThey exhibited less antisocial behavior, which might be associated with separation from the mother at birth,\u201d they added.\nBut overall, the findings support the benefits of kangaroo mother care, the team concluded.\n\u201cIt is a gentle, effective method that avoids the agitation routinely experienced in a busy ward with preterm infants.\u201d\n\nAnd it\u2019s safe, WHO added.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "\"There is a tremendous lack of kidneys for transplant,\" he explained.\nNew, less toxic treatments for hepatitis C opened the door for transplanting infected kidneys and then successfully treating the infection, Reese said.\nUsing hepatitis C-infected kidneys would expand the organ pool and save lives, said lead researcher Dr. Peter Reese.\nBut the cost effectiveness of using these kidneys versus remaining on dialysis would be significant, he noted.\nAbout 15 percent of dialysis patients have HCV, the researchers said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "Wisdom teeth, also called the third molars, are four teeth that grow at the very back of each corner of the mouth.\nThe question comes down to which side of the fence medical professionals fall on\n\nIt's worth noting that oral surgeons make a good chunk of their paychecks by removing wisdom teeth, so there is a financial incentive involved.\nBut taking out wisdom teeth when there aren't any symptoms is where the professionals get into it.\nSo the question comes down to which side of the fence medical professionals fall on, and what works best for their patients.\nA simple surgical extraction for a wisdom tooth that's showing through the gums should run about $230, according to Healthcare Bluebook.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story includes direct quotes from three dental experts and several groups and publications, we can be sure the story isn\u2019t based entirely on a news release.", "answer": 1}, {"article": "\u201cThat\u2019s a simple enough statement, and people are not put off by that,\u201d she said.\n\u201cWe are now trying to see if people can learn, perform and have continuing confidence without the physician reinforcement,\u201d said Robinson.\n\u201cThere was concern that they might be embarrassed by examining areas of the body that aren\u2019t normally seen close up,\u201d said lead author Dr. June Robinson, of Northwestern University Feinberg School of Medicine in Chicago.\nEach person in the study was trained on how to find melanoma and attended booster sessions every four months.\nFor now, she said people can go to the American Academy of Dermatology's website to learn the steps - known as the ABCDEs - of finding melanoma (bit.ly/2h9zl0Y).\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "A news release\u00a0from Northwestern University is likely the\u00a0spark responsible for the news story, but the writer has clearly contacted the lead researcher independently and included information beyond what is written in the news release.", "answer": 1}, {"article": "(H\u00f6gqvist Tabor says it's tricky because it depends on the individual, and can range from a few beats per minute to 10 beats per minute.)\nIf you\u2019re curious exactly what kind of increase in resting heart rate you should look out for, Clue hasn\u2019t revealed that information yet, but says it will publish that and other data in a paper later.\nAnd the study had one particularly unexpected outcome.\nThe happy discovery was similar to one earlier this year, when a man posted on Reddit about how his wife\u2019s Fitbit showed an uptick in her resting heart rate.\nAnd that's provided that a couple doesn't have any other fertility-related problems.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story goes beyond any news release we could find related to the work.", "answer": 1}, {"article": "Cocoa or cacao beans are not beans but the seeds of the fruit of the Theobroma cacao tree.\nA new study suggests that dark chocolate and cocoa powder may be the next \"super foods\" thanks to their high antioxidant content.\nTwo groups of antioxidants in particular, polyphenols and flavonols, which are found in various fruits and seeds, have been the focus of much research due to their potentially healthy effects.\nFoods and fruits high in these antioxidants have been dubbed as \"super foods\" or \"super fruits\" by the media.\nAntioxidants are a group of compounds known to fight the damaging effects of oxidative stress on cells within the body and are increasingly thought to have many heart-healthy properties.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story doesn\u2019t seem to have lifted anything directly from this news release put out by the journal\u2019s publisher.", "answer": 1}, {"article": "Restless leg syndrome (RLS) is a neurologic disorder causing unpleasant sensations and an urge to move the legs when at rest.\nThe eight-week clinical trial involved 30 otherwise healthy adults with moderate to severe restless leg syndrome.\nPatients using the RLS device also reported an 82 percent decrease in sleep loss.\nAs an osteopathic physician, it's a challenge to balance the need to restore sleep while preventing additional harm from medication.\nDisclosures: Dr Kuhn worked without compensation through Lake Erie Research Institute (LERI) during the 5 years of the study of the device and is now receiving compensation for that work.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t use sensationalist language. But it\u2019s still a problem that the release presents this foot wrap as if it were the first and only non-drug treatment for RLS and thus offers something entirely new to patients.", "answer": 1}, {"article": "Functional MRI scans generate a dynamic map of the outer surface of the brain, showing changing hot spots of activity over time.\nIt's exciting to think that these individual differences may be related to personality, cognitive ability, or psychiatric or neurological disease.\nWe show here that it's not measuring what you're thinking, but how your brain is organized.\nAll of the scanned brains belonged to young, healthy scientists and doctors.\nAlthough the technique's potential to identify brain disorders and diseases was noted years ago, fcMRI-based diagnostic tests have yet to make their way into doctors' offices.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The headline and opening paragraph are misleading since they suggest there\u2019s already a medical application for this research. It\u2019s important to remember, though, that this is basic science research that may or may not eventually lead to clinical applications after much more research years into the future.", "answer": 0}, {"article": "Moffitt is the No.\nThe researchers report that the dendritic cell vaccines were well-tolerated and patients only experienced low-grade toxicities.\nThey also show that the vaccine was able to stimulate an immune response in the majority of the patients.\nResearchers from Moffitt Cancer Center report that a dendritic cell vaccine that targets the HER2 protein on breast cancer cells is safe and effectively stimulates the immune system leading to regression of early-stage breast cancer.\nThe researchers previously developed a vaccine that helps the immune system recognize the HER2 protein on breast cancer cells.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The lead says the vaccine targets \u201cearly-stage breast cancer\u201d but calling the abnormal cells present with DCIS \u201cbreast cancer\u201d is misleading. They\u2019re abnormal cells that line the milk ducts of the breast, with the potential to advance to an invasive cancer but they have not spread outside the breast.\nAlso, the news release states that patients \u201conly\u201d experienced low-grade toxicities. We don\u2019t like the word \u201conly\u201d because it downplays adverse effects that could be significant for patients who experience them.\nFinally, we take issue with the headline, \u201cVaccine Shows Promising Results for Early-Stage Breast Cancer Patients.\u201d With less than a third of patients seeing a tangible result in their tumors and no data on long-term outcomes versus a control group, there\u2019s no way to justify the description \u201cpromising.\u201d", "answer": 0}, {"article": "Feifel recalls one patient whose depression would disappear like magic after a dose of ketamine.\nAnd Paul jumped at the chance to try ketamine.\nHe didn't qualify for most research studies because of his suicidal thoughts.\nAnd Paul has spent much of his adult life searching for a treatment that would give him some relief.\nAnd it didn't have the FDA's OK for treating depression.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story goes beyond any news release.", "answer": 1}, {"article": "THURSDAY, Oct. 14, 2010 (HealthDay News) -- With the aim of catching autism in children at an earlier age than currently possible, scientists are exploring the potential of using MRI scans as a screening tool.\n\"[But] this work adds an important piece of information to the autism puzzle,\" she said.\nUsing MRI imaging, the team searched for differences in brain activity patterns in the microstructure of white matter tissue in 80 autism patients between the ages of 10 and 35.\nThis tissue, the authors noted, is known to play a role in communication between various brain regions.\nAnderson and his colleagues, who reported no conflicts of interest, published their findings in the Oct. 15 online issue of Cerebral Cortex.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story relies far too much on a press release from the journal Cerebral Cortex.", "answer": 0}, {"article": "During a salvage radical prostatectomy, the prostate gland and surrounding tissue are surgically removed to keep the cancer from spreading.\n\"By studying a national database of prostate cancer cases, we found that a procedure known as salvage radical prostatectomy can greatly increase a man's chance of survival when traditional radiation therapy has failed to eradicate the cancer.\"\n\"Because radical prostatectomy is a complex surgery, there can be a reluctance to undergo the procedure,\" Pokala said.\n\"However, this study shows that it is a viable treatment option.\nNow, a University of Missouri School of Medicine researcher has found that a complex procedure to remove the prostate achieves excellent long-term survival for men after radiation therapy has failed.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release did not use unjustifiable language.", "answer": 1}, {"article": "Researchers at Brigham and Women's Hospital and Harvard Medical School set out to test melatonin's effects...\nThat's why there's so much interest in a study in the current issue of the journal Sleep.\nWhat was lacking was clear evidence that taking melatonin in supplement form had the same sleep-inducing effect.\nBut the scientific evidence has been slim.\nMillions of jet-lagged and sleep-deprived Americans--citing countless self-help articles--insist they do.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not appear to be based solely or largely on a press release. ", "answer": 1}, {"article": "(Flexible sigmoidoscopy, which looks at the lower part of the large intestine, has been shown by randomized trials to prevent deaths from colorectal cancer but isn\u2019t reimbursed as well as colonoscopy and is on the decline in the U.S.)\n\nColonoscopy is the most popular test in the U.S.\n(Wender doesn\u2019t recommend the OTC tests that are available.)\nAccording to public health experts, that\u2019s a bad thing.\nNo one is arguing colonoscopy is a bad test.\nThere\u2019s variation in the quality of the test, depending on who\u2019s doing it.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no indication that this story relied on a news release.", "answer": 1}, {"article": "Asthma has complicated Todd Anderson's life ever since he was 3 years old. Doing sports\u2014even stairs\u2014had been difficult. Cigarette smoke, pollen, disinfectants or a passing whiff of perfume could set off a severe asthma attack. \"It feels like your chest is clenching up like a fist,\" says Mr. Anderson, a 29-year-old music teacher in the New York City schools.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\nThe story does not appear to be based on a news release. However, all of the patients quoted in the story were provided by the device manufacturer. Technically, we must give the story a satisfactory score on this criterion since there is no evidence it relied solely or largely on a news release, even though it violates the spirit of the criterion.\n", "answer": 1}, {"article": "Nov. 18, 2012 -- Researchers say they've been able to use nanoparticles to stop multiple sclerosis (MS) in mice that are bred to have the disease.\nWhat remains to be seen is whether the researchers have picked the right proteins that might turn off the disease in humans, he says.\n\u201cWill these peptides actually induce tolerance in people?\n\u201cThis technology could be very effective,\u201d says Timothy Coetzee, PhD, chief research officer for the National Multiple Sclerosis Society.\nThe particles are about 200 times smaller than the thickness of a human hair.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a press release.", "answer": 1}, {"article": "But are they receiving it?\nThis fear, however, is not based on actual evidence and cannot be used to suppress or otherwise keep the public uninformed of what is clearly known about the lower risks of these products,\u201d adds Kozlowski, PhD, one of the world\u2019s leading researchers on smoking behavior.\n\u201cYet, such facts are being kept from adult consumers of legal tobacco/nicotine products, either by not informing or actively misinforming consumers.\nA briefing posted on the site specifically states: \u201cCompared to tobacco products, electronic cigarettes are significantly safer.\u201d\n\nIn their paper, the researchers note that information on comparative risks is common for other products and activities, like over-the-counter medicines and even safety ratings of vehicles.\nThis \"information quarantine\" in turn helps explain the woeful lack of public knowledge about relative risks, violating basic consumer rights as well as the public health principles of individual rights and health literacy, the researchers say.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release says that the study authors \u201cfound that the Mayo Clinic perpetuated a misrepresentation discovered in 2003 \u2014 erroneously informing visitors that smokeless tobacco was as dangerous as cigarettes. The day after the article was released, the Mayo Clinic removed the headline, replacing it with the still misleading statement that smokeless tobacco was \u2018not a safe product.'\u201d\nThe news release does not say why that is misleading.\nIt adds that \u201cmany government websites are actually misleading or under-informing the public\u201d when it comes to learning about the differences in risk among certain types of nicotine products, but offers no examples.\n\u201cThis in turn helps explain the woeful lack of public knowledge about relative risks, violating basic consumer rights as well as the public health principles of individual rights and health literacy,\u201d it says, but does not tell us just how woeful that lack of public knowledge about relative risks is.", "answer": 0}, {"article": "Research has shown that our unhealthy eating habits and sedentary lifestyles are playing a major role in the development of lifestyle-related metabolic diseases such as diabetes, heart disease and obesity.\nThe fasting regime helped lower fat build-up in the white fat by increasing the brown-like fat (involved in burning energy and producing body heat) of mice on the high fat diet.\nThe research team in this study wanted to better understand the reactions that interventions such as fasting trigger on a molecular level in the body.\nThe lower body weight of the mice in the fasting group was not the only effect.\nThrough an analysis into the underlying biology involved, the researchers found that such intermittent fasting tempers an immune reaction in fat cells.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We think the headline is stretching things by stating \u201cOn and off fasting helps fight obesity.\u201d\nThe average reader likely assumes the obesity referred to is in humans and not mice. The release doesn\u2019t clarify that the study was only in mice until the fourth sentence.\n\u201cUp to sixteen weeks of intermittent fasting without otherwise having to count calories helps fight obesity and other metabolic disorders. Such fasting already shows benefits after only six weeks. This is according to a study by Kyoung-Han Kim and Yun Hye Kim in the journal Cell Research which is published by Springer Nature. Intermittent fasting in mice helped to kick-start the animals\u2019 metabolism and to burn fat by generating body heat. The research team was led by Hoon-Ki Sung of The Hospital for Sick Children in Ontario, Canada.\u201d", "answer": 0}, {"article": "Foods to avoid\n\n Dairy: Milk, ice cream, yogurt, cottage and ricotta cheeses (except for lactose-free versions)\n\n Fruits: Apples, peaches, pears, watermelon, cherries, figs\n\n Vegetables: Garlic, onions, leeks, asparagus, cauliflower or large servings (more than \u00bd cup) of broccoli and Brussels sprouts\n\n Grains: Wheat (except in sourdough bread), rye, barley\n\n Legumes and nuts: Cashews, kidney beans, soy beans and soy milk\n\n Sweeteners: Honey, fructose, xylitol, agave syrup\n\nFoods to include \n\n Dairy and dairy substitutes: Kefir, almond milk, coconut milk\n\n Fruits: Bananas, blueberries, grapes, oranges, strawberries\n\n Vegetables: Carrots, green beans, bell peppers, potatoes, tomatoes\n\n Grains: Rice, oats, gluten-free bread (but check labels for high-FODMAP ingredients)\n\n Legumes and nuts: Peanuts, pecans, walnuts\n\n Sweeteners: Cane sugar, aspartame, stevia\nIt\u2019s not known if the diet leads to any nutritional deficiencies or keeps working in the long run \u2014 especially for patients who get little support from doctors or dietitians.\n\u201cPhysicians are largely administering the diet by giving patients sheets of paper with foods to exclude,\u201d Chey says.\nFor growing numbers of people suffering from digestive ills, the answer is \"yes,\" at least for a while.\nIf giving up some foods might lessen that misery, many people are game, she says.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The multi-source, multi-study nature of this story makes enterprise more likely and reliance on a news release less likely.", "answer": 1}, {"article": "While skeptics may question the idea of using psychedelics as treatment for psychological distress, Hendricks emphasizes that he does not advocate for rampant recreational use of psychedelics, or widespread legalization.\nThe study, published recently in the Journal of Pharmacology, analyzed data from an annual survey conducted by the National Survey on Drug Use and Health that measures substance abuse in relation to mental illness.\nIn recent years, some scientists, such as this study\u2019s lead researcher, Peter S. Hendricks, have been pioneering innovative treatments to help decrease the suicide rate.\nA lack of resources and funding is a hindrance to continuing studies, however, as psychedelics are still classified as schedule 1 narcotics in the U.S. and criminal offenses accompany their possession.\nOnly two population studies to date, this one included, specifically address the relationship between mental illness and psychedelics.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article links to a news release about the study, but includes other information, too.", "answer": 1}, {"article": "USUALLY NOT THE FIRST STEP\n\n\u201cI have a long list of chronic pain patients coming to seek acupuncture,\u201d said Jongbae Park, head of Asian Medicine & Acupuncture Research at the University of North Carolina at Chapel Hill School of Medicine.\nIt\u2019s usually \u201cnot their first approach to address the condition,\u201d he said - rather people seek acupuncture when traditional care fails to stop their pain.\nIn those cases, he said, acupuncture is very safe - and the main downsides are costs and the inconvenience of getting to a clinic.\n\u201cThis provides evidence that they would be justified in considering\u2026 acupuncture,\u201d he told Reuters Health.\nThat either means many of the three million Americans that get acupuncture every year are \u201cwasting their time\u201d - or others who forgo it are missing out on potential benefits, Vickers said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story has enough independent reporting for us to be confident it wasn\u2019t based on a press release.", "answer": 1}, {"article": "\u201cI was exhausted all the time, from the time I woke to the time I went to bed,\u201d says Turner.\nThe doctors measured everything from brainwaves to breathing \u2014 what they found surprised Turner.\nLights out for the 69-year-old meant sleeping for a couple of hours before being jolted awake in the middle of the night and lying there electrified.\n\u201cBefore, I'd be awake constantly, but when I sleep now, I am asleep.\nFor Kothare, the out-of-pocket expense for the device, the risks of surgery, plus the potential for the mechanism \u2014which moves the tongue forward \u2014 to break, doesn\u2019t make it a viable option for everyone.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We could not locate a news release.", "answer": 2}, {"article": "A qualified claim means there is evidence supporting the claim, but it is not conclusive.\nThe label warns that evidence is limited.\nWhile many foods like whole grains, nuts and supplements carry qualified health claims stating that they may reduce the risk of diseases like cancer or heart disease, this is the first time a food product label will be allowed to make a qualified claim that it reduces the risk of an allergy, officials said.\nA new powdered peanut product is the first food item allowed to claim it may reduce peanut allergies in infants, though parents of susceptible babies are urged to consult a doctor before trying it.\nThe Food and Drug Administration allowed the new item, developed by a physician, to make the claim just months after the nation\u2019s top allergy experts reversed longstanding advice on preventing peanut allergies, dropping recommendations to withhold all peanut-containing foods in early childhood in favor of early, frequent exposure, starting with peanut powder or extract for infants beginning to eat solid food.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to be based on a news release.", "answer": 1}, {"article": "Traumatic injuries to the head, often from car accidents, tend to sever brain cell connections and leave many neurons intact.\nWithout this context, Dr. Fins said, the imaging tests could create some confusion, because like any medical tests they may occasionally go wrong, misidentifying patients as exhibiting consciousness or lacking it.\nThis means by definition that the young woman has transitioned from an unresponsive, vegetative state to a sometimes responsive condition known as a minimally conscious state, Dr. Laureys said in an interview.\nBy contrast, brains starved of oxygen \u2014 like that of Ms. Schiavo, whose heart stopped temporarily \u2014 often suffer a massive loss of neurons, leaving virtually nothing unharmed.\nThe imaging technique, called functional M.R.I., reveals changes in activity in specific brain regions.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story quotes multiple, independent researchers and clinicians, the reader can safely assume that the story does not rely on a press release as the sole source of information.", "answer": 1}, {"article": "Lauren Gravitz is a science writer and editor in Hershey, Penn.\nRight now, the longest patients have been on one of these new therapies is one to two years.\nAt their best, the headaches are an annoyance.\nAbortive medications still work, except when they don't.\nSo for those of us who get numerous migraines each month, the prospect of a new approach feels almost life-changing.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story doesn\u2019t rely on a news release.", "answer": 1}, {"article": "\"It wasn't a huge, overwhelming difference,\" O'Neil said.\nSo incremental improvements such as the ones seen in the MUSC-led study are important.\nThe multi-site study's results were statistically and clinically significant, O'Neil said.\nThat's why he said it was important for MUSC to be involved in the study, which was funded by a grant from the commercial weight loss program, Weight Watchers.\nThe Weight Watchers study is new evidence of what that help might include when it comes to a side effect of weight gain: Type 2 diabetes.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t employ sensational language. Those who stick with the release to the end will probably come away with an understanding of the modest benefits of the Weight Watchers program in terms of weight loss and blood sugar control. But some of the language in the lede and early paragraphs of the release are overstated and somewhat misleading.", "answer": 1}, {"article": "Women are also more likely to experience a condition known as left bundle branch block, a pattern of disorganized electrical impulses that responds well when the left side of the heart is treated with a pacemaker.\n\u201cWe think this is the first (study) to show this.\u201d\n\nMoss said women have often been overlooked in studies of heart disease, which until recently were dominated by men.\nThe findings come from a large Boston Scientific study of cardiac resynchronization therapy known as MADIT-CRT, in which a pacemaker is used to restore normal coordinated heart beats in people whose damaged hearts are less efficient at pumping blood.\n\u201cWe found there was a dramatic reduction not only in heart failure events, but a very dramatic reduction in death from any cause,\u201d Moss said in a telephone interview.\n\u201cOur finding was unexpected, but extremely important because this is the only heart treatment that is clearly better in women than men,\u201d Dr. Arthur Moss of the University of Rochester Medical Center, whose study appears in the Journal of the American College of Cardiology, said in a statement.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We\u2019re going to rule this Not Applicable because it\u2019s an odd case.\nDifferent quotes are attributed to the researcher \u2013 some from \u201ca statement\u201d and some from a telephone interview.\nWe can\u2019t be sure how much original reporting was done.\nAn older press release (June 2010) may have been the source for some of the information presented in this story. http://bostonscientific.mediaroom.com/index.php?s=43&item=932", "answer": 2}, {"article": "They had 68 percent fewer spine fractures and 40 percent fewer hip fractures than the study participants who got dummy shots.\nStill, he called the drug a \"tour de force of modern molecular medicine\" because it is potent and was designed by making antibodies cloned over and over from cells in the lab to block one pathway involved in the how the body naturally breaks down bone cells.\nDenosumab, an injection just under the skin, would have to compete against eight major types of pills and injected medicines, including estrogen and generic and brand-name Fosamax pills, long the market leader.\nDr. Lenore Buckley, a professor at Virginia Commonwealth University, said all these drugs carry some risks.\nThat's important because many patients stop taking other drugs due to side effects or frequent dosing.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This piece included several independent sources and therefore, does not rely on the news release.\u00a0 ", "answer": 1}, {"article": "Senator Arlen Specter, a Pennsylvania Democrat and longtime advocate for cancer screening, said in an interview: \u201cAnd this Pap smear guideline is yet another cut back in screening?\nThe doctors\u2019 group also felt it was safe to test women less often because cervical cancer grows slowly, so there is time to catch precancerous growths.\nDr. Kevin M. Holcomb, an associate professor of clinical obstetrics and gynecology at NewYork-Presbyterian/Weill Cornell hospital, said that when he heard the advice to delay Pap testing until 21, \u201cMy emotional response is \u2018Wow, that seems dangerous,\u2019 and yet I know the chances of an adolescent getting cervical cancer are really low.\u201d\n\nAs with the new mammogram recommendations, women may not readily give up a yearly cancer test.\nIt is by no means clear that doctors or patients will follow the new guidelines.\nIn addition, Dr. Saslow said, doctors in this country have been performing 15 million Pap tests a year to look for cervical cancer in women who have no cervix, because they have had hysterectomies.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not draw from any of the press releases associated with this story. ", "answer": 1}, {"article": "In the United States, about 10 percent of people say they have chronic insomnia, according to the U.S. Centers for Disease Control and Prevention.\nStandard sleep medications work more widely throughout the brain, Bazil explained, which is why they can have a host of side effects.\nFor most people, he said, medication should be a temporary treatment; behavior change is the long-term fix.\nThe effect was essentially comparable to what has been seen with other sleep medications, said Bazil, who was not involved in the research.\nIt's promising news, Bazil added, that there were no serious side effects in this study.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely on a news release.\n\u00a0", "answer": 1}, {"article": "Other scientists and companies have long sought ways to measure risk from multiple, additive gene effects \u2014 the \"poly\" in polygenic \u2014 and Myriad Genetics has begun selling a type of polygenic test for breast cancer risk.\nBut specialists in heart disease and genetics who weren't involved with the research called the new findings exciting because of their scope.\nEach variation alone would have only a tiny effect on health.\nIt doesn't require the most sophisticated type of genetic testing.\nAn unhealthy lifestyle could overwhelm the protection of good genes.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There\u2019s no indication that this story relied on a news release.", "answer": 1}, {"article": "\"We estimate that use of [Brilinta] instead of [Plavix] for one year in 1,000 patients with acute coronary syndromes and who are planning to undergo an invasive strategy at the start of drug treatment would lead to 11 fewer deaths, 13 fewer myocardial infarctions, and six fewer cases of stent [clotting] without an increase in the rates of major bleeding or transfusion,\" conclude study researcher Christopher P. Cannon, MD, and colleagues.\nAnd in the new study, patients had less bleeding after stent installation.\nBoth drugs increase the risk of dangerous bleeding.\nBrilinta reduced overall death rates by 1.1% .\nThe new kid on the block is AstraZeneca's ticagrelor, to be named Brilinta if the experimental drug gets FDA approval.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\u00a0Does not appear to rely solely on a press release.", "answer": 1}, {"article": "For more on losing weight, visit the U.S. National Library of Medicine.\nA potential player in fighting the obesity epidemic, lorcaserin is a new type of weight-loss drug that works by acting on serotonin, a chemical associated with feelings of well-being and feeling full, and does not appear to increase blood pressure or cause any other heart problems, according to the researchers, whose work was sponsored by the drug manufacturer.\nFDA briefing documents posted online Tuesday acknowledged Qnexa's effectiveness in helping patients lose weight, but said the review panel should take into account a number of potential nervous system and psychiatric side effects, the Associated Press reported.\n\"If weight-loss drugs are tailor-made to hit only the right receptor, based on physiological knowledge, it seems to be possible to develop weight-loss medications that do not possess any serious adverse effects,\" Astrup added.\nIt helped patients in clinical trials lose as much as 13 percent to 15 percent of body weight.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We rule this satisfactory because it\u2019s clear that the story goes beyond the news release. \nBut the top of the story does feature some marketing-like language, including these two quotes: \"In this long-term study of lorcaserin for treating patients for obesity, there was good weight loss, outstanding safety profile and the drug was extremely well-tolerated,\" said lead researcher Dr. Steven Smith\u2026 \"As patients are looking for additional options and physicians are looking for new tools, [lorcaserin] provides us with a look into the future for what\u2019s going to be available for helping patients lose weight,\" he added.", "answer": 1}, {"article": "According to Hazinski, one easy way to remember the rhythm is that it is roughly equivalent to the beat of the 1977 Bee Gees' disco hit \"Stayin' Alive.\"\nHe said the latest research on CPR supports the notion that in the critical minutes before an ambulance or defibrillation device arrives, it is very important to provide uninterrupted, deep chest compressions.\nThat's a risk well worth taking when the odds of survival without CPR are so slim.\nAt best, CPR is a desperate measure.\nThe Heart Association also stressed that three-quarters of sudden cardiac arrest cases outside the hospital occur in the home.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no evidence that the story relied solely or largely on a press release.", "answer": 1}, {"article": "Regions of the brain that typically contain accumulated tau protein include the temporal lobe, parietal lobe and occipital lobe, among others; grey matter in the cerebellum is thought to contain low or no tau in patients with Alzheimer's.\nThese three most promising tracers were previously tested in nonhuman primates, and the results looked promising enough to test in people.\nTwo studies will be published back-to-back in the December issue of Journal of Nuclear Medicine--one as featured article of the month--describing testing of three candidate molecules in patients with Alzheimer's disease, as well as the use of one molecule to measure the accumulation of tau proteins.\nAs part of a longer term project funded by F. Hoffman-La Roche, the team previously tested a collection of approximately 550 potential tracer molecules and identified six promising tracers, eventually narrowing them down to three to be made and tested as candidate Tau PET radiopharmaceuticals.\nThis study was funded by an F. Hoffmann-La Roche Ltd. contract to The Johns Hopkins University.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "For the most part, the release does not cross the line in its use of language. However, we think it\u2019s premature to call this a \u201cpromising diagnostic tool,\u201d as the headline does.", "answer": 1}, {"article": "For Patients and the General Public:", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The phrases \u201c\u2018promise for patients\u201d and \u201ctreatments on the horizon\u201d teeter towards unjustifiable language since the trials being described have produced data on how likely the treatments are to make it through a phase\u00a03 trial, rather than being meaningful for patients and doctors. We don\u2019t think the language is so sensationalistic as to warrant an unsatisfactory rating.\nThe release seems to be making the case that the trial design, rather than the drug data, is the cause for excitement.", "answer": 1}, {"article": "In recent years, surgical techniques, anesthesia and other medical care advanced, and death rates fell.\nEven more impressive: 65 percent survived without any long-term complications \u2014 a \u201cvery, very remarkable\u201d result, Kurlansky said.\nThe studies were reported at an American Heart Association conference this week in New Orleans.\nOverall, 90 percent survived their surgery to leave the hospital.\nEven 90-year-olds are having open-heart surgery, said Dr. Harlan Krumholz, a Yale University cardiologist who has researched older heart patients.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It is unclear as to how much the story relied on a press release.", "answer": 2}, {"article": "Severe obesity is associated with serious physical and psychological conditions affecting quality of life.\n\u201cThe median BMI reduction of 10 kg/m2 with the lap band is a good result when compared to BMI reduction using the few medications available or lifestyle measures, which is around 1-3 kg/m2,\u201d says Dr Pe\u00f1a.\n\u201cAlthough gastric banding has been controversial and is currently less used in adults with severe obesity, lap band surgery is one of the most studied surgeries for obesity management, has a high safety record and can be a temporary option to manage severe obesity during adolescence,\u201d says Mr Khurana, who is also a Senior Lecturer in the University of Adelaide\u2019s Discipline of Paediatrics.\nHowever there is no data available in Australian adolescents beyond 24 months post-surgery.\n\u201cLap band surgery is reversible and allows time for adolescents to mature to make a more informed decision on a permanent surgical procedure if required later on in life.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The researchers use terms such as \u201csafe\u201d and \u201ceffective\u201d to describe the outcome of the banding process. This was apparently not true for at least a third of the sample. Sources in the release do emphasize the use of lap bands as a temporary option for teens, an important point.", "answer": 1}, {"article": ".\nWHO: Lawrence Fine, M.D., chief of the Clinical Applications and Prevention Branch at NHLBI and a co-author of the study, is available to comment on the findings and implications of this research.\nThese additional results of the Systolic Blood Pressure Intervention Trial (SPRINT) appear in the current online issue of the Journal of the American Medical Association (JAMA).\nWHAT: NIH-supported researchers are reporting additional details about a widely-publicized study that linked a systolic blood pressure target under 120 mm Hg (millimeters of mercury) with reduced cardiovascular disease and a lower risk of death.\nAlthough the standard blood pressure treatment goal is 140 mm Hg, various medical panels have provided inconsistent guidance about what is the optimal blood pressure goal for the senior population.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release does not appear to use any unjustifiable language. We also were glad to see that patients are cautioned to discuss \u2014 not request \u2014 this treatment approach with their doctors.", "answer": 1}, {"article": "BOSTON (Reuters) - If you\u2019re checking into the hospital for surgery, doctors may soon be swabbing your nose in an effort to prevent an infection from appearing after your operation.\nThe research team, led by Dr. Lonneke Bode of Erasmus University Medical Center in Rotterdam, estimated that 250 patients would need to be screened to prevent one infection.\nThe treatment combination also shaved two days off a typical 14-day stay in the hospital.\nThe new study, published in the New England Journal of Medicine, used a rapid test to identify which patients, most of whom were scheduled to undergo surgery, had the bacteria in at least one nostril.\n\u201cPreventing one infection will pay for thousands of these screenings,\u201d Dr. Henri Verbrugh of Erasmus, a coauthor of the study, said in a telephone interview.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\u00a0The article does not appear to be based on a news release.", "answer": 1}, {"article": "UCH-L1 is released by brain nerves when they\u2019re stressed, and its levels rise more rapidly immediately after injury and peak at eight hours.\nAnd because levels of GFAP tend to remain higher for many days, Papa says it might be useful in cases where patients don\u2019t come in immediately after a head injury, thinking they\u2019re okay, but see the doctor several days later because they\u2019re concerned.\nBut there aren\u2019t good ways to distinguish between mild blows that don\u2019t require additional care and mild to moderate traumatic brain injury (TBI), which could have more serious consequences.\n\u201cI don\u2019t think a blood will be the be-all and end-all but it would be a beautiful tool for us to have in the clinic to support a lot of our decision making.\u201d\n\nTesting for levels of UCH-L1, for example, might be helpful for emergency medical teams in an ambulance trying to assess whether a patient has any serious head injuries, since its levels peak in the hours immediately after a trauma.\nMORE: A New Blood Test to Diagnose Concussions On The Field\n\nIn the emergency room, a blood test for UCH-L1 could also help doctors decide which patients should get a CT scan \u2014 the higher their levels of the protein are, the more likely they are to have TBI and would benefit from a scan, while those with lower levels probably don\u2019t need one.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes quotes from the lead researcher that did not appear in the news release, so we\u2019ll count this as Satisfactory.", "answer": 1}, {"article": "In the balloon-catheter method, also known as Mammosite, a doctor inflates a balloon in the tumor cavity, and a catheter delivers the radioactive pellet.\nCancer Treatment Centers was among the first to adopt brachytherapy for breast cancer patients a decade ago, Kelly said.\nShe returned twice a day for treatment.\nHer first oncologist suggested the traditional approach.\nThe shorter treatment duration encouraged McCartney to have brachytherapy.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if the story was based largely on a news release. ", "answer": 2}, {"article": "\"Are [aromatase inhibitors] better than tamoxifen?\nAromatase inhibitors are not effective in this age group, the experts note.\nAll three aromatase inhibitors on the market - Arimidex (anastrozole), Femara (letrozole) and Aromasin (exemestane) - were essentially equal in their benefit.\nYes, in two areas: preventing recurrent disease in other parts of the body and in preventing a second, separate breast cancer.\n\"In general, for postmenopausal women, we are offering them aromatase inhibitors based on the single studies that have been referenced [in these guidelines] and what has already been reported in national meetings.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n", "answer": 1}, {"article": "Media campaigns, increased tobacco and tightening of smoking laws have all had an effect as well.\n\u201cPatient compliance is a very big issue,\u201d said Dr. Richard Hurt, director of the Nicotine Dependence Center at the , who was not involved in the study.\nThe use of replacement products made no difference, whether they were taken for the recommended two-month period (they usually were not), or with the guidance of a cessation counselor.\nThe study did not follow people over time.\nDoctors who treat smokers said that the study findings were not unexpected, given the haphazard way many smokers used the products.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not rely on any press release.", "answer": 1}, {"article": "The General Director of the Danish section of MSF Jesper H. Brix notes:\n\n\"Acute malnutrition is still a major global health problem.\nThe results of the study can be used directly both in the treatment and prevention of acute malnutrition.\nResearchers from the University of Copenhagen and humanitarian organizations have conducted a large study in Burkina Faso in West Africa treating more than 1600 children with acute malnutrition.\nPrevious research has focused on treatment of severe acute malnutrition.\nSo, I hope we can use the results to provide the best possible treatment for more vulnerable children.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release claims in the first paragraph that \u201ccorn-soy porridge should be replaced with \u00a0a lipid-based nutrient supplement (LNS)\u201d [emphasis ours]. The researchers in the original study are careful to qualify their recommendation with the need for a cost-effectiveness analysis as well as more study about the role of soy and milk in food supplements. We\u2019d like to have seen correspondingly moderate claims in the news release.", "answer": 0}, {"article": "Vitamin C is an important building block for the growth and repair of tissues throughout your body, including skin, tendons, ligaments and blood vessels.\nThe message from the researchers, Senay observed, is that, if your activity profile doesn't match that of people like these, vitamin C won't keep colds away.\nIt makes us look toward other methods, aside from vitamin C, Senay concluded.\nShe explained that a review of numerous studies concluded that vitamin C isn't what it's cracked up to be, failing to help prevent the common cold in any meaningful way, except in some people exposed to extremely high stress.\nBut, she emphasized, this doesn't mean vitamin C is useless, not by a long shot.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Like most media reports of this study, this one drew heavily on the Cochrane abstract itself.\u00a0It shares some language with other reports, but not in a way that demonstrates lack of rigor. ", "answer": 1}, {"article": "It will also help remove the uncertainty surrounding which sub type of the disease an individual has and therefore be a catalyst for better outcomes for all people with MS.\"\n\nMultiple Sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS).\nPublished today in Scientific Reports, the discovery identifies tiny 'dysregulated' micro-RNA molecules that correctly diagnose MS and discriminate between patients at different disease stages - all in a simple blood test.\nThe research team assessed the utility of microRNAs (miRNA) in serum (blood) exosomes as biomarkers of MS disease.\nA breakthrough study led by the University of Sydney's Brain and Mind Centre and Royal Prince Alfred Hospital has revealed unique molecules in the blood of people with Multiple Sclerosis (MS) that could become definitive diagnostic biomarkers of the world's most common neurologic disability in young adults.\nMS is a chronic disease, so current diagnostic and monitoring tests are costly and still have limited utility to discriminate between different stages of the disease.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Unfortunately, the news release labels this diagnostic effort as \u201ca breakthrough study\u201d in the very first sentence of the text. Bad idea.\nThe release engages in unjustifiable language elsewhere, too. This statement:\n\u201cThis, in turn may lead to fewer relapses and a slower loss of brain volume, resulting in slowing or potentially halting progression of the disease for the person living with MS. It will also help remove the uncertainty surrounding which sub type of the disease an individual has and therefore be a catalyst for better outcomes for all people with MS.\u201d\nis unjustifiably optimistic about a blood test that \u201cmight\u201d diagnose a condition and is totally unproved at this stage. Even if the test works well for diagnostic purposes, there\u2019s no guarantee that patients will experience better treatment outcomes because of it.", "answer": 0}, {"article": "During such a surge, healthy vessels dilate, or relax, but unhealthy ones stiffen and narrow, impairing blood flow and indicating possible incipient heart disease.\nThe volunteers, all of whom exercised, generally became more physically fit during the study, Dr. Stewart said.\n\u201cThose on the high-fat diets showed no harmful impacts\u201d after 45 days or so, she said.\nAnd at least in the short term, there were no apparent harmful effects.\nStill, the early results are thought-provoking.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure of the extent to which the story may have relied on a news release.\u00a0 We do know that that the work hasn\u2019t even been presented at a conference yet, much less published.", "answer": 2}, {"article": "Patients getting canakinumab also suffered significantly more deaths from infections than those on placebo - but, on the positive side, they appeared to be at lower risk of cancer.\nCanakinumab had stirred considerable scientific interest because it appears to finally deliver proof that fighting inflammation offers a promising new way to counter heart disease in patients who already get cholesterol-lowering treatment.\n\u201cIn view of the additional oncology findings, we don\u2019t think you should just think about this as a cardiovascular drug,\u201d Narasimhan said.\nNovartis had said in June that the drug met its goal in the study but details were only unveiled at European Society of Cardiology meeting in Barcelona.\n\u201cIf the company cuts the price of the product in its current orphan indications, then it instantly sacrifices sales which currently total about $400 million per year with the hope that future sales in a new CV setting will more than offset this,\u201d Anderson said in a note.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on the news release.", "answer": 1}, {"article": "Independent committees look at the details of the patients and how well they are doing in drug trials like these.\nBut they are not free of side-effects.\nThe researchers wanted to see how it worked against the standard chemotherapy cocktails.\nUsually, cancer drugs are only tested at first in patients who have tried everything else available and their cancer has come back, anyway.\nKeytruda was being tested for the first time in 305 lung cancer patients who had not been treated at all yet.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story is not not overly reliant on a news release.", "answer": 1}, {"article": "\"I've been treating cocaine-addicted patients for something like 25 years, more, and I've never heard of anybody throwing away cocaine,\" says Dr. Charles Dackis of the University of Pennsylvania, who led a pilot study that suggested modafinil more than doubled addicts' chances of going cocaine-free for at least three weeks.\nThe prospect of that double-whammy has the National Institutes of Health spending $10.8 million researching modafinil as a potential cocaine treatment.\nAddiction specialists gave it a look because even though modafinil isn't a classic stimulant, it triggered something in the brain to also improve patients' mood, energy levels and ability to concentrate _ effects that might counter cocaine withdrawal.\nHundreds of cocaine users are testing whether that legal pill, called modafinil, could help them kick the addiction, and there's early evidence that it may.\nBut for Dr. Nora Volkow, director of NIH's National Institute on Drug Abuse, the narcolepsy medicine tops the list of promising potential therapies.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "No evidence this is taken from a press release. There are reputable sources from the NIH National Institute of Drug Abuse cited, in addition to the principal investigator of the pilot study. ", "answer": 1}, {"article": "In the 1960s sitcom Leave It to Beaver, Beaver Cleaver was so impressed by his dad's tales of ice cream and pretty nurses that he schemed to have his tonsils out, even though he didn't need it.\nSo the doctor recommended tonsillectomy.\nObviously, parents could use some help in deciding whether surgery is needed.\nThat's never without some risk.\nBy then, Tyler had been dealing with this for almost three years.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story definitely does not rely on a news release.", "answer": 1}, {"article": "\"In many of those cases we decide, 'OK, this lesion is too small to be treated with a filling.'\nA new procedure used by Phark and other doctors claims to stop the progress of cavities without drills or Novocain.\nBecause it's so new, it's still unclear how the Icon resin filling holds up over time.\nHopefully it works.\nThat cringe-worthy sound may be on the way out.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\nThe story does not appear to be based on a news release.", "answer": 1}, {"article": "THE AMERICAN SOCIETY OF ANESTHESIOLOGISTSFounded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific society with more than 52,000 members organized to raise and maintain the standards of the medical practice of anesthesiology.\nResearchers found the higher the PIP scores, the lower the EPDS scores.\nIn the study, researchers reviewed the medical records of 201 women who used epidural analgesia and had their pain assessed using a 0-10 scale during labor.\n\u201cLabor pain matters more than just for the birth experience.\nNewswise \u2014 CHICAGO \u2013 Epidural anesthesia may do more than relieve pain during labor; in some women it may decrease the likelihood of postpartum depression, suggests a preliminary study presented at the ANESTHESIOLOGY\u00ae 2016 annual meeting.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Nothing jumped out at us here that wasn\u2019t covered in our \u201cdisease mongering\u201d criteria.", "answer": 1}, {"article": "But the F.D.A.\nThere was no plaque when their brains were biopsied.\nSome patients would be demented, others not.\nOther companies, still doing their studies, did not yet have data to examine.\nIt worked, the Swedish doctors told Dr. Mathis in an excited phone call.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This is not a news release story. This is a story based largely on early access to the scientist as a buildup to the meeting where the results will be discussed, which is a similar but different animal.", "answer": 1}, {"article": "(Reuters) - U.S. health regulators said on Tuesday they approved a stent by Abbott Laboratories that is the first designed to be absorbed into the bloodstream after it is implanted.\n\u201cThere are no longer going to be permanent metal implants in the artery.\u201d\n\nAbsorb releases the drug everolimus to combat the growth of scar tissue that can form within a stent and cause the artery to narrow again, the U.S. Food and Drug Administration, which approved the stent, said.\nAbbott plans to roll out the device to about 100 hospitals in the next several months as it trains surgeons on the implant procedure before ramping up sales, said spokesman Jonathon Hamilton.\nAbbott said it expects the risks to lessen as surgeons gain experience with it.\nAnalysts have predicted Absorb will gain a market niche but not surpass drug-dispensing metal stents such as Xience in share until longer-term data show more favorable clinical results.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Although the story seems to be reasonably independent of the two available press releases found in the course of this analysis, its positive assessment of the new stent is consistent with the tone of the Abbott Labs\u2019 release.\n\u00a0", "answer": 1}, {"article": "The women were followed for an average of about 3.5 years.\n\"These findings really emphasize how important it is for all women with a family history of early breast or ovarian cancer to undergo genetic testing,\" said Dr. Virginia Kaklamani, co-author of an editorial that accompanied the study.\nKaklamani added that she hoped the findings would encourage more women to ask their primary care physicians whether they are candidates for genetic counseling.\nTUESDAY, Aug. 31, 2010 (HealthDay News) -- Women who carry genetic mutations that boost their odds of breast and ovarian cancer can live longer and reduce their cancer risk by having preventive surgery, a new study suggests.\nSilver added that women who are found to carry one of these genetic mutations face \"a very complex set of considerations, so the more hard facts you can give them, the better.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story includes comments from interviews with experts and does not appear to rely on a news release.", "answer": 1}, {"article": "Nov. 8, 2011 -- A vaccine for breast and ovarian cancer that has spread to other parts of the body shows promise, according to a preliminary study of 26 patients.\nOverall, however, the limited success in some patients and the complete success in one is good news, he says.\nThe study, funded by the National Cancer Institute, is published in Clinical Cancer Research.\nAs exciting as that is, he says, \"a lot of work needs to be done to prove whether this can be effective [for more patients].\"\nOne woman who got the investigational vaccine now has no X-ray evidence of cancer, says study researcher James Gulley, MD, PhD.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a news release.", "answer": 1}, {"article": "Scientists have used a form of stem-cell therapy to improve survival rates for the most severely sick lupus patients, a group that usually has no remaining treatment options.\n\nLupus is an autoimmune disease that attacks an individual's own organs, causing symptoms that range from swollen joints and skin rashes to severe damage to kidneys, lungs and other parts of the body.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "", "answer": 2}, {"article": "The researchers hypothesize that the antidepressant effects of diclofenac and minocycline may be due, at least in part, to their abilities to reduce inflammation.\nThe research team focused on patients in the database who received ketamine, narrowing their study population down to approximately 41,000.\nThat control group eliminated the possibility that people who take ketamine have less depression because they have less pain.\nThat's why they compared ketamine patients with patients taking other pain medications.\nThe study, published May 3 in Scientific Reports, also uncovered antidepressant effects for three other drugs typically used for other purposes -- Botox, the pain reliever diclofenac and the antibiotic minocycline.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There is no unjustifiable language in the release.", "answer": 1}, {"article": "As a result, sticky mucus builds up in a patient's lungs, causing infections and making it hard to breathe.\nThe first prediction turned out to be right.\nBut they also thought a drug to treat the disease was in reach.\nShe knew within days that something was different.\nThey're also likely to be expensive.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a press release.", "answer": 1}, {"article": "About the Alzheimer's Research and Prevention Foundation\n\nThe Alzheimer's Research and Prevention Foundation is a non-profit organization dedicated to reducing the incidence of Alzheimer's disease by conducting clinical research and providing educational outreach about the lifestyle changes that can help prevent Alzheimer's disease.\nWhile preliminary studies have suggested a link between meditation, a sense of spirituality or faith and the risk of Alzheimer's disease, the article's author, Dharma Singh Khalsa, M.D., states that a cultivation of higher levels of psycho-social well-being, such as independence, resilience and life purpose represents \"an important new frontier that deserves further research as it is freely available to anyone, anytime, anywhere.\"\nKhalsa's article highlights the principles and practices of this 12-minute meditation, with corresponding SPECT scans showing how it successfully activates the posterior cingulate gyrus, an important region of the brain that helps regulate memory and emotional function.\nThe full text of \"Stress, Meditation, and Alzheimer's Prevention: Where the Evidence Stands\" can be accessed at http://content.iospress.com/articles/journal-of-alzheimers-disease/jad142766.\n\"We've been studying the impact of meditation on memory for more than 20 years, and are as encouraged as we've ever been on its powerful role in maximizing brain health,\" said Khalsa, president and medical director of the Alzheimer's Research and Prevention Foundation and a clinical associate professor of integrative medicine at the University of New Mexico School of Medicine.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "In order to accept several of the release\u2019s claims such as \u201cKirtan Kriya is a safe, affordable, fast, and effective way to keep the brain spiritually fit\u201d you have to be open-minded to the precepts of holistic medicine \u2014 that optimal health can be achieved by giving balanced attention to a person\u2019s body, mind, spirit, and emotions. We are open-minded to exploring claims and research by all, as long as it\u2019s backed up by good evidence. This wasn\u2019t.", "answer": 0}, {"article": "DOI: 10.1001/jamacardio.2016.4828\n\nCONTACT: For more information or to schedule an interview, please contact the NHLBI Office of Science Policy, Engagement, Education, and Communications at 301-496-5449 or nhlbi_news@nhlbi.nih.gov (link sends e-mail)\n\nPart of the National Institutes of Health, the National Heart, Lung, and Blood Institute (NHLBI) plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders.\nWHO: Jerome Fleg, MD and Yves Rosenberg, MD, M.P.H., Division of Cardiovascular Sciences, NHLBI, NIH, are available to comment on the findings and implications of this research.\nThe study, funded by the National Heart, Lung, and Blood Institute (NHLBI), appears in the December 28 issue of JAMA Cardiology.\nHowever, a randomized study is needed to confirm these findings, according to the authors.\nIn addition to NHBLI, the study received funding from the NIH's National Institute of Diabetes and Digestive and Kidney Disease, the National Institute of Aging, and the National Eye Institute.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We do not believe there is any unjustifiable language in the release.", "answer": 1}, {"article": "Chronic diseases of aging, like diabetes, hypertension, heart problems, cancer, joint disorders and Alzheimer\u2019s, are all believed to have inflammation in common.\nTo the age-old question \u201cIs coffee bad for you?\u201d, researchers are in more agreement than ever that the answer is a resounding \u201cno.\u201d A new study published in the journal found that older people with low levels of inflammation \u2014 which drives many, if not most, major diseases \u2014 had something surprising in common: they were all caffeine drinkers.\nWe are able to point, with a much higher resolution picture, at aging and the things that should be markers for inflammation.\u201d\n\nThe key will be to figure out when the inflammatory response starts to spiral out of control.\nCaffeine inhibits this circuit and turns the inflammatory pathway off, the researchers say.\nThe goal isn\u2019t to make every trace of inflammation disappear, the scientists stress.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to be based on a news release.", "answer": 1}, {"article": "Health officials in Norway recommend that pregnant women (and women who are trying to get pregnant) take 400 micrograms of folic acid per day.\nIt\u2019s unclear how these findings apply to mothers and children in the United States.\nThe researchers also found that the popularity of folic acid supplements rose as time went on.\nNor did they find any link between fish oil supplements and risk of ASDs.\nBut not all mothers were equally likely to take folic acid supplements.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "In addition, Drs.\nNow the test is being used to monitor for disease recurrence.\nThe pump is reusable; the balloon, microchip, and lab test together cost around $20, all supporting the increasing acceptance of breath tests as a cost-effective, easy-to-perform, non-invasive, and rapid option for the diagnosis of lung cancer.\nBeing able to identify this lung cancer \u201csignature\u201d through a simple breath test has emerged as one of the most promising ways to diagnose the disease.\nNewswise \u2014 Chicago \u2014 A single breath may be all it takes to identify the return of lung cancer after surgery, according to a study posted online today by The Annals of Thoracic Surgery.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t use any unjustifiable or sensational language.", "answer": 1}, {"article": "Guyuron, chair of plastic surgery at University Hospitals Case Medical Center in Cleveland, went on to identify four common \"trigger sites\" and publish studies showing that, in selected patients, surgical decompression of nerves in one or more of these sites provides lasting migraine relief. He has also taught 250 plastic surgeons around the world (none in the Philadelphia area) to perform the outpatient operation, which costs an average of $10,000 and is not covered by many insurers.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a press release.", "answer": 1}, {"article": "Tamoxifen blocks the effect of the hormone estrogen, which fuels tumor growth in estrogen receptor-positive cancers that account for about 65 percent of cases in premenopausal women.\nThere was virtually no difference in death and recurrence between the two groups during the five years of extra tamoxifen.\nThe new study, known as Atlas, included nearly 7,000 women with ER-positive disease who had completed five years of tamoxifen.\nWhether these differences are big enough to cause women to take the drug for twice as long remains to be seen.\nDr. Eric P. Winer, chief of women\u2019s cancers at the Dana-Farber Cancer Institute in Boston, said that even women who completed their five years of tamoxifen months or years ago might consider starting on the drug again.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It is clear that this story did not rely on a news release.", "answer": 1}, {"article": "\"Not every cancer cell becomes a metastatic cancer cell.\nThe more tumor cells a woman had in her bloodstream, the higher the likelihood of relapsing or dying, according to the report.\nIn the new study, if even one cell was detected in the bloodstream, a woman had a greater chance of her cancer recurring and of dying.\n\"This may help with prognosis and staging of the cancer and, in the future, with targets for breast cancer treatments,\" said study lead author Dr. Anthony Lucci, a professor of surgery at the University of Texas MD Anderson Cancer Center, in Houston.\nThe problem is that just having circulating tumor cells may not be enough information to foretell the future, she noted.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The piece does not appear to solely rely on a press release because several quotes are included from experts not associated with the study.", "answer": 1}, {"article": "Professor Norman Ratcliffe said, \"There is currently no accurate test for prostate cancer, the vagaries of the PSA test indicators can sometimes result in unnecessary biopsies, resulting in psychological toll, risk of infection from the procedure and even sometimes missing cancer cases.\nOur aim is to create a test that avoids this procedure at initial diagnosis by detecting cancer in a non-invasive way by smelling the disease in men's urine.\nThe results of the pilot study using the GC sensor system indicate that it is able to successfully identify different patterns of volatile compounds that allow classification of urine samples from patients with urological cancers.\nEven with detailed template biopsies there is a risk that we may fail to detect prostate cancer in some cases.\nThe test involves inserting urine samples into the Odoreader that are then measured using algorithms developed by the research team at the University of Liverpool and UWE Bristol.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release contains several instances of unjustifiable language when it calls the test \u201crevolutionary\u201d and says earlier diagnosis is \u201curgent.\u201d Examples:\nIn fact, earlier diagnosis often does not yield expected benefits, because it\u2019s difficult to tell which cancers are aggressive and fast-growing and which ones grow so slowly that they would never cause a problem during the patient\u2019s lifetime.\nThe release also suggests the test could replace biopsy when there\u2019s no evidence for that. \u201cAn accurate urine test would mean that many men who currently undergo prostate biopsy may not need to do so,\u201d according to the release.", "answer": 0}, {"article": "Please use our search feature and update your bookmarks. Thank you!", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "In the headline the release refers to estriol as a \u201csafe\u201d hormone. We think it would have been better to qualify the hormone as \u201csafer\u201d than others.", "answer": 0}, {"article": "While the disease is rare, with about 3,100 new diagnoses and 330 deaths in the United States each year, it often goes undiagnosed until it affects vision. Sacks \u2014 known for books including Awakenings and The Mind's Eye, in which he tells the story of his own cancer \u2014 said his symptoms hit suddenly, wiping out a triangular chunk of the vision in his right eye.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We could find no evidence that the story relied solely on a news release.", "answer": 1}, {"article": "As measured by an electroencephalogram (EEG), small children's brains show a specific pattern of activity when they look at a picture of a human face.\nJust the reverse happens in children with autism.\nNormal child development depends on interactions with parents and other people.\nWithout such interactions, language and social skills do not develop.\nBut that's not all, researchers Geraldine Dawson, PhD, and colleagues report.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "\u201cA 5 percent loss of weight is associated with a 50 percent lower risk of diabetes and a 10 percent loss is associated with an 80 percent lower risk.\u201d\n\nPatients in Bohula\u2019s study did see improvements in hypertension and blood sugar levels with weight loss.\nThe media attention that followed would scare patients off diet pills for years \u2014 a fear that continues today.\nThe latest generation of drugs seems to do just that.\nBut there still \u201care relatively low rates of use.\n\u201cThat\u2019s why treatment of hypertension is so effective.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "The U.S. Food and Drug Administration approved the first therapy to treat an underlying cause of cystic fibrosis, a pill that targets a genetic mutation affecting a small minority of patients suffering from the life-threatening breathing disorder.\n\nThe drug, Kalydeco, from Vertex Pharmaceuticals Inc., will be among the most expensive therapies on the market, costing $294,000 a year.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely solely on a news release.", "answer": 1}, {"article": "\u201cI knew immediately I was on the drug\u201d and not the placebo, said Daniela Velasco, an event planner in Playa del Carmen, Mexico.\nThe constant itch, to say nothing of the disfigurement, can be so unbearable that many patients consider suicide.\nThere has never been a safe and effective treatment.\nFor some, relief was almost instantaneous.\nWithin a couple of weeks, the ugly red rash that had covered 90 percent of her body was almost gone.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It is clear that the story includes original reporting. \u00a0\u00a0", "answer": 0}, {"article": "Genomic Health Inc. has struck a deal to commercialize a new blood test that can help advanced prostate cancer patients decide whether to try costly new-generation drugs or rely on much cheaper traditional chemotherapy to improve their chances for survival.\n\nThe test, developed by closely held Epic Sciences Inc., San Diego, detects a mutation associated with a poor response to two new drugs, Xtandi from Medivation Inc. and Astellas Pharma Inc. of Japan, and Zytiga from Johnson & Johnson.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The writer\u00a0has clearly interviewed his sources and included substantially more information than available from news releases by either Epic Sciences or Genomic Health.", "answer": 1}, {"article": "To learn more, visit stjude.org or follow St. Jude at @stjuderesearch\nShe said that the findings could have important applications for prevention, prognosis and treatment.\n'Since reduced AIM2 activity in colorectal cancer patients is associated with poor survival, it might be useful to detect the level of AIM2 expression in polyps taken from colonoscopy and use this as one of the biomarkers for prognosis,' Kanneganti said.\nRather, he said, AIM2 was known to work in the immune system to detect invading bacteria and viruses and help 'alert' the immune system to battle them.\n'However, our work is the first to identify AIM2's role in controlling proliferation of intestinal stem cells.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "This release is unsatisfactory for two reasons. First, the headline is wildly misleading. Cancer patients expecting to read about new treatments will be brought up short, because the findings here (however promising) are still only findings from an animal model. It\u2019s not clear when or if there will even be the clinical studies that can reveal whether or not treatments based on boosting AIM2 have any benefits. (Remember, this study only looked at the problems that follow impairment of AIM2.) Second, the release waits until the eighth paragraph (the second page, if you were to print it out) to tell readers that the work was done in an animal model. That\u2019s a crucial piece of information, and should have been made clear in the headline and lead.", "answer": 0}, {"article": "Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by red, swollen and cracked skin with intense itching.\nIt has been estimated that approximately 18 million people are living with AD in the U.S. and this disease accounts for up to 20% of patient visits to dermatology offices.\nAbout MM36\n\nMedimetriks has sole, exclusive US rights to MM36.\nThe successful results of the Phase 2 trial of MM36 have been published by the Journal of the American Academy of Dermatology (JAAD), the leading peer-reviewed journal in dermatology.\n\"Based on the results of this study, it appears that MM36 could address an important unmet need in dermatology.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release does not employ unjustifiable language.", "answer": 1}, {"article": "JACC is ranked No.\nThe study and editorial are part of a comprehensive Population Health Promotion issue of the Journal of the American College of Cardiology focusing on issues that broadly impact public health and the prevention of cardiovascular disease and related conditions.\nProgram, researchers in Madrid implemented a three-year healthy lifestyle intervention for 3 to 5 year olds that used their school, teachers and families to promote cardiovascular health through healthy diet, increased physical activity, understanding of the human body and managing emotions.\nThe largest positive changes in body fat were seen in the 3-year-old group that received three years of interventions.\nIn an accompanying editorial, Deepak L. Bhatt, M.D., M.P.H., executive director of interventional cardiovascular programs at Brigham and Women's Hospital Heart and Vascular Center and professor of medicine at Harvard Medical School in Boston, said the program is groundbreaking, and follow-up studies to further pinpoint the exact mechanisms by which the program achieved positive effects on young children's health will be vital for implementing the program in other areas and informing the design of future global programs.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The biggest claim is that the intervention \u201cimproves their [preschoolers] knowledge, attitude and habits toward healthy diet and exercise and can lead to reduced levels of body fat.\u201d\u00a0That claim is not unjustified, but rather the data seems to show the improvement is slight.\nBut we think it\u2019s unjustified to predict that these results will \u201ctranslate to a lifelong understanding of healthy habits\u201d as the release claims. There\u2019s no data at all to suggest that these changes would be sustained beyond the active intervention period.\nWe\u2019re similarly concerned with a quote pulled from the accompanying editorial which states that there is a need to pinpoint the mechanisms through which the intervention \u201cachieved positive effects on young children\u2019s health.\u201d We\u2019re not at all sure that a slight increase in knowledge a very small reduction in bodyfat represent \u201cpositive effects on health.\u201d Health encompasses much more than these things.", "answer": 0}, {"article": "For more information, visit www.chronothera.com.\nThe data were presented today at the Society for Research on Nicotine & Tobacco's 22nd Annual Meeting.\n\"Gums and patches are designed to help manage cravings, but they are only 5 to 9 percent effective.\n\"Achieving statistical significance in a 24-subject trial is very striking and happens infrequently in biopharma; so these results are very encouraging,\" noted Wende Hutton, general partner at Canaan Partners and a member of Chrono's board of directors.\nThe clinical trial was a randomized, double blinded study of 24 adult males who smoked 11 or more cigarettes per day, indicating a high level of nicotine dependence.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release makes numerous unjustifiable claims about the product. Here is a sampling:\n\u201cOur goal is to solve this crisis of public health with an innovative, integrated smoking cessation solution, and the data we presented demonstrates that we are on the right path.\u201d\u00a0 It\u2019s unrealistic to claim that this particular nicotine replacement therapy \u2014 added to the many available \u2014\u00a0 will solve smoking addiction.\n\u201cChrono\u2019s first application is in smoking cessation, enabling smokers to overcome the world\u2019s deadliest addiction.\u201d There\u2019s no data presented about actual quit rates in this study.\n\u201cAchieving statistical significance in a 24-subject trial is very striking and happens infrequently in biopharma; so these results are very encouraging.\u201d A 24 subject trial doesn\u2019t prove anything.", "answer": 0}, {"article": "In a study recently published in the European Journal of Applied Physiology, Seeley and a group of BYU colleagues, as well as Dr. Eric Robinson from Intermountain Healthcare, measured inflammation markers in the knee joint fluid of several healthy men and women aged 18-35, both before and after running.\nSpecifically, they're looking to do similar tests on people who have suffered ACL injuries.\n\"Instead, this study suggests exercise can be a type of medicine.\"\nBYU professors Sarah Ridge and Ty Hopkins were also coauthors on the study.\n\"It flies in the face of intuition,\" said study coauthor Matt Seeley, associate professor of exercise science at BYU.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t include unjustifiable, sensational language. However, the focus on a study with functionally only 6 subjects isn\u2019t at all as revealing as the headline suggests.\nIt reads: \u201cRunning may also slow the process that leads to osteoarthritis.\u201d That\u2019s confusing. Besides slowing the process, what does running do?", "answer": 1}, {"article": "The researchers believe that adding probiotics to the peanut allergens may be important in improving the children\u2019s tolerance to the food, but Dr. Anna Nowak-Wegrzyn, an associate professor of pediatrics at Icahn School of Medicine at Mt.\nThe results are encouraging, allowing the children who were treated to eat peanuts without fear of an allergic reaction.\nThe Australian team added probiotics to further enhance the gut\u2019s ability to accept the peanuts and not trigger an immune reaction.\nBut the new findings provide even more evidence that using peanuts to treat peanut allergy, and to re-train the immune system to be less allergic, can be effective.\nThe study, published in the journal , follows up on children enrolled in an earlier study of an immunotherapy treatment, which combined probiotics with small doses of peanuts that were designed to gradually train the children\u2019s immune systems to accept the peanut allergen rather than treat it as something foreign.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "By talking to an independent source, the story goes beyond a news release.", "answer": 1}, {"article": "\u201cIt\u2019s easier to pop a pill,\u201d Dr. Altman said.\nBut a number of new controlled trials and meta-analyses like Dr. Moore\u2019s suggest that topical Nsaids are as effective as their oral counterparts for treating osteoarthritis in the knee and hand as well as musculoskeletal injuries like soreness and tendinitis.\nIn clinical trials, the skin creams are linked to a higher rate of redness, irritation and rash.\nThe risks in the most vulnerable population \u2014 people with other illnesses, like liver disease, or those on blood thinners \u2014 are not known, because these patients are generally excluded from studies.\nStill, in one of the only head-to-head trials between topical and oral Nsaids, subjects taking the pills had a much higher rate of indigestion, diarrhea, abdominal pain, abnormal liver tests and anemia than those using the creams.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story includes several experts and mentions multiple studies.", "answer": 1}, {"article": "\u201cThey\u2019ll feel measurably better.\u201d\n\n\u201cThe patient population was really quite ill and had very high disease activity, and despite that we saw nice response rates,\u201d Sandborn said.\nThe rate of infections and other serious side effects was similar in the Stelara and placebo groups, researchers said.\nThat compared with a response rate of 23.5 percent of patients who received a placebo.\nHe said a 100-point drop in the CDAI was clinically meaningful to patients.\nThe intravenous biotech drug met the primary goal of the study as almost 40 percent of patients who received the 6 milligrams per kilogram of weight dose of Stelara achieved a clinical response \u2014 defined as a 100-point reduction in the Crohn\u2019s Disease Activity Index (CDAI) \u2014 after six weeks of treatment.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "", "answer": 1}, {"article": "Critically ill children in intensive care are unable to eat independently.\nThese findings provide strong evidence against current practice and can thus be expected to change paediatric intensive care worldwide.\nPrevious research by Professor Van den Berghe and her team (2011 and 2014) had already shown that early artificial feeding should be avoided to treat adults in intensive care.\nThe current standard of care for such children is based mostly on the assumption that they need to eat to regain their strength.\nAn international team of researchers from University Hospitals Leuven (Belgium), Sophia Children's Hospital Rotterdam (The Netherlands), and Stollery Children's Hospital Edmonton (Canada) has now challenged the validity of this common practice.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release makes some unattributed and over-the-top statements including \u201cThe results are remarkable\u201d\u00a0 and \u201cThese findings\u2026can thus be expected to change pediatric intensive care worldwide.\u201d", "answer": 0}, {"article": "\"Our urine test would serve as a molecular triage,\" he says, \"at times supplementing Pap test information.\nThe next step, the researchers report, was to verify that the four-gene test worked using freely circulating DNA from blood and urine, rather than DNA taken directly from cervical tissue.\nTo further improve the accuracy of the test, the investigators added a new gene marker to the test.\nThe researchers tested the value of these genes as markers using 214 cervical cell samples collected from women undergoing Pap smears at Hospital Dr. Hernan Henriquez Aravena in Chile.\nUsing all four genes, the test now had a sensitivity of 90.9 percent and a specificity of 60.9 percent.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The text is explanatory and not dominated by florid language or predictions. However, if the trial\u2019s results came from better tissue samples than would routinely be available (sophisticated lab sampling versus testing performed in a clinic) the release may paint a rosier picture of the test than is warranted. ", "answer": 1}, {"article": "Deaths from adenomatous lung cancer were cut 30 percent, those from colorectal cancer 40 percent, and those from prostate cancer 10 percent.\nYes, scientists have already published strong evidence suggesting aspirin can cut bowel cancer and deaths.\nA final word about dose: The new study didn't find any additional anticancer benefit for aspirin doses above 75 milligrams a day -- the British dose for a \"baby\" aspirin.\nTo be sure, the U.S. Preventive Services Task Force's currently recommends against taking aspirin to prevent colorectal cancer, the type of cancer for which there is the largest body of scientific work.\nFor cancer prevention experts, the British study is provocative and significant.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story does not appear to rely on a news release.", "answer": 1}, {"article": "Both Florbetapir F 18 and florbetaben help diagnose Alzheimer's by sticking to beta amyloid clumps and emitting radioactivity, which can then be picked up by a PET scan.\nIt's an early test for those who already have cognitive concerns and who wonder whether Alzheimer's disease may be the cause.\nWith growing understanding that the changes of Alzheimer's disease may be decades in the making, the value of early detection is gaining adherents, said Weiner.\nAnd since no treatment currently works to stem the inexorable progress ofAlzheimer's, who would pay for a costly test to detect it early -- and why?\nThose questions are no longer hypothetical.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "To our knowledge, the story did not rely on a press release.", "answer": 1}, {"article": "In one study, researchers found that people who have long telomeres, the small strips of DNA that cover the ends of chromosomes, have a 30 percent increased risk of developing colon cancer.\nSavings over time on a more accurate test done fewer times could justify the higher cost of the Cologuard test, Ahlquist said.\nAhlquist noted that the test still needs to be refined.\nAccording to Ahlquist, Cologuard is the first noninvasive test to detect pre-cancerous polyps, he added.\nAhlquist noted that the cost of the test has not yet been established.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does not appear that the story relied on a news release, but we are curious why both this story and the Philadelphia Inquirer used the same \u201cHoly Grail\u201d analogy.", "answer": 1}, {"article": "Urothelial carcinoma is the most common type of bladder cancer and occurs in the urinary tract system, involving the bladder and related organs.\nTherefore, today the FDA also approved the Ventana PD-L1 (SP142) assay to detect PD-L1 protein expression levels on patients' tumor-infiltrating immune cells and help physicians determine which patients may benefit most from treatment with Tecentriq.\nThe FDA granted the Tecentriq application breakthrough therapy designation, priority review status and accelerated approval for this indication.\nThese severe immune-mediated side effects involve healthy organs, including the lung, colon and endocrine system.\nThe Ventana PD-L1 (SP142) assay companion diagnostic for Tecentriq is marketed by Ventana Medical Systems, based in Tucson, Arizona.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We found no unjustifiable language.", "answer": 1}, {"article": "Malignant pleural mesothelioma is a rare and aggressive cancer that represents about 90 percent of all malignant mesothelioma cases.\nThere are multiple studies going on right now to confirm these findings, which the authors note is a necessary step before the drug can become a standard second-line therapy.\nThe study, published this month in The Lancet Oncology, is the first to show a positive impact from checkpoint inhibitor immunotherapy drugs on this disease.\nPHILADELPHIA - Pembrolizumab, an antibody drug already used to treat other forms of cancer, can be effective in the treatment of the most common form of mesothelioma, according to a new study led by investigators from the Perelman School of Medicine at the University of Pennsylvania.\nThis poor prognosis is partially due to the fact that most patients are not diagnosed until they are already at a late stage of the disease.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The lead author is quoted as saying: \u201cwe\u2019ve found this new class of drugs, checkpoint inhibitors, seems to be more effective than what\u2019s been available in the past.\u201d It is unclear that the trial proved its effectiveness and it certainly wasn\u2019t compared to another drug.\nAnd as noted above, claiming effectiveness based on a phase1b safety trial is unjustified and potentially dangerous since the drug is available to physicians who treat other cancers, they could use the drug to treat mesothelioma off label.", "answer": 0}, {"article": "States that permitted medical dispensaries -- regulated shops that people can visit to purchase cannabis products -- had 3.742 million fewer opioid prescriptions filled per year under Medicare Part D, while those that allowed only home cultivation had 1.792 million fewer opioid prescriptions per year.\n\"There is a great deal of movement in the Northeast, with New Hampshire and New Jersey being well-positioned to legalize adult use,\" Moore said.\nAll of these states include chronic pain -- either directly or indirectly -- in the list of approved medical conditions for marijuana use, according to Bradford.\n\"I don't think that's the only reason, but certainly, it was too easy at many points to get prescriptions for opioids.\"\n\"So dispensaries are much more powerful in terms of shifting people away from the use of opiates.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not appear to be based on a news release.", "answer": 1}, {"article": "(Boston)--Despite the continued controversy surrounding the use of testosterone in men who have testosterone deficiency (hypogonadism), a new study has found that long-term use of testosterone therapy not only improves vigor and vitality, but may reduce the risk of death due to cardiovascular (CV) disease.\nThese findings appear online in the Journal of Cardiovascular Pharmacology and Therapeutics.\n\"The low CV events observed in the T-group compared to the untreated (control) group strongly suggest that TTh is protective.\nIn the non-treated control group, there were 21 deaths, 19 of which were related to CV events.\nIn addition, T is essential for overall health and well-being and for the prevention of osteoporosis.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The wording is cautious in most respects.", "answer": 1}, {"article": "\"It may be that it helps with relaxation of muscles that are tense,\" Deyo says.\nNo one knows exactly how massage works to relieve pain, says Dr. Richard Deyo of Oregon Health Sciences University, who also took part in the study.\nPeggy O'Brien-Murphy was among the study participants.\nFor an active person, this was devastating.\nNow, a study in the July 5 issue of the Annals of Internal Medicine shows that massage is an effective treatment for lower back pain.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does not appear that the story relied solely or largely on a news release.", "answer": 1}, {"article": "Oct. 25, 2010 -- Aspirin , already linked in some studies to a lower risk of developing colon cancer , may also cut the risk of dying of prostate cancer by more than half, a large study suggests.\nAspirin and other anticlotting medications carry risks of their own, chiefly bleeding, Zietman says.\nThis study was presented at a medical conference.\nThe risk that cancer spread was also reduced by anticlotting medications, from 7% to 3%.\nResearchers stress the findings are preliminary and that men with the cancer should not reach for the aspirin bottle in an attempt to improve their health.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\nThe story includes quotes from a news conference.", "answer": 1}, {"article": "In an email, Gunter said she frequently prescribes high-frequency TENS (pulses between 50 and 120 hertz at a low intensity) to treat patients who suffer through their periods: \"I have done so for more than 15 years.\nAs far as gadgetry for women's health goes, this one is novel.\n(The Association of Obstetricians and Gynecologists wouldn't comment on Livia because no studies on it have been published.)\nFor now, it's only possible to preorder the device (at a cost of $85) and wait six months for it to ship.\nHe explained that the key to the device is TENS (transcutaneous electrical nerve stimulation), those electronic nerve stimulators you've probably seen in strip malls that hook up to the body to treat neck or back pain.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story clearly does not rely on a press release.", "answer": 1}, {"article": "First published on July 1, 2008 at 12:00 am\nThe study's lead author, Dr. Paul M. Palevsky, said the results may lead to a large savings in U.S. health care costs, estimated at $100 million to $250 million a year for this type of patient.\nDr. Bonventre wrote that the study had \"a predominance of male patients,\" so there is a question of whether its results can be applied to female patients.\nThroughout the study, patients remained in intensive or less intensive therapy, although as their clinical conditions changed, they could change forms of therapy, Dr. Palevsky said.\n\"When a patient transitions from one therapy to another, the dialysis dose is unlikely to be equivalent,\" he said, adding that results could be affected by different methods in the high-intensity and low-intensity groups.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if the story relied solely or largely on a news release. ", "answer": 2}, {"article": "\"There are a number of components that lead to a man having normal fertility potential,\" Brannigan said.\nAt-home sperm tests are a fairly new idea, Imler said, but SpermCheck Fertility is not the first one.\nThe male reproductive system should not be oversimplified, Brannigan said.\nSpermCheck Fertility is the only FDA-approved home sperm test currently on the market and available in retail stores, Lopez said.\nScott said she wished the test had been available when the couple was struggling to conceive their first child.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a press release.", "answer": 1}, {"article": "People with insomnia may have one or more sleep problems, including difficulty falling asleep, trouble staying asleep and difficulty getting back to sleep after waking in the night.\nOn average, it took patients 21.6 fewer minutes to fall asleep with the 40 mg dose of MK-4305 than a placebo on night one, Merck said.\nThe drug, MK-4305, helped patients sleep for a larger percentage of eight hours spent in bed at one night and at the end of four weeks of treatment, Merck said.\nThe company said it is testing only the 40 mg and 20 mg doses in the Phase III study among younger patients and 30 mg and 15 mg doses in the late stage trial of elderly patients.\nThe drug also demonstrated superiority to placebo in the time it took to fall asleep and time spent awake after initially falling asleep, Merck said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to present\u00a0a single fact not found in the drug company\u2019s press release, and it only quotes one person, the Merck VP who is quoted in the press release. One quote appears to be original and the other is straight out of the release, here referred to as \"a statement.\" Here is the release: http://www.merck.com/newsroom/news-release-archive/research-and-development/2010_0609.html", "answer": 0}, {"article": "Probabilities may not grab all patients by the collar. But telling someone he or she has a better than 1-in-3 chance of dying before the next decade's out (or even a better than 1-in-10 chance) would probably be a sobering reminder to hit the gym. The authors said the metric \"can be used to communicate fitness-related risk and motivate behavioral change after exercise stress testing.\"", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story uses a quote from this news release, but doesn\u2019t alert readers to that fact. This gives the impression that the researcher was interviewed, when that doesn\u2019t seem to be the case.", "answer": 0}, {"article": "LONDON (Reuters) - An \u201celectronic nose\u201d could be used as a simple breath test to detect lung, breast, bowel and prostate cancers, Israeli scientists said Wednesday.\nTheir findings, published in the British Journal of Cancer, build on earlier research published by scientists at the same institute last year showing that a sensor made with gold nanoparticles could detect lung cancer in breath.\n\u201cIf we can confirm these initial results in large-scale studies, this new technology could become a simple tool for early diagnosis of cancer along with imaging,\u201d said Abraham Kuten of Technion Israel Institute of Technology.\nKuten and his colleagues studied the breath of 177 people \u2014 some healthy and some with various types of cancer \u2014 to detect the different chemicals emitted from the surface of cancer cells as they grow.\nUsing the sensor to pinpoint chemical variations, the team found they could not only distinguish between healthy and malignant breath but also identify the four different common tumor types.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "", "answer": 2}, {"article": "Traditionally, dentists were taught that the only way to deal with decay was to drill it out.\nWhen Featherstone put his patients on personal treatment plans, he found the strategy worked.\nThat's still important in some cases, Featherstone says, but without fixing the underlying problem of bad bacteria, patients just keep coming back for more fillings.\nAnd he expects that at some point all dentists will follow a preventive protocol.\nBut if you catch decay early, Featherstone says, it can be reversed using fluoride treatments like varnish and concentrated toothpaste and gels.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This piece doesn\u2019t appear to rely on a news release; the reporter interviewed a number of experts and referred to several publications.\n\u00a0", "answer": 1}, {"article": "As rates of sugar-related disorders such as diabetes, obesity and heart disease climb, many experts believe that when Americans rid themselves of fat, they simply replaced it with sugar in all its forms.\nThey\u2019re worried that the findings may shift attention away from what they consider to be the more fundamental issue \u2014 that overall, we\u2019re eating too much.\nThis study does hint however, at what might be happening.\n\u201cThis is causation.\u201d\n\nThe diet he provided the children isn\u2019t considered ideal from a health perspective \u2014 starches are still a considerable source of calories and can contribute to weight gain.\nThat\u2019s the point.\u201d\n\nMORE: The Trouble With Sugar Free Kids\n\nNot everyone is convinced that the results definitely prove sugar, and not weight loss, is the culprit, however.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There\u2019s enough original reporting here for us to be sure this story didn\u2019t rely on a news release.", "answer": 1}, {"article": "\"[The study is] one of the first studies that evaluated the role of Mediterranean diet on metabolic syndrome, and revealed a beneficial association- quite a big influence, taking into account that the Mediterranean diet is a non-pharmacological mean,\" said study author Demosthenes Panagiotakos, from the Department of Science of Dietetics-Nutrition at Harokopio University of Athens in Greece.\nThe syndrome is present when someone has three of those five risk factors.\nThe Mediterranean diet isn't just a little extra olive oil, noted Dr. Robert Eckel, an endocrinologist and past president of the American Heart Association.\nAnd just a few years earlier, over 9 percent of adolescents ages 12-19 were classified as having the syndrome.\nAside from helping to prevent the metabolic syndrome\u2013 a cluster of risk factors for heart disease and diabetes- a new study in the Journal of the American College of Cardiology says, the diet can have positive global effects on the individual risk factors: low HDL (\"good\") cholesterol, high triglycerides, high blood pressure and a high blood sugar rate, as seen by your doctor through a blood test.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not rely solely on a news release.", "answer": 1}, {"article": "UT Southwestern physicians provide care in about 80 specialties to more than 100,000 hospitalized patients, 600,000 emergency room cases, and oversee approximately 2.2 million outpatient visits a year.\nThe new study appears in Circulation, a journal of the American Heart Association.\nPrevious studies from Dr. Levine's research program have shown substantial improvements in cardiac compliance in young individuals after a year of training, but surprisingly little change if the training was started after age 65.\nCollaborators on the study included first author Dr. Erin Howden, Research Fellow with UT Southwestern's Graduate School of Biomedical Sciences and the IEEM and now a faculty member at the Baker Heart and Diabetes Institute in Melbourne, Australia.\nAnd the exercise needs to be performed four to five times a week.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "This is key problem posed by this news release: Implying that there is damage in an aging heart that can be reversed, without justifying the use of the word \u2018reverse.\u2019\nAlso, the phrase \u2018heart aging\u2019 does not come from the study, is not commonly used by either cardiologists or general practitioners, and is potentially misleading for readers.", "answer": 0}, {"article": "Ancient Greek and Chinese medical practitioners used a patient\u2019s scent to make diagnoses.\nThese molecules offer a whiff of who we are, revealing age, genetics, lifestyle, hometown \u2014 even metabolic processes that underlie our health.\nBut not every physician\u2019s nose is a precision instrument, and dogs, while adept at sniffing out cancer, get distracted.\nEach of us has a unique \u201codorprint\u201d made up of thousands of organic compounds.\nBlindfolded, would you know the smell of your mom, a lover or a co-worker?\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We could not locate a news release, but there\u2019s enough original reporting that we\u2019re comfortable rating this Satisfactory.", "answer": 1}, {"article": "Professor Elwood said: \"Our review, based on the available evidence, suggests that low-dose aspirin taken by patients with bowel, breast or prostate cancer, in addition to other treatments, is associated with a reduction in deaths of about 15-20%, together with a reduction in the spread of the cancer.\n\"Whilst we know a low-dose of aspirin has been shown to reduce the incidence of cancer, its role in the treatment of cancer remains uncertain.\nThe study was the longest of its kind to probe the influence of environmental factors in chronic disease.\n\"There is a growing body of evidence that taking aspirin is of significant benefit in reducing some cancers,\" said Professor Peter Elwood who led the research published in the journal PLOS ONE.\n\"The results from six studies of other cancers also suggest a reduction, but the numbers of patients were too few to enable confident interpretation.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We didn\u2019t see anything glaring in the body of the release. The headline: \u201cTaking aspirin could increase cancer survival by 20 percent\u201d captures attention but might have been more faithful to the study by making it clear than only a correlation was found between aspirin and lowered cancer risk.", "answer": 1}, {"article": "Dr Allan Pantuck, the lead clinician of the study, added, \"With fixed dose therapy, patients are often switched to other drugs when they no longer respond to treatment.\nThe research team successfully utilised CURATE.AI to continuously identify the optimal doses of each drug to result in a durable response, allowing the patient to resume a completely normal and active lifestyle.\nOur clinical study has shown that dosing can profoundly affect the efficacy and safety of treatment.\nThis advance is expected to dramatically improve response rates for all combination therapies that are being developed for oncology as well as virtually all other diseases.\nThis new study demonstrates that CURATE.AI can optimise multi-drug regimens.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release uses unsatisfactory language throughout. We\u2019ll provide two examples here. The release tells readers that this study \u201cdemonstrates that CURATE.AI can optimise multi-drug regimens.\u201d No, it doesn\u2019t. This study focuses on the experience of one patient. Did the use of CURATE.AI improve the patient\u2019s treatment? It\u2019s impossible to tell \u2014 because it is one patient. We simply cannot determine what the cancer\u2019s progression would have been, since we can only the see the data on one individual. The release also states that \u201cCURATE.AI is applicable to all diseases and all patients\u201d \u2014 a claim that the release (and related study) cannot support in any way.", "answer": 0}, {"article": "Moderate-fat diet with one avocado a day lowered 'bad' cholesterol by 13.5 mg/dL\n\nThe researchers found that participants' levels of low-density lipoprotein (LDL) - referred to as the \"bad\" cholesterol - were an average of 8.3 milligrams per deciliter (mg/dL) lower after following the lower-fat diet without an avocado and 7.4 mg/dL lower after following the moderate-fat diet without an avocado, compared with their baseline average.\nAlthough these findings demonstrate that an avocado a day alongside a moderate-fat diet has the potential to reduce bad cholesterol, the team notes that their research was a controlled feeding study.\nStill, the team believes their findings indicate that people should consider replacing saturated fatty acids in their diet with healthier fats from avocados and other sources.\nIt should be noted that this research was supported by the Hass Avocado Board, but the researchers say the organization played no other role in the study.\nWhat is more, the team found that a number of additional blood measurements - such as total cholesterol, small dense LDL, triglycerides and non-HDL (high-density lipoprotein) - were better after participants followed the moderate-fat diet with one avocado a day, compared with the other two diets.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story uses several quotes directly from this\u00a0American Heart Association news release without noting that\u2019s the case. For example:\nThe story does list the news release in the reference list of sources, but if you\u2019re going to rely on a canned statement, we\u2019d expect to see some acknowledgment of that fact in the text of the story.\nThere also doesn\u2019t appear to be any information contained in the article that isn\u2019t also in the news release.\nIt\u2019s clear that the three competing stories that covered this study at least spoke with study researcher Penny Kris-Etherton.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070805/13knee.htm was not found on this server.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "No obvious use of text from the press release.", "answer": 1}, {"article": "Data from nearly 9,500 people on five continents shows that amyloid can appear 20 to 30 years before symptoms of dementia, that the vast majority of Alzheimer\u2019s patients have amyloid and that the ApoE4 gene, known to increase Alzheimer\u2019s risk, greatly accelerates amyloid accumulation.\nThe findings also confirm that amyloid screening, by PET scan or cerebral spinal fluid test, can help identify people for clinical trials of drugs to prevent Alzheimer\u2019s.\nThe largest analysis to date of amyloid plaques in people\u2019s brains confirms that the presence of the substance can help predict who will develop Alzheimer\u2019s and determine who has the disease.\n\u201cThe papers indicate that amyloid imaging is important to be sure that the drugs are being tested on people who have amyloid,\u201d said Dr. Roger Rosenberg, the director of the Alzheimer\u2019s Disease Center at the University of Texas Southwestern Medical Center at Dallas, who wrote an editorial about the studies.\nExperts say previous trials of anti-amyloid drugs on people with dementia failed because their brains were already too damaged or because some patients, not screened for amyloid, may not have had Alzheimer\u2019s.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the article contains comments from sources who appeared to have no involvement with the research, we are confident this article didn\u2019t rely solely on a press release.", "answer": 1}, {"article": "\"For example, we know that certain changes in the retina, like thinning tissue [due to cell loss] or weakening electrical activity, occur alongside loss of brain tissue and reduced brain activity in patients with neurological disorders like multiple sclerosis and Parkinson's disease.\n\"However, since every prior study has found that people with schizophrenia exhibit reduced retinal wave forms and slowed retinal responses, our research shows that we closing in on an accurate test that is faster, less invasive, inexpensive and more accessible to patients.\"\nThe results show the device accurately indicated reduced electrical activity in the retina in multiple cell layers in the participants who had schizophrenia, including in cell types that had not been studied before in this disorder.\nIn the just-published study, the researchers evaluated 50 participants: 25 with schizophrenia and 25 with no diagnosed psychiatric disorder.\nWe and other researchers are now investigating whether retinal changes are related to brain structure and function changes in schizophrenia.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The lead sentence oversold this study, indicating that it showed how a common device \u201cmay hold the key to faster diagnosis of schizophrenia, predicting relapse and symptom severity and assessing treatment effectiveness.\u201d\nThe news release headline also over-reaches. A better headline might have been the sub-title: \u201cResearchers explore eye function in schizophrenia as a window into the brain.\u201d\nBut further down the news release quoted a researcher stating that the study \u201cshould help generate further research\u201d into developing a test clinicians can use to diagnose, treat and monitor people with schizophrenia.\nAnd at the end a quote \u2014 from lead author Docia Demmin \u2014 tempered the assertion by stating \u201cit\u2019s too soon to call this a diagnostic tool.\u201d", "answer": 0}, {"article": "At 40Hz the flicker of the light is barely discernible and would be \u201cnot offensive at all\u201d for a person to have in the background.\nThe study, published on Wednesday in the journal Nature, hinges on the observation that Alzheimer\u2019s patients show a loss of synchronised brain activity, known as gamma oscillations, which is linked to attention and memory.\n\u201cIf humans behave similarly to mice in response to this treatment, I would say the potential is just enormous, because it\u2019s so non-invasive, and it\u2019s so accessible,\u201d said Li-Huei Tsai, director of the Picower Institute for Learning and Memory at MIT, and the paper\u2019s senior author.\nDavid Reynolds, chief scientific officer at Alzheimer\u2019s Research UK, said: \u201cIt is conceivable that changing brain cell rhythms could be a future target for therapies, but researchers will need to explore how light flickering approaches could not only reduce amyloid in the visual area of the brain but in those areas more commonly affected in Alzheimer\u2019s.\u201d\n\nThe authors suggest that it may be possible to take a multi-sensory approach, using a combination of flashing lights and vibrating chairs.\nNext, the scientist showed that gamma oscillations could also be stimulated non-invasively in the visual brain region simply by exposing the mice to a flickering light.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The study quotes two independent experts, which is good. But, it uses quotes taken directly from PR materials from the research organization without attribution:\nExample, this quote:\n\u201cIf humans behave similarly to mice in response to this treatment, I would say the potential is just enormous, because it\u2019s so non-invasive, and it\u2019s so accessible,\u201d said Li-Huei Tsai, director of the Picower Institute for Learning and Memory at MIT, and the paper\u2019s senior author.\nIs taken from here, which published this as:\n\u201cBut if humans behave similarly to mice in response to this treatment, I would say the potential is just enormous, because it\u2019s so noninvasive, and it\u2019s so accessible.\u201d", "answer": 0}, {"article": "Studies of adults find that social jet lag is associated with higher BMI, insulin resistance, depression, and a higher likelihood to engage in dangerous behaviors like smoking.\nBut even if later school start times only improve sleep time, that\u2019s a positive step for public health.\nThere are some limitations to mention about the new meta-analysis.\nBut it\u2019s not a foregone conclusion that later start times will ensure teens sleep more.\nThis is a solution supported by both the America Medical Association and the American Academy of Pediatrics.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story\u00a0does not rely on the news release.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070311/19clot.htm was not found on this server.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\u00a0There was a second source questioning the MRI data, so it does not appear that the story relied solely or largely on a news release.\u00a0 ", "answer": 1}, {"article": "Gluck et al.\nOn each visit, the participants ate a weight-maintaining diet for five days.\nThen for three days, they unknowingly received either active or sham (fake) transcranial direct current stimulation, or tDCS.\nObesity 4 Nov.\n\nNIDDK Research Clinical Psychologist Marci Gluck, Ph.D., is available to comment on this study.\nMore study is needed to confirm the safety and effectiveness of tDCS for weight loss.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We might have liked a headline that said \u201cTiny study showed some possible benefit to brain stimulation.\u201d But the release did not use unjustifiable language.", "answer": 1}, {"article": "Sharon Samuels was a teenager when she was first diagnosed with essential tremor.\nFor now, the treatment has had an immense impact on patients\u2019 lives.\nHe added that since these patients were only followed for a year, there isn\u2019t enough data available yet to determine the long-term efficacy of the treatment.\nBut the procedure brings lasting side effects in some patients, and its long-term usefulness is still being studied.\nThat needs to be shown.\u201d\n\nThe researchers are in the process of collecting this data; the clinical trial will run until December.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely solely on the news release, which we also reviewed.", "answer": 1}, {"article": "Instead, they pass through to the large intestine, where they draw water into the gut and start to ferment.\nGibson estimates that, overall, about 10 percent of the population may be FODMAP-sensitive.\nBut there\u2019s a problem with a low-FODMAP diet.\n\u201cFollowing strictly the low-FODMAP diet is associated with changes in the microbiota that many would not equate with good health,\u201d says Gibson, who stresses that a low-FODMAP diet should be used to reduce specific symptoms, not as a way to improve health.\nUnless you have specific symptoms that a low-FODMAP diet alleviates, Gibson says, \u201cenjoy your FODMAPs!\u201d\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no evidence of a press release as the source of the story.", "answer": 1}, {"article": "The etonogestrel implant is a small plastic rod resembling a matchstick that is inserted under the skin in the upper arm.\nWith both implants and IUDs, fertility returns quickly as soon as the devices are removed.\nTheir effectiveness rivals that of sterilization.\nThe copper IUD does not contain hormones.\nWomen using it report a significant reduction in menstrual blood loss.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "After consulting with several breast surgeons and reconstructive surgeons, Ms. Burt opted for a nipple-sparing mastectomy performed by breast surgeon Tihesha Wilson, M.D., Assistant Medical Director of Valley\u2019s Breast Center.\nValley was the first hospital in northern New Jersey where an innovative technique \u2013 called pre-pectoral placement of a tissue expander -- was utilized during breast reconstruction surgery following a mastectomy.\n\u201cThis variation of a standard technique used during breast reconstruction will revolutionize the post-operative recovery in patients who meet certain criteria for the procedure,\u201d notes Dr. Small.\n\u201cThis was a long journey,\u201d says Ms. Burt, a publicist for the San Francisco-based Fat Wreck Chords music company.\nIn addition to exceptional cosmetic results, the technique is likely to improve clinical outcomes as evidenced by ongoing research that shows women who undergo this procedure experience less pain and a shorter recovery period.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Hyped terms like \u201cinnovative\u201d and phrases such as \u201chas the potential to be a \u2018game-changer'\u201d are found throughout this release \u2014 and there\u2019s almost nothing to back them up.", "answer": 0}, {"article": "In a mobile stroke unit, a specialized ambulance is equipped with a CT scanner, a paramedic, a critical care nurse, a CT technologist and a neurologist in person or by telemedicine.\nThat is why patients need a CT scan to confirm the type of stroke before receiving tPA.\nThe association has strict policies to prevent these relationships from influencing the science content.\nThe study was funded by the Arline and Henry Gluck Foundation.\nThe association makes no representation or warranty as to their accuracy or reliability.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The language is generally cautious enough in the release. The errors are mostly of omission.", "answer": 1}, {"article": "A 33-year-old Queens woman who was treated by Batzofin last week fits that bill. Married for two years, she failed to get pregnant through intercourse, with and without drugs. When Batzofin told her about his new procedure, she said, \"Let's go for it.\"", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if this story is based on information from a press release. ", "answer": 2}, {"article": "Happiness won\u2019t help you live longer (but unhappiness won\u2019t kill you either)\n\nGuinea is finally declared Ebola-free, but that does not mean the crisis is over\n\nMost popular Washington Post health stories of 2015: A mother tells her story of how she lost her darling daughter a few weeks short of her 29th birthday when she stepped in front of a train in Baltimore.\nBut some doctors and researchers were puzzled by the fact that in head-to-head comparisons between the two classes of drugs they appeared to equally safe and effective.\nThe new analysis, published in Mayo Clinic Proceedings on Monday, involves a second look at 106 randomized trials with 254,301 patients that took place after 2000 and shows that during this time period patient outcomes on the two medications were remarkably similar.\nThat led many doctors and standards groups to conclude that ACE inhibitors were more effective than ARBs.\nThe other piece of good news regarding the medications is that ACE inhibitors, as well as many ARBs, are now generic -- meaning that the cost difference is minimal.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It would be difficult to conclude that this story relied solely on a news release, given that it provided some facts not present in the NYU release.\u00a0 However, the story does not stray far from the information included in the release and could benefit from additional source information and comment.\u00a0 However, its similarity to the NYU news release is far less than that of a HealthDay story about the same research.", "answer": 1}, {"article": "Screening patients for heart disease with a heart-imaging test prompted greater follow-up care but had little to no effect on the number of heart attacks and other cardiovascular events in those patients, a new study found.\n\nResearchers at Johns Hopkins Hospital in Baltimore led the study, which was published online Monday in the Archives of Internal Medicine.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not appear to rely on a news release.", "answer": 1}, {"article": "Hot flashes and night sweats are the most common symptoms of menopause, affecting some 80% of women.\nThe alternative therapy reduced hot flashes by as much as 74% in the study conducted by researchers at Baylor University\u2019s Mind-Body Medicine Research Laboratory and funded by the National Institutes of Health.\nA total of 187 postmenopausal women who reported having at least seven hot flashes a day, or 50 a week, were recruited for the trial.\nThe progression is familiar to most women of a certain age.\nOnly hormone therapy, which many women can\u2019t take or want to avoid, is more effective for treating the most common symptom of menopause, says researcher Gary R. Elkins, PhD.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a press release. There is evidence of original reporting, with the two comments from the researcher and the NAMS director.", "answer": 1}, {"article": "All rights reserved.\nAmerica's favorite dietary supplements, multivitamins, modestly lowered the risk for cancer in healthy male doctors who took them for more than a decade, the first large study to test these pills has found.\nThat is less effective than a good diet, exercise and not smoking, each of which can lower cancer risk by 20% to 30%, cancer experts say.\nThe National Institutes of Health paid for most of the study.\nThe result is a surprise because many studies of individual vitamins have found they don't help prevent chronic diseases and some have even caused problems.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that this story wasn\u2019t based on a press release.", "answer": 1}, {"article": "The higher a person's insulin levels are, the more likely they are to have or develop insulin resistance, which can increase blood sugar levels and diabetes risk.\nPeople who have a gastric bypass often have nutritional and vitamin deficiencies, Lenhard said.\nIn fact, the majority of the participants \u2014 83 percent \u2014 had only one or no risk factors three years after their surgeries.\nThe study authors had no part in which procedures the teens received.\nThe findings are important because many of the participants in this study likely already had some level of cardiac damage, such as thickened arteries or heart walls, says Geetha Raghuveer, a pediatric cardiologist at Children's Mercy Kansas City in Missouri who was not involved in the study.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "Dec. 14, 2009 -- A less invasive needle biopsy may be nearly as effective as surgical biopsy at diagnosing breast cancer, and with far fewer side effects.\nThey say additional studies are needed to find out what factors affect the accuracy of core-needle breast biopsy.\nThe results showed that core needle biopsies were about as accurate as open surgery at detecting cancerous vs. noncancerous breast lesions.\nResearchers say needle biopsy has fewer complications and a shorter recovery time than open surgical biopsy, but some women and doctors may have concerns about the accuracy of the procedure compared with traditional open surgery methods of breast cancer diagnosis.\nA new review of more than 80 studies on the two breast cancer screening methods shows breast needle biopsy was able to distinguish between cancerous and noncancerous breast lesions with about the same accuracy as surgical biopsy and less than half the risk of complications.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It is difficult to tell if this story is generated directly from a news release, especially since the lead study author is the only source cited.", "answer": 2}, {"article": "CT scans expose patients to radiation, for example, which can increase the likelihood of developing cancer.\nUsing national data, the researchers found the rate of so-called pulmonary embolisms, or PEs, nearly doubled with the introduction of a new powerful diagnostic test more than a decade ago.\nBut with increasingly sophisticated tools, doctors may be spotting clots that would never have been fatal in the first place.\nThe new findings add to other evidence showing that medical testing is on the rise across the U.S., although in many cases the impact on overall health remains unclear.\n\u201cRather than an epidemic of disease, we think the increased incidence of PE reflects an epidemic of diagnostic testing that has created overdiagnosis,\u201d the researchers write in the Archives of Internal Medicine.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely solely on a news release.", "answer": 1}, {"article": "\"Shireen had the idea, 'Why can't I just test my food and figure out what's in it?'\nNima is not FDA-approved and it's not intended for medical use, but the company intends it as a \"consumer\" tool to use when dining out, Sundvor said.\nMarilyn Grunzweig Geller, chief executive officer of the Celiac Disease Foundation, said she is not familiar with the new gluten-sensing device and was unable to comment on it directly.\nThe company, 6SensorLabs, has started taking pre-orders for the device it calls Nima, which can test food for gluten and get rapid results, said co-founder and chief technology officer Scott Sundvor.\nThe company plans to deliver the product by the middle of next year after they've tested it more thoroughly, Sundvor.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story uses information from the company, but did do further reporting, including interviews with a company founder and the Celiac Disease Foundation CEO.\n\u00a0", "answer": 1}, {"article": "They form when the skin is rapidly stretched, such as during puberty, pregnancy, and rapid weight gain, says Joshua Zeichner, MD, director of cosmetic and clinical research at Mt.\nThe study, funded by Merz Pharmaceuticals, which makes the cream, was presented at the annual meeting of the American Academy of Dermatology.\nThe marks slowly fade and become flat on their own, but that can take years.\nAnd it has sulfur, which fights bacteria and infection, and a moisturizing cream to help rehydrate the skin, Draelos says.\nHe was not involved with the research.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It doesn\u2019t appear that the story relied solely on a news release. ", "answer": 1}, {"article": "Every year, U.S. News & World Report asks experts to rank various diets to help the tens of millions of dieters in the United States and around the globe make informed dietary decisions that can help them achieve healthier lifestyles.\nThe panel of experts -- including nutritionists and doctors specializing in diabetes, heart health and weight loss -- scored each diet for short-term and long-term weight loss.\nThe DASH diet scored highest when it comes to healthy eating, followed by the TLC diet.\nThe Raw Food diet was also considered the most difficult diet to follow, though it was one of the top ranked weight-loss diets, the panel found.\nOn the opposite end of the list, the Whole30 diet -- a 30-day program that bans processed foods, legumes, grains, dairy, alcohol and added sugar -- ranked as the worst overall diet on the list, the new report said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "As noted above, the story appears to rely exclusively on a news release.\nIt could have been much stronger had the story included some of the survey results which are linked and available online.", "answer": 0}, {"article": "Involuntary muscle spasms (spasticity) are common symptoms of MS.\n\"Considering the distress and limitations spasticity brings to individuals with MS, it is important to carefully weigh the potential for side effects with the potential for symptom relief, they say in the news release.\nBut subjective assessment of relief of spasticity suggested significant improvement after treatment, they write.\nSide effects varied greatly and depended on the amount needed to limit spasticity, the researchers write.\nThe researchers say that many existing therapies for this condition are difficult to obtain, ineffective, or associated with intolerable side effects.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story discloses that it lifted a quote from a news release.\u00a0 We appreciate that admission.\u00a0 But we judge the story unsatisfactory on this criterion because it clearly relied on a news release without putting any independent perspective in the story \u2013 something other stories managed to do easily (See \"Source\" criterion below.)\u00a0 It\u2019s difficult to see how/if any independent reporting went into this story. ", "answer": 0}, {"article": "Switching to AstraZeneca PLC's breast-cancer drug Arimidex after treatment with older drug tamoxifen not only helps women live longer, but also increases their chances of staying cancer-free after initial therapy for breast cancer, according to a study in the online edition of the Lancet Oncology medical journal.\n\nThe data, which come from more than 4,000 patients in three clinical trials, have shown that switching treatment from tamoxifen to Arimidex reduces the risk of dying by 29%.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We cannot determine if this information is from a press release. No independent sources are interviewed to provide perspective on the study and shift in treatment.\u00a0 ", "answer": 2}, {"article": "Use of osteoporosis drugs, once heavily advertised by celebrity spokeswomen, has dropped by more than 50% in recent years amid reports of such serious side effects as sudden bone fractures.\n\nYet many experts say the benefits of the drugs, known as bisphosphonates, far outweigh the risks for many users.\n\nAn analysis in the New England Journal...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story clearly goes well beyond what would be found in any news release.", "answer": 1}, {"article": "Learn more about intrauterine devices from the Association of Reproductive Healthcare Professionals.\nThe researchers randomly assigned nearly 600 women with heavy menstrual bleeding to receive either the IUD or standard medical care.\nBritish researchers found that the treated IUD was more effective at reducing the effects of heavy menstrual bleeding (also called menorrhagia) on quality of life compared to other treatments.\nResults of the study, which was funded by the United Kingdom's National Institute of Health Research, appear in the Jan. 10 issue of the New England Journal of Medicine.\nSerious side effects were similar between the groups.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not appear to rely on a press release.", "answer": 1}, {"article": "If doctors know someone is at risk for premature labor earlier in pregnancy, they might start efforts to help delay labor, such as recommending bed rest.\nBut the findings are promising, particularly because premature delivery is such a serious problem.\nThe test, if it does turn out to work in clinical trials, would be cheaper than ultrasound, said Quake.\nThe scientists analyzed 20,000 genes to find the ones that were active during pregnancy and labor.\nHowever, a new blood test \u2014 which is still experimental and not yet available outside of a research lab \u2014 can pick up on gene activity in the body that suggests a pregnancy is at risk for preterm delivery, according to a study published Thursday in the journal Science .\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We didn\u2019t detect any obvious signs of copy/pasting claims, researcher quotes, etc.", "answer": 1}, {"article": "Asthma patients suffer fewer attacks and need fewer hospital visits.\nBut several five-year studies showed no long-term safety issues.\nBut three five-year studies have already been completed.\nDr. McEvoy argued that it made economic sense, and earlier this year Health Partners agreed.\nSince then, about 650 patients across the country have had the procedure.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story has plenty of original reporting. No doubts here.", "answer": 1}, {"article": "Lung cancer kills more Americans than any other type of cancer, nearly 160,000 last year.\nJanne, also a professor at Harvard Medical School, said more research is needed before lung cancer patients should be routinely treated with Opdivo, Keytruda or similar drugs.\nFor other patients, researchers expect other drugs will be needed, too.\nBut there are still a lot of unanswered questions about immune therapy.\n\"It is early days for the successes of immune therapy,\" said Mark Fishman, president of the Novartis Institutes for BioMedical Research, a research arm of drug company Novartis, which is taking a different approach to turning the immune system against cancer.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Don\u2019t get us wrong \u2014 it\u2019s clear that the main \u201cnews\u201d here is based entirely on a company news release. However, since the story includes context from multiple sources and finds background information not included in the Bristol-Myers Squibb materials, it meets our standard for this criterion. That\u2019s why we\u2019re rating it satisfactory.", "answer": 1}, {"article": "Jerry St. Peter, Vice President and Head of Sun Ophthalmics, added: \"A key strategic imperative for our ophthalmic business is to participate in the rapidly growing, underserved, and dynamic Dry Eye market, which is expected to reach $5 billion by 2020.\nAdverse events reported in the trial were mild to moderate in nature and similar to other approved drugs in the category.\nResearch in dry eye: report of the Research Subcommittee of the International Dry Eye WorkShop (2007).\nLifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.\n\"As a clinician who specializes in diagnosing and treating dry eye, this novel formulation of cyclosporine A would be a unique and welcome addition to our armamentarium to treat these patients\".\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release does not appear to use any unjustifiable language.", "answer": 1}, {"article": "A new study offers a fresh strategy for treating patients suffering from both coronary artery disease and heart failure, afflictions linked to poor quality of life and high risk of death that affect as many as two million Americans.\n\nThe 1,212-patient study calls into question the need for immediate bypass surgery in these patients\u2014an approach commonly recommended by doctors. The study, called Stich, found benefits in treating people with medication only, and in treating people with a combination of bypass surgery and medication....", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a news release.", "answer": 1}, {"article": "The amygdala processes incoming emotionally salient stimuli, whereas the prefrontal cortex, as the executive center of the brain, decides whether the incoming stimuli are noteworthy.\nThe initial results demonstrate that the efficacy of this digital therapeutic is comparable to drug therapy, with a highly favorable safety profile.\nThis treatment was developed at the Icahn School of Medicine at Mount Sinai by Brian Iacoviello, PhD, an Assistant Professor of Psychiatry who is Director of Scientific Affairs for Click Therapeutics, and Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean and Professor of Psychiatry, Neuroscience, and Pharmacological Sciences.\nThis aims to balance brain activity in these regions to work in concert with each other.\nMSIP is responsible for the full spectrum of commercialization activities required to bring the Icahn School of Medicine's inventions to life.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Some of the language appeared to swerve into exaggeration but was not unjustifiable.", "answer": 1}, {"article": "Dr Carol Routledge, from Alzheimer's Research UK, said: \"The diseases that cause dementia begin in the brain up to 20 years before any symptoms start to show, presenting a vital window of opportunity for us to intervene before widespread damage occurs.\nThe Alzheimer's algorithm was able to teach itself to recognize patterns in brain scans that indicated disease.\nIt proved to be 100 percent accurate at detecting Alzheimer's disease many years before the patient was later diagnosed.\n\"Although the sample sizes and test sets were relatively small, the results are so promising that a much larger study would be worthwhile.\"\n\"It was able to predict every single case that advanced to Alzheimer's disease.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "One of the quotes came directly from the news release but was not attributed.\nIt\u2019s worth noting that the news release was superior to the story in terms of useful details.", "answer": 0}, {"article": "Side effects of dopamine agonists can include euphoria, hallucinations, weight loss, nausea, insomnia, tiredness or weakness, dizziness and drowsiness.\nNonetheless, for people with moderate to severe restless legs syndrome symptoms, these medications provided important benefits, at least in the short term, Wilt said.\nThe harms of medications may outweigh benefits for these individuals, Wilt said.\nPatients should tell their doctors if they have bothersome sensations in their legs that include distressing, irresistible urge to move them that is relieved by rest, Wilt said.\n\"Up to 25 to 50 percent with even moderate to severe and longstanding symptoms stop taking these medications after more than a year due to either side effects or lack of benefit,\" he noted.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story didn\u2019t rely solely or largely on this press release about the study.", "answer": 1}, {"article": "At the same time, we studied a small sample of patients, so our results should be interpreted with caution,\" Fried added.\nStimulation of the entorhinal cortex -- a region considered crucial to transforming daily experience into lasting memories -- produced the improvement, the researchers said.\nSo it's difficult to generalize this study's results to other diseases that affect memory, she said, and the research didn't show if effects of temporary deep brain stimulation last beyond the study period.\nAlthough the results are still preliminary, the method may potentially hold promise for boosting memory in patients with early Alzheimer's disease, the researchers said.\n\"Critically, it was the stimulation at the gateway into the hippocampus, and not the hippocampus itself, that proved effective,\" senior study author Dr. Itzhak Fried, a professor of neurosurgery at the David Geffen School of Medicine at UCLA, said in a university news release.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does attribute quotes from a researcher to a news release, but it also includes quotes from at least one other source, so it does not appear to rely only on the release.", "answer": 1}, {"article": "\u201cTherefore, it is important to study the factors associated with the diagnosis of colon cancer occurring after colonoscopy.\u201d\n\nDuring a colonoscopy, a flexible camera is passed through the colon in search of abnormal growths known as polyps and other warning signs of early tumors.\n\u201cThese patients were referred for colonoscopy, most commonly due to symptoms,\u201d Lieberman said.\nCanadian researchers note that their finding should be a heads-up to clinicians performing the exam, as well as to patients preparing for it.\nBoth groups could do things to improve the detection rate, they said.\n\u201cThis is very different from a population undergoing screening.\u201d\n\nColonoscopy would probably miss a smaller percentage of cancers in such a large population, Lieberman said, because the rate would be lower.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story does not rely on a news release.", "answer": 1}, {"article": "Those with a higher PSA velocity \u2014 the level rose more than a count of 0.35 a year \u2014 had a 54 percent survival rate, while those whose PSA rose more slowly had a 92 percent survival rate.\nThe work is \"another step on the road to more sophisticated\" prostate cancer screening and treatment, Dr. Timothy Church of the University of Minnesota wrote in an editorial accompanying the work.\nA study with just 20 deaths is far too small to prove the value of PSA velocity, cautioned Dr. Durado Brooks, a prostate specialist with the American Cancer Society.\nYet routinely biopsying men with low PSA would worsen another problem, overdiagnosis.\nAnd men diagnosed with prostate cancer whose PSA is rising slowly may be ideal candidates for monitoring instead of surgery or other treatment, he added.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story quoted the lead author, an editorial writer, and an American Cancer Society official, it is unlikely the story relied solely or largely on a news release.\u00a0 ", "answer": 1}, {"article": "The Journal of Medical Entomology is published by the Entomological Society of America, the largest organization in the world serving the professional and scientific needs of entomologists and people in related disciplines.\nThe effectiveness of the device came as a pleasant surprise to the researchers.\nClip-On caused high mosquito mortality and knockdown rates up to 0.3 meters from the device, enough to protect a single person wearing the device.\nA product called the OFF!\u00ae Clip-On\u2122 repellent device could be an effective tool for preventing bites from the Aedes aegypti mosquito -- the primary vector of Zika, chikungunya, dengue, and yellow fever -- according to an article in the Journal of Medical Entomology.\nSkepticism is inherent to the trade.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The headline for this release is dangerously misleading: \u201cClip-on device offers protection against mosquitoes that transmit Zika.\u201d That statement is simply unjustifiable given the study\u2019s lack of real-world significance. \u00a0The last line in the release also seems particularly unjustifiable: \u201c\u2026it was nice for a change of pace that one of these devices could actually do some good.\u201d We don\u2019t think this study showed very much at all. \u00a0 ", "answer": 0}, {"article": "\"I called the doctor back in and said, 'We're doing the chemo.'\nThe drawback of that study, Dr. Glick notes, is that it was not a large prospective randomized clinical trial, the gold standard in medicine.\nAnd while some, including Dr. Winer, predict that the use of chemotherapy will almost certainly decline in the years ahead, for now most doctors are sticking with the current guidelines, waiting for expert advice from national panels on what to do.\nThe study is ethical, said Dr. Larry Norton of Memorial Sloan-Kettering Cancer Center in New York, because the only women whose treatment will be decided at random are those in a kind of gray area, not women for whom chemotherapy would be a clear benefit or clearly unnecessary.\nThat has led doctors to feel most at ease giving very aggressive treatments to almost everyone.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "No evidence this information is taken solely from a press release. There are several sources cited other than the study authors, and these sources provide perspective on the idea of less chemotherapy for women who may not benefit as much from certain regimens. ", "answer": 1}, {"article": "Philadelphia, PA, April 18, 2017 - In the past, all forms of metastatic prostate cancer have been considered incurable.\nWhile the study is only a first step, one-fifth of the patients treated had no detectable disease, with an undetectable prostate-specific-androgen (PSA) and normal blood testosterone, after 20 months.\nLonger follow-up is needed to determine whether these patients were in fact cured.\nThe authors proposed that this end point may serve as a first step toward establishing a curative paradigm.\nThe results suggest that some men who have previously been considered incurable can possibly be cured; investigators also establish a new paradigm for testing various drug combinations in conjunction with local treatment of the prostate to determine which is the best approach (ie, has the highest undetectable disease rate).\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The subhed, or secondary headline, for the release states that \u201ca new paradigm including drug therapy, surgery, and radiation may cure previously incurable cancer.\u201d And the first sentence of the release says: \u201cIn the past, all forms of metastatic prostate cancer have been considered incurable.\u201d (Emphasis added.) But lower down, the release notes that this study \u201cis only a first step,\u201d that \u201cLonger follow-up is needed to determine whether these patients were in fact cured\u201d and that \u201cthe longevity of effect is essential to prove the point of curability.\u201d In other words, this is a small study that absolutely can\u2019t prove whether a cure is possible. It\u2019s a promising first step, but it is only a first step \u2014 and should be approached with cautious language. Using cautious language later in the release doesn\u2019t make up for over-reaching language at the top.\nThe author is quoted in the news release as saying that \u201cthe endpoint also shifts the paradigm from palliation to cure,\u201d a comment that goes beyond the data. The study does not provide sufficient data to know whether the three-pronged treatment can \u201ccure\u201d cancer. Therefore, we don\u2019t know whether the surrogate endpoint is clinically meaningful.", "answer": 0}, {"article": "In nonsurgical spinal decompression, a patient is placed on a special type of table with harnesses on the pelvis and rib cage.\n\u201cDecompression on the West Coast is a dime a dozen, but here in the Midwest, they are almost unaware of it.\nThe treatment, which includes several 20-minute procedures and rehabilitation, costs between $3,500 and $4,000.\nIt is less than half the cost of surgery but is rarely covered by insurance.\nIt is designed for patients who have not had surgery.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no way to know if the story relies on a press release as the sole source of information.", "answer": 2}, {"article": "For that reason, UV devices are often used for sterilization \u2014 for medical equipment in hospitals, for example, or drinking water for backcountry campers.\n\u201cIf you have a lamp over the surgical site that can sterilize the air, you can prevent the bacteria from floating down and contaminating the wound.\u201d\n\nBrenner can\u2019t predict how long it might take for these lamps to be commercially available, but he says he\u2019s \u201cextremely optimistic\u201d about the technology.\n\u201cThink about doctor\u2019s waiting rooms, schools, airports and airplanes\u2014any place where there\u2019s a likelihood for airborne viruses.\u201d And unlike the flu vaccine, he says, far-UVC light is likely to be effective against all airborne microbes, including newly emerging virus strains.\nBut conventional germicidal lamps aren\u2019t safe for humans to be around.\n\u201cWe don\u2019t see cost as being a limiting factor here.\u201d\n\nUVC lamps could also have potential implications in clinical settings, as well \u2014 in the operating room during surgeries, for example.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "While the story didn\u2019t offer much more than what was stated in the news release, it does appear to contain original quotes.", "answer": 1}, {"article": "According to the Centers for Disease Control and Prevention, about 610,000 Americans die of heart disease each year, accounting for 1 in 4 deaths.\nA government panel of experts released updated guidelines today spelling out who should be taking a daily low-dose aspirin for heart health, which also offers the added benefit of protection against colorectal cancer.\nThose who would benefit from the regimen, according to the U.S. Preventive Services Task Force, must meet a strict list of criteria -- including a high risk of heart disease and a low risk of bleeding side effects.\nAt this time, the task force reports that more research is needed to assess whether taking aspirin is beneficial for people who are younger than 50 or those who are 70 and older.\n\"The task force recommends that all patients talk to their doctor to evaluate their risk for cardiovascular disease and bleeding before making a decision about aspirin use, but this is particularly important for people in their 60s,\" Bibbins-Domingo said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "While there were some passages in the story that read very similar to the news\u00a0release, because this included an original interview, it rates as Satisfactory, though just barely.", "answer": 1}, {"article": "Essential fatty acids are substances that are not produced by the human body and are only available from diet.\nThe study, published Monday in the journal Reproductive Health, found that taking capsules containing about 1 gram of a blend of three essential fatty acids produced a significant reduction in PMS symptoms.\nAccording to the study, the 120 women who participated reported few side effects, and most of those were mild and may have been due to sensitivity to mineral oil, the placebo taken by some of the participants.\nThe study, authored by researchers from the Federal University of Pernambuco, is not the first to address the possible link between PMS and essential fatty acids, substances that play a complicated role in a woman's reproductive system.\nAccording to the study, women who took the supplements for six months saw a bigger benefit than those who took them for three months.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story shows no sign of original reporting and may have relied largely on a release. But since we didn\u2019t find a news release, we\u2019ll rule this Not Applicable.", "answer": 2}, {"article": "RELATED: What we know about how cancer starts could all be wrong\n\nIn January 2013, nearly four months after Landon\u2019s initial diagnosis, the two went from Utah to Colorado, where Riddle purchased an alternative treatment fraught with complicated politics and plenty of skepticism\u2014especially when it comes to saving the life of a preschooler with a potentially fatal disease.\nBut Landon appeared to be among a small percentage of children with leukemia for whom the treatment was unbearable, excruciating.\nShe was willing to do whatever it took to keep him on cannabis.\nThe chemo had compromised his immune system so severely that he caught every bug in the hospital, just about every strain of stomach viruses, influenza and the common cold.\n(Due to HIPAA patient privacy laws, Children\u2019s Hospital Colorado was unable to comment on Landon\u2019s case for this story.)\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes multiple sources and appears to be original reporting.", "answer": 1}, {"article": "Aromatase inhibitors block an enzyme that the body needs to produce estrogen.\nExperts said the study was significant because some women and their doctors choose to continue aromatase inhibitors past the standard five years.\nDr. Debra Patt, a breast cancer specialist at Texas Oncology who was not involved in the study, called the difference of a few percentage points in the risk of recurrence (95 percent vs. 91 percent) \u201csubstantial.\nThe trial included 1,918 postmenopausal women who had what\u2019s called hormone-receptor positive breast cancer, in which the hormones estrogen or progesterone fuel the proliferation of cells.\nThe study did not continue long enough to discover whether the lower risk of developing cancer in the opposite breast translated into a lower risk of death.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story had interviews with independent sources and does not appear to be copied from a news release.", "answer": 1}, {"article": "A study shows that not all good fats are the same when it comes to protecting your health\n\nA study shows that not all good fats are the same when it comes to protecting your health.\nReviewing the dietary advice as a whole is important, says Alice Lichtenstein, a spokesperson for the association, since changes in one area could have unexpected, and potentially harmful, effects on other eating habits.\nThe latest results, however, raise questions about that advice.\nRamsden says the findings provide some refined understanding of unsaturated fats, which come in different chemical forms that may have varying benefits or risks.\n\u201cJust looking at one individual component puts undue emphasis on that component, and may lead to unanticipated consequences.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story has enough original reporting that we can be sure it wasn\u2019t based on a press release.", "answer": 1}, {"article": "Heart researchers have long known that plaques in coronary arteries start out as pimplelike bumps but get waxy and hard and filled with calcium as time passes.\nAccording to today\u2019s guidelines, half had risk scores high enough that a statin would be recommended or should be considered.\nIt turned out that the actual incidence of heart attacks or disabling chest pain in those with zero calcium was half or less than what the risk calculator predicted.\nDr. Nasir said he has been using the study\u2019s findings in his clinic.\nAll had heart scans, and half had no calcium visible on the scans.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story clearly does not rely on a news release.\u00a0There is original reporting that includes feedback from the original authors of the paper as well as independent experts.", "answer": 1}, {"article": "Visit the U.S. National Cancer Institute for more on aspirin and cancer risk.\nMoreover, the benefit of aspirin in reducing overall cancer risk appeared to depend on how much one took.\n\"The results of ongoing research to develop more tailored treatment based upon a personalized assessment of risks and benefits is critical before recommending aspirin for preventing cancer,\" she said.\nSpecifically, no link was found between aspirin use and a lower risk of breast cancer, advanced prostate cancer or lung cancer, the researchers said.\nThe benefit was no longer seen within four years of stopping it, the researchers found.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story rates a Satisfactory because it clearly went beyond both the American Association of Cancer Research news release\u00a0and this news release from the Harvard School of Public Health. However, it\u2019s equally clear that these news releases and the conference presentation were the primary basis for the story. As noted above under the Novelty criterion, we think a story that provided \u00a0a broader, more inclusive view of the evidence would been more useful to readers.", "answer": 1}, {"article": "Trials of that vaccine in people, which is also based on man-made copies of virus proteins, began on August 2, when the first study volunteer was given a vaccination through a needle free injector, said Dr. Anthony Fauci, head of the National Institute for Allergy and Infectious Diseases.\nThe protein/cold virus vaccine was especially effective, sparking a significant immune response after just one dose.\nThe results were \u201cstriking,\u201d said study coauthor Dr. Dan Barouch, a professor of medicine at Beth Israel Deaconess Medical Center and Harvard Medical School.\nThis kind of vaccine is much safer than ones that depend on live virus particles to foster immunity.\nRight now, just one of those three vaccines will be progressing to clinical trials.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The news story does not appear to be based on a news release.", "answer": 1}, {"article": "If green coffee extract were a medication seeking approval from the Food and Drug Administration, these results would make it a viable candidate \u2014 more than 35% of subjects lost more than 5% of their body weight, and weight loss appeared to be greater while subjects were taking the pills than when they were on the placebo.\nThe pilot study drew strong cautions from several scientists who weren't involved in the research.\nOf the 16 volunteers, six wound up with a body mass index in the healthful range.\nThere were no signs of ill effects on any subjects, Vinson reported Tuesday.\nThe trial was conducted in India and paid for by Applied Food Sciences Inc. of Austin, Tex., a manufacturer of green coffee bean extract.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because of the strong independent perspectives used, it\u2019s clear the story did not rely solely on a news release.", "answer": 1}, {"article": "Published in the New England Journal of Medicine, the study found that, among uninfected women, Gardasil 9 was 97 per cent effective at preventing high-grade cervical, vulvar and vaginal disease caused by HPV 31, 33, 45, 52 and 58, and was equally effective as the current Gardasil vaccine in preventing diseases caused by HPV 6, 11, 16 and 18.\nThe new vaccine, Gardasil 9, is not only safe but will offer greatly improved protection against cervical and other cancers.\nThe new vaccine offers significantly greater protection than the current vaccine, which protects against only two cancer causing types of HPV.\nUntil late last year, there were two available vaccines to protect against HPV related disease (Cervarix and Gardasil).\nThe development of the new Gardasil 9 vaccine makes an important step in that direction.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Quotes from Dr. Cuzik are enthusiastic but could not be described as unjustified. He says, \u201cThis is a significant achievement. The new vaccine, Gardasil 9, is not only safe but will offer greatly improved protection against cervical and other cancers. Eventually this will mean less screening is needed, as women will have greater protection from the outset.\u201d\u00a0\u00a0We\u2019d add that while his statement may be accurate, the promise of the vaccine will only be achieved with higher vaccination rates\n\u00a0", "answer": 1}, {"article": "Jamie Stagl worries that women with breast cancer don\u2019t get enough help coping with their diagnosis.\nIf a woman\u2019s stress level remains high indefinitely after diagnosis, she may have a worse outcome than if she can bring it back down, Stagl said.\nThe positive results surprised even Stagl.\n\u201cThis is really a teachable moment.\u201d\n\nThe skills taught in the course are useful at many stressful moments, Porter said, not just when cancer is diagnosed.\nStagl doesn\u2019t know whether the women are still using the techniques they were taught \u2014 which include mindfulness, deep breathing, visual imagery, cognitive behavioral therapy, and learning how to ask for help from friends and family.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The reporter went beyond the material in the news release.", "answer": 1}, {"article": "The test, called a liquid biopsy, screens for cancer by detecting tiny bits of DNA released by cancer cells into blood.\nResearchers said their results showed promise in the approach of blood screenings for cancer, but noted further \u201cclinical development\u201d was needed.\nThe test was most accurate for diagnosing pancreatic, ovarian, liver and gallbladder cancers, correctly finding the diseases in at least four out of five patients.\nResearchers hope the test will become part of a \u201cuniversal screening\u201d tool that doctors can use to detect cancer in patients.\nProf Nicholas Turner from the Institute of Cancer Research in London described the findings as really exciting and as a possible universal screening tool.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We couldn\u2019t find a related news release. Because the story includes quotes from people not affiliated with the study, we think it\u2019s safe to assume the story didn\u2019t rely on one.", "answer": 2}, {"article": "... Then a lot of guys eventually were like, 'I'll go.\n\"To a certain extent, I was surprised by the magnitude of the effect of the intervention,\" said Ciantel Blyler, a clinical pharmacist at Cedars-Sinai Medical Center in Los Angeles who was a co-author of the study.\nAdditionally, more research is needed to determine whether similar study results would occur on a national level, since the study was conducted only in the Los Angeles area.\nAs a blood pressure monitor squeezed snugly around his arm, the pharmacist counseled Thomas, 49, on his diet and stress level while checking his blood pressure.\nShe then helped Thomas find a medication better suited for his body.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This does not appear to rely on a news release.", "answer": 1}, {"article": "Images on paint can display on the left, a cancer free mouse; image on right illustrates how the tumor paint shows cancerous cells even after the cancerous organ has been removed.\n\nWhen treating cancer with surgery, there's nothing as important as making sure that every last bit of the disease has been removed. That's not always possible, since tumors have nasty habits of embedding themselves within healthy tissue and of breaking away and spreading malignancies to other parts of the body. But Researchers at Seattle's Fred Hutchinson Cancer Research Center have come up with an innovative way of giving surgeons the upper hand against these wily tumors. They have created a molecular \"paint\" that coats cancer cells so doctors can see the wayward cells that they may otherwise miss.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if the story relied largely or solely on a news release, but it is clear that the story quotes only one researcher from only one hospital. ", "answer": 2}, {"article": "Dr. David Rosenstreich, director of the division of allergy and immunology at Montefiore Medical Center in New York City, added: \"An objective and fast test for diagnosing asthma would be helpful, and this test seems to be a non-invasive way of sampling for the underlying problem.\nThe electronic nose was able to correctly differentiate healthy people from those with physician-diagnosed asthma in 87.5 percent of the cases.\nEach test is non-invasive, requiring only the use of exhaled air.\nTo do this, all of the study volunteers were given all three tests.\nThose with asthma had a history of allergies, and none had been treated with corticosteroids for at least four weeks prior to the start of the study.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that this story wasn\u2019t based exclusively on a news release.", "answer": 1}, {"article": "Being around for my daughter, my son, my wife.\nSandoval is alive today because of an experimental form of immunotherapy called CAR-T.\nAbout eight months after a single treatment, 39 percent of patients had no evidence of cancer.\nDespite chemotherapy and a stem cell transplant, the cancer returned before his daughter\u2019s first birthday.\n\u201cThat\u2019s actually quite remarkable knowing that at best only one out of 10 of these patients could have complete disappearance of their lymphoma with standard chemotherapy,\u201d Locke said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There are interview quotes from a patient and a researcher that do not appear in the company news release.", "answer": 1}, {"article": "Surgical removal of cancerous tissue also can spur the spread of cancer in the body.\n\u201cThis method is effective for both diagnosing and treating metastasis cancer and can be used in combination with traditional chemotherapy and radiation therapy,\u201d he added.\n\u201cSo the cancer trap is really complementary to current cancer treatments and especially beneficial at the early stages when it is difficult to see if the cancer is spreading as there are few cancer cells.\nThis cancer trap can be used for early diagnosis and treatment of metastasized cancer.\nWe have also found it very effective in late stage cancers to stop the spread of the disease and to prolong lifespan,\u201d he added.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release tells readers that \u201cThis cancer trap can be used for early diagnosis and treatment of metastasized cancer.\u201d The release also says \u201cThis method is effective for both diagnosing and treating metastasis cancer and can be used in combination with traditional chemotherapy and radiation therapy\u201d and \u201cWe have also found it very effective in late stage cancers to stop the spread of the disease and to prolong lifespan.\u201d Those are bold statements. But the release provides no information to support them and in fact raises doubt about their veracity when they state that no clinical trials have been done. Instead, the release also includes language that raises questions about the extent to which anyone knows how well the technology will perform in human patients. If the researchers have evidence that this technology is a significant advance for cancer diagnosis and treatment, the release doesn\u2019t share it. While it may be interesting and newsworthy that a patent has been issued for this idea, this type of coverage is misdirected. It would be better covered in a brief report that states that the patent have been issued based on the hypothesis and suggests next steps in research.", "answer": 0}, {"article": "With the FDA's announcement, drugs like pembrolizumab have also begun to change the way that physicians, patients and government regulators think of cancer. No longer will they see all cancers of the lung, breast, colon, brain, liver, pancreas and prostate as distinct from one another. Instead, they will look for the common genetic mutations that give rise to cancers no matter where they're found. And they'll treat those cancers with a drug that uses that common signature as a homing beacon, either for the immune system or for targeted cancer drugs to attack.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story appears to include original reporting.", "answer": 1}, {"article": "Food sources of vitamin D include milk, breakfast cereals and orange juice fortified with vitamin D, as well as some fatty fish, like salmon and mackerel.\nThe findings, Laaksi said, offer \u201csome evidence\u201d of a benefit from vitamin D against respiratory infections.\nLaaksi said that larger clinical trials looking at different doses of vitamin D are still needed before the vitamin can be recommended for curbing the risk of respiratory infections.\nSome researchers believe that people need more vitamin D than is currently recommended, and that intakes above 2,000 IU per day are safe.\nOn average, men who took vitamin D missed about two days from duty because of a respiratory infection, compared with three days in the placebo group.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story quotes an e-mail exchange with the lead researcher, so it\u2019s clear it didn\u2019t rely solely on a news release. ", "answer": 1}, {"article": "\u2018What insanity is that?\u2019 Hundreds of NC children are being killed or injured by guns.\n\nDid you realize that in the past five years, hundreds of teens and youth have been killed or hurt by gunfire in North Carolina? Here\u2019s what some say you can do about it.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "No obvious reliance on a press release.", "answer": 1}, {"article": "Medtronic Inc. and Eli Lilly & Co. agreed to collaborate on an early stage research project for a potential Parkinson's-disease treatment that involves delivering medication directly to the brain\u2014a goal that has long eluded drug makers.\n\nThe pact, announced Tuesday, adds to Medtronic's roster of projects aimed at using implantable drug pumps and catheters to circumvent the blood-brain barrier. The tightly packed network of cells in brain capillaries only lets certain substances through, such as key nutrients, making brain-based...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story didn\u2019t rely solely on a news release.", "answer": 1}, {"article": "When his heart disease was first diagnosed four and a half years ago, Mr. Del Sontro, now 50, told his cardiologist he wanted to run one more Bay to Breakers race, a century-old 12-kilometer race in San Francisco.\nDr. Biesecker acknowledged that there was no guarantee of success.\nThat strategy alone, Dr. Biesecker said, has eliminated the vast majority of candidate genes.\nStill, Mr. Del Sontro is preparing for the worst.\nResearchers\u2019 ignorance of these control regions and what many of them do might doom the effort.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is enough original reporting here that we can be sure the story wasn\u2019t based on a press release.", "answer": 1}, {"article": "Joslin has one of the largest diabetes training programs in the world, educating 150 M.D.\n\u201cThe results clearly remove any doubts about anti-VEGF drugs\u2019 efficacy in treating DME.\nOne year after starting treatment, all participants had improved vision.\nPhysicians now have robust data to help them counsel patients and make informed decisions regarding treatment options,\u201d says study co-author Lloyd P. Aiello, M.D., Ph.D., Professor of Ophthalmology at Harvard Medical School, Director of Joslin\u2019s Beetham Eye Institute, co-head of Joslin's Section of Vascular Cell Biology, and founding chair of the DRCR Network.\nAt the start of the trial, 660 adults with DME were enrolled: their average age was 61 years and 90 percent had type 2 diabetes.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "No claims that do not appear in the original paper are made in the release.", "answer": 1}, {"article": "\"Pecans are naturally high in monounsaturated and polyunsaturated fats, so replacing a portion of the saturated fat in the diet with these healthier fats can explain some of the cardio-protective effects we observed,\" said lead researcher, Diane McKay, Ph.D. \"But pecans also contain a number of bioactive plant compounds as well as vitamins and essential minerals that all likely contributed to this benefit.\nIn this placebo-controlled crossover study of 26 men and women (average age 59 years), all meals were provided to carefully control their food intake.\nThe study was funded by the National Pecan Shellers Association.\nBoth the control diet and the pecan-rich diet were low in fruits, vegetables and fiber.\nWhile a growing body of evidence has linked tree nuts such as pecans to reduced risk of CVD, this is the first study to look at the effects of pecan consumption on factors other than blood lipid levels and specifically those related to T2D.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We did not find unjustifiable language.", "answer": 1}, {"article": "But from other research \"we know it's safe to place an electrode in the nucleus accumbens, it's safe to stimulate it electrically, and we expect to be able to tune [the electrode] as we already do with DBS.\nPlus, the treatment seemed specific to the food addiction.\nTrouble is, the moderation wore off in a few days, and the DBS also interfered with the animals' social behavior.\nThe current study used a brain stimulation device already approved for hard-to-treat epilepsy.\nThat got Halpern thinking about a newer system \u2014 one that doesn't stimulate continuously, like DBS, but switches on briefly only after sensing a trouble signal, much like a pacemaker monitors and responds to abnormal heart rhythms.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article did include one source not directly involved with the research.", "answer": 1}, {"article": "No question,\u201d he said.\nThe Phase II study included 173 women whose cancer had spread and who had received other treatments.\nThe best overall tumor response rate, of 20 percent, was in those given Erbitux.\nIt is the first time researchers have shown that a drug like Erbitux, which targets a protein called epidermal growth factor involved in cancer cell growth, can provide substantial benefit in difficult-to-treat \u201ctriple negative\u201d breast cancer.\nDr. Fabrice Andre from Institut Gustave Roussy in Villejuif, France, who was not involved in the research, said the results were \u201cextremely important\u201d but echoed the view that the findings now had to be confirmed in larger-scale clinical tests.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "", "answer": 1}, {"article": "Consumers can wake up with Red Bull and then wind down with Slow Cow.\nNow, the field includes a slew of new drinks promising a better night's sleep using such ingredients as melatonin, valerian root and - think turkey - tryptophan.\nThey're the inverse of energy drinks.\nOral doses of melatonin haven't worked much better at inducing sleep than a placebo in most studies, Scharf says, and a single, concentrated shot of the stuff doesn't exactly mimic the body's time-release system.\nThe back of the Snooz'n bottle says the beverage will \"combat stress, energy drinks and sleeplessness\" and takes about 30 minutes to take effect.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story wasn\u2019t based on a news release.", "answer": 1}, {"article": "J Natl Cancer Inst.\nThese key benefits of 3D MAMMOGRAPHY\u2122 could lower the costs associated with needless follow-up exams, and improve patient experience for women seeking a more accurate screening mammogram.\nThere can be no assurance the systems will achieve the benefits described here, or that such benefits will be replicated in any particular manner with respect to an individual patient.\n\"This new analysis confirms that Genius\u2122 3D MAMMOGRAPHY\u2122 exams reduce unnecessary follow-up exams in dense-breasted women.\nThis has the potential to provide health systems and insurance companies with significant cost savings, reduce patient stress and expenses, and alleviate challenges for referring physicians who are tasked with relaying mammography results to their patients.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "While the release generally uses appropriate language, we\u2019re flagging it for the claim that \u201can estimated 10 million women in the U.S. benefited from a Genius exam.\u201d Even if 10 million women received exams, not all of them benefited. We think the release should have included some backup for a claim this bold.", "answer": 0}, {"article": ".\nDiagnostic Photonics, a start-up company Boppart co-founded that also collaborated on the study, is commercializing the OCT probe technology for broader use.\nThe researchers will continue clinical studies with the OCT device, looking at other types of solid-state tumors.\nThe National Institutes of Health supported this work.\nThe diagnosis is made based on subjective interpretation and often other pathologists are consulted.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Pretty careful narrative prose.", "answer": 1}, {"article": "First, help with work or school such as assistance in deciding which classes or opportunities are most appropriate, given a person\u2019s symptoms.\nThe team recruited 404 people with first-episode psychosis, mostly diagnosed in their late teens or 20s.\nOver two years, both groups showed steady improvement.\nAbout half got the combined approach and half received treatment as usual.\nThe gains for those in typical treatment were apparent to doctors, but much less obvious.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story shows original reporting and does not rely on a news release.", "answer": 1}, {"article": "For instance, it only became apparent after about five years for esophageal, pancreatic, brain, and lung cancer; about 10 years for stomach and colorectal cancer; and about 15 years for prostate cancer.\nThe investigation also showed that the benefits of taking aspirin increased over time.\nThe study looked at eight trials examining the effects of a daily dose of aspirin on preventing heart attacks involving 25,570 patients, 674 of whom died from cancer.\nA previous study by the same authors showed that low doses of aspirin (75-300 milligrams) reduced the number of cases of colorectal cancer by a quarter and deaths caused by the disease by more than a third.\nThe latest study confirms the earlier results and concludes that similar effects can be shown for other types of cancers.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story does not appear to rely on a news release.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061015/23addict.b.htm was not found on this server.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because two independent sources were quoted, it is unlikely this story was based solely or largely on a news release. ", "answer": 1}, {"article": "Atrial fibrillation is a common heart abnormality that affects nearly 3 million American adults.\nThat's true even for people at low risk of a stroke who wouldn't normally be given blood thinners.\nThe longer the delay in giving blood thinners, the more the risk for dementia, the researchers said.\nThis study shows that treatment delays of even one month can greatly increase the incidence of cognitive [mental] decline,\" Lee said.\nThe researchers said that the key is to start blood thinners, such as warfarin, soon after atrial fibrillation is diagnosed.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The reporter clearly sought out at least one additional source, so there is evidence of enterprise here.", "answer": 1}, {"article": "Graphic artist Colleen Kelly decided in 2000 that she had nothing to lose by enrolling in an experimental study of VNS.\nA report by Harvard Pilgrim Health Care, an influential mental health insurer in Boston, called it \"experimental, investigational and unproven.\"\nBecause that study lacked a control group and because patients received other depression treatments after the device was implanted, there is no way to know whether the device was responsible.\nThe St. Louis resident credits the implant he received five years ago with saving his life.\nRobert \"Skip\" Cummins, Cyberonics's CEO, dismissed such criticism and said his company, whose sole product is VNS, faced similar skepticism after the device was approved for epilepsy in 1997.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no evidence that this story relied on a news release. ", "answer": 1}, {"article": "Unlike the 2012 campaign, which aired for 12 consecutive weeks, the 2014 campaign aired in two phases, from February 3 to April 6 and from July 7 to September 7.\nThe website includes detailed assistance developed by the National Cancer Institute to support smokers trying to quit.\nTips ads encourage smokers to call 1-800-QUIT-NOW or to visit www.cdc.gov/tips to view the personal stories from the campaign.\nThose new ads featured people and their struggles with smoking-related health issues, including cancer, gum disease, premature birth, and stroke caused by smoking combined with HIV.\nWith a year-round campaign we could save even more lives and money.\u201d\n\nTips, the first federally funded anti-smoking paid media campaign, features former smokers talking about their smoking-related illnesses.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "This one is borderline. We understand what the CDC is trying to accomplish, and we sympathize with its goals. However, if a release is going to include a phrase like the one in a quote that says Tips is \u201cextremely cost-effective and a best buy,\u201d it should provide the numbers to back that up. That said, there is nothing completely over-the-top here, and the vast bulk of the language \u2014 including the headline and lead paragraph \u2014 are written responsibly. Ergo, the satisfactory rating. The quote from the co-author most misrepresents the actual study findings.", "answer": 1}, {"article": "Seattle researchers found that those who received either relaxation massage or structural massage, which involved manipulation of muscles and ligaments, had less pain and better functioning for up to a year compared to those getting \"usual medical care,\" which included medication and physical therapy.\nThe cost of SMT sessions varies widely depending on the region, Perle said.\nMore than 6,000 patients were included in the compilation of results, which the study authors said were sparse in data indicating participants' overall recovery, quality of life and ability to return to work.\n\"With low back pain, there are many reasons people don't get better,\" added Perle, also a professor of clinical sciences in the College of Chiropractic at the University of Bridgeport in Connecticut.\nBut which treatment is right for any patient depends not only on their specific pain, but their doctor's recommendations and their own comfort level with various options, said Stephen Perle, a spokesman for the American Chiropractic Association.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article did not appear to rely on a news release.", "answer": 1}, {"article": "This patient appears to have a fully functioning immune system, they found, which appears genetically identical to cells from the donor \u2014 not the patient\u2019s own immune cells.\nSchneider\u2019s team found no evidence of HIV anywhere.\nSchneider\u2019s team has been following the patient, taking samples from his colon, liver, spinal fluid and brain as he developed various conditions that justified the tests.\n\u201cOur results strongly suggest that cure of HIV has been achieved in this patient,\u201d they wrote in the journal Blood.\nIt requires destruction of a patient\u2019s own bone marrow \u2014 itself a harrowing process \u2014 and then a transplant from a donor who has a near-exact blood and immune system type.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not rely on a news release.", "answer": 1}, {"article": "Among parents of children with autism, Mr. Frank said, \"some will say, 'Come on, who are you kidding?'\nThe Children's Institute plan would be taking what is arguably a fringe movement into the mainstream: It would be the first autism treatment of this kind staged in an American hospital setting.\nWith roots in autism treatment theories that until now have lived mostly on the Internet, the pediatric clean room plan would be the first of its kind in a mainstream American hospital environment.\nBasically, it would be pushing a \"reset\" button on the child's body, with the hope of wiping autistic symptoms away.\nWith so many doubts -- and so few answers -- about effective autism treatments among the growing community of families affected by the condition, the institute said openness is vital to the experimental method's success.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It is not clear if the story relied largely on a news release, but it is clear that the story is dominated by the perspective of only the lead investigator.\u00a0 ", "answer": 2}, {"article": "Most people turning to surgery for weight loss are probably concerned with how many pounds they can expect to shed.\nThe cost of the surgery was about $30,000, which exceeds the savings observed directly.\nAlso, at two years after surgery, data were available for less than half the patients.\nA year after surgery more than 80 percent of patients were no longer taking any of the diabetes medicines they had been on before the operations.\nThe costs were compared with the median annual health costs before surgery -- $6,367.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "1clip_filelist.xml\"/>\n\n\n\n \nAlthough it does not appear that anyone was interviewed for this story, it does include some information that was not included in the new releases from the Archives of Surgery and Johns Hopkins Medicine.\n\u00a0\nResources:\nArchives of Surgery article abstract:\nhttp://archsurg.ama-assn.org/cgi/content/abstract/145/8/726 \nArchives of Surgery release:\nhttp://pubs.ama-assn.org/homepage/media/2010a/0816.dtl#1\nJohns Hopkins Medicine release:\nhttp://www.hopkinsmedicine.org/news/media/releases/national_study_shows_weight_loss_surgery_frees_most_obese_type_2_diabetics_of_insulin_and_other_sugar_controlling_drugs\n\u00a0\n", "answer": 1}, {"article": "\u201cSometimes serious addiction needs to be coaxed down the stairs one at a time, not thrown off the top floor,\u201d said Dr. Abrams, who was not involved in the study.\nStill, some researchers not involved in the study said the topic required more work.\nThe study was funded by Pfizer, the drug company that makes Chantix, a treatment that costs about $250 a month.\nAbout 1,500 patients at 61 clinics in the United States and abroad participated in the study.\nIf such studies were funded by the government, which sustains a lot of academic research, taxpayers would bear the burden for what the company would eventually profit from, he said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes quotes from sources that are not included in JAMA\u2019s news release on the journal article.", "answer": 1}, {"article": "It\u2019s easy to get into the habit of popping a pill to have a good night\u2019s sleep. Insomnia, which affects a third of adults, becomes more common as we age.\n\nBut as evidence has mounted about the risks of drugging the brain to induce or maintain slumber, more doctors are steering patients away from sleep aids, including over-the-counter medications, and are offering innovative behavioral-change solutions.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "During the luteal phase, estrogen and progesterone levels are at their highest, which may help a woman keep addictive cravings at bay and reduce feelings of cigarette withdrawal.\nThey called for more studies to help understand all the factors that contribute to sex and gender differences in smoking.\nNone of the study participants were enrolled in a smoking cessation program or were trying to quit.\nThe brain scans showed that during the follicular stage, cigarette imagery activated five areas of the brain which the researchers say are linked to higher-level cravings.\nResearchers asked each participant to smoke one cigarette 30 to 40 minutes before undergoing an fMRI, or brain scan.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The spin that\u2019s prevalent in this story probably originated with this press release headlined, \u201cWomen, quitting smoking for New Years? Time it with your period!\u201d However, the story includes quotes from the original study, so it appears that the press release was not the only source of information used for the story. We\u2019ll call this satisfactory.", "answer": 1}, {"article": "The requested URL was not found on this server. That\u2019s all we know.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a press release. ", "answer": 1}, {"article": "The biopharma company Amarin is making some heart-medicine history Monday with its proprietary, prescription formulation of fish oil, called Vascepa.\n\nIn a stunning clinical trial result that upends years of skepticism about the long-term heart benefit of products containing omega-3 fatty acids, Amarin\u2019s Vascepa significantly reduced the risk of deaths, heart attacks, strokes, and other serious cardiovascular events compared to a placebo.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story relies on a news release from the company that produces Vascepa. Although some cautionary comments and quotes are included, this story is not really about the results of a trial of Vascepa (which the company has yet to fully release), but only about a news release and company statements that make claims about trial results. This case illustrates how it is impossible to do a good job reporting on a drug trial when the sponsors do not release critical details of the trial.", "answer": 0}, {"article": "(Reuters Health) - Exposing sleeping people to a series of short flashing lights at night might help them adjust more quickly to time zone changes, according to a new U.S. study.\nIn a previous study, the short flashes of light at night did not interrupt sleep or reduce its quality, he added.\n\u201cFor moving your system to an earlier time, such as would be necessary when traveling West-to-East, light during the last few hours of the night is ideal.\u201d\n\nThe night flashes require special technology and equipment, beyond just a smartphone, which are still in development, Zeitzer said.\n\u201cHowever, the treatments that are developed for jet lag can be used for less prevalent, though far more significant societal problems including delayed sleep in teens (in whom we have an ongoing clinical trial using the flash technique) and shift workers who try to flip between a night time schedule for work and a day time schedule for leisure,\u201d he told Reuters Health by email.\n\u201cThis clock remains synchronized with the external day through regular exposure to light.\u201d\n\nNighttime flashes change the timing of the circadian clock, he said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Given the helpful comments from an outside (not involved in the study) researcher, we would say the report did not substantially rely on a news release.", "answer": 1}, {"article": "\"It's a very important trial,\" added Dr. Angeles Alvarez Secord, associate professor of gynecologic oncology at Duke Comprehensive Cancer Center in Durham, N.C. \"I've been using [the IUD] clinically for several years now for this purpose in patients who desire future fertility and some patients who cannot undergo surgery or who are at high risk for surgical complications.\nBakkum-Gomez has also used the method in her practice and is conducting a study of the IUD, which was originally designed as a contraceptive device, for this purpose.\nNine of the women in the study successfully delivered babies.\nThe IUD was removed at the end of the year if there was no evidence of cancer.\nIn background material, the researchers stated the progestin-releasing IUD should be effective in treating AEH and also early endometrial cancer, as long as those patients were evaluated with laparoscopy, ultrasound and MRI to make sure their cancer had not spread and there was no simultaneous ovarian cancer.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story quotes several independent experts, the reader can assume that the story did not rely on a press release as the sole source of information.", "answer": 1}, {"article": "Powers said, \"I think what's going to happen is that we will develop systems of rapid triage and rapid transport.\nAll of these studies showed that the device can safely and effectively stop a stroke by removing blood clots, he added.\nThe major risk of using the device is that it could tear an artery and cause bleeding in the brain, particularly since it will be used on people who have already received very potent blood thinners, Kandzari said.\nThe procedure must start within six hours of the onset of a stroke, which means that emergency teams and hospitals will have to move fast, Powers said.\nThat last point is especially important, because the stent retrieval device will not fit into the smaller blood vessels that branch out further into the brain, Powers said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story quotes the author of the guidelines, and one other expert who is not an author. It does not rely solely on the news release.\n\u00a0", "answer": 1}, {"article": "Among the 88 participants with moderate-to-severe disease who were given intravenous infusions of either teprotumumab or a dummy drug every three weeks for eight treatments, 43 percent who got the real drug had a reduction of at least 2 millimeters in eye protrusion by the sixth week compared to 4 percent in the placebo group.\nThe typical treatment for Graves\u2019 eyes is glucocorticoids, which are not always effective and also have side effects, the study team notes.\nThis eye condition usually lasts one to two years and often improves on its own, according to NIDDK.\nThe duration of response to the autoimmune inflammatory disease, along with the quick response to initial therapy, suggests fewer infusions may be just as effective, \u201cbut future studies will sort that out,\u201d Smith said.\n\u201cIn virtually all the responders, the changes are frequently what anyone would call dramatic,\u201d said lead study author Dr. Terry Smith of the University of Michigan Medical School in Ann Arbor.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There\u2019s no evidence that the story relied solely on a news release.", "answer": 1}, {"article": ".\nThe control group, however, had no clinically relevant alterations in their microbiota composition, Luzi said.\nLuzi said scientists now know that an impaired gut microbiota can alter the brain's signals for appetite and satiety, or fullness.\nHe and his co-workers studied whether dTMS could improve the gut microbiota composition in obese persons and, if so, by what underlying mechanisms.\nResults of the fecal analysis demonstrated that, after five weeks, dTMS-treated subjects had greatly increased quantities of several beneficial bacterial species with anti-inflammatory properties, such as are found in healthy people.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Though the release does take liberties in stating the conclusion of the study, it stays away from sensational language about the dTMS and its potential role in weight loss and microbial changes.", "answer": 1}, {"article": "Reductions were seen of 35 percent at 10 weeks, and just over 22 percent at one year, for those given real acupuncture, compared with 24.5 percent and 5 percent, respectively, for those given sham acupuncture, the researchers said.\nHowever, although taking less pain medication, acupuncture patients were using higher levels of antidepressants after one year, which may have artificially boosted the positive results, he said.\nStill, Shrikhande said, \"the findings in this study help demonstrate that acupuncture is a safe and effective treatment for chronic pain patients.\"\nThe condition affects up to 5 percent of the population, Vas said.\nAccording to the study authors, nine out of 10 patients try some form of alternative therapy, such as massage or acupuncture, in addition to their regular pain medication.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is enough original reporting here that we can be confident the story is not based on a news release.", "answer": 1}, {"article": "Kite Pharma is racing to get the first FDA approval of an experimental gene therapy to fight cancer.\n\nAn experimental gene therapy that turns a patient\u2019s own blood cells into cancer killers worked in a major study, with more than one-third of very sick lymphoma patients showing no sign of disease six months after a single treatment, its maker said Tuesday.\n\nIn all, 82 percent of patients had their cancer shrink at least by half at some point in the study.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story included the perspective of one independent source and did not appear to rely heavily on the news release.\n\u00a0", "answer": 1}, {"article": "But at this stage, the company itself has been careful not to promote its device directly to consumers since its F.D.A.\nBut doctors are free to use devices off label. )\nThat said, a doctor with a Zeltiq device isn\u2019t hard for patients to find.\nMs. Bonvouloir hasn\u2019t given up on Zerona.\n(His partner, Dr. David J. Goldberg, was an investigator for Zeltiq.)\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not draw from a news release. ", "answer": 1}, {"article": "Atrial fibrillation also increases the risk for dementia.\nDuring the study, more than 26,000 of the 440,000 participants, all with atrial fibrillation, were diagnosed with dementia.\nHowever, the findings show that people with atrial fibrillation should start taking blood thinners as soon as possible after their diagnosis and continue to take the drugs, Friberg noted.\nThe findings strongly suggest that blood thinners reduce the risk for dementia in people with atrial fibrillation, but proving that would not be possible, the Swedish researchers said.\nWhen the researchers focused on people who continued to take the drugs, they found an even larger reduction (48 percent) in the risk for dementia.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Several quotes are taken directly from this European Heart Journal news release. While the story acknowledges the source of the quotes, it doesn\u2019t seek out any outside voices or perspectives to complement the coverage. The predictable result is a relatively weak and unbalanced story.", "answer": 0}, {"article": "\u201cThe increased levels of testosterone explain the greater reported sexual satisfaction,\u201d he said.\nFagiolini\u2019s team recruited 38 men diagnosed with either hypoactive sexual desire disorder or sexual arousal disorder \u2013 both characterized by a lack of interest in sex.\nBut after treatment, the group exposed to the bright light was scoring sexual satisfaction scores of around 6.3.\n\u201cBefore treatment, both groups averaged a sexual satisfaction score of around 2 out of 10.\nIn contrast, the control group only showed an average score of around 2.7 after treatment.\u201d\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story relies very heavily\u00a0on a news release from the European College of Neuropsychopharmacology, but doesn\u2019t cite it.\nFor example, several quotes appear in both the news story and the news release:\nA quote in the story:\n\u201cThe increased levels of testosterone explain the greater reported sexual satisfaction,\u201d he said. \u201cIn the Northern hemisphere, the body\u2019s testosterone production naturally declines from November through April, and then rises steadily through the spring and summer with a peak in October.\u201d\nwas also in the news release as:\n\u201cThe increased levels of testosterone explain the greater reported sexual satisfaction. In the Northern hemisphere, the body\u2019s Testosterone production naturally declines from November through April, and then rises steadily through the spring and summer with a peak in October.\u201d\nThe reliance on the news release extended to passages in the story that weren\u2019t quotes, such as this statement:\n\u201cLow sexual desire affects significant numbers of men after the age of 40, with studies finding that up to 25% of men report problems.\u201d\nWhich appeared in the news release as:\n\u201cLow sexual desire can affect significant numbers of men after the age of 40, with studies finding that up to 25 percent of men report problems.\u201d", "answer": 0}, {"article": "Older age and African-American race are risk factors for colon cancer, and there is evidence linking obesity and a sedentary lifestyle to the disease as well.\nHenderson\u2019s team also found that the beneficial effect of HRT was stronger among women who had had a first-degree relative diagnosed with colon cancer.\nFamily history of colon cancer is an established risk factor for the disease, but only one study, according to Henderson\u2019s team, has looked at whether family history affects the link between HRT and colon cancer risk \u2014 and it found no evidence that it did.\nThe findings, reported in the American Journal of Epidemiology, support the theory that estrogen offers some protection against colon cancer.\nBut they point to a need for further study into the different effects of HRT on specific organs, write the researchers, led by Dr. Katherine DeLellis Henderson of the City of Hope National Medical Center in Duarte, California.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There\u2019s no evidence that this story relied on a news release. ", "answer": 1}, {"article": "\"And I thought, 'If we could do that in people, this is going to be amazing.'\nAllison's treatment was still experimental, but if it worked, it had the potential to save Belvin's life.\nBelvin was the first recipient of the immunotherapy that Allison had ever met.\nWhat Belvin didn't know at the time was that a revolutionary treatment for melanoma had begun testing in clinical trials.\nAs it happens, Belvin was also in New York \u2014 a patient of Dr. Jedd Wolchok at Sloan Kettering.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release at all.", "answer": 1}, {"article": "Further,Dr.\nCrucially, this woman was in good health, suggesting that therapies aimed at blocking PCSK9 would not only be effective, but also safe.\nWe\u2019d exhausted the other options in trying to control his cholesterol.\u201d\n\nTwo months after he started his biweekly injections of the new drug, Mr. Brown\u2019s LDL cholesterol level was down to 111 \u2013 not quite normal, which is 100 or less \u2013 but an almost 50 percent reduction from the level it had been for years.\nDr. Cohen, Professor of Internal Medicine and with the McDermott Center, holds the C. Vincent Prothro Distinguished Chair in Human Nutrition Research.\nEven with this trio of medicines, Mr. Brown\u2019s LDL cholesterol level hovered around 200.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We would like to give the release a pass here, because we already dinged the release for the way it discusses cholesterol under \u201cDisease Mongering.\u201d However, we can\u2019t. Here\u2019s why: the release refers to this drug class as a \u201cgame-changer\u201d in its headline. What does that mean? Even accepting the fact that the headline says the drug was a \u201cgame-changer\u201d for only one patient, it\u2019s still pretty fuzzy. Did the drug lower the patient\u2019s LDL cholesterol to optimal levels? No, and the release itself says as much. Did the drug significantly reduce the patient\u2019s risk for future heart problems? It\u2019s not clear, because the release doesn\u2019t address that. If a release is going to use hyperbolic language \u2014 whether it\u2019s a \u201cgame-changer\u201d or a \u201cbreakthrough\u201d or a \u201choly grail\u201d \u2014 it needs to clearly lay out the results to back it up. That is not the case here.", "answer": 0}, {"article": "Finasteride blocks the conversion of testosterone to dihydrotestosterone, a hormone active mostly in the prostate and the scalp, and that all prostate cancers need to grow.\nThe reason was that the results were overwhelmingly compelling \u2014 men taking the drug were not getting prostate cancer.\nThe study researchers, though, wondered if that conclusion was correct.\nNow, though, prostate cancer specialists have a new problem: How can they change the drug\u2019s image?\nMaybe, they thought, by shrinking the prostate, the drug was just making it easier to find aggressive tumors.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "While there is no press release in evidence, it is curious that the journal in which the new analysis was published has a link to the New York Times article on the journal\u2019s website.\u00a0 Why would a journal do that?\u00a0 Isn\u2019t the journal article itself good enough for its readers?\u00a0 Does it need the Times to legitimize the study?\u00a0 Odd.\u00a0 ", "answer": 1}, {"article": "In the 1970s, the FDA required warnings on drugs containing progesterone, as 17-HP does, because of an increased risk of birth defects.\nInterestingly, the drug is not new \u2014 it's just taken a long and circuitous route to approval.\nThat's why it's a pretty big deal that the Food and Drug Administration has OK'd a drug, called 17-HP, that experts say could make a dent in the preemie problem.\nEveryone in this field is mindful of the long-running tragedy of vaginal and other cancers and male urinary disorders that resulted from the last drug thought to prevent premature birth \u2013 a synthetic estrogen called diethylstilbesterol, or DES.\nAnd even for the 30,000 or so women who are eligible, 17-HP, which will be marketed as Makena, isn't a magic bullet.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear the story didn\u2019t rely solely on a news release.", "answer": 1}, {"article": "The U.S. National Institute on Deafness and Other Communication Disorders has more about ear infections in children.\n\"The results of this study clearly show that for treating ear infections in children between 9 and 23 months of age, a five-day course of antibiotic offers no benefit in terms of adverse events or antibiotic resistance,\" Hoberman said.\nWEDNESDAY, Dec. 21, 2016 (HealthDay News) -- A shorter period of antibiotic treatment for ear infections in young children does more harm than good, a new study finds.\nThe study included 520 youngsters with ear infections.\nThese infections are the most common reason why children are given antibiotics, the University of Pittsburgh researchers noted.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story is reliant on the news release, but we were pleased that it does disclose this openly. However, all the content seemed to be copied or minimally rewritten from the news release. There is nothing in the story that didn\u2019t also appear in the release, such as an independent perspective.", "answer": 0}, {"article": "Sept. 26, 2017.\nThe research, published Sept. 26 in the Journal of the American Medical Association, reports results from the clinical trial known as GIFT (Genetics Informatics Trial of Warfarin to Prevent Deep Venous Thrombosis).\nNo patient died during the trial.\nUnlike prior studies, GIFT took into account genetic variants in three genes for 11 days of warfarin therapy.\nGIFT showed that precision-medicine based on clinical factors and three genes improves the safety of initiating warfarin therapy.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Overall the language is careful and contextual. The headline should have been toned back a bit to note that this is early research and more study is needed before concluding that \u201cGenetic testing helps set safe dose of common blood thinner,\u201d as the headline now states.", "answer": 1}, {"article": "In a hip replacement, an artificial joint comprising a ball and socket is implanted to replace the natural ball and socket in the pelvis, enabling movement that is typical of the hip joint.\nAll 192 patients underwent a total hip replacement through the high-risk algorithm, with dual mobility implants being used in 143 of the cases.\nUsing the risk assessment tool, the researchers identified 192 of 1,009 patients as high risk for a dislocation after surgery.\nThis exhibit in greater details demonstrates the treatment algorithm, patient cases, and the success with use of the standardized stepwise risk assessment and treatment algorithm to address dislocation risk in patients with spinal deformity.\nAll patients who undergo hip replacement at NYU Langone Orthopedic Hospital now go through the risk assessment screening and treatment algorithm prior to surgery.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "No unjustifiable language.", "answer": 1}, {"article": "\u201cHe said, \u2018Doc, give me what I got last time.\nUntil there are answers, Zarate of the mental health institute said ketamine should be a last-resort treatment for depression after other methods have failed.\nThe company filed a new drug application in September.\nKhare said the burgeoning field \u201cis like a new frontier\u201d where doctors gather at meetings and compare notes.\n\u201cIt truly has revolutionized the field,\u201d changing scientists\u2019 views on how depression affects the brain and showing that rapid relief is possible, said Yale University psychiatrist Dr. Gerard Sanacora, who has done research for or consulted with companies seeking to develop ketamine-based drugs.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a news release.", "answer": 1}, {"article": "\"The endometrium feeds the baby up until the eighth week of pregnancy.\n\"This study has shown that the EFT can also be an important tool for patients with recurrent pregnancy loss,\" he said.\n\"We are very pleased to find that these results reinforce the evidence that progesterone could be a very beneficial, inexpensive, and safe treatment for many women with a history of recurrent pregnancy loss,\" said Stephenson.\n\"The positive results show us that next we need to study progesterone as a treatment for recurrent pregnancy loss with a prospective randomized trial to validate the findings.\"\nTo determine whether a woman's endometrium (uterine lining) is healthy and can sustain the embryo, the research team used the endometrial function test (EFT\u00ae), which was created by study co-author Harvey J. Kliman, M.D., director of the Reproductive and Placental Research Unit in the Department of Obstetrics, Gynecology and Reproductive Sciences at Yale School of Medicine.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There is no obvious use of unjustified language, but the last paragraph contains some somewhat intemperate language from one of the co-investigators who said:\u00a0\u201cWe are very pleased to find that these results reinforce the evidence that progesterone could be a very beneficial, inexpensive, and safe treatment for many women with a history of recurrent pregnancy loss.\u201d\nBeneficial? Inexpensive? Safe? \u00a0None of these attributes were described adequately in this news release.", "answer": 1}, {"article": "Heterosexuals who are HIV negative can significantly reduce their risk of infection by taking a daily dose of an antiviral drug, according to a new study by the Centers for Disease Control and Prevention.\nIn fact, an interim review of the Partners data on effectiveness was so compelling that the trial was stopped early and the placebo arm was discontinued.\nThe CDC says the next step is to fully review all the data and begin to develop guidelines for the use of these drugs in heterosexual men and women here in the U.S.\nClear evidence Baeten said, that PrEP substantially reduces infection risk.\n\"Taken together, these studies provide strong evidence the power of this prevention strategy.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to take its content directly from\u00a0news releases put out by the University of Washington or the CDC, and it quotes a researcher who was not directly involved with either study, so we can be sure the story meets our standard here.", "answer": 1}, {"article": "The 54-year-old said: \"I knew straight away that I had been given the drug.\nThe research was funded by Novartis Pharmaceuticals, National Institute for Health Research (NIHR) and the EU (AirPROM), and is described by the lead researcher as \"a game changer for future treatment of asthma.\"\n\"This new drug could be a game changer for future treatment of asthma\" - Professor Chris Brightling, NIHR Senior Research Fellow at the University of Leicester\n\nThe first new asthma pill for nearly 20 years has the power to significantly reduce the severity of the condition, a study led by the University of Leicester has found.\nProfessor Christopher Brightling, who is a NIHR Senior Research Fellow and Clinical Professor in Respiratory Medicine at the University of Leicester, led the study at the NIHR Respiratory Biomedical Research Unit, which is based at the Glenfield Hospital in Leicester.\nThe study was designed primarily to examine the effects on inflammation in the airway by measuring the sputum eosinophil count.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release gets credit for having a conservative headline \u2014 \u201cAsthma pill could reduce symptoms in severe sufferers\u201d \u2014 but then loses it when it allows the main researcher to proclaim, \u201cThis new drug could be a game changer for future treatment of asthma.\u201d\u00a0 Then it follows that up with what basically is a testimonial from one of the participants in the study who says, \u201cI felt like a completely different person\u201d after taking the drug, adding, \u201cFor me, it felt like a complete wonder drug and I can\u2019t wait for it to be available because I really think it could make a huge difference to me.\u201d\u00a0 She closes by saying that after stopping taking the drug, her health started to \u201cgo downhill again very quickly.\u201d\u00a0 Her comments may be factual and might fit well in marketing advertising but they have no place in a news release explaining new health research.\nInterestingly, the University had also issued a second release related to the same research but not linked in the original release, that offered commentary from two unaffiliated experts. One offered that \u201cThe data strongly support further studies,\u201d while the other said, \u201cMore research is needed and we\u2019re a long way off seeing a pill for asthma being made available over the pharmacy counter.\u201d\u00a0 Both comments would have improved the value of the initial release, had they been included.", "answer": 0}, {"article": "Anthony Cunningham, Executive Director of the Westmead Institute for Medical Research in Australia and Principal Investigator of the ZOE-70 study said: \"These data show that this investigational vaccine maintains high efficacy against herpes zoster in people over 70 and 80 years of age, the age groups who are most affected by the disease.\nThe primary objective of this study is the overall vaccine efficacy against shingles in people aged 50 years or older, compared to placebo.\nThe co-primary objectives of the pooled analysis over both studies are the assessment of overall vaccine efficacy in reducing the risk of developing shingles and PHN in people aged 70 years and over, using pooled data from both ZOE-70 and ZOE-50 studies.\nThe study, from which headline results were reported in October 2015, showed that the two-dose candidate shingles vaccine had 90% efficacy (95% confidence interval: 84-94%) compared to placebo in people over 70 years old.\nThe candidate vaccine was shown to be 89% (95% confidence interval: 68-97%) efficacious in preventing PHN in people aged 70 years and older and 91% efficacious (95% confidence interval: 75-98%) in people aged 50 years and over1.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The language in the news release is straightforward and matter-of-fact. The closest it comes to hyping the study results is a quote from the GSK senior vice president for vaccine research calling the\u00a0findings \u201cremarkable.\u201d", "answer": 1}, {"article": "The dorsal root ganglions are nerve cells, on both sides of each of the spine's vertebra, and are the gateway to pain between nerves in different parts of the body, spinal cord and brain.\nThe goal of this study, he said, was to judge the effectiveness of the therapy over a long period.\nIt shows long-term data that patients experienced significant pain relief and functional improvements, she said.\nOne pain specialist not involved with the study saw the benefits of this procedure.\nFor most patients, the device reduced pain by 33 percent, which was significant, the researchers reported.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story doesn\u2019t appear to rely on a news release.", "answer": 1}, {"article": "Some patients experience grueling withdrawal if taken off opioids, while for others the symptoms are much less severe.\nBut as Stanford pain specialist Sean Mackey emphasized to me, opioids should not be a first-line treatment due to the risks, and alternatives should be tried first.\n\u201cThese non-opioid strategies that were tested in these research studies are not adequately available.\nThat doesn\u2019t mean that reducing prescriptions is a mistake.\nMost of the studies analyzed were of poor quality \u2014 meaning there\u2019s a serious need for better research in this area.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We didn\u2019t detect any evidence of copy-and-paste press release quotes or passages in this story.", "answer": 1}, {"article": "\u2022 4.9 million babies are born with a serious birth defect worldwide every year\n\u2022 3.3 million children under five die from serious birth defects annually\n\u2022 Congenital heart disease is the most common form of birth defect, affecting 1 in 100 babies\n\u2022 42 babies are born with a heart defect in Australia every week\n\u2022 30 babies will undergo heart surgery in Australia every week\n\u2022 Heart defects account for 30% of deaths in children under five\n\n[1] Baker H, DeAngelis B, Holland B, Gittens-Williams L, Barrett T Jr. Vitamin Profile of 563 Gravidas during Trimesters of Pregnancy.\nThis discovery is akin to the revolutionary breakthrough made last century that confirmed folic acid supplementation can prevent spina bifida and other neural tube defects in babies.\n\u201cJust like we now use folate to prevent spina bifida, Professor Dunwoodie\u2019s research suggests that it is probably best for women to start taking vitamin B3 very early on, even before they become pregnant.\nhttp://www.nejm.org/\n\nThis study would not have been possible without the generous support of the Chain Reaction Foundation, the Key Foundation and the National Health and Medical Research Council.\nThe landmark study found that a deficiency in a vital molecule, known as NAD, can prevent a baby\u2019s organs from developing correctly in the womb.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "This news release has some of the most sensationalist language that we\u2019ve ever seen, to a level that is truly egregious. The release lauds the discovery as \u201chistoric,\u201d \u201cone of the greatest discoveries in pregnancy research,\u201d a \u201cbreakthrough,\u201d a \u201clandmark,\u201d \u201ca blockbuster,\u201d \u201crevolutionary.\u201d \n\u201cThis will change the way pregnant women are cared for around the world,\u201d said the executive director of the Victor Chang Cardiac Research Institute in the release. He also said that this research \u201cwill be one of our country\u2019s greatest medical discoveries.\u201d \u00a0\u00a0\nApparently the news release hype generated some backlash since the Institute released an update\u00a0urging women to continue following their doctor\u2019s orders and not increase their intake of niacin on their own. Yet even as they walked back some of their larger claims (\u201cThe Victor Chang Institute would never suggest that this discovery will explain all causes of miscarriage and birth defects\u201d), the update still emphasized that this study was a \u201csignificant advance\u201d in the understanding of miscarriages and birth defects. \u00a0", "answer": 0}, {"article": "Clostridium novyi flourishes in low-oxygen environments.\nPatients in this clinical trial were left with the bacterial infection for one week, and then everyone was given antibiotics to kill off the Clostridium novyi-NT, Janku said.\nA potentially dangerous bacteria appears to target malignant cells and could provide a new means of fighting cancer, a small, preliminary study reports.\nThe strain used in this clinical trial, Clostridium novyi-NT, had been weakened to prevent it from producing its toxin, which can be lethal in humans, Janku said.\nFirst, the bacterial infection itself could cause direct destruction of the tumor cells, Janku said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely solely on a news release.", "answer": 1}, {"article": "One found improvement in infants given fennel extract compared to infants given a placebo; another found that infants given a tea containing chamomile, vervain, licorice, fennel and balm-mint seemed to work; while a third found infants given a tea containing fennel, lemon balm and chamomile cried less than infants given a placebo.\nBut those studies were small and flawed, so no conclusions can be made about the technique, according to the new review.\nAll of the trials reviewed had \"major limitations,\" such as having too few patients, relying on parental reports of symptoms, or the study design (such as not being double-blinded).\n\"This is pertinent given that simethicone is considered the best available and most commonly prescribed treatment for colic, although it previously has been shown to be no more effective than the placebo,\" according to the authors.\nThis may help if the underlying cause of colic is cramping or discomfort due to an immature digestive tract, although that is just a theory, Brown added.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story goes well beyond any news release.", "answer": 1}, {"article": "Jan. 25, 2010 -- A low-carbohydrate diet may have health benefits that go beyond weight loss.\nResearchers say studies have already shown that the two weight loss methods are effective at promoting weight loss, but it's the first time the health effects of each have been compared head to head.\n\"It's important to know you can try a diet instead of medication and get the same weight loss results with fewer costs and potentially fewer side effects,\" Yancy says.\nA new study shows that a low-carbohydrate diet was equally good as the weight loss drug orlistat (the active ingredient in Alli and Xenical) at helping overweight and obese people lose weight, but people who followed the low-carb diet also experienced a healthy drop in their blood pressure levels.\n\"If people have high blood pressure and a weight problem, a low-carbohydrate diet might be a better option than a weight loss medication.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story lifts two quotes directly from a news release put out by Duke University. While the story admits that\u00a0the quotes\u00a0came from\u00a0a release,\u00a0it doesn\u2019t\u00a0perform\u00a0the basic task of finding another source to provide an alternate\u00a0viewpoint. The reader is left wondering if this is journalism or simply an extension of the Duke University press office. \u00a0", "answer": 0}, {"article": "\"The band has a spotty history,\" Deveney said.\n\"[I] therefore think patients will continue to ask for the procedure.\"\nBut he cautioned that patients undergoing band surgery should do so knowing that they need to commit themselves to rigorous long-term follow-up.\nAlmost 50 percent had to have the bands entirely removed, while 60 percent needed to undergo subsequent surgery.\nWith gastric bypass that's not as much of an issue.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely solely on a press release.", "answer": 1}, {"article": "A study of more than 20,000 patients with traumatic injuries and at risk of bleeding to death found those who were treated with tranexamic acid were significantly less likely to die than those who got a placebo.\nAlso, there was no difference in deaths from clots blocking blood vessels in either group, a potential safety concern for the medicine.\nThat improvement may not seem so dramatic, but drug is pretty easy to give -- an initial 10-minute infusion within 8 hours of injury, followed by a second infusion over 8 hours.\nAnd the result is a life saved.\nIt doesn't cost much.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "While there\u2019s no evidence that this story lifted anything directly from a news release, we can\u2019t be sure to what extent this story may have relied on one.\u00a0We\u2019ll call it not applicable.", "answer": 2}, {"article": "\"We should offer all women the possibility of a cure.\"\nThe possibility of a 50 per cent cure rate would be a significant improvement over the current 20 per cent survival rate resulting from more conventional treatment options offered to patients, which consist of a combination of different methods including: chemotherapy before surgery; post-operative chemotherapy delivered intravenously to the whole body (as opposed to localized into the abdomen); and surgery that leaves minimal residual disease in the abdomen, rather than removing all visible cancer cells.\n\"Women need support to endure surgery and the rigours of intraperitoneal chemotherapy, but should be encouraged to do so whenever possible, considering the potential survival benefits,\" said Narod.\nBased on an analysis of existing evidence, published in an opinion article in the Nature Reviews Clinical Oncology journal on January 20, Dr. Narod argues that to achieve a cure, rather than simply delay progression or reoccurrence of the disease, women should be first treated with aggressive surgery to remove all clinically-detectable cancer cells, followed by targeted chemotherapy to the abdomen (intraperitoneal chemotherapy).\nUp to half of women with advanced-stage ovarian cancer might be cured, compared to the current 20 per cent survival rate, argues Dr. Steven Narod, senior scientist at Women's College Research Institute, who calls for a new standard of treatment for women with late-stage ovarian cancer.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We think great care needs to be used when discussing potential cures for cancer and this release doesn\u2019t meet our standard. The first problem is the claim that \u201cup to 50 percent of women with advanced stage ovarian cancer could be cured,\u201d which is repeated three times in the release. Where does that number come from? What evidence supports such a claim? The release doesn\u2019t tell us. And the fact that women lived for a long time after their treatment does not necessarily mean that they were cured of the disease. They may have survived in spite of relapses.\nSecond, the release makes some curious statements. For example, the release states \u201cwe should offer all women the possibility of a cure.\u201d This intimates that many medical professionals treating advanced stage ovarian cancer patients are not trying to cure their patients. In addition, according to the release itself, there is already a 20% survival rate for advanced stage ovarian cancer patients, meaning there is already a \u201cpossibility of a cure.\u201d We suspect that the release was trying to stress that the new standard of care it is endorsing could significantly improve the likelihood of patient survival. If so, it should have simply said that.", "answer": 0}, {"article": "Wasting syndrome is characterized by a loss of weight and muscle atrophy, and largely found in patients who suffer from cancer, kidney disease, chronic obstructive pulmonary disease, and heart failure.\nThe discovery was a \u201cserendipitous finding\u201d in the lab of Rajan Sah, M.D., Ph.D., assistant professor of Internal Medicine and Molecular Physiology and Biophysics at the University of Iowa.\n\u201cWe tested these compounds in sedentary mice and found a dramatic improvement in exercise endurance and a mild increase in muscle size of certain muscle groups,\u201d Sah says.\n\u201cThe treatment of cachexia just doesn\u2019t exist.\nThe intellectual property associated with this discovery was recently licensed by the UI Research Foundation to Innovus Pharma, an over-the-counter consumer goods and specialty pharmaceutical company that commercializes non-prescription medicine and consumer care products.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release uses the word \u201ccure\u201d in the headline, which is unjustified.", "answer": 0}, {"article": "Flu season has already begun, and last year\u2019s was one of the most lethal in decades; about 80,000 Americans died of flu or its consequences, the Centers for Disease Control and Prevention said earlier this month .\nThe pill will cost $150, according to a spokeswoman for Genentech, which will sell Xofluza in this country.\nThe first new flu drug in 20 years won approval Wednesday from the Food and Drug Administration.\nGenentech will offer coupons that lower the price to $30 for patients with health insurance and to about $90 for the uninsured.\nstill strongly recommends that every American over the age of six months get a flu shot as soon as possible.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The work goes well beyond what you would find in any news release. We particularly applaud the story\u2019s discussion of viruses developing resistance to antiviral drugs.", "answer": 1}, {"article": "Hospitals take over with more sophisticated cooling equipment.\nThough it's not unusual to have debate over new therapies, the benefits of induced hypothermia is not a new discovery.\nColumbus is already part of the program, called Cardiac Arrest Registry to Enhance Survival.\nBut MetroHealth and Cleveland EMS officials say they aren't convinced the therapy is proven enough to rewrite the book on cardiac arrest treatment.\n\"I am still amazed that lots of physicians are not aware of the technology,\" Blitz said in an e-mail.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because of the numerous sources cited, it\u2019s clear that this story didn\u2019t rely on a news release.", "answer": 1}, {"article": "The U.S. Centers for Disease Control and Prevention has more on hepatitis C.\nAnd there's another potential problem with existing treatments.\nHowever, Meanwell said, it could become part of a combination treatment of several drugs.\nCombination treatments using these drugs will become the standard treatment for many people, he said, and boost cure rates into the range of 70 to 80 percent.\nFor now, much of the attention in the world of liver disease is on two drugs -- telaprevir and boceprevir -- that Schiff expects will become available within the next year and a half.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure to what extent this story relied on a news release, so we\u2019ll call it not applicable.", "answer": 2}, {"article": "The World Health Organization estimates that more than 300 million people suffer from clinical depression world-wide. But cost, time, stigma, distance to travel, language barriers and other factors prevent many from seeking help.\n\nNow, a growing group of health-care providers are betting that technology\u2014from web-based courses to mobile apps that send prompts via text\u2014can help bridge that gap.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story integrates studies and sources, making reliance on news releases unlikely.", "answer": 1}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nHealth care professionals should review the prescribing information in the labeling for detailed information about the approved uses.\nPatients should not receive Ilaris if they are allergic to canakinumab or any of the ingredients in Ilaris.\nPatients should not get live vaccines if receiving Ilaris.\nThe most common adverse reactions for these indications are injection site reactions and being more susceptible to catching colds.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t engage in unjustifiable or sensational language.", "answer": 1}, {"article": "Michael Burk found walking increasingly painful last year. Crossing the street and tying his shoes became challenges, and colleagues noticed he was limping at work.\n\nOn a recent morning, Mr. Burk reported to the Hospital for Joint Diseases, part of NYU Langone Medical Center in New York City, for hip-replacement surgery. His surgeon had promised him a better quality of life, and said both the operation and recovery would be quick.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "A news release issued last March cites the work of Dr. Davidovitch.\u00a0So it\u2019s clear that he and his institution are promoting his work with this procedure. It also cites some of the drawbacks and concerns raised above. But this story clearly went beyond any such release and includes lots of original reporting.", "answer": 1}, {"article": "ADVERSE EVENTS \n\nNasal pain, discomfort or burning (10.3%); transient electrical discomfort (5.2%); nosebleed (5.2%); nasal congestion (3.1%); headaches (2.1%); trace blood, dot heme in nostril (2.1%); facial pain (2.1%); sore eye (1.0%); sinus pain (1.0%); periorbital pain (1.0%); runny nose (1.0%); nasal ulcers (1.0%); and light-headedness (1.0%).\nThere have been two clinical studies showing positive safety and effectiveness of the device in the increase of tear production completed with 145 aqueous deficient dry eye adult patients.\nStudy 2 is a prospective, single-arm, multicenter, open-label clinical trial in which participants used TrueTear\u2122 to stimulate tear production for 180 days.\nAll device-related adverse events were mild in nature.\nThe new advancement is an addition to Allergan's current eye care portfolio.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "As noted above, the release includes a quote calling the device a breakthrough. This language seems premature for a device that has been tested in only 145 patients for at most six months (and many of those patients tried the device on only a single day), and before any trials have been done that compare the device to existing treatments.", "answer": 0}, {"article": "The researchers thank the Biotechnology and Biological Sciences Research Council (Grant 324594, Systems Biology studentship for J.M.H.\nThe researchers argue that the drug could be cheaper to produce, less harmful to healthy cells than existing treatments and has been shown to be active against cancer cells which have become resistant to platinum-based drugs.\nThe research could also lead to substantial improvements in cancer survival rates, suggests co-researcher Dr Isolda Romero-Canelon:\n\n\u201cCurrent statistics indicate that one in every two people will develop some kind of cancer during their life time, with approximately one woman dying of ovarian cancer every two hours in the UK according to Cancer Research UK and two deaths every hour from bowel cancer.\nSimilar results were obtained by the National Cancer Institute USA in tests conducted on 60 cell lines.\nThis can lead to a wide-range of side-effects from renal failure to neurotoxicity, ototoxicity, nausea and vomiting.\u201d\n\n\u201cExisting platinum-based cancer treatments often become less effective after the first course, as cancer cells learn how they are being attacked, but our new osmium compound with its different mechanism of action, remains active against cancer cells that have become resistant to drugs such as Cisplatin\u201d.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The claim of increased potency, based on cell line research and with no qualifications, is not justifiable. The release also states,\u00a0\u201cEffectiveness shown in tests on ovarian and bowel cancer.\u201d\nWe think people reading will think the research showed the compound killed ovarian and bowel cancer IN PATIENTS not just in a petri dish.", "answer": 0}, {"article": "This website is archived for historical purposes and is no longer being maintained or updated.\nDepartment of Health and Human Services Secretary Sylvia M. Burwell has made addressing opioid abuse, dependence, and overdose a priority and work is underway at multiple HHS agencies on this important issue.\nA majority of states have adopted national guidelines that prohibit basic EMS staff from administering the drug as an injection.\nHHS\u2019 Health Resources Services Administration recently released a grant opportunity aimed at reducing opioid overdose deaths in rural communities through funding for communities to purchase naloxone and train health care professionals and emergency medical staff on its use.\n\u201cMany of these deaths can be prevented by improving prescribing practices to prevent opioid addiction, expanding the use of medication-assisted treatment, and increasing use of naloxone for suspected overdoses.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "From the evidence presented, it is not justifiable to say that \u201cExpanding Naloxone use could reduce drug overdose deaths and save lives.\u201d Has it ever saved a life? Certainly. But that\u2019s not made clear in this release. Would it save more lives if more people administered it? That\u2019s a reasonable assumption, but it\u2019s not something the study being reported on was designed to prove.", "answer": 0}, {"article": "\u201cThe length of statin use, both greater than six months and greater than five years of use was associated with reduction in colorectal cancer risk.\u201d\n\nThe group of statins that showed the greatest effect in reducing risk are classified as lipophilic: atorvastatin (Lipitor), fluvastatin (Lescol), lovastatin (Altocor, Altoprev, Mevacor), pitavastatin (Livalo), and simvastatin (Zocor),\n\nColorectal cancer is the third most common type of cancer in the U.S.; 102,900 new cases of colon cancer are diagnosed in men and women every year, and about 39,670 new cases of rectal cancer are diagnosed annually.\n\u201cOur findings suggest that randomized controlled trials designed to test the hypothesis that statins reduce the risk of colorectal cancer are warranted.\u201d\n\nThis study was presented at a medical conference.\n\u201cObservational studies have suggested that long-term use of statins is associated with reduced risk of several cancers, including breast, prostate, lung, pancreas and liver,\u201d says Samadder in the news release.\nAlso, the longer patients used statin drugs, the greater their reduction in risk for colorectal cancer.\nThe findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story admits that it pulled its quotes from a news release?\u00a0 Why?\u00a0 And why no interview quotes from an independent expert?\u00a0", "answer": 0}, {"article": "According to traditional medicine, specific acupuncture points on the skin are connected to internal pathways that conduct energy, or qi (\u201cchee\u201d), and stimulating these points with a fine needle promotes the healthy flow of qi.\nThe study, which followed 150 pregnant women with major depression, tested \u201cdepression-specific\u201d acupuncture against massage and acupuncture sessions that, according to traditional Chinese medicine, does not specifically target depression.\nResearchers found that after eight weeks, women who received depression-specific acupuncture were more likely to have a treatment response \u2014 meaning the severity of their symptoms fell by at least half and they no longer met all of the criteria for diagnosing major depression.\nOverall, 63 percent responded to the therapy, versus 37 percent of the \u201ccontrol\u201d acupuncture group and half of the massage group, according to findings published in the medical journal Obstetrics & Gynecology.\nIt is unclear, Manber said, why acupuncture might help lessen the severity of depression.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "", "answer": 1}, {"article": "\"It's been a miracle to me,\" Wolfe said.\nThe Topamax group cut back to six drinks a day, on average, assuming everyone who dropped out of the study relapsed into heavy drinking.\nIt's unclear how many relapsed after quitting the pill.\nIt's unclear whether the findings will make a dent in an addiction that affects millions of Americans.\nThe drug costs at least $350 a month, plus the price of doctor's visits.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not appear to rely on a press release.", "answer": 1}, {"article": "A type of sleeping pill that several major pharmaceutical companies are racing to develop received good news yesterday when Swiss biotech company Actelion Ltd. reported positive clinical data.\n\nSleep experts say the drug class needs further study but could potentially offer some benefits beyond Ambien, the top-selling drug in the $3.8 billion global market for sleeping pills. While Ambien and similar drugs, called nonbenzodiazepine drugs, are effective and easily tolerated by most people, some insomniacs don't respond to the...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story is about what appears to be a corporate-sponsored presentation at the World Sleep Congress.\u00a0 While this is not technically a news release, readers should know that it is somewhat comparable.\u00a0 Until more work is done and peer-reviewed, they may not be getting the entire picture.\u00a0 See our primer on some of the pitfalls of reporting news from scientific meetings.", "answer": 2}, {"article": "There is no single known cause of alcoholism, but the researchers wrote that about two-thirds of alcohol dependence could be attributed to genetic factors and one-third to environmental causes like stress or emotional problems.\nThe review covered only carefully controlled trials.\nDespite the largely negative findings, John F. Kelly, a clinical psychologist at Harvard, said he still believed that A.A. and other 12-step programs were effective.\nBut observational data can.\u201d\n\nIt is unlikely that substance abuse experts will widely reject A.A. on the basis of these findings.\nThe paper was published last week in The Cochrane Library, a journal devoted to systematic reviews of health care interventions.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Information in this story does not appear to be taken from a press release. ", "answer": 1}, {"article": "\u201cThe key question is, will the consumer view as credible that ingesting a pill will prevent (sun) damage?\u201d\n\nIn another experiment, Laboratoires Inneov scientists gave the tanning pill to 80 women and asked them to sunbathe as they normally would over the summer, applying sunscreen at their discretion.\nHe pointed out it was hard to draw any conclusions from this part of the study because it didn\u2019t include any data.\nOf more than a dozen researchers and dermatologists contacted about the quality of this study, only Schalock agreed to comment.\nSchalock told Reuters Health he has a \u201chard time seeing that statistically or scientifically they have proven it.\u201d\n\nThe fact that the company did the testing itself could also raise a red flag.\nWhile some people will want to see and feel an impact, he said, for many the clinical claim alone suffices.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear this story didn\u2019t rely on a news release but was a fine piece of enterprise journalism. ", "answer": 1}, {"article": "-- Icing the bottom of the foot, sometimes using ice to massage the heel area\n\n-- Using cups made of gel in shoes to cushion the heel (and many orthopedic surgeons say expensive custom-made orthotics are not necessary)\n\n-- Wearing a night splint, a simple brace that holds the foot in a flexed position to keep the plantar fascia stretched during sleep\n\n-- Physical therapy, though some studies indicate that some PT practices such as ultrasound and whirlpool are not helpful\n\n-- Use of NSAID (non-steroidal anti-inflammatory) drugs such as ibuprofen and naproxen\n\n-- Corticosteroid injections into the heel, though this is controversial and should not be used repeatedly\n\n-- Backing off activities like running until the pain goes away, and then reinitiating them gradually\n\nAbout 90 percent of sufferers will get better with time.\nDuggal says foot specialists don't really know what causes the pain of plantar fasciitis.\nBut while inflammation can be involved in plantar fasciitis, it doesn't seem to be the cause, Duggal says.\nTwo days later, she says her foot felt bruised, but she didn't have enough pain to require medication.\nSo the hope is that platelet injections will stimulate healing without the damaging effects of shock-wave therapy.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story is clearly not based on a news release.", "answer": 1}, {"article": "SAMe may influence the expression of genes involved in depression or alter the function of different receptors and structures that transport neurotransmitters in the brain.\nDr. Nelson, who was not involved in the Harvard study, said the results need to be replicated in a larger study, and that more information is needed on dosing, side effects and long-term treatment with SAMe, among other things.\nThat\u2019s probably the best hypothesis.\u201d\n\nOther studies have suggested that SAMe can relieve symptoms of depression.\nThe research offers hope to patients who haven\u2019t been helped by traditional antidepressant treatment.\n\u201cIn the last 60 years of depression research, all the treatments have focused on similar mechanisms of action.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We haven\u2019t been able to find evidence that the article relied on a news release.\u00a0", "answer": 1}, {"article": "In one study, the number of daily hot flashes experienced by postmenopausal women taking 1,800 milligrams of the drug per day declined from around 10 to around 2.\nAbout 60% of women who took the experimental drug in one study reported side effects, compared to about 50% of women taking placebo pills.\nBut side effects, including dizziness and daytime sleepiness, were commonly reported by users.\n\u201cThis drug was about 60% to 65% effective, which is about the same efficacy that has been reported with antidepressants [for treatment of hot flashes].\u201d\nNAMS founder and former executive director Wulf Utian, MD, says Serada does not appear to be as effective as hormonal therapy, but it may be a useful alternative treatment for women who can\u2019t take hormones or don\u2019t want to.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "", "answer": 1}, {"article": "Dr. William Nelson, co-vice chair of the SU2C Scientific Advisory Committee and director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland, said:\n\n\"Understanding the link between prostate cancer and DNA repair mutations is incredibly important for patients and their families.\nIts efforts have helped produce a 20-fold increase in government funding for prostate cancer.\nThe trial is a milestone in cancer treatment as the first to show the benefits of 'precision medicine' in prostate cancer - with treatment matched to the particular genetic characteristics of a man's tumour.\nIt is a centre of excellence with an international reputation for groundbreaking research and pioneering the very latest in cancer treatments and technologies.\nToday it leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There is some unjustified language here that is inappropriate\u00a0including the phrases: \u201cpioneering drug,\u201d \u201ca milestone in cancer treatment,\u201d \u201d a significant step forward\u201d and \u201ccutting-edge genomic sequencing, and \u201chighly effective at treating men with DNA repair defects.\u201d Let\u2019s recall that the drug hasn\u2019t been shown to help anyone live longer.", "answer": 0}, {"article": "HIV, which stands for human immunodeficiency virus, infects and can destroy or change the functions of immune cells that defend the body.\nHis lab was the first to identify the proteins that can bind marijuana compounds on the surface of immune cells.\n\u201cIn fact, those who used marijuana had levels pretty close to a healthy person not infected with HIV.\u201d\n\nKaminski, director of MSU\u2019s Institute for Integrative Toxicology, has studied the effects of marijuana on the immune system since 1990.\nUp until then, it was unclear how these compounds, also known as cannabinoids, affected the immune system.\nYet, even with this therapy, certain white blood cells can still be overly stimulated and eventually become inflammatory.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We find the headline and the quotes in the story unjustifiable given the lack of supporting evidence. This is significant speculation on a study this small with a protocol that appears to be little more than surveys plus blood cell examination.", "answer": 0}, {"article": "The studies suggest that fewer physicians are recommending annual mammograms for women in their 40s, fewer patients in that age group are getting screened and that tumors found through routine mammography are more likely to be detected in early stages of cancer.\nThese cancers were more treatable because they were caught in earlier stages, Plecha said.\n\"The benefit in 40- to 49-year-old women is pretty small,\" said Dr. Virginia Moyer, chair of the task force, about annual mammograms.\n\"I would still recommend screening mammograms starting at age of 40,\" because cancers caught earlier would be more curable.\n\"The benefit is modest enough it needs to be an individual decision,\" Moyer said about mammograms for women in their 40s.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear the story didn\u2019t rely solely on a news release.", "answer": 1}, {"article": "In traditional Chinese medicine, acupuncture involves inserting long, very thin needles just beneath the skin's surface at specific points on the body to control pain or stress.\nTheir study isn't proof, but it adds to evidence that acupuncture may benefit a range of conditions.\nThe analysis was more rigorous than most research based on pooling previous studies' results, because the authors obtained original data from each study.\nThe new analysis was published online Monday in Archives of Internal Medicine.\nAcupuncture skeptic Dr. Stephen Barrett said the study results are dubious.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There was enough original reporting that we can sure the story didn\u2019t rely on a press release.", "answer": 1}, {"article": "The group that received standard education lowered their scores by an average of 1 point.\nThe program, Black said, did not specifically address sleep -- a topic that might only stir anxiety in people who are already worried about a lack of sleep.\nIn fact, they did better than their counterparts who were given conventional lessons on good sleep habits, the study authors said.\nBlack said the benefits of mindfulness training were on par with what's been found in studies of sleep medications and cognitive behavioral therapy -- a form of \"talk therapy\" that is often helpful for insomnia, for example.\nIn basic terms, it helps them relax -- a \"necessary prerequisite\" for sleep, Black noted.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a press release.", "answer": 1}, {"article": "The F.D.A.\nEveryone agrees that clinical evidence about the relative risks in different types of patients is only beginning to emerge.\nEven stenting proponents worry about overuse of the technology in challenging cases.\nBy contrast, they say, carotid surgery -- called endarterectomy -- has no significant room for improvement.\nAnd advocates of the technology say that more recent data show that stenting success rates are climbing, now that the systems use temporarily implanted filters to catch bits of life-threatening plaque knocked loose during the procedure.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "", "answer": 1}, {"article": "Dr. Christopher B. Granger, the study\u2019s lead author and a professor of medicine at Duke University, said, \u201cI think this is a profound trial result that will have a major impact on the practice and management of patients with atrial fibrillation.\nThe first new drug, Pradaxa, from the German drug maker Boehringer Ingelheim, was introduced in the United States last fall.\nThe companies\u2019 stock soared after they released a brief statement about the stroke and bleeding benefits in June.\nThe study included 18,201 people in 1,034 clinical sites in 39 countries and was consistent worldwide, the sponsors said.\nIts New York-based makers are marketing powerhouses with the top two best-selling drugs in the world, Lipitor from Pfizer and Plavix from Bristol-Myers Squibb.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Did not appear to rely solely on a news release.", "answer": 1}, {"article": "\"This is pretty exciting,\" said Alycia Halladay, senior director for environmental and clinical sciences for Autism Speaks, an autism advocacy group.\nThe Norwegian study is the largest to date on the benefits of folic acid for autism prevention, and marks one of the first tangible things a woman can do to reduce her risk of giving birth to a child with the disorder.\nBut some experts aren't quite ready to tout the benefits of folic acid too loudly, particularly for autism prevention.\n\"While the current study suggests such protection... the data really do not establish anything close to a causal connection.\"\n\"It actually supports the idea of actionable things women can do before they become pregnant, and right as conception happens.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is enough original reporting that we can be sure this wasn\u2019t based on a press release.", "answer": 1}, {"article": "FcMBL binds to pathogens and pathogen-released fragments, known as Pathogen-Associated Molecular Patterns (PAMPs) by recognizing carbohydrate molecules on their surface.\nTogether, the findings suggest that the FcMBL-based pathogen detection technology with its rapid handling time, high sensitivity and broad specificity towards infection-causing pathogens could provide a real-world advance to diagnose life-threatening infections in both clinical microbiology laboratories and point-of-care settings.\nNow, a Wyss Institute team led by Donald Ingber reports in eBioMedicine that it has filled this void with a rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.\nThe potential of this assay to detect pathogen materials was demonstrated in both animal studies and a prospective human clinical study, whose results also suggest that it also could serve as a companion diagnostic to monitor the success of antibiotic and dialysis-like sepsis therapies.\nPrevious efforts in Ingber's team at the Wyss Institute have established FcMBL as a key component of an advanced dialysis-like, pathogen-extracting therapeutic device, and of a method for the fast retrieval of infectious pathogens from complex clinical samples to enable their identification and antibody susceptibilities.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Although, as noted earlier, there is some overstatement and a bit of hyperbole, the text does offer context and some cautions where needed.", "answer": 1}, {"article": "Many researchers have found that statin drugs, which include Pfizer Inc\u2019s Lipitor and AstraZeneca Plc\u2019s Crestor, have effects far beyond lowering cholesterol and reducing the risk of heart disease.\nSamadder\u2019s team did what is known as a meta-analysis, combining the findings of 22 scientific studies with more than 2.5 million volunteers.\nThe longer people took the highly popular cholesterol-lowering pills, the lower their risk of later developing colon cancer, the researchers told a meeting of the American College of Gastroenterology.\n\u201cOur findings suggest that randomized controlled trials designed to test the hypothesis that statins reduce the risk of colorectal cancer are warranted,\u201d Samadder added in a statement.\nAnd U.S. health officials have been watching data that suggests some statins such as Merck & Co\u2019s blockbuster drug Vytorin may actually raise the risk of cancer, although they have saidf this is unlikely.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\u00a0Both quotes came from a university news release. Why?\u00a0 And why no interview with an independent expert?\u00a0 \u00a0 ", "answer": 0}, {"article": "Why Biogen is breathing a sigh of relief with the latest Alzheimer\u2019s data\n\nWe already know Eli Lilly\u2019s big bet on Alzheimer\u2019s disease didn\u2019t work. But a deep dive into just how it failed has provided a bit of encouragement to Biogen and the many companies still hoping to succeed where their rival fell short.\n\nLilly\u2019s treatment, solanezumab, had no significant effect on the buildup of toxic brain plaques believed by many to be responsible for Alzheimer\u2019s neuron-destroying effects. The company had already disclosed that the treatment failed to improve patients\u2019 cognition and function, but the new data, released Thursday night, shed some important light on the underlying biology.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There appears to be original reporting and perhaps use of one (at least) news\u00a0release.\n\u00a0\n\u00a0", "answer": 1}, {"article": "\"What they do is give you a really small dose, like a crumb, basically,\" explains Jula.\nIt's become the gold standard test to rule out an allergy.\nIn Jula's case, her allergists at National Jewish Health in Denver, Colo., repeated the standard allergy blood tests last summer.\nThat's when they realized she may have outgrown her egg allergy.\nLanser says it can be tricky to diagnose food allergies.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story quotes one outside expert, so it appears not to rely on a news release.", "answer": 1}, {"article": "Symptoms of heart failure include fatigue, breathlessness and swelling in the limbs.\nBut the study was small, and the stem cells had only a minor impact on patients' heart function.\nFor now, he stressed, all stem-cell therapies for heart failure remain experimental.\nThe tactic appeared safe, the researchers said, and there were signs of symptom improvements over the next six months to a year.\nThe patch tactic could have some advantages, said senior researcher Dr. Yoshiki Sawa, of Osaka University.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Goes well beyond a news release, and certainly far beyond what was provided in the news release from the American Heart Association.", "answer": 1}, {"article": "(Intralipid infusions are increasingly popular, but the practice was found not to help in a 2016 study of older women with a history of miscarriage.)\nThat patient is now considering an egg donor.\nBut the report doesn\u2019t note that just 1 percent of women have that condition in the first place, making the odds still overwhelmingly in her favor.\nFor Smith, who works as a foster parent providing intensive care in Northern California, there\u2019s nothing more important than family.\nThat\u2019s why Smith and her husband have spent about $70,000 over the past four years trying, without success, to get pregnant.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This enterprise story goes far beyond any information provided by the company marketing Fertilome.", "answer": 1}, {"article": "47(5) pp.\nThe Agency for Healthcare Research and Quality (AHRQ) reported significant improvements in the safety of metabolic/bariatric surgery due in large part to improved laparoscopic techniques.\nResults of the study were based on a double-blinded randomized, sham-controlled trial of 387 patients, about half of whom received treatment with the Obalon balloon and the other half with a sugar-filled sham capsule designed to look like the device.\n\u201cThe significant weight loss achieved with the Obalon 6-Month Balloon System is maintained at 12 months,\u201d said Aurora Pryor, MD, study co-author and Chief Bariatric, Foregut and Advanced GI Surgery, Stony Brook University.\nAll patients at the 15 study sites also underwent 25 minutes of lifestyle therapy administered by a blinded registered dietitian every three weeks.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t rely on sensational language. However, it could mislead some readers about the devices benefits and soft-pedal its potential harms through this quote: \u201cThe significant weight loss achieved with the Obalon 6-Month Balloon System is maintained at 12 months,\u201d said Aurora Pryor, MD, study co-author and Chief Bariatric, Foregut and Advanced GI Surgery, Stony Brook University. \u201cThis combination of lifestyle modification and balloon therapy provides a new low risk option for patients struggling with obesity.\u201d", "answer": 1}, {"article": "According to the U.S. Department of Agriculture\u2019s 2010 Dietary Guidelines, most Americans don\u2019t get enough fiber.\n\u201cIncreasing dietary fiber intake in the general public is of great public health significance,\u201d the Chinese team concludes.\nThat was after accounting for differences in risk factors like alcohol drinking, weight, hormone replacement therapy and family members with the disease.\nThe results \u201ccan identify associations but cannot tell us what will happen if people change their behavior,\u201d said John Pierce, a cancer research at the University of California, San Diego, who was not involved in the work.\nIf it turns out to cut cancer risk as well, that would be an extra bonus, Clarke said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story clearly did not rely on a news release.", "answer": 1}, {"article": "BMI is a calculation of body fat based on height and weight, and a BMI of more than 30 is considered obese.\nCaution is vital when using any drug that has been approved for one condition for another, Sandon said.\nThe authors said such side effects were typically \"mild.\"\nBut they also suffered more side effects than patients not taking the medication.\nPsychological factors or lifestyle factors may play a role, he said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a press release.", "answer": 1}, {"article": "\"But in an emergency room, while there are challenges as well, bedside blood tests are much more readily drawn and quickly analyzed so you can often get the results in minutes.\nSome of those compounds had been pegged as potential telltale signs of heart failure.\nDr. Gregg Fonarow, a professor of cardiology at the University of California, Los Angeles, said that if further research were able to establish its effectiveness, a breath-driven tool for identifying heart failure would be a helpful diagnostic innovation -- but more so in a doctor's office or clinic than in the hospital.\nThis study is really a proof of concept.\nThe investigators stressed that their evaluation is based on a small group of participating patients, and that more extensive research will have to be done to confirm their initial success.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "\u201cIf out of 10 years the patients have left to live we can keep them at home in a relatively mild state of the disease for three, four, five years, it\u2019s a lot.\u201d\n\nAccording to Alvaro Pascual-Leone, director of the hospital\u2019s Berenson-Allen Centre for Non-invasive Brain Stimulation, brain stimulation - or transcranial magnetic stimulation - involves a very low current applied to a specific part of the brain and is approved by the FDA for treatment of a variety of ailments and diagnostic applications.\nNeuronix received European approval several months ago and has installations in the UK and Germany.\nThe device, which combines electromagnetic stimulation with computer-based cognitive training, is already approved for use in Europe, Israel and several Asian countries such as Singapore.\n\u201cWe see improvement lasting for 9-12 months and the good thing is that patients can return and undergo treatment again,\u201d Baror said.\n\u201cYou stimulate the brain on a biological level as well as on a cognitive level,\u201d Neuronix CEO Eyal Baror told Reuters, saying this double approach created longer-lasting benefits.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There\u2019s no evidence that the story relied on a Neuronix corporate news release, even though the story still relied on company management or -funded spokesmen and still read like a news release.", "answer": 1}, {"article": "Cancer is the No.\nIt was even more accurate in finding late-stage cancers, but the goal would be to catch cancer in its earliest, easiest-to-treat stage.\nBut there\u2019s nothing yet that can detect cancer in someone who has not yet been diagnosed.\nResearchers say they have taken a big step towards developing a test that can tell people if they have cancer long before the first symptoms show up.\nThe genetic sequencing is also expensive right now \u2013 on the order of several thousand dollars for the 30,000 repeats the team did.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There\u2019s no indication that this story relied on a news release.", "answer": 1}, {"article": "\u201cRemember this day.\nAn editorial in the New England Journal of Medicine, where the Merck monotherapy results were published, said Keytruda could become \u201ca new standard of care\u201d.\nLead researcher Martin Reck of Germany\u2019s Lung Clinic Grosshansdorf predicted that testing for the PD-L1 biomarker would now become standard \u201cfrom today\u201d.\nIt was a major setback for Bristol, wiping out around a quarter of the company\u2019s market value, and it has caused investors to rethink prospects for immunotherapy treatments.\nMerck had already said in June that Keytruda worked in the trial but the scale of the benefit was only disclosed at ESMO.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story apparently stems from a European oncology conference and a newly published study in the New England Journal of Medicine. The resources available to journalists at the conference\u2013news release? press conference?\u2013are not clear. But it\u2019s clear from the quotes in the story that at least some original reporting went into the piece.", "answer": 1}, {"article": "U.S. alone, seventy-five percent of teens and adults are vitamin D deficient.\nThanks to the work of the research team and the pioneering work of the Boston University Photonics Center on UV LEDs, we may soon see innovative treatment options like simple integration with a wearable device could aid millions of people.\"\nThis device for making vitamin D is ideally suited for patients with fat malabsorption syndromes including inflammatory bowel disease and gastric bypass surgery.\nThe research shows that RayVio's UV LEDs could be used for treating patients that are vitamin D deficient.\n\"This study will lead to a new generation of technology that can be labeled as photopharmacology in which the use of LEDs with targeted wavelengths can cause specific biologic effects in human skin to help treat and prevent chronic illnesses.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We wish the news release had used more neutral, cautionary language, especially in its quotations. Red flags are raised when we see unsubstantiated, extolling phrases, such as \u201cthis study will lead to a new generation of technology\u201d and \u201cpotentially improve and save hundreds of thousands of lives.\u201d Furthermore, this technology has \u201cenormous\u201d potential.\nTherefore, we rate this one Not Satisfactory.", "answer": 0}, {"article": "The U.S. Preventive Services Task Force recommendations state that most women begin mammography at age 50.\nBreast cancer risk assessments are typically not a part of standard care for this age group, the researchers noted.\nThe study also found a significant percentage of women would qualify for other breast screening methods, including breast MRI and genetic testing, Plichta said.\nBut the review of female patients between the ages of 40 and 44 found that 50 percent had an above-average risk for breast cancer, and therefore would be eligible to begin screening mammography at age 40, said lead researcher Dr. Jennifer Plichta.\nThe analysis was designed to look at new breast cancer screening guidelines from the American Cancer Society and the American Society of Breast Surgeons.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It did not rely on the news release (which quoted a different researcher), and didn\u2019t mislead with the headline from the news release that implied that half of all women between the ages of 40-44 were at risk for breast cancer; however, the first sentence in the story did lead with the misleading line.", "answer": 1}, {"article": "While other studies have found a link between eating chocolate and reduced stroke risk, this research found a slight difference in protection, depending on type of stroke.\nThe new Swedish study echoes previous research in men and women.\n\"The protection started at more than 45 grams [about 1.5 ounces] a week,\" says researcher Susanna C. Larsson, PhD, of the Karolinska Institutet in Stockholm, Sweden.\nThe research is published in the Journal of the American College of Cardiology.\nIt also adds new information.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the study includes comments from an independent expert, we can be sure it didn\u2019t rely excessively on any press release.", "answer": 1}, {"article": "Their median age was in the mid-50s, and they were followed for a median of 6.3 years.\nThere are a fair number of serious complications.\nBut doctors have continued to think that even microscopic disease in the lymph nodes should be cut out to improve the odds of survival.\nBut Dr. Carlson said that some of his colleagues, even after hearing the new study results, still thought the nodes should be removed.\nIf any are positive, the disease could become deadly.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story goes well beyond any news release.", "answer": 1}, {"article": "LONDON -- GlaxoSmithKline PLC said it has produced an effective bird-flu vaccine for humans and could begin producing the shots at year's end, leaving it to governments to decide whether to begin ordering the shots.\n\nGlaxo, the world's second-biggest drug maker by sales behind Pfizer Inc., called the findings a breakthrough but said it needs to gather additional data before it can answer several important questions, including how much of the vaccine it will be able to manufacture.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Although there is no way to know if the story relied on a press release as the sole source of information, all of the content it contains is from the drug company.", "answer": 2}, {"article": "\"Those stem cells are given back to the patient where they can go back to the bone marrow and make the blood cells for the rest of the patient's life,\" Kohn said.\nIt's a genetic disorder that leaves the body with a weakened immune system, making infants extremely vulnerable to illness.\nDr. Kohn is currently working with the FDA to make his treatment available nationwide.\nClinical trials for that treatment are now underway.\nDr. Kohn said of an experimental treatment for SCID, \"It's gone from a 'one day, maybe' to a real clinical reality.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We couldn\u2019t find any recent news release that this story might have been based on. And although it\u2019s similar to a 2014 news release that we identified above, it has quotes that are different and appear to reflect original reporting. We\u2019ll give the benefit of the doubt here.", "answer": 1}, {"article": "Boston, MA - Women who eat more high-fiber foods during adolescence and young adulthood--especially lots of fruits and vegetables--may have significantly lower breast cancer risk than those who eat less dietary fiber when young, according to a new large-scale study led by researchers at Harvard T.H.\nOther Harvard Chan School researchers involved in the study included Heather Eliassen, associate professor in the Department of Epidemiology, and Xiaomei Liao, research scientist in the Departments of Epidemiology and Biostatistics.\nThe study will be published online February 1, 2016 in Pediatrics.\nThe researchers looked at a group of 90,534 women who participated in the Nurses' Health Study II, a large long-running investigation of factors that influence women's health.\nThe study was supported by National Institutes of Health grants R01 CA050385 and UM1 CA176726 and a grant from The Breast Cancer Research Foundation.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "While the headline and some of the quotes from researchers suggest there\u2019s a cause-effect relationship between high fiber and breast cancer, we\u2019ve already commented on that. They may have alluded to a breakthrough, but did not explicitly say it. We\u2019ll give them a pass.", "answer": 1}, {"article": "Lower disk herniation results when the insulating disks that sit between spinal vertebrae tear open, allowing jelly-like material to protrude and exert pressure on surrounding nerve roots.\nThe therapy is not new, having first received U.S. Food and Drug Administration approval in the 1980s.\nHe noted that because \"the majority of people with back pain improve with time and exercise alone,\" it remains an open question as to whether the pRF procedure really cured the condition.\n\"Steroid injections are effective only in portion of the patients, and generally require more sessions,\" he noted.\n\"Best case, I think [pRF] could be an option for people if they [have already] failed therapy and medication,\" said Park.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story doesn\u2019t rely on a news release.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/060723/31robot.htm was not found on this server.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "No obvious elements of a press release. ", "answer": 1}, {"article": "When it reaches the area of the heart that causes abnormal rhythms, the tissue is ablated, or destroyed.\nPatients in the Medtronic-sponsored trial who underwent the cryoablation procedure \u2014 which involves using a catheter to freeze away the heart tissue where the problem originates \u2014 was just as safe as drugs used to treat the condition and far more effective, meeting the study\u2019s primary goal of eliminating atrial fibrillation one year after the procedure.\nLess than 1 percent of patients treated with cryoablation were hospitalized for a recurrence of the disease, compared with 6 percent in the drug group.\nDubbed Stop-af, the Medtronic trial showed that almost 70 percent of patients who had cryoablation remained free of the condition after one year, compared with just 7 percent of patients who received drug therapy, according to data presented at the American College of Cardiology meeting in Atlanta.\nA small pilot study funded by St. Jude Medical Inc STJ.N compared the two therapies in a sicker population of patients and also found that the procedure worked better than drugs.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure of the extent to which this story was influenced by a new release, so we judge this criterion Not Applicable. ", "answer": 2}, {"article": "\"It was surprising, and exciting,\" Dr Belmer said.\n\"This opens the way to look at if neurogenesis is associated with other substance-abuse deficits, such as in memory and learning, and whether this compound can reverse these.\"\n\"While it could possibly have that effect, it might be able to help reboot the brain and reverse the deficits the alcohol abuse causes - both the inhibition to the brain's ability to regenerate, and the behavioural consequences that come from what alcohol is doing to the brain, like increases in anxiety and depression.\"\nIt is commonly used there and shown to be highly effective in treating general anxiety and well tolerated with limited adverse effects.\"\nAlcohol is specifically very damaging for neurons.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release takes the wrong tack when it suggests that a model of selectively-bred mice exposed to alcohol for two hours every 24 hours has relevance to what it refers to as human \u201calcoholism.\u201d\u00a0 Without an explanation, the cautious reader should worry that the diagnosis of \u201calcoholism\u201d in rodents is itself close to disease mongering, without any explanation of the mouse model of disease being validated in humans.\nWe also found the release\u2019s final quote troubling: \u201cWhile it could possibly have that effect, it might be able to help reboot the brain and reverse the deficits the alcohol abuse causes \u2014 both the inhibition to the brain\u2019s ability to regenerate, and the behavioural consequences that come from what alcohol is doing to the brain, like increases in anxiety and depression.\u201d\u00a0 These are pretty strong claims to be made based only on early studies in mice!", "answer": 0}, {"article": "Parkinson's disease is a degenerative condition that affects the central nervous system.\nHe also said it will be important to confirm these findings in other studies and learn the mechanism of how berries and other flavonoids appear to offer some protection against Parkinson's disease.\nBut, he added, it's important for people to realize that this research isn't applicable to people who already have the disease.\n\"Berries could be a neuroprotective agent.\nAlso, recollections of dietary intake may be faulty, and it's possible that other properties of fruits and vegetables might have influenced the results, the authors said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We don\u2019t think this story was based on a press release.", "answer": 1}, {"article": "\"It was the end of our world and we didn't know why, because this child was a perfectly normal healthy child, Never had a problem,\" Miller says.\nFDA said it asked the company to dig deeper into its data on Singulair for evidence of possible links to suicide.\nFDA said it is reviewing a handful of reports involving mood changes, suicidal behavior and suicide in patients who have taken the popular allergy and asthma drug.\nMerck officials stressed that the FDA's inquiry is based on reports, not clinical studies - which are the standard tool for evaluating drug safety.\nThe agency said it has not established a \"causal relationship\" between Merck's drug and suicidal behavior.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The report was triggered by the FDA\u2019s action, not a company press release. ", "answer": 1}, {"article": "\u201cThe difference is, the length of stay is cut in half,\u201d he said.\nUnlike other surgeries, there are no minimally invasive alternatives for valve repairs, he said.\nA stabilizer held a section of the beating heart in place so he could secure the new coronary artery.\nThose limitations haven\u2019t deterred hospital executives, though, who see the robotic systems as crucial for attracting and retaining surgeons and patients.\nThe da Vinci is criticized by health policy experts as the poster child for the medical arms race \u2014 the competitive fever among hospitals to buy new technology whether or not it improves care.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There does not appear to be a press release associated with this report. ", "answer": 2}, {"article": "U.S.\nTo management's knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.\nUSRM has been a part of more than 10,000 stem cell procedures in the past 19 years for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases.\n\"Use of one's own healing cells to help repair damaged tissue rather than having to cut open or manipulate the damaged area to try to reduce pain and restore function is the most elegant form of regenerative medicine we have today.\"\nThe paper outlines the case study of a 56-year-old male with a chronic meniscus injury.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The quote from the lead investigator suggests the procedure is more advanced than it is:\u00a0 \u201cUse of one\u2019s own healing cells to help repair damaged tissue rather than having to cut open or manipulate the damaged area to try to reduce pain and restore function is the most elegant form of regenerative medicine we have today (emphasis added).\u201d\u00a0 According to the NIH, \u201cAnimal and small pilot human studies are currently paving the way for large scale clinical trials to treat many intractable diseases.\u201d", "answer": 0}, {"article": "Finally, in 2000, a group of researchers including Dr. Segal in Toronto, J.\nOthers, like Dr. Linehan, insist that patients in severe mental distress are the best candidates for mindfulness.\nDr. Kabat-Zinn taught the practice to people suffering from chronic pain at the University of Massachusetts medical school.\nThe question, said Linda Barnes, an associate professor of family medicine and pediatrics at the Boston University School of Medicine, is not whether mindfulness meditation will become a sophisticated therapeutic technique or lapse into self-help clich\u00e9.\nThe goal of mindfulness meditation was different, to foster an awareness of every sensation as it unfolds in the moment.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a press release and there is a great deal of independent reporting.", "answer": 1}, {"article": "Other texts might include something like, \"Hi, Elizabeth.\nAnd it worked to improve not just one risk factor for heart disease, but many.\nIt can be hard to view those everyday decisions in light of more distant consequences, like having another heart attack or not living as long a life as desired.\nBut texting, that old-school technology, may deserve some of that spotlight, too.\nThere's a lot of hype over mobile health interventions these days, Chow says.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Since the story includes quotes from an interview, we can be fairly certain it went beyond the related JAMA news release.", "answer": 1}, {"article": "LONDON (Reuters) - British scientists have discovered a \u201crogue gene\u201d which helps cancer spread around the body and say blocking it with the right kind of drugs could stop many types of the disease in their tracks.\nChantry said in a telephone interview the findings mean drugs could be developed in the next 10 years that could be used to halt the aggressive spread of many forms of cancer, including breast cancer, brain, colon and skin cancer.\nHe said his team is now working with other scientists to try to design a drug which could interrupt the gene\u2019s activity.\nResearchers from the University of East Anglia said their findings could lead within a decade to the development of new medicines to halt a critical late stage of the disease known as metastasis, when cancer cells spread to other parts of the body.\nIf a drug was developed that deactivated WWP2, he said, conventional therapies such as chemotherapy and radiotherapy could be used on primary tumors with no risk of the disease taking hold elsewhere.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely solely on a news release.", "answer": 1}, {"article": "People with cluster headaches can have as many as eight per day in bouts that last for weeks or months.\nNo serious harmful side effects were reported after high-flow oxygen treatment, according to the report published in the Dec. 9 issue of the Journal of the American Medical Association.\n\"This work paves the way for further studies to optimize the administration of oxygen and its more widespread use as an acute attack treatment in cluster headache, offering an evidence-based alternative to those who cannot take triptan agents,\" they concluded.\nHigh-flow oxygen also provided better pain relief at 30 and 60 minutes.\nTUESDAY, Dec. 8, 2009 (HealthDay News) -- High-flow oxygen appears to be an effective treatment for cluster headaches, British researchers have found.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story appears to depend solely on the Journal of the American Medical Association press release. It uses the same quotes in their entirety. All facts in the story also appear in the press release. If the reporter did any independent research there is no evidence of it. ", "answer": 0}, {"article": "\"That's where the money is,\" Malmgren said.\nMalmgren, a breast cancer survivor, says more focus should be placed on the benefit of early diagnosis, because it often means less treatment is needed.\nHowever, she said, the study does not provide support for all women aged 40 to 49 to have routine mammograms.\n\"The data from randomized trials and modeling show there is a very modest improvement in mortality with mammograms from 40 to 49,\" she said.\nIn 2009, the U.S. Preventive Services Task Force issued mammogram recommendations.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It appears that the story did not rely solely on a news release.", "answer": 1}, {"article": "Another sensor, just approved by the F.D.A.\nOver the next six weeks of testing, I came down to earth as I realized that while the sensor enabled me to drastically cut my usual number of lows, it did not eliminate them.\nEven with the help of an expert trainer from MiniMed, I found that injecting the catheter took much more dexterity than injecting one for a pump.\nThe main problem was that the sensor was simply not as accurate as a blood-glucose tester.\nBut none are as accurate as a standard blood-sugar test.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if the story relied largely on a news release. No sources are quoted anywhere in the story. ", "answer": 2}, {"article": "So far, however, there is little scientific proof of their effectiveness\u2014many studies of probiotics have involved less-than-rigorous...\nBut some researchers are investigating the beneficial bugs for conditions that have nothing to do with the digestive tract.\nThey are live microorganisms\u2014or \"good\" bacteria\u2014that when consumed in capsules or yogurt are said to confer a health benefit.\nOne of the fastest-growing dietary supplements, probiotics are now prominent on drug and big-box store shelves.\nPhoto: AP.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There are enough original sources\u00a0that we can be sure\u00a0the story wasn\u2019t based on a press release.", "answer": 1}, {"article": "Without strong evidence for its efficacy, the American Congress of Obstetricians and Gynecologists does not include the treatment in its Practice Bulletin for Urinary Incontinence in Women. L. Elaine Waetjen, professor of obstetrics and gynecology at the University of California, Davis Medical Center, who has spent more than 15 years treating women for this problem, said that there is \"no scientific evidence that the O-Shot works for incontinence and there is also no clear biological mechanism for why it should treat this condition.\"", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We did not find a news release.", "answer": 2}, {"article": "The skin, she says, \"has been irreparably damaged by the stretch [and it] doesn't shrink down like the rest of the body does.\nSeven weeks after surgery, Baez concluded the pain and effort had been worth the result: an end to the recurrent skin infections in her thighs and abdominal folds.\nIt was very painful.\nThat should be the norm, says Holland.\nJust walking was painful.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This article does not appear to be based solely or largely on a press release.", "answer": 1}, {"article": "After six months, only 31% of patients on FOLFIRINOX reported a decent quality of life, compared with 66% of those on gemcitabine.\nPart of the group was given gemcitabine, the most favored treatment according to oncologists.\nOnly about 6 percent of those with the diagnosis live longer than five years.\nFor most patients, the prognosis is grim.\nThe purpose of the study was to record the overall survival rates of each group.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Not applicable. We can\u2019t be sure of the extent to which the story relied on any news release, as no one is interviewed.", "answer": 2}, {"article": "The machine, which is made by the Bedford company Hologic and developed partly at MGH under Rafferty\u2019s supervision, produces images that are so vivid and clear they seem to speak out loud: \u201cHey, right here!\nThere\u2019s an intuitive argument for why 3-D mammography might be more accurate.\nOnly a prospective, randomized trial with mortality as its \u201cendpoint\u201d can say for sure, and that\u2019s how long it takes to conduct one.\nTrials like this are the gold standard of medical evidence.\nSo perhaps it\u2019s not surprising that the company\u2019s PowerPoint presentation to the FDA included the unsubtle phrase \u201chuge breakthrough,\u201d or that the first American patient to undergo 3-D mammography \u2013 Laura Lang, a polished 55-year-old Boston marketing executive and breast cancer survivor \u2013 did so in front of a CBS camera crew last February.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because this article includes includes quotes about mammography in general\u00a0from Dr. Otis Brawley of the American Cancer Society and about the 2009 mammography guidelines issued by the United States Preventive Task Force from Dr. Daniel Kopans, it does not appear to rely solely on a news release.", "answer": 1}, {"article": "\"I could ride a bike!\nThey gave it to Alex for free.\nIn truth, she had been more concerned about getting him therapy for his autism-related delays -- the limb difference was secondary.\nWyatt also learned to adapt.\nThere were other things the 12-year-old boy said he would do if he had two hands.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "Other researchers contributing to this study include: Robert L. Coleman, M.D., Alpa M. Nick, M.D., Pedro T. Ramirez, M.D., Lois M. Ramondetta, M.D., Diana Urbauer, Jack L. Watkins, all from MD Anderson; Susan K. Lutgendorf, Ph.D. from University of Iowa; Sanjeev Kumar, M.B., B.S.\nThis was not true for patients who took SBBs.\nFurther examination revealed that NSBB users had improved overall survival regardless of the presence of such prognostic factors or comorbidities.\n\"The stratification of patients by beta-blocker use and selectivity in this study makes it unique among all other studies examining the impact of these drugs on cancer.\nAccording to Sood, the usefulness of beta-blockers was unclear until now.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The headline and lead paragraph reach further than the journal article can support. The rest of the release is much better, but it\u2019s hard to make up for a misleading first impression.", "answer": 0}, {"article": "Researchers have long known that people who are very thin tend to have a shorter life expectancy, often because they're dealing with cancer or other serious illnesses.\nBut there's not much data to back the notion that a bit more pudge is protective.\nAnd all of the people in this study are white, so that's a limitation.\nBut that might be changing, at least when it comes to risk of death.\nBut this does raise the prospect of whether it may soon be time to tweak the official definition of normal, healthy weight.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "Men and women with mildly high blood pressure who ate three kiwi fruits a day for eight weeks had systolic blood pressure levels that were 3.6 millimeters of mercury lower than those of volunteers who ate an apple a day.\nBecause this study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\nDon't start popping lutein in supplement form based on these results, he noted.\nDr. Elliott M. Antman, a professor of medicine at Harvard Medical School in Boston, said that while promising, the new study is small.\nModeration is the key with kiwis or any food, he said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does not appear that the story relied on a news release.", "answer": 1}, {"article": "And in an accompanying journal editorial, medical professors Dr. Bo Abrahamsen and Dr. Opinder Sahota wrote that due to study limitations, \"it is not possible to provide reassurance that calcium supplements given with vitamin D do not cause adverse cardiovascular events or to link them with certainty to increased cardiovascular risk.\nThe case against calcium became stronger when researchers added in data from 13 other, unpublished trials involving almost 30,000 women.\nBut even when added to previous studies with similar findings, the new conclusions don't necessarily mark a death knell for calcium supplements, say the authors of a study released online April 19 in the BMJ.\nIn addition, the mammoth, U.S.-government funded Women's Health Initiative (WHI) earlier found no negative link between calcium and heart health.\n\"Our own recommendation is to critically review the use of calcium supplements, since the data in this paper suggests that they do more harm than good,\" added Reid, who is professor of medicine and endocrinology at the University of Auckland in New Zealand.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story goes well beyond any news release.\n", "answer": 1}, {"article": "Their median age was 63.\nIn retrospective research, it's impossible to filter out the countless reasons that a woman and her doctor might have made the decision to treat the cancer with or without surgery, leaving the conclusions unreliable for clinical decision-making, he said.\nA large, randomized, prospective study currently being conducted by the Eastern Clinical Oncology Group should produce the most reliable data on the subject to date, he said.\nTwo small prospective studies have suggested no survival difference among women with Stage 4 breast cancer who have surgery and those who don't, he said.\nBut with better therapies to control the cancer systemically and improved imaging that finds ever-smaller deposits of cancer in other parts of the body, it may be time to see whether surgery also can help increase the length of survival times, they said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story doesn\u2019t seem to be based on news releases we found online. The Washington Post article shows evidence of original reporting \u2013 shown by the comments from the two independent sources and two study authors \u2013 and also cites the JAMA Surgery paper.", "answer": 1}, {"article": "U.S. doctors do at least two stenting procedures these days for every coronary bypass operation.\nNow the biggest collection of cases so far comes out in favor of surgery on the all-important question of mortality.\nThat can call into question the ultimate relevance of the findings.\nBut Dr. Laura Mauri says in an accompanying editorial that the new study can't settle any debates.\nThe study also appears online in the New England Journal of Medicine.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a press release.", "answer": 1}, {"article": "Hospice care is intensive palliative care including home nursing, but insurers and Medicare usually cover it only if the patient abandons medical treatment and two doctors certify that death is less than six months away.\nThis trial was paid for by the American Society of Clinical Oncology and private philanthropy.\n\u201cThe billing is complicated, and for many physicians that\u2019s enough of a deterrent to not bother.\u201d\n\nDr. Cooney herself had such care along with surgery and chemotherapy for ovarian cancer in 2008.\n\u201cBut I couldn\u2019t have completed the program without the psychosocial support.\u201d\n\nPalliative care experts now want to study patients with other cancers, heart disease, stroke, dementia and emphysema.\n\u201cWe thought it made sense to start them at the time of diagnosis.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story was not based on a press release.", "answer": 1}, {"article": "Radiologists and urologists have been frustrated for decades by the inability of conventional imaging tests, such as CT and MRI, to distinguish benign from malignant kidney tumors.\nThe research team reports that the potential improvement in diagnostic accuracy will spare thousands of patients each year in the United States alone from having to undergo unnecessary surgery.\nThe addition of sestamibi SPECT/CT increased the reviewers\u2019 diagnostic certainty in 14 of the 48 patients, or in nearly 30 percent of all cases.\nFOR IMMEDIATE RELEASE\n\n\n\nNewswise \u2014 The latest in a series of studies led by researchers at Johns Hopkins Medicine shows that addition of a widely available, noninvasive imaging test called 99mTc-sestamibi SPECT/CT to CT or MRI increases the accuracy of kidney tumor classification.\nFollowing surgery, similarly \u2018blinded\u2019 pathologists analyzed the tumors without knowing the radiologists\u2019 imaging results.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release does not rely on unjustifiable language.", "answer": 1}, {"article": "\"All living cells undergo cell division and palbociclib's unique capacity to halt the cell division process (also known as the 'cell cycle') therefore has potentially broad applicability,\" said the study's lead author Amy S. Clark, MD, MSCE, an assistant professor of Hematology/Oncology at Penn's Perelman School of Medicine and ACC.\nAt the recommended doses, evidence of the desired drug effect in tumors has been obtained using novel PET imaging at Penn.\nAnother phase 2 trial with 29 sarcoma patients treated with palbociclib showed a progression-free survival of 66 percent at 12 weeks.\nIt is the first CDK4/6 inhibitor to be approved for the treatment of breast cancer.\nIn addition to inhibiting the cell cycle, palbociclib has been shown, for example to alter several recently described non-cell cycle functions of CDK4/6, a finding expected to expand its therapeutic role, O'Dwyer added.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "While the language used is professional in tone it includes some overly optimistic statements such as \u201cpotentially broad applicability\u201d and \u201creal promise for addressing a variety of cancers\u201d which suggests the drug sponsors are angling for future applications beyond those that have been studied. It is too early in the process of studying the drug to be so optimistic about treatment success \u2014 at least not without providing some tempering language to balance expectations.", "answer": 0}, {"article": "April 18, 2011 -- The FDA has approved a new noninvasive portable device for the treatment of a deadly type of brain tumor. The device uses electrical fields to slow and possibly reverse tumor growth.\n\nThe device, manufactured by Novocure, is called the NovoTTF-100A System and is meant for adults with glioblastoma multiforme that recurs or progresses after chemotherapy and radiation treatment.\n\nGlioblastoma multiforme is a common type of brain cancer, and the tumor is highly resistant to standard treatments, such as surgery, radiation, and chemotherapy, the FDA says in a statement.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story admits it drew its information from a company news release and an FDA news release.\nWas it that urgent that this be published before a live person could actually be interviewed?\nAnd if we accept the FDA as the primary source, then the only source was the company spokesman, who is not an independent voice on this product and its potential.", "answer": 0}, {"article": "U.S. regulators in October approved Keytruda on an accelerated basis for patients with advanced non-small cell lung cancer whose tumors produce PD-L1.\nSafety of Keytruda was consistent with what had been seen in previous trials among lung cancer patients, Merck said in a release that included only summary \u201ctopline\u201d information from the results.\nThe approval was contingent on the company providing more detailed data in the future on Keytruda\u2019s safety and effectiveness.\nMore detailed data from the study will be provided soon, Merck said, adding that it will ask the U.S. Food and Drug Administration later this year to add the new data to the drug\u2019s package insert label.\nPatients whose tumors had especially high levels of PD-L1 also went longer without a progression of disease than those taking docetaxel, Merck said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "While the story does offer some additional background information, it appears to draw almost exclusively from Merck\u2019s news release.", "answer": 0}, {"article": "Dec. 20, 2010 -- Scientists using brain scanning technologies say they have been able to predict with 90% accuracy which children with dyslexia will be able to improve reading skills over a period of a few years.\n\nResearchers say their findings reveal activity in specific brain regions during reading that could eventually lead to new treatments for people with dyslexia.\n\n\u201cAt this time, we cannot say which treatment type will each child benefit from,\u201d study researcher Fumiko Hoeft, MD, PhD, an imaging expert at Stanford University, tells WebMD in an email. \u201cBut with more research, and if researchers combine it with intervention studies, then we should be able to identify brain patterns that are predictive of responding to one type of intervention or another.\u201d\n\nShe says in a news release that the study \u201cgives us hope that we can identify which children might get better over time\u201d and that the findings represent \u201ca huge step forward.\u201d\n\nThe discovery of brain regions involved in the learning disorder \u201cmay provide a mechanism for enduring improvement that promotes relatively successful reading development,\u201d according to the study, published in the Dec. 20 issue of the Proceedings of the National Academy of Sciences.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\n\nAt least three quotes come from a news release. Other quotes came from responses to e-mailed questions \u2013 which may not provide the same insight as a telephone or in-person interview. We appreciate the labeling of the comments as coming from e-mail exchanges and news releases. But we don\u2019t think the best journalism was employed on this criterion.\u00a0 Why the reliance on a news release?\u00a0 And why not at least a phone interview with McCandliss?\n", "answer": 0}, {"article": "Mammograms, for example, prevent 25 percent of breast cancer deaths, and the PSA test for men has not been shown to prevent prostate cancer deaths.\nDr. Ransohoff and other screening experts say patients should continue to have the test, because it is still highly effective.\nCT colonoscopies, so-called virtual colonoscopies, are not a solution, some screening experts said.\nOne solution, supported by six studies, is to be sure there is just a short time between when patients finish taking the strong laxative that cleanses their bowel and the colonoscopy, Dr. Rex said.\nStill, he said, that does not mean that patients should have more frequent colonoscopies.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story quotes multiple experts, the reader can assume the story does not rely on a press release as the sole source of information.", "answer": 1}, {"article": "\u201cBut it does give us hope.\u201d\n\u201cWe have to be mindful of the placebo effect, and we have to take [the findings] with a grain of salt,\u201d Matthew Sullivan, an associate professor of microbiology at The Ohio State University, said in the release.\nChildren without autism were used as a control for the study, the news release reported.\nResearchers also asked the children\u2019s doctors to perform pre- and post-diagnostic evaluations, which suggested lasting benefits.\nOne of the study\u2019s limitations is its small size, and researchers cautioned that families should not try to replicate the treatment at home.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story appears to rely heavily on the news release, but it does at least cite the news release and provide a link to it. The news release includes this statement, which appears repeated almost word-for-word in the story.\nFrom the news release:\n\u201cWe have to be mindful of the placebo effect and we have to take it with a grain of salt,\u201d said Sullivan, an associate professor of microbiology at Ohio State. \u201cBut it does give us hope.\u201d\nThe passage as it ran in the news release:\n\u201cWe have to be mindful of the placebo effect, and we have to take [the findings] with a grain of salt,\u201d Matthew Sullivan, an associate professor of microbiology at The Ohio State University, said in the release. \u201cBut it does give us hope.\u201d", "answer": 0}, {"article": "Most are still of the opinion that sunscreens with an SPF of up to 50, and containing avobenzone and oxybenzone, efficiently protect the skin from both UVA and UVB ultraviolet rays.\nOur two cents' worth:There's no reason not to take a flyer on Fernblock \u2014 actress Reese Witherspoon gives it a hearty endorsement - but keep slathering up, too.\nIf you're squeamish about vitamin A, there are a number of alternatives.\nAs an alternative, there's a relatively new product called Fernblock, which claims to protect the skin internally by systemically inhibiting the absorption of ultraviolet rays.\nYour skin vs. the sun: A sunscreen pill?\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does not seem to be covering any specific news release.", "answer": 2}, {"article": "THC interacts with receptors in the brain\u2019s endocannabinoid system, which is involved in many physiological functions, including pain, mood, memory and appetite.\nWith a cannabinoid like THC, which does have adverse effects in certain individuals, there would be worries about the chronic dosing of this kind of medicine.\n\u201cTogether, these results reveal a profound, long-lasting improvement of cognitive performance resulting from a low dose of THC treatment in mature and old animals,\u201d the scientists write.\n\u201cThis paper is addressing a possible role for that compound in memory and cognition, which is relevant to disorders such as Alzheimer\u2019s and other dementias.\u201d\n\nHe said that while it is important to remember the study was carried out on mouse models, the differences in the effect of the drug on younger animals versus older animals tells us a lot about our understanding of the differences between old and young brains.\nMoving this research forward, however, will be problematic: \u201cTesting in humans is going to be difficult.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Oxford University in mid-March issued a news release about its recently opened program to study the therapeutic potential of cannabinoids, a fact cited high up in the Newsweek article. We could not locate a release from University of Bonn or Nature Medicine, so we\u2019ll rate this N/A.", "answer": 2}, {"article": "African-American women are more likely than white women to report hot flashes.\nAlthough the benefit was modest, it appeared to be significant enough that women might consider trying it, the researchers said.\nThe hot flashes increased after the women stopped taking the drug but not among those taking a placebo.\nThe study found none.\nAn antidepressant can help alleviate hot flashes that plague many menopausal women, according to new federally funded research.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This blog post did not include any external perspective on the study, so we can\u2019t be sure to what extent it may have relied on a press release.", "answer": 2}, {"article": "A systematic review of C.B.T.\nMy sleep log also helped me be more objective.\nMany nights I might have considered \u201cbad\u201d \u2014 and fretted over \u2014 were ones in which I got only one hour less sleep than my target of seven hours.\nAnd as studies show, it works better than drugs.\nRecognizing that\u2019s not really so bad helped me relax, and relaxing helped me get more and better sleep.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a news release.", "answer": 1}, {"article": "Prostate cancer is very common, showing up in 240,000 U.S. men every year.\n\u201cOur findings with Western diet and prostate cancer-specific mortality, however, were surprising, in part because there are very little data regarding how diet after diagnosis may impact disease prognosis.\u201d\n\nThe findings could be important for many men.\n\u201cOur results suggest that the same dietary recommendations that are made to the general population primarily for the prevention of cardiovascular disease may also decrease the risk of dying from prostate cancer among men initially diagnosed with nonmetastatic disease (cancer that has not spread),\u201d said Dr. Jorge Chavarro of Brigham and Women\u2019s Hospital and Harvard Medical School, who led the study.\nIt\u2019s yet another piece of evidence showing that the so-called Western diet can worsen the risks for cancer, as well as all sorts of other diseases from heart disease to Alzheimer\u2019s.\nChavarro and colleagues studied 926 men who had prostate cancer that hadn\u2019t spread.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "A\u00a0news release\u00a0was issued by Harvard\u2019s school of public health about these findings. The story includes quotes from the same Harvard researcher who is quoted in the news release, but the quotes are different, suggesting that original reporting was done. This makes the grade for\u00a0Satisfactory.", "answer": 1}, {"article": "Compared with the 16% of people who didn't drink coffee at all, those who downed two or more cups each day were about 18% less likely to have died during the study period. In addition, those who drank just one to six cups of coffee per week were 12% less likely to die. Both of these figures were calculated after taking into account known risk factors for early death, such as smoking (which is often paired with coffee drinking), diet and body mass index.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "DCIS affects one out of every five women diagnosed with breast cancer in the United States, and is often treated with surgery followed by radiation therapy and/or hormonal therapy.\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the benefits of the test to physicians, patients and payors.\n\"These results highlight the need to optimize treatment of this non-invasive, indolent form of breast disease, and the importance of Oncotype DX in helping physicians reduce over- and under-treatment of DCIS.\"\nConducted in collaboration with Partnership for Health Analytic Research, this prospective study analyzed 115 patients from 10 cancer centers in the United States.\nAdditionally, the test predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The press release did not use unjustifiable language. But as noted above, we think the terminology used is confusing.", "answer": 1}, {"article": "\u201cIt cannot be simplified to a neat, effortless passage of the infant through the birth canal,\u201d he said.\nAnal samples from the swabbed group, oddly, contained the highest abundance of bacteria usually found in the mouth.\nAs the operations began, the gauze was pulled out and placed in a sterile collector.\nBut in terms of their bacterial colonies, the infants swabbed with the microbes closely resembled vaginally delivered babies, she found, especially in the first week of life.\nThey are doing it themselves.\u201d\n\nDr. Brubaker is one of them.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article clearly goes beyond the news release.\n\u00a0", "answer": 1}, {"article": "Autism spectrum disorder (ASD) includes a range of conditions, including Asperger syndrome, that affect a person\u2019s social interaction, communication, interests and behaviour.\nThey point to several study limitations, such as the potential for confounding and difficulty assessing type, timing and dose of supplements.\nThe researchers stress that their findings cannot establish cause and effect, but say they raise questions about a possible association that warrant further investigation.\nHowever strengths included the relatively large population-based sample size and the advanced analytical methods used to gauge the robustness of findings.\nMore boys are diagnosed with the condition than girls.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release does not use unjustified language.", "answer": 1}, {"article": "Parents get frustrated with the FDA recommendations not to use cold medicines in kids under the age of 4 because they are left with few options.\nThere were no side effects in the two other groups.\nThe next day parents were questioned about their child's symptoms overnight.\nSome were treated with Vicks, some with a placebo consisting of petroleum jelly and others got no treatment at all.\nThat night, 30 minutes before bedtime, Vicks or petroleum jelly was rubbed onto the child's chest and neck.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\nThe story does not appear to rely on a news release.", "answer": 1}, {"article": "A three-year-old Silicon Valley start-up, Counsyl Inc., won the Bronze Innovation Award for its simple, low-cost genetic test that can alert prospective parents who might be carrying genes that could cause hereditary diseases in their children.\n\nCounsyl's technology promises a \"high quality-of-life impact for families at risk for conceiving children with familial diseases,\" says Larry Bock, an Innovation Awards judge and special limited partner at venture firm Lux Capital. \"This technology bundles previously...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story is part of a larger awards package that involved asking a panel of judges to review innovations and decide which ones deserved special merit. It was not based on a release.", "answer": 1}, {"article": "[2] Quotes direct from author and cannot be found in text of Article.\n\"We have identified a cardiac troponin concentration (less than 5 nanograms per deciliter; <5 ng/L) below which patients are at very low risk of heart attack either during the admission or in the ensuing 30 days.\nUsing this threshold in routine practice could potentially double the number of patients suitable for immediate discharge directly from the emergency department, say the authors.\nThese patients are therefore potentially suitable for immediate and safe discharge from the emergency department.\nUse of this approach is likely to have major benefits for both patients and healthcare providers.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Readers might interpret one of the quotes in this release as suggesting that the study is absolutely conclusive in terms of safety and efficacy. \u201cThese patients are therefore potentially suitable for immediate and safe discharge from the emergency department. These findings could dramatically reduce unnecessary hospital admissions and provide substantial cost savings for healthcare providers.\u201d But since the language used elsewhere is more measured, we\u2019ll let this one go with a warning.", "answer": 1}, {"article": "Vemurafenib, approved in 2011, can cause non-lethal skin cancers.\nFor the first time, however, patients such as Herry have options.\nPatients with a limited time to live may not be so positive, Turnham says.\nDoctors now dare to hope that giving these new drugs in sequence, or in combination, will help people with melanoma live for years while feeling relatively good.\nBut after decades of failure, the spate of new drugs is helping more patients than ever before, giving people like Herry more time and better quality of life, Schuchter says.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely on a news release.", "answer": 1}, {"article": "Performed through the urethra, an urologist uses the UroLift System to push aside the obstructive prostate lobes and positions small, tailored permanent UroLift implants to hold the prostate lobes in the retracted position.\nPatients recover from the procedure quickly, and return to their normal routines with minimal downtime.\nThe UroLift System provides an alternative to tissue removing surgery for the treatment of an enlarged prostate.\nMost symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure.\nMost symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The description is mostly free of unjustified language, except for the headline, which uses one of the 7 words you shouldn\u2019t use in medical news:\u00a0 \u201cbreakthrough.\u201d Is it proper to call something a \u201cnew breakthrough\u201d when it has apparently been on the market for four years? And when its effectiveness compared with other approaches hasn\u2019t been properly established?", "answer": 0}, {"article": "Benign prostate hyperplasia, also known as enlarged prostate, is a non-cancerous condition familiar to millions of aging males.\nCurrent surgical procedures typically require no more than one night in the hospital and complications such as incontinence and impotence are uncommon, he said.\nOther minimally invasive treatments for enlarged prostate that are currently available are less effective and have a greater risk of a need for reoperation, according to background materials that accompanied the study.\nDr. Franklin Lowe, associate director of urology at St. Luke's-Roosevelt Hospital in New York City, said PAE was \"unlikely\" to be used much to treat enlarged prostate.\nSince the study is being presented at a medical meeting and has not yet been published in a peer-reviewed journal, the findings should be considered preliminary.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not appear to rely solely on a news release.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070520/28diet.b.htm was not found on this server.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if the story relied solely or largely on a news release.\u00a0 We do know that it only quoted one source \u2013 a study author.\u00a0 ", "answer": 2}, {"article": "\u201cIt\u2019s like you\u2019re possessed,\u201d said Lorie Novak, who has suffered from chronic migraines since childhood.\nBut the companies\u2019 fortunes are intertwined, he said, and \u201cthe class only wins if headache care in America improves.\u201d\n\nAiming to prevent migraines before they start\n\nThere\u2019s plenty of room for improvement.\nTargeting CGRP is not a particularly new idea.\nLike many patients, she didn\u2019t respond to any of the preventative therapies available.\nThat medication, Topamax, has been dubbed dubbed \u201cSleepomax\u201d by doctors and patients because it\u2019s also a heavy sedative.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The inclusion of four drug companies in this story suggests that the reporter engaged in substantial enterprise reporting. That feeling is bolstered by the use of two testimonials from migraine sufferers.", "answer": 1}, {"article": "The findings \"are pretty much in line with what all the other studies have shown comparing Atkins and low-fat diets,\" said Bonnie Brehm, assistant professor of nutrition at the University of Cincinnati College of Nursing and co-author of two, independent studies of the Atkins diet.\nBoth the authors and other weight-loss experts were quick to note that the new findings did not answer the question of what is the best way for most people to shed weight.\nAll also reported having cut their intake -- some by as much as 500 calories per day at two to six months -- but then gradually adding back many of those calories.\nThe latest findings add to a growing body of evidence that the high-protein Atkins diet does not cause the harmful heart and artery effects long feared by many researchers.\nWomen who followed the Atkins plan had a significant drop in triglycerides, one of the unhealthful blood fats linked to a higher risk of heart disease.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not appear to have relied solely or largely on a press release.", "answer": 1}, {"article": "Anorexia has one of the highest mortality rates of any psychiatric disorder and is among the most common psychiatric disorders in girls aged between 15 and 19 years.\nCommenting on the results of this small trial, Janet Treasure and Ulrike Schmidt of King\u2019s College London\u2019s Institute of Psychiatry said the technique looked promising and would give hope to patients with especially pernicious forms of anorexia.\nThis success, in a small study designed as a pilot to test the safety of the technique, suggests larger trials will confirm the effectiveness of the deep brain stimulation (DBS) device, the researchers wrote in the medical journal The Lancet.\nImplanting the DBS device requires minimally invasive surgery which can be completely reversed if problems occur, the researchers said.\nUnder previous therapies, none had shown progress.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does not appear that story relied solely or largely on a news release.", "answer": 1}, {"article": "The hormone progesterone also feeds uterine fibroids, so blocking its effects may help treat painful fibroids.\nAlthough EllaOne is not available in the U.S., an FDA advisory panel recently voted that it should be.\nIt is effective for up to five days after unprotected sex.\nThe new drug is manufactured by HRA Pharma, a European pharmaceutical company, which provided funding for the new study.\nAs of now, EllaOne is used in Europe as a morning-after pill because it blocks the effects of key hormones -- namely progesterone -- involved in ovulation.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story quotes several indepdent experts, the reader can assume that the story did not rely on a press release as the sole source of information.", "answer": 1}, {"article": "Toshiaki Higashihara, President & COO of Hitachi, Ltd. stated that, \u201cWe are greatly honored that Johns Hopkins selected Hitachi as their proton partner.\nThe next-generation system \u201cPROBEAT\u201d, which comes with IMPT (Intensity Modulated Proton Therapy) and cone-beam CT, will have improved spot scanning capability in all 3 gantry-type treatment rooms, along with a fixed irradiation room dedicated to cancer research.\nHitachi has delivered the first hospital based spot scanning system in May 2008 and has treated over 1,500 patients to date.\nIn fiscal year 2015 (ending March 2016), one of Hitachi's new PBT site is planning to start treatment of patients.\nHitachi will continue to globally expand the healthcare business where proton therapy is its flagship solution, and contribute to cancer treatment around the world.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "While there are several questionable claims made in the release, we think those have been addressed in other areas of the review. We didn\u2019t see any examples of over-the-top language.", "answer": 1}, {"article": "Dr. John Richmond disagrees.\nThe authors of the study discourage patients from getting this treatment.\nThe researchers in Switzerland reviewed the existing studies and concluded that viscosupplementation was associated with an increase in these and other adverse events.\nHowever, Richmond says patients considering viscosupplementation should discuss this as a treatment option with their doctor.\nIn a meta-analysis of 177 reports that included data on more than 12,000 patients with osteoarthritis in the knee, researchers at the Institute of Social and Preventive Medicine at the University of Bern in Switzerland concluded that the treatment \"has minimal benefits and potential for harm.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure of the extent to which the story may have relied on a news release.", "answer": 2}, {"article": "It may also improve vision in those with mild myopia (nearsightedness).\nReading at our normal pace, the brain has only about 250 milliseconds to do this work until the eyes automatically move onto the next letter or word.\nIt should be acknowledged that some researchers involved in many of these studies have financial ties to GlassesOff.\nHowever, other studies with no commercial links obtained similar results, and several scientists I spoke to, including those without ties to GlassesOff, thought the science behind the app was credible.\nAfter training, the older adults\u2019 ability to see low-contrast images improved to the level that the college-age ones had before training.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Although the Glassesoff app team recently issued a media \u201ckit\u201d and news release, the story\u2019s author has clearly been using the product for months. There is much original reporting and we don\u2019t see any evidence that the story relied excessively on a news release.", "answer": 1}, {"article": "Air is suctioned through the side channels to emulate breathing.\nMore often than not, these studies produce mixed data that don\u2019t tell researchers much about whether it is safe and effective for humans.\n\u201cBiology is very complex.\u201d\n\nIncorporating the chips into drug testing could save millions of dollars and years of time on research.\nThis proved the chips could provide real world information to scientists studying the effects of new drug compounds.\nThe project has received support from the National Institutes of Health and the FDA.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The Newsweek report does not rely on any news releases that we found online.", "answer": 1}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nEpclusa also carries a warning not to use with certain drugs that may reduce the amount of Epclusa in the blood which could lead to reduced efficacy of Epclusa.\nKnowing the genotype helps inform treatment recommendations and the duration of treatment.\nThe U.S. Food and Drug Administration approved Epclusa to treat adult patients with chronic hepatitis C virus (HCV) both with and without cirrhosis (advanced liver disease).\nEpclusa is a fixed-dose combination tablet containing sofosbuvir, a drug approved in 2013, and velpatasvir, a new drug, and is the first to treat all six major forms of HCV.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There was no unjustifiable language.", "answer": 1}, {"article": "That view is shared by Deborah Giaschi, a professor of ophthalmology and visual sciences at the University of British Columbia in Vancouver who has conducted MRI studies of the brains of people with dyslexia. \"There's really no scientific basis\" for ChromaGen lenses, she says. In her opinion, the claim that the lenses slow down visual processing doesn't make sense. Even if the lenses had that effect, she doesn't see how that would help anyone read.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that independent research and reporting was done by the writer.", "answer": 1}, {"article": "It matters.\nThat finding opened the door to potential targeted, molecular therapies for melanoma, which has been sorely lacking in effective treatments.\nThe current standard treatments for metastatic melanoma -- chemotherapy and interleukin-2 (IL2) -- only have response rates in about 15 percent of these patients, said Dr. Paul Chapman, senior author of a study in which the findings are described.\nThe average survival time for someone diagnosed with melanoma is nine to 11 months, added Chapman, who is an attending physician in the Melanoma Sarcoma Service at Memorial Sloan-Kettering Cancer Center in New York City.\nOne expert cautioned that it's too early to say whether the drug will actually prolong patient's lives, or if it might be helpful to patients in earlier stages of the disease.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We feel pretty confident that this story didn\u2019t rely on a news release.", "answer": 1}, {"article": "It was Kyle Henn, recovering from his own PTSD after surviving the plane crash, who recommended eye movement desensitization and reprocessing therapy, or EMDR.\nEMDR, Henn said, allowed her to have a do-over \u2014 to be able to grieve properly and then to move beyond grief.\nBut after the whirlwind passed, unaddressed grief remained with her.\nThis distraction had a positive effect on her, she said, allowing her to dive deeply into the therapy without freezing in the face of fear.\nThe ordeal didn\u2019t end with the news of Nate\u2019s death.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The heavy focus on an individual and her efforts to handle her PTSD symptoms suggests that a news\u00a0release was not a driver here.", "answer": 1}, {"article": "They then matched each statin user \u2014 who was aged over 40 when first prescribed a statin between 1995 and 2006 \u2014 with up to five non-statin users for comparison.\nDouglas noted that since this study looked at patients who were already taking statins when they developed pneumonia, a full randomized clinical trial was needed to find out whether starting a statin at the time of diagnosis has a similar effect.\n\u201cGiven the potential low number needed to treat to prevent a death suggested by this study, we believe that a strong case exists for randomized trials of statins in people with serious infection to determine if a simple and practical intervention at the point of diagnosis of pneumonia has a beneficial effect.\u201d\n\nDouglas\u2019s team, whose research was published in the British Medical Journal, used data from computerized medical records of doctors\u2019 practices in Britain to identify statin users.\n\u201cStatins are safe, cheap, and an easy intervention in terms of delivery,\u201d said Ian Douglas, a lecturer in epidemiology at the LSHTM who led the research.\nPrevious studies have suggested statins, which are also available as cheaper generics, may be linked to better outcomes after bacterial infection.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story seems to have taken several\u00a0quotes and passages almost directly from this news release put out by the London School of Hygiene and Tropical Medicine without stating this was the case.\nExample:\nStory: \u201cPatients with a record of pneumonia were followed for six months to see if they died, and the researchers found that 13 percent (109 out of 847) of statin users died compared with 20 percent (578 out of 2,927) of non-statin users.\u201d\nPress release: \u201cPatients with a record of pneumonia were followed for six months to see if they died and the scientists found that 13% (109 out of 847) of statin users died compared with 20% (578 out of 2927) of non-statin users\u201d.  This is simply not good journalistic practice.  In addition, the story says the\u00a0research was published in the British Medical Journal, but our reviewers could find no evidence that the study had been posted on the BMJ website at the time of their writing. This increases our concern that the story is simply republishing a press release without ever actually examining\u00a0the study.\n[Update: the article is now available on BMJ with a publication data of Wednesday April 6, whereas the\u00a0story stated that it was published on Tuesday April 5.]", "answer": 0}, {"article": "The lower the amount of free PSA, the more likely cancer is the cause and the more likely the disease is aggressive, requiring treatment, according to Dr. Patrick C. Walsh, a Johns Hopkins urologist and the author of \u201cDr.\nFor them, if other factors like prostate infection are not the cause of the high level, a biopsy is in order.\nBut, he added, \u201cIf we biopsied every man with a PSA below 4, we\u2019d be looking at a sea of cancers that would never grow to be life threatening.\u201d\n\nThese facts and the results of a recent study by Dr. Carter, among others, indicated that rather than acting on the basis of a single PSA test, the rate of change in levels over time is a better indicator of who might have a serious cancer.\n\u201cEven long-distance bikers do not have prostate trauma\u201d that causes their PSA to increase, Dr. Carter said.\n\u201cWe don\u2019t want to miss the possibility of a life-threatening disease, but we end up diagnosing and treating disease that would never have caused harm.\u201d\n\nThe new guidelines will lower the PSA level at which a biopsy should be considered, because, as Dr. Carter put it, \u201cthere\u2019s no level below which we can tell a man he doesn\u2019t have prostate cancer or life-threatening prostate cancer.\u201d\n\nAs one important trial showed, among men with a very low PSA \u2014 that is, a reading below the current cutoff of 4 \u2014 biopsies found that 15 percent had prostate cancer.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the article cites several sources, it is unlikely that it relied solely or largely on a news release. ", "answer": 1}, {"article": "Many pregnant women who have symptoms of depression worry that taking antidepressants might harm their unborn babies -- so they stop taking their medications, say researchers at the Stanford University School of Medicine.\nThe study included 150 pregnant women diagnosed with major depressive disorder.\nThe researchers say up to 14% of pregnant women may suffer from depression.\nThe study is published in the March issue of Obstetrics & Gynecology.\nAcupuncture might be a useful alternative, they say, because a study of pregnant women shows that the procedure works in reducing depressive symptoms better than other non-pharmacological techniques.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The information in this story was taken largely from a press release", "answer": 0}, {"article": "As we cut calories and lose weight, our resting metabolic rate eventually slows and our bodies become less efficient at shedding mass in a process known as adaptive thermogenesis.\nAnd while it\u2019s common to regain a few pounds after returning to previous eating habits, the two-week dieters kept the pounds off, maintaining a nearly 18-pound loss six months after the study.\nThis story was updated to include analysis from weight loss researcher Krista Varady, PhD, a nutrition professor at the University of Illinois, Chicago.\nThe experimental group stuck to the eating plan for two weeks, before ditching the diet for two weeks.\nThe dieters ate enough calories to maintain their weight during the off period.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There was a news release issued by the University of Tasmania but the article did quote an outside source.\n\u00a0", "answer": 1}, {"article": "\"This particular product plays very strongly into where we see the market going,\" he said.\nThe company says this is a major step forward in treating PAD because, unlike stents, atherectomy \"leaves no metal behind.\"\nThe results showed that atherectomy, the practice of trimming away the plaque that causes peripheral artery disease (PAD), is just as effective at restoring blood flow as traditional angioplasty and stents.\nThomas Gunderson, a senior analyst for Piper Jaffray & Co., said the Covidien study could lead to greater use of atherectomy and a bigger market.\nThe study is the largest to look at the effectiveness of atherectomy, Covidien said, and enrolled 800 patients at 47 centers in the U.S. and Europe.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Although the story is filled with company perspectives, there\u2019s no evidence it relied solely or largely on a news release.\u00a0 It did, though, appear to lift one paragraph from a company news release.\nStory:\nAccording to the American Heart Association, about 10 million people in the U.S. are affected by PAD, which can lead to heart attack, stroke, amputation and death. It occurs when arteries in the legs become narrowed or blocked by plaque. Blockages can result in severe pain, limited mobility and nonhealing leg ulcers.\nNews release:\nAccording to the American Heart Association, approximately 10 million people in the U.S. are affected by PAD, which is one of the most common vascular diseases and can lead to heart attack, stroke, amputation and death. It occurs when arteries in the legs become narrowed or blocked by plaque; these blockages can result in severe pain for patients, limited physical mobility and non-healing leg ulcers.\n\u00a0", "answer": 1}, {"article": "The most common side effects of atezolizumab included skin rash, colitis, and low thyroid hormone.\nThis is the first phase III trial of an immunotherapy-based combined modality treatment to show a significant improvement in progression-free survival in advanced squamous NSCLC, according to the authors.\nAlthough the rate of severe side effects was higher with the combined modality treatment than with chemotherapy alone (68% vs. 57%), it had a manageable safety profile, consistent with known safety risks of the individual therapies.\nPatients with EGFR or ALK gene changes in the tumor received targeted treatments before starting therapy on this trial.\nAlthough the difference between treatment groups is modest, a statistically significant improvement shows that, overall, people with advanced squamous lung cancer can benefit when immunotherapy is added to standard treatment, according to the authors.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release could be rated as satisfactory on the criterion, if readers assume that the claims of \u201crapid change in clinical practice\u201d refer only to immunotherapy in general, not to the drug tested in this trial. Since this drug has not shown longer overall survival, it is likely that any changes in prescribing will favor a competing drug that has now demonstrated longer survival results.", "answer": 0}, {"article": "; Eur Uro 2016 \n\niii Loeb et al.\nSince the introduction of the SelectMDx test in mid-2016, over 23,000 patients have been tested and 15 commercial contracts have been signed with US based insurance companies.\nThe researchers found that incorporating SelectMDx resulted in an average gain of 0.045 life years, or approximately 16 days, in full health gained at a cost-savings of $1,694 for each patient undergoing biopsy.\nResearchers analyzed the impact of utilizing the non-invasive diagnostic test prior to prostate biopsy.\n\"We believe that this strategy improves the value of conventional risk assessment strategies through improvements in both quality and cost, the numerator and denominator of the health care value equation.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Much of the release focuses, appropriately, on the cost-effectiveness of the test at an aggregate level.", "answer": 1}, {"article": "On average, using probiotics reduced a bout of diarrhea by more than a day, and reduced the risk of a prolonged diarrhea episode -- four days or more -- by 59 percent.\nEven so, Allen says more research is needed to determine the specific strains of bacteria that are most effective.\nAllen says that since the original review, there's been increasing interest in probiotics and, therefore, more research.\nThe review confirms the findings of another review in 2004, which also showed that probiotics had some effect against diarrhea.\nAuthors of the review note that probiotics can work in several ways, including robbing the offending bacteria, viruses or parasites of nutrients.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure of the extent to which the story relied on a news release.\u00a0 We do know that only the lead author of the study was quoted.", "answer": 2}, {"article": "People with poorly controlled diabetes, for example, may have breath that smells fruity due to an overproduction of chemicals called ketones; people with kidney or liver failure can have fishy breath.\nCleveland Clinic pulmonologist Peter Mazzone, MD, who is conducting lung cancer studies, says a breath test for cancer may be a reality in as little as five years if all goes well.\nIn a new study from Italy, researchers were able to identify patients with colorectal cancer with an accuracy of over 75% by analyzing samples of their breath.\nThe lung cancer device Mazzone is testing, called an \"electronic nose\" sensor, changes color based on the chemicals in the breath.\n\u201cThere is still quite a bit of work to be done.\u201d\n\nMazzone says the breath functions in the body in much the same way that the exhaust system functions in a car, and what comes out gives a sense of how things are working inside.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story pulls a quote from\u00a0one of the study authors from this press release, but it acknowledges that the source was \u201ca statement\u201d rather than\u00a0an interview. It\u2019s clear that reported actually consulted a second expert as well. Another borderline call for which we\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": "Tobacco use accounts for some 85 percent of lung cancer cases in the U.S., and one estimate puts a smoker\u2019s lifetime absolute risk of developing lung cancer between 12 percent and 17 percent.\nThe high so-called \u201cfalse positive\u201d rate is an issue, said Dr. James Hanley of McGill University, who also reviewed the findings for Reuters Health, but many mammograms also find lesions that turn out to be benign.\nThe data are \u201cconsistent\u201d with earlier studies but there are still many issues to resolve regarding lung cancer screening, Johnson said.\nAnd for lung cancer, doctors know there is a high false-positive rate and have a set protocol to follow in order to determine which lesions are dangerous, added Johnson.\nThis latest study, published in the journal Lung Cancer, looked at death rates in a different, smaller population of heavy smokers, and estimated that those who received up to two CT scans would have between a 36 and 64 percent lower risk of dying, compared to those who went unscreened.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\nThe story clearly does not rely on a news release.", "answer": 1}, {"article": "When all seizures were taken into account, children who did not have surgery were four times more likely to have a seizure during that year than youngsters in the surgery group, the researchers calculated.\nYet the cases were judged to be a success because the seizures decreased in frequency over time.\n\u201cThe results are impressive,\u201d he told Reuters Health by phone.\nHe was not involved in the research.\nNot only \u201cdoes it reassure us that several surgical procedures are effective,\u201d she said, it demonstrates that surgery \u201cshould be done as early as possible\u201d once it becomes clear that a child is not responding to two anti-seizure medications.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article quotes outside sources.", "answer": 1}, {"article": "Partial replacements, also known as unicompartmental replacements, are suitable for people who have arthritis in just one side of the knee, usually the inner.\nResearchers from the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS) publishing in the BMJ Open journal found that the less invasive procedure was being used less than it could be.\n\u201cThis has allowed us to provide strong proof that partial knee replacements are both better for patients and cheaper for the NHS.\u201d\n\nWhether people had a partial or total replacement varied by surgeon, as did the success of the operation, the researchers discovered.\n\u201cIf we see surgeons carrying out this procedure more often, the proportion of knee replacements that are partials would increase from the current figure of 9% and we would see an increase in future economic and population health gains.\u201d\nThose surgeons who carried out more partial replacements had better outcomes from them than surgeons who did fewer.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It appears that all of the information in the story, including the quotes from the study authors, comes from a news release issued by the study authors\u2019 research institution. The story does not credit the news release.\nFor example, this quote appears in both the news story and the news release:\n\u201cThe main strength of this study is that we were able to use real data, from very large numbers of people, about their actual operations, their GP visit, and their own reported quality of life outcomes in a way that is not always possible.\u201d", "answer": 0}, {"article": "For more information on biopsies, visit the U.S. National Library of Medicine.\nFor these areas, open biopsies are easier to do and need less imaging guidance, Kwan's team noted.\nIn addition, image-guided biopsies are more accurate, Quencer said.\n\"Doing image-guided biopsy allows more definitive diagnosis and shorter hospital stays,\" said Dr. Robert Quencer, chair of radiology at the University of Miami Miller School of Medicine, who was not involved on the study.\nMoreover, by 2008, 67 percent of these biopsies were being done through the skin with the help of CT scans, ultrasound and MRI, Kwan's group found.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does not appear that the story relied solely on a news release. ", "answer": 1}, {"article": "More adults and kids taking Prozac, known generically as fluoxetine, had at least a 50 percent improvement in scores on depression tests after six weeks compared to those assigned to take a placebo pill.\nIrving Kirsch, who studies antidepressants and placebos at Harvard Medical School in Boston, said the new report didn\u2019t make him more optimistic about the drugs.\n\u201cThere are alternative treatments for depression that also produce about the same symptom reduction as the drugs do, but without the risk of side effects,\u201d Kirsch added, including psychotherapy and exercise.\nStill, Gibbons said that the improvement in symptoms for the average patient wasn\u2019t insignificant.\nStill, not everyone in the studies improved \u2014 on average, about five people had to be treated with one of the drugs for one person to feel better, and the benefits seemed to be diminished among some of the oldest patients.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not rely on a news release.", "answer": 1}, {"article": ".\nThe risk of dying from any cause or having a stroke was 23 to 34 percent higher in patients who discontinued anticoagulation therapy compared to those who resumed it.\n\"They should also take into account that the benefit-to-risk ratio of post-hemorrhage use of anticoagulation is not the same for all medications.\"\nFurthermore, restarting therapy with the new oral anticoagulant dabigatran was associated with a lower risk of recurrent hemorrhage in these cases than the old standby drug warfarin.\n\"Our results should encourage clinicians to seriously consider resuming anticoagulation among patients who survived a major bleeding event, particularly if the source of bleeding was identified and addressed,\" said senior author Samir Saba, M.D., associate professor of medicine and associate chief of cardiology at UPMC Heart and Vascular Institute.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Given that many people read only the headline, we think this one should have been far more nuanced. \u201cDabigatran superior to warfarin when anticoagulation is resumed after bleeding\u201d should be qualified with the fact that this was the finding of one study, which needs to be repeated and confirmed with other data. The results should have been presented as very preliminary, but they were described in much more definitive terms.", "answer": 0}, {"article": "\u201cIt all depends on how you approach risk,\u201d Dr. Zelen said.\nBut, cancer experts said, no one would do such a study today when mammograms are generally agreed to prevent breast cancer deaths.\n\u201cWe were surprised,\u201d said Dr. Mette Kalager, the lead author of the paper who is a breast surgeon at University and a visiting scientist at the Harvard School of Public Health.\nTwo percent is an estimate, Dr. Welch said.\n\u201cThis is the first time researchers used real populations to compare the effects of treatment and mammography in the modern era of treatment,\u201d Dr. Kramer said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\nThe story includes comments from several sources and does not appear to rely on a news release.", "answer": 1}, {"article": "But it also lowered women's risk of dying from breast cancer by 11% and men's risk of dying from prostate cancer by 23%.\n\"This study found strong evidence that aspirin use may reduce cancer death.\nCao hopes her study will continue to broaden the body of research to include cancer-related deaths overall.\nThe study was well conducted and was able to control for a number of important confounders.\nNot everyone can take aspirin, particularly if you are at high risk for ulcers and gastrointestinal bleeding.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story is similar to the news release, yet it does contain several quotes from the lead researcher that were not found in the news release. This earns it a barely passing satisfactory.", "answer": 1}, {"article": "The ancient art of applying suction cups to the body has gotten a boost from several new studies that show it helps relieve a variety of painful conditions. But scientists say larger, more rigorous studies are needed.\n\nCupping, as the practice is called, was performed traditionally in China and other countries, and is now available from acupuncturists, and some chiropractors and massage therapists in the U.S. In the traditional method, called fire cupping, a ball of burning cotton is briefly placed inside a glass cup to heat...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a press release.", "answer": 1}, {"article": "\u201cThat would be the quickest path to insolvency,\u201d he said.\nEteplirsen, which Sarepta says has shown no side effects so far, is vying with a similar drug being developed by GlaxoSmithKline to become the first medicine that works by directly countering the cause of the disease.\nEteplirsen could also be the first drug to reach the market for Sarepta since it was founded 32 years ago.\nThose with the disease make barely any dystrophin, a protein necessary for muscles to function.\nWhile the company excluded those boys from its analysis as outliers, the Food and Drug Administration might not do so.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a press release.", "answer": 1}, {"article": "Caucasian men more commonly reported circumcision (69%) than African American men (43%).\nIt's important to note, right off the bat, that this study is not purporting to establish a cause and effect relationship.\nA few potential caveats to note include the reliance on self-reporting when it comes to a man's history of STIs, as well as his sexual partners.\nThe bottom line from the American Cancer Society: While this is an interesting finding, it's not likely to spur any change in recommendations or medical practice.\nThe good news, we're told, is that there are many things we can do \u2013 or not do \u2013 in our adult lives to lower our risk of developing different types of cancer.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story is not based on a press release as far as we can tell.", "answer": 1}, {"article": "Since 2013, the American Academy of Pediatrics endorses a wait-and-see approach, seeking to let more earaches heal on their own without antibiotics.\nMoms have flooded https://www.facebook.com/ClearPop with glowing testimonials for this simple drug-free solution that:\n\n-can be given along with analgesics or antibiotics.\nCLINICAL TESTS\n\nChildren diagnosed with Acute Otitis Media, or ear infection, consumed the xylitol and Vitamin C-based product in pediatric offices.\nWALNUT CREEK, Calif., Jan. 15, 2016 /PRNewswire/ -- Child screams from the pain of earache; exhausted parent ventures to drugstore in wee hours to find\u2026nothing.\nFull study report at http://clearpop.com \n\n\n\nEAR INFECTION AND ANTIBIOTICS\n\nEar infections are the Number One reason kids aged 5 and under receive oral antibiotics.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release does contain unjustifiable language, such as in the headline \u201cClinical study finds a specialized lollipop can end a kid\u2019s earache in nine of ten cases,\u201d but we won\u2019t double-ding the source since we\u2019ve already commented on most of these concerns under other criteria.", "answer": 1}, {"article": "Visit the U.S. Centers for Disease Control and Prevention for more on obesity.\nSix months after the balloons were removed, nearly 90 percent maintained the weight loss they achieved during treatment, Pryor said.\nThe results were also presented at a medical meeting in May.\n\"The long-term results are dependent on patients keeping their motivation to stay with their diet and exercise programs.\"\nThe balloon treatment will be available starting in January, but the cost hasn't been announced, Pryor said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes several quotes from independent sources, as well as important details that were not included in a news release from the organizers of the the medical meeting where these results were presented. (We also reviewed the news release.)", "answer": 1}, {"article": "All rights reserved.\nThe results translate to 43 fewer heart attacks and strokes per 100,000 people, said lead author Dr. Eric Brandt, a Yale University cardiology fellow.\nDr. Mark Creager, former American Heart Association president, said the results echo previous studies \u201cand are consistent with the thinking of most scientists\u201d on potential benefits of these bans.\nThe study hints at the potential for widespread health benefits from an upcoming nationwide ban, the authors and other experts say.\nHis study was published Wednesday in JAMA Cardiology.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Although Yale University did issue\u00a0a news\u00a0release, this story contains details not available in that text.", "answer": 1}, {"article": "The Institute carries out rigorous studies that discover the mechanisms of age-related disease and disability; lead to the prevention, treatment and cure of disease; advance the standard of care for older people; and inform public decision-making.\nBased in Boston, the non-profit, non-sectarian organization has provided communities and health care for seniors, research into aging, and education for geriatric care providers since 1903.\nHebrew SeniorLife, an affiliate of Harvard Medical School, is a national senior services leader uniquely dedicated to rethinking, researching and redefining the possibilities of aging.\nSaid Co-author Douglas P. Kiel, M.D., M.P.H., Director, Musculoskeletal Research Center at Hebrew SeniorLife's Institute for Aging Research.\nThis makes bone density testing even more useful in screening.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The language seems appropriate.", "answer": 1}, {"article": "Airways became less likely to close off after exposure to an allergen.\nThe drug also improved overall airway function, an effect researchers hadn't expected, Israel said.\nTwo generic versions of the drug were launched last year, which could make it less pricey than new-wave asthma drugs headed for the market, Israel added.\n\"Further studies will be needed to assess its utility in moderate asthma.\"\nSide-effects were not as severe as expected, he added.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "Prostate cancer killed an estimated 258,000 men around the world in 2008 and is the second most common cause of cancer death in men in the United States.\n\u201cThe protein is easy to detect because it is found in urine and would potentially be a very simple test to carry out on men to identify those most at risk of developing the disease,\u201d said Hayley Whitaker of the Cambridge institute, who led the study.\nCommenting on the study, Kate Holmes of the UK\u2019s Prostate Cancer Charity, said they could prove very valuable in future.\nWhitaker said that while it could be around five years before the results of this study are translated into a test for doctors to use in clinics, she hoped it would then also help them to determine which patients have aggressive tumors.\nScientists from the Cancer Research UK Cambridge Research Institute and the Institute of Cancer Research (ICR) said the protein, called microseminoprotein-beta or MSMB, is found at reduced levels in men diagnosed with the disease and are also lower in men with more aggressive forms of the cancer.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\u00a0Does not appear to rely solely on a news release", "answer": 1}, {"article": "A health claim, in the language of the FDA, characterizes the relationship between a substance and a reduction in the risk of contracting a particular disease.\n\"There is no credible evidence to support qualified health claims for green tea or green tea extract and a reduction of a number of risk factors associated with (cardiovascular disease),\" the FDA said on its Web site last week.\nThe Food and Drug Administration said it reviewed 105 articles and other publications submitted as part of the petition but could find no evidence to support claims of the beverage's health benefits.\nNonetheless, the belief that drinking green tea confers health benefits has driven its popularity over the past decade, the Tea Association of the United States has said.\nA message left for the AAC Consulting Group, a Rockville, Md., company that filed the petition, also was not immediately returned.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if the story relied solely or largely on a news release. ", "answer": 2}, {"article": "The requested URL /usnews/health/articles/061008/16healthwatch.htm was not found on this server.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if the story relied solely or largely on a news release, although only the study author is quoted and no independent source was used. ", "answer": 2}, {"article": "New York Eye and Ear Infirmary of Mount Sinai is ranked No.\nThis is the first study to demonstrate that among advanced cancer patients admitted to an inpatient oncology service, standardized use of triggers for palliative care consultation is associated with substantial improvement on multiple quality measures.\nThe palliative team was composed of one board certified PC physician, one nurse practitioner, one social worker, a chaplain, and one to two trainees.\nConsultation with the palliative care team included establishment of goals of care, advance care plans using standardized communication protocols, transition planning and symptom assessment and treatment using the Edmonton Symptom Assessment Scale (ESAS).\nPhysicians are affiliated with the renowned Icahn School of Medicine at Mount Sinai, which is ranked among the highest in the nation in National Institutes of Health funding per investigator.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There is no sensational language in this release. The tone is objective and factual.", "answer": 1}, {"article": "(Reuters) - Pivotal trial results for Merck & Co Inc\u2019s immunotherapy drug Keytruda show that it lengthened survival by three months, or nearly 40 percent, for patients with advanced bladder cancer who had stopped responding to chemotherapy.\nThe Merck drug is awaiting U.S. Food and Drug Administration approval, but Tecentriq was approved by the agency last year, contingent on verification of its clinical benefit.\nMerck announced in October that the second-line bladder cancer study met its main goal and was stopped early.\nThe company is currently enrolling patients in a phase three trial of Keytruda, combined with chemotherapy, as an initial treatment for bladder cancer.\nAccording to the FDA approval letter, the company has until December to submit the full trial data to the agency.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes original background information on similar drugs from other competitors.", "answer": 1}, {"article": "'This is not the end': Using immunotherapy and a genetic glitch to give cancer patients hope\n\nNew shingles vaccine is highly effective \u2014 and in short supply\n\nResearchers use immune-cell 'army' to battle another tough cancer\nShlomo Shinnar, president of the American Epilepsy Society and a neurologist at Montefiore Medical Center in New York, has said the drug will be \u201ca very valuable addition\u201d to the limited options for treating severe childhood-onset epilepsy.\nThe drug is the first treatment approved for Dravet syndrome.\nThe drugmaker is testing other CBD treatments for glioblastoma and schizophrenia.\nFDA Commissioner Scott Gottlieb said the approval was \u201ca reminder that advancing sound development programs that properly evaluate active ingredients contained in marijuana can lead to important medical therapies.\u201d The medication, tested in three randomized, placebo-controlled trials with more than 500 patients, was effective in reducing seizures, the FDA said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This did not rely solely on the FDA\u2019s news release.", "answer": 1}, {"article": "Industry analysts have estimated that 10 to 15 percent of Americans with Type 1 diabetes \u2014 perhaps 400,000 of them \u2014 use either a continuous glucose monitor or an insulin pump, or in some cases both.\nThe study not only indicated that the algorithm system prevented very low glucose overnight, Dr. Hovorka said, but it also indicated that the experimental system was better able to keep blood glucose in an acceptable range.\nEven so, Dr. Kowalski said, using separate devices that are not designed to work in concert poses limits to treatment, particularly overnight.\nAlthough the Lancet study was small \u2014 only 17 children completed the entire protocol \u2014 it is significant because it demonstrated that a computer algorithm could safely interpret glucose data and calculate appropriate insulin doses for a pump, he said.\nDr. Renard, whose commentary accompanied the study in The Lancet, has been a consultant and speaker for several makers of diabetic products, he said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not rely on any news release.", "answer": 1}, {"article": "Dr. Henderson stated, \"Misconceptions about ketamine abound among psychiatrists, particularly related to possible chemical dependence problems.\nIts findings stand in direct contrast to warnings from the American Psychiatric Association (APA).\nDr. Henderson's findings challenge the oft-held beliefs that ketamine must be given frequently to have any benefit and that ketamine has no long-lasting benefit.\nThrough a handful of ketamine infusions directed by Theodore Henderson, MD, PhD, refractory depression symptoms can be relieved significantly and persistently.\nAnother conclusion Dr. Henderson highlights is ketamine infusions can relieve refractory depression symptoms persistently, perhaps for years.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release does not engage in the use of unjustifiable language by calling the treatment a \u201ccure\u201d or \u201cbreakthrough.\u201d", "answer": 1}, {"article": "However, men who took three pills daily were more likely to suffer mild to moderate diarrhea: 14% vs. 2% of those who took one pill.\nAt the start of the study, the men's PSA levels were doubling every 12 months.\nThe study was presented at the Genitourinary Cancers Symposium.\nAfter six months of taking the capsules, it took 19 months for their PSA levels to double.\nThe new study involved 92 men with cancer that had not spread beyond the prostate and rising PSA levels.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely on a news release.", "answer": 1}, {"article": "Army veteran Vivian Cooke has long struggled with debilitating depression.\n\u201cI had less problems with depression.\u201d\n\nEven though the study she took part in is now over, she said she will continue to get Botox injections.\nFinzi notes previous studies show between 50 to 60 percent of patients may benefit from the treatment.\nAs for Cooke, she said she noticed a change in her depression almost immediately.\n\u201cSo Botox basically inhibits the muscle and calms it down, so it becomes more difficult to feel those negative emotions.\u201d\n\nThe makers of Botox recently announced plans for the final phase of testing it as a treatment for depression.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story doesn\u2019t appear to rely on a news release. It includes comments from Dr. Finzi.", "answer": 1}, {"article": "For ongoing (or chronic) pain \u2014 a sore lower back, say, or the kind of degenerative arthritis that typically develops with age \u2014 ibuprofen still outperforms acetaminophen.\nFever is another area where acetaminophen can help, said Moore.\nIt turns out this is another fascinating problem area for pain researchers.\n(Ibuprofen also has potential side effects; more on that below.)\nI didn't think much about whether it was more or less effective than any other type of over-the-counter pain reliever, and I suspect the same is true for many folks.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Since this article was prompted by a reader question and includes comments from three expert sources, we are confident it isn\u2019t based on a news release.", "answer": 1}, {"article": "Natural Cycles uses a woman's body temperature and menstrual cycle data to tell her when she is fertile.\nFor starters, it can only protect against pregnancy, not STIs.\nYou don't actually need an app to practise natural family planning \u2013 although it does cut down on paperwork.\nBut natural family planning is not for everyone.\nAnd if you're considering ditching the Pill because remembering to take it each day is too much effort, you probably won't like having to remember to take your temperature every morning.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This article did not rely on a news release.", "answer": 1}, {"article": "Cancer cells remain elusive and tough to locate, but a new crop of nuclear-imaging tests promises to lead to more accurate prognosis and treatment.\n\nThe tests use imaging agents that combine radioactive isotopes with targeted molecules that can spot cancer at the cellular level. The ability to accurately locate the cancers helps physicians make better and earlier diagnoses\u2014and may eventually make possible targeted nuclear-medicine therapies that identify and kill cancer cells, but not the surrounding healthy cells.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There were news releases issued recently by one of the companies involved in the commercialization of the tests, but the article does not appear to rely on them.", "answer": 1}, {"article": "In nonblood-based tumors, such as melanoma, only about one-half of patients have T cells in their tumors that can be harvested, and only about one-half of those harvested cells can be grown.\nNoonan says the small trial helped her and her colleagues learn more about which patients may benefit from MILs therapy.\nNoonan says the research team has used these data to guide two other ongoing MILs clinical trials.\nFor the clinical trial, the Johns Hopkins team enrolled 25 patients with newly diagnosed or relapsed multiple myeloma, although three of the patients relapsed before they could receive the MILs therapy.\nOne year after receiving the MILs therapy, 13 of the 22 patients had at least a partial response to the therapy, meaning that their cancers had shrunk by at least 50 percent.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "This release is conservative throughout in its choice of language in describing this research which, based on its findings, might be ripe for exaggeration.", "answer": 1}, {"article": "A birth-control pill that eliminates women's monthly periods could hit pharmacy shelves later this year, marking the latest effort by a drug company to expand a contraceptive's features beyond preventing pregnancy.\n\nSince \"The Pill\" was introduced nearly a half-century ago, most regimens have mimicked a woman's cycle by having a pill-free week each month when women can have bleeding and other symptoms.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article cites one independent expert, and so does not appear to have relied exclusively on a press release.", "answer": 1}, {"article": "Traditional knee surgery cuts through muscles and tendons.\nO'Brien spent just a few hours in the hospital after surgery before she was well enough to go home.\nO'Brien successfully charted the course and headed out of the hospital to a smooth recovery.\nFor Linda O'Brien, a grandmother and scratch golfer, chronic knee pain was making life unbearable.\n\"I'll be chipping and putting in three weeks \u2014 maybe four,\" joked O'Brien from the operating table.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if this story relied solely or largely on a news release, although the lack of input from independent sources is a concern. ", "answer": 2}, {"article": "1.\nThe study is published in Annals of Internal Medicine.\nResearchers sought to determine the clinical effectiveness of acupuncture or Alexander Technique lessons compared with usual care for persons with chronic, nonspecific neck pain.\nBoth interventions had a high rate of acceptability, and greater adherence was associated with better pain outcomes.\nThe researchers found that acupuncture and the Alexander Technique lessons both led to a significant reduction in neck pain at 12 months compared with usual care alone.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release maintains an objective, scientific\u00a0voice throughout the piece.", "answer": 1}, {"article": "Researchers conducted a randomized, double-blind, placebo-controlled study of 40 postmenopausal women ages 45 to 65 with high blood pressure.\nThe improvement, the scientists write, was moderate compared with that of blood pressure medicines.\nThere were no significant changes in the placebo group.\nThe lead author, Sarah A. Johnson, a postdoctoral researcher at Florida State University, said she saw no reason for people to radically change their diet, but that if they are not eating blueberries, they might want to try them.\nBut, they say, eating blueberries in larger amounts or for longer periods could increase the effect.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Since the story includes comments from an interview with the lead researcher, we can be sure it wasn\u2019t based entirely on a press release.", "answer": 1}, {"article": "\"There was a trend toward less severe psoriasis severity in people taking statins,\" says researcher Adam Perry, a fourth-year medical student at Emory University in Atlanta.\nAnd no one should start taking statins in an attempt to ward off psoriasis symptoms, doctors stress.\nBut the findings, presented at the American Academy of Dermatology annual meeting, raise an interesting possibility worthy of further study, experts agree.\nThe study is preliminary and doesn't prove cause and effect.\nMarch 8, 2010 (Miami Beach, Fla.) -- Once again, cholesterol-lowering statin drugs have been shown to be good for more than the heart.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\u00a0Does not appear to rely exclusively on a news release.", "answer": 1}, {"article": "Public health officials also waged awareness campaigns about prevention, reminding people to practice safe sex with condoms and get tested, and that early HIV treatment can save lives.\nThe mosaic approach seems promising in very early clinical research\n\nIn the 35 years of the HIV epidemic, only four HIV vaccine concepts have been tested in humans.\nBut so far, the HIV community is carefully watching the Ad26 vaccine research because the approach seems quite promising.\nSo it\u2019s difficult to think about how a single shot might work against all the different HIV subtypes circulating around the world.\n\u201cThe mosaic strategy is one way to attempt to deal with the global virus diversity.\u201d\n\nA word of caution, though: We\u2019re only in the early phase of human testing, and the vaccine could ultimately fail to prevent the virus from spreading among people.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is little evidence of an overreliance on a news release, especially with the use of many caveats warning that this research shouldn\u2019t be overinterpreted and the use of at least one outside source.", "answer": 1}, {"article": "But study author Anna Giuliano believes that, \"vaccinating males would have a direct benefit that men would receive, as well as a community benefit.\nAmong participants who completed the three-vaccine series, Gardasil afforded 90 percent protection against HPV.\nStudies have shown it to be about 100 percent effective in preventing precancerous cervical lesions in females.\n\"This well-designed study reinforces the idea that there is value in vaccinating young men against a virus that is nearly ubiquitous among sexually active individuals.\"\nAll were HPV-free at the beginning of the trial, and were followed for about three years.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story shows evidence of original reporting. ", "answer": 1}, {"article": "The page may no longer exist or may have moved to another web address. Try again to locate what you want by choosing a section from the navigation menu at left, viewing our Site Map or using the search box below.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no evidence that this story relies on a press release.", "answer": 1}, {"article": "(Reuters Health) - People struggling with irritable bowel syndrome (IBS) might feel better with antidepressants or psychotherapy, a recent study suggests.\nStill, a psychological evaluation may make sense for IBS patients because it\u2019s possible their symptoms might be a byproduct of untreated depression, said Dr. Agnieszka Kulak-Bejda, a psychiatry researcher at the Medical University of Bia\u0142ystok in Poland who wasn\u2019t involved in the study.\nAlthough the use of antidepressants is common among IBS patients, psychotherapy is not, the study authors note.\nA family of medicines known as tricyclic antidepressants were more effective at relieving global symptoms of IBS, the analysis found.\nAnother drawback is that these studies weren\u2019t designed to prove how antidepressants or psychotherapy might directly improve IBS symptoms.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story incorporates original reporting and does not appear to be based on a news release.", "answer": 1}, {"article": "Dr Weaver said: \"We have shown that all our patients in the study had their insulin doses reduced after taking metformin and have not suffered any serious adverse effect.\n\"The results, which indicate that metformin, a drug commonly used in the treatment of Type 2 diabetes, could also have a powerful effect in people with Type 1 diabetes is unexpected.\n\"For the first time, this study has shown metformin has additional benefit beyond improving diabetes control when given to patients with relatively well controlled Type 1 diabetes.\nShe believes this new research is a major development in understanding the best ways to further improve treatment in Type 1 diabetes.\n\"We have established the drug increases patients own vascular stem cells, which will help delay or slowdown heart disease.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "This release does not appear to offer any unjustifiable language per se. However, the release seems to point only towards this being\u00a0totally beneficial without any statement about the likelihood that this \u201cbasic science\u201d study would translate to clinically important patient centered outcomes.\nAnd there are statements that are clearly overreaching. For example, \u201cWe have established the drug increases patients own vascular stem cells, which will help delay or slowdown heart disease.\u201d It\u2019s not at all clear that increasing vascular stem cells will delay or slow down heart disease. We\u2019d need another much larger larger study to show that.\nFinally, use of anecdotal statements from a trial participant offers little of value for readers. We don\u2019t know if his was the best experience among all the participants, or the worst, or somewhere in between.  ", "answer": 0}, {"article": "Insulin helps glucose (sugar) enter cells to provide fuel for those cells.\nWhen treatment was stopped, the benefits gradually tapered off, Baker said.\nThe study medications were supplied by the manufacturer of the growth hormone-releasing hormone.\nDr. Joel Zonszein, an endocrinologist from Montefiore Medical Center, in New York City, praised the study but said some questions still remain.\nBenefits from the treatment lasted as long as people stayed on the treatment.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There\u2019s no sign that the story relied on a news release.", "answer": 1}, {"article": "Food sources of vitamin E include wheat germ, nuts such as almonds and hazelnuts, vegetable oils such as sunflower and safflower oils, and some green vegetables, such as spinach and broccoli.\nWhen Breteler\u2019s team considered a number of other factors \u2014 including participants\u2019 age, education, weight, and smoking and drinking habits \u2014 high vitamin E intake was linked to a one-quarter reduction in dementia risk.\nAccording to Breteler\u2019s team, studies should continue to look at the relationship between antioxidant intake and dementia \u2014 including whether antioxidant consumption at different points in life might have different effects on dementia risk.\nAnd it supports findings from some previous research that dietary vitamin E, in particular, might be related to a lower risk of dementia.\nHowever, the new study followed participants for a longer period than most previous studies on antioxidants and dementia.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "While the story doesn\u2019t appear to have lifted anything directly from the press release issued for this study, it also doesn\u2019t\u00a0seem to have interviewed anyone about the research. Since we can\u2019t be sure to what extent the story relied on\u00a0a release, we\u2019ll call it not applicable.", "answer": 2}, {"article": "It's a substantial number of women,\" Lyman said.\nIn a telephone interview, Gary Lyman of the American Society of Clinical Oncology said the findings will probably prompt the group to revise its recommendations for breast cancer patients accordingly.\nThe study, involving nearly 900 women who were treated at 115 sites across the country, found that those who did have their lymph nodes removed were no more likely to survive five years after the surgery than those who did not, the researchers reported in a paper published in the Journal of the American Medical Association.\nThe study provides \"strong evidence\" that many women can safely forgo lymph node removal, they wrote.\nIn an accompanying editorial, Grant Walter Carlson and William Wood of Emory University in Atlanta called the study an \"important contribution\" that represents the latest development in breast cancer treatment, which has steadily been moving toward less-aggressive options, sparing women from unnecessary surgery and follow-up therapy.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article includes information from a telephone interview with Gary Lyman of the American Society of Clinical Oncology which recommends surgery and treatment options for patients. And it includes comments from editorial authors.", "answer": 1}, {"article": ".\n\"These findings are the first example of a precision therapy that is uniquely effective in a subgroup of patients with treatment-resistant COPD.\"\nThe METREO results narrowly missed statistical significance.\nThe safety profile of mepolizumab did not differ from placebo in either trial.\nThe first trial, termed METREX, was conducted at 117 sites in 15 countries from 2014 to 2017.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "No unjustifiable language is used in this news release.", "answer": 1}, {"article": "JACC is ranked No.\nThey also looked a several early indicators of heart disease.\nThe mission of the College is to transform cardiovascular care and to improve heart health.\nResearchers from Emory University Hospital in Atlanta set out to learn more about the relationship between depressive symptoms and heart disease.\n\"There are many patients with heart disease who also experience depression - we need to study whether encouraging them to exercise will reduce their risk of adverse outcomes.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release contains no sensational language promoting, say, exercise as the holy grail of curing cardio diseases.", "answer": 1}, {"article": "The scans, called coronary computed tomography angiography or CCTA, produce a detailed image of the heart that reveals cholesterol buildups in the coronary arteries.\nYet there\u2019s no evidence that treating people based on heart scan results does any good, said Dr. John McEvoy, of Johns Hopkins Ciccarone Center for the Prevention of Heart Disease in Baltimore, who led the new study.\nIn an editorial, Dr. Michael S. Lauer of National Heart, Lung, and Blood Institute in Bethesda, Maryland, said the new study serves as a reminder of the downsides of screening.\nAccording to McEvoy, doctors should focus on patients\u2019 lifestyle and traditional risk factors such as smoking and obesity.\n\u201cTesting might lead to more harm than good,\u201d McEvoy told Reuters Health, adding that heart scans may cost $600 or more.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely on a news release.", "answer": 1}, {"article": "Their average dose of mealtime insulin decreased by seven units (30%) and their need for all-day insulin dropped by eight units (32%).\nThose who continued treatment for a full year continued these improvements and felt much better overall, says study leader Paresh Dandona, MD, of the State University of New York, Buffalo.\nYet all patients' blood sugar peaked and dipped at unpredictable intervals.\nAnd during Victoza treatment, patients needed less and less insulin.\nThis appeared to be due to reduced appetite and food intake.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story acknowledges in a footnote that a news release from the Endocrine Society was used as source material. However, we could not locate a copy of this release online to evaluate it. Since there were no expert sources cited\u00a0other than the lead researcher on the study, we can\u2019t be sure to what extent this story relied on the Endocrine Society release for its content. We\u2019ll rate this one not applicable.", "answer": 2}, {"article": "Makers include General Electric Co\u2019s GE Healthcare Siemens AG, Toshiba Corp, Hitachi and Philips.\nThe researchers waited until an independent panel could document a 20 percent reduction in cancer deaths, or could determine that there was no significant benefit.\nDr. Bruce Johnson of the Dana Farber Cancer Institute in Boston, who is on the board of the American Society of Clinical Oncology, said he doubted most people would see the findings as a green light to smoke.\n\u201cThis screening does not prevent lung cancer and it does not protect the large majority of subjects from death by lung cancer,\u201d Varmus said.\nHer ideas were controversial to start with and widely disregarded when other researchers found her work had been paid for by a tobacco company.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did rely a little too heavily on press releases. For example, one quote from the study\u2019s leader, Dr. Denise Aberle, is from this release. And her other quote and a quote from Dr. Christine Berg, are from this release. Only the Berg quote is attributed to \u201ca statement.\u201d\u00a0 To lift quotes from news releases without attribution is not good practice.", "answer": 0}, {"article": "March 15, 2010 -- A common pain reliever may help people with type 2 diabetes control their blood sugar levels.\nHowever, it also has been shown to increase protein in the urine and its long-term safety will need further investigation.\nThat prompted researchers to take another look at salsalate in reducing blood sugar levels.\nOther markers of glycemic control and heart disease risk also improved in the three salsalate groups compared with the placebo group.\nDue to the small size of the study and short follow-up time, researchers say it's too soon to recommend use of salsalate for the treatment of type 2 diabetes.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article does not appear to rely largely on the news release. Unlike the other article we reviewed, it contains several pieces of information not found in the news release.", "answer": 1}, {"article": "Nov. 24, 2016.\n\u201cWith standard aggressive chemotherapy, we only see about 20 to 30 percent of these patients achieving remission, which is the critical first step to have a chance to cure patients with additional therapies.\nThe current study involved 116 patients treated with decitabine at the Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital, and at the University of Chicago.\nThe study, by a team of scientists at Washington University School of Medicine in St. Louis, is published Nov. 24 in The New England Journal of Medicine.\nBut surprisingly, AML patients whose leukemia cells carried mutations in a nefarious cancer gene called TP53 consistently achieved remission after treatment with decitabine.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There is no unjustifiable language used and it is made clear that decitabine is not a cure for these patients.", "answer": 1}, {"article": "The Department of Nutrition, Exercise and Sports conducts research, education, innovation, and dissemination of information in nutrition, human physiology and sports at the highest international level, and incorporates the humanities as well as health and social sciences.\nThe research analyzed data from three diet clinical trials which collectively looked at more than 1,200 individuals - Diet, Obesity, and Genes (DiOGenes); the OPUS Supermarket intervention (SHOPUS); and the Nutrient-gene interactions in human obesity (NUGENOB).\nThe latest findings, as published in AJCN, concluded that a personalized nutritional approach based on an individual's biomarkers will lead to improved weight loss and maintenance success.\nThe latest findings, as reported in AJCN, have garnered international support with further analysis conducted by researchers from the University of Colorado, Tufts University, and Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Fisiopatolog\u00eda de la Obesidad y Nutrici\u00f3n (CIBER OBN).\nThe different studies (six in total) employed a variety of nutrition strategies, including caloric restriction and ad libitum diets, varying the contributions of carbohydrate and fat, and increasing fiber intake.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Calling the findings a \u201cbreakthrough in personalized nutrition\u201d seems unjustified given we\u2019re provided no results.", "answer": 0}, {"article": "\u2022 Kim TI, Lee YK, Park SG, et al.\nBrain research.\n2012; http://www.ndss.org/Down-Syndrome/What-Is-Down-Syndrome/.\nThe FEBS journal.\nThe study was conducted at the IMIM-Hospital del Mar Medical Research Institute in Barcelona, Spain.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release does not use unjustifiable, sensational language.", "answer": 1}, {"article": "Heart disease is still the leading killer of Americans \u2014 790,000 people have heart attacks each year \u2014 and stenting is a mainstay treatment in virtually every hospital.\nThe devices are lifesaving when used to open arteries in patients in the throes of a heart attack.\nOther estimates are far higher.\nSometimes patients get stents when they have no pain at all, just blockages.\nTheir study focused on the insertion of stents, tiny wire cages, to open blocked arteries.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not rely on the news release.\n\u00a0\n\u00a0", "answer": 1}, {"article": "In Belgium, engineer and nuclear physicist Yves Jongen is pioneering a new therapy that targets cancers with proton radiation; a therapy that offers precision and minimal side effects.\nOther centers, however, are currently in development.\nWhile proton therapy is a giant step forward, it's not yet the magic bullet that clinicians are looking for.\nAs the fame of the process has started to spread, some people have been taking desperate measures to get treatment.\n\"I started to designing equipment (for) proton therapy of cancer -- that was a radically new idea,\" Jongen told CNN.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We are not aware of any news release that prompted this story. But because no independent perspective appears \u2013 only the inventor/entrepeneur is interviewed \u2013 and because there isn\u2019t any true news in the piece, the only grade we can give the story under these circumstances is a questioning Not Applicable.", "answer": 2}, {"article": "The risk of lung cancer death was 30 percent lower, the risk of colorectal cancer death was 40 percent lower and the risk of esophageal cancer death was 60 percent lower, the study reported.\nThe specific dose of aspirin taken did not seem to matter \u2014 most trials gave out low doses of 75 to 100 milligrams \u2014 but the participants in the longest lasting trials had the most drastic reductions in cancer death years later.\n\u201cThis is important as a proof of principle that a single simple compound like aspirin can reduce the risk of cancer substantially,\u201d said the study\u2019s lead author, Dr. Peter M. Rothwell, professor of neurology at the University of Oxford.\nAs part of the new study, published online Monday in the journal Lancet, researchers examined the cancer death rates of 25,570 patients who had participated in eight different randomized controlled trials of aspirin that ended up to 20 years earlier.\nParticipants who had been assigned to the aspirin arms of the studies were 20 percent less likely after 20 years to have died of solid tumor cancers than those who had been in the comparison group taking dummy pills during the clinical trials, and their risk of gastrointestinal cancer death was 35 percent lower.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story does not appear to rely on a news release.", "answer": 1}, {"article": "LONDON -- Sanofi-Aventis SA's obesity drug Acomplia can improve blood-sugar levels and weight loss in diabetic patients, according to a study presented at the World Diabetes Congress in South Africa.\n\nThe findings from the clinical trial have shown newly diagnosed patients with type-two diabetes who weren't taking antidiabetic drugs had significantly improved blood-sugar levels and lost more weight with Acomplia, compared with a dummy pill over a period of six months. In addition, Acomplia -- also known as rimonabant -- helped...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story turned to several independent sources, it does not appear that it relied solely or largely on a news release. ", "answer": 1}, {"article": "S. Raman; M. Pless; A. Cubillo; A. Calvo; R. Hecht; C. Liu; E. Chan; J. Chesney; A. Prat; David Geffen School of Medicine, University of California, Los Angeles, CA;, Department of Oncology, Kantonsspital Winterthur, Winterthur, Switzerland; HM Universitario Sanchinarro, CIOCC, Madrid, Spain; Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain; Amgen Inc., Thousand Oaks, CA; James Graham Brown Cancer Center, University of Louisville, Louisville, KY; Hospital Cl\u00ednic, University of Barcelona, Barcelona, Spain.\nAmgen, the pharmaceutical company that makes T-VEC, was a sponsor of the trial.\n\"This minimally invasive treatment offers patients a novel way to directly and indirectly attack the cancer cells.\"\nAs part of the study, researchers will follow patients for up to two years, and new trials to investigate the effectiveness of the drug in treating advanced cancer in the liver are being planned.\nPatients were given escalating doses of T-VEC, up to the maximum FDA-approved dose for melanoma.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news releases used restrained language.", "answer": 1}, {"article": "The drugs, which include Depakote, Lamictal, Topamax, Keppra, Lyrica and Neurontin, are sometimes prescribed for chronic pain and headaches, as well.\nDoctors said Thursday that the increased risk did not outweigh the benefits of the drugs.\nDrugs for epilepsy, bipolar illness and mood problems double the risks of suicidal thoughts and behavior, and patients taking them should be watched for sudden behavioral changes, drug regulators have said.\nThe increased risks, while double in relative terms, are small.\nThese medications are primarily used to help epileptics control seizures and to calm the surges in energy and mood that, along with bouts of depression, characterize bipolar disorder.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is independent reporting and no evidence that information in this story is taken directly from a press release.", "answer": 1}, {"article": "Drug list (formulary): To see a list of covered drugs for the plan you\u2019re considering, use the drop-down menus below.\n\nIf your employer is offering coverage, contact HR for the pharmacy plan name.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "", "answer": 1}, {"article": "Like rheumatoid arthritis, osteoarthritis is a chronic, degenerative joint disease.\nStudy researcher Gabriel Chodick, MD, called the risk reduction \"important and meaningful,\" but he says more research is needed to confirm the association.\nThe study appears in the September issue of the journal PLoS Medicine.\nThe regular use of statins was associated with a 42% reduction in rheumatoid arthritis (RA) risk in a newly reported study of patients enrolled in one of Israel's largest health plans .\nBetween 1998 and 2007, 2,578 new cases of rheumatoid arthritis were identified in this group.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\nThe story does not appear to be based on a news release.", "answer": 1}, {"article": "\"We have been trying as doctors for centuries to find a treatment that actually reverses heart injury,\" Eduardo Marban, MD, PhD, tells WebMD.\nMarban, director of the Cedars-Sinai Heart Institute in Los Angeles, led the study.\nIt's the first completed, controlled clinical trial showing that scarred heart tissue can be repaired.\nIf so, this could change the nature of medicine.\nHe invented the \"cardiosphere\" culture technique used to create the stem cells and founded the company developing the treatment.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not rely on this press release from Cedars-Sinai Medical Center.\n\u00a0", "answer": 1}, {"article": "We know from our own anecdotes that we have saved a lot of lives.\u201d\n\nDr. Lepor said that he had just met a woman who had smoked for 50 years and was concerned about her risk.\nThe wording of the ad seemed to be aimed at a broad group, ranging from heavy smokers to women who had never smoked, Dr. Brawley said.\nBut because the study was stopped early, a full analysis of the harms caused by screening scans is still months away.\nIn the release, Dr. Norman E. Lepor said the scans were an \u201cindispensable\u201d part of annual exams for patients who have smoked for 10 years.\nIn the study, even experienced radiologists at major cancer centers had a high rate of false positives, suggesting that the rate would be even higher in the real world.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This column did not rely on a news release.", "answer": 1}, {"article": "increases at age 4, although no cognitive benefit was seen in infants or 7-year-olds.\nThat study\u2019s lead author, Dr. Ingrid Helland of Oslo University Hospital, said that perhaps the benefit shown at age 4 existed at 7 but was difficult to identify amid other developmental factors.\nThe lead researcher, Dr. Maria Makrides of the University of Adelaide in Australia, said this suggested that full-term babies already get enough DHA in the womb, and that \u201cthere\u2019s no extra boost\u201d from getting more.\nHe said more research was needed, but for now, \u201cI think the market is running way out in front of the science.\u201d\n\nScientists agree that DHA, naturally transmitted to a fetus through the placenta in the last half of pregnancy, is important, probably to visual and brain development.\nShe said babies in her study might have received more DHA than those in this study.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear the story did not rely on a news release. ", "answer": 1}, {"article": "Bernard M.Y.\nTwo died within a few weeks of developing the disorder, with one cause of death mentioning the muscle disorder as a contributing factor.\nThis trial looked at the benefits of statin therapy with 80 milligrams (mg) versus 20 mg simvastatin (Zocor) among 12,000 heart attack survivors.\nThe study was supported by a grant from Merck (manufacturer of the simvastatin).\nIn the first study, researchers at Oxford and the University of Sydney in Australia collected data from studies on 170,000 patients who took part in 26 trials.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "The study comes a month after Gov.\nThey say the test's value is limited because it doesn't identify which plaque are stable and which could rupture and cause a heart attack.\nThe Texas law will require insurance companies pay $200 of the bill for patients to get the test every five years.\nIt eventually attracted attention in cardiology circles, where the scans' costs and benefits are the subject of much debate.\nThe American Heart Association did not endorse the legislation, which Khera estimates could result in millions of Texans being screened.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\nThe story includes quotes from independent experts and other information that was not in the news release about the journal article.", "answer": 1}, {"article": "Corticosteroids are involved in a wide range of physiological processes in the body, including regulating metabolism, blood pressure and helping the body to cope with physical stress.\nThe researchers tested the therapy in a small group of patients with Addison's disease.\nThe new treatment - expected to have fewer side effects than existing therapies - could help people with disorders of the adrenal gland whose bodies are unable to produce a class of steroids called corticosteroids.\nThe therapy could help people with conditions such as Addison's disease and congenital adrenal hyperplasia, who need steroid treatment to avoid the risk of potentially fatal illness during physical stress.\nDr Mark Nixon, of the BHF Centre for Cardiovascular Science at the University of Edinburgh, said: \"The discovery of this selective corticosterone pump in fat cells could lead to a completely new approach in our search for safer steroid medications.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We rate this borderline satisfactory. While the sources in the story are optimistic while somewhat guarded, often employing conditional tense verbs (\u201ccould provide a safer alternative\u201d), and the release lead sentence makes it clear that this new treatment is not yet available, the release headline (\u201cStudy paves way for steroid treatments with fewer side effects\u201d) seems\u00a0overly optimistic about a new treatment that has not yet survived clinical testing.\nIt\u2019s not until you read to the end of the release that you find more tempered language:\n\u201cThe researchers say that, with further research, these findings may one-day lead to improved therapies for other conditions that respond to steroid treatment, including asthma and rheumatoid arthritis.\u201d", "answer": 1}, {"article": "Both VEGF Trap-Eye and Lucentis block a protein called vascular endothelial growth factor that causes blood vessels to grow and leak into the eye.\nDr. Peter J. Francis, an associate professor at the Oregon Health and Science University, which will be a site for the trial, says the eye is a good place to test stem cell therapy because it is accessible.\nAlso, he said, there is less chance of rejection of the implanted cells because the eye is shielded somewhat from the body\u2019s immune system.\nIt is likely to be several years before such a treatment can reach the market, if it works.\nStill, even starting the trial could be a boost to Advanced Cell, which often makes headlines but has struggled to raise money.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story seems to have relied on the company for the substance of this story and quoted only one researcher who was affiliated with the study\u00a0(not counting\u00a0the father of the child with Stargardt\u2019s macular dystrophy, which, as discussed above under the Disease Mongering criterion, was not the main focus of the story). Since no independent sources\u00a0were\u00a0referenced, we can\u2019t be sure to what extent this story may have relied on a release. We\u2019ll call it not\u00a0applicable.", "answer": 2}, {"article": "Dr. Farah, who serves as the Chief Medical Officer for the Phoenix Health Center in Hagerstown, prior NE Regional Medical Director for United Healthcare Clinical Services and Director ASAM explains, \"Based on ASAM's definition of addiction, about half of substance abuse is due to genetic factors.\nStudy author, Gregory A. Smith, M.D, former Director of Pain Management at Harbor UCLA, explains, \"Having used this technology for 6 years, this data provides further evidence that clinicians can use Proove Opioid Risk\u00ae for ruling out patients unlikely to exhibit aberrant behaviors, and identifying high-risk patients for alternative therapies.\"\nProove\u00ae's medical advisory board is led by those NIH-funded researchers and the company has licensed some of its technology from leading academic centers, such as the University of North Carolina at Chapel Hill, the University of Utah, and other institutions.\nThis study shows that analyzing genetics with lifestyle and behavioral variables in a predictive algorithm can accurately stratify patient risk.\"\nPositioned as The Healthcare Decision Company,\u2122 Proove\u00ae's patented technology platform combines genetic, clinical, environmental and lifestyle information to help clinicians better evaluate pain sensitivity, assess risk for opioid use disorder, predict therapeutic response to pain medications, and assess drug metabolism for the many medications used in chronic pain patients.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release avoids using unjustifiable or sensational language. It provides a little background on the factors that contribute to substance abuse.", "answer": 1}, {"article": "Lumbar disk herniation is a common, often debilitating, condition that affects the disks that act as cushions between the vertebrae of the lower spine.\nIn 128 patients, the pRF treatment was delivered directly under CT guidance to the root of the nerve.\nThe results of the study are superior to those typically reported for usual care strategies and injections and may help a substantial number of patients with sciatic disk compression to avoid surgery, Dr. Napoli added.\nPatients who received pRF saw greater overall improvement in pain and disability scores during the first year.\n\"Pulsed radiofrequency creates a nerve modulation, significantly reducing inflammation and its associated symptoms,\" said study senior author Alessandro Napoli, M.D., Ph.D., professor of interventional radiology at Sapienza University of Rome in Italy.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The headline is misleading. The source of back pain is usually unknown and even if an imaging study demonstrates a disc herniation it is usually not the identifiable cause of the pain. The title could lead people to seek treatment for their imaging finding but not resolve their pain.\nIt\u2019s unjustified to make broad claims as found in the headline based on unpublished data.", "answer": 0}, {"article": "Feb. 1, 2012 -- A new drug appears to be effective for shrinking uterine fibroids and controlling the heavy menstrual bleeding they often cause, according to new research from Europe.\nIn one study, the drug ulipristal acetate proved to be much more effective than a placebo for shrinking the non-malignant uterine tumors.\nBoth studies appear in the Feb. 2 issue of The New England Journal of Medicine.\nUlipristal acetate is the active chemical in the emergency contraceptive sold in the U.S. as Ella, but the daily doses taken by the fibroid patients in the studies were much smaller than those in the contraceptive.\nIf trials now under way in the U.S. prove positive, New Jersey-based Watson Pharmaceuticals Inc. and Swiss-based PregLem hope to market ulipristal acetate as a fibroid treatment under the trade name Esmya, says Watson spokesman Charlie Mayr.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Neither story relied on a press release.", "answer": 1}, {"article": "test found a small cancer, and he does not want to take a chance that it will grow slowly and not cause him problems.\nYet changing medical practice can be difficult.\nscreening is controversial at any age.\nOften it is easier to just order the test.\nA 75-year-old Connecticut man said he had the test because he was healthy and wanted to stay that way.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not rely solely or largely on a news release.", "answer": 1}, {"article": "Asthma on the Rise in U.S.\nThe study did not look at possible side effects of kampo herbs.\nNorth American allergy experts tell WebMD that although they find the preliminary findings fascinating, further study is needed before they would recommend the herbs.\nSymptoms completely disappeared in 94% of patients taking kampo herbs after an average of 16 days, Shimoide says.\nHerbs used in the current study include Scutellaria root, Coptis rhizome, gardenia fruit, hoelen, cinnamon bark, and Glycyrrhiza (aka licorice) root.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does not appear that the story relied on a news release.", "answer": 1}, {"article": "Early menopause is often a side effect for women treated with chemotherapy for breast cancer, but a new study reveals some guarded promise for preventing early menopause breast cancer patients.\nThey conclude that using assisted reproductive technology \u2013 such as storing eggs before chemo, is \u201cthe most effective option for fertility preservation.\u201d\nPatients were randomly selected to be treated with chemotherapy alone or with chemotherapy and triptorelin, a drug, called a GnRH analogue, that prevents the ovaries from releasing eggs.\nFor younger women still hoping for children, these treatments can cause devastating short-term or long-term loss of menstrual periods, and loss of fertility.\nAn accompanying editorial by Dr. Hope S. Rugo and Dr. Mitchell P. Rosen of the University of California-San Francisco says that trptorelin therapy should not be recommended as a standard treatment and should be approached with caution in women with hormone-sensitive disease.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article did an adequate job of citing the original study and the associated editorial but omitted some significant detail needed to help the reader reach a clear understanding. .\n", "answer": 1}, {"article": "\"Previous patients got sick, but it wasn't clear at the time whether it was due to the T cells or an infection,\" said pediatric oncologist Stephan Grupp, who oversaw Emily's care at Children's Hospital of Philadelphia. \"Now we know the main reason they were sick was the cells. But now we can intervene. She taught us.\"", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is enough original reporting that we can be sure this story wasn\u2019t based on a press release.", "answer": 1}, {"article": "Like mifepristone, ella is a type of drug known as a selective progesterone receptor modulator (SPRM) that interferes with the hormone progesterone, which is critical for pregnancy.\nHRA is not seeking to sell ella without a doctor\u2019s prescription.\nIf approved, Watson Pharmaceuticals Inc would sell the drug in the United States.\nHRA Pharma\u2019s drug, approved last year in Europe under the name ellaOne, has re-ignited debate over \u201cmorning-after\u201d pills in the United States, where reproductive issues are a constant political issue.\nIf it is approved, it should be clearly labeled as an abortifacient, which would limit its distribution, the American Association of Pro Life Obstetricians & Gynecologists said in a letter to the FDA earlier this month.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Not applicable because we can\u2019t be sure if the story relied solely on a press release.", "answer": 2}, {"article": "Invented 16 years ago by a radiologist who got the idea while playing video games on a flight simulator during advanced training at Johns Hopkins, virtual colonoscopy has become an increasingly popular alternative to standard, or optical, colonoscopy, which is typically performed by a gastroenterologist.\nLike other mass screening tests including mammography, the overarching question is whether the benefits of virtual colonoscopy outweigh the risks.\nInitially regarded as a high-tech novelty, the new procedure has in recent months received key endorsements as a first-line screening test from influential medical groups, notably the American Cancer Society, after several large studies found it to be effective at finding large polyps.\nMedicare's decision has sparked a furious lobbying campaign.\nCurrently about half of Americans over 50 are screened for the disease; some shun traditional colonoscopy, which is the only way to remove polyps, because of its invasive nature.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story quotes multiple sources, the reader can assume the story did not rely on a press release as the sole source of information.", "answer": 1}, {"article": "Where did this Ron DeSantis come from? Florida\u0092s governor surprises everyone but himself.\n\nA month into his term, Gov. Ron DeSantis has shattered assumptions that he would govern exclusively from the right. He has drawn unexpected praise from Republicans and Democrats.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not appear to rely on a press release.", "answer": 1}, {"article": "The scientists, meanwhile, collected blood samples from the men several weeks before the race, as well as immediately before to the start, at the finish line and on select days afterward.\nBut, said Dr. Scherr, it almost certainly involves the beverage\u2019s rich bouquet of polyphenols, chemical substances found in many plants that, among other things, \u201csuppress viral replication\u201d and \u201cinfluence the innate immune system positively,\u201d all beneficial for fighting off a cold.\n\u201cIt can be speculated that the training frequency could be higher (with shorter breaks after vigorous training sessions)\u201d in those drinking beer, he wrote in an e-mail response.\nJust how nonalcoholic beer eases the ravages of strenuous marathon training and racing is still being investigated.\nIt began with human marathoners completing a punishing, unsimulated race, and showed demonstrable benefits, in terms of minimizing postrace damage.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There was an American College of Sports Medicine news release for the abstract, but it doesn\u2019t appear to have been relied upon.\u00a0 Maybe it should have been, since the news release actually includes a disclaimer the story did not include \u2013 that the research was presented at a professional meeting but has not been peer-reviewed.", "answer": 1}, {"article": "Among 46 chronic pain sufferers, those who spent time each day in a sauna for four weeks enjoyed a 54% improvement in sleep quality and were 27% more likely to return to work compared to a no-sauna group.\nThe heart health benefits were even greater for men who sweated it out in a sauna more frequently.\nBeever makes it clear all of these reports were based on small groups and require further study.\nHe says there\u2019s evidence to support the use of infrared saunas for high blood pressure, congestive heart failure and chronic pain.\nBeever\u2019s review also looked at some of the other purported health benefits of infrared saunas\u2014including pain management.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Multiple sources would suggest low reliance on a news release.", "answer": 1}, {"article": "Breakfast on the diet might consist of bacon, eggs with cheese, and a cup of heavy cream diluted with water; some children drink oil to obtain the fats that they need.\nAs the first randomized trial of the diet, the new study lends legitimacy to a treatment that has been used since the 1920s but has until recently been dismissed by many doctors as a marginal alternative therapy.\nBreaking the diet with so much as a few cookies can cause seizures to flare up.\nA formerly controversial high-fat diet has proved highly effective in reducing seizures in children whose epilepsy does not respond to medication, British researchers are reporting.\n\u201cThis is the first time that we\u2019ve really got Class 1 evidence that this diet works for treatment of epilepsy,\u201d said Dr. J. Helen Cross, professor of pediatric neurology at University College London and Great Ormond Street Hospital.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if the story relied solely or largely on a news release.\u00a0 As noted before,\u00a0 a news story that covers a not-yet published journal article should be more explicit about its sources of information. ", "answer": 2}, {"article": "In 1917, two German inventors first used pressurized pure oxygen to treat decompression sickness, which occurs when undersea divers return to the surface too quickly.\nSpecialists told her the operation probably had caused collateral brain trauma.\nHyperbaric therapy, he said, can return them to full function, even years after the injury.\nThe hyperbaric treatment healed his feet \u2014 and also revived his ability to speak.\nSince then, he said, he has treated about a half-dozen brain-injury patients, with mostly positive results.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "While Drs.\nThe FAME 2 trial was supported by St. Jude Medical.\nThe trial was initially sponsored by St. Jude Medical, a global medical device company, until the three-year follow-up.\nThe present analysis was not supported by industry funding.\nSt. Michael's Hospital provides compassionate care to all who enter its doors.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There is no unjustifiable language.", "answer": 1}, {"article": "Modern water dispensers may be more effective than old-fashioned water fountains since water quality and cleanliness may deter kids from using older fountains, and they're not as efficient at serving large numbers of children, experts noted in an accompanying editorial.\nThe editorial, entitled \"Power of a Simple Intervention to Improve Student Health: Just Add Water,\" said the study's findings are significant.\nIn this study, the findings demonstrate that water access in schools can promote healthy weight outcomes among students,\" Turner and Hager said.\n\"Even a small, straightforward, relatively inexpensive policy intervention was associated with a small but statistically significant drop,\" Elbel told CBS News.\n\"Sometimes, a very simple intervention can have a powerful effect,\" wrote Lindsey Turner, of Boise State University, in Idaho, and Erin Hager, from the University of Maryland School of Medicine, in Baltimore.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article does not rely on any news releases we found online. There is also evidence of original reporting in the lead researcher\u2019s second comment, as he \u201ctold CBS News.\u201d", "answer": 1}, {"article": "TMS treats conditions by delivering brief, powerful magnetic field pulses that stimulate nerve cells in the brain.\nThe approval was based on a clinical trial of 100 people with obsessive-compulsive disorder, where roughly half received treatment with TMS and the other half had a sham treatment that didn't deliver the electromagnetic pulses.\nPeople who were taking medication for OCD continued to do so for the trial.\nOverall, 38% of the people with the real device responded to the treatment compared with 11% of those with the sham device.\nA response was considered a 30% reduction in the Yale-Brown Obsessive Compulsive Scale (YBOCS) score, which is used to measure the severity of OCD symptoms.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story didn\u2019t include anything significant that wasn\u2019t in the FDA or Brainsway news releases. The only thing we spotted that diverged from the news releases was that BuzzFeed used numbers from the NIH on how many people have OCD.", "answer": 0}, {"article": "Tremors limited to the hand and forearm, for instance, might respond better than tremors that also affect the shoulder.\nMuscle weakness was the most common side effect in this study, van der Walt said.\nLarger studies, of more-diverse groups of MS patients, are needed, he said.\nThe study\u2019s lead researcher agreed on the need for more work.\nIf Botox is eventually approved for this MS symptom, LaRocca said it will be important for doctors to get training in how to give the injections \u2014 since the drug has to go into carefully chosen locations in the muscle.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely on a news release.", "answer": 1}, {"article": "\"So many people say `how can cancer screening be harmful?'\nHPV tests were twice as good as Paps for predicting risk.\nThe new study was the first big one to examine a newer screening tool, HPV tests, with or without Pap smears in routine practice.\nThat's still the best way to check for ovarian cancer in those cases.\nIt didn't prevent deaths and led to thousands of false alarms, unneeded surgeries and serious complications.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story goes far beyond any news release.", "answer": 1}, {"article": "; Francesca Cesari, MSc., Ph.D.; Anna Maria Gori, MSc.\nIn an editorial accompanying the study, Cheryl A. M. Anderson, Ph.D., M.P.H., M.S., an associate professor of preventive medicine at the University of California, San Diego, in California, wrote that there were similarities between the two diets that may explain the results.\nAnderson, who was not involved in the study, added that promoting both diets by healthcare professionals \"offer a possible solution to the ongoing challenges to prevent and manage obesity and cardiovascular diseases.\"\nMost participants were able to stay on both diets.\nThe association has strict policies to prevent these relationships from influencing the science content.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The headline of this news release is not justified because the study did not investigate the impact of these diets on preventing heart disease.\nAlso, stating that these two diets are \u201clikely equally effective in reducing the risk of heart disease and stroke\u201d is not supported by the study, which looked at surrogate markers, not disease incidence or prevalence.", "answer": 0}, {"article": "\"We were pleased by the results of this first clinical study,\" he says.\nThe research was presented at the American Association for Cancer Research's special conference, Colorectal Cancer: Biology to Therapy.\nAt the meeting, Ahlquist presented the results of the first clinical evaluation study, which enrolled 1,100 patients.\nAt the same meeting, other researchers reported that they have new clues about how DNA characteristics can help predict colon cancer risk.\nAlthough colon cancer is the second leading cause of cancer death for men and women in the U.S., many adults don't undergo the screenings once they reach age 50 (or earlier for those with a family history), Ahlquist told a news conference.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story appears to be based on things said at a news conference, not things said in a news release.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/02/15/national/a141001S34.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Given the multiple sources cited, it does not appear this story was based solely on a news release", "answer": 1}, {"article": "Lack of F.D.A.\nThere was a great need, the authors concluded, to \u201cimprove awareness of this important advice.\u201d\n\nThe fact that fish oil is also sold as a nutritional supplement has made it harder for some doctors to regard it as a powerful drug, experts said.\nThis summer, a critical review of existing research in BMJ, The British Medical Journal, \u201ccast doubt over the size of the effect of these medications\u201d for the general population, said Dr. Roger Harrison, an author of the paper, \u201cbut still suggested that they might benefit some people as a treatment.\u201d\n\nDr. Harrison said he believed that people should generally increase their intake of omega-3 acids, best done by eating more fish.\nThe fact that heart patients receive such different treatments in sophisticated hospitals around the world highlights the central role that drug companies play in disseminating medical information, experts said.\nMarylou Rowe, a spokeswoman for Reliant Pharmaceuticals, which owns the license for the drug in the United States, said that further trials of Omacor would be needed for it to be licensed for heart attack patients in the United States.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story used multiple sources, it does not appear to have relied on a news release, although it does focus disproportionately on one commercially available product.", "answer": 1}, {"article": "\u201cOur lab is on an island in the South.\nNot everyone is convinced of the effectiveness of after-sun care.\n\u201cThat can make sun-exposed skin feel better,\u201d she said, \u201cBut there\u2019s nothing you can do to reverse sun exposure.\u201d And while Henry Lim, president of the American Academy of Dermatology, believes that the Yale study was important, he cautions that you only have a three-hour window after sun exposure to take advantage of any potential product benefits\u2014and that antioxidants \u201care notoriously not very stable and must be formulated carefully in order to be effective.\u201d\n\nBut believers like True Nature Botanicals\u2019 Ms. Peterson are undeterred.\nI know that it\u2019s not realistic to say \u2018no sun.\u2019 \u201d\n\nShe is, however, quite knowledgeable about how to be safe when you\u2019re in the sun.\nThis information is in the early stages of transforming the category of after-sun care\u2014a category traditionally limited to aloe vera-laden moisturizers and gels that lowered the temperature of sun-parched skin but not much else.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article includes comments from independent experts so it does not appear to have relied solely on a news release.", "answer": 1}, {"article": "\"There were times when I would yell at myself: 'I can't do this.\nOf course, the results of the study are only preliminary.\nThe potential to alarm a child isn't worth it, and he doesn't trust that this method would offer definitive information.\nBecause of this, Weiner said, three-dimensional letters and numbers, perhaps made out of plastic or clay, help a dyslexic child grasp the shapes better.\nA study led by Fumiko Hoeft, psychiatry researcher at Stanford University School of Medicine, used brain imaging to answer this question.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\nThe story does not appear to rely on a news release.", "answer": 1}, {"article": "GeneSight's test is covered by Medicare for patients under the care of psychiatrists and who have failed to achieve satisfactory results with at least one antidepressant. The company has coverage with some commercial payers and is working to widen that coverage, said Myriad Genetics spokesman Ron Rogers. The Genomind Genecept Assay is partly covered by Medicare and Medicaid. If the out-of-pocket cost for people with commercial plans is more than $300, Genomind will contact the client before processing the test. The company also has a financial assistance program for uninsured patients.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This article does not rely solely on a news release and quotes outside sources.", "answer": 1}, {"article": "Currently, the U.S. Preventive Services Task Force recommends that biennial screenings start at age 50 for most women, while the American Cancer Society advises that annual screenings begin at age 45.\nBut only 29 women fell into the \"never had a mammogram\" group.\nAnd Dr. Len Lichtenfeld, deputy chief medical officer for the American Cancer Society, noted that this was an observational study that only looked at the experience of one institution.\nThe second group also included women who had never had a mammogram.\nPort's study included more than 1,100 women diagnosed with breast cancer at the Dubin Breast Center.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story goes beyond what was contained in a news release on the presentation at the American Society of Breast Surgeons annual meeting.", "answer": 1}, {"article": "It will still grow shorter and slower than scalp hair,\u201d he said.\nThe hairs were removed in a diffuse pattern, so there were no bald spots on the legs after the procedure.\n\u201cHe was self-conscious about the problem and resorted to styling his hair forward to obscure the hairline,\u201d Dr. Umar wrote in his report.\n\u201cIf you transplant leg hair on the head, it\u2019s not going to start acting like head hair.\n\u201cThey\u2019ve been told to forget about it by many other clinics.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to be based on a press release", "answer": 1}, {"article": "\u2022 Khin NA, et.al.\nWhat makes this even more significant is that the response was rapid and this milestone was achieved in patients deemed to be treatment-resistant.\nThese findings represent two of the five Phase 3 studies that comprise Janssen's treatment-resistant depression program with esketamine nasal spray.\nThe study in elderly patients with treatment-resistant depression was a Phase 3, double-blind, multicenter, active-controlled study.\nHowever, the study narrowly missed statistical significance for its primary efficacy endpoint.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The headline refers to \u201crapid improvements in depressive symptoms.\u201d The word \u201crapid\u201d can mean different things to different people. But the key endpoint highlighted in the release was a change in baseline depression symptom scores at day 28 of the trial. For people experiencing depression, 28 days may not seem \u201crapid.\u201d In addition, the release includes three bullets just under the headline. These are clearly placed to serve as highlights for readers. The second bullet notes: \u201cStudy in elderly patients is the first large clinical trial in treatment-resistant depression in this population.\u201d Lower down, the release tells readers that: \u201cData from a second study, in elderly patients aged 65 and older with treatment-resistant depression, which is the first study of its kind, showed treatment with flexibly dosed esketamine plus a newly initiated oral antidepressant demonstrated clinically meaningful effects compared to placebo nasal spray plus a newly initiated oral antidepressant.\u201d Wow! But wait a second. The very next sentence notes that the study missed statistical significance. We applaud the decision to tell readers that the study didn\u2019t have any statistically significant findings. But the fact that they trumpeted those (statistically insignificant) findings first is problematic.", "answer": 0}, {"article": "Patients lie in a CT scanner, which takes a series of pictures from a variety of different angles, and a computer compiles the snapshots in two different ways.\nBut according to Dr. Marc Gollub, director of CT and gastrointestinal radiology at Memorial Sloan-Kettering Cancer Center, \u201cthe radiation is much lower than a regular CT scan and has not been proven to be of any risk.\nAnd given the relatively low cost of investing in the software and other equipment required to run a virtual scan, more hospitals may be adding the option to their patient services.\nAdd to that the aggressive public awareness campaign for colonoscopy screening led by celebrities like Katie Couric, who allowed TV cameras in as she got her first test, and it\u2019s clear why more people are familiar with the scope than with its virtual cousin.\nVirtual colonoscopy is a good option for those who can\u2019t be sedated for colonoscopy, or who simply can\u2019t tolerate the scope.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not appear to rely on a news release.", "answer": 1}, {"article": "For more information on bisphosphonates, visit U.S. Food and Drug Administration.\nAnderson Cancer Center, was not involved in the study but put it in perspective.\nThe focus was on disease-free survival.\n\"As a whole, the study is negative,\" study author Dr. Robert Coleman, a professor of medical oncology at the University of Sheffield in England, said during a Thursday news conference on the findings.\nOther studies underway may provide a clearer answer, she said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article did not appear to be overly reliant on a news release.", "answer": 1}, {"article": "A pack year means smoking one pack a day for 30 years, or a variation like two packs daily for 15 years.\nAlso, about half of patients screened continue to smoke so screening might also be a logical point for smoking intervention, Schroeder said.\nFollowing the trial, the National Comprehensive Cancer Network, a nonprofit organization of cancer centers that develop guidelines for cancer diagnosis and treatment, along with the United States Preventive Services Task Force, which makes recommendations for preventive medicine, recommended screening high-risk individuals on a slightly broader scale, which the Lahey and Augusta area screening used.\nLike the previous experiences, the Augusta area screening that started in 2014, also reiterated the ability of LDCT to find lung cancer early, said Schroeder, corresponding author of the study in Southern Medical Journal.\nThe pioneering National Lung Screening Trial, which began in 2002 and included 33 largely urban centers, found 292 cases of lung cancer among the 26,722 high-risk individuals screened in the first year, for a rate of 1.1 percent.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The headline states that \u201cFree lung-cancer screening in the Augusta area finds more than double the cancer rate of previous screenings.\u201d That\u2019s the first thing the reader sees, and it\u2019s a real attention-grabber. However, it is misleading. At first glance, many readers are likely to think that the rate of lung cancer in the Augusta area has more than doubled since the last time there was a lung-cancer screening initiative. That would be incorrect, given that this appears to be the first such initiative focusing on the Augusta area. Rather, the rate of lung cancer among \u201chigh risk\u201d patients screened in the Augusta initiative was more than double that of high risk patients screened during a national screening initiative launched in 2002. That was cleared up a bit in the first paragraph. However, while the release clearly thinks this information is sufficiently important to merit making it the headline, it doesn\u2019t give readers any information about why the cancer rate may be higher in Augusta. Even if the researchers don\u2019t know, it\u2019s important to just come out and say that. We urge research institutions to provide some discussion of those problems they highlight in news releases \u2014 and to take special care when writing headlines to ensure that readers don\u2019t get the wrong idea.", "answer": 0}, {"article": "Most thyroid cancers can be treated successfully, but advanced cases can be difficult to treat, especially if they do not respond to radioactive iodine (RAI) therapy.\nThe work is being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting which begins tomorrow in Chicago.\nIn blocking this activity, these new immunotherapy drugs help T cells get back to work in protecting the body.\nThis appears to be due to increased use of technology to detect thyroid nodules that may not otherwise been found previously.\nIt\u2019s an exciting time in early phase drug development when we are observing these results in so many different types of cancer.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t engage in unjustifiable language.", "answer": 1}, {"article": "Symptoms include serious memory loss, confusion, and mood changes that develop gradually and worsen with time.\nCoffee was the main, or only source, of caffeine among people in the study.\nThe findings will appear in the Journal of Alzheimer's Disease.\nThis is equivalent to drinking several cups of coffee a few hours before giving blood.\nThe new study included 124 people aged 65 to 88 who had mild cognitive impairment, which is the medical term for mild memory loss.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not rely excessively on this press release put out by the University of South Florida.", "answer": 1}, {"article": "UW-Madison establishes state\u2019s first and only addiction hotline for providers\n\nIn what is believed to be a national first, the University of Wisconsin-Madison, in conjunction with UW Health, has established a new resource for Wisconsin primary-care physicians and other providers to help them successfully manage patients with...\nFor the first time in Wisconsin, a research team will test a personalized cell therapy to treat a common and serious complication in bone-marrow transplant patients.\nUW team shows progress in search for new antibiotics\n\nCollecting bugs across the globe is paying off for a multidisciplinary research team at the University of Wisconsin-Madison.\nThe Wisconsin Partnership Program at the UW School of Medicine and Public Health announces four new awards through its Collaborative Health Sciences Program.\nThomas Mackie to lead new joint innovation initiative between UW Health and School of Medicine and Public Health\n\nUW Health has selected Thomas \u201cRock\u201d Mackie to be the inaugural leader of the health system\u2019s innovation initiative, which it is pursuing in partnership with the UW School of Medicine and Public Health.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "No unjustifiable language identified.", "answer": 1}, {"article": "Anton P. Porsteinsson, MD, Professor of Psychiatry at the University of Rochester School of Medicine and Dentistry and Director of the Alzheimer's Disease Care, Research and Education Program at the University of Rochester in Rochester, NY, and an investigator in the North American Phase 3 clinical trial, commented: \"The genetically-defined population of APOE4 carriers has an 8-12 fold increased risk of developing AD and has more rapidly progressive disease, usually becoming symptomatic a decade earlier than non-carriers of the APOE4 genotype.\nThe results published in JPAD are the first evidence from a large clinical trial to associate efficacy of an amyloid-targeted agent with APOE4 status in AD patients.\nThe efficacy and safety analyses with tramiprosate published in JPAD reveal a therapeutic effect in patients who are carriers of APOE4 after segmenting them from the larger, non-genetically-defined study population in the Phase 3 clinical program, involving more than 2,000 AD patients in North America and Europe.\nThese analyses with tramiprosate in the APOE4 subgroups are compelling, and suggest a meaningful clinical benefit, on top of the existing symptomatic AD treatments, in Alzheimer's patients who are in great need of new treatments.\nThese efficacy analyses evaluated patient subgroups based on the number of \u03b54 alleles of apolipoprotein E (APOE4), a major genetic risk factor in up to 65 percent of patients with AD.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There is no unjustifiable language outside of the claims already critiqued under the Benefits and Novelty criteria.", "answer": 1}, {"article": "February 28, 2017 - For infants with congenital malformations of the ear, a treatment system called EarWell can gently reshape the ear--avoiding the pain and cost of later surgery, reports a study in the March issue of Plastic and Reconstructive Surgery\u00ae, the official medical journal of the American Society of Plastic Surgeons (ASPS).\nEarWell treatment was highly successful in correcting or reducing the severity of congenital ear malformations.\nArticle: \"Classification of Newborn Ear Malformations and their Treatment with the EarWell Infant Ear Correction System\" (doi: 10.1097/PRS.0000000000003150)\n\nFor more than 70 years, Plastic and Reconstructive Surgery\u00ae (http://www. )\nBut lack of awareness of this nonsurgical alternative is a key limiting factor.\nThe researchers review their experience with nonsurgical correction of congenital ear malformations in 175 infants.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We\u2019ve already dinged the release for problems with language under the section on disease mongering. We don\u2019t want to penalize them twice for the same thing, so it earns a satisfactory rating here.", "answer": 1}, {"article": "Two drugs once widely used to treat Parkinson's disease sharply increase the risk of heart-valve damage, researchers have found. The studies immediately prompted calls for the treatments to be discontinued or patients more closely monitored.\n\nPatients who take the drugs, pergolide or cabergoline, are four to seven times as likely to suffer damage to their heart valves as patients who don't take either one, according to two studies published in today's New England Journal of Medicine.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "No obvious use of text from the press release.", "answer": 1}, {"article": "Suboxone works by taking the place of the opioids in the receptor - not only shutting off withdrawal symptoms but also blocking the effects of any new drugs.\nThe hope is one day that Suboxone can do for painkiller addiction that drugs like Prozac did for depression: convince the public that addiction is a brain disease, not a character flaw.\nBut, as CBS News contributor Dr. Sanjay Gupta reports, he's willing to talk about how prescription painkillers took over his life: Ten OxyContin pills a day, costing up to $12,000 a month.\nHere's how it works: When people are addicted, new receptors are created in the brain, which crave opioids.\nFor Brian, life now involves not only counseling and but a personal inventory as well.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article does not rely on any press release. It does, however, appear to draw heavily on an article appearing in the Fall 2007 issue of NYU Physician, a publication of the New York University School of Medicine and Hospital Centers, employer of study lead investigator Marc N. Gourevitch.\nThe NYU Physician piece focuses on the story of Brian, the same man who is the focus of the CBS News segment. \nThe CBS piece appears to adapt language from the magazine article. In one place the article reads: \u00a0\nThe hope is that this will eventually do for drug addiction what SSRI\u2019s like Prozac did for depression: convince both primary-care physicians and the public that addiction is a chronic brain disease, not a character flaw.\nThe physician-reporter in the CBS piece says:\nThe hope is that one day Suboxone can do for painkiller addiction what drugs like Prozac did for depression: convince people that it\u2019s more of a brain disease, not so much a character flaw.", "answer": 0}, {"article": "Viagra, known generically as sildenafil, is sold by Pfizer Inc for erectile dysfunction and under the brand name Revatio to treat a heart condition called pulmonary hypertension.\nTests in mice genetically engineered to have a condition similar to Duchenne muscular dystrophy showed the drug could improve how the heart works, Joseph Beavoa of the University of Washington and colleagues at the University of North Carolina found.\n\u201cAlthough PDE5 inhibitors will certainly not cure DMD, the current studies suggest that they could be used in combination with current or future therapies,\u201d the researchers wrote.\nIt is not clear just how the drug is helping the mice, they reported in the Proceedings of the National Academy of Sciences, but they said it may be worth trying it as a treatment for muscular dystrophy.\nMany patients die of heart failure and most patients with the condition die before age 40.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\nThe story quotes the journal article in the Proceedings of the National Academy of Sciences. It does not appear to rely only on a news release.", "answer": 1}, {"article": "Vegetable and canola oils, soybeans, flaxseed, walnuts and vegetables including spinach, kale and salad greens are also a source of omega-3 fatty acids.\nThe study was published Tuesday in the print edition of the journal Neurology.\nTan said the next step in the research is to follow these people to see if the risk factors they observed translates into a higher rate of cognitive deterioration.\nThe only people who should avoid DHA are patients on a blood thinner like Cumadin, he added.\nTan\u2019s team studied 1,575 people with an average age of 67 who were free of dementia.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We\u2019ll flag the story here for pulling a quote directly from an American Academy of Neurology press release without stating that was the case. Here is the quote in question, which is attributed to a researcher with the study: \u201cPeople with lower levels of omega-3 fatty acids had lower brain volumes that were equivalent to about two years of brain aging.\u201d The story does make it sound as though the reporter talked directly to the researcher, so it\u2019s not clear exactly what happened.\u00a0 But it\u2019s fishy.", "answer": 0}, {"article": "Women ages 50-59 had 13,288 mammograms, 1,659 callbacks (12.5% recall rate), 371 biopsies, and 103 cancers detected, while women ages 60-69 had 12,119 mammograms, 1,239 callbacks (10.2% recall rate), 302 biopsies and 89 cancers detected.\nBy adding the women ages 40-49 to the screening population of 50 and over, the overall callback rate increased 1.5%, the biopsy rate increased 0.1% and 19.3% more cancers were detected.\nOverall, 41,028 mammograms were performed with 5,196 callbacks (12.7% recall rate), 1,164 biopsies, and 326 cancers detected.\nThe Society's mission is to improve health through a community committed to advancing knowledge and skills in radiology.\nThe study to be presented by Abid Irshad of the Medical University of South Carolina examined the effectiveness of screening mammography between ages 40-49 in comparison to age groups 50-59 and 60-69.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "No unjustifiable language.", "answer": 1}, {"article": "Though randomized controlled clinical trials of bright light are difficult to do properly \u2014 one expert is fond of saying that it is difficult to \u201cblind\u201d studies of bright light \u2014 the American Psychiatric Association considers bright-light therapy an effective low-risk treatment for both S.A.D.\n\u201cIf you can fix the drift, you can fix the depression.\u201d\n\nLight therapy may even help with major nonseasonal depression, experts say, and with sleep disorders.\nAnd because it has few side effects, researchers are studying whether light therapy can help with depression during pregnancy and be used to treat elderly people with dementia.\nPatients generally sit in front of the light box, which can be as small as 9 by 11 inches and 5 inches deep, with the bright light emanating from the square surface, in the morning.\nBut while bright-light treatment is helpful, he said, it is not sufficient for him.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story quotes four different people \u2013 two patient and two researchers. It does not appear to rely on a news release.", "answer": 1}, {"article": "Antioxidants are found in different levels in fruits and vegetables, such as blueberries or broccoli.\nBrosius was skeptical of the benefits, although he said the juice was unlikely to cause harm.\n\u201cThis study does not demonstrate anything special about pomegranate juice,\u201d she told Reuters Health in an e-mail.\n\u201cWho the heck knows what the active ingredients are?\u201d\n\nMarion Nestle, a nutrition expert at New York University, said the effects might not be unique to pomegranate juice.\nThe findings were presented at the American Society of Nephrology\u2019s meeting in Denver \u2014 aka Renal Week \u2014 and have not yet been vetted by independent experts.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely solely or largely on a news release.", "answer": 1}, {"article": "In addition to retaining its first place ranking for the best hospital in the Twin Cities and second in the State of Minnesota in the U.S. News & World Report's 2016-17 best hospital rankings, Abbott Northwestern has received nursing magnet certification, a recognition earned by only five percent of hospitals nationwide.\nThe study, funded by Engelsma Family Foundation and Abbott Northwestern Hospital Foundation, was published recently in The Breast Journal, the official journal of the National Consortium of Breast Cancers.\nPhysicians at the Virginia Piper Cancer Institute wanted to know if surgical procedures to test the lymph nodes for cancer were always necessary.\nThe Institute was founded in 1990 at Abbott Northwestern Hospital.\nThe Virginia Piper Cancer Institute\u00ae, part of Allina Health, provides comprehensive care through all aspects of cancer prevention, early detection and treatment to help individuals maintain quality of life and find ways to live with and beyond cancer.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "No unjustifiable language employed in this release.", "answer": 1}, {"article": "March 29, 2011 -- A minimally invasive procedure that cuts off the blood supply to an enlarged prostate may help when medications fail, and it appears to provide good symptom control without sexual dysfunction, a new study shows.\nThe authors report that the dead tissue required surgical removal.\nDespite the promising results of this small trial, experts said it was far too early to recommend PAE to patients.\nThe study was presented at the Society of Interventional Radiology annual meeting in Chicago.\n\u201cThe results are excellent.\u201d\n\nIn a small pilot study, most men were able to leave the hospital four to eight hours after the procedure, which is called prostatic artery embolization (PAE), researchers report.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely solely on a news release.", "answer": 1}, {"article": "\"It is not inconceivable that in the near future you will see the I-Portal goggle used on every sideline in America,\" Hoffer said.\nThe results of the trial met the expectations of Hoffer and his team of researchers.\nThe research findings published by PLOS ONE help support their objective.\nWith these findings, it appears the I-Portal goggle may be a solution.\n\"This work opens the door for site of injury testing and access to physiologic tests for athletes of all ages.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release does not use sensational language. While the statement \u201cIt is not inconceivable that in the near future you will see the I-Portal goggle used on every sideline in America\u201d is over-the-top we addressed our concerns about that under the novelty criteria.", "answer": 1}, {"article": "In the study entitled \"Long-term physiological T3 supplementation in hypertensive heart disease in rats,\" aging female rats with hypertension progressing to heart failure were treated for one year (half their lifetime) with a low oral dose of the active form of thyroid hormone, T3.\n\"Thus, T3 treatment inhibited the major cause of stiffening of the heart in hypertension.\nThe experts once warned that Beta blockers were too dangerous to use in heart failure patients.\nGerdes has long argued that medical opinion on thyroid treatment for patients with heart disease is largely shaped by outdated studies that used toxic doses of thyroid hormones.\nThe majority of those patients are elderly women with high blood pressure.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release makes very clear that this was an animal study, from the headline through the body of the text. It also puts the work into context, and uses cautious language when describing effects (e.g., \u201cencouraging cardiac improvements\u201d).", "answer": 1}, {"article": "Overweight or obese people, however, exist in a state of chronic inflammation.\nWhile IL-6 has normal functions in the body, elevated levels are associated with an increased risk of developing certain cancers and diabetes and may be implicated as a cause of depression, Duggan said.\n\"That suggests vitamin D can augment the effect of weight loss on inflammation.\"\nBiomarkers of inflammation were measured at the beginning and end of the study.\nDuggan encourages women to speak to their health care providers about measuring their levels of vitamin D to determine the most appropriate dosage.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "None detected.", "answer": 1}, {"article": "\u201cIt\u2019s a promising result from an interesting data set,\u201d he said.\nThe new analysis was by Dr. Jerri Edwards of the University of South Florida, whose mentor, Dr. Karlene Ball of the University of Alabama at Birmingham, sold her rights to the program to Posit Science.\nThe institute is part of the National Institutes of Health, which funded the study.\nThe study, known as Active, examined the effects of cognitive training programs on 2,785 healthy older adults.\nEdwards said she was frustrated with the scientific debate, which is one reason she agreed to present her findings before they were published.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Several sources were interviewed including Dr. John King, who was involved in the original study, and\u00a0Mayo Clinic Alzheimer\u2019s expert Dr. Ronald Petersen. Based on this, it does not appear the story was based solely on a news release.", "answer": 1}, {"article": "Sabourin Lussier, born with spina bifida, faced the possibility of kidney failure when she was just 19 years old. Her bladder, damaged by the devastating birth disorder, leaked uncontrollably and often backed urine up into her kidneys.\n\nA conventional surgery to reconstruct her bladder with intestinal tissue threatened further health complications. So in May 2000, Ms. Lussier and her mother, Gail Johnston, agreed to an experiment under which she and eight other patients with spina bifida would receive partial, laboratory-built...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no evidence this is taken directly from a press release. The reporter makes an effort to interview several surgeons and experts in the field of tissue regeneration.", "answer": 1}, {"article": "\"It's very exciting,\" Klein says.\nWhile Americans spend an estimated $1 billion on nonprescription weight loss products, few if any of those products have undergone the rigorous testing that is required by the FDA for prescription medications.\nAnd many consumers may be put off by the drug's significant gastrointestinal side effects, including flatulence, diarrhea and anal leakage.\nAt the current recommended prescription dose -- 120 milligrams taken up to three times per day, for example up to 360 milligrams daily -- about 70 percent of users experience gastrointestinal complications, Klein says.\nBut it's important to know that the weight loss that's typical for users of the drug -- 5 to 10 percent of total weight -- will be less than many dieters expect.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "", "answer": 2}, {"article": "Follow us: twitter.com/CocoaHealthSci\n\nIn 1911, Frank C. Mars made the first Mars candies in his Tacoma, Washington kitchen and established Mars' first roots as a confectionery company.\nThis study, conducted by researchers from Italy's University of L'Aquila and Mars, Incorporated, reinforces the results of several recent cognitive studies--throwing more light on the important role diet plays in maintaining cognitive health.\nExcitingly, there was also evidence of improvements in these cardiometabolic outcomes.\nThis test product is currently not commercially available.\nThis second study just published in the AJCN looked to address this question.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release skates along the line here, as does the video. It uses phrases such as \u201care encouraging,\u201d and \u201csupport the idea that,\u201d and \u201ccan play an important role\u201d. We\u2019ll award a satisfactory, although the cumulative effect of this language does bring the release to the brink of Not Satisfactory.", "answer": 1}, {"article": "Aug. 10, 2011 -- Two of three patients dying of chronic lymphocytic leukemia (CLL) appear cured and a third is in partial remission after infusions of genetically engineered T cells.\nBut the therapy worked vastly better than University of Pennsylvania researchers David L. Porter, MD, Carl H. June, MD, and colleagues had dared to hope.\nWhat's new about the current treatment is the addition of a special signaling molecule called 4-1BB.\nThis may be why relatively small infusions of the CAR T cells had such a profound effect.\nThe treatment success came in a pilot study that was only meant to find out whether the treatment was safe, and to determine the right dose to use in later studies.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story went well beyond any news release, but one could argue that the extensive use of patient quotes taken from a university news release is not the best journalistic practice.", "answer": 1}, {"article": "\"Transfer between hospitals takes a lot of time,\" said Turner.\nIf so, the VIPS device could have widespread clinical implications, helping emergency personnel decide whether to take a patient to a comprehensive stroke center or a primary stroke center for treatment.\nThe VIPS device requires very little training to operate compared to that required to learn standard emergency examination skills, thereby reducing the possibility of human error during emergency diagnosis.\nThe researchers hope that the device will save valuable time -- especially important in stroke where time is brain -- when it is deployed with emergency medical personnel in the field.\nThis places the VIPS device above standard physical examination tools used by emergency personnel that display specificity scores between 40 and 89 percent.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There is no inappropriate language used here, but there is a simile that might be suspect:\n\u201cThis could potentially be something like a defibrillator,\u201d said Turner. \u201cYou can find out if a patient is having a stroke, just like you can put a defibrillator on a patient to see if they\u2019re having a heart attack.\u201d\nThat comparison is fairly flawed. Monitors diagnose arrhythmias. ECGs diagnose heart attacks. Defibrillators shock patients who are having an arrhythmia during their heart attack.", "answer": 1}, {"article": "Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School.\n\"Proton radiotherapy is still not widely available in the U.S. or around the world, but it is increasingly recognized for its potential to reduce the side effects of treatment, particularly in the pediatric population,\" says Torunn Yock, MD, MCh, MGH Department of Radiation Oncology, lead and corresponding author of the report.\n\"At experienced centers, proton therapy has a proven track record of treatment success and safety.\"\n\"Our results indicate that proton therapy maintains excellent cure rates in pediatric medulloblastoma while reducing long-term side effects, particularly in hearing and neurocognitive function, and eliminating cardiac, pulmonary, gastrointestinal and reproductive effects,\" says Yock, who is an associate professor of Radiation Oncology at Harvard Medical School.\nSignificant hearing loss was seen in 12 percent of patients three years after treatment and in 16 percent at five years, which compares with around 25 percent reported in studies using photon radiotherapy.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "This is a tough call, but we believe the release uses unjustifiable language with this quote from one of the researchers: \u201cWhile we are currently investigating quality of life differences between proton and photon treatment, I truly believe that \u2013 particularly for the youngest children \u2013 the ability to offer them proton therapy can make a big difference in their lives.\u201d\nThis statement plays to emotions, and the researcher essentially acknowledges that the statement isn\u2019t justified since the appropriate comparative research hasn\u2019t been done. The families of pediatric cancer patients want to believe, but scientists need to base their statements, not on beliefs, but on data from the highest quality comparative studies we can ethically perform.", "answer": 0}, {"article": "The Mount Sinai Hospital is in the \"Honor Roll\" of best hospitals in America, ranked No.\nThe research also determined that the best surgical approach for cochlear implant procedures did not involve drilling into the bone around the ear.\n\"This study is a breakthrough for patients with hearing loss, and improvements in practice and techniques will allow them to enjoy many hearing benefits such as music enjoyment, listening in complex environments, and sound localization.\"\nThis research was supported by the National Institute on Deafness and Other Communication Disorders the National Center for Advanced Translational Sciences.\nThe results, published in the June 23, 2017, online edition of The Laryngoscope, may transform how doctors approach cochlear implant procedures to give patients the best possible outcomes.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t engage in sensational language. But absent any numbers to describe the benefits or details about the evidence and what makes any of the approaches novel, the release doesn\u2019t explain what makes this study a\u00a0\u201cbreakthrough.\u201d", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061210/18vitamin.htm was not found on this server.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not appear to rely solely or largely on a press release.", "answer": 1}, {"article": "Rather, surgeons move electronic instruments that are linked to the movement of other instruments inside the body, while they watch a three-dimensional image of what\u2019s going on inside.\nIn this case, the robot could turn what would have to be an open surgery into a simpler one.\nThe robot-surgeon team might not have outperformed the surgeon alone because the procedure was a relatively simple one.\n\u201cWe were surprised that (surgery with the robot) did not have better outcomes than (the surgeon alone), as we have always believed if you can see more and see better you can do more and do better,\u201d the authors write.\nThere was no difference in how much blood patients lost, and there were no complications in either group.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because of the second source who was quoted, it does not appear that this story relied on a news release. ", "answer": 1}, {"article": "AMG145, along with other PCSK9 inhibitors being developed by companies like Pfizer, Regeneron Pharmaceuticals Inc in partnership with Sanofi and Roche, is a man-made antibody.\nThe new drug, given by injection every four weeks, is part of a promising new class of biotech medicines known as PCSK9 inhibitors designed to target a protein that prevents the body from removing artery blocking LDL cholesterol from the bloodstream.\nThe most common side effects seen in the trial were injection-site reactions, cold-like symptoms and headache.\nThe trial, presented here at the annual scientific meeting of the American Heart Association, included 168 patients with heterozygous familial hypercholesterolemia, in which a defective gene inherited from one parent impairs the ability to properly metabolize LDL.\nPatients treated with a placebo saw a 1 percent increase in LDL cholesterol.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is little to go on to determine what source was relied on.", "answer": 2}, {"article": "\"This is the first study looking at women who have failed so many other treatments,\" Krop tells WebMD.\nThe findings were presented at the San Antonio Breast Cancer Symposium.\nThe women remained cancer-free for an average of seven months -- results unheard of in patients this sick, he says.\nThey had been treated with an average of seven different therapies, including Herceptin, Tykerb, and Xeloda, and each had failed.\nAll the women, who had breast tumors for an average of three years, had cancer that had metastasized, or spread to other parts of the body.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article does not appear to have overly relied on a news release. The investigator and specialist quotes were \"as told to WebMD.\"", "answer": 1}, {"article": "The spectrum of ADHD and related disorders is broad, and there is no one-size-fits-all treatment.\n\u201cWe tried some medication therapies that ended up being really a nightmare for us, and making matters worse.\u201d\n\nMedication is often the first line of defense in conventional medicine for kids with ADD and ADHD, with doctors prescribing everything from stimulants to antipsychotics and even antidepressants to help control the symptoms.\n\u201cI thought we weren't going to get accepted to the program, and they told us they could help us and we never looked back.\u201d\n\nThe specialized learning centers, of which there are now 80 throughout the country, were developed by Dr. Robert Melillo, a neurology researcher and author of the book \u201cDisconnected Kids,\u201d to help balance the brains of kids with learning disorders, like Mallory.\n\u201cIf you get a child who has really strong left brain and delayed right brain, those are kids that may be labeled with attentional problems or behavioral problems or social issues,\u201d Melillo said.\nFor Mallory, the disorder led to a pattern of epic meltdowns which left Amy reeling\u2014 and willing to try anything to control them.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "When a story reports on just one person\u2019s experience from just one commercial treatment center and ends by including a link to the commercial operation\u2019s website, it sure smacks of a PR news release at play. \u00a0But we don\u2019t have any direct evidence of that, so all we can give this story is a Not Applicable score on this criterion because of our uncertainty.", "answer": 2}, {"article": "Added Dr. John C. LaRosa, president of the State University of New York (SUNY) Downstate Medical Center in New York City: \"It's very preliminary but it's important because the last drug out of the barrel of this type was not a success.\nIt also didn't result in the blood pressure increases that helped doom torcetrapib.\n\"We saw very encouraging reductions in clinical events,\" said Dr. Christopher Cannon, lead author of the study, which also appears in the Nov. 18 issue of the New England Journal of Medicine.\nOther experts are intrigued by the findings, but note that the research is still in very early stages.\nA big study to confirm the results would take four to five years to complete so the drug is still years away from market, said Cannon, who is a cardiologist with Brigham and Women's Hospital in Boston.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "Viagra is one of three licensed drugs to treat erectile dysfunction, Davies explained. The other two are Cialis and Levitra. They can take from half an hour to several hours to work, and they're not for everyone: Men who've had a stroke or heart attack are told to use the drugs with caution, reports the Daily Mail. Even those without medical issues simply don't like the wait.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story cites the London Daily Mail newspaper as its source. We can\u2019t judge the extent to which the London story or the NY story may have been based on a news release.\u00a0\u00a0 ", "answer": 2}, {"article": "Toxins produced by bacteria, such as salmonella, can severely harm the digestive system by damaging nerves critical to healthy gut function.\nThe tests, created by Mark Pimentel, MD, director of the GI Motility Program and Laboratory, confirm when a patient has developed IBS because of food poisoning, a major cause of the disorder.\nThe new blood tests identify the presence and amount of specific antibodies reacting to the toxins.\nFor more information on IBS and the new blood test for the disorder, watch this video:\n\nFirst Ever Blood Test for IBS\n\nCedars-Sinai has entered into an exclusive license agreement with Commonwealth Laboratories for several patent applications covering the blood tests, developed by Pimentel to detect both anti-CdtB and anti-vinculin antibodies in the diagnosis of irritable bowel syndrome and inflammatory bowel disease.\n\"The fact that we can now confirm the disease through their blood, not their head, is going to end a lot of the emotional suffering I have seen these patients endure.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "This is a big one. The headline of the release states that \u201cDefinitive tests for irritable bowel syndrome developed\u2026\u201d. However, it would be far more accurate to say that \u201cReasonably accurate tests for diagnosing diarrhea-predominant IBS caused by food poisoning developed\u2026\u201d. The tests are a significant advance, but are still far from foolproof \u2014 after all, \u201cmore than 90 percent accurate\u201d is also \u201calmost 10 percent inaccurate.\u201d Further, it\u2019s not clear how many cases of IBS are caused by food poisoning, or whether identifying such patients with this test will improve their outcomes. All in all, not nearly as \u201csimple\u201d as the release suggests.", "answer": 0}, {"article": "\"That's about what you see with standard drug therapy,\" says researcher J. David Prologo, MD, assistant professor of interventional radiology at Case Western Reserve University\u2019s School of Medicine in Cleveland.\nBut other experts tell WebMD that questions about the long-term consequences remain.\nA time to ejaculation of more than two minutes is normal, he tells WebMD.\nResearchers tested the technique on 24 men who hadn't been helped by standard treatments.\nThe findings were presented here at the annual meeting of the Radiological Society of North America.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story does not rely excessively on any press release.", "answer": 1}, {"article": "A 6-month supply of vitamin D supplements can be bought for less than $10, and many multivitamins contain the recommended daily dose of vitamin D.\n\nAs for calcium, the NIH advises 1,000 mg per day for men ages19-70, and then 1,200 mg per day for men older than 70.\nDespite the findings, people still need to get enough calcium and vitamin D to reduce the risk of osteoporosis, or bone thinning, said Dr. Mone Zaidi, an osteoporosis researcher at the Mount Sinai School of Medicine in New York, who was not involved in the study.\nHowever, there isn\u2019t enough data to say if vitamin D can help treat or prevent these diseases, Zaidi said.\nAdding the supplements to the exercise program provided no extra benefit, hinting that the men already had enough vitamin D and calcium in their diets to be able to boost their bone strength through exercise alone.\nIt\u2019s most common in older women, but about seven percent of white men and five percent of black men are affected, according to the American College of Physicians.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear the story didn\u2019t rely solely on a news release.", "answer": 1}, {"article": "Aging is never easy, particularly during menopause. But for 30 years women could at least depend on estrogen and progestin supplements, a comforting hormonal hand to hold that would not only ease the uncomfortable symptoms of getting older but also keep skin supple and hair lustrous. Doctors even encouraged women well into their 70s to take the treatments, on the basis of studies showing that they protected against heart disease and cushioned bones against osteoporosis-related fractures.\n\nIt seemed almost too easy--and it was. In 2002 the quick pharmaceutical fix was all but snatched away when a large government study found that...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no way to know if the story relied on a press release as the sole source of information.", "answer": 2}, {"article": "The decrease we saw was larger than is seen with the currently used medications,\" Lanctot said.\nAgitation is a frequent symptom of advanced Alzheimer's, Lanctot explained.\nMarinol is now being tested for its usefulness in treating Alzheimer's symptoms, Lanctot said.\n\"It's a milder form of TCH\" compared to whole-leaf marijuana, Lanctot said.\nThe study was to be presented Tuesday at the Alzheimer's Association meeting in Chicago.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story doesn\u2019t not rely on the news release issued by the Alzheimer\u2019s Association.", "answer": 1}, {"article": ".\nAnd patients would need a special device to get it deep into the nose.\nThe lower dose seemed more effective than the higher one.\nThe solution was a special device made by Kurve Technology that delivers a spray of insulin deep into the nose.\nThat led to the current study, lasting four months.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story contains enough independent context that we can be sure it wasn\u2019t based on a news release.", "answer": 1}, {"article": "Imaging equipment makers such as GE Healthcare, Siemens, Philips and Toshiba Medical Systems are working to develop low-dose CT scanners.\nThe findings, published in the Archives of Internal Medicine, add to mounting evidence that Americans are overexposed to radiation from diagnostic tests, especially from a specialized kind of X-ray called a computed tomography, or CT, scan.\nRedberg, who wrote a commentary on the studies, said U.S. doctors\u2019 enthusiasm for the tests has led to an explosion in their use that is putting patients at risk.\nThe researchers said efforts need to be taken to minimize CT radiation exposure, including reducing the number of unnecessary tests, cutting the dose per study, and standardizing the doses across facilities.\n\u201cIt\u2019s estimated that just from the CT scans done in one year, just in 2007, there will be 15,000 excess deaths,\u201d Redberg said in a telephone interview.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no evidence that the story relied solely or largely on a news release.", "answer": 1}, {"article": "Seventeen percent were having moderate to severe vasomotor symptoms, and 18 percent reported moderate to severe sexual symptoms.\nThere is also, she said, a complete lack of understanding that for most women, these symptoms are not fleeting.\n\u201cWomen and doctors simply are not aware that symptoms can last this long.\u201d\n\nFinally, many women don\u2019t realize that non hormonal options can be safe and effective, she added.\nThe findings may be applicable to other countries, too, according to senior author Dr. Susan R. Davis from Monash University in Melbourne.\n\u201cExtrapolating our findings to 3.7 million Australian women aged 40 to 64 years, we found that 455,000 women are likely to have moderate to severe vasomotor symptoms, with most women (385,000) remaining untreated,\u201d they write.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes comments from an independent expert, so we can be sure it went beyond any news release.\n\u00a0", "answer": 1}, {"article": "\"Normally when you make drugs, it's hard to say 'attack only that protein.'\nObviously, the process will have to be refined and optimized before it's actually used for treatment.\nBut the work that nabbed the prize was done in worms -- a far cry from humans.\n\"This is one step away from getting into the actual DNA.\"\nThe experiment proceeded just as planned, as biopsies later showed.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear the story didn\u2019t rely solely on a news release. ", "answer": 1}, {"article": "Having a large waistline, high blood pressure, high blood sugar, low levels of HDL (good) cholesterol and high levels of triglycerides, are among the factors that make up metabolic syndrome.\n\u201cCurcumin is the active ingredient of the famous spice turmeric and has a long history of culinary and medicinal use in the Asian countries,\u201d said the study\u2019s senior author Amirhossein Sahebkar.\n\u201cCurcumin is a very safe natural supplement, and there is no severe adverse event associated with its use, even at high doses,\u201d Sahebkar said.\nHowever, owing to limited safety information, pregnant and lactating women should avoid using this supplement, Sahebkar said.\n\u201cThe findings of our studies, along with clinical findings reported by other groups, indicate the usefulness of daily use of curcumin supplement for the prevention and treatment of several diseases,\u201d Sahebkar said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes extensive quotes from an interview with one of the researchers, which goes beyond the news release.", "answer": 1}, {"article": "Sales rose 82 percent from 2008 to 2009, reaching $430 million.\nIt is not clear how or why the claims for high vitamin D levels started, medical experts say.\nAnd there is evidence that excess calcium can increase the risk of heart disease, the group wrote.\nBut, the committee concluded, a level of 20 to 30 nanograms is all that is needed for bone health, and nearly everyone is in that range.\nMost people need to take supplements to reach levels above 30 nanograms per milliliter, he added.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story was not based on a news release.", "answer": 1}, {"article": "From a crusty baguette to a big thick steak, some foods may be hard to digest, particularly as we age. Enzyme capsules taken before a meal can relieve discomfort by helping the body to break down problem foods, say companies that sell the pills. Doctors say some enzyme supplements work well, but others need more human studies.\n\nDigestive enzymes are proteins that work like scissors to break down foods. The pancreas, where many of these enzymes are made, can slow down as we age, which can result in bloating and other gastrointestinal...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is enough original reporting that we can be sure the story wasn\u2019t based on a press release.", "answer": 1}, {"article": "Doctors spin a few tablespoons of a patient's own blood, separating out the platelets.\nHe is one of the few patients to get it so far \u2014 clinical trials are now testing PRP's safety and effectiveness.\nIt's called Platelet Rich Plasma therapy \u2014 or PRP.\nBornstein was thrilled to get back on the field quickly.\nA leading sports medicine expert, he believes we can speed up the body's ability to heal itself with a remarkably simple technique.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if the story relied solely or largely on a news release.\u00a0 We do know that it publicized the work of only one physician. ", "answer": 2}, {"article": "\"I've been through it, it was the past, time to move on,\" he said.\nAfter several trips to the doctor, the Mullins received the worst possible news.\nToday, there's no stopping 8-year-old Brian Mullin on the Wiffle ball field.\nThis new treatment is still experimental, but it's a step forward in the strategy of manipulating a person's own immune system to fight cancer.\nIt was neuroblastoma, a rare but deadly form of childhood cancer.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Did not rely exclusively on a press release.", "answer": 1}, {"article": "The American Heart Association has more on heart failure.\nResults were even more heartening at higher doses, where participants had an 88 percent decrease in risk for death, cardiac transplant, hospitalizations and other outcomes, the study authors said.\nThe enzyme regulates calcium cycling, which, in turn, is involved in how well the heart contracts, the researchers said.\nAt both six months and a year later, the patients who had received the new gene saw their risk for death, cardiac transplantation, worsening heart failure and hospitalization decline by half.\nRedberg cautioned that the study was still preliminary and \"requires more investigation.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "At least the story discloses that the quotes from the lead research are taken from a university news release.", "answer": 0}, {"article": "Subsequently, a clinician will help a patient learn to slow down or speed up those brain waves, through a process known as operant conditioning.\nDr. Norman Doidge, a psychiatrist at the Center for Psychoanalytic Training and Research at Columbia and the author of \u201cThe Brain That Changes Itself\u201d (Viking, 2007), said he considered neurofeedback \u201ca powerful stabilizer of the brain.\u201d Practitioners make even more enthusiastic claims.\nThe treatment is also gaining attention from mainstream researchers, including some former skeptics.\nWhen it comes to to the actual devices, Dr. Kerson, at the International Society for Neurofeedback and Research, cautioned that they should never be used without experienced supervision.\nThese issues, they say, can be represented on a \u201cbrain map,\u201d the initial EEG readings that serve as a guide for treatment.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to be based on a news release.", "answer": 1}, {"article": "\"Here, fertility is very important to many young women,\" he said.\nAnd no cancer developed in the transplanted tissue, Jensen said.\nAnd for 15 of the women, transplantation had taken place more than five years earlier, the researchers said.\nDr. Avner Hershlag, chief of the Center for Human Reproduction at North Shore University Hospital in Manhasset, N.Y., called the new research \"innovative and exciting.\"\nThe women's average age when the tissue was removed and frozen was nearly 30.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not appear to rely on a news release, and had independent comments.", "answer": 1}, {"article": "Trials were conducted on nine healthy individuals in a blinded comparative study on absorbable versus fermentable carbohydrates.\nNew trials of a breakthrough swallowable sensor have revealed the device is 3,000 times more accurate than current technology used to diagnose many gut disorders.\nThe findings show the revolutionary gas-sensing capsule developed by researchers at RMIT University in Melbourne, Australia, could surpass breath testing as the benchmark for diagnosing gut disorders, paving the way to solving previously undiagnosed conditions.\n\"Importantly this test is non-invasive and allows the patient to continue with their daily life as normal.\"\nSuch an immune mechanism has never been reported before.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The use of the words \u201cbreakthrough\u201d and \u201crevolutionary\u201d is quite premature in referring to trial results of 12 healthy subjects.\nAlso, inclusion of this quote by the study lead is potentially very misleading:\nThis gives us confidence that our new technology could potentially solve many mysteries of the gut and help the large portion of the population who have not been able to find a useful diagnosis or treatment for their symptoms.", "answer": 0}, {"article": "Nearly 25 percent of those ages 65 to 74 and 50 percent of those who are 75 and older have disabling hearing loss.\nMED-EL expects that the SYNCHRONY EAS Hearing Implant System will be available in the coming months.\nUNC participated in the EAS System clinical trials and implanted the device in more patients than any other hearing center that participated.\n\u201cOn average, patients performed more than twice as well on tests of speech understanding with EAS than they did with their hearing aids preoperatively, which speaks to the benefits of this technology,\u201d Pillsbury said.\nThe SYNCHRONY EAS implant best assists people whose hearing loss is referred to as \u201cski-slope\u201d hearing loss, based on the steeply sloping image that appears on an audiogram when a patient has more trouble hearing higher-frequency sounds.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t rely heavily sensational language.", "answer": 1}, {"article": "(A white light signals a \"moderate\" likelihood, while a blue light means the odds are low.)\nTwo patients ultimately had the implants removed.\nBut experts said the results are promising, and should prompt further studies.\nThose patients went on to the next four-month phase, where the devices were activated to give warnings.\nThe findings, reported online May 2 in the journal Lancet Neurology, are based on only 15 patients, and the device worked far better in some than others.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There\u2019s no evidence that the story relied on a news release.", "answer": 1}, {"article": "Additional UT Southwestern researchers include lead authors Dr. Wenfang Chen, Haley Hill, Alana Christie, and Min Soo Kim, as well as Eboni Holloman, Andrea Pavia-Jimenez, Farrah Homayoun, Dr. Yuanqing Ma, Dr. Nirav Patel, Dr. Guiyang Hao, Qurratulain Yousuf, Allison Joyce, Dr.\nHIF-2 inhibitors also are the target of UTSW's recent $11 million SPORE (Specialized Program of Research Excellence) award.\nPart of the SPORE grant, one of just two directly related to kidney cancer in the nation, is focused on further researching HIF-2 inhibitors.\nIn a previous report, Dr. Kevin Courtney, Assistant Professor of Internal Medicine and a coauthor of the current study, reported at the American Association of Clinical Oncology annual meeting that HIF-2 inhibitors were safe in patients and had activity even in heavily pretreated patients.\nResearchers surprisingly found a subset of tumors that do not respond to the drug, but were able to identify biomarkers that, once verified, would help determine which patients are more likely to benefit from HIF-2 therapies.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "While the headline and lead sentences are overt exaggerations, we\u2019ve dealt with that issue elsewhere in the review. The release doesn\u2019t otherwise rely heavily on sensationalist terms so we rate it satisfactory. As mentioned above, there is a potential that some patients might be given false hope from the release if they are unfamiliar with the long trial process ahead.", "answer": 1}, {"article": "During the next seven years, the cancer returned in 256 women (16.7 percent) in the special diet group and 262 women (16.9 percent) in the comparison group.\nAll the women had been successfully treated for early-stage breast cancer.\nResearchers noted that none of the breast cancer survivors lost weight on either diet.\nThe study appears in today's Journal of the American Medical Association.\nThe average age was 53 when the study began.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to be taken directly from a press release and there is independent reporting.", "answer": 1}, {"article": "Attorney James Tuffin followed his usual daily routine last week: He ran five miles and drove to his office on suburban Long Island. In between, he stopped at Advanced Radiation Centers in North Hills, N.Y. There, he drank a quart of water, lay down on a treatment table and watched as a high-tech linear accelerator rotated around him for 90 seconds, blasting his cancerous prostate with radiation.\n\n\"On a good day, I'm in and out in a half-hour,\" says Mr. Tuffin, 54 years old, who was midway through his scheduled 45...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We are tempted to give this an unsatisfactory score, but because we see no text that is identical in the story and in the company\u2019s news releases, we will post a N/A score because of our uncertainty.\u00a0 What fuels our suspicion is:", "answer": 2}, {"article": "Menstrual cramps, known by the medical name dysmenorrhea, typically begin just before or at the start of a woman's menstrual period and can last several days.\nAnd since the study period lasted only two months, there was no way to tell whether such a high dose produced any toxic long-term effects.\nExperts wondered if women with higher blood levels would experience such dramatic cramp relief as observed in the study.\nGraham and Rabin agreed that much larger trials should be done before they would recommend vitamin D3 use to any of their patients for cramp relief.\nThe study was published Feb. 27 in the Archives of Internal Medicine.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article does not appear to be based solely on a press release.", "answer": 1}, {"article": "Visit http://www.\nThe study, New Multiple CT Assessment of Acute Stroke Patients: Are We Ready for Prime Time?, shows that recent advances in imaging software in the angiosuite give neurointerventionalists the essential details required to diagnose a patient with large vessel occlusion (LVO) for an endovascular thrombectomy (EVT).\nThis study suggests that in the future, stroke patients can bypass the CT scan or emergency department and go directly to the angiosuite for imaging and proper care.\nPreliminary results show that the cone beam imaging software compares favorably with baseline and follow-up CT scans.\nThe lead PI on this study, Professor Vitor Mendes Pereira, concluded by saying, \"By reducing intra-facility transfer times, patients can receive EVT treatment sooner, which can significantly impact patient outcomes\".\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The title of the release is unjustified. There is nothing in the study that supports the claim that this technology reduces brain damage. At best one can say it could lead to faster treatment. Whether that would be better or not requires future research.", "answer": 0}, {"article": "Actually, nitrous is making a comeback in U.S. maternity circles. It has remained a staple of childbirth in Canada, Australia, and Britain \u2014 Catherine, Duchess of Cambridge (the former Kate Middleton), who welcomed her third royal baby, Louis Arthur Charles, last month, reportedly has used it. But it basically disappeared in the United States in the 1970s. American women preferred to be numbed below the waist with epidural anesthesia, or at least that became the gold standard for pain relief.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story doesn\u2019t appear to rely upon a news release.", "answer": 1}, {"article": "Aneurysms are weakening, or bulging, of blood vessels that can rupture and become life-threatening.\n\u201cPrior to gaining approval from the Food and Drug Administration, patients with many types of aneurysms and aortic conditions had limited treatment options,\u201d said Azizzadeh, director of Vascular Surgery at the Smidt Heart Institute at Cedars-Sinai.\nAfter my recovery, I know I will feel stronger and healthier, and will remain forever grateful.\u201d\n\nSince Angelino\u2019s surgery, Azizzadeh who, in conjunction with medical device company Medtronic, served as the national principal investigator in clinical tests of the device \u2013 has performed several additional, successful surgeries.\nCompared to other technologies, the stent graft can travel through smaller, curvy vessels and better adjust to a patient\u2019s anatomy.\n\u201cI feel very lucky to have benefited from this new and improved surgical technique and for the great doctors who cared for me.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t engage in unjustified language.", "answer": 1}, {"article": "Women are considered obese at a BMI of 30 and morbidly obese at 40 (which is typically about 100 pounds over a woman's ideal body weight), yet almost a third of women presenting for bariatric surgery did not identify themselves as obese.\nThe study speaks both to the benefits of bariatric surgery and to the tremendous toll obesity takes on health.\nModesitt, of the UVA's Division of Gynecologic Oncology in the Department of Obstetrics and Gynecology, was most surprised by the dramatic changes seen in the patients' metabolic profiles derived from the gut microbiome, the population of microorganisms living inside us.\nWhile the study speaks to the transformative effect bariatric surgery can have, Modesitt urged people to avoid gaining weight in the first place and for those seeking to lose weight to exercise and eat more healthily before turning to surgery.\nThe study looked at the effects of bariatric surgery in a relatively short timeframe, one to three years after surgery.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "This news release gets ahead of itself with the headline as noted above. The claim of a \u201cdramatic\u201d cancer-prevention benefit is just not tenable. The researchers found that precancerous changes resolved in a small number of women, and that there was a \u201chuge alteration\u201d in these women\u2019s gut bacteria. But as the study author readily admits, it\u2019s not clear whether such changes in gut bacteria have any relationship at all to cancer risk. Similarly, all the other outcomes (weight loss, glucose/insulin levels) may have a relationship with cancer, but whether the impact of surgery is enough to affect actual cancer rates is unknown. With so much uncertainty, why frame these results as a \u201cdramatic\u201d benefit in the headline?", "answer": 0}, {"article": "To survive with very little sunlight, they have evolved to convert light into energy with incredible efficiency, Emberton\u2019s team said in a study published in the journal Lancet Oncology.\nResults of a trial in 413 patients showed that the drug, which is activated with a laser to destroy tumor tissue in the prostate, was so effective that half the patients went into remission, compared with 13.5 percent in a control group.\nIn the trial, only 6 percent of patients treated with VTP needed radical therapy compared with 30 percent of patients in the control arm who were under active surveillance.\nThe trial involved 47 treatment sites in 10 European countries, most of which were performing VTP for the first time.\n\u201cThese results are excellent news for men with early localized prostate cancer, offering a treatment that can kill cancer without removing or destroying the prostate,\u201d said Mark Emberton, a University College London consultant urologist who led the trial.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This coverage is based entirely on a news release\u00a0(which we also reviewed), with no attribution to let readers know that there\u2019s no actual reporting here. In some cases, entire paragraphs were lifted from the news release with only minor stylistic changes. The following paragraphs are almost word-for-word like those in the news release:\nMen with low-risk prostate cancer are currently put under active surveillance, where the disease is monitored and only treated when it becomes more severe. Radical therapy, which involves surgically removing or irradiating the whole prostate, has significant long-term side effects so is only used to treat high-risk cancers.\nWhile radical therapy causes lifelong erectile problems and incontinence, VTP only caused short-term urinary and erectile problems which resolved within three months, the researchers said. No significant side-effects remained after two years.\nIn the trial, only 6 percent of patients treated with VTP needed radical therapy compared with 30 percent of patients in the control arm who were under active surveillance.\nThe trial involved 47 treatment sites in 10 European countries, most of which were performing VTP for the first time.\nThe VTP treatment is now being reviewed by the European Medicines Agency (EMA) for possible license, but it likely to be several years before it can be offered to patients more widely.", "answer": 0}, {"article": "\"'Promising' is the perfect way to describe our findings,\" said study lead author Dr. David Woodrum, an interventional radiologist at the Mayo Clinic in Rochester, Minn. \"But whether or not this minimally invasive approach would ultimately become a primary method of treatment in the future will depend on the long-term results of this trial, which is still under way.\nAt least in the short-run -- meaning three months after the procedure -- the intervention known as \"cryoablation\" appeared to kill all targeted tumors that had spread to the lung from elsewhere, preliminary results suggest.\nBut they acknowledged that more research needs to be done to track the treatment's impact over the long haul.\nFor his part, Dr. David Carbone, a professor and director of the James Thoracic Center at the Ohio State University Wexner Medical Center, said that the findings regarding cryoablation are \"not incredibly novel,\" given that the procedure has been around for years.\nThe procedure is performed by an interventional radiologist on patients coping with metastasized lung tumors, the researchers noted.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There isn\u2019t any evidence that the story relied solely or largely on a news release.", "answer": 1}, {"article": "Current methods for determining if a prostate has become cancerous include a physical examination of the prostate (known as a digital rectal examination or DRE), MRI scans, a biopsy or tests to determine levels of the chemical prostate-specific antigen (PSA) in the blood.\nThe Dundee University-based team say they have used an ultrasound process called shear wave elastography (SWE) to detect prostate tumours.\nWe can now see with much greater accuracy what tissue is cancerous, where it is and what level of treatment it needs.\nOne in eight men will develop the condition at some point in their lives with more than 47,000 new cases being diagnosed every year.\n\u201cThe technique now needs to be tested in a much larger number of men to confirm just how well it can detect the aggressive cancers, while also ruling out those who do not have prostate cancer,\u201d said Simon Grieveson, head of research funding at Prostate Cancer UK, which funded the Dundee project (with support from the Movember Foundation).\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story is peppered with slightly modified versions of statements from the university\u2019s news release.\u00a0 A slight change here or there in both quoted and paraphrased statements isn\u2019t enough to qualify this as independent reporting. The news release\u2013while boosterish\u2013at least included where the research was published, a fact missing in the news story.\nThe release said: \u201cEach carries significant problems. The PSA test are not offered as standard treatment and the results can be unreliable. The DRE is not good at identifying which cancers are benign and which need treatment. MRI scans are not available across the country and cannot always give a definitive answer. The biopsy is invasive, carries risk of infection and is expensive.\u201d\nWhich the story parrots: \u201cEach carries problems. PSA results can be unreliable; a DRE is not good at identifying which cancers are benign and which need treatment; MRI scans cannot always give a definitive answer; while a biopsy carries a risk of infection and is expensive.\u201d", "answer": 0}, {"article": "\"(But) we used aspirin long before we knew how it worked.\nThose who got the therapy also had significantly more improvement in other measures of symptoms, according to the study that will appear today in the Journal of the American Medical Association.\nShe said she worried about having the surgery, but it got to the point where she felt as though she had run out of options.\nBeyond that, doctors need to do a better job of optimizing drug therapy, he said, noting that there are thousands of potential combinations of drugs that can be used to control symptoms.\nNausieda said much of the benefit found in the study could be due to a placebo effect.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Based on the number of sources cited, it\u2019s clear this story didn\u2019t rely solely or largely on a news release. ", "answer": 1}, {"article": "She said that, \"though this study includes a small sample size followed for a short period of time, the results are promising in that TAK-875 appears to be effective for glycemic [blood sugar] control without significant risk for hypoglycemia or weight gain.\nThe study was funded by Takeda Pharmaceutical (which is developing the drug), and appears online Feb. 26 in The Lancet.\nOther diabetes experts had mixed views on the new findings.\nHowever, like Wissner-Greene, Sood said that \"further investigation is warranted, especially including [heart disease] patients.\"\nThe trial, led by Dr. Charles Burant of the University of Michigan Medical School, included 426 patients with type 2 diabetes who were not getting adequate blood sugar control through diet, exercise or treatment with the first-line diabetes drug metformin.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on this press release from the University of Michigan.", "answer": 1}, {"article": "\"If you have your choice, you want to get poked with a needle or you want to try this?\nNow, Gomaa's lab is looking beyond the flu vaccine.\nAnd the patch can be administered by people who aren't trained health professionals.\nGomaa's hope is that vaccine patches will cost less than vaccinations do now.\nA number of the people in the flu patch study applied it to themselves.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story does not appear to rely on a news release.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070107/15downs.htm was not found on this server.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story quotes multiple experts, the reader can assume the story does not rely on a press release as the sole source of information.", "answer": 1}, {"article": "Phentermine is commonly used as a short-term weight loss treatment, and was previously paired with fenfluramine to make the successful but now-discontinued weight loss drug Fen-phen.\nAccording to the manufacturer's study, the two drugs, when taken together, and at controlled-release doses, were very safe.\nThe study was funded by the pharmaceutical company Vivus, which combined the two drugs into one pill called Qnexa, and petitioned the U.S. Food and Drug Administration for approval in October 2010.\nAccording to the report, there were specific concerns about each drug's safety individually; specifically Topamax, which is reported to cause some psychiatric and cognitive side effects and may cause clef palate birth defects if taken while pregnant.\nTwo existing drugs, in combination, have shown significant promise in promoting weight loss, according to a new report.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not rely solely on a news release.", "answer": 1}, {"article": "March 16, 2010 -- An experimental type of highly focused radiation therapy may control inoperable lung cancer tumors and help people with the deadly disease live longer.\nIn the study, researchers evaluated the safety and effectiveness of SBRT in treating 55 people with early-stage but medically inoperable lung cancer.\nThis type of radiation therapy has not yet been approved by the FDA as a lung cancer treatment, but this study brings it one step closer.\nResearchers say that rate of tumor control is more than double that found with conventional radiation treatment for inoperable lung cancer.\nThe next step is a clinical trial to evaluate the therapy in a larger number of patients and determine the proper dosage for maximum benefit and minimal risk.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no way to know if the story relied on a press release as the sole source of information.", "answer": 2}, {"article": "Researchers compared 136 women with rheumatoid arthritis with 544 healthy women of similar age.\nThe community-based approach and the fact that data on breast-feeding was collected before the onset of disease give the study strength.\nBut they found that the number of children born to a mother did not affect the results.\n\u201cBreast-feeding for an entire year is difficult for many women,\u201d said Dr. Mitra Pikwer, the lead author and an intern at Malmo University Hospital in Malmo, Sweden.\nThe study appeared online May 13 in The Annals of Rheumatic Diseases.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\nThere is no obvious use of text from a news release.\n", "answer": 1}, {"article": "In 2016, he was ranked the No.\nThese results, published today online ahead of print in the American Journal of Medicine, with an accompanying editorial by the editor-in-chief, show that Plaque HD\u00ae, produced statistically significant reductions in dental plaque and inflammation throughout the body as measured by hs-CRP.\nBased on these findings, Hennekens and colleagues are drafting an investigator initiated research grant proposal to the National Institutes of Health (NIH) under the direction of co-author Patrick E. McBride, M.D., M.P.H., professor of medicine and interim associate dean for faculty affairs at the University of Wisconsin School of Medicine and Public Health.\nThe original research from the landmark Physician's Health Study, in which Hennekens was the founding principal investigator, was the first to demonstrate that hs-CRP predicted future heart attacks and strokes.\nLast month, the prestigious New England Journal of Medicine ranked the original manuscript by Hennekens and colleagues on aspirin, inflammation and cardiovascular disease, published in 1997, as their most influential original report of the last 20 years.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "As noted above, the sub-heading (\u201cFindings support reductions in heart attacks and strokes\u201d) overstates the conclusion of the small, pilot trial. And the release repeatedly states or implies that reducing levels of hs-CRP provides a health benefit, which is a matter of ongoing debate.\nThere is also no support provided for the claim that Dr. Hennekens has \u201csaved more than 1.1 million lives.\u201d Where does this number come from? Whatever his contributions to medical science, it is hard to imagine that he personally can claim credit for saving more than 1 million individual lives.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070902/10healthwatch.htm was not found on this server.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no way to know if the story relied on a press release as the sole source of information.", "answer": 2}, {"article": "Platelet-rich plasma (PRP) is blood that has been spun in a centrifuge to separate the blood cells.\n\u201cPRP is probably the best treatment for chronic refractory lateral epicondylitis if it is used after classical types of treatment like rest, braces, nonsteroidal anti inflammatory drugs, cortisone injections or physiotherapy have all failed,\u201d Thanasas said.\n\u201cWhole blood treatment is a god alternative in remote areas or in health systems that do not support financially the use of PRP,\u201d he told Reuters Health in an email.\nThe findings were published in The American Journal of Sports Medicine.\nNEW YORK (Reuters) - Blood injections, especially of platelet-rich blood, into the affected area help relieve the pain associated with \u201ctennis elbow\u201d where other treatment methods have failed, according to a Greek study.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a news release.", "answer": 1}, {"article": "Everyone loses some bone with aging - women abruptly at menopause when estrogen levels decline, men more slowly as male hormones decline over time.\nIf a person simply stands, the muscles accommodate and do most of the work, he said - with no benefit to the bone.\nBut remember: Not exercising also puts you at risk.\nOther exercises - such as front and lateral raises with free weights - focus on the spine at chest level.\nBeyond walking, weight lifting and other resistance training may improve bone mineral density in the lower back, and maintain bone density in the hips.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not seem to rely on a press release.", "answer": 1}, {"article": "Excluding prostate cancer, researchers found about a 12 percent reduction in overall cancer occurrence and said the protective effect seemed to be greater in people who had previously battled cancer.\nThe protective effect of the daily pill was described as \u201cmodest\u201d by the trial investigators who emphasized that the primary use of vitamins was to prevent nutritional deficiencies.\nThe research was sponsored by the National Institutes of Health.\n\u201cIt doesn\u2019t seem like there is any particular risk associated with taking a vitamin and there might be a small benefit,\u201d said Dr. David Weinberg, chief of the department of medicine at Fox Chase Cancer Center in Philadelphia.\n\u201cOur trial took a very commonly used multivitamin that has basically low levels of all the different essential vitamins and minerals.\u201d\n\nThe findings suggest that the biggest health benefit may come from a broad combination of dietary supplements, he said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There\u2019s enough original reporting that we can be sure it wasn\u2019t based on a press release.", "answer": 1}, {"article": "A growing number of doctors are offering an expensive laser procedure they say zaps away a common fungus that causes ugly, discolored nails. Published data on laser treatment for nail fungus is scant, but early results suggest it is a reasonable option for people who don't want the side effects of oral medications.\n\nOnychomycosis, or fungal infection of nails\u2014most often on the toes\u2014affects about 12% of Americans, according to the American Academy of Dermatology. Some people are genetically prone to it. Others, including swimmers...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Given the number of sources cited, it\u2019s clear the story didn\u2019t rely solely or largely on a news release.", "answer": 1}, {"article": "But another finding from that study sheds an interesting light on one of 5-Hour Energy\u2019s central claims \u2014 that the energy shot, unlike competitors\u2019, produces \u201cNo Crash Later.\u201d\n\nAccording to the study, 24 percent of test participants who received 5-Hour Energy had reactions similar to a \u201cmoderately severe crash that left them extremely tired and in need of rest, another drink or some other action,\u201d lawsuit filings show.\nMs. Lutz, the Living Essentials spokeswoman, said the bold \u201cNo Crash Later\u201d statement on product labels was followed by a special mark.\nShe added that another study showing the benefits of 5-Hour Energy was undergoing \u201cpeer review\u201d for possible publication in a scientific journal.\nThat mark, which also appears on the back label, explains in fine print that \u201cno crash means no sugar crash.\u201d\n\nThat is hardly surprising, because 5-Hour Energy does not contain sugar.\nThat study found a benefit when 5-Hour Energy was compared to a placebo like flavored water, she said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story was clearly not based on a press release.", "answer": 1}, {"article": "In the UK, at least 40,000 people a year die prematurely from air pollution, with a cross-party committee of MPs calling it a \u201cpublic health emergency\u201d.\nBilstein said the inhaler could be useful around the world, as particulate air pollution is not just a European problem: \u201cEspecially in Asia \u2013 China in particular \u2013 the demand for such a product is even higher.\nRussell, who also lectures at Imperial College and Oxford University, said it might also be useful for the treatment of asthma, COPD and other lung diseases, not only prevention.\n\u201cThe point that it can prevent the lung inflammation induced by ultrafine particles is established \u2013 there is no more doubt,\u201d Krutmann said.\nThe best thing is that we have clean air because then we don\u2019t need any prophylactic treatment.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Technically, the story was not pulled from a press release. We do wonder however why the story was thought to be newsworthy at this time since\u00a0trial\u00a0results are apparently to be published soon.", "answer": 1}, {"article": "Drugs such as aspirin and ibuprofen treat inflammation, the body's immune response to infections or pathogens.\n\"The findings suggest that inflammation may contribute to the pathogenesis of depression,\" Khandaker said.\nKhandaker said that five of the 20 studies focused on one specific cytokine.\n\"We need more studies,\" he said, particularly research involving patients with depression who are inflamed but healthy to investigate the effect of these drugs on depression.\nTheir potential side effects also must be investigated, Khandaker said, adding that \"we and other research groups from both sides of the Atlantic are currently planning and conducting such randomized control trials.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story, as noted earlier, relies heavily on a news release, but CNN\u2019s writer did interview an independent source.", "answer": 1}, {"article": "Weight gain is a common side effect of Zyprexa.\nThe new study was intended in part to clarify the trade-off between the risks and the potential benefits of preemptive treatment.\nThose on medication gained an average of 20 pounds during the study.\nThe scale rates severity of more than a dozen symptoms, including suspiciousness, grandiosity and bizarre thoughts.\n\"The positive result was only marginally significant, and the negative result was clear,\" said Dr. Thomas McGlashan, a professor of psychiatry at Yale and the study's lead author.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "No evidence this story relies on a press release. Sources other that the study authors are cited and provide some perspective on the treatment and outcome of the trial. ", "answer": 1}, {"article": "Your cells might be aging faster than you are, and new tests purport to help you find out.\n\nA few companies are offering mail-order testing to measure the length of people\u2019s telomeres, the protective caps of DNA on the ends of chromosomes that have been likened to the plastic tips that prevent shoelaces from fraying. Telomeres gradually shorten as people age and eventually may disappear, leaving cells vulnerable to disease and death.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "Dr Arthur Roach, Director of Research at Parkinson's UK, which funded the study said:\n\n\"People affected by Parkinson's, their carers, and health and social care professionals have said that preventing falls and improving balance is the biggest unmet need for people living with the condition, other than finding a cure.\n\"This trial shows that there may be drugs already available, being used for other purposes, that can be tested to help treat Parkinson's.\nThis is a real breakthrough in reducing the risk of falls for people with Parkinson's.\"\nScientists have discovered that a commonly prescribed dementia drug could hold the key to helping prevent debilitating falls for people with Parkinson's.\nDr Henderson and her team at the University of Bristol studied 130 people with Parkinson's who had fallen in the past year.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The lead investigator of the research, one of two medical professionals quoted in the release, goes overboard in calling the study findings \u201ca real breakthrough in reducing the risk of falls for people with Parkinson\u2019s.\u201d Parkinson\u2019s UK\u2019s research director \u2013 as well as the study itself \u2014 takes a more measured approach in summarizing the study\u2019s impact. Dr. Arthur Roach is quoted in the release saying the study shows \u201cthere may be\u201d existing drugs that can help prevent falls and that the research \u201ctakes us a step closer to improving quality of life and finding better treatment\u2019s for people with Parkinson\u2019s.\u201d That\u2019s a much more measured and accurate description than calling it this small and preliminary study a \u201cbreakthrough.\u201d\nIt also seems inappropriate to bring a patient testimonial into the mix as this release does. It quotes a patient who has Parkinson\u2019s who experienced a fall who says the potential to find a treatment that prevents falls would allow her to have surgery for a fractured hip and give her confidence to go shopping without having to \u201cconstantly rely on the goodness of strangers to pick me up when I fall.\u201d\nAlso, the actual title of this study, \u201cRivastigmine for gait stability in patients with Parkinson\u2019s (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial\u201d clearly mentions that this is preliminary, but including the \u2018phase 2 trial\u2019 in the title. This is not mentioned anywhere in the release and may lead readers to believe this process is farther along than it really is.", "answer": 0}, {"article": "Asked if the 34% improvement in cognitive decline is meaningful to a patient, Carrillo said, \"I have a family member with AD.\nLarger studies in many more patients are needed before the drug will be available, though, she says.\nThe results really became clear when the researchers looked only at those patients with mild, early-stage disease.\nThere was even a hint that the drug helped to slow the decline in functioning.\nThe latest results come from a combined analysis of a 1,012-patient study and a 646-patient study, both of which involved people with mild to moderate Alzheimer's disease.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to be based on a news release.", "answer": 1}, {"article": "\u201cWe\u2019ll also advance key parts of our tobacco plan very soon,\u201d he said.\nThe move was part of a comprehensive plan the agency announced last summer to regulate tobacco and nicotine, FDA Commissioner Scott Gottlieb said on a call with reporters.\nThe comment period will be open through mid-June, said Mitch Zeller, director of FDA\u2019s Center for Tobacco Products.\nThe FDA is seeking additional research and data for public review, Gottlieb said, as it tries to develop a nicotine product standard.\nThe FDA will seek public input and scientific research on the role that flavors such as menthol play in tobacco addiction, and for the regulation of premium cigars, Gottlieb said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not appear to rely solely on a news release.", "answer": 1}, {"article": "ASDs mainly affect a person\u2019s social interaction and communication, with symptoms that can include speech disturbances, repetitive and/or compulsive behaviour, hyperactivity, anxiety, and difficulty adapting to new environments.\nScientists said their research found a link between ASD and damage to proteins in blood plasma.\nHowever, researchers believe their new tests could reveal yet-to-be-identified causes of ASD.\nWe hope the tests will also reveal new causative factors.\nThe outcome was a diagnostic test better than any existing method.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story lifts quotes and almost entire sentences from a news release with no apparent original reporting.", "answer": 0}, {"article": "It\u2019s common for people who suffer from irritable bowel syndrome (IBS) to also struggle with depression.\nThose changes in brain activity \u201csupport the notion that this probiotic has anti-depressive properties,\u201d the authors wrote in their paper.\nFor the new research, scientists from McMaster University in Canada recruited 44 adults with IBS as well as mild to moderate anxiety or depression.\n\u201cWe know that one part of the brain, the amygdala, tends to be red hot in people with depression, and it seemed to cool down with this intervention,\u201d says McIntyre, who was not involved in the new research.\nMost previous research on this topic has been on healthy people without mood disorders.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "By incorporating perspectives from\u00a0an independent expert, the story does a good job of not relying solely on a\u00a0news release.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Middle-aged women may find some relief from hot flashes and other menopause problems with soy supplements, according to Chinese researchers.\nBut a U.S. expert wasn\u2019t convinced by the results, which run counter to other published studies.\n\u201cThe majority of them are showing no benefit,\u201d said William W. Wong, a nutrition researcher at Baylor College of Medicine in Houston who wasn\u2019t involved in the new work.\nHe said it was \u201chard to believe\u201d that soy would have an effect on these women.\nThe new study, published in the journal Menopause, is based on 90 Chinese women.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The journalist sought out another expert in the field who had conducted similar studies in the U.S. without the same findings.", "answer": 1}, {"article": "Another person said of their pet birds: \"If I didn't have my pets I think I would be on my own.\nThe pets provided more than just emotional support and companionship, participants said.\nBrooks says, \"Many felt deep emotional connections with their pet that weren't available from friends and family.\"\nSixty percent of the people who considered pets to be a part of their social networks placed them in the central, most important circle \u2014 the same place many people put close family and social workers.\nOne study participant placed birds in his closest social circle.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to be drawn primarily from a news release.", "answer": 1}, {"article": "The brain\u2019s synapses control how much of these chemicals are released, and drugs like Zoloft effectively prevent the little serotonin being produced from reabsorbing back into the nerve cells from which they were released, resulting in a higher concentration of serotonin.\nMore studies will be needed to determine whether this method can be used as a widespread treatment for other brain-related disorders, but if today\u2019s research is any indication, TMS could be a key to improving the lives of Americans suffering from a multitude of disorders.\nThe biggest drawback to TMS, according to advocates, is the limitations on just who can undergo the treatment.\nEven those who are approved to undergo the treatment face another barrier as TMS is not widely covered by health insurance.\nAt this point, specific symptoms can be targeted depending on the patient\u2019s needs.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "While a news release does not seem to be at the base of this story, the text seems to have stemmed in part from another journalistic effort: an NPR story in 2016.\u00a0 That suggests only modest enterprise work here.", "answer": 1}, {"article": "Feb. 1, 2010 -- Twelve weeks of fish oil pills made teens at high risk of psychosis much less likely to become psychotic for at least one year.\nIt's also not clear how fish oil might prevent psychiatric disorders.\nIt's not clear whether the fish oil pills help people with established psychosis.\nAmminger and colleagues warn against over-interpretation of their findings.\nThat's the same level of efficacy seen with antipsychotic medications, note study researcher G. Paul Amminger, MD, of the University of Vienna, Austria, and colleagues.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There does not appear to be a news release associated with this story.\u00a0\u00a0", "answer": 2}, {"article": "In the study, men taking an angiotensin receptor blocker had a 24 percent lower incidence of dementia than those taking other cardiovascular drugs.\nThe risk was nearly halved for those taking both angiotensin-targeting drugs.\nWolozin said that it's not clear why the drugs would have a beneficial effect on the brain, but improved blood flow probably plays a role.\nCaution was urged by Dr. Richard B. Lipton, vice chairman of neurology at Albert Einstein College of Medicine in New York City, who has done work on the genetics of Alzheimer's disease.\nBut there have been a number of observational studies implicating various molecules, including estrogens, in dementia, he said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There\u2019s no evidence that the story relied on a news release.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/12/national/a180226S32.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not appear to have relied on a press release. ", "answer": 1}, {"article": "This condition occurs when the cushions, or discs, that serve as shock absorbers for the spine become inflamed and bulge or break open.\nNone of the people in this study had been helped by other nonsurgical therapies, and supporters say the new therapy could become a standard treatment for such patients.\nStill, ozone therapy could even help many patients with unrelenting back pain to avoid surgery, Lehnert tells WebMD.\nLehnert presented the findings here at the annual meeting of the Radiological Society of North America.\nBut a back pain specialist who spoke to WebMD says that further research is needed.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story used several sources and did not appear to rely upon a press release.", "answer": 1}, {"article": "When planning a day at the beach, should you add Polypodium leucotomos to your picnic basket? The company that sells the natural fern extract says a daily dose can help protect against sunburn, sun-related aging and even genetic mutations that cause skin cancer. Dermatologists say preliminary evidence suggests the extract does protect against the sun -- but don't throw away your sunscreen yet.\n\nEvery year, 36% of U.S. adults get at least one sunburn, according to the federal Centers for Disease Control and Prevention....", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no way to know if the story relied on a press release as the sole or main source of information.", "answer": 2}, {"article": "But for relapsed ovarian cancer, surgery is usually not an option.\nDoctors are convinced that if the initial diagnosis can be made early, which is very difficult, the cancer can be treated by surgery.\nThe finding is another in a series suggesting that early detection of cancer might not always lead to better outcomes for patients.\nBut she stopped short of saying it should be eliminated, saying that in any event, patients would not accept that.\nMoreover, the extra chemotherapy seemed to worsen the quality of life.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story quotes multiple experts, the reader can assume that the story did not rely on a press release as the sole source of information.", "answer": 1}, {"article": "Packaged in powder form and mixed with liquid, alginate expands in the stomach to form a thick gel, mimicking the effect of a large meal.\nAccording to the researchers, the higher sodium content of the alginate drink \u2014 a little over one gram per dose, or about half a teaspoon of salt \u2014 could have offset any potential blood-pressure reducing effect of the supplement.\nBut that was only the case among people who stuck with the diet study over a few months.\nNeither the researchers nor the participants knew who was receiving the seaweed supplement.\nFor Mette Kristensen, one of the study\u2019s authors, the message seems clear: \u201cIf you actually comply with the treatment, you do have the improvement in weight loss.\u201d\n\nHowever, effects on blood pressure were less promising.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear the story didn\u2019t rely solely on a news release.", "answer": 1}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nThese findings indicate that the test can reliably predict the absence of intracranial lesions and that health care professionals can incorporate this tool into the standard of care for patients to rule out the need for a CT scan in at least one-third of patients who are suspected of having mTBI.\nThe Brain Trauma Indicator was reviewed under the FDA\u2019s De Novo premarket review pathway, a regulatory pathway for some low- to moderate-risk devices that are novel and for which there is no prior legally marketed device.\nThe FDA reviewed and authorized for marketing the Banyan Brain Trauma Indicator in fewer than 6 months as part of its Breakthrough Devices Program.\nThe FDA evaluated data from a multi-center, prospective clinical study of 1,947 individual blood samples from adults with suspected mTBI/concussion and reviewed the product\u2019s performance by comparing mTBI/concussion blood tests results with CT scan results.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We did not identify any unjustifiable language. The purpose of the test is somewhat mis-characterized, though, as a test for evaluating mild TBI, when in reality it is designed to diagnose intracranial lesions or structural brain damage.", "answer": 1}, {"article": "Autism is characterized by difficulties in social interaction, communication, and understanding other people\u2019s emotions and behavior.\nHe said the findings, published in the journal Autism Research, were very preliminary, but if confirmed in several more and larger studies, they might replace current subjective tests now used to diagnose the disorder.\n\u201cHowever, it has been shown that in the early stages of development, individuals have been aided by intense one-on-one caring to help them with language, social function with their peers and also with emotional problems,\u201d he said.\nBy measuring six aspects of the brain\u2019s circuitry, the test was able to correctly pick out people who had been diagnosed with autism with 94 percent accuracy.\nLange said the findings should help make the process of diagnosing autism more scientific because it would rely on a test rather than a subjective assessment.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a news release.\u00a0The story provides quotes from the investigators that do not appear in the institutional press release. Having said that the press release provides a far more balanced story that this one does.", "answer": 1}, {"article": "Kids with August birthdays are more likely to get an ADHD diagnosis.\nThe results for both techniques were very positive.\nThe participants in the small study ranged in age from 20 to 70 and had suffered from back pain for an average of 7.3 years.\nThe second group participated in cognitive behavior therapy (CBT) to change pain-related thoughts and behaviors during eight weekly two-hour group sessions.\nThe results of one of those studies are out Tuesday in JAMA.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is little in the story that is not found in the two news releases issued on this study. (Those releases can be found here and here.)", "answer": 0}, {"article": "Discarding an unused embryo, which has the potential to develop into a baby, has weightier implications for many than discarding unused eggs.\nFreezing eggs now is no guarantee of a baby later.\nCheck out more than one clinic and make sure you know what it defines as a \u201csuccess\u2019\u2019 \u2014 a viable transferring of an egg leading to a baby, or just a safely thawed egg.\nThings to consider before freezing your eggs\n\n\u25a0 Beware of a false sense of security.\nShe owns her eggs, no question.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story did not rely on a news release. ", "answer": 1}, {"article": "Bleier said the device, which consists of a lead wire and a neurostimulator the size of a stopwatch, is implanted on top of a buttock muscle. Patients don't feel it when they sit down and you can't see its imprint under a tight pair of pants. Patients can try the stimulation for two weeks with the pacemaker outside the body before deciding whether to have it implanted, an outpatient procedure. Medicare pays about $21,500 for the device and treatment.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely solely or largely on a news release.", "answer": 1}, {"article": "Troponin I is a protein that is released into the bloodstream when the heart muscle has been damaged such as during a heart attack.\nA more sensitive test could save a lot of money, she noted.\nThe new test yields sensitive results in three hours.\nNot all EKG readings are abnormal during a heart attack, Chaparro explained.\n\"If the patient presents to an emergency room less than three hours after chest pain, we can make a diagnosis of a heart attack.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There\u2019s no evidence that the story relied solely or largely on a news release.", "answer": 1}, {"article": "Inside the brightly lit storefront in Brooklyn, N.Y., business was brisk as employees combed, washed and blow-dried little heads.\n\n\u201cDo I have a lot of lice?\u201d a boy asks the woman combing his hair slathered in Pantene conditioner.\n\nIt\u2019s the busiest time of the year for companies like Lice Busters, a family-run business Dalya Harel started in...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story doesn\u2019t appear to rely on a news release.", "answer": 1}, {"article": "\u2022 None 6 things you can do right now to help prevent the flu \n\n\n\nThe drug uses a different approach to fight the flu than other medications.\nThe experimental drug worked three times faster than another antiviral drug, Tamiflu, the company told the Journal.\nIn a clinical trial, a single dose of the drug made by the pharmaceutical company eliminated the virus from people's bodies in a median time of 24 hours, The Wall Street Journal reported.\nThe experimental drug, however, kicks into action earlier, working to block the virus from hijacking cells in the first place, the Journal said.\nJapanese drug regulators could approve the drug for use in Japan by early March, the Journal reported.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s hard to categorize just what this story relied on for sources. The company\u2019s website did not show a news release. The article itself is an example of what some would call \u201cshovelware\u201d or a \u201ccut and paste\u201d form of publishing that scoops up data from previously published news articles and plops them into a news feed or web site. Readers are better served by offering them a link to the original news source, which this article does. But they were ill-served by the skimpy and misleading article that preceded the link.", "answer": 2}, {"article": "Dr Iain Foulkes, Cancer Research UK's executive director of research and innovation, said: \"It's exciting to see how Cancer Research UK's partnerships with both academia and industry are bringing urgently needed new tests and treatments to patients.\nUltimately, a candidate molecule called ICEC0942 suppressed tumour growth in a wide range of cancer types in lab tests.\nThe drug may not become available to patients for a number of years yet, but researchers believe that if clinical trials are successful, it could be used to tackle a variety of treatment-resistant cancers.\nThe trial is still ongoing, so results are not available yet.\nIn a bid to come up with new forms of treatment that work in a distinct way from established ones, chemists, biologists and clinicians at Imperial College London collaborated on creating a new drug, the properties of which are reported in the journal Molecular Cancer Therapeutics.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Overall, the language is restrained, although one quote applauds researchers for bringing \u201ca new treatment from discovery to clinical testing in record time.\u201d It remains to be seen whether this is an effective treatment.", "answer": 1}, {"article": "Studies conducted by the CDC through its Adult and Youth National Tobacco Surveys found increased experimentation by youth trying out e-cigarettes but not conventional cigarettes.\nThat's backed up by Etter's research as well as a recent study by researchers at Penn State College of Medicine, in which e-cigarettes were found to be less addictive than tobacco cigarettes.\nBut as it seems e-cigarettes are here to stay, most calls are for informed regulation rather than prohibition.\nThe growing fear is the increasing domination of big tobacco in the e-cigarette market, which was once seen as a competitor.\nBut some critics argue these electronic nicotine delivery systems (ENDS) are fueling a new addiction to nicotine -- particularly among young people experimenting with them.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is enough original reporting here that we can be sure the story does not rely on a press release.\n\u00a0", "answer": 1}, {"article": "When researchers compared patients who had gastric bypass surgery to those who lost the same amount of weight by dieting, they found that the surgery patients had lower levels of amino acids that have been linked to insulin resistance.\nBut researchers say the preliminary findings could one day lead to diabetes treatments.\nThe study was small, including just 10 patients who had the surgery and 11 patients who followed severely calorie-restricted diets.\nAnd the patients in both groups had lost just a fraction of the weight they needed to lose at the time of the analysis.\nNow a new study from Duke University Medical Center and Columbia University may help explain why.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story indicated that it drew some of its information from a news release. But it also included interviews with one of the researchers and with an American Diabetes Association official.\u00a0 So it did not appear to rely solely on a news release.", "answer": 1}, {"article": "Two new just-released studies offer fresh insights into the best way to lose weight and keep it off. Jennifer Corbett Dooren has details on The News Hub. Photo: Bloomberg\n\nA diet based on healthy carbohydrates\u2014rather than a low-fat or low-carbohydrate diet\u2014offers the best chance of keeping weight off without bringing unwanted side effects, a study published Tuesday in the Journal of the American Medical Association suggests.\n\nStudy participants following a low-glycemic-index diet, which is similar to a Mediterranean diet and focuses on fish, fruit, vegetables, nuts and whole grains, also saw improved cholesterol levels and other important markers that lower the risks of developing heart disease...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story quotes one of the researchers, and we couldn\u2019t find any evidence that it relied too much on this press release.", "answer": 1}, {"article": "In a study published in the Jan. 19 issue of Neurology, Carlesimo and colleagues found that DTI scanning predicted declines in memory performance with more accuracy than traditional MRI.\n\"This type of brain scan appears to be a better way to measure how healthy the brain is in people who are experiencing memory loss,\" Carlesimo says in a news release.\nBut it is increasingly clear that DTI can also be used to identify very small structural changes in the gray matter of the brain, which is critical for learning and memory, researcher Giovanni A. Carlesimo, MD, PhD, of Italy's Tor Vergata University tells WebMD.\nThe technique, known as diffusion tensor imaging (DTI) or diffusion MRI, is used to assess changes in the white matter regions of the brain.\nJan. 6, 2010 -- A new imaging technique that measures the random motion of water within the brain may prove useful for detecting early signs of Alzheimer's disease.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure of the extent to which the story was primarily driven by a news release.\u00a0 The story acknowledges that the quote from the lead author of the research came from a news release. ", "answer": 2}, {"article": "Not so long ago, in 2000, the American Academy of Pediatrics recommended that allergenic foods be kept away from infants until they were at least a year old, and often older.\nThat warning was especially strong for those with a family history of allergies.\nEarly introduction didn\u2019t seem to make a difference for autoimmune diseases, at least according to the available evidence; eating gluten young wasn\u2019t associated with the risk of developing celiac disease.\nThe authors of the just-published study reviewed all of the available evidence on the topic and included 146 studies in their final analysis.\nThis is relatively new thinking.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story doesn\u2019t offer much beyond the\u00a0news release, but it doesn\u2019t appear to use verbatim phrases or quotes.", "answer": 0}, {"article": "SAN FRANCISCO \u2014 Tech company developer conferences always feature a wacky demo or three.\nThe goal of further research is to determine whether Emma Watch could help other people with similar Parkinson\u2019s symptoms.\"\nBut at Build 2017 in Seattle Wednesday, Microsoft went for the waterworks at the conclusion of CEO Satya Nadella's keynote address: it showcased a prototype watch that temporarily eliminated the arm shaking that often plagues those suffering from the neurological disease Parkinson's.\nWorking with graphic designer and Parkinson's sufferer Emma Lawton, 32, the researchers developed a watch \u2014 which they named Emma \u2014 that, according to Microsoft, \"vibrates in a distinctive pattern to disrupt the feedback loop between brain and hand.\"\nAfter a speech that both heralded and warned about coming leaps in technological power, Nadella screened a video that told the story of two British Microsoft Research employees, Haiyan Zhang and Nicolas Villa, who developed the tremor-interrupting device for a BBC documentary, The Big Life Fix.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story makes clear that its genesis came from a video and talk at the \u201cBuild 2017\u201d conference in Seattle.", "answer": 1}, {"article": "Grocers shelves add new coconut-water products regularly.\nEven so, Little, a coconut enthusiast, doesn\u2019t recommend loading up on coconut fats.\nIt\u2019s the whole coconut that needs to be talked about.\u201d\n\nEntrepreneurs are talking about the whole coconut these days.\n\u201cIt\u2019s trickling down to the mass market.\u201d\n\nThe company is growing so quickly, he said, it had to hunt for coconuts from outside of Brazil, where it previously harvested most of its fruit.\nIn the past couple of years a couple of brands have figured out the right angle \u2014 electrolytes and hydration.\u201d\n\nCraven estimated the coconut-water market at about $100 million annually right now, but companies are doubling their sales year after year.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a news release. But we wouldn\u2019t be surprised if future news releases and other marketing efforts won\u2019t be spawned by such coverage.", "answer": 1}, {"article": "Spinal fluid can also reveal the disease but that can be a difficult and painful test.\nToday only an autopsy can establish for sure that a patient had Alzheimer's.\nThere is still plenty of lab work to be done, more rigorous research before it's proven a simple blood test can diagnose Alzheimer's, but those working on the test are hopeful it can be approved for use by 2009, adds Blackstone.\nAccording to a paper published in the online edition of the British journal Nature Medicine, preliminary studies by a team of scientists led by a Stanford neurology professor show the test is yielding promising results in predicting which patients with mild memory loss are at high risk of developing Alzheimer's disease.\nIn a study of 259 blood samples, the test identified early markers for Alzheimer's with 90 percent accuracy, reports CBS News correspondent John Blackstone.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if the story relied solely or largely on a news release.\u00a0 ", "answer": 2}, {"article": "Also low are haddock, pollock, flounder and sole, Atlantic croaker, crawfish, catfish, trout, Atlantic mackerel, crab and mullet.\nCurrently fewer than one in five Americans eats the recommended two servings a week of fish.\nIn addition to the usual warnings about high mercury fish, Consumer Reports added marlin and orange roughy to the list.\nBut a federal panel has reignited the debate about the benefits and risks of eating tuna and other seafood during pregnancy.\nThe advisory committee has recommended that these agencies \u201cre-evaluate\u201d their stance on tuna for pregnant women.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to draw on a news release at all.", "answer": 1}, {"article": "Moffitt is the No.\nThe study was supported by funds received from the American Cancer Society and the DeBartolo Family Personalized Medicine Institute Pilot Research Awards in Personalized Medicine.\nThe researchers found that delaying surgery due to neoadjuvant radiation therapy was not a detriment to survival.\nThese data are promising, but randomized clinical trials are needed to confirm the benefit of neoadjuvant radiation therapy.\nThey included female patients in the analysis who were diagnosed between 1973 and 2011 with early-stage breast cancer.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t engage in sensational language.", "answer": 1}, {"article": "The second study, published in 2013, had a similar set up \u2014 37 people complaining of gastrointestinal problems, randomized into high-gluten, low-gluten and no-gluten groups.\nIt\u2019s hard to test for gluten sensitivities.\nIf you think avoiding gluten will make you feel better, there is a reasonable chance that it will \u2014 even if gluten is irrelevant.\nFor those of you keeping track at home, that means that while 30 percent of Americans are trying to cut gluten from their diet, probably at most only 1 percent of Americans may have NCGS.\nSomewhere in that gap, a diet fad is thriving.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story clearly goes beyond any news release.", "answer": 1}, {"article": "The quality of what you get can differ from one practitioner to another,\" said Manber.\nA response rate was defined as a 50 percent reduction in depression symptoms, Manber said.\nAnd, she cautioned, suicidal thoughts are never normal and are a sign that you should seek help.\nMONDAY, Feb. 22, 2010 (HealthDay News) -- Women who experience depression during pregnancy may have another treatment option, new research suggests.\nSymptoms include sad, hopeless feelings that persist, generally for more than two weeks, Lusskin said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does not appear that the story relied on a new release. ", "answer": 1}, {"article": "A female testosterone patch showed promise at boosting older women's enjoyment of sex, but concerns about the cancer risk of hormone therapies mean U.S. women won't be getting an equivalent of Viagra anytime soon.\n\nProcter & Gamble Co., the Cincinnati consumer-products giant, has worked since 1999 to secure U.S. approval for its Intrinsa patch, intended to increase sex drive and satisfaction in women after menopause.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if the story relied largely on a news release.\u00a0 We do know that the only sources quoted are drug company representatives. ", "answer": 2}, {"article": "Oxytocin is produced naturally in the bodies of humans and animals.\nResearchers who were not involved in the study praised the work, saying the findings were promising and could lead to the first effective treatment for the central problems affecting people with autism.\nAlthough more research is needed to confirm and explore the findings, the results are the latest in a growing body of evidence indicating that the hormone could lead to ways to help people with the often devastating brain disorder function better.\nWhile cautioning that more research is needed on children and additional patients to make sure oxytocin is safe and effective, advocates for families with children with autism welcomed the findings.\nBut Sirigu was among those who said the finding should encourage more research on the potential benefits of oxytocin itself, especially for children.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\u00a0The story does not appear to rely on a news release.", "answer": 1}, {"article": "For more about multiple sclerosis, visit the National Multiple Sclerosis Society.\nStill, one MS specialist who reviewed the new study said patients need to be cautious about taking the drug.\nThe decision to start Lemtrada should be made in the context of the risks, including infusion-associated reactions, infections, and autoimmune adverse events, she said.\nBecause of the potential for side effects, people who received this treatment have to undergo monthly blood and urine tests for four years after the last dose, Giovannoni said.\n\"Although alemtuzumab [Lemtrada] treatment is associated with safety risks, those risks are manageable in most patients,\" Miskin said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "Immunotherapy usually starts with clinicians harvesting immune system cells called T cells that have attached themselves to a tumor in an effort to attack.\nThe last step was to infuse the resulting army of cancer-fighting clones back into the patient.\nSeveral independent researchers said the study results were promising.\nThe immunotherapy allowed him to return to work three weeks after treatments began.\nBut Yee bet that the extra effort would pay off with better results and fewer side effects.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely solely on a news release.", "answer": 1}, {"article": "Women between 40 and 49 were screened every two years, and women 50 to 74 were screened roughly every three years.\nHe said the new findings do not speak to the frequency of screening issue, but they do make clear that screening works.\n\u201cI think for anybody who was beginning to have their faith shaken in the value of mammography, these data show mammography is quite valuable as a public health approach to reducing deaths from breast cancer,\u201d Smith said.\n\u201cOur results indicate that in 1,000 women screened for 10 years, three breast cancer deaths would be prevented,\u201d Duffy said, adding that most of the deaths prevented would have occurred more than a decade after the screening had started.\n\u201cEveryone must make up their own mind, but certainly from combined results from all the screening trials, mammography in women aged 40-49 does reduce deaths from breast cancer,\u201d he said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This piece does not rely on a press release.\n", "answer": 1}, {"article": "Despite a similar number of reported cases of breast cancer among African-American and European-American women, African-Americans experience a more aggressive clinical course and a 40 percent higher death rate than European-Americans among premenopausal and menopausal breast cancer patients.\nThis is the first clinical study to suggest that neoadjuvant chemotherapy (treatment prior to surgery) may improve breast cancer recurrence rates and patterns in African-Americans.\nThe researchers studied rates and patterns of tumor recurrence after hormone, radiation and chemotherapy among African-American and European-American breast cancer patients.\nThe study was funded by the National Cancer Institute of the National Institutes of Health.\nThe patients' self-reported races were primarily African-American and European-American.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There was no sensational or unjustifiable language, though the news release could have done a better job of stressing this was a data analysis conducted via combing through medical records \u2014 and not a clinical trial.", "answer": 1}, {"article": "(Reuters Health) - When a migraine strikes, patients might one day be able to make the experience less painful by using a smartphone-controlled device to deliver mild electric shocks to their arm, a company-funded experiment suggests.\n\u201cAll stimulation treatments given so far have been in the head,\u201d said lead study author Dr. David Yarnitsky, an advisory board member for Theranica, the company developing the device.\nOne shortcoming of the current study is that researchers didn\u2019t examine how long the pain relief lasts beyond two hours, Schoenen said by email.\n\u201cThe percentage of attacks for which TENS is sufficient as sole treatment and allows sustained pain relief remains to be determined,\u201d Schoenen cautioned.\nResearchers asked participants to put the device on their upper arm as soon as possible after the start of a migraine and use it for 20 minutes.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not rely on the\u00a0news release.", "answer": 1}, {"article": "Brain imaging has become a popular subject of research in recent years as the technology to be able to scan, store and analyze the terabytes of information in the pictures has become more affordable.\nNow scientists believe that they have a way to distinguish between those paths, at least in terms of language ability, in the toddler years using brain imaging.\nSuch research has become critically important as the number of children diagnosed with autism has soared in recent decades to 1 in 68.\nFiguring out a child's trajectory once he or she is diagnosed is just as challenging.\nScientists have looked at numerous possible causes, from genetics to environmental exposure, but no definitive answers.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story appears to rely heavily on a news release, since the single quote attributed to the source was lifted word for word from the news release. The article might have been improved by using more data on the study protocol available from the news release, or better yet \u2014 the study and an additional expert or two. However, it\u2019s noted that the article has some useful information that the news release didn\u2019t include, namely, the ages of the test subjects when they were initially tested and when they had their followup MRIs (12-29 months for the initial test and followup at 30 to 48 months).", "answer": 0}, {"article": "Guidelines also suggest that pregnant women not drink more than two cups a day.\nThere\u2019s almost no evidence for that at all.\nI can\u2019t think of any other product that has this much positive epidemiologic evidence going for it.\nBut it\u2019s way past time that we stopped viewing coffee as something we all need to cut back on.\nMost of us aren\u2019t drinking coffee because we think it will protect us, though.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s difficult to envision a news release that could account for this story.", "answer": 1}, {"article": "\"For research, there's a lot of value,\" Knopman says.\nAnd it does leave one wondering if a lot more worry will be generated by the notion of \"preclinical Alzheimer's,\" when science and medicine can't offer anything to ease those fears.\nIt also doesn't change the very limited treatment choices.\nAlzheimer's is just one possible cause.\nThe distinction is nothing to worry about for patients and their families.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\nThis story does not appear to rely on a news release.", "answer": 1}, {"article": "The journal is abstracted and indexed in Biological Abstracts, Current Awareness in Biological Sciences, Chemical Abstracts, Current Contents, Excerpta Medica, Index Medicus, Nutrition Abstracts and Science Citation Index.\nThe metabolic and microbial findings from this study provide a foundation for a larger clinical trial in the pediatric population.\nThis work was supported by grants from the BMO Financial Group Endowed Research Fund in Healthy Living, Alberta Children's Hospital Foundation, Alberta Children's Hospital Research Institute and the Canadian Institutes of Health Research (MOP115076-1).\nBethesda, MD (June 5, 2017) -- There may soon be a new tool in the fight against childhood obesity.\nFollow us on Twitter @AmerGastroAssn, @AGA_Gastro (New!)\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The language is mostly justifiable. A quote from the researcher calling the results \u201cfantastic\u201d is a bit over-the-top.", "answer": 1}, {"article": "Compared to 52 women who only received an American Cancer Society pamphlet on chemotherapy, the 48 women in the texting group reported an overall lower level of distress and a higher quality of life during their therapy.\nOne of the patients texted the program 1,217 times.\nThey also felt they had better communication with their doctors.\nSurprisingly, the older the patient, the greater the likelihood that she would text back, seeking more information.\nThe feasibility study was designed to see if texting could relieve some of the anxiety that comes with the fatigue, hair loss and other body changes that can accompany anticancer drugs.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story didn\u2019t rely on a news release.", "answer": 1}, {"article": "A growing number of doctors who treat the estimated 6.4 million American children diagnosed with A.D.H.D.\nIn an email, Dr. Wilens said he had not received \u201cany personal income\u201d from the pharmaceutical industry since 2009.\nAnd other research has raised new concerns.\nIn arguing for \u201cnormalization,\u201d Dr. Wilens cited a major review in the Journal of Clinical Psychiatry in late 2013, which looked at 29 brain-scan studies.\nexperts challenge this conclusion.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story appears to be based on original reporting and the expertise of the writer.", "answer": 1}, {"article": "Drug recipients could blow out more than 10% more air from their lungs compared with patients who were not taking the drug, and were about half as likely to have a \u201cpulmonary exacerbation\u201d or a worsening of their lung disease that often requires hospitalization.\nThere is no cure for this disease and existing treatments just help alleviate some of the symptoms.\nAbout 1,000 new cases are diagnosed each year, according to the Cystic Fibrosis Foundation, and the average person with the disease dies before age 40.\nIn an editorial accompanying the study, Dr. Pamela Davis, of Case Western University paraphrased Winston Churchill, \u201cThis study is also a great victory in the war against genetic diseases and marks the end of the beginning for the treatment of the cystic fibrosis defect.\u201d\n\nIvacaftor has been submitted to the FDA for approval, and could be available next year, according to Konstan.\n\u201cIt really is a major milestone in the treatment of cystic fibrosis,\u201d he says.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\nThe story does not appear to rely on a news release.", "answer": 1}, {"article": "Older people tend to get less slow-wave sleep and are at greater risk for memory impairment.\nBut first, says Zee, larger and longer studies are needed to confirm the findings and show that there are benefits to long-term use, rather than on just one night.\n\u201cIt\u2019s just noticeable enough that the brain realizes it\u2019s there, but not enough to disturb sleep.\u201d The sounds were timed to match their slow-wave oscillations.\nZee says that the effectiveness of pink noise is all in the timing.\nNorthwestern has a patent pending on the new technology, and one of the study authors has cofounded a company that plans to market it commercially.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article does not seem to rely solely on a news release, but not including independent sources is a shortcoming which is addressed under the Independent Sources & Conflicts of Interest criteria.", "answer": 1}, {"article": "The Kennedy Institute's Professor Kim Midwood said: 'What is particularly exciting is that when we looked at samples taken from people before their arthritis began, we could see these antibodies to cTNC up to 16 years before the disease occurred - on average the antibodies could be found seven years before the disease appeared.\nThis latest research provides the basis of tests that could improve diagnosis and, importantly, detect disease at a very early stage, with the promise even that people at risk of developing rheumatoid arthritis can be followed before the disease begins.\nA team from the Kennedy Institute of Rheumatology at Oxford University found that a blood test that looks for antibodies that recognize the protein tenascin-C could reliably show those who will contract the condition.\nThat might also indicate whether it could be used in tests to indicate the disease.\nFor that reason, tests that spot antibodies to citrullinated proteins are already used to diagnose the disease.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release suggests the test will \u201cimprove diagnosis\u201d and help patients get the right treatment early in order to manage their disease. It\u2019s too early to make such claims about a test still under development. For the reasons cited, this release does an inadequate job in placing this potential test into a larger context.", "answer": 0}, {"article": "People with abdominal obesity are at higher risk of heart disease and early death than people with slimmer waistlines.\nThat intensity was equivalent to brisk walking for the previously sedentary participants, Ross told Shots.\nThey also wore accelerometers to track their physical activity during the rest of the day, to make sure the more intense exercisers weren't compensating with more time on the sofa.\nThat exercise prescription was about the same as in the government guidelines.\nThe rest of us want to know how much we have to exercise to see health benefits.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Direct quotes from both the study author and an exercise expert show original reporting beyond any news release.\n\u00a0", "answer": 1}, {"article": "\"Weight loss was similar but substantial in both groups we studied, but blood pressure improved more in the low-carb dieters,\" said study author Dr. William Yancy Jr., an associate professor of medicine at Duke University Medical Center and a staff physician at the Department of Veterans Affairs Medical Center in Durham, N.C.\n\n\"There are options out there.\nThe more intensive intervention was more successful with 31 percent losing more than 5 percent of their body weight, compared to just 9 percent of the Internet group.\nTheir study, published in the Jan. 25 issue of the Archives of Internal Medicine, found that both diets helped participants lose almost 10 percent of their body weight.\nYancy said the blood pressure and cholesterol drops might have been even more impressive if people had stayed on their medications, but as they lost weight and normalized these readings, the doctors took them off blood-pressure and cholesterol drugs.\nThe group taking orlistat received a 120-milligram dose of the drug three times daily and got less than 30 percent of their calories from fat.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story quotes two sources, including one of the researchers on the study and an independent expert.\u00a0The content of the story does not appear to be\u00a0lifted from\u00a0the press release put out by Duke University about the study.\u00a0", "answer": 1}, {"article": "I think there is a greater capacity to be open-minded and let science dictate our conclusion, not politics,\u201d Grob said.\nIt revives a promising field of study lasting from the 1950s to the early 1970s that suggested some patients experienced powerful and sustained improvement in mood and anxiety from hallucinogens.\nGrob\u2019s study looked to see whether psilocybin could help ease some of the anxiety of dying cancer patients.\nThe treatments were given in random order and neither the doctors nor the patients were told which compound was administered.\nPatients seemed somewhat less anxious, they reported in the Archives of General Psychiatry.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "", "answer": 1}, {"article": "Patients with Type-1 diabetes typically compensate by monitoring their blood sugar levels every few hours and injecting themselves with insulin as many as five times a day.\nBut other doctors said that even if the benefits of the therapy are temporary, the research provides valuable insight into the mechanism behind the disease.\nThe experimental therapy eliminated the need for insulin injections for months or even years in 14 of 15 patients who were recently diagnosed with the disease.\nEven if patients continue to require insulin shots, the treatment should be considered a success if it halts the destruction of beta cells, said Dr. Jay Skyler, with the Diabetes Research Institute at the University of Miami Miller School of Medicine, who wrote an editorial accompanying the study.\nThe treatment had no effect on one patient, whose disease had already progressed too far, doctors decided.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story had input from several sources, including one not involved in the research, it's safe to assume it did not rely solely or largely on a news release. ", "answer": 1}, {"article": "Alzheimer's disease is the most common cause of dementia, and two out of three Alzheimer's cases are women.\nThe study also showed that the postmenopausal removal of ovaries, uterus or both was not significantly linked to the risk of Alzheimer's disease, irrespective of the indication of surgery or hormone therapy use.\nThe newest results were published recently in Neurology and Maturitas and the earlier results in the Journal of Alzheimer's disease.\n\"In the light of these findings, hormonal replacement therapy may have a beneficial effect on cognition if started early, around the time of menopause.\nThe study explored the association between postmenopausal hormone replacement therapy, Alzheimer's disease, dementia and cognition in two nation-wide case-control studies and two longitudinal cohort studies.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t rely on sensational language. With the exception of the headline (\u201cPostmenopausal hormone therapy exceeding ten years may protect from dementia\u201d) and some vague claims, the language in the release is essentially in line with the findings of the studies being discussed. The release does say that the results were weak,\u00a0which is also what the studies said.", "answer": 1}, {"article": "The U.S. Food and Drug Administration said Tuesday it has approved Cotellic, a drug produced by Swiss biotech company Roche, for use in combination with the vemurafenib medication as a treatment for advanced melanoma.\n\nThe drugs are intended to target the illness after it has spread to other parts of the body or can\u2019t be removed by surgery.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story appears to rely exclusively on a news release from the FDA and there are many similarities in the text of the two documents. Unfortunately, the story leaves out much of the quantitative data and other useful details included in the FDA news release.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Considering having a surgeon remove your cancerous prostate using a robot?\nAnd while some studies showed low complication rates, the researchers add, those rates went up when doctors used a standardized approach to reporting complications.\nIn about one in 250 surgeries, the robot failed to work properly.\nIn the current study, Murphy and his team looked at 68 studies of robot-assisted laparoscopic surgery to better understand its downsides.\nAlso, the researchers add, robot-assisted surgery is no easier to perform and has no better outcomes in patients with conditions that can worsen surgical outcomes, such as being obese, having a large prostate, or having had previous surgery in the area.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\u00a0Does not appear to rely exclusively on a press release.", "answer": 1}, {"article": "\u201cI\u2019ve been doing clinical trials for 30 years in C.F.\nStill, the news is expected to be greeted favorably by doctors and patients and by Wall Street.\nThe long time needed to develop a drug for cystic fibrosis is a lesson for those expecting a quick payout from the sequencing of the human genome, which was completed a decade ago.\nBut since there are only about 1,200 Americans who are candidates for the drug, the price is likely to be tens of thousands of dollars a year.\nNow, 22 years later, a drug that tries to compensate for the genetic defect might be nearing the market.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We would normally chastise this type of reporting but think that in this instance it is reasonable. Cystic fibrosis is a terrible disease that has defied attempts at a cure or even a satisfactory treatment. A drug that shows promise, albeit with the information dissemination coming from a press release, is newsworthy.", "answer": 1}, {"article": "The P-Cure team is committed to enabling all oncology centers and hospitals globally to establish cost-effective proton therapy services for the best possible care and cure,\u201d said Dr. Marash.\nIn addition to the clinical benefits of P-Cure\u2019s solution, there are also significant economic advantages to treating patients in a seated position.\nThe P-Cure system is based on a diagnostic-quality computed tomography (CT) enabling treatment planning, positioning and treatment delivery for cancer patients in a seated position.\nThe P-Cure gantry-less system significantly reduces many factors associated with proton therapy including the capital cost of equipment and construction, the size of a single room center or multi-room expandable center and the time from center planning to treatment.\nThe P-Cure Patient-Centric solution is a paradigm shifting change from the current method of treatment with the patient in the horizontal position.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release uses the terms \u201cclinical breakthrough\u201d and \u201cparadigm shifting\u201d\u00a0 to describe the device but without the evidence (as noted above), this falls short. It\u2019s unclear that the benefits will be apparent to the average patient undergoing this form of cancer treatment.\nIt could be that the statement that the device is a \u201cparadigm shifting change from the current method of treatment with the patient in the horizontal position\u201d is justifiable \u2014 if a bit too ebullient \u2014 since the paradigm for proton therapy now has people lying down. If this treatment is successful it will have more people sitting up.\u00a0We would prefer, though, that if a release is going to make as many claims as this one does that it provide some evidence.", "answer": 0}, {"article": "(Reuters) - Medtronic Inc, a manufacturer of pacemakers, heart stents and spine products, has developed a device to tackle another common health problem: erectile dysfunction.\nAfter three months the results were promising, the company said.\nHe also noted that men who take certain drugs for heart disease cannot use the popular pills.\nRogers said it could be several years before Medtronic undertakes a much larger late-stage trial.\n\u201cED is largely a vascular disease and that\u2019s why Medtronic was interested in this,\u201d said Dr. Jason Rogers of UC Davis Medical Center, one of the researchers of the company-sponsored trial.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Not applicable.\u00a0 We can\u2019t be sure of the extent to which the story relied on a news release.\u00a0 We do know that the company-sponsored investigator was the only source quoted.", "answer": 2}, {"article": "CHICAGO\u2014For patients facing a choice between bypass surgery and a popular, less-invasive procedure to treat heart blockages, surgery improves chances of long-term survival, researchers said Tuesday.\n\nIn a study that analyzed data on nearly 190,000 Medicare patients treated between 2003 and 2007, 16.4% of surgery patients had died after four years, compared with 20.8% treated with angioplasty and a stent to prop open diseased vessels.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a press release.", "answer": 1}, {"article": ".\nThis study also confirmed that SecA inhibitors have the potential for being broad-spectrum antimicrobials, can directly block virulence factor production and can null the effect of efflux pumps.\nHe co-led the study with Phang C. Tai, Regents' Professor of Biology at Georgia State, who is an expert on the functions of SecA in bacteria.\nTheir study showed that small molecule analogs that target the functions of SecA, a central part of the general bacterial secretion system required for viability and virulence, have potent antimicrobial activities, reduce the secretion of toxins and can overcome the effect of efflux pumps, which are responsible for multi-drug resistance.\nATLANTA--A novel class of antimicrobials that inhibits the function of a key disease-causing component of bacteria could be effective in fighting methicillin-resistant Staphylococcus aureus (MRSA), one of the major drug-resistant bacterial pathogens, according to researchers at Georgia State University.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We\u2019re rating this Satisfactory for balance and having an objective voice but we think readers would appreciate more explanation of technical terms and concepts.", "answer": 1}, {"article": "The Centers for Disease Control and Prevention estimates there are 300,000 sports concussions among children each year.\nBut for students such as Aldrich, who don't know their baseline, extra caution is the doctor's order.\n\u2026 It's like a sophisticated video game, but the numbers that are generated from the report are critical in helping to better identify the severity and recovery from the injury.\"\nHe wants her to avoid exerting herself, physically and mentally, because a \"bump on the head\" is a lot more dangerous than it sounds.\nTo avoid permanent injury, Aldrich will have to play it safe and wear a helmet on the field from now on.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no obvious use of text from the press release.", "answer": 1}, {"article": "But in this case, if anything, we're taking money out of our own pockets.\"\nThe American Cancer Society, which has led the opposition to the mammography guidelines issued by the U.S. Preventive Services Task Force, was involved in the discussions leading up to the Pap test guidelines and will consider them in reevaluating its own recommendations, an official said.\nThe change comes amid sharp controversy over new recommendations from a federal task force that women wait until age 50 before they begin having routine mammograms and that women age 50 to 74 scale back to getting the exams routinely every two years.\n\"We are persuaded that the guidelines are really consistent with the evidence,\" said Robert Smith, the society's director of cancer screening.\nThe National Cervical Cancer Coalition, a patient advocacy group, endorsed the recommendations.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not draw from any of the press releases associated with the guidelines\u2019 release. ", "answer": 1}, {"article": "; Menno V. Huisman, M.D., Ph.D.; Pieter W. Kamphuisen, M.D., Ph.D.; J\u00f6rg Kreuzer, M.D.\nThe study was funded by Boehringer Ingelheim.\nThe association has strict policies to prevent these relationships from influencing the science content.\nThis reassurance could lead to more strokes prevented by increasing the use of an effective blood thinner.\"\nVideo clips with researchers/authors of the studies will be added to the release link as available.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t over-reach in this regard.", "answer": 1}, {"article": "People who have chronic inflammation because of chronic infection, autoimmune disease or conditions such as obesity have a higher cancer risk because of damage to normal cells.\nThis is a neat solution: blocking the uptake of a nutrient needed by prostate cancer cells with nutrients that are commonly in the human diet.\nPublished online this week in Precision Oncology, the new paper uses a novel analytical approach to screen numerous plant-based chemicals instead of testing a single agent as many studies do, discovering specific combinations that shrink prostate cancer tumors.\nFunders of this research include that National Institutes of Health and the University of Texas System.\n\"These nutrients have potential anti-cancer properties and are readily available,\" says Tiziani.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We rate this as unjustifiable for the over-reaching headline: \u201cStarving prostate cancer with what you eat for dinner.\u201d That\u2019s exacerbated by the lead: \u201cWhen you dine on curry and baked apples, enjoy the fact that you are eating something that could play a role starving \u2014 or even preventing \u2014 cancer.\u201d", "answer": 0}, {"article": "Stroke is the single largest cause of adult disability and the third-largest cause of death in the developed world.\nExperts commenting on the findings said they had \u201cenormous potential to change clinical practice\u201d and raised the question of whether most stroke patients with motor skill problems should be treated with this relatively cheap type of antidepressant.\nRoger Bonomo, director of stroke care at Lenox Hill Hospital in New York, said another way to look at the implications of this trial would be as justification for treatment of post-stroke depression before it progresses.\nCommenting on the study, Robert Robinson and Harold Adams from the University of Iowa in the United States, said it could change the way doctors treat stroke victims in future, but more research is needed to see if the effects continue over time.\n\u201cThe positive effect of the drug on motor function... suggests that the neuronal ... action of SSRIs provides a new pathway that should be explored further,\u201d said Francois Chollet of Toulouse University Hospital, who led this research.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "A modest search didn\u2019t turn up any evidence that this article relied on a news release.", "answer": 1}, {"article": "Clots are often the cause of heart attacks, and health authorities urge people with symptoms to go to the hospital immediately so that doctors can use balloons and stents, or clot-dissolving drugs, to try to prevent heart damage.\nHer report is the latest warning from researchers who suspect that stents are being overused and may even be causing heart attacks and deaths.\nThe ones who might benefit, they say, are a small minority \u2014 perhaps 10 to 15 percent \u2014 who cannot take the class of heart medicines known as beta blockers, which have been proved to increase survival after a heart attack.\nThe median time since the heart attack was eight days.\nThe study showed there was no need for the procedure.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story does not appear to rely exclusively on a press release", "answer": 1}, {"article": "Obese children who cut sugar from their diets saw improvements in markers of heart disease after just nine days, a study in Atherosclerosis found.\nThe only change was their sugar intake: The researchers swapped foods high in added sugars, like pastries and sweetened yogurts, for options like bagels and pizza.\n\u201cWithout changing total carbohydrate, or fat, or protein, we were able to accomplish this enormous improvement in their cardiovascular risk factors,\u201d unrelated to weight loss, he said.\nThough this study is small and short-term, it builds on this group\u2019s previous research implicating added sugars as a contributor to metabolic disorders and heart disease.\n\u201cSugar calories are not like other carbohydrate calories,\u201d said Dr. Robert Lustig, a co-author of the study and professor of pediatrics at Benioff Children\u2019s Hospital at the University of California, San Francisco.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The UCSF news\u00a0release provided a lot of information about this study, but the blog post\u00a0sticks with\u00a0a short summary of the\u00a0findings. The one quote in the story appears to be original, and not taken from the news release.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/02/09/national/a005536S75.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no evidence that this story relied solely or largely on a news release. ", "answer": 1}, {"article": "Age-related macular degeneration (AMD) is a condition that affects older people.\nIt provides an image that has been magnified more than two times, the FDA says in a news release.\nTraining would also be needed to verify that there is sufficient peripheral vision in the untreated eye.\nIt is intended for use in only one eye because the other eye is used for peripheral vision, the FDA says.\nThe device is intended for patients 75 and older with severe to profound vision impairment that has been stable over time due to blind spots from end-stage AMD.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "At least the story acknowledged that much of its information came from news releases, but we don\u2019t understand why it was necessary to rely on news releases.\u00a0 The story was posted a day later than AP\u2019s.\u00a0 Why no independent interviewing? ", "answer": 0}, {"article": "For years, women took estrogen or a combination of estrogen and progestin to help alleviate hot flashes and other symptoms of menopause, and in the belief that the drugs had a host of health benefits, including protecting their hearts.\nIn fact, the women who took the hormone ended up being at somewhat higher risk for fractures.\nBut the Women\u2019s Health Initiative stunned doctors and women when researchers reported that the risks of the hormones outweighed any benefits.\nThere\u2019s some good news and some bad news for women who took estrogen to help them get through menopause until the health risks of taking the hormone were discovered.\nThe women had taken estrogen for about six years.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story does not appear to rely solely on a news release. No one is quoted in the story \u2013 only apparent paraphrasing from the study and editorial. ", "answer": 1}, {"article": "Toenail fungus causes nails to become thick, yellow and brittle in a way that looks pretty ugly and can be painful.\n\u201cI\u2019ve had patients come in who have had laser procedures and not seen long-term success.\u201d\n\nFirestone also says that over-the-counter antifungal nail creams and ointments rarely work because they can\u2019t penetrate the nail root.\nThere\u2019s no one route of infection, but sources include pedicures and locker room showers.\nIn this case, there is a chance.\u201d\n\nEven John Strisower, the founder of PinPointe USA, says patients should expect at least a minimal reinfection within five years after laser treatment.\nPodiatrists have begun using a laser treatment that combats the infection \u2014 or wastes their patients\u2019 money because it doesn\u2019t work, depending on whom you ask.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story is not based on a news release. We are going to give this one the benefit of the doubt but wonder where some of the information about the success rate with the Pinpointe FootLaser comes from. The only source we could locate was the company\u2019s press release noting approval of the device by the FDA.", "answer": 1}, {"article": "\"What we found was a very coherent pattern of less cervical cancer among people who\u2019ve used the IUD based on thousands of women \u2014 and the pattern wasn't subtle at all, it was stunning,\" Dr. Victoria Cortessis, the study's lead author and associate professor of clinical preventive medicine at the Keck School of Medicine at the University of Southern California, told BuzzFeed Health.\n\nIUDs are small, T-shaped devices that are placed in the uterus to prevent sperm from reaching an egg. They are a highly effective form of birth control and they can offer protection against pregnancy for up to three, five, or ten years.\n\nThe study is the first of its kind to combine and analyze data from multiple studies to look at the issue. \"We went through all of the relevant human epidemiological data on this topic and narrowed it down to 16 high-quality observational studies of over 12,000 women from all over the world,\" Cortessis says.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The author appears to have interviewed the lead author of the study in addition to reading the news release. The story also quotes statistics from the World Health Organization.", "answer": 1}, {"article": "\"Many of the lifesaving drugs used in the treatment of heart attack patients work by inhibiting platelets and preventing blood clotting.\nThe serpent-medicine connection isn't new, one cardiologist noted, since venom typically kills by disrupting the blood's clotting mechanisms.\nThe snake's venom contains a protein called trowaglerix, the researchers explained.\nStill, experiments in animals often don't translate to success in humans, so further research is needed.\nIn the new study, a team led by Tur-Fu Huang, a pharmacology researcher at National Taiwan University, focused on the venom of the Tropidolaemuswaglerix snake -- a Southeast Asian species known as Wagler's pit viper or the Temple viper.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The study includes an independent source, and there\u2019s no evidence that it relied excessively on this news release about the study.", "answer": 1}, {"article": "\"We talk with older folks and many say, 'I can't exercise, but maybe I can become more physically active.'\n\"Walking was the cornerstone of the program,\" says Thomas Gill, a professor of geriatrics at the Yale School of Medicine and an author of the study, which appears in Annals of Internal Medicine.\nCardinal says older adults need to realize that exercise can greatly improve their quality of life by maximizing function as long as possible.\n\"Prescribing exercise may be just as important as prescribing medications \u2014 perhaps even more important in some cases,\" the editorial said.\nThe study followed participants for about 2.7 years, and found that the physical activity program cut the amount of time that people spent with a \"major mobility disability\" \u2014 defined as being unable to walk a quarter mile \u2014 by 25 percent compared to the education program.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no evidence that this story relied on\u00a0a news release.", "answer": 1}, {"article": "In the United States, the National Heart, Lung and Blood Institute, a unit of the National Institutes of Health, is supporting efforts by two separate groups, one led by Dr. O. H. Frazier of the Texas Heart Institute in Houston, the other by Dr. Leonard A. R. Golding of the Cleveland Clinic.\nThe device was developed over 15 years by a team that included Alain F. Carpentier, the French surgeon-scientist who, along with Albert Starr, received the 2007 Albert Lasker Award for Clinical Medical Research.\nIts device, powered by a small air compressor that can be carried in a backpack, has been implanted in more than 800 patients as a bridge before transplant.\nAnother device is being developed by scientists at the Helmholtz-Institute for Biomedical Engineering at the University of Aachen in Germany.\nCiting World Health Organization data that shows heart disease is the world\u2019s leading cause of death, Mr. Conviti, the Carmat chief executive, estimated the potential market at \u201ca minimum\u201d of 100,000 patients a year in the United States and Europe.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because of the background given about other devices approved or in development, and because of the quote from one surgeon who uses a competing device, we think it\u2019s unlikely that the story relied soley on a news release. ", "answer": 1}, {"article": "Doctor Challenges Cause Of MS And Treatment\n\nOne day 7 years ago, after a long walk with his dog along the Hudson River in Manhattan, Marc Stecker noticed he was limping.\nStecker says if he had it to do over again, he would have waited for more research.\nAlthough the doctor who treated him in New York found a significant blockage, he was unable to correct it, Stecker says.\nStill, some would say Stecker was lucky.\nRobert Zivadinov of the Buffalo Neuroimaging Analysis Center in New York says that not only is the procedure unsafe and costly to many patients, it is impeding necessary research.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story is clearly not based on a news release.", "answer": 1}, {"article": "Studies with animals have shown memory improvement, but there is debate about the impact of calorie restriction on humans\u2019 cognitive function.\nParticipants were advised by dietitians but monitored their own eating over three months, Dr. Fl\u00f6el said.\nThe other groups showed no significant change.\nThe calorie-restricted group averaged 20 percent improvement in memory performance.\nA third group made no dietary changes.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story turned to several sources and did not appear to rely solely or largely on a news release. ", "answer": 1}, {"article": "\"It didn't stop the drinking,\" says researcher David M. Penetar, PhD, assistant professor of psychology at McLean Hospital and Harvard Medical School.\nHe studied the extract puerarin.\n\"They still drank, but they drank less.\"\nThe study is published in Drug and Alcohol Dependence.\nIt is one of the substances known as isoflavones found in kudzu.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story wasn\u2019t based on a press release.", "answer": 1}, {"article": "\u2022 Gaziano TA, Fonarow GC, et al.\nThey should not do both.\nHCUP facts and figures: statistics on hospital-based care in , 2009. : Agency for Healthcare Research and Quality, 2011.\nYou should not place undue reliance on these statements.\nCirculation.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There was no unjustifiable language.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - A less common form of obesity surgery may spur more weight loss than its far more popular cousin, gastric bypass \u2014 but at the price of greater long-term risks, researchers reported Tuesday.\nIn the U.S., he said, about one in three weight-loss surgery candidates have a BMI of 50 or higher.\nThat, he added, makes the risks of duodenal switch seem even less worthwhile.\nBut those levels were near-normal (in both groups) to begin with, Livingston noted.\nMore extensive monitoring after duodenal switch, Sovik noted, can help detect and manage side effects.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "No, it does not rely on a news release.", "answer": 1}, {"article": "Vertigo -- episodes of dizziness that can last for minutes or days -- may be triggered by a number of health issues, ranging from an inner ear disorder to tumors.\nThirty-five study participants had this form of vertigo.\nPreventative medication was given to 20 of the 35 people with the newly detected type of vertigo.\nFor the study, researchers recruited 338 people who had vertigo with an unknown cause.\nAfterwards, a video recorded the patients' eye movements.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story seems to rely heavily on information from a news release.\u00a0 It lifts a quote directly from an American Academy of Neurology news release\u2013without attribution\u2013and appears to have borrowed several descriptions with only limited rewriting.\nFor example, this quote that appears in the story:\n\u201cThese conditions can be difficult to diagnose and quite debilitating for people, so it\u2019s exciting to be able to discover this new diagnosis of a condition that may respond to treatment,\u201d said Dr. Ji-Soo Kim, a researcher at Seoul National University in South Korea.\nAlso appears in the news release.", "answer": 0}, {"article": "Furthermore, a study from the University of Rochester, published in March in Environmental Health Perspectives, found that men with shorter anogenital spans had lower sperm counts, poorer quality sperm, lower sperm concentrations and lower motility.\nBut one urologist said the the finding is too preliminary to introduce into clinical practice, however.\nOne expert who's done her own research in this area applauded the study.\n\"Together the two studies make a strong case that this simple measure (the anogenital distance) reflects early genital development and predicts semen quality and fertility,\" she said.\nSwan said that she and her colleagues published similar findings last month.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely solely on a news release.", "answer": 1}, {"article": "\u201cShe sent me a picture of Giovanni playing in his front yard,\u201d Kefalis said.\nOne sign: Dr. Biffi is now head of the gene therapy program at Dana-Farber/Boston Children\u2019s Cancer and Blood Disorders Center.\nAnd when Kefalis learned about the Italian trial, and the fact that Amy Price had to keep going back to Milan with Giovanni and Ceci, it was clear she would use the money to help families get to Italy.\nAnd it runs in families.\nBut if you look closely, you\u2019ll see small memorials to one more: Liviana, who died in 2013 at the age of 5\u00bd of a rare, nightmare disease called late infantile metachromatic leukodystrophy.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to be based on any particular publication or event, so the reporting is original and does not rely on a news release.", "answer": 1}, {"article": "\u201cHe said, \u2018I don\u2019t want to spend my time doing this,\u2019 \u201d recalled his son, Dr. Gerald A. Hladik.\nHis father\u2019s eventful medical history included a serious stroke and coronary bypass surgery.\nGerald J. Hladik was 74 when the day long anticipated by his doctors arrived: His kidneys, damaged years earlier by a viral infection, had lost 85 percent of their function.\n\u201cDialysis may have prolonged his life, but I suspect only by a couple of months,\u201d Dr. Hladik said.\nAn IBM retiree, he loved fishing, boating and gardening \u2014 and hated hospitals.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This article does not in any way appear to rely on a news release.", "answer": 1}, {"article": "Ulcerative colitis, which affects about 38,000 people in the United States annually, is a chronic condition causing abdominal pain, intestinal ulcers, bloody diarrhea and weight loss.\nBoth 6 mg/kg and 130 mg doses of the intravenous treatment showed clinical remission in significantly more patients, compared with those on placebo, after eight weeks, the company said.\nThe treatment and the placebo arms reported similar proportion of side effects, with one patient on the 6 mg/kg dose dying following excessive bleeding, J&J said.\n\u201cMore than half of UC patients have not experienced remission with currently available treatment options,\u201d the study\u2019s lead investigator Bruce Sands said.\nThe patient had no prior history of high blood pressure or cirrhosis, the drugmaker said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The release appears to be drawn almost entirely from a news release (including a slightly paraphrased quote from a researcher involved with the study). The only departure from the release that we could find was a reference to other, currently available treatments for UC.", "answer": 0}, {"article": "Dry needling may be a viable treatment alternative to cortisone injection for patients with chronic, intermittent pain and tenderness on the outside of the hip, thus avoiding the potentially harmful effects of steroids\n\nDry needling may be a viable treatment alternative to cortisone injection for patients with chronic, intermittent pain and tenderness on the outside of the hip, thus avoiding the potentially harmful effects of steroids, according to a new study published in the April 2017 issue of the Journal of Orthopaedic & Sports Physical Therapy\u00ae (JOSPT\u00ae).\nCo-authors on the paper are Bryce C. Allen, MD, and Yolanda Munoz Maldonado, PhD, also with Baylor Scott & White Health.\nDr. Brennan cautions that while this study uses a larger sample than most, further studies are warranted.\nThis study is the first to directly compare these two treatments for the syndrome.\n\"Evidence for dry needling of the hip in lieu of steroid injection is in its infancy,\" acknowledges lead author Kindyle L. Brennan, PT, PhD, with Baylor Scott & White Health.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The language is this news release is restrained.", "answer": 1}, {"article": "Age-related macular degeneration, or AMD, is the leading cause of vision loss among seniors, gradually eroding crucial central vision.\nIt turns out that nearly 6 in 10 of the study\u2019s participants carry a gene variation that makes part of the immune system go awry \u2014 a genetic flaw already known to increase the risk of getting macular degeneration in the first place.\nWASHINGTON\u2014An experimental drug is showing promise against an untreatable eye disease that blinds older adults \u2014 and intriguingly, it seems to work in patients who carry a particular gene flaw that fuels the damage to their vision.\nAnd it\u2019s important for patients to know what type they have.\nThe hypothesis: Genentech\u2019s drug, lampalizumab, essentially offers a backup method for tamping down the immune reaction.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "With the two outside experts quoted, the story does not appear to rely on a news release.", "answer": 1}, {"article": "Most American women begin to experience menopause around age 50, with some changes in their menstrual cycles earlier.\nThe sheer number of choices today and the need for a thorough initial health assessment make the decision on hormone therapy highly dependent on close communication between a woman and her doctor, experts say.\n\u201cThis requires a thorough exam and a thorough history, and individualized care, but women need to know: It\u2019s not a death sentence or a dependence.\nWhy wouldn\u2019t you want to learn about it?\u201d\n\nBio-identical hormones, which come from plants, are getting a lot of attention and add to the confusion about the treatment.\nIt\u2019s no longer that you need to stay away from hormone replacement therapy, it\u2019s that you need to use it wisely.\u201d\n\nThat wisdom comes from a careful medical assessment and ongoing surveillance of blood pressure, blood work, breast changes, side effects and effectiveness.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We don\u2019t see any evidence that the story relied solely or largely on a news release.", "answer": 1}, {"article": "''It's been known anecdotally,\" says researcher Mark Ware, MD, assistant professor of anesthesia and family medicine at McGill University in Montreal.\nBut Ware's study is more scientific -- a clinical trial in which his team compared placebo with three different doses of cannabis.\nThe new study ''adds to the trickle of evidence that cannabis may help some of the patients who are struggling [with pain] at present,\" Henry McQuay, DM, an emeritus fellow at Balliol College, Oxford University, England, writes in a commentary accompanying the study.\nThe research is published in CMAJ, the Canadian Medical Association Journal.\n\"About 10% to 15% of patients attending a chronic pain clinic use cannabis as part of their pain [control] strategy,\" he tells WebMD.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story goes beyond the release.", "answer": 1}, {"article": "Prof Johann de Bono, Regius professor of cancer research at the ICR, and consultant medical oncologist at the Royal Marsden NHS foundation trust, said: \u201cOur study identifies, for the first time, genetic changes that allow prostate cancer cells to become resistant to the precision medicine olaparib.\n\u201cFrom these findings, we were able to develop a powerful, three-in-one test that could in future be used to help doctors select treatment, check whether it is working and monitor the cancer in the longer term.\nThe test, developed by researchers at the Institute of Cancer Research (ICR) in London and the Royal Marsden NHS foundation trust, picks out men suitable for treatment with olaparib, part of a revolutionary class of drugs called \u201cPARP-inhibitors\u201d, which stops damaged cells from repairing themselves.\nThe ICR chief executive, Prof Paul Workman, said the test could \u201cusher in a new era of precision medicine for prostate cancer\u201d.\nThe liquid biopsy, less invasive than a tissue biopsy, also detects early signs of resistance to olaparib and monitors the cancer\u2019s evolution over time, according to the paper, published in Cancer Discovery on Monday.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It appears that the story heavily relied on this news release from the\u00a0UK\u2019s Institute of Cancer Research. And without attribution. For example, this quote that appears in the news release appears verbatim in the news story:\n\u00a0\n\u201cOur study identifies, for the first time, genetic changes that allow prostate cancer cells to become resistant to the precision medicine olaparib.\n\u201cFrom these findings, we were able to develop a powerful, three-in-one test that could in future be used to help doctors select treatment, check whether it is working and monitor the cancer in the longer term. We think it could be used to make clinical decisions about whether a PARP inhibitor is working within as little as four to eight weeks of starting therapy.\n\u201cNot only could the test have a major impact on treatment of prostate cancer, but it could also be adapted to open up the possibility of precision medicine to patients with other types of cancer as well.\u201d", "answer": 0}, {"article": "HONG KONG (Reuters) - Boosting the effect of acupuncture needles with small electric currents may be effective in treating depression, a study in Hong Kong has found.\nHalf the patients received electroacupuncture nine times over three weeks, while the other half - the placebo group - only had needles inserted superficially into their heads.\nThey were later assessed by experts for their depression levels and the group that received genuine electroacupuncture was found to be a lot happier.\n\u201cThe drop (in depression scores) among the group receiving active treatment was more significant than the placebo group,\u201d said Roger Ng, another researcher in the group, which published their findings in the journal PLoS (Public Library of Science) ONE.\n\u201cWhen the acupoints are stimulated, some brain centres responsible for producing serotonin are stimulated,\u201d explained Ng, a consultant at the department of psychiatry at the Kowloon Hospital in Hong Kong.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure of the extent to which the story may have relied on a news release.", "answer": 2}, {"article": "\u201cHeating ducts that have mold and spores in them can make respiratory symptoms worse in the winter when hot air is blowing through them.\nThe app also provides Mayo Clinic \u201cmessage cards\u201d that give relevant information and recommendations for ways to keep your indoor environment healthy.\nThe Awair app is free to download, but each device costs $199 dollars.\nEvery room in your house could be susceptive to some form of an air pollutant, but now there is a new device and app that says it can help you breathe easier by tracking air quality.\nThe device collects data such as indoor temperature, humidity, carbon dioxide, fine dust particles and VOCs.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to stem from a specific news release.", "answer": 1}, {"article": "The closed loop insulin delivery system, for example, computes insulin doses and administers them according to glucose levels detected by a sensor.\nSeveral weeks later, the participants came back for another meal and switched overnight regimens.\nHovorka's team is one of several working to produce an effective artificial pancreas, also known as a closed loop system or closed loop delivery.\nWithout replacement insulin, people with type 1 diabetes couldn't survive.\nThe current study included 24 people with type 1 diabetes and challenged an artificial pancreas prototype in two different real-life scenarios.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely solely on a news release, but we do think the story relied too heavily on the study\u2019s abstract. It should have gone deeper into the story to provide readers context.", "answer": 1}, {"article": "Both the American Heart Association and the World Health Organization recommend getting at least 150 minutes of moderate- to high-intensity physical activity a week for cardiovascular and overall health.\nThe study could not prove a cause-and-effect relationship between exercise and the risk of depression, but the authors say it strongly suggests one\u2014especially because they controlled for other potential factors, including age, gender, social support, smoking, drinking and body mass index.\n\u201cThere is good evidence that physical activity can help people recover from depression, though we recommend it be used in addition to the usual treatments we would prescribe for established depression, like medication and counseling,\u201d says Harvey.\n\u201cOur study takes this a bit further and shows that exercise may also have a role in preventing people developing depression in the first place.\u201d\nIt\u2019s also possible, they add, that exercise may trigger changes in self-esteem, the release of mood-boosting endorphins and the production of certain proteins.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on the\u00a0news release as it includes quotes from an email interview with the author. However, it did not provide any information not already found in the news release.", "answer": 1}, {"article": "Others mixed them with applesauce and cinnamon in a blender or chopped them up and added them to meatloaf, hamburger, and spaghetti sauce.\nTheir study is part of a growing body of evidence that men\u2019s dietary and lifestyle choices might affect their fertility.\nThe researcher looked at sperm concentration, vitality, ability to move, shape and size, and chromosome abnormalities, all thought to be related to fertility.\nThe new study, funded in part by the California Walnut Commission, enrolled 117 men aged 21 to 35 who ate a typical Western diet.\nHalf the men were randomly assigned to eat 2.5 ounces of walnuts a day, along with their usual diet.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no evidence that the story was based on a press release.", "answer": 1}, {"article": "Doctors can slow macular degeneration with vitamins, laser surgery, stem cell treatments, and even implantable miniature telescopes.\n\u201cWe want to create a new class of devices with drastically improved capabilities to help people with impaired vision,\u201d Silva said.\n\u201cThis is definitely a game changer,\u201d Dr. Kapil Bharti, an investigator at the National Eye Institute in Bethesda, Maryland who is not involved with the research, says.\nBut Dr. Grazia Pertile, director of ophthalmology at the Sacred Heart Don Calabria in Negrar, Italy and one of the Italian researchers, said in a written statement that her team's device could be \u201ca turning point in the treatment of extremely debilitating retinal diseases.\u201d\n\nShe\u2019s not alone in that assessment.\nRelated: This Revolutionary Gene-Editing Tool Could Change the World\n\nWhen the prosthesis was tested in rats, the animals' pupils constricted in response to exposure to light.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This is a barely passing satisfactory, since this story contains one independent source who wasn\u2019t in either of the two releases used for this story.\nBut, it relies heavily on the news releases regardless. For example, this quote appears both in the UCSD\u00a0news release and the news story (but isn\u2019t attributed to the news release in the story):\n\u201cWe want to create a new class of devices with drastically improved capabilities to help people with impaired vision,\u201d Silva said.", "answer": 1}, {"article": "\u201cPeople who smoke a pack of cigarettes a day are chronically inflaming their lungs,\u201d he says.\nPerhaps more intriguing are additional results that Ridker reported, related to cancer.\nWhen it comes to heart disease, however, it\u2019s clear that inflammation-fighting medications like canakinumb may represent the next generation of treatment.\nBut whether anti-inflammatory agents, like canakinumab, or even over-the-counter drugs like aspirin, should be part of standard cancer treatment isn\u2019t clear yet.\nThe inexpensive CRP test could identify those with higher inflammation, who might be candidates for taking a drug like canakinumab.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on the news release.", "answer": 1}, {"article": "Hot flashes, which mostly affect women transitioning to menopause and already in that phase of life, involve a sudden sensation of heat, sometimes accompanied by sweating or visible reddening of the skin.\nAnd right now, HRT is the only treatment approved by the U.S. Food and Drug Administration for cooling hot flashes.\nAnd for now, he noted, it\u2019s also not clear why antidepressants would have effects on hot flashes.\nThose findings appear in a separate report in the journal Menopause.\nSo far, Freedman noted, the only hot-flash treatment that has consistently worked in studies is hormone replacement therapy (HRT).\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article does not appear to rely solely on a press release.", "answer": 1}, {"article": "But what about Alzheimer\u2019s?\nOne recent analysis of previous studies found that people who took a low dose of aspirin every day for several years reduced their risk of developing Alzheimer\u2019s by 13 percent.\nIt\u2019s believed that aspirin, and possibly other nonsteroidal anti-inflammatory drugs, may reduce or head off that process.\nThe claim that aspirin can prevent the disease stems from the notion that Alzheimer\u2019s is caused by inflammation that disrupts proteins in the brain.\nDoctors have long said that an aspirin a day can help ward off heart attacks.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story appears to have drawn on the results from different research studies and does not appear to rely exclusively on a press release.\n\u00a0", "answer": 1}, {"article": "To learn more about hypertension, visit the U.S. National Library of Medicine.\nThe procedure is safe as well as effective, the study authors said.\nIf it is applicable, it could mean patients need not take blood-pressure drugs, Esler suggested.\n\"High blood pressure is a major contributor to heart attack, stroke, heart failure, and [kidney] failure,\" said Fonarow, who was not involved in the study.\nSingh also noted that although this procedure is used in other countries it is not yet approved in the United States.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did pull a researcher quote from a journal news release, but there\u2019s no evidence that it relied solely or largely on a news release.", "answer": 1}, {"article": "When patients are in an abnormal irregular heart rhythm called atrial fibrillation, blood clots can form in the LAA, which can then circulate out through the bloodstream and cause stroke.\nHowever, longer-term results are needed to be completely certain of the device's value in clinical practice, he said.\nIt has been suggested that as treatment for atrial fibrillation, the Watchman device may be preferable to standard blood thinning medications, such as warfarin, which raise the risk of bleeding.\nThe researchers found that while results from the trials varied, the device did appear to be more cost-effective in the larger, longer-term trial.\n\"Based on that, the study may provide more certainty in terms of cost-effectiveness.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The \u201cmay be\u201d in the title is a big maybe, and given the data (of this study and the individual clinical trials) the results may be presented more optimistically than is warranted by the data.\nBy using the passive voice in the following sentence, the news release misses an opportunity to be clear: \u201cIt has been suggested that as treatment for atrial fibrillation, the Watchman device may be preferable to standard blood thinning medications, such as warfarin, which raise the risk of bleeding.\u201d\nWho has suggested this? The device maker? We are not told.", "answer": 0}, {"article": "\u201cThe baby will grow and the biodegradable material will disappear,\u201d he said.\nHe said bioresorbable materials have great potential for other uses, particularly for stents to repair the pulmonary arteries and aortas of babies.\n\u201cThe trial\u2019s results would be equivalent to an excellent metallic stent - that type of performance,\u201d said Dr. Patrick Serruys, a cardiologist from Erasmus University Hospital in Rotterdam, who led the study.\nThe findings, which follow similarly promising 6-month and 9-month data on the plastic device, were described at the annual scientific sessions of the American College of Cardiology in New Orleans.\nSerruys said current stents are essentially \u201ccages\u201d that hamper the flexibility of arteries and make them more prone to reclogging as they develop scar tissue and plaque builds up.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Not applicable because we can\u2019t be sure of the extent to which the story relied on a news release.\u00a0 We do know that no independent expert was quoted in the story.", "answer": 2}, {"article": "Therefore, despite pancreatic cancer representing less than 3% of all cancer cases, more people currently die from it than breast cancer.\nA new blood test developed by researchers at Lund University in Sweden, Herlev Hospital, Knight Cancer Center and Immunovia AB, can detect pancreatic cancer in the very earliest stages of the disease.\nThis provides information about the development of tumours long before being visible on CT or detected by ctDNA.\nThe study used samples from patients in both Denmark and the US, at different stages of the disease.\nSince the immune system is the first to respond to threats like complex diseases, such as cancer, autoimmune diseases and infections, the microarray was designed to mirror this early response.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The preliminary nature of these findings render the headline phrasing premature and unjustifiable.", "answer": 0}, {"article": "Although TEPI patch remains highly tacky and adheres well to skin, it is not uncomfortable to peel off, unlike many traditional plasters.\nHe said Medherant\u2019s technology would eliminate most side effects created by oral medication.\nWe\u2019re controlling the dosage and we\u2019re keeping it there for a prolonged period of time.\u201d\n\nThe patches could help treat conditions like chronic back pain, neuralgia and arthritis without the need to take potentially damaging doses of the drug orally.\nLee told Reuters that many commercial patches do not contain pain relief agents at all, and merely sooth the body with a warming effect.\nHaddleton says the technology has exciting potential for other medications, such as opioid painkillers.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that some original reporting was done in an interview, so the story does enough to clear our bar. That being said, the end result doesn\u2019t seem to be much different than this December 2015 news release.", "answer": 1}, {"article": "Adults with arm or leg pain caused by a sprain, strain or fracture.\nThe study did not assess longer-term pain reduction.\nWithin two hours, all participants reported essentially identical declines in pain, about four points on the scale.\nData on pain came from the participants' ratings; no information on side effects was collected.\nThe research described in Quick Study comes from credible, peer-reviewed journals.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story included information that was not found in the release.", "answer": 1}, {"article": "Those are also symptoms of a deficiency of B12, a key nutrient needed to make red blood cells and DNA and keep the nervous system working right.\n\nVitamin B12 deficiency is officially considered rare, affecting about 1 in 1,000 Americans, according to a 2005 study. But the incidence...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does not appear that the column relied solely or largely on a news release.", "answer": 1}, {"article": "NEW YORK (Reuters) - The U.S. Food and Drug Administration approved on Tuesday the sale of Amgen Inc\u2019s osteoporosis drug Prolia to help prevent fractures in post-menopausal women just days after the medicine received European approval.\nThe approval comes with a risk evaluation and mitigation strategy (REMS) that includes a medication guide for patients and information for healthcare providers that explains the risks and benefits of the drug, the FDA said.\nAmgen said the drug will be available within the next two weeks and cost $825 per 60 milligram injection based on wholesale acquisition cost.\nAmgen last month applied for U.S. approval to market the drug for reduction of fractures and other skeletal-related problems in patients with advanced cancer.\n\u201cI believe it will have gradual uptake in the commercial setting given that this is a silent disease and existing therapies are pretty good,\u201d Schmidt said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "", "answer": 1}, {"article": "\"We have no right as parents or as physicians or adults to strap them down and chop off a normal part of their body.\nSome think the academy's position is long overdue, and that the group should have gone even further and more forcefully recommended circumcision.\nChapin and other critics argue that the scientific evidence is questionable.\n\"There is clear evidence that supports the health benefits of circumcision,\" said Susan Blank, who led the 14-member task force that formulated the new policy being published in the journal Pediatrics.\nAt that time, the group, which represents about 60,000 pediatricians nationwide, concluded that there was no clear evidence for or against circumcising newborns.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article does not rely solely on a press release and attempted to obtain quotes from individuals not involved in the policy recommendations.", "answer": 1}, {"article": "In the United States, an estimated 42,000 corneal grafts a year are performed using tissue from posthumous donors, but there are sometimes problems with rejection and experts say failure rates are significant.\nThe biosynthetic corneas also became sensitive to touch and the treated eyes began producing normal tears, the researchers said.\nThe scientists, whose work was published Wednesday in the Science Translational Medicine journal, said their findings offered hope for the millions of people who go blind each year because of a worldwide shortage of corneas for donation.\nFagerholm said the patients in this trial had no problems with rejection and did not need long-term immune suppression drugs to help their bodies accept the corneas.\n\u201cThis study ... is the first to show that an artificially fabricated cornea can integrate with the human eye and stimulate regeneration,\u201d said May Griffith of the Ottawa Hospital Research Institute, who led the study.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The first quote appears to come straight out of the press release, with some words cut out. Here\u2019s the quote from the release. \"This study is important because it is the first to show that an artificially fabricated cornea can integrate with the human eye and stimulate regeneration,\" said senior author Dr. May Griffith of the Ottawa Hospital Research Institute, the University of Ottawa and Link\u00f6ping University. \"With further research, this approach could help restore sight to millions of people who are waiting for a donated human cornea for transplantation.\" And here\u2019s the one from the story. \"This study \u2026 is the first to show that an artificially fabricated cornea can integrate with the human eye and stimulate regeneration,\" said May Griffith of the Ottawa Hospital Research Institute, who led the study. There are few facts in the story that are not in the release. So, while we can\u2019t say the story relied solely on a news release, there\u2019s some suspicion that it relied too much on it \u2013 and yet, in the end, felt more enthusiastic than the news release. ", "answer": 0}, {"article": "An experimental spray improved sex for some men who regularly experience premature ejaculation, according to the results of two studies set to be presented Tuesday at a urology conference.\n\nMen who applied the aerosol spray, a mixture of the anesthetics lidocaine and prilocaine, reached orgasm a mean of 3 minutes 18 seconds after beginning sex, compared with about 56 seconds for those who got a placebo spray. The 539 men completing the two studies, who were randomly assigned to the real drug or the fake version, had an average...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Clearly, there is no published study. The company involved in the drug did issue this press release (http://www.renalandurologynews.com/novel-treatment-for-premature-ejaculation-shows-promising-results/article/171435/)There are some differences between the numbers used in the story and the numbers in the press release, but it\u2019s not clear how much of this is because of different caveats. (The number of men who actually completed the study, for example, versus all of those who were involved.) The story goes well beyond the release and was finished before the press conference at the AUA meeting.", "answer": 1}, {"article": "\u201cI would be with Ava during the day, and then when Jay got home, he would stay with Ava, and I would spend time with Audrey,\u201d she said.\nThe doctors assured the family that it was typical leukemia \u2014 and curable.\nNow she was in a much more dangerous category: children whose leukemia no longer responds to chemo.\nThat\u2019s a major achievement in a group whose cancer is emboldened by every treatment failure.\n\u201cWe\u2019re kind of up against the edge.\u201d\n\nFry thinks she might be able to undergo a second round of her latest immunotherapy, as long as her cancer is still producing CD22 proteins.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story definitely involved a great deal of reporting, and does not appear to be based on a news release.", "answer": 1}, {"article": "A viral vector is a virus that has been modified to deliver foreign genetic material into a cell.\nThe boy is currently on chemotherapy, the study authors noted.\nThe National Marrow Donor Program has more on Wiskott-Aldrich syndrome.\nIn fact, the experiment was largely successful, with cells now able to produce WAS protein, resulting in increased platelet counts and improvement of some immune-system cells.\n\"But they're not an easy group of patients to transplant.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story doesn\u2019t appear to be based on a news release.", "answer": 1}, {"article": "Cancer cells are coated by platelets when they enter the bloodstream and are on their way to spreading.\nAn initial review at six years suggested that those taking the combination therapy had a 43 percent reduced risk of dying from prostate cancer, while side effects were not \"major,\" Mason said.\nOf the almost 2,000 patients on anticoagulants in the study, 1,649 were taking aspirin, 428 warfarin, 287 clopidogrel (Plavix), 26 enoxaparin, and 408 a combination of blood thinners.\nOf the blood thinners used in the study, aspirin was the one which seemed to account for most of the benefit, the researchers said\n\nThere has already been some evidence that cancer and the body's coagulation system might be linked in some way.\n\"This benefit was seen whether these patients were treated with surgery or radiotherapy,\" Choe added.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\n \nThe story uses quotes from a news conference, not just what was written in the news release. However, it repeats the inaccurate wording of that news release in saying the study showed aspirin and other anticoagulants may cut the risk of prostate cancer death, when the researchers were careful to note that they only identified an association between anticoagulant use and lower prostate cancer death rates, not whether one caused the other.", "answer": 1}, {"article": "Drs.\nAsher and Burri, along with their co-investigators, now recommend that patients with one to three brain metastases should no longer receive routine whole brain radiation therapy, and should be treated with focused therapy alone to better preserve cognitive function and quality of life.\nHowever, the data from our study shows that clinicians can no longer simply rely on the results of traditional lab tests or scans to assess the value of care; we have to understand the total impact of cancer therapies on our patients.\"\nThis is a very relevant finding, as over 200,000 patients still receive whole brain radiation in the United States each year, and the majority of patients with brain metastases have a limited number (typically three or less) of brain lesions.\nAlong with Dr. Paul Brown at Mayo Clinic, they spearheaded an international, multi-institutional, randomized trial that will ultimately improve the standard of care for patients with a specific type of brain tumor, brain metastases, by reducing the toxicity of their treatment without reducing the effectiveness.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t go overboard with sensational language. But as mentioned above, phrases such as \u201csubstantially less toxic\u201d and \u201cbetter quality of life\u201d without quantification, along with tangential promotion of related research by the institution\u2019s researchers, tilt the release toward marketing.", "answer": 1}, {"article": "By far, the lowest incidence of colorectal cancers was seen in pesco-vegetarians, people who eat fish at least once a month but eschew all other types of meat. Compared to omnivores, pesco-vegetarians were 43% less likely to be diagnosed with these cancers during the course of the study.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does draw from a JAMA news release, but the reporter clearly dug into the paper for additional information. Still, we would prefer if the story had included input from researchers with relevant expertise who were not affiliated with the paper.", "answer": 1}, {"article": "Among them: engaging in regular physical activity, maintaining a healthy weight, and not smoking cigarettes.\nMany other strategies will also reduce the risk of cancer, he says.\nThe benefit, however, may not be as great as believed, says researcher Eric Jacobs, PhD, of the American Cancer Society.\nEven so, he says, \"our results provide additional support for the potential benefit of daily aspirin for [reducing] cancer mortality.\"\nThe new analysis is published in the Journal of the National Cancer Institute.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There\u2019s no evidence this story relied on a news release.", "answer": 1}, {"article": "The average daily dose of insulin dropped almost 39 percent after 12 weeks for the group with some beta cell function and 25 percent in those with no beta cell function, suggesting that the group with no beta cell function now produced insulin.\nThis was an initial clinical trial designed to test for safety.\nBoth experts said the treatment appears safe, with no risk of rejection.\nBoth groups were given stem cell educator therapy.\nResults of the study were published online Jan. 9 in the journal BMC Medicine.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "\"What we wanted to find out was: 'Would cooling the surface of the brain of insomnia patients result in lower metabolism and improved sleep?\nThe cap is not yet available to consumers, although the lead researcher, Dr. Eric Nofzinger, has plans to bring it to market, Buysse said.\nBecause this study was extremely small and presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal and confirmed in larger studies.\nDr. William Kohler, medical director of the Florida Sleep Institute, said the concept was exciting and worth further research in larger studies that include body temperature measurements and brain imaging tests.\nThe cooling cap was, however, associated with an increased amount of slow-wave sleep -- or the deepest, restorative portion of sleep, the researchers reported.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "Sacroiliac joint dysfunction is a common cause of disabling pain in the lower back, buttocks, or groin.\nThe study is the first randomized controlled trial to directly compare the results of surgical and nonsurgical treatment for SIJ dysfunction.\nBased on reduction in pain and absence of complications at 6 months, treatment was rated successful in 81 percent of subjects assigned to the SIJ implant procedure, compared to 26 percent with nonsurgical treatment.\nThe results show \"clinically and statistically important\" improvements in clinical outcomes for patients undergoing the SIJ implant procedure, according to Dr. Cher and colleagues, with \"profound differences\" between the surgical and nonsurgical groups.\nThe minimally invasive SIJ implant approach evaluated in this trial has been cleared by the US Food and Drug Administration.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There were several instances of careless language in the release including the phrases: \u201cclinically and statistically important\u201d improvements in clinical outcomes for patients and \u201cprofound differences\u201d between the surgical and nonsurgical groups. \u201cProfound\u201d is in the category of \u201cbreathtaking\u201d and is inappropriate in a news release.\nIn addition, the claim that the procedure \u201cProduces significant and lasting improvements in pain, disability, and quality of life\u201d is not justified. Even the study authors acknowledged that it is unclear how these improvements will look in the long term.", "answer": 0}, {"article": "Caused by defective genes, cystic fibrosis affects multiple organs.\nAlthough HGH not a cure for the disease, which afflicts 30,000 people in the U.S., the researchers found that it reduced the number of hospitalizations among those who have the disease.\nBut with antibiotics and other medical advances, the median age for people with the disease increased to 37 by 2008.\n\"Hopefully, this is going to encourage cystic fibrosis care providers to use it more frequently in patients at the lower end of weight and of short stature,\" Lapin said of the findings.\nHuman growth hormone is a promising tool in treating cystic fibrosis, a new University of Connecticut study suggests.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "", "answer": 1}, {"article": "FRANKFURT (Reuters) - Merck KGaA said that its immunotherapy Bavencio, jointly developed with Pfizer, delayed the progression of kidney cancer when used in combination with Pfizer\u2019s Inlyta drug in a late-stage study.\n\nThe drug combination led to longer progression-free survival in patients with advanced renal cell carcinoma (RCC) when compared with a control group on older Pfizer drug Sutent, the German drugmaker said in a statement on Tuesday.\n\nThe trial will continue to show whether Bavencio plus Inlyta also prolongs patients\u2019 lives.\n\nWhile the company said the benefit was statistically significant, they did not specify the duration of progression-free survival. A detailed analysis would be submitted for presentation at a medical congress, it added.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story appears to be drawn entirely from a news release issued by Merck KGaA, the company that makes Bavencio. Of course, it could also have stemmed from a news release issued by Pfizer, the company that makes Inlyta. Given that the story attributes the information solely to Merck makes its release the likely source.\nUltimately, it makes little difference: No reporting appears to have gone into the story.", "answer": 0}, {"article": "In general, the risk of developing colorectal cancer varies with age, race, ethnicity and lifestyle.\nDr. Friis emphasized that people should not start taking aspirin or NSAIDs on the basis of the new findings.\n\u201cLow dose aspirin, already taken regularly by millions, reduces the risk of colorectal cancer,\u201d he told Reuters Health by email.\nNonaspirin NSAIDs were also protective against colorectal cancer with consistent long-term use, \u201cand there was some indication that even non-continuous use of these agents may be (marginally) effective for the prevention of colorectal cancer,\u201d Dr. Friis said.\nOn the other hand, merely having taken aspirin did not alter the colorectal cancer risk, they reported in Annals of Internal Medicine.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The fact that the story includes comments made directly to Reuters Health shows that it does not\u00a0rely on a news release.\n\u00a0", "answer": 1}, {"article": "The National Institutes of Health, as well as the Michael J.\nIn a proof-of-concept study, published in the journal Neurobiology of Disease, the drug nortriptyline, which has been used to treat depression and nerve pain, stopped the growth of abnormal proteins that can build up in the brain and lead to the development of the disease.\nCollier is already looking for funding for the next phase of his research and hopes to lead a human clinical trial using the drug in the future.\n\"What we've essentially shown is that an already FDA-approved drug that's been studied over 50 years and is relatively well tolerated could be a much simpler approach to treating the disease itself, not just the symptoms,\" Collier said.\nCollier and collaborator Katrina Paumier, an assistant professor of molecular medicine, began looking at previous patient data to see if individuals who were on antidepressants experienced any delay in their need to go on a standard Parkinson's therapy called levodopa.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The headline and lead sentence suggest there is \u201cproof\u201d that nortriptyline slows progression of Parkinson\u2019s in people. Here\u2019s the first sentence:\n\u201cMichigan State University scientists now have early proof that an antidepressant drug that\u2019s been around for more than 50 years could slow the progression of Parkinson\u2019s.\u201d\nThe most we can say is based on this study is that researchers established an association between nortriptyline and Parkinson\u2019s progression, and that the drug seems to affect proteins related to the disease in mice.\nThat\u2019s not proof \u2014 early or late \u2014 that the drug could slow Parkinson\u2019s in people, and the statement is unjustified.", "answer": 0}, {"article": "In coherent breathing, the goal is to breathe at a rate of five breaths per minute, which generally translates into inhaling and exhaling to the count of six.\nThe subjects\u2019 saliva was tested at various intervals during the exercise.\nThe research was presented in May at the International Congress on Integrative Medicine and Health in Las Vegas.\nThe findings were published in the journal BMC Complementary and Alternative Medicine in August.\nWhile the study was small and lacked a control group, Dr. Streeter and her colleagues are planning a randomized controlled trial to further test the intervention.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "Professor Francesca Cordeiro at UCL Institute of Ophthalmology, who led the research, said: \"Detecting glaucoma early is vital as symptoms are not always obvious.\nFurther studies will now be carried out to into DARC and how it can be used not only to diagnose and treat glaucoma patients but also for other neurodegenerative conditions.\nIn clinical trials, the pioneering diagnostic -- developed by researchers at University College London (UCL) and the Western Eye Hospital -- allowed doctors to see individual nerve cell death in the back of the eye.\nA SIMPLE eye test could help solve the biggest global cause of irreversible blindness, glaucoma.\nThe technique developed is called DARC, which stands for detection of apoptosing retinal cells.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There is some credulity-stretching language, such as when Bethan Hughes, from Wellcome\u2019s Innovation team, said: \u201cThis innovation has the potential to transform lives for those who suffer loss of sight through glaucoma, and offers hope of a breakthrough in early diagnosis of other neurodegenerative diseases.\u201d\nThe suggestion that early detection leads to prevention in sight loss is also unwarranted. The study was to test the safety of the test, not to measure outcomes in terms of preventing blindness.", "answer": 0}, {"article": "\"It's clear that these medications are beneficial,\" said Wadden, who has been a paid consultant to pharmaceutical companies as well as Weight Watchers. \"Unfortunately, there's a sense that they must not work if you have to take them indefinitely. But I think obesity medications should be used on a long-term basis for chronic weight management, just as I take a [cholesterol-lowering] statin and a blood-pressure medication for the long term.\"", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a news release.\n\u00a0", "answer": 1}, {"article": "And, yes, they do get into the brain,\" Fleming explains.\nAnother surprise was a decrease in serotonin in brains of pigs fed the prebiotic.\nFortunately, modern infant formulas are getting closer to the real thing with the help of University of Illinois researchers.\nIf they spent more time with the new toy, that was an indication that the piglet recognized it as new and preferred it.\nAlthough more work is needed to tackle remaining questions, the study adds to the growing body of research suggesting a strong and potentially modifiable link between the gut and the brain: a link that makers of infant formula should strongly consider.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There is no mention in the title or first paragraph that this was piglet research (which could be misleading for those who only read the title and the first paragraph) yet the language used was largely appropriate.", "answer": 1}, {"article": "Sorry. The page you requested is not available", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no evidence the article draws from a press release.", "answer": 1}, {"article": ".\n\"Many would have predicted that tendon healing is inflammation-linked,\" said Thoru Pederson, Ph.D., Editor-in-Chief of The FASEB Journal, \"but that the anti-inflammatory roles of TSCs could be so potent, and so amplifiable, is a striking finding.\"\nIn vivo, the researchers evaluated inflammatory responses by TSCs, including infiltration of macrophages (white blood cells that consume damaged or dead cells) and expression of anti-/proinflammatory cytokines, at different time points.\n\"Inflammation plays a critical role in acute and chronic tendon injuries and healing,\" said Chang H. Lee, Ph.D., a researcher involved in the work and an assistant professor at the Regenerative Engineering Laboratory (Columbia University Irving Medical Center, New York).\n\"Our findings represent an important foundation for the development of a new treatment that would regulate overwhelmed inflammation for tendon ruptures and tears, tendonitis, tendinopathy, and other tendon injuries and diseases.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t engage in sensational language. However, the release headline and some of the quotes by researchers appear more optimistic than warranted based on the preliminary nature of the work.", "answer": 1}, {"article": "Sometimes, individuals with CDE have trouble opening their eyes, but Tomei said she went to the doctor and reported mild but incessant itchiness and dryness, and was diagnosed with CDE.\nOn Restasis.com, you can take the brand\u2019s \u201cdry eye quiz\u201d\u2014 for every quiz taken, Allergan has agreed to donate $1 to the organization.\nIf you think you may be suffering from CDE, Tomei advised visiting your doctor to receive a diagnosis.\n\u201cIt was as simple as going to the doctor, getting a prescription and trying RESTASIS\u00ae,\u201d Tomei, 51, who stars in the upcoming \u201cSpider-Man: Homecoming\u201d movie, told FoxNews.com.\nThe quiz on Restasis.com can help individuals learn whether they\u2019re a candidate for the drug.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely solely on the news release, since it includes novel quotes from Marisa Tomei. That would normally merit a Satisfactory rating. However, considering Tomei has a partnership with the drug manufacturer, it\u2019s hard to say this story\u00a0really goes a step beyond the PR effort.\u00a0We\u2019ll split the difference and give this a\u00a0N/A rating.", "answer": 2}, {"article": "Insulin may have a relationship with cancer.\n\"The evidence in diabetic humans is very convincing and very strong,\" added Dr. Phillip Dennis, a senior investigator with the U.S. National Cancer Institute and senior author on the lung cancer paper.\nAt this point, no one knows if metformin is safe in non-diabetic populations but some clinical trials are starting to look at the issue, Lippman said.\nThis adds credence to the idea that metformin's value is in its ability to lower overall insulin levels in the body, Cantley said.\nOthers believed that the finding might influence the choice of drugs in people with diabetes.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that this story did not rely solely or largely on a news release. ", "answer": 1}, {"article": "The researchers compared breast cancer deaths in women who had a breast cancer diagnosis in counties that had screening with deaths in counties that did not.\nThe study\u2019s conclusions contrast with those of a report last year by the United States Preventive Services Task Force, an independent group that issues guidelines on cancer screening, questioning the benefit of screening women younger than 50.\nThe study\u2019s authors include Dr. Stephen Duffy, an epidemiologist at the University of London, and Dr. Laszlo Tabar, professor of radiology at the University of Uppsala School of Medicine in Sweden, who have long been advocates of mammography screening.\nThe new study took advantage of circumstances in Sweden, where since 1986 some counties have offered mammograms to women in their 40s and others have not, according to the lead author, Hakan Jonsson, professor of cancer epidemiology at Umea University in Sweden.\nBut their results were greeted with skepticism by some experts who say they may have overestimated the benefit.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\nIt\u2019s clear that the story was not based on a news release.", "answer": 1}, {"article": "Most of the time, concussion testing in youth sports falls to volunteer coaches or parents with little if any medical experience.\nThe pace-along-the-tape test was also relatively accurate.\nEye tests can tell evaluators a great deal about how well someone\u2019s brain is working.\nIdeally, this assessment should be administered and evaluated by a medical professional.\nBut it had not been evaluated for use in young athletes.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story relies on one source \u2013 the lead author \u2014 but quotes in the story are different from the news release so we can assume the author interviewed the study author.", "answer": 1}, {"article": "Leukemia is the most common childhood cancer and accounts for about 30 percent of all childhood cancers.\nIn addition, more high-quality studies are needed to clarify the biological mechanisms underlying this association between breastfeeding and lower childhood leukemia morbidity,\u201d the study concludes.\n\u201cBecause the primary goal of public health is prevention of morbidity, health care professionals should be taught the potential health benefits of breastfeeding and given tools to assist mothers with breastfeeding, whether themselves or with referrals to others who can help.\nThe authors suggest several biological mechanisms of breast milk may explain their results, including that breast milk contains many immunologically active components and anti-inflammatory defense mechanisms that influence the development of an infant\u2019s immune system.\nBreast milk is meant to exclusively supply all the nutritional needs of infants and current recommendations include exclusively breastfeeding for the first six months of life to optimize growth, development and health.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "While the suggestion that breastfeeding reduces leukemia rates is questionable, we\u2019ve already flagged the release for that concern.\u00a0The release makes no other unwarranted claims and its tone is generally measured.", "answer": 1}, {"article": "However, prostate cancer is one of the few cancers that\u2019s not strongly linked to smoking (and falling cigarette consumption over the past 40 years is a major reason for falling cancer rates).\nIt\u2019s saying that, for most men, the (albeit small) risk of sexual dysfunction and urinary leakage from eventual treatment is not worth it, given the even smaller chance that PSA testing could save your life.\nMany health experts think that\u2019s too much risky treatment to justify the results.\nAs for the new paper this week, which suggests that three times as many men would be diagnosed each year with metastatic prostate cancer if it weren\u2019t for PSA testing, that study is published in the journal Cancer \u2014 and its numbers deserve a little explanation.\nBut that decision does remain a judgment call.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a press release.", "answer": 1}, {"article": "Patients with cancers of the immune system, like multiple myeloma, are especially susceptible to common infections, and a bout of the flu can lead to serious illness and even death.\nThis study was supported by the Arthur R. Sekerak Cancer Research Fund a Yale Cancer Center philanthropic fund.\nThe high-dose vaccine (Fluzone High-Dose) was approved in 2009 by the FDA as a single dose for adults over 65.\n\"Using an approved flu vaccine in a novel dosing schedule yielded promising results for a group patients at high risk for infection,\" Branagan said.\nThe Yale researchers developed a strategy that entailed offering patients a high-dose flu vaccine followed by a second high-dose booster shot one month later.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t use overly unjustifiable language.", "answer": 1}, {"article": "Though CA125 is valuable to look for recurrence of cancer, it is not recommended for screening because it can surge, for example, during menstruation. However, guidelines from the American College of Obstetricians and Gynecologists and the National Comprehensive Cancer Network (NCCN) recommend a CA125 test plus vaginal ultrasound imaging for a woman with nonspecific symptoms that could signal ovarian cancer, such as bloating and pain. A CT or MRI scan may be added, although these are expensive. A biopsy is usually avoided because it could spread cancer cells.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This appears to be an enterprise story, and does not rely on a news release.", "answer": 1}, {"article": "EULAR aims to promote, stimulate and support the research, prevention, and treatment of rheumatic diseases and the rehabilitation of those it affects.\nIn some cases however, patients maintained a clinical response after stopping the TNFi altogether.\nTo be eligible, patients had to demonstrate stable low disease activity (DAS28 less than 3.2) for over three months.\n\"Findings from our study have shown that adopting a TNFi dose reduction strategy can still meet this objective, with no compromise on symptom control for the patient and offering a more cost-effective option by substantially reducing the high drug costs associated with TNFi maintenance therapy.\"\nOf the 47 patients who reduced, then stopped their TNFi after six months, 45% (21/47) succeeded without flaring, and their final mean DAS28 score after stopping treatment was 2.2, demonstrating low disease activity.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The language used in the release does not appear to oversell the findings in the study.", "answer": 1}, {"article": "Along with obesity, high levels of blood fats can lead to heart disease and other health problems, including diabetes.\nThat allowed Neal and his team to determine how many children who actually had high cholesterol would have been missed if they had been screened based on federal guidelines.\nIndeed, of all the children in the study whose LDL levels were above 160, one-third were in the group who would not have been screened.\nNeal's data show that may not be the case.\nThe next update of the recommendations is expected in spring 2011.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story does not appear to be based on a news release.", "answer": 1}, {"article": "1Wiseman JT, Guzman AM, Fernandes-Taylor S, et al.\nThe study results appear as an \"article in press\" on the website of the Journal of the American College of Surgeons ahead of print.\n\"This approach allows us to intervene at an earlier time rather than waiting for patients to come back in after the problem has already developed past the point of being able to manage it on an outpatient basis.\"\nThis protocol also has a cost-savings component, in addition to the patient safety and satisfaction aspects.\nDr. Gunter said they were very successful in giving patients knowledge and access to technology so they could participate in the study.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The headline overreaches when it states that the app \u201ccan reduce readmissions and improve patient care.\u201d The study\u2019s conclusion is far more nuanced: \u201cPreliminary results indicate the ability to detect and intervene on wound complications.\u201d", "answer": 0}, {"article": "Researchers from Leeds Metropolitan University in the U.K. steeped thyme, marigold, and myrrh in alcohol to make what's called a tincture, and then tested them on the bacteria that cause acne.\nBut some U.S. dermatologists are quick to caution that while intriguing, this research is still preliminary, and thyme-tinged acne treatments are not yet ready for prime time.\nThey all had greater antibacterial effect after five minutes compared to lab specimens exposed to plain alcohol, but thyme was the most potent.\nIn fact, the thyme tincture was more powerful than standard concentrations of benzoyl peroxide, which is the active ingredient in many acne products.\nThe new findings were presented at the Society for General Microbiology's Spring Conference in Dublin.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The only quotes from the researchers themselves came from a news release, but there were four independent experts quoted.\u00a0 So the story didn\u2019t technically rely solely or largely on a news release \u2013 which is our criterion.", "answer": 1}, {"article": "And is the outcome the same for everyone?\u201d\n\nPuigserver, who runs a cancer biology lab at Dana-Farber Cancer Institute, noted that addressing health and aging through metabolism involves a complex web of pathways and mechanisms.\n\u201cThis space is traditionally driven by marketing language,\u201d said Kal Vapuri, whose New York firm Trisiras Group is one of Elysium\u2019s initial funders.\nAnd what exactly is being repaired in the body?\n\u201cWhat does it mean, to improve metabolic health?\n\u201cBut we will be data-driven and will communicate the complexities of science in simple ways.\u201d\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article goes beyond any press release", "answer": 1}, {"article": "Neurostimulation works by sending low-intensity electrical impulses to targeted portions of the spinal cord.\nThere is considerable data showing connections between the brain, nervous system and heart, said Torre, but until now, no one has attempted to take advantage of the relationship therapeutically.\nTorre said though patients may feel some euphoria in the early days, it likely will take about a month before doctors have a good idea whether the therapy is working.\nThe therapy passed a first test Monday evening as doctors adjusted the electrical impulse level to Bardwell's satisfaction.\nMonday's implantation marked the beginning of Torre's Phase 1 clinical trial of the therapy, the first time what is known as neurostimulation has been used to treat heart failure.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Although there are some similarities in wording between the story and this press release put out by Methodist Hospital, we didn\u2019t find any exact\u00a0duplication of text. And since the story\u00a0includes interviews with a researcher\u00a0and patient, we can be sure it didn\u2019t rely exclusively on the release for content.", "answer": 1}, {"article": "The researchers noted that thousands of people in this final group were participants in the Women\u2019s Health Initiative, a long-term study sponsored by the National Heart, Lung and Blood Institute in the U.S. Earlier reports based on data gathered by the Women\u2019s Health Initiative found that calcium and vitamin D supplements were associated with a lower risk of fractures, but only for women who took hormone therapy after menopause. To get a clearer picture of the direct link (if any) between supplements and fracture risk, Zhao and his colleagues opted not to include data from women on hormone therapy.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "Lead researcher Professor David Newby, of the BHF Centre for Cardiovascular Science at the University of Edinburgh, said: \"This relatively simple heart scan ensures that patients get the right treatment.\nThe study had previously found that around a quarter of patients had their diagnoses reclassified after receiving the scan, prompting new treatments in many cases.\nThis is the first study to look at the impact of the scans on long-term survival rates.\nThis is the first time that CT guided management has been shown to improve patient outcomes with a major reduction in the future risk of heart attacks.\nAfter receiving the scan, the number of patients suffering a heart attack within five years dropped by 40 per cent, the study found.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The title is misleading because it implies it\u2019s the scan itself that cuts heart attack risk and save lives.\nBut the study cannot account for whether this risk reduction \u2014 which was quite modest \u2014 may be attributable to lifestyle changes subsequent to the scan, or that the findings from the scan lead to more aggressive pharmaceutical management of risk factors. The published study notes that this is likely the case \u2014 and that\u2019s the whole point \u2014 having more accurate diagnoses may have the downstream effect of better management.", "answer": 0}, {"article": "Related: New Test Detects Heart Disease Risk, Especially for Black Women\n\nIt\u2019s not just the fat cells that lead to heart disease, the No.\nRelated: Why Young Women are Having Heart Attacks\n\nThe team studied more than 450 people having heart bypass surgery, removing some of the fat clogging their arteries.\n\u201cTreatments that are known to reduce the risk of heart attacks, such as statin drugs, reduce inflammation much more than any detectable reduction in coronary artery narrowing,\u201d said Oxford\u2019s Keith Channon, who also worked on the study.\nIt\u2019s inflammation, also.\nResearchers say they\u2019ve developed a better way of scanning someone\u2019s heart to predict who is most at risk of a heart attack or stroke \u2014 long before conventional imaging methods can do it.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We could not locate a release from the University of Oxford or Science Translational Medicine.", "answer": 2}, {"article": "- People born without the CCR5 gene are generally healthy, but will deleting it have unforeseen consequences?\nThe sixth man also had modified cells, but fewer than expected.\nThe research was only meant to show that, so far, it seems feasible and safe.\nThis is the first time researchers have permanently deleted a human gene and infused the altered cells back into patients.\nThe results announced Monday at a conference in Boston left experts cautiously excited.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely on a news release.", "answer": 1}, {"article": "In the new study of 24 patients, scores on a standard test measuring the disturbances of memory, language, attention, and other cognitive skills that are hallmark symptoms of Alzheimer's disease dropped an average of slightly more than five points in those treated with IVIG.\nThe IVIG treatment also appeared to slow the rate of brain shrinkage by about 45%, he tells WebMD.\nThe findings were presented at the American Academy of Neurology meeting.\nIt's a form of intravenous immunoglobulin, or IVIG, drugs that are usually used to treat immune system disorders.\nResearchers believe the drug can replenish a depleted pool of natural antibodies against beta-amyloid protein, which forms the sticky plaques that riddle Alzheimer's patients' brains.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There\u2019s no evidence that the story relied solely on a news release. ", "answer": 1}, {"article": "He explained: \"When teixobactin was discovered it was ground breaking in itself as a new antibiotic which kills bacteria without detectable resistance including superbugs such as MRSA.\nThe Lincoln team has successfully synthesized new simplified versions of teixobactin which harness the same powerful antibiotic effects in a way that could be produced on a commercial scale.\nThe breakthrough by researchers at the University of Lincoln, UK, marks another important step to realising the potential of teixobactin in aiding the global fight against antibiotic-resistant pathogens.\nScientists working to develop a 'game-changing' new antibiotic have made a significant advance towards creating commercially viable drug treatments by producing two simplified synthetic versions of the substance which are just as potent at killing superbugs like MRSA as its natural form.\nWe have been investigating a way to simplify the design while retaining the high potency against resistant bacteria such as MRSA.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release writers call this work a \u201cbreakthrough.\u201d That\u2019s what they also said in a release about an earlier research report from the researchers last June. Release writers were a bit more measured in a release issued in January, calling a research report from the team a \u201csignificant step.\u201d", "answer": 0}, {"article": "But Johannesdottir added that \"we hope that our finding will inspire more research on skin cancer prevention.\nMeanwhile, Dr. William Ting, a private practice dermatologist in San Ramon, Calif., praised the study despite agreeing that many factors are at play when it comes to skin cancer formation.\nHowever, the team suggested that past investigations into how NSAIDs may affect skin cancer risk, in particular, had key design problems that undercut efforts to nail down any NSAID-skin cancer connection.\nThe authors noted that prior work supported the notion that NSAIDs may offer some measure of protection against cancer (most notably colorectal cancer), by specifically impeding the cancer-causing activities of COX-2 (cyclooxygenase) enzymes.\nThe study appears in the May 29 online issue of the journal Cancer.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes interviews with one of the study authors and an independent expert. It was not based on a press release.", "answer": 1}, {"article": "Animals such as scorpions have venoms that block potassium and other ion channels.\nThe contributors are affiliated with one or more of the following institutions: Baylor College of Medicine, Peptides International, Inc. and Icahn School of Medicine at Mount Sinai.\nA group of researchers led by Dr. Christine Beeton at Baylor College of Medicine has found that one of the hundreds of components in scorpion venom can reduce the severity of the disease in animal models, without inducing side effects associated with similar treatments.\nThe study appears in the Journal of Pharmacology and Experimental Therapeutics.\n\"Although these results are promising, much more research needs to be conducted before we can use scorpion venom components to treat rheumatoid arthritis,\" Beeton said.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The headline overreaches when it wrongly declares that scorpion venom \u201ccan reduce severity of rheumatoid arthritis\u201d without alluding to the lack of testing in humans.\u00a0 It would have been better if it included \u201cin rats\u201d in the title.", "answer": 0}, {"article": "Interventional radiologists perform GAE for knee pain by inserting catheters through a pinhole-sized incision, blocking the very small arteries or capillaries within the lining of the knee, reducing the inflammation caused by osteoarthritis.\nTogether the scales represent an 80 percent improvement in function compared with pre-procedure conditions.\nThis prospective, multicenter clinical trial evaluated 13 patients with severe osteoarthritis pain.\nWhile preliminary data shows that the treatment does work and is feasible, it has only been used in a clinical trial setting.\nThis study builds on the growing international research around GAE and osteoarthritis.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The headline and sub-head (touting \u201clong-term relief\u201d) claim benefits that aren\u2019t supported by the evidence reported on this small, brief study.", "answer": 0}, {"article": "The United States recommends that men and women over age 31 eat 420 and 320 milligrams of magnesium daily, respectively.\n\u201cDietary magnesium intake is inversely associated with risk of stroke, specifically ischemic stroke,\u201d wrote lead author Susanna Larsson, a professor at the Karolinska Institute in Stockholm, Sweden.\nMost of the studies allowed the researchers to rule out other factors, such as family history.\nAbout 6,500 of them, or three percent, had a stroke in the time they were followed.\nMore in-depth studies are needed before researchers can say that the magnesium was what actually reduced the stroke risk, she added.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not appear to rely on a news release.", "answer": 1}, {"article": "WASHINGTON (Reuters) - An experimental drug being developed to fight influenza may fight a common but little-known virus called parainfluenza virus, researchers and the company said on Friday.\nMoscona said tests were needed that would show the drug actually helped reduce disease symptoms in animals.\nA spokesman for NexBio, David Wurtman, said the company would seek Food and Drug Administration approval to test Fludase in people with parainfluenza.\nThe researchers said that means patients with flu-like symptoms could get the drug without the need for a test to show whether their infection was caused by influenza or parainfluenza.\nDr. Anne Moscona of Weill Cornell Medical Center in New York and colleagues tested varying doses of the drug, also known as DAS181, in lab dishes and on cotton rats, a species accepted by scientists for testing parainfluenza.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "       \n \nNot applicable because we can\u2019t be sure of the extent to which the story may have been influenced by a news release.\u00a0 We do know that the researcher\u2019s quote came from a statement, not from an interview. And the only other attributed comment came from a drug company spokesman. \n ", "answer": 2}, {"article": "This is in line with some of our recent studies which indicate that the GI tract microbiome in Alzheimer's is significantly altered in composition when compared to age-matched controls, and that both the GI tract and blood-brain barriersbecome significantly more leaky with aging, thus allowing GI tract microbial exudates (e.g.\nIn a new clinical trial, scientists show that a daily dose of probiotic Lactobacillus and Bifidobacterium bacteria taken over a period of just 12 weeks is enough to yield a moderate but significant improvement in the score of elderly Alzheimer's patients on the Mini-Mental State Examination (MMSE) scale, a standard measure of cognitive impairment.\nEven though this increase is moderate, and all patients remained severely cognitively impaired, these results are important because they are the first to show that probiotics can improve human cognition.\nIn mice, probiotics have indeed been shown to improve learning and memory, and reduce anxiety and depression- and OCD-like symptoms.\nFuture research, on more patients and over longer time-scales, is necessary to test if the beneficial effects of probiotics become stronger after longer treatment.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "In line with its interpretation of the study\u2019s novelty, the news release does not engage in sensational language nor does it overstep the conclusions drawn from the journal article. The release highlighted that, \u201cFuture research, on more patients and over longer time-scales, is necessary to test if the beneficial effects of probiotics become stronger after longer treatment.\u201d Quotes were included from the researchers that showcased their optimistic yet conservative viewpoints on what the results may indicate and how they move forward to additional research on this topic.\nHowever, a comment on the general usefulness of probiotics may have been a bit biased toward the supplement. The statement, \u201cProbiotics are known to give partial protection against certain infectious diarrheas, irritable bowel syndrome, inflammatory bowel disease, eczema, allergies\u2026\u201d, etc., portrays probiotics as a recognized beneficial treatment or prevention strategy for these conditions, when that is certainly not the case. Much of the probiotic research done on individuals with these conditions has shown mixed results \u2013 and even then, has only shown benefit in specific populations. This is not strong enough evidence to describe them as known to be beneficial.", "answer": 1}, {"article": "According to the Skin Cancer Foundation, metastatic melanoma accounts for only about 1 percent of skin cancer cases but causes the majority of skin cancer deaths.\nOne cancer surgeon who reviewed the findings was impressed.\nShe said any advance in the care of aggressive melanomas is welcome news for patients.\nAll underwent surgery for their cancer before they began treatment with either Opdivo (nivolumab) or Yervoy (ipilimumab), the drug that's the current standard of care.\nThe international study was funded by Opdivo's maker, Bristol-Myers Squibb, and included more than 900 patients with stage III and stage IV melanoma.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story goes beyond the news release associated with the research.\n\u00a0", "answer": 1}, {"article": "The surgically reconstructed knees and the conservatively treated joints experienced similar (and high) levels of early onset knee arthritis, a common occurrence after an A.C.L.\nThe authors of the study are less sure.\nTwenty-three subjects of that group did eventually have the operation.\nThe ultimate lesson of The New England Journal study is almost certainly that more science on the subject is needed.\nTwenty-five percent of those in the physical therapy group eventually tore their meniscuses.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear the reporter did plenty of her own legwork.", "answer": 1}, {"article": "MDMA is believed to raise levels of the feel-good brain chemical serotonin and the so-called \"bonding hormone,\" oxytocin.\n(All of the participants received additional therapy sessions that did not involve the drug.)\nOn two separate occasions, 12 of the people took a dose of MDMA and then spoke for several hours with a pair of trained therapists.\nThe resulting sense of euphoria and emotional warmth seems to help patients connect with their therapists, says Michael Mithoefer, M.D., the lead author of the study and a Mount Pleasant, South Carolina-based psychiatrist who specializes in PTSD.\nTwo months later, 10 of the 12 people who took MDMA had improved to the point where they no longer met the diagnostic criteria for PTSD, and three participants whose condition had prevented them from holding down a job were able to return to work.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story provides almost no information outside of the press release\u00a0from the journal. The one added detail about the downsides of Ecstasy would have required 30 seconds of Google searching. Nonetheless, we can\u2019t be sure of the extent to which the story actually relied on a news release, so we rule this not applicable. ", "answer": 2}, {"article": "In one patient who had Alzheimer\u2019s, the pathologist and the radiologist analyzing the scan did not see much plaque, but the computerized analysis of the scan and the two autopsy reports did.\nAlthough the scans looked promising, the companies needed to show that what they revealed was the same as what a pathologist would see on autopsy.\nNeither the radiologists nor the pathologists knew whether the patients had dementia.\nAnd the data showed that the scans were completely accurate in ruling out Alzheimer\u2019s pathology: unlike doctors, they never said people had Alzheimer\u2019s pathology when they did not.\nThat was what Avid demonstrated with its study, presented Sunday by its medical director, Dr. Christopher M. Clark.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because of the multiple sources quoted, it\u2019s clear this story did not rely solely on a news release. ", "answer": 1}, {"article": "Doctors can try to treat glioblastoma with surgery to remove the cancerous cells, and blast them with radiation and chemotherapy.\nCurrently, most people diagnosed with the condition die within two years.\nThe animals dosed only with the stem cells developed tumors.\nA vaccine against the Zika virus could one day be used to fight the deadly brain cancer that claimed the life of Senator John McCain, according to a study in mice.\nAs both the Zika virus and glioblastoma can affect the brain, the team hypothesized that the former could be harnessed to treat the latter.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story cites an expert not affiliated with the research project, and gives a full background regarding the Zika virus and Senator John McCain. It does not appear to rely on a news release.", "answer": 1}, {"article": "Whereas in Parkinson's disease and essential tremor, the target for the electrodes are nodes within the motor circuits, the Alzheimer's study targeted the fornix, which is part of the memory pathway.\nWhile the study was relatively small, we believe the data suggest that DBS surgery targeting the fornix can be performed safely in this patient population.\nThe ADvance Trial, using a device from Functional Neuromodulation, Inc., is aimed at evaluating the safety, efficacy and tolerability of DBS in this patient population.\nDr. Ponce adds that the next step is evaluating the efficacy and longer-term safety of the treatment, which will not be known until the last patient completes the two-year evaluation later this year.\nResults from the Phase 2 study, reported in the Journal of Neurosurgery on Dec. 18, 2015, demonstrated the safety of DBS in Alzheimer's patients.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There is no explicitly unjustifiable language in this story, however, one wonders why this story was written at all. True, it reports that results of a phase 2 trial \u201csuggest that DBS surgery targeting the fornix can be performed safely in this patient population.\u201d For reasons described under the Harms section, for which we already gave the release a failing grade, we wonder if this news release accurately portrayed the device\u2019s safety, and if the study really met its safety endpoint.", "answer": 1}, {"article": "Prescribing testosterone for age-related deficiency \u2014 which is only vaguely defined \u2014 took off in 2000. The trend was driven not by solid scientific evidence, but by the introduction of convenient, rub-on testosterone products, the first being Androgel. Many men are put on testosterone with no tests of their levels or despite tests showing normal levels, a study of Medicare claims found.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story\u00a0does not rely on a news release.\n\u00a0", "answer": 1}, {"article": "\n\u2022 People who have had Type 2 diabetes for up to 10 years can reverse their condition\n\nA new study from Newcastle University has shown that people who reverse their diabetes and then keep their weight down remain free of diabetes.\nIn fact, after 6 months a thirteenth patient had reversed their diabetes.\nIf you have had the diagnosis for longer than that, then don't give up hope - major improvement in blood sugar control is possible.\nThe group included many people with longer duration diabetes, defined as more than 8 years and ranging up to 23 years.\nThis caused international interest, but the study was very short as it was only eight weeks and the question remained whether the diabetes would stay away.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We\u2019re rating this category unsatisfactory for a number of reasons. First, the blatant claim that diabetes can be \u201creversed\u201d rather than pushed into remission for 6 months based on results from 12 participants who represent less than half of those tested. Second, the lead investigator is first described as \u201cworld-renowned\u201d while readers would be hard-pressed to recognize his name. The description of the funders touts its \u201cworld-class expertise,\u201d a descriptor which, while it might be correct, offers readers little to help them understand this study.", "answer": 0}, {"article": "Baselga reports receiving honoraria from Roche; other co-authors report receiving speaking fees or honoraria from GlaxoSmithKline and fees from other drug companies.\nThey looked to see which drug was better at eliminating invasive cancer in the breast and metastatic cells in the lymph nodes.\nGlaxoSmithKline, the maker of Tykerb, helped fund the study.\nThose given Tykerb alone had a 25 percent response.\nThat's the effect on overall survival in using the two-drug approach.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does not appear that the story relied on a news release.", "answer": 1}, {"article": "Learn more about omega-3 fatty acids, including DHA, and infant health from the March of Dimes.\nBut, she added that the supplements did appear to be safe for pregnant women to take.\nThe treatment group received 400 milligrams of DHA each day, beginning when they were between 18 and 22 weeks pregnant.\nMore than 800 Mexican women were included in the study.\nAt times, however, babies in the DHA group experienced longer duration of rashes and vomiting, the study authors noted.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "This benefit is thought to come from the omega-3 fatty acids in fish, although studies of fish oil supplements have produced disappointing results in people who already have Alzheimer's.\nRaji presented the findings here at the annual meeting of the Radiological Society of North America.\n\"The new study is the first to establish a direct relationship between fish consumption, brain structure, and Alzheimer's risk,\" Raji says.\nSeveral studies have linked a diet rich in certain fish to a reduced risk of Alzheimer's disease.\nIn a new study, imaging scans showed that regular fish-eaters were less likely to have brain cells die off in the area of the brain responsible for short-term memory -- recalling a phone number that was just heard, for example.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely on a news release.\n ", "answer": 1}, {"article": "Studies in mice, dogs, pigs, and monkeys have shown that so-called focused ultrasound waves can be used to heat tiny bubbles that then mechanically push open gaps in blood vessels, allowing drugs to leak out into the brain.\nHall felt nothing from the seconds-long bursts from 1,024 ultrasound beams aimed at different points around her skull, and an MRI scan confirmed that the brain barrier was successfully traversed.\nBecause the trial was designed solely to determine the safety of focused ultrasound to the brain, the patient was not given a therapeutic dose of doxorubicin and the procedure is not expected to help in her recovery, Mainprize said.\n\u201cIt really opens up a lot to the imagination.\u201d\n\nMost drugs are blocked from entering the brain by the \u201cblood-brain barrier,\u201d which protects against infection, but also makes it tricky to treat brain tumors, diseases like Alzheimer\u2019s, and mental illness.\nNew, safe doses of drugs will need to be determined, once medication is not being diverted by the blood-brain barrier, noted Dr. Gordon Li, a neurosurgeon at Stanford.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Although a news conference and news release were clearly what sparked the story, the author interviewed outside experts, so we can be sure there was some original reporting done.\n\u00a0", "answer": 1}, {"article": "A rare and aggressive form of skin cancer, MCC, is 35 times less common than melanoma, but on average, it is about three times more likely to be deadly.\nTom Judd, who lives near Portland, Oregon, knows what it is like to be diagnosed with a deadly cancer for which there is no approved drug.\nHe is a leading expert on MCC and a pioneer of immunotherapy for the disease.\nAvelumab is the first FDA-approved treatment for metastatic MCC and the first disease that the drug has ever been approved to treat.\nA practicing physician, he treats patients with MCC and other skin cancers at Seattle Cancer Care Alliance, Fred Hutch\u2019s clinical care partner.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t use sensational or unjustified language.", "answer": 1}, {"article": "Brain waste includes amyloid \u03b2 (amyloid) and tau proteins, chemicals that negatively affect brain processes if they build up.\nDr. Benveniste cautioned that while the research team speculates that the human glymphatic pathway will clear brain waste most efficiency when sleeping in the lateral position as compared to other positions, testing with MRI or other imaging methods in humans are a necessary first step.\n\u201cThe study therefore adds further support to the concept that sleep subserves a distinct biological function of sleep and that is to \u2018clean up\u2019 the mess that accumulates while we are awake.\nThe method enables researchers to identify and define the glymphatic pathway, where cerebrospinal fluid (CSF) filters through the brain and exchanges with interstitial fluid (ISF) to clear waste, similar to the way the body\u2019s lymphatic system clears waste from organs.\n\u201cIt is interesting that the lateral sleep position is already the most popular in human and most animals \u2013 even in the wild \u2013 and it appears that we have adapted the lateral sleep position to most efficiently clear our brain of the metabolic waste products that built up while we are awake,\u201d says Dr. Nedergaard.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The Not Satisfactory rating here applies to the accompanying artwork as much as it does the text \u2014 the illustration depicts a human, but we think it would have been more appropriate to show a sleeping rodent. The release also makes statements that clearly refer to humans or refer to rodents and humans as interchangeable, and we don\u2019t think the disclosure near the bottom that \u201ctesting with MRI or other imaging methods in humans are a necessary first step\u201d is enough to counterbalance this.", "answer": 0}, {"article": "For example, some early cancers may not secrete DNA fragments into the bloodstream and require other types of detection.\nDoctors will also need a clear assessment of their accuracy.\nThe tests must be ordered by a doctor, based on a patient\u2019s risk profile.\nThe company is focusing on mutations that are relatively well-understood, and for which there are specific treatments, said Chief Executive Jim Plante.\nSeveral oncology experts said liquid biopsy tests like Pathway\u2019s, while exciting, still require large clinical studies proving they help people beat cancer through early detection.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story went beyond any news release that may have been issued.", "answer": 1}, {"article": "According to the FDA, \"Testosterone products are FDA-approved only for use in men who lack or have low testosterone levels in conjunction with an associated medical condition.\nThe findings may sway the ongoing debate over testosterone therapy's benefits and risks, especially for the heart.\nBarua and colleagues say they don't know the exact reasons for testosterone's apparent benefits for the heart and overall survival.\nWhile the new study results do seem to advocate for testosterone replacement therapy, Barua stresses the need for \"appropriate screening, selection, dosing, and follow-up of patients to maximize the benefit of testosterone therapy.\"\nSo far, the medical community lacks results from any definitive clinical trial that might provide clear guidance.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "While we felt that the news release worked hard to push the argument that testosterone therapy that returns the level of the hormone to \u201cnormal\u201d offers a health benefit, the careful reader will find cautionary information that tempers that claim.", "answer": 1}, {"article": ".\nThis press release contains forward-looking statements.\nThis data highlighted compelling early results using the company's MRIdian system for the treatment of inoperable, locally advanced pancreatic cancer.\nFurther studies, including the planned prospective multi-institutional study referenced in this press release, as well as patient data covering longer periods of time post-treatment, could lead to different or contrary results from those expressed during ASTRO or in the poster presentation.\nThe early results highlighted above, along with other data obtained using MRIdian will be tested in a multi-center, prospective, single-arm clinical trial for inoperable, locally advanced or borderline resectable pancreatic cancer.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "No unjustifiable language was identified in the news release.", "answer": 1}, {"article": "As a nicotine-gum addict, Mike Metzger used to worry about the warning on its label: \"Stop using the nicotine gum at the end of 12 weeks.\"\n\nBut that was before a prominent smoking-cessation scientist, K. Michael Cummings, told him to keep chewing the gum as long as it helped him stay off cigarettes. So 15 years after quitting smoking, Mr. Metzger, a 63-year old retired New York telephone worker, still chews 16 pieces of nicotine gum a day.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story didn\u2019t rely on any news release.", "answer": 1}, {"article": "To resolve that possibility, a new trial is under way at 20 cancer centers, including M.D.\nAlmost all the patients mounted an immune response.\nThe trial's big surprise was that the chemotherapy didn't stop the vaccine from prompting a strong immune response and instead enhanced it.\nHe appeared to be beating the cancer with the combination therapy.\nHe noted the impressive results could be the result of cherry-picking patients, accepting only those whose tumors had been excised by surgery and radiation.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if the story relied solely or largely on a news release. We do know that it only quoted two researchers who were involved in the current study.\u00a0 ", "answer": 2}, {"article": "For at least 2,000 years Chinese healers have used acupuncture to treat pain and other ailments.\nBut that result has been called into question because the patients in the sham group probably figured out they were not getting the real thing.\n\u201cThere is a body of literature that argues that the whole approach to studying acupuncture doesn\u2019t lend itself to the Western reductionist scientific method.\u201d\n\nBut the study\u2019s lead author, Dr. Maria E. Suarez-Almazor, notes that the sham treatment was developed with the help of trained acupuncturists.\nAnd critics contend that the study was poorly designed.\nNow Western doctors want proof that it works.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article clearly did not rely on a news release.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070506/14healthwatch.lede.htm was not found on this server.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no way to know if the story relied on a press release as the sole source of information, although the only source is the author of a study in a journal.\u00a0 ", "answer": 2}, {"article": "Depression presents an enormous disease burden, with a reported 350 million people worldwide suffering from the disease, but traditional SSRI treatments carry a burden of their own - in dollars and side effects.\nTheir results showed that magnesium is safe and effective and comparable to prescription SSRI treatments in effectiveness.\nThe study team found that in 112 participants with analyzable data, consumption of magnesium chloride for six weeks resulted in a clinically significant improvement in measures of depression and anxiety symptoms.\nIn addition, these positive effects were shown quickly, at two weeks, and the supplements were well tolerated and similarly effective regardless of age, sex, or use of antidepressants, among other factors.\nDepression symptom assessments were conducted on all participants on a bi-weekly basis.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release doesn\u2019t use sensational language.\u00a0", "answer": 1}, {"article": "Referring to Lozano's second clinical study, Dr. Nader Pouratian, a neurosurgeon and DBS researcher at UCLA, comments, \"The recent deep brain stimulation trial for Alzheimer's disease clearly demonstrates the safety of this approach for trying to treat the progression of disease.\nGiven that so few people have had electrical stimulation applied to memory circuits, perhaps the most significant finding was that both the surgery itself and DBS of the fornix appear safe.\nHis group launched a test in six patients and published the results in the Annals of Neurology in 2010.\nLike in Lozano's study no serious side effects were seen.\nUsing a 3-dimensional brain mapping technique called standardized low-resolution brain electromagnetic tomography, or sLORETA, Lozano's group uncovered an explanation for the unexpected findings.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely solely on a news release.", "answer": 1}, {"article": "Past studies have found that compared with people without fibromyalgia, those with the disorder have higher rates of stressful life events, such as childhood abuse, marital problems and high levels of job stress.\nNone of the women in the control group had a comparable improvement.\nThe therapy involves an educational component where patients learn about the emotion-pain connection.\nIn addition, the control group received no active therapy to serve as a comparison.\nThe study, of 45 women with fibromyalgia, found that those who learned a technique called \u201caffective self-awareness\u201d were more likely to show a significant reduction in their pain over six months.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story interviewed the author of the study, so it\u2019s apparent that it was not lifted entirely from a news release. \n", "answer": 1}, {"article": "Before delivery, 68 percent of tenofovir-treated mothers had HBV loads below 1 million copies per milliliter, compared to 2 percent of nontreated mothers.\nMoving forward, longer term, observational studies are needed to confirm the safety of fetal exposure to tenofovir treatment, says Pan.\nThe current standard of care is to provide vaccine and immune globulin to reduce transmission rates.\nTreatment effectively reduced the viral load of the pregnant women, says Pan.\nThose with a high viral load should receive tenofovir treatment starting at gestational week 30 until delivery to reduce the risk of transmission to their infants.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "This release does not use any unjustifiable language.", "answer": 1}, {"article": "\"Fast and junk food seem like an easy and affordable option for busy parents, but defaulting to high-fat, high-sugar, high-calorie foods is putting their children's health and future at risk,\" Heller said.\nA more health-conscious diet was associated with small increases in IQ, she said.\nThe key seemed to be the diet at age 3, since diet at 4 and 7 seemed to have no effect on IQ, the research team noted.\nCommenting on the study, Samantha Heller, a dietitian, nutritionist and exercise physiologist in Fairfield, Conn., said that \"most of us do not realize that the foods we eat have direct consequences on brain growth, function and performance.\"\nHowever, to truly understand the effect of diet on children's intelligence, further studies are needed, they said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story is not based on a press release.", "answer": 1}, {"article": "\u201cBut even without that firm answer at this point I don\u2019t see the harm in supplementing.\u201d\nThe study, presented at the American Society of Reproductive Medicine annual meeting, was in mice, so more research needs to be completed before omega 3 foods or supplements become part of treatment for infertility.\n\u201cBased on this study, it looks very encouraging that omega 3s can potentially improve fertility,\u201d says Skaznik-Wikiel.\nMore studies need to replicate and confirm the role that omega 3 fatty acids might play in fertility, but for now, Skaznik-Wikiel says that there isn\u2019t much harm in consuming more omega 3 fats.\nBut other studies Skaznik-Wikiel has done with mice suggests that these fats may lower levels of inflammation that can adversely affect ovarian function.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The reporter who wrote this story does appear to have interviewed the lead researcher on the study, so the story does not appear to rely entirely on a news release.", "answer": 1}, {"article": "6 Kowdley KV, et al.\n\"These data establish the use of the oral direct-acting antivirals as an important treatment option in HCV-infected children aged six to 11 years old.\"\nThis ongoing, open-label study enrolled 90 children aged between six and 11 years with chronic HCV, mostly genotype 1 (n=86).\nExpert Rev Gastroenterol Hepatol.\n\"This study is a breakthrough for the management of children aged six to 11 years old with Hepatitis C, demonstrating that the new DAA regimen is highly efficacious and, more importantly, safe in this group of HCV-infected children\", said Prof Frank Tacke, University Hospital Aachen, Germany, and EASL Governing Board Member.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release uses two words \u2014 \u201ccure\u201d and \u201cbreakthrough\u201d \u2014 that we advise journalists to avoid because they are imprecise and tend to sensationalize.", "answer": 0}, {"article": "U.S. guidelines recommend Americans consume less than 2.3 g of salt daily, or 1.5 g for certain people who are more at risk for high blood pressure or heart disease.\nThe Cochrane review attracted sharp criticism from nutrition experts.\nWhile previous trials have found there is a blood pressure benefit from cutting salt, research has yet to show if that translates into better overall heart health in the wider population.\nSimon Capewell, a professor of Clinical Epidemiology at Liverpool University, said the review was \u201cdisappointing and inconclusive\u201d and did not change public health consensus that dietary salt raises blood pressure.\nThis gave the researchers enough data to be able to start drawing conclusions, they said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story does not appear to rely on a news release.", "answer": 1}, {"article": "Dr Golam Khandaker, who led the study, says: \"It's becoming increasingly clear to us that inflammation plays a role in depression, at least for some individuals, and now our review suggests that it may be possible to treat these individuals using some anti-inflammatory drugs.\n\"We will need clinical trials to test how effective they are in patients who do not have the chronic conditions for which the drugs have been developed, such as rheumatoid arthritis or Crohn's disease.\n\"It's too early to say whether these anti-cytokine drugs can be used in clinical practice for depression, however,\" adds Professor Peter Jones, co-author of the study.\nThe team of researchers carried out a meta-analysis of these clinical trials and found that the drugs led to an improvement in the severity of depressive symptoms independently of improvements in physical illness.\nMeta-analyses of the other types of clinical trials showed similar results.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There is no unjustifiable language used in the release.", "answer": 1}, {"article": "After her mother unexpectedly died from a tear in the wall of her heart at age 63, Patricia Walters talked to her doctor, Leslie Cho, about how to better monitor her own heart health.\n\nPregnant at the time with her own daughter, Ms. Walters, now 46, says she was \"a nervous wreck\" worrying that she, too, might face serious cardiac risk.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "No evidence of a press release as a source.", "answer": 1}, {"article": "The study, published in the December 26 issue of the Journal of Clinical Oncology, showed that patients treated with reduced radiation had less difficulty swallowing solids (40 percent versus 89 percent of patients treated with standard doses of radiation) or impaired nutrition (10 percent versus 44 percent of patients treated with regular doses of radiation).\n\u201cAnd while traditional chemoradiation has demonstrated good tumor control and survival rates for patients, too often they encounter unpleasant outcomes that can include difficulty swallowing solid foods, impaired nutrition, aspiration and feeding tube dependence,\u201d said Dr. Burtness.\n\u201cToday, many younger patients are presenting with HPV-associated squamous cell carcinoma of the oropharynx,\u201d said Dr. Burtness.\n\u201cYounger patients may have to deal with these side effects for decades after cancer treatment.\n\u201cWe found there are some patients have very high cure rates with reduced doses of radiation,\u201d said Barbara Burtness, MD, Professor of Medicine (Medical Oncology), Yale Cancer Center, Disease Research Team Leader for the Head and Neck Cancers Program at Smilow Cancer Hospital, and the chair of the ECOG-ACRIN head and neck committee.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t rely on\u00a0sensational language but the frequent use of the term \u201ccure\u201d seems misleading, especially when we aren\u2019t provided specifics on the treatment outcomes. These cancers can certainly recur after treatment, so how did the researchers establish whether patients were cured or not?", "answer": 0}, {"article": "\"Ultrasound is portable, cost-saving and safer for children than an X-ray because it does not expose them to radiation,\" says Dr. Tsung.\nThe research team was led by James Tsung, MD, MPH, Associate Professor in the Department of Emergency Medicine and Department of Pediatrics at the Icahn School of Medicine at Mount Sinai, and former clinical fellow Brittany Pardue Jones, MD, who's currently Assistant Professor in the Department of Pediatrics at Vanderbilt University School of Medicine.\nFurther research is needed to investigate the impact of lung ultrasound on antibiotic use and stewardship.\nThe Mount Sinai Hospital is ranked as one of the nation's top 10 hospitals in Geriatrics, Cardiology/Heart Surgery, and Gastroenterology, and is in the top 25 in five other specialties in the 2014-2015 \"Best Hospitals\" issue of U.S. News & World Report.\nMount Sinai's Kravis Children's Hospital also is ranked in seven out of ten pediatric specialties by U.S. News & World Report.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We don\u2019t believe the news release relies on unjustifiable language to summarize the potential benefit of substituting ultrasound over X-Ray in screening for pediatric pneumonia.", "answer": 1}, {"article": "I couldn't get anything done,\" Ham said.\nThen, a friend mentioned marijuana, which Maine had legalized in 1999 for chronic pain and scores of other medical conditions.\n\"However, I think one place where sometimes cannabis advocates go too far is when they talk about using cannabis to treat opioid addiction.\"\nGetting on that list is crucial and has resulted in a tug of war in many states, including several in which veterans have been unsuccessful in getting post-traumatic stress disorder approved for marijuana treatment.\nIt would also be wrong to portray marijuana as completely safe, they say, because it can also be addictive.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Due to the wide range of interviewees quoted, this story does not appear to rely on a news release.", "answer": 1}, {"article": "An 18-week clinical study of CoolSculpting in submental fat treatment found that 77 percent of patients showed improved appearance of lax tissue and 75 percent of patients reported their chin looked more toned following treatment.3\n\n\"In my own patients, I have noticed the improved appearance of lax tissue when using the CoolMini\u00ae applicator for the CoolSculpting\u00ae system to treat the submental area,\" said Jeffrey S. Dover, MD, FRCPC, Co-Director of SkinCare Physicians of Chestnut Hill, Mass.\nThe CoolSculpting procedure is not for everyone.\nMillions of CoolSculpting treatments have been performed in more than 80 countries.\nAllergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.\nCoolSculpting is available through a network of CoolSculpting Centers worldwide.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release does not include sensational, unjustifiable language.", "answer": 1}, {"article": "Source: Brightling C, et al.\nBy measuring the sputum eosinophil \u2014 the inflammation marker that shows how white blood cells increase during asthma attacks \u2014 the researchers were able to track the effects of the drug.\n\u201cA unique feature of this study was how it included measurements of symptoms, lung function using breathing tests, sampling of the airway wall and CT scans of the chest to give a complete picture of how the new drug works,\u201d said Brightling in the press release.\nWe already know that using treatments to target eosinophilic airway inflammation can substantially reduce asthma attacks.\u201d\n\nUltimately, the researchers hope that the drug \u201ccould likewise help to stop preventable asthma attacks, reduce hospital admissions and improve day-to-day symptoms \u2013 making it a \u2018game changer\u2019 for future treatment,\u201d said Brightling.\nThe pill may be a \u201cgame changer for future treatment of asthma,\u201d said Professor Chris Brightling, a National Institute for Health Research (NIHR) Senior Research Fellow at the University of Leicester, in a press release.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "While the story uses original wording and cites a University of Leicester news release as the source of some of its information, it does not appear that the story offered anything beyond what is in the news release. (We also reviewed the news release.)", "answer": 0}, {"article": "In 2014, prostate cancer was the leading cause of newly diagnosed cancers in men and the second leading cause of cancer death in men.\nWhen compared to surrounding healthy tissues, it\u2019s hoped that contrast enhanced MRIs will reveal the shape and nature of any tumors present.\nThe technique is also valuable in surgical planning and image staging, said David S. Karow, MD, PhD, assistant professor of radiology at UC San Diego and the study\u2019s corresponding author.\n\u201cThis new approach is a more reliable imaging technique for localizing tumors.\nIn a related paper to be published in the journal Frontiers in Oncology, the same team of researchers reported that RSI-MRI appears to predict tumor grade.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "As discussed above, this release harbors many unsupported claims that are not justifiable based on the evidence presented.", "answer": 0}, {"article": "No more than a few days later, the samples were transported to labs at the university, where they remained frozen until they were processed by researchers. This ensured that none of the bacteria had a chance to grow or change from the time the sample was collected. Also, it guaranteed that all samples were treated the same way.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because it appears to have original statements from one of the researchers, the story does not appear to have\u00a0relied solely on a news release.\n\u00a0", "answer": 1}, {"article": ".\nBottom Line: The investigational anticancer therapeutic abemaciclib, which targets CDK4 and CDK6, showed durable clinical activity when given as continuous single-agent therapy to patients with a variety of cancer types, including breast cancer, non-small cell lung cancer (NSCLC), glioblastoma, and melanoma, according to results from a phase I clinical trial.\nHow the Study Was Conducted and Results: Patnaik, Shapiro, and colleagues enrolled 225 patients with a variety of types of advanced cancer in the phase I clinical trial designed to evaluate the safety and preliminary efficacy of abemaciclib.\n\"The results of the trial supported the FDA decision to grant breakthrough therapy designation to abemaciclib (previously known as LY2835219) for patients with refractory hormone receptor-positive advanced or metastatic breast cancer,\" added Patnaik.\nShapiro served on an advisory board for Lilly during the conduct of the study; reports receiving personal fees from Lilly, GI Therapeutics, Vertex Pharmaceuticals, and grants from Lilly for work other than reported here; and is an investigator on several trials using other CDK4/6 inhibitors, including palbociclib and ribociclib.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release avoids unjustified claims, although the overall cast is entirely positive, leaving it to journalists and other readers to balance the rosy image with some skepticism.", "answer": 1}, {"article": "Researchers around the world are seeking ways to regenerate damaged hearts, spines and skin with stem cells. At an operating table here recently, Kotaro Yoshimura leaned over a 51-year-old woman and put stem cells to use for a different purpose: cosmetic breast surgery.\n\nDr. Yoshimura jabbed the underside of the woman's left...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story has a great deal of independent reporting and does not rely solely on a press release for information about this procedure.", "answer": 1}, {"article": "It has been 51 years since the first birth-control pill became available in the U.S., bringing dozens of contraceptive options for women in its wake. There are currently two options on the market for men\u2014vasectomy or a condom.\n\nThe research pipeline is full of possibilities, though. Scientists at Columbia University Medical Center have halted sperm production and started it again in mice with no apparent side effects, using a drug that blocks receptors for vitamin A. An injectable synthetic substance, in Phase 3 clinical trials...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Solid, independent reporting.", "answer": 1}, {"article": "The Ache: Nearly 5,000 people a year die from choking in the U.S., according to the nonprofit National Safety Council.\n\nThe Claim: Two new easy-to-use devices work like plungers to suck out obstructions in the airway, providing another option if standard treatment\u2014such as abdominal thrusts developed in 1974 by Henry Heimlich\u2014fail to clear the airway, say the companies who sell them.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does not appear that the article solely relies on a news release as several independent sources were interviewed.", "answer": 1}, {"article": "For more on irregular heartbeats, visit the U.S. National Library of Medicine.\nThe findings are reported by study author Dr. Vivek Y. Reddy, a senior faculty member in medicine and cardiology at the Mount Sinai Medical Center in New York City, and colleagues in the May 26 online edition of Circulation: Arrhythmia and Electrophysiology.\nThe current study focused on 27 patients (66 percent men), all of whom were diagnosed with a form of atrial fibrillation.\nThis, they said, is due to the procedure's use of a slender medical device called an endoscope, which when inserted into the target region provides a continuous real-time image of the culprit cells.\nIn fact, with this new approach, the study team found that physicians could destroy such cells with 100 percent accuracy.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story admits it\u2019s based on an American Heart Association news release.\u00a0 There\u2019s no sign of any independent reporting or vetting. ", "answer": 0}, {"article": "\"It's odd and it's tough and people say, 'I'm sorry.'\nBut it's hard to know what would have happened without them.\n\"And nothing moved,\" Gambuti said.\nMason said he was already noticing changes.\nAnd after six months, he was noticing changes then, too.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "Merck & Co. and Schering-Plough Corp. said a long-awaited trial showed their cholesterol drug Vytorin failed to slow progression of heart disease better than a cheaper drug, threatening the companies' $5 billion-a-year cholesterol-fighting franchise.\n\nSchering-Plough's shares fell 8% to $25.52 and Merck declined 1.3% to $59.78 at 4 p.m. in New York Stock Exchange composite trading.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We have problems with the fact that we don\u2019t know the source of the story.\u00a0 Was it the \"conference hosted by Morgan Stanley earlier this month\" that the story mentions?\u00a0 We don\u2019t know.\u00a0 But because the ENHANCE trial data hasn\u2019t been published, we should have been told the source.\u00a0 Nonethless, because we have no direct evidence of any language being lifted directly from a company news release, we give this criterion a shrug-of-the-shoulder and an N/A score.\u00a0 \n\u00a0", "answer": 2}, {"article": ".\nIf approved, lorcaserin would be Arena's first marketable product.\nThe drug also proved to be highly selective, meaning it hit the intended targets inside the body and did not cause troubling side effects.\nThe drug was pulled from the market in 1997, costing Wyeth millions of dollars.\nThe trial looked at the effects of three dose levels of the drug.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if the story relied solely or largely on a news release.\u00a0 This was a San Diego paper reporting on a San Diego company\u2019s product in \"mid-stage\" trials.\u00a0 It\u2019s doubtful the paper would report on similar results from a company located somewhere else.\u00a0 ", "answer": 2}, {"article": "\u201cMany have been told all their lives that if they ingest peanuts they will have a severe reaction and die,\" he said.\nIt could be several more years before the patch will be available for consumers.\nAt the end of a year, 50 percent of those wearing the high-dose 250 microgram patch were able to tolerate consuming at least one gram of peanut protein.\nFor those plagued with peanut allergies, protection may eventually come in the form of a patch worn on the skin, a new study suggests.\nWith this you just slap a little patch on their backs.\u201d\n\nAlthough some volunteers experienced redness and itchiness at the site of the patch, there were no serious side effects.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Since the story includes a comment from an independent expert, we can be sure it didn\u2019t rely excessively on a news release. That being said, a news release issued for the study had some useful\u00a0information for the reader, including sponsorship details, that we wish had made it into the story.", "answer": 1}, {"article": "Dec. 21, 2009 -- A fatty substance found naturally in the lungs may provide a natural defense against respiratory syncytial virus (RSV) infection.\nNew research suggests the substance, a lipid known as POPG, may prevent RSV infection as well as limit the spread of the virus once infection has occurred.\nTherefore, together with the results of this study, researchers say the compound merits further research as a treatment for RSV infection in humans.\nApplying POPG to the cells after RSV infection also inhibited the spread of the virus to neighboring healthy cells.\nIn addition, the study showed treating infected mice with POPG dramatically reduced infection and prevented the spread of the inflammatory cells into the lungs.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The only quote is attributed to a news release.\u00a0 Why didn\u2019t WebMD call the researcher for an interview?\u00a0 ", "answer": 0}, {"article": "\"Our finding is so exciting because there is already an approved drug against RANKL called \u201eDenosumab\u201d.\nScientists at the University of Maryland School of Medicine in Baltimore have already tried the preventive use of a RANKL blocking drug in mice.\nAn already approved drug could be quickly available and would then be the first breast cancer prevention drug.\nIn 2010, Josef Penninger, the scientific director of IMBA in Vienna and his team have shown that sex hormones can trigger breast cancer (Schramek et al., Nature) through proteins called RANKL and its receptor RANK, which are key factors in bone metabolism.\nA multinational research effort now made the discovery that RANKL is also the main driver of BRCA1 mutation-driven breast cancer.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release appears overly optimistic throughout considering the research has not yet been performed in humans. Statements like those below may give false hopes to women or encourage them to undergo additional genetic screening when the drug isn\u2019t even tested or approved for use in breast cancer prevention.\nIn addition, the mention of the actress Angelina Jolie seemed inappropriate, considering that this celebrity had a very rare genetic condition that led her to take drastic measures in undergoing prophylactic mastectomies. This reference is more likely to confused\u00a0than inform the reader.", "answer": 0}, {"article": "Texas rep expects Trump to make case for a border wall at State of the Union\n\n\"We're going to keep working to secure the border, and not blink until we either get it done or the voters get to speak in 2020\"", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if the story relied solely or largely on a news release. ", "answer": 2}, {"article": "Pain scores for children in both the oral morphine and ibuprofen groups were similar, but the children receiving oral morphine reported more adverse effects, such as nausea, vomiting, drowsiness, dizziness and constipation.\nIn the first 24 hours, more than 80% of the children in the study needed pain relief at home.\nThe study included 154 children aged 5 to 17 years who underwent minor orthopedic surgery, such as keyhole surgery on joints, ligament and tendon repair, suture or hardware removal at London Health Sciences Centre in London, Ontario.\nThey note that as neither treatment completely relieved pain, more research is needed into effective pain relief, especially for more severe pain.\nThe study was conducted by researchers from London Health Sciences Centre, Schulich School of Medicine & Dentistry, Western University, London, Ontario; Women and Children's Health Research Institute, University of Alberta, Edmonton, Alberta; and Children's Hospital of Wisconsin, Milwaukee, Wisconsin.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "No unjustifiable language was noted.", "answer": 1}, {"article": "And if you wake up in the middle of night and don\u2019t fall back asleep easily, get out of bed.\u201d\n\n\u201cYou don\u2019t want to have any linkage between the experience of lying in bed and being awake,\u201d he said.\nWhen the researchers looked at information from a different, more in-depth sleep monitoring system, however, they failed to find significantly better outcomes with the behavioral therapy.\nThese improvements were sustained for at least 6 months, and were backed up by data from a sleep monitor worn on the wrist or ankle.\nThe new results were similar to those previously published on the more intense cognitive behavioral therapy.\nAnd the risks may be even more pronounced among older patients, added senior author Timothy Monk, also of the University of Pittsburgh.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\nThe story does not appear to rely on a news release.", "answer": 1}, {"article": "The average age of people in both groups was 73.\nThe findings, presented Sunday, Nov. 25 at the Radiological Society of North America meeting in Chicago, suggest that doctors may one day be able to use widely available tests to tell people their risk of developing dementia before symptoms arise.\nWhen the researchers focused on specific parts of the brain most likely to show damage, the accuracy rose to 95 percent.\nAlthough there are no drugs available yet to prevent or delay the onset of Alzheimer's disease, identifying those at high risk of developing dementia within the next few years could still be beneficial, the researchers said.\n\"We showed that a single MRI scan can predict dementia on average 2.6 years before memory loss is clinically detectable, which could help doctors advise and care for their patients.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release quoted a researcher saying \u201cdoctors might soon be able to tell people whether they are likely to have Alzheimer\u2019s develop in the next few years.\u201d Given that this study involves looking at scans of only a few dozen patients, that seems like a reach.", "answer": 0}, {"article": "As many as 20 percent of American adults have some symptoms of irritable bowel syndrome, according to the National Institutes of Health.\nThe developer, Ironwood Pharmaceuticals, said the drug, linaclotide, met all the goals in the first late-stage trial testing it as a treatment for the type of irritable bowel syndrome accompanied by constipation.\nAn experimental drug can reduce abdominal pain and increase bowel movements in people with irritable bowel syndrome, a condition that affects millions of Americans, the drug\u2019s developer said Monday.\nThe condition is poorly understood and somewhat vaguely defined, so estimates are not very precise.\nLaxatives can relieve the constipation but often do not help with the pain, said Dr. Chey, who is a consultant to Ironwood.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Since the story includes interviews with two experts \u2014 an IBS expert who consults for the drug manufacturer and the company CEO \u2014 we can be sure the study wasn\u2019t based entirely on a press release.", "answer": 1}, {"article": "Dennis Halmi, a member of the Bluepoint Surgical Group in Woodbridge, says that in 2002 \"we did a handful\" of second operations on obesity patients, \"maybe five, six.\nIt's not always clear why.\nOf course, a second obesity surgery comes with increased risk.\nNo obesity operation is \"a magic bullet.\"\nIf the patient doesn't go in for adjustments, the whole thing won't work.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not appear to rely on a press release.", "answer": 1}, {"article": "Varenicline contains no nicotine.\n\"The trial and error approach is not optimal.\"\nAnd given how difficult it is to kick the habit, smokers need all the help they can get to succeed the first time they try, Lerman said.\nThis post has been updated.\nThis may seem like common sense, but no one had ever tested it before, she said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story clearly includes an interview and went beyond the news release.\nSee:\u00a0http://www.uphs.upenn.edu/news/News_Releases/2015/01/lerman/", "answer": 1}, {"article": "Bladder cancer is the fourth most common cancer in men, but it is less common in women.\nThree Loyola Medicine urologists, Marcus Quek, MD, Gopal Gupta, MD, and Alex Gorbonos, MD, are co-authors of the study.\nLoyola is among 15 centers that participated in the nationwide trial of 350 patients, who were randomly assigned to undergo robotic surgery or open surgery to remove cancerous bladders.\nMAYWOOD, IL - Robotic surgery is as effective as traditional open surgery in treating bladder cancer, according to a landmark study published in the journal Lancet.\nResearchers wrote that the findings \"underscore the need for further high-quality trials to assess surgical innovation before this surgical technique is widely adopted in clinical practice.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t employ unjustified, sensational language.", "answer": 1}, {"article": "In skin testing, a practitioner makes rows of pricks on a patient\u2019s back or forearm so allergen-containing extracts can seep into the skin.\nFor that reason, he and other experts say, most sufferers never even see an allergist.\nBecause they were not considered very sensitive, physicians were left with a lasting impression that blood testing was inferior to skin testing.\nWhile most allergy patients are seen by these generalists, he says, many allergies are not adequately diagnosed.\n(And many sufferers of seasonal and pet allergies know what they\u2019re allergic to, so they don\u2019t need a diagnosis.)\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story quotes multiple experts, the reader can assume the story does not rely on a press release as the sole source of information.", "answer": 1}, {"article": "\u2022 Never eat seaweed that is washed up on the beach.\nIn the article the authors offer suggestions to how both individual consumers and the food industry can use seaweed to make our everyday meals healthier.\nHe and the co-authors suggest that seaweed should be added fast food, thus making this type of food healthier.\nAdding seaweed to processed foods such as frozen pizzas, hot dogs and dried pasta will reduce cardiovascular diseases, concludes a new scientific article.\nBy adding seaweed to processed foods we can make food healthier.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Let\u2019s start with the headline:\n\u201cFood industry can help lower cardiovascular diseases by adding little seaweed to products.\u201d\nThere is no evidence presented in this news release to support this statement. Nor this one:\n\u201cSeaweed\u2019s content of potassium salts does not led to high blood pressure \u2013 unlike the sodium salts, typically encountered in the processed food.\u201d", "answer": 0}, {"article": "The latest health and science updates, breakthroughs, research, and the best in investigative and informative journalism.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no evidence that this article relied on a news release.", "answer": 1}, {"article": "[1] Quotes direct from authors and cannot be found in text of Article.\nSurprisingly, the findings also revealed that the standard altona RT-PCR test, under the conditions deployed in the field, was itself an imperfect reference standard.\n[1]\n\nIn this study, the researchers compared the diagnostic accuracy of the new RDT against the benchmark RT-PCR test (altona Diagnostics) being used for clinical diagnosis in the field reference laboratory run by Public Health England at Port Loko in Sierra Leone.\nThe study is the first to show that a point-of-care EVD test (ReEBOV Antigen Rapid Test; Corgenix) is faster than and as sensitive as a conventional laboratory-based molecular method used for clinical testing during the recent outbreak in Sierra Leone.\n[1]\n\nWriting in a linked Comment, Dr Nahid Bhadelia from Boston University School of Medicine and Boston Medical Center, Boston, USA says, \"[This study] validates the accuracy of the ReEBOV RDT in patients who are well into their illness...suggesting it could be used to triage this subset of patients if RT-PCR is not available, particularly in those with a high index of clinical suspicion for a differential diagnosis...the data presented provide crucial information about the point of-care function of this rapid diagnostic test, such as ease of use, quality of samples taken at the bedside, and the concordance with venous samples...the results raise caution regarding the performance of the widely used altona RT-PCR assay, which the authors suggest might have underperformed because of laboratory specific technical and performance factors.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There are a couple of points of contention here. The term \u201cgame-changer\u201d used in the headline is rarely justified, but we think the release provides the evidence to show that this test could, in fact, be a game changer. In addition, we\u2019re not sure that the test is \u201cas sensitive as a conventional laboratory-based molecular method used for clinical testings.\u201d In reality, it did as well as one manufacturer\u2019s test in the field, but worse than another\u2019s.\u00a0But we\u2019re inclined to give this a Satisfactory rating, since the rest of the release is well-hedged and caveated.", "answer": 1}, {"article": "Dying tumor cells release cell-free DNA (cfDNA) into the blood, where cancer-specific methylation changes can be detected at any disease stage.\nSuch promising results combined with the simplicity of the test, could allow us to detect lung cancer at the early stages and hence improve 5-year survival from about 15% to about 50-70%.\nTo date, there is no adequate screening process for the early detection of lung cancer, bringing 5-year survival rate to approximately 15%.\nTherefore, a screening test aimed at the entire risk group to assist in the early detection of the disease is highly needed and can dramatically increase lung cancer survival.\nI am therefore very encouraged with the results of this study, showing that EpiCheck has the ability to identify both non-small-cell and small-cell lung cancer at early stages, with a high level of sensitivity and specificity.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release uses exaggeration to describe the results. One example:\nSuch promising results combined with the simplicity of the test, could allow us to detect lung cancer at the early stages and hence improve 5-year survival from about 15% to about 50-70%. This will offer significant added value in the fight against lung cancer.\nThat\u2019s pure conjecture.\u00a0", "answer": 0}, {"article": "\u201cThis is literally on the cutting edge of where the field is,\u201d Dr. DeKosky said.\nAnd when \u2014 researchers optimistically are saying \u201cwhen\u201d these days \u2014 drugs are shown to slow or prevent the disease, the thought is that people will start having brain scans or spinal taps for Alzheimer\u2019s as routinely as they might have colonoscopies or mammograms today.\nDoctors might want to use the test in cases where they want to be sure of the diagnosis.\nAnd they might want to offer the test to people with milder symptoms who want to know whether they are developing the devastating brain disease.\nThey note that it is not reliable enough \u2014 results can vary by lab \u2014 and has been studied only in research settings where patients are carefully selected to have no other conditions, like strokes or depression, that could affect their memories.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story does not appear to rely on a news release.", "answer": 1}, {"article": "To address this gap, researchers conducted a randomized controlled trial including 352 healthy infants from 3 pediatric outpatient clinics, including 7 physician practices, who received scheduled vaccinations in their first year of life.\nThe study was conducted by researchers at SickKids, the University of Toronto, York University and several Toronto-based pediatricians.\n\"The effects of consistent pain management on the development of preprocedural anxiety (fear), hypersensitivity to pain and compliance with future vaccination warrant future investigation,\" they recommend.\nThe infants were randomized to 1 of 4 groups: placebo control; video instruction to parents on how to soothe their baby; video plus oral sugar solution; and video, oral sugar solution and lidocaine applied to the skin.\nFor babies under age 1 year, lidocaine cream, combined with a small amount of sugar given by mouth and infant soothing, can help relieve pain from routine vaccinations, according to a study in CMAJ (Canadian Medical Association Journal).\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Nothing over-the-top here, though we feel the news release\u2019s headline isn\u2019t supported by the release itself, let alone the study.", "answer": 1}, {"article": "Second, the DRCR Network study is the first multi-center, randomized clinical trial to show how ranibizumab and the laser work together to improve treatment,\" Williams said.\nThe American Academy of Ophthalmology will review the study findings and make recommendations on whether Lucentis plus laser treatment should be the preferred treatment for a large number of patients with DME.\nThe study, published online in the journal Ophthalmology, was conducted by the Diabetic Retinopathy Clinical Research (DRCR) Network.\nBut researchers say it can also improve vision in people with DME, a common form of diabetic retinopathy.\nThis is a \"seminal\" study,\" added Dr. George A. Williams, a board member of the American Academy of Ophthalmology and chair of the ophthalmology department at Oakland University William Beaumont School of Medicine.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Relies totally on a news release.\u00a0 No sign of independent reporting. ", "answer": 0}, {"article": "Worse, Anderson says, \"I could feel the tumors getting bigger.\nAfter one year, the once palpable tumors were no longer detectable in diagnostic scans.\nTwo years ago, she gained access to an experimental immune-enhancing treatment in clinical trials at Providence Cancer Center in Portland.\nStill, the study stands as \"a major landmark in cancer immunotherapy,\" says Dr. Bernard Fox, president of the International Society for Biological Therapy of Cancer.\nResearchers linked 14 deaths to the study drugs, half caused by immune-system reactions.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely solely on a news release. ", "answer": 1}, {"article": "Uterine serous carcinoma makes up less than 10 percent of all cancers of the endometrium, or lining of the womb, diagnosed in the United States each year, but it accounts for more than a third of the 10,000 endometrial cancer deaths annually.\nThe results of the trial, published online ahead of print on March 27 in the Journal of Clinical Oncology, show that the drug extended the length of time to tumor progression by four to eight months in the seven-year trial.\nBut the results of the trial, they add, were strong enough to warrant submission to the National Comprehensive Cancer Network, which guides the design of standard treatment plans around the country.\nFader cautions that a larger study of the drug combination, or other combinations, is needed to confirm the findings and potentially extend survival even more.\nThe researchers say this may lead to new national guidelines for treating this cancer subtype, known as uterine serous carcinoma.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release\u2019s headline is misleading when it claims the new combo \u201cimproves survival.\u201d The study found some patients had four to eight months of progression-free survival. That\u2019s not the same things as overall survival and that needed clarification.\nWe give the release credit for taking a more cautious tone in other parts of the release.", "answer": 0}, {"article": "Good overall health was defined as having no major chronic diseases, such as heart disease or diabetes, as well as having no significant decline in their thinking or physical abilities.\nNow, the researchers stressed that wasn\u2019t the case for women who consumed more than two drinks a day or four drinks or more at a time.\nFor women who like a nice glass of wine at the end of the day, there\u2019s more good news: Even middle-aged women can have about a drink a day of any kind of alcoholic beverage as part of what they do to try to stay healthy as they age, according to new research.\n\u201cThese data suggest that regular, moderate consumption of alcohol at midlife may be related to a modest increase in overall health status among women who survive to older ages,\u201d the researchers wrote.\nThat was after accounting for other factors, such as smoking.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Since there were no independent perspectives, we can\u2019t tell to what extent this story may have relied on this news release.", "answer": 2}, {"article": "But when it recurs and becomes metastatic, it's very difficult to treat,\" she explained.\nO'Shaughnessy, who is co-director of breast cancer research at Baylor-Sammons Cancer Center, US Oncology, and Texas Oncology in Dallas, said the results of a larger (about 500 patients) phase 3 trial should be available within one to three months.\nThe findings were enough to generate the interest of Dr. Lisa A. Carey, the co-author of an accompanying editorial.\nIn the meantime, she pointed out, a woman walking through a clinic door who is diagnosed with triple-negative breast cancer shouldn't panic.\nThis was a phase 2 trial.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The piece includes information beyond that available in the press release from Sanofi-Aventis.", "answer": 1}, {"article": "WINSTON-SALEM, N.C. - Aug. 17, 2015 - Every year falls affect approximately one in three older adults living at home, with approximately one in 10 falls resulting in serious injury.\nFunding for the study was provided by the Wake Forest Translational Science Institute and Center for Integrative Medicine and the Claude Pepper Older Americans Independence Center of Wake Forest Baptist.\n\"Falls in homebound older people often lead to disability and placement in a nursing home,\" said Denise Houston, Ph.D., R.D., associate professor of gerontology and geriatric medicine at Wake Forest Baptist and lead author of the study.\nSixty-eight study participants received either a monthly vitamin D supplement of 100,000 international units or placebo delivered with their MOW meal.\nThe Wake Forest Baptist team currently is conducting a clinical trial to try to determine how vitamin D affects risk factors for falls such as balance and muscle strength and power.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release does not use language that goes beyond what the study itself justifies.", "answer": 1}, {"article": "1 Sperling RA, Aisen PS, Beckett LA, et al.\nThe concept that cognitive decline can be identified early and prevented by applying quantitative brain imaging techniques is the focus of \"Hot Topics in Research: Preventive Neuroradiology in Brain Aging and Cognitive Decline,\" a review published online in American Journal of Neuroradiology (AJNR).\nThese markers, including structural, functional, and molecular imaging are being used in the AD diagnositc criteria [AA/NIA], (1)\" says Howard Aizenstein, M.D., Ph.D., a psychiatrist at University of Pittsburgh.\nSuch work is already happening at UCLA and other institutions that meld these approaches into novel ways to improve patient care.\n\"Recent advances have improved the ability to characterize imaging markers along the trajectory of Alzheimers disease, starting in the pre-clinical phase.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The language of the release bordered on sensational, with neurologist Majid Fotuhi touting the benefits of quantitative MRI technology and claiming it will have a \u201chuge impact in the future of diagnosis and treatment of Alzheimer\u2019s disease.\u201d The release never clarifies the how and why of this statement.", "answer": 0}, {"article": "The combination of Yervoy and the newer Opdivo also reduced the risk of disease progression by 60 percent compared with Yervoy alone through 11 months of follow-up in previously untreated patients with advanced melanoma, researchers found.\nTwenty-two percent of those combination patients had a complete response, meaning no sign of tumor.\nOverall survival data was not yet available.\nBut after 11 months, more than half of the combination group had yet to see their disease worsen.\nThe complete response rate was 22 percent.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story adds some additional information not found in the Bristol-Myers Squibb release.", "answer": 1}, {"article": "The median age was 75 years (range 41to 94).\n\"In addition to providing important support for using SBRT to treat early-stage lung cancer in elderly patients, these findings highlight the value of multi-institutional collaborations and large data sets that can provide statistically meaningful answers to critical questions about treatment outcome and guide clinical decision making.\"\nThe study evaluated safety and efficacy outcomes of 1,083 patient reports collected in a multi-institutional database.\n\"This study is the largest series of its type to evaluate SBRT outcomes in patients aged 80 years and older,\" says Joel Goldwein, MD, Senior Vice President, Medical Affairs for Elekta.\nThe results of our study clearly support the use of SBRT for elderly patients, especially those who may not be able to tolerate longer courses of radiotherapy or more invasive treatment options,\" says Meredith Giuliani, MBBS, FRCPC, MEd, a radiation oncologist in the Cancer Clinical Research Unit at Princess Margaret Cancer Centre, University Health Network in Toronto and lead study author.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t rely on sensational language. But given the lack of data to back up the claims in the headline and lead of the release, we have to say that the claims being made in the release are unjustified.\nA more appropriate headline, supported by the study data, would be:\n\u201cNew Data From the Elekta Lung Research Group Show Stereotactic Body Radiation Therapy Provides Similar Results in Elderly Compared with Younger Patients With Early-stage Lung Cancer\u201d\nas opposed to\n\u201cNew Data From the Elekta Lung Research Group Support the use of Stereotactic Body Radiation Therapy in Elderly Patients With Early-stage Lung Cancer.\u201d\nOne could argue that this is a fairly subtle difference, but it is a large one. Even if the release provided additional data that showed SBRT compared favorably to other treatments, it would still have needed to compare outcomes of those over age 70 treated with SBRT and other treatments to make this claim.", "answer": 1}, {"article": "All of these study participants \u2014 largely people in their 70s, all with a diagnosis of either \"mild cognitive impairment\" or atypical dementia \u2014 are living with the unconfirmed suspicion that they have Alzheimer's. The study is underwritten by the Centers for Medicare & Medicaid Services and the Alzheimer's Assn. It set out to find out whether knowing \u2014 getting the costly test that would offer either confirmation or reprieve \u2014 would change the way that patients with cognitive troubles are treated, or the way that they plan their lives.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to be based on a news release.", "answer": 1}, {"article": "The Site is down for maintenance.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does not appear that the story relied solely on a news release.", "answer": 1}, {"article": "Foods with fiber, such as fruits, vegetables and whole grains, can reduce cholesterol levels, while carbohydrates that are low in fiber tend to raise triglyceride levels and lower \"good\" HDL cholesterol levels.\nWhat effects, if any, the prunes had on cholesterol levels were not mentioned in the study abstract.\nDespite the addition of several hundred calories a day to their diet, the apple-eating women didn't gain weight over the course of the study.\nThe addition of apples to the diet probably kept the women feeling fuller because of the fiber content in the apples, she explained.\nThe researchers theorized that the nutrients in apples may reduce inflammation in the body.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Although the story sought an independent expert\u2019s input, the basis of the story was apparently a news release because that\u2019s the source of the only quote given from the researcher.\u00a0 And the story admits it relied on an abstract of a paper that hadn\u2019t even been presented yet.", "answer": 0}, {"article": "Dr Douglas Morrison, author of the paper from the Scottish Universities Environmental Research Centre at the University of Glasgow, commented: \"We developed inulin-propionate ester to investigate the role of propionate produced by the gut microbiota in human health.\nThis study illustrates very nicely that signals produced by the gut microbiota are important for appetite regulation and food choice.\nThis study is filling in a missing bit of the jigsaw -- and shows that this supplement can decrease activity in brain areas associated with food reward at the same time as reducing the amount of food they eat.\"\nThe team found that when volunteers drank the milkshake containing inulin-propionate ester, they had less activity in areas of their brain linked to reward -- but only when looking at the high calorie foods.\nThese show that altering how the gut works can change not only appetite in general, but also change how the brain responds when they see high-calorie foods, and how appealing they find the foods to be.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release is somewhat weakened by \u201comissions\u201d of information, rather than by unjustifiable language.", "answer": 1}, {"article": "While the function of sweating is to prevent overheating, those affected sweat even when the body does not need cooling.\n(Reuters) - Dermira Inc said its experimental topical therapy for excessive underarm sweating was successful in two late-stage studies, bringing it one step closer to providing an easy-to-use therapy for the often embarrassing condition.\nIn the first trial, a significant improvement in the severity of sweating was seen in 52.8 percent of the patients treated with the drug, compared with 28.3 percent patients in the control group, on a scale designed by the company.\nAbout two-thirds of the total 697 enrolled in the two trials for the company\u2019s topical treatment, DRM04, were treated with wipes containing DRM04, while the rest were not.\nIn the second trial, a significant improvement was seen in 66.1 percent of the drug-treated patients, compared with 26.9 percent in the control group.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story didn\u2019t appear to rely primarily on the news release, as we don\u2019t see signs of quotes or text being lifted directly without acknowledgment. We\u2019ll rate this N/A.\nHowever, the release does have additional valuable context that we wish had been included (with acknowledgement), such as study details\u00a0and\u00a0adverse effects of the medication.\n\u00a0", "answer": 2}, {"article": "In rural or underserved areas, doctors sometimes must rely on a patient's symptoms or use their own judgement in looking at test sample color results to determine whether a patient has an infection.\nThe WSU researchers found that their portable smartphone reader worked nearly as well as standard lab testing in detecting 12 common viral and bacterial infectious diseases, such as mumps, measles, herpes, and Lyme Disease.\nCollaboration with Ping Wang, associate professor of Pathology and Laboratory Medicine at the University of Pennsylvania's Perelman School of Medicine, enabled the design and implementation of the key clinical validation study.\nThe work could lead to faster and lower-cost lab results for fast-moving viral and bacterial epidemics, especially in rural or lower-resource regions where laboratory equipment and medical personnel are sometimes not readily available.\nThe researchers tested the device, which is about the size of a hand, with 771 patient samples at Hospital of University of Pennsylvania and found that it provided false positives only about one percent of the time (was 97. to 99.9 percent accurate).\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release includes several speculative claims that this device could perform better than existing devices in reducing public health program costs, health care access and delivery, infectious disease control and more. None of these important goals has been tested.", "answer": 0}, {"article": "When the researchers used the longer Tao brush, they were able to detect endometrial cancer in all but 7% of the women who had the disease, and close to half of the ovarian cancers. Combined with the fact that these tests were performed with a mere swipe of the uterine wall, these measures of \u201csensitivity\u201d \u2014 the ability to detect cancers that are actually there \u2014 represent a major improvement over the screening tests currently available.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We didn\u2019t detect any copy-pasted quotations from a Johns Hopkins Medicine news release, nor other obvious signs of reliance on a press release.", "answer": 1}, {"article": "Tobias Hartmann, the project's coordinator, said, \"We have known for a while that diet can reduce the risk of developing dementia.\nThe clinical trial, headed by Professor Hilkka Soininen is part of a large EC project (LipiDiDiet) to explore the therapeutic and preventative impact of nutrition on neuronal and cognitive performance in ageing, AD and vascular dementia.\nThis is the first time a randomised, double-blind, clinical trial has shown that a nutritional intervention can help to conserve the ability of patients with very early AD (pre-dementia) to carry out everyday tasks, such as paying bills, or finding your way around, as measured by the Clinical Dementia Rating-Sum of Boxes (CDR-SB) - a combined measure for the ability to think and perform everyday tasks.\nThe LipiDiDiet study illustrates that this nutritional intervention can help to conserve brain tissue and also memory and patients' ability to perform everyday tasks - possibly the most troubling aspects of the disease.\nAs part of the LipiDiDiet project, the first randomised clinical trial to investigate the effects of a medical food Fortasyn Connect (Souvenaid), in patients with very early AD (pre-dementia), has just been completed.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release includes some statements that raise a red flag when we see them and the evidence provided in the release doesn\u2019t support them. Some examples:\n\u201cThis is exciting because it shows that in the absence of effective drug options, we really have found something that can help slow down some of the most distressing symptoms in very early AD (pre-dementia); especially in those who started the intervention early. Indeed those patients who have lost the least cognitive function, have the most to gain.\u201d\n\u201cThe LipiDiDiet study illustrates that this nutritional intervention can help to conserve brain tissue and also memory and patients\u2019 ability to perform everyday tasks \u2013 possibly the most troubling aspects of the disease.\u201d\nThe evidence presented doesn\u2019t demonstrate that the nutrition drink \u201ccan help slow down\u201d early Alzheimer\u2019s memory loss nor that it \u201ccan help to conserve brain tissue.\u201d\nBut while this is a close call, we\u2019ve already come down hard on this release for similar issues and these statements arguably aren\u2019t egregious enough to merit another ding here. So we\u2019ll rule it Satisfactory with reservations.", "answer": 1}, {"article": "\"The results and especially the rapidity of the effects observed in the gantenerumab trial went beyond our expectations,\" Luca Santarelli, MD, study co-author and Roche senior vice president of neuroscience, writes in an email.\nThe study is published in the online edition of Archives of Neurology.\nThe experimental compound, known as gantenerumab, is being developed by Roche, the Swiss pharmaceutical company.\nTherefore, it's not known if reducing the amount of them will slow or stop the disease.\nWhat is not entirely known at this point, though, is if these plaques cause Alzheimer's or are by-products of the disease.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There was clear evidence of independent reporting.", "answer": 1}, {"article": "Flare-ups , which involve excruciating joint pain, redness, swelling and warmth, can last days or weeks.\n\"(And) this trial provides well-controlled evidence that this IL-1 blocker is effective in preventing acute gout flares in this setting,\" he added.\nDr. Michael A. Becker, a professor emeritus of medicine at the University of Chicago, described the findings as \"very promising.\"\nHowever, he cautioned that the high cost of rilonacept will most likely curtail its use.\nTHURSDAY, Jan. 5, 2012 (HealthDay News) -- Preliminary findings suggest a drug used to treat another disease might also reduce painful flare-ups in gout patients starting new medication regimens.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story admits that it lifted its investigator quotes from this journal news release.\nIf the investigator wasn\u2019t available immediately, this story was not of such urgent importance that it couldn\u2019t have waited until someone involved in the research could be interviewed.", "answer": 0}, {"article": "Healthy cartilage that covers the bone surfaces in the knee joint transfers these high loads from the lower leg to the upper leg.\nAn eight week return to running programme using the anti-gravity treadmill was individually designed by Dr Hambly.\nThe team individually tailors rehabilitation programmes to support people in returning to sport and exercise activities after injury or surgery.\nPatients recovering from knee operations are being helped back to sport and exercise through expert rehabilitation at the University of Kent.\nNot only does the tailored anti-gravity treadmill programme provide a great environment for healing, it also helps the person restore their belief that they can make a successful return to the sport they love.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We did not find unjustifiable language \u2014 just exaggeration.", "answer": 1}, {"article": "Metastatic SCCA, a cancer often associated with human papillomavirus (HPV) infection, is normally treated with chemotherapy, although no trials have established a standard of care.\nThe study employed the monoclonal antibody nivolumab, one of the drugs represented among the growing arsenal of immunotherapy therapies.\nThe study revealed encouraging correlations between immunologic biomarkers and responses to treatment.\nStudy results showed a decrease in frequency of CD8 T-cells in post-treatment tumor samples among responder-patients.\nThe phase II study, for which findings are being presented at this week's American Association for Cancer Research's annual meeting in New Orleans, was designed and led by researchers at The University of Texas MD Anderson Cancer Center's Human Papillomavirus-Related (HPV) Cancers Moon Shot Program.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "No outright sensational language, but the news release failed to explain its use of the word \u201cencouraging\u201d to describe study findings. There is no quote from a researcher to back up that adjective. The study abstract only mentions \u201cpotential correlations\u201d between immunological biomarkers and clinical outcomes to nivolumab.", "answer": 1}, {"article": "CNN Films Presents:\" Glen Campbell ...\nThe main goal of the current study, which included 119 patients, was to find out whether high doses of resveratrol could be safe.\n(The current study was a phase 2 trial, typically meant to evaluate safety and get an early look at efficacy of a new drug.)\nThe current study used high doses of resveratrol to increase the chances that enough of the compound got into the brain to have an effect.\nAnd anecdotally, patients who took resveratrol told the researchers that they felt like they were maintaining their mental ability.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This went well beyond any news release on the work.", "answer": 1}, {"article": "DURHAM, N.C. - Most high-risk lung cancer patients might not need annual low-dose computed tomography (LDCT) screenings if they are cleared of disease in their initial test, according to a study led by a Duke Cancer Institute researcher.\nAn additional 75 patients (0.4 percent of the initial negative group) were diagnosed with lung cancer between the first and second annual screening.\nHe added that improving the accuracy of LDCT screening for lung cancer would also significantly reduce the number of annual screens.\nOf the initial 19,066 participants with a negative initial LDCT scan, 444 (2 percent) were diagnosed with lung cancer at the time of the last available follow-up.\nThe researchers determined that eliminating the first annual screening after the initial negative test might have resulted in, at most, an additional 28 lung cancer deaths in the LDCT group (186 vs. 212 deaths per 100,000 per years) over the course of the study.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release has suitable, measured language throughout.", "answer": 1}, {"article": "Toni Weiser is a veteran of skin-cancer removals. The 75-year-old retired teacher in Santa Fe, N.M., says she\u2019s had at least eight basal and squamous cell cancers scraped, frozen and surgically excised from her arms, face and shoulders.\n\nWhen a basal-cell cancer reappeared on Mrs. Weiser\u2019s nose last year, her dermatologist suggested a new, painless, nonsurgical treatment and she eagerly agreed. After 16 treatments with a small radiation device held millimeters from her nose, the tumor was gone. \u201cI felt nothing\u2014just some mild...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is enough original reporting that we can be sure the story didn\u2019t rely on a press release.", "answer": 1}, {"article": "It is less common than Type 2 diabetes, which is associated with obesity.\nBurt, who wrote the study protocol, said the research was done in Brazil because U.S. doctors were not interested in the approach.\nFor now, the new treatment does not apply to the nearly 20 million Americans with Type 2 diabetes, reports CBS News medical correspondent Dr. Jon LaPook.\nBurt and other diabetes experts called the results an important step forward.\nIn addition, Ross said that the study should have had a comparison group to make sure the treatment was indeed better than standard diabetes care.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Since the story quoted two expert sources \u2013 and one of them was apparently not involved in the research \u2013 it is safe to assume the story did not rely solely or largely on a news release.\u00a0 ", "answer": 1}, {"article": "Other sources include pink grapefruit, watermelon, and guava.\n\u201cThe results support the recommendation that people get more than five servings of fruits and vegetables a day, which would likely lead to a major reduction in the number of strokes worldwide, according to previous research.\u201d\n\nOther studies have shown that high lycopene levels may be linked to a reduced risk of certain cancers.\nTomatoes are not the only food that is rich in this antioxidant.\n\u201cThis study adds to the evidence that a diet high in fruits and vegetables is associated with a lower risk of stroke,\u201d says researcher Jouni Karppi, PhD, of the University of Eastern Finland in Kuopio.\nThe findings appear in the Oct. 9, 2012, issue of Neurology.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story pulls some text and a quote directly from a press release without acknowledging the source. Here\u2019s the comparison:\nStory:\nThe new study included slightly more than 1,000 men from Finland aged 46 to 65. Researchers measured the level of lycopene in their blood when the study began and followed the men for about 12 years. During that time, 67 men had a stroke.\n\u201cThis study adds to the evidence that a diet high in fruits and vegetables is associated with a lower risk of stroke,\u201d says researcher Jouni Karppi, PhD, of the University of Eastern Finland in Kuopio. \u201cThe results support the recommendation that people get more than five servings of fruits and vegetables a day, which would likely lead to a major reduction in the number of strokes worldwide, according to previous research.\u201d\nPress release:\nThe study involved 1,031 men in Finland between the ages of 46 and 65. The level of lycopene in their blood was tested at the start of the study and they were followed for an average of 12 years. During that time, 67 men had a stroke.\nAmong the men with the lowest levels of lycopene, 25 of 258 men had a stroke. Among those with the highest levels of lycopene, 11 of 259 men had a stroke. When researchers looked at just strokes due to blood clots, the results were even stronger. Those with the highest levels of lycopene were 59 percent less likely to have a stroke than those with the lowest levels.\n\u201cThis study adds to the evidence that a diet high in fruits and vegetables is associated with a lower risk of stroke,\u201d said study author Jouni Karppi, PhD, of the University of Eastern Finland in Kuopio. \u201cThe results support the recommendation that people get more than five servings of fruits and vegetables a day, which would likely lead to a major reduction in the number of strokes worldwide, according to previous research.\u201d", "answer": 0}, {"article": "For example, many hips and knees use a combination of metal and polyethylene parts, and continuous motion can wear away small polyethylene particles.\nThat said, some patients are determined to push the envelope, and some doctors give their blessing.\n\"Pre-hab\"\u2014building up strength before the surgery\u2014is just as important as re-hab afterward, they say.\nThe biggest variable is patients themselves.\nPatients say that regaining function after surgery requires enormous mental and physical effort.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story did not appear to rely on a press release.\n\u00a0\n", "answer": 1}, {"article": "I didn\u2019t even know I had cancer until after the surgery to remove the tumor,\u201d Hopper told NBC News.\nThe Duke team tested 61 glioma patients over five years.\n\u201cThe average survival rate for all malignant brain tumor patients is only 34.7 percent,\u201d the group says.\nThese patients have a \u201cdismal\u201d prognosis, the Duke team wrote in the New England Journal of Medicine.\nJust 14 percent were still alive two years after diagnosis and 4 percent were alive three years later.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story does not rely on a Duke news release although it does mimic the news release\u2019s cause-and-effect framing.", "answer": 1}, {"article": "Prostate cancer cells express up to 100 times more PCA3 RNA than do normal cells.\nThe PSA test detects prostate-specific antigen, a protein given off by all prostate cells.\nThe test, which is approved in some European countries but not in the U.S., detects genetic material -- RNA -- from prostate cancer gene 3 or PCA3.\nThe PCA3 test can do things the PSA test can't, says Jack Groskopf, PhD, of Gen-Probe Inc., which manufactures the test and funded the new research.\nBut it improves the ability to diagnose prostate cancer, Groskopf says.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\u00a0The story reported that the information it contained was based on a presentation that occurred prior to the start of the 2010 Genitourinary Cancer Symposium. \u00a0It does not appear to include information from independent sources. This is news coverage via news conference \u2013 far from best practice. \n", "answer": 0}, {"article": "Barley reduced both low-density lipoprotein, or LDL, and non-high-density lipoprotein, or non-HDL, by seven per cent.\nDespite its benefits Dr. Vuksan said barley is not as well-established as some other health-recommended foods -- such as oats.\nThe research review, published today in The European Journal of Clinical Nutrition, included 14 studies on clinical trials conducted in seven countries, including Canada.\nIt is the first study to look at the effects of barley and barley products on both LDL and non-HDL cholesterol in addition to apolipoprotein B, or apoB, a lipoprotein that carries bad cholesterol through the blood.\nHowever, Dr. Vuksan's research and work focuses on how dietary and lifestyle changes can reduce these risk factors.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t engage in sensationalist or unjustified language.", "answer": 1}, {"article": "Oral and injectable medications are also prescribed.\nHowever, previous research led by Dr. Zhovtis-Ryerson's group found extending the dose up to 8 weeks did not negatively affect the medication's efficacy in a retrospective sample of 2,000 people.\nThe results showed clinically and statistically significant risk reductions with all definitions.\nThe findings could influence how neurologists prescribe the medication.\n\"Our safety findings are clinically and statistically significant, and we believe that extending the dosing schedule of natalizumab is practice changing and may save lives.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release goes over-the-top in claiming that this preliminary study (whose data are not even released in a peer-reviewed journal) is \u201cpractice changing and may save lives.\u201d", "answer": 0}, {"article": "Dr. Gaetan Michel, Chief Executive Officer of Volition's wholly-owned subsidiary, Belgian Volition SPRL, commented, \"We would like to thank the Walloon Region for their continued support of the company.\nIf these results are validated in larger trials, they will present a potentially significant new market opportunity.\nVolition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties.\nBased on this data, we believe that this test could assist clinicians in more accurate patient selection for prostate biopsy and treatment and substantially reduce the amount of unnecessary procedures in men with low-grade tumors or no tumor.\nThese forward-looking statements relate to the effectiveness of Volition's bodily-fluid-based diagnostic tests as well as Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and/or other disease applications.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release highlights the test\u2019s \u201c94% accuracy\u201d in the headline and text but only after reading the entire release does it become clear that this is very preliminary work, and the claim is unjustified.", "answer": 0}, {"article": "\"The truth is that quit smoking programs, like other programs that treat addictions, often have fairly low success rates. But that doesn't mean they're not worthwhile or that you should be discouraged. Your own success in quitting and staying that way is what really counts, and you have some control over that. Even if you don't succeed the first few times, keep trying. You can learn from your mistakes so that you'll be ready for those pitfalls next time.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Despite the lack of original comments, this LA Times article does not appear to be based on any news releases we found online.", "answer": 1}, {"article": "Prostate cancer begins when cells in a man\u2019s prostate gland mutate and start to grow uncontrollably.\nThis procedure is the first in the world that is precise enough to potentially avoid negative ramifications like urinary incontinence or sexual impotency.\n\u201cThe side effects of current prostate cancer treatments can be extremely traumatic.\nThe fusion of MRI and ultrasound imaging technology that we use to accurately identify and diagnose the cancer, combined with the extreme precision of the gold nanoshells in targeting the diseased cells, allows us to be incredibly accurate at obliterating them.\nI am excited as we continue tracking the progress of this groundbreaking improvement to prostate cancer care.\u201d\n\nDoug Flewellen, the first patient in Texas to receive the new method of care, says for him, the procedure was a no-brainer.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "This news release is flush with unjustifiable language including describing gold nanoparticles\u00a0as \u201ctumor-seeking missiles on a mission to remove prostate cancer.\u201d\u00a0 It would be nice to see a description of a cancer treatment that didn\u2019t rely on military metaphors.\nAlso objectionable: \u201cThis procedure is the first in the world that is precise enough to potentially avoid negative ramifications like urinary incontinence or sexual impotency.\u201d\u00a0 Really?\u00a0 What about active surveillance?\n\u201cThis therapy could be life-changing\u2026.\u201d True. But where is the evidence to justify that claim?\nWhile patients are entitled to their own opinions and beliefs, the news release has some over-riding responsibility to offer context. The patient said:\u00a0 \u201cI wasn\u2019t afraid to try the most cutting-edge technology.\u201d \u00a0But the release could have explained that patients should always be aware that there are risks in participating in trials involving experimental treatments.", "answer": 0}, {"article": "\u201cThe weight that it takes them one year to lose is typically back in two months,\u201d often because a body with longstanding obesity defends itself against weight loss by drastically reducing its metabolic rate, an effect not seen after bariatric surgery, which permanently changes the contours of the digestive tract.\n\u201cI haven\u2019t come across a patient yet who wouldn\u2019t recommend it,\u201d Dr. Twells said in an interview.\nIn reviewing studies that followed patients for five to 25 years after weight-loss surgery, Dr. Twells and colleagues found major long-lasting benefits to the patients\u2019 health and quality of life.\n\u201cMost say they wish they\u2019d done it 10 years sooner.\u201d She explained that the overwhelming majority of patients who undergo bariatric surgery have spent many years trying \u2014 and failing \u2014 to lose weight and keep it off.\nMatched with comparable patients who did not have surgery, those who did fared much better physically, emotionally and socially.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to be based on a news release.\n\u00a0", "answer": 1}, {"article": "NEW YORK -- Scientists acknowledged that an HIV vaccine recently tested in Thailand may be less effective than they originally suggested, but said it still provided valuable leads for further research.\n\nWhen first publicly disclosing the outcome of the vaccine trial in September, researchers said the vaccine had lowered the risk of infection by about 31%. That result was modest but statistically significant. Coming after two decades of failed HIV-vaccine trials, the announcement was welcomed by researchers around the world.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to be based on a press release. ", "answer": 1}, {"article": "New research is helping Pfizer Inc. build a case for getting an important drug in its portfolio approved to treat a mysterious pain condition that could offer a big additional source of sales.\n\nThe New York drug maker said Tuesday that Lyrica, already on the market to treat certain types of pain, reduced painful symptoms among sufferers of fibromyalgia, a chronic and controversial condition that may affect as many as six million Americans. And today, it will unveil results from another study that it says shows Lyrica has a lasting...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can't be sure if the story relied solely or largely on a news release. However the story used the same statistics that appeared in a Pfizer news release about the estimated number of Americans with fibromyalgia, and the numbers presented in the article for the data presented at the American Academy of Neurology meeting.", "answer": 2}, {"article": "Anthony's asthma diminished over time, and he says he can still play soccer, run fast and breathe \"just fine.\"\nThe severity of this and the other two problems that turned up as a result of the abnormal EKGs are reason enough, Debauche says, to screen all school athletes nationwide.\nDebauche says the heart screening turned out to be life-saving for this student athlete.\nThe student now has an implantable defibrillator and is awaiting a heart transplant.\nThere's no official policy from the American College of Cardiology, but officials say most members support screening student athletes.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes two interviews and does not rely unduly on any news release that we could identify.", "answer": 1}, {"article": "Dr. Stehling is a German Professor of Radiology, a former Associate Professor at Boston University and served as Research Assistant to Sir Peter Mansfield, Prof of Physics and Nobel Prize winner in Medicine in 2003 (for discoveries concerning magnetic resonance imaging).\nDr. Stehling has treated the most prostate cancer patients in the world using this image guided treatment, while generating the best therapeutic results.\nThe study which was conducted at the Prostata Center of Offenbach, Germany (www.prostate-center.org) will be presented today at the annual meeting of the Radiological Society of North America (RSNA).\nFor the study, Dr. Stehling and his team of researchers evaluated data from 265 patients with primary (stages T1-T4) and recurrent PCa after surgery, radiation therapy and HIFU.\nCHICAGO, Dec. 2, 2015 /PRNewswire/ -- An analysis of clinical data from over 200 patients treated by Dr. Michael Stehling found that a new procedure that uses MR and ultrasound to guide treatment to the precise tumor location allows for faster recovery times and lower side effects in all stages of prostate cancer.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There are a few sentences in this release that we can\u2019t confirm and sound unjustifiable. Here are two examples, with our comments in italics.\n\u201cDr. Stehling has treated the most prostate cancer patients in the world using this image-guided treatment.\u201d\nWe would have preferred the number of patients he has treated, rather than \u201cmost in the world.\u201d\n\u201cData found that the most common side effects are either eliminated or greatly reduced using image-guided treatment.\u201d\nWe believe you can\u2019t claim both \u201celiminated\u201d and \u201creduced\u201d at the same time. It is one or the other.", "answer": 0}, {"article": "\"So we thought, 'What if we change that by injecting the therapy drug into the metastatic lesions and change the microenvironment of the cancer?'\nThe research showed that using the immunotherapy drug pembrolizumab and the experimental agent SD-101, a sequence of nucleic acids that mimics a bacterial infection, altered the microenvironment around the tumor in a way that enabled the immune system to more effectively attack the cancer.\nThe research was an early-stage study, conducted to test the side effects and best dosage of a potential new combined therapy, and the findings were published today in the journal Cancer Discovery.\nThe study was funded by Dynavax Technologies Corp., which provided SD-101.\nThe study highlights the need for more research into combination therapies like this one, because many people with cancer do not respond to immunotherapy or experience a reoccurrence of their tumors after treatment.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The headline \u201cshows promise for beating advanced melanoma\u201d is more wishful thinking than based on what the study was designed to do\u2013and found. There is also no way of knowing if the \u201cnew treatment is more effective,\u201d as the subheadline states. This was not a randomized trial. And there is absolutely no evidence that \u201cit could help some people with advanced melanoma, an aggressive form of skin cancer, live longer.\u201d", "answer": 0}, {"article": ".\n\"High-frequency ultrasound provides almost microscopic resolution and enables us to get size, shape and extent of the lesion prior to biopsy.\"\nThe researchers performed biopsies on the 134 solid lesions they detected.\nDr. Eliot L. Siegel, vice chairman of the radiology department at the University of Maryland School of Medicine in Baltimore and the study's lead author, said in the news release that \"dermatologists tend to biopsy any lesions that seem visually suspicious for disease.\"\nThey also calculated the elasticity ratio of the lesions and adjacent normal skin and used laboratory analysis to confirm their diagnoses.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story appears to lift content directly from the Radiology Society of North America\u2019s press release, available at: http://www.rsna.org/Media/rsna/RSNA09_newsrelease_target.cfm?id=441. Not only are the same numbers used in the story as the press release, but the same quotes and very similar text are used in both. The story gives no evidence of any independent reporting other than reading the press release to generate the story.\n", "answer": 0}, {"article": "MRI highlights angiogenesis, the formation of new blood vessels, especially those that feed cancerous tissues.\nHowever, still more research is needed to clarify the role of MRI in this population, she said.\nWhile the society recommends neither for nor against MRI imaging for those with a personal history of breast cancer, he said it regularly reviews study findings to determine if the guidelines need updating.\nDeMartini was scheduled to present the findings Sunday at the annual meeting of the Radiological Society of North America in Chicago.\nOverall, the MRI detected 25 of 27 cancers, DeMartini said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\n\nThe story includes a comment from an independent expert, so it\u2019s clear that it didn\u2019t rely solely on a news release.\n", "answer": 1}, {"article": "CAM2038 has the potential to alter the current treatment paradigm for opioid dependence,\" said Sharon Walsh, Ph.D, Professor of Behavioral Science and Director of the Center on Drug and Alcohol Research, University of Kentucky, \"Because of its long acting properties, CAM2038 may decrease patient and physician burden, improve access to treatment, and obviate public health concerns about illicit diversion of buprenorphine.\"\nFurthermore, CAM2038 was well tolerated across the course of treatment.\nThe CAM2038 products are designed for administration by healthcare personnel to ensure proper delivery that minimizes the risks of diversion, abuse, misuse, and accidental exposure.\nFour more trials, including two Phase 3 studies, are currently ongoing.\nCamurus' clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release doesn\u2019t use overly promotional or inexact language.", "answer": 1}, {"article": "Frustrated by the high relapse rate of traditional addiction treatments, scientists are working on a strategy that recruits the body's own defenses to help addicts kick drug habits.\n\nThe new approach uses injected vaccines to block some addictive substances from reaching the brain. If a vaccinated addict on the path to recovery slips and indulges in a drug, such as tobacco or cocaine, no pleasure will result.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story is not based on a news release.", "answer": 1}, {"article": "\"When parents have a child diagnosed with an autism spectrum disorder, one of the first questions they often ask is 'how did this happen?'\nBetween 10 percent and 15 percent of autism cases can be traced to a known genetic cause, the researchers noted.\nBut that leaves 85 percent or more families with little explanation for the disorder, Marion said.\nStandard practice is to offer children with autism two tests as a first-line genetic work-up: karyotype and fragile X testing, the researchers said.\nThe main purpose of genetic testing of children with autism is to help parents determine if they're at a higher risk of having another child with autism, Marion said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "", "answer": 1}, {"article": "On the other hand, it is unclear whether a donor could potentially transmit a disease to the recipient in the process.\nThe phase I results from 53 patients are not definitive proof that the treatment is effective, but do suggest so, Hare said.\nAn area of improvement would be making the stem cell treatment more efficient, he said.\nThis method of intravenous injection means that the procedure theoretically could be performed in a doctor's office or clinic, increasing the accesibility to patients, Karp said.\nThere was no change or increase in side effects in treatments getting higher doses of cells, but it seemed that the treatment was more effective -- at least in terms of reducing electrical problems -- in the high dose group, he said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There\u2019s no evidence that the story relied on a news release. ", "answer": 1}, {"article": "ASTRO publishes three medical journals, International Journal of Radiation Oncology\n\u2022 Biology\n\u2022 Physics (www.redjournal.org), Practical Radiation Oncology (www.practicalradonc.org) and Advances in Radiation Oncology (www.advancesradonc.org); developed and maintains an extensive patient website, RT Answers (www.rtanswers.org); and created the Radiation Oncology Institute (www.roinstitute.org), a nonprofit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment.\n\u201cAfter following patients for more than five years, we found that serious side effects from a brief course of SBRT were uncommon and that cancer control rates were very favorable compared to historical data.\nBiochemical failure was assessed using the ASTRO-consensus and the nadir+2 definitions.\nFewer than two percent of all patients experienced serious side effects in the five years following SBRT.\n\u201cSingle-institution studies on the use of SBRT as the primary treatment for prostate cancer have illuminated the treatment as a cost-effective and faster alternative to IMRT,\u201d said Robert Meier, MD, lead author of the study and a radiation oncologist at Swedish Medical Center in Seattle.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release does not contain any unjustifiable or sensational language. But as noted above, the favorable results in terms of benefit are not surprising and attributing them to the treatment could be viewed as unjustified. ", "answer": 1}, {"article": "The beneficial effects of traditional acupuncture, according to the researchers, did not appear to be associated with changes in levels of hormones that trigger menopause and its associated symptoms.\nAfter 10 weeks, the women in the traditional acupuncture group had significantly less severe hot flashes and mood swings than those who'd gotten the fake treatment.\nThe research included 53 postmenopausal women, with about half receiving traditional Chinese acupuncture twice a week and the others given sham acupuncture treatments.\nThe findings were published online March 7 in Acupuncture in Medicine.\nThough the researchers acknowledged that they did not monitor how long symptom relief lasted, they suggested that traditional acupuncture may offer an alternative for women who can't or don't want to use hormone replacement therapy to ease menopause symptoms.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story admits that its source was a journal news release.\u00a0 A for honesty.\u00a0 F for independent journalism.", "answer": 0}, {"article": "Broccoli has been linked to a growing list of health benefits, such as a reduced risk of cancer and osteoporosis. New research suggests consuming broccoli could also slow or reverse blood-vessel damage and atherosclerosis due to high cholesterol.\n\nThe study, in Experimental Biology and Medicine, found that a high-cholesterol diet combined with supplements containing sulforaphane, a natural compound in cruciferous vegetables such as broccoli and Brussels sprouts, significantly reduced levels of LDL, the so-called bad cholesterol,...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We could not locate a news release related to this research article, although it seems implausible that WSJ reporters are scouring obscure research journals such as this one for story ideas. But while we have no evidence that the story relied excessively on any news release, we\u2019re hesitant to give credit because there\u2019s no evidence of original reporting. We\u2019ll rate this Not Applicable.\n\u00a0", "answer": 2}, {"article": "In 2015, he was ranked the No.\nThe researchers selected 69 as the lower age limit because Medicare coverage of the general population begins at age 65, and the exposure of interest was regular mammography screening in the four years immediately preceding breast cancer diagnosis.\nAlthough many guidelines rely on self-reports, Hennekens and his collaborators from Baylor College of Medicine and Meharry Medical College, used the Surveillance, Epidemiology, and End Results (SEER) program file linked to the Medicare administrative claims file, which allowed them to identify screening mammography use from 1995 to 2009 from 64,384 non-Hispanic women (4,886 black and 59,498 white).\nFAU is ranked as a High Research Activity institution by the Carnegie Foundation for the Advancement of Teaching.\nIn 2013, he received the \"Fries Prize for Improving Health\" and in 2014, he received the Alton Ochsner Award for his pioneering work on smoking and health.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Aside from the fear-inducing litany of statistics found in the first paragraph (addressed under the Disease Mongering criteria), the rest of the release is free of unjustifiable language.", "answer": 1}, {"article": "Zied is also the author, with Ruth Winter, of a book titled \"So What Can I Eat?\"\nNow, there's new information showing how important folic acid is.\nIt's a tremendous challenge for parents to teach their teenagers and \"tweens\" everything they ought to know.\nBut a few small lessons now can turn out to be valuable later in life.\nDr. Emily Senay discussed it on The Early Show Tuesday.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can't be sure if the story relied solely or largely on a news release. ", "answer": 2}, {"article": "Atopic dermatitis is the most common of the many types of eczema; onset typically begins in childhood and can last through adulthood.\nThe safety and efficacy of Dupixent have not been established in the treatment of asthma.\nThe FDA granted the application for Dupixent Priority Review and Breakthrough Therapy designation.\nDupixent is administered as an injection under the skin.\nThe most common side effects include injection site reactions; cold sores in the mouth or on the lips; and eye and eyelid inflammation, including redness, swelling and itching.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release does not use any unjustifiable language.", "answer": 1}, {"article": "So does cardiologist Roger Blumenthal, who heads the Ciccarone Center for the Prevention of Heart Disease at Johns Hopkins.\nIt's important to note that statin drugs are generally safe, and harms are uncommon.\nAnd it is only useful as a screening test for people who haven't had heart disease.\nYet that kind of dialog is increasingly the expectation.\nThey worry that it will trigger overtreatment of conditions that the scan will pick up, but which don't require urgent attention.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There was a good range of interviewees with no reliance on a news release", "answer": 1}, {"article": "Some doctors are raising concerns about a new cancer-treatment device that uses electrical jolts to zap tumors but that hasn't been through a large clinical trial to prove it's safe and effective in people.\n\nThe device, called NanoKnife, is currently being used in about 13 U.S. hospitals including Baptist Health Medical Center in Little Rock, Ark., University of Louisville, and Shands Hospital/University of Florida in Gainesville, Fla. Each machine costs as much as $300,000. Some of the hospitals are aggressively promoting...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story does not rely on a news release.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - In a small study, people who had chronic pain as a result of damage to the nervous system reported feeling less pain, as well as less depression and anxiety, when they smoked marijuana compared to when they smoked a drug-free placebo.\nDuring each treatment, participants were asked about their pain, sleep patterns, mood, and overall quality of life.\n\u201cThese need to be considered before the drug becomes prescribable.\u201d\nMost patients did not report feeling \u201chigh\u201d at any point during the study.\nThe study\u2019s five-day treatment sessions also leave questions about patients with chronic conditions who might need treatment for months or years.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story goes well beyond the release.\u00a0Here\u2019s the release.", "answer": 1}, {"article": "New Rochelle, NY, June 19, 2017-A pilot feasibility study to determine if young children with autism spectrum disorder (ASD) and their parents would tolerate and adhere to an office- and home-based acupuncture/acupressure intervention showed completion of all 16 biweekly sessions and measurements of their effects before, during, and after the protocol.\nThe study design and results, which suggest further controlled studies of this intervention approach in ASD, are published in the Journal of Alternative and Complementary Medicine (JACM), a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.\nCoauthors Lana Warren, EdD, OT/L and Patricia Rao, PhD, Kennedy Krieger Institute, Baltimore, MD, and David Paton, DAc, LAc, Starting Point Acupuncture and Health Services, Catonsville, MD, identified the most positive outcome of the study as the high compliance rate, with all parents of the children ages 3-10 completing the intervention.\nIn the article entitled \"A Pilot Observational Study of an Acupressure/Acupuncture Intervention in Children with Autism Spectrum Disorder,\" most parents reported that the intervention had a positive impact on their relationship with their child.\nA complete list of the firm's more than 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t rely on sensational language. We do caution that when a news release includes a quote that says a study offers \u201chopeful signs for families,\u201d it should be obvious why those families should be hopeful. This release doesn\u2019t do that, because it is not clear how or whether these patients were better off at the end of the study than they were at the beginning. It\u2019s not as egregious as releases (or news stories) that claim amazing results based on limited data, but no release (or news story) should leave readers no wiser at the end than they were at the beginning.", "answer": 1}, {"article": "For men, the difference came out to 103 fewer cancer deaths a year per 100,000 people; for women, the number was 42.\nBecause the study wasn\u2019t a clinical trial, it\u2019s hard to know if the findings can be chalked up to aspirin or if something else is at play.\nOne of the problems with the new study as well as with previous aspirin trials, he said, is something called detection bias.\nAnd the final chapter on the popular but controversial drug has yet to be written, experts say, because like earlier research the new work has considerable limitations.\nBut he added that it will take scientists a few years to mull over all of the existing evidence.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely on a news release.", "answer": 1}, {"article": "Can a high-tech scan reveal whether Alzheimer's disease is the cause of your forgetfulness? Advocates of Positron Emission Tomography scans for the diagnosis of Alzheimer's say the scans significantly aid in the early and accurate diagnosis of the memory-robbing disease. Neurologists say PET is useful in distinguishing between Alzheimer's and a similar-acting dementia. However, opinions differ on whether the scans are useful in predicting the likelihood of Alzheimer's in people with only mild memory problems.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if the story relied on a press release. However, given that sources from several institutions were interviewed, it appears that independent reporting took place.", "answer": 1}, {"article": "\"When people have serious injuries, whether from accidents or violence, and when they have severe hemorrhage they can bleed to death.\nIn fact, a trial to see whether TXA can reduce postpartum bleeding has started, the team noted.\n\"I think people should consider it [TXA] following trauma on the basis of this study,\" he said.\nLevy however, cautioned that the results of this study apply only to TXA and do not mean that people should try similar drugs hoping for similar results.\nDr. Jerrold H. Levy, deputy chair for research at Emory University School of Medicine in Atlanta and author of an accompanying journal editorial, said that, \"these data are really neat, because any therapy to reduce mortality in trauma is, I think, a major finding.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story quotes\u00a0two expert sources, one of whom was not mentioned in the press release issued to promote\u00a0the study. This is enough to rule out the possibility that the story was based entirely on a release.", "answer": 1}, {"article": "Recently, he says, urologists \"have begun to realize these criteria are not adequate.\nThey say what's really needed is a set of tests that classify prostate tumors by what genes are turned on or off in the cells.\nEven so, Andriole says, the findings may not make too much difference in the real world.\nOnce this is sorted out, doctors treating prostate cancer will be less like the blind men who try to guess what kind of creature they're dealing with when they grasp the elephant's trunk or tail.\nThe new study discrediting the test, coupled with persistent questions about how useful prostate screening is for most men anyway, add up to a whole lot of discussion points patients should take to their doctors.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not appear to rely solely on a news release.", "answer": 1}, {"article": "\u201cEven though this is still lab-based ... it validates the idea of developing small molecules against epigenetic switches,\u201d he said in an emailed comment.\nIn a study published in the journal Nature, scientists from the British drugmaker collaborating with the charity Cancer Research UK (CRUK) and Cellzome AG found that the experimental drug, called I-BET151, mimics a chemical tag which is key to preventing the process of activating the leukemia genes.\n\u201cWe urgently need better ways to treat children with more aggressive forms of leukemia, such as MLL,\u201d said Lesley Walker, CRUK\u2019s director of information.\nUsing I-BET151 to treat leukaemias in mice and human cancer cells in a lab, the researchers found that the chemical could halt the disease, paving the way for more research to be done in first-stage, or so-called Phase I, human trials.\n\u201cThis ... is an exciting new avenue for drug discovery which we hope will be useful for other types of cancer in addition to MLL-leukaemias,\u201d said Tony Kouzarides of the Wellcome Trust/CRUK Gurdon Institute at Cambridge University, who co-led the study.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The following entire phrases/sentences of the Reuters story are lifted verbatim from a Cancer Research UK news release:\n\u201cMLL leukaemia is thought to account for up to 80 per cent of children below two years of age diagnosed with acute leukaemia, and up to one in 10 cases in adults. Most patients don\u2019t respond well to standard leukaemia treatments and often the cancer comes back.\nThe disease is caused when a gene called MLL gets fused to another gene. This disrupts the normal function of MLL by creating a new \u2018fusion protein\u2019 that behaves inappropriately, switching on genes that drive the development of leukaemia. \u2026 MLL-fusion proteins are targeted to leukaemia-causing genes by proteins from the BET family, which recognise certain chemical \u2018tags\u2019 on chromatin, the scaffold on which DNA is organised.\u201d\nAnd this quote from Dr Lesley Walker, Cancer Research UK\u2019s director of cancer information, was also used verbatim in the Reuters story:\n\u201cwe urgently need better ways to treat children with more aggressive forms of leukaemia, such as MLL. Although this research is only in the lab at the moment, we hope it will move quickly towards clinical trials in patients.\u201d", "answer": 0}, {"article": "A total of 117 clusters (or \"rings\") were identified, each made up of an average of 80 people.\nThe vaccine is the first to prevent infection from one of the most lethal known pathogens, and the findings add weight to early trial results published last year.\nMerck has also submitted the vaccine to WHO's Emergency Use and Assessment Listing procedure, a mechanism through which experimental vaccines, medicines and diagnostics can be made available for use prior to formal licensure.\nTo assess safety, people who received the vaccine were observed for 30 minutes after vaccination, and at repeated home visits up to 12 weeks later.\n[1]\n\nThe vaccine, called rVSV-ZEBOV [2], was studied in a trial involving 11,841 people in Guinea during 2015.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The Lancet news release eschews sensational language in reference to either Ebola or the vaccine.\u00a0However,\u00a0the statement that there was a dramatic effect (0 deaths vs 23 deaths)\u00a0suggests that this is a super vaccine and perhaps too good to be true. ", "answer": 1}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nEfficacy of Intrarosa, a once-daily vaginal insert, was established in two 12-week placebo-controlled clinical trials of 406 healthy postmenopausal women, 40 to 80 years of age, who identified moderate to severe pain during sexual intercourse as their most bothersome symptom of VVA.\nIntrarosa, when compared to placebo, was shown to reduce the severity of pain experienced during sexual intercourse.\nThe U.S. Food and Drug Administration approved Intrarosa (prasterone) to treat women experiencing moderate to severe pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.\nThe safety of Intrarosa was established in four 12-week placebo-controlled trials and one 52-week open-label trial.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release does not use unjustifiable, sensational language. The single quote from the FDA spokesperson also contains neutral, measured language.", "answer": 1}, {"article": "When symptoms abate and they feel better, they may go all out, exercising, doing errands and socializing.\nAll of them received medical care for symptoms like pain, insomnia or anxiety.\nShe's skeptical about the Lancet study, pointing out that patients improved only moderately, and not much more than those who were counseled about pacing themselves.\nAnd a third received the cognitive behavioral talk therapy.\nBut he cautions against overdoing it.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not rely on a news release.", "answer": 1}, {"article": "Each year, almost 800,000 Americans suffer a stroke, and more than 140,000 die.\nThe death rate in the trial was very low, but risks varied depending on the procedure.\nDr. Walter J. Koroshetz, deputy director of the institute that sponsored the North American trial, said the Crest trial was the first in which the results of stenting and surgery had been found to be equivalent \u2014 suggesting that the stent procedure had improved with time.\nMost of the patients had an artery blockage greater than 70 percent.\nThe most important message is that the overall death rate was extremely low, 0.6 percent, said one of the study\u2019s principal investigators, Dr. Gary S. Roubin, the chairman of cardiovascular medicine at Lenox Hill Hospital in New York.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story is not based on a press release.", "answer": 1}, {"article": "No one knows why some women have this capability and others do not, but for those who lack it the Inovio vaccine is \"giving our immune system a little boost,\" Kim said.\nGiven those drawbacks, it\u2019s not appropriate to draw too many conclusions from this study, says Dr. Diane Harper, a prominent HPV researcher at the University of Missouri \u2013 Kansas City\u2019s School of Medicine.\nThe vaccine consists of three injections in the arm over three months, Kim said.\nThis happens in anywhere from 10% to 25% of women infected with HPV, Kim said.\nThe vaccine trains T-cells in the body to go after cervical cells with potentially cancerous genes embedded in them.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a press release.", "answer": 1}, {"article": "The way it works: A doctor draws a vial of your blood and separates it into its key components, the red blood cells, the clear serum and the platelets. The physician then adds vitamins and amino acids to the mix, and the enriched serum is injected into your face.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We don\u2019t know if the story relied on a news release, but we do know the story was lifted from the UK Daily Mail.\u00a0 There is no evidence of any independent reporting. ", "answer": 2}, {"article": "Fat tissue has been linked to higher levels of damaging metabolic stress compounds, so losing weight and becoming more fit may create more hospitable conditions for sperm and improve its quality and volume.\nNow, researchers publishing in the journal have found that another lifestyle change\u2014exercise\u2014may also help improve sperm quality.\nThey wanted to see what effect different types of exercise, and different intensity activity, had on sperm quality and count.\nIn the current study, the men in the moderate intensity, continuous activity program showed the most improvements compared to men in the other two more intense groups.\nThere are already plenty of reasons to exercise, and now better quality sperm is one more worth noting.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no indication that this story relied on a news release.", "answer": 1}, {"article": "An experimental drug has proved effective at treating an aggressive form of breast cancer in patients who aren't responding to the widely used drug Herceptin, giving hope to women with otherwise limited treatment options, said drug maker GlaxoSmithKline PLC, presenting the results Saturday at the American Society of Clinical Oncology meeting in Atlanta.\n\nWhen taken with a standard chemotherapy treatment in a clinical study, the new drug, Tykerb nearly doubled the time to 8.5 months before the average patient's breast cancer...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story acknowledges that it took a quote from the principal investigator from a statement released by the drug company. The only other perspective in the story comes from a drug company staff scientist. There is no evidence of any independent reporting. ", "answer": 0}, {"article": "Researchers from Norway and Harvard University compared the death rates from breast cancer in four groups: one group of women from 1996 through 2005 who were living in Norwegian counties with screening; another group in the same time period who were living in counties without screening; and two similar groups from 1986 through 1995.\nIt concluded the availability of mammography screening corresponded with a reduction in the rate of death from breast cancer, \"but the screening itself accounted for only about a third of the total reduction.\"\n\"Among women in the nonscreening group, there was an 18 percent reduction in the rate of death from breast cancer, as compared with the preceding 10-year period, presumably as a result of increased breast-cancer awareness, improved therapy, and the use of more sensitive diagnostic tools,\" the findings state.\nThe publication notes that in 2002, the World Health Organization concluded that mammography screening for women between ages 50 and 69 reduced the death rate from breast cancer by 25 percent.\nThe study, published in the New England Journal of Medicine, analyzed data from more than 40,000 women with breast cancer.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "", "answer": 1}, {"article": "\"Women should recognize that CAD comes with some potential risks,\" Fenton said.\nOne limitation of the study, he said, is that the researchers cannot say for sure it was the computer-aided detection that made the difference.\nThe additional tests that turn out to be unnecessary, because no cancer is found, are not desirable, he said.\nNow, with about 75 percent of mammograms adding it, it is even more common, Fenton said.\nDr. Daniel Kopans, a professor of radiology at Harvard Medical School and senior radiologist in the breast imaging division at Massachusetts General Hospital, said the study provides additional information to doctors and women, but has some limitations.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "By including quotes from the lead author & from an independent source, the article clearly has not relied solely on a press release.", "answer": 1}, {"article": "Psoriasis is a chronic condition that causes an overproduction of skin cells, resulting in inflamed, red lesions or plaques, which can be itchy and painful.\nOn a media briefing following the release of J&J\u2019s trial results, Novartis said it expected the data to have \u201climited clinical relevance\u201d and no impact on plans to expand the Cosentyx label.\nAbout 7.5 million Americans live with plaque psoriasis, of which 20 percent have moderate-to-severe form of the disease, J&J said.\n\u201cThese results imply that Cosentyx remains a good option for moderate-to-severe psoriasis patients that want to achieve more rapid skin clearance,\u201d brokerage Jefferies wrote in a note following the results.\nJ&J is positioning Tremfya as a better alternative to Cosentyx as it seeks to take market share away from Novartis\u2019s drug, which was launched two years ago and is among the top-selling treatments in the $11 billion global psoriasis market.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The only quote used is drawn directly from the news release, without attribution.", "answer": 0}, {"article": "U.S. prisons are experimenting with a high-priced monthly injection that could help addicted inmates stay off opioids after they are released, but skeptics question its effectiveness and say the manufacturer has aggressively marketed an unproven drug to corrections officials.\nThe drug\u2019s manufacturer hopes prisons will be the gateway to a larger market.\nWhen the injections stopped, many in the study relapsed.\nThe drug has no street value or abuse potential.\nThe results, published in March in the New England Journal of Medicine, have been promoted by the drugmaker, Ireland-based Alkermes, as it markets Vivitrol to U.S. correctional systems.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This appears to be an enterprise story, with as strong a focus on the cautionary aspects of Vivitrol\u2019s use in prisons as on the drug\u2019s potential benefits.", "answer": 1}, {"article": "Their systolic blood pressure, which was in the normal range when the study began, dropped by 4.5 mmHG, while their diastolic blood pressure dropped by 3.1 mmHg.\nPeople in the second group were placed on a three-month test of the fasting-mimicking diet.\nIn effect, the diet reduced the study participants' risks for cancer, diabetes, heart disease and other age-related diseases, according to the findings published Feb. 15 in Science Translational Medicine.\nThe phase II trial, conducted by researchers at the USC Leonard Davis School of Gerontology, demonstrated a host of benefits from the regimen.\nThe researchers said further investigation will determine whether the benefits of the diet can continue for several months.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t engage in sensational language but its headline is problematic. It promises that a diet lowers risks for major diseases. A researcher later contradicts that claim by saying this early study only shows safety.\n\u201cBut this is the first randomized clinical trial with enough participants to demonstrate that the diet is feasible, effective and safe for humans.\nLarger FDA studies are necessary to confirm its effects on disease prevention and treatment,\u201d he added.\u201d\nCalling for \u201clarger FDA studies\u201d may also be misconstrued by some readers. The FDA does not conduct clinical trials. Rather, it has internal and advisory experts that assess the validity of trials as part of its approval process.", "answer": 0}, {"article": "Amgen reported just $40 million in third-quarter sales.\nNo new safety problems cropped up in the 27,500 patient study called Fourier, Amgen said.\nThe company said Repatha would be well on its way to becoming a $1 billion seller if all prescriptions written had been filled.\nThe primary goal also included need for a new artery-clearing procedure and hospitalization for angina.\nBut those who control budgets wanted concrete proof that the drug could actually reduce the risk of heart attacks and death before making it easier for patients to get the medicine.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story contained some information not found in the news release, such as the cost of the drug, so some original reporting was done. See our review of the news release.", "answer": 1}, {"article": "As myelin damage continues over the course of the disease, neurons progressively lose their ability to reliably transmit electrical signals, resulting in progressive loss of vision, weakness, walking difficulties, and problems with coordination and balance.\nIn light of previous laboratory studies of the antihistamine compound at UCSF, the researchers said, the drug most likely exerted its effect by repairing damage MS had inflicted on myelin, an insulating membrane that speeds transmission of electrical signals in the nervous system.\nThe new results are particularly notable, Chan said, because patients in the trial had suffered from MS symptoms caused by injury to myelin for years.\nThe researchers said that the Phase II results, published online on 10 October, 2017 in The Lancet, are the first in which a drug has been shown to reliably restore any brain function damaged by a neurological disease in human patients.\nThe drug tested in the trial, clemastine fumarate, was first identified as a candidate treatment for MS in 2013 by UCSF's Jonah R. Chan, PhD, Debbie and Andy Rachleff Distinguished Professor of Neurology, vice chief of the Division of Neuroinflammation and Glial Biology, and senior author of the new study.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The headline (\u201cAllergy drug improves function in patients with chronic injury from multiple sclerosis\u201d) may be misleading to some readers since improving function in the usual sense implies a clinical benefit and that is clearly not the case here.The study did not report on improvements in loss of coordination or balance and other common symptoms of the disease.\nThe very specialized laboratory test used to measure the speed of visual transmission did show an improvement in a surrogate for the disease, but not as claimed in another sentence as \u201crestores nervous system function in patients.\u201d \nAside from that, the news release avoids unjustifiable, sensational language and, instead, continually warns readers that this drug is \u201cnot a cure.\u201d", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070225/5disease.htm was not found on this server.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no way to know if the story relies on a press release as the sole source of information.", "answer": 2}, {"article": "Researchers at the University of Colorado and University of Michigan studied some of the same risk models used by the U.S. Preventive Services Task Force (USPSTF) to issue controversial breast screening guidelines in 2009.\nShe said breast mammograms have contributed significantly to reducing deaths from breast cancer, a fact that should not be ignored in favor of mathematical models.\nHis team calculated that a woman who gets a yearly mammogram starting at age 40 cuts her risk of dying from breast cancer by 71 percent compared to a 23 percent reduction in risk if a woman followed the task force recommendations.\nWhen they were issued, the task force\u2019s guidelines contradicted years of messages about the need for routine breast cancer screening starting at age 40, kicking off a fury of protest among breast cancer experts and advocacy groups who argued the recommendation of fewer screenings would confuse women and result in more deaths from breast cancer.\nBut Helvie and colleague Edward Hendrick of the University of Colorado wrote that \u201cthe USPSTF chose to ignore the science available to them and overemphasized the potential harms of screening mammography, to the serious detriment of U.S. women who follow their flawed recommendations.\u201d\n\nDr. Carol Lee who chairs the American College of Radiology\u2019s Breast Imaging Commission said the new study highlights the risk of setting policy based on the conclusions of one group of scientists.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a news release.\u00a0 It includes quotes from one of the authors of the new analysis and from the chair of the American College of Radiology\u2019s Breast Imaging Commission.", "answer": 1}, {"article": "In postpartum depression, the GABA pathway may play a key role in regulating hormones that researchers believe can lead to PPD.\nSage Therapeutics is the developer of brexanolone injection and sponsor of the trials.\nNewswise \u2014 CHAPEL HILL, NC \u2013 UNC researchers say the results from the multi-site phase 2 and 3 trials of brexanolone injection are not only promising, but could change the way postpartum depression (PPD) is treated.\nThe reduction of symptoms in the patients receiving brexanolone injection was maintained throughout the last study visit at Day 30.\nAnother 107 women were administered a placebo and evaluated during the same timeframe.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There is no unjustifiable language.", "answer": 1}, {"article": "\"We were worried that there'd be too much scar tissue in the retina itself to be able to deliver the material to the correct spot,\" he said.\nBut the most dramatic result brought Manuela one step closer to her dream of reading.\n\"She said 'no problem,' which was probably oversimplified.\nAfter her surgery the difference was dramatic.\nTwo months later, it was time for follow-up assessments.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if the story relied solely or largely on a news release.\u00a0 But we do know that the segment did not include any perspectives from independent experts unaffiliated with the experiments. ", "answer": 2}, {"article": "And tobacco kills one in 10 people worldwide, according to the World Health Organization.\nTo see if Chantix, which is manufactured by Pfizer, could help smokers quit without going cold turkey, Ebbert and colleagues randomly assigned 1,510 people at 61 centers in 10 countries to receive either the drug or a placebo for 24 weeks.\nThey asked study participants to reduce cigarette use by 50 percent by the fourth week, and by 75 percent by the eight week, with the goal of quitting by week 12.\n\u201cThis allows us to reach a much broader population of smokers who aren\u2019t willing to quit abruptly or set a quit date, and it shows that people can quit without going cold turkey,\u201d said lead study author Dr. Jon Ebbert, a professor in primary care and internal medicine at the Mayo Clinic in Rochester, Minnesota.\nOther treatments, such as nicotine patches and gum, can also help some smokers cut back gradually, she said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The release include quotes and additional background material that go well beyond JAMA\u2019s news release on the study.", "answer": 1}, {"article": "Radiology is edited by Herbert Y. Kressel, M.D., Harvard Medical School, Boston, Mass., and owned and published by the Radiological Society of North America, Inc.\n\nRSNA is an association of more than 54,000 radiologists, radiation oncologists, medical physicists and related scientists promoting excellence in patient care and health care delivery through education, research and technologic innovation.\nResearchers said that in some cases MRI findings of additional cancers not seen on mammography may necessitate a change in treatment.\nOf the 2,021 patients, 285, or 14 percent, had additional cancer detected on MRI that was hidden from view on mammography.\nIn addition, the MRI-detected multicentric cancers were greater than 1 centimeter in size in 25 percent of the 73 patients.\n\"The results show that multicentric cancer detected on breast MRI after mammography appears to represent a larger tumor burden in approximately a quarter of patients and can result in potential changes to cancer grade and treatment,\" Dr. Iacconi said.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release is careful to say that preoperative MRI may reveal additional cancers that breast cancer patients and their physicians may want to take into account as they plan treatment.", "answer": 1}, {"article": "The American Orthopaedic Society for Sports Medicine (AOSSM) is the premier global, sports medicine organization representing the interests of orthopaedic surgeons and other professionals who provide comprehensive health services for the care of athletes and active people of all ages and levels.\n\"This type of osteochondral allograft transplantation has traditionally been used in younger active patients with cartilage disorders.\nGreatest changes were seen in the ability of patients to perform Sports and with improvement in healthful daily activity.\nA statistically significant improvement for both groups was noted for the final follow-up for IKDC and all five KOOS sub-scores.\nAOSSM is also a founding partner of the STOP Sports Injuries campaign to prevent overuse and traumatic injuries in kids.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release is very careful to use cautious language, such as noting in the headline that \u201colder patients with knee pain may benefit\u201d [emphasis added] from the relevant treatment technique.", "answer": 1}, {"article": "Currently, most aspects of cataract surgery, including the initial incision and the breakup and removal of the clouded lens from the lens capsule, are performed manually by the surgeon.\nAlthough approved by the FDA, the femtosecond laser procedure is not widely used in the U.S., according to the American Academy of Ophthalmology.\nThe surgery is performed to remove the natural lens of the eye after it has become clouded over time.\n\"If you have a technique to soften the cataract, there appears to be less chance of damage [to the eye ],\" Salz says.\nThat's important because ultrasound can cause collateral damage to the eye, he says.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes commentary from an\u00a0expert who wasn\u2019t involved in either study, so we can be sure it wasn\u2019t based entirely on news releases.", "answer": 1}, {"article": "When Ali Andrew Li was born on Jan. 7, he was gently placed on his mother's chest, where doctors cleaned and examined him and covered him with a warm blanket.\nNot only is the baby happier, she says, but his or her vitals are more stable.\nThat \"magic\" can also happen between baby and father, too, says Gray, if there's skin-to-skin contact.\nAnd if mothers or babies are very sick and have to be isolated, Gray suggests mothers take any opportunity to hold their infant skin to skin.\nAt Ronald Reagan UCLA Medical Center where Ali was born, the technique is routinely practiced for healthy mothers and newborns.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story doesn\u2019t not appear to rely on a news release.", "answer": 1}, {"article": "Among the 620 adults (average age, 71 years; 74 percent women) who were randomized, 96 percent completed the study.\nFurther studies are needed to help identify which patients will not benefit from casting.\nCasting required less operating room time compared with surgery.\nThe researchers add that close contact casting may be an appropriate treatment for older adults with unstable ankle fracture.\nAt 6 months, casting resulted in measures of ankle function equivalent to that with surgery.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release does not rely on sensational or exaggerated language.", "answer": 1}, {"article": "In MS, it\u2019s the fatty protective sheath around the nerves; in type-1 or juvenile diabetes it\u2019s cells in the pancreas that make insulin; in rheumatoid arthritis it\u2019s tissue in the joint.\nIt\u2019s a kind of introduction that familiarizes the T-cells with the body\u2019s normal cells.\nBut polystyrene is no good to use in people.\nIf the treatment was done as soon as the mice had their first MS-like attack, the attacks stopped.\nThese new nanoparticles stopped the course of a MS-like disease in mice, the researchers found.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a press release.", "answer": 1}, {"article": "His \"tactile imaging system\" capitalizes on the fact that cancerous lumps tend to feel harder and less movable than harmless abnormalities such as fluid-filled cysts or fibrous nodules. The fist-sized, $1,000 machine \u2014 with an elastomer probe, a light, and a camera \u2014 acts like ultrasensitive fingertips. It measures the size, elasticity, and mobility of a breast lump, then a computer program converts the data into a score from 1 to 5, with scores under 2 likely to be benign.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure of the extent to which a news release may have influenced this story.\u00a0 As noted, only the developer is quoted.", "answer": 2}, {"article": "Collaborating with Dr. De Giglio were Francesca Tona, M.D., Francesca De Luca, Psy.D., Nikolaos Petsas, M.D., Ph.D., Luca Prosperini, M.D., Ph.D., Valentina Bianchi, Psy.D., Carlo Pozzilli, M.D., Ph.D., and Patrizia Pantano, M.D.\nThe results suggest that video-game-based brain training is an effective option to improve cognitive abilities of patients with MS.\nThe results provide an example of the brain's plasticity, or ability to form new connections throughout life.\n\"This means that even a widespread and common use tool like video games can promote brain plasticity and can aid in cognitive rehabilitation for people with neurological diseases, such as multiple sclerosis.\"\nAt follow-up, the 12 patients in the video-game group had significant increases in thalamic functional connectivity in brain areas corresponding to the posterior component of the default mode network, which is one of the most important brain networks involved in cognition.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release does not appear to use unjustifiable language.", "answer": 1}, {"article": "According to the National Center for Health Statistics, an estimated 25.3 million Americans, or 11.2 percent of U.S. adults, experience chronic pain.\nSo it makes sense that Jay jumped at the chance to experience long-term pain relief with the help of a spinal-cord stimulator.\nShe is hardly alone in her suffering.\nA next-generation implant deep in Jay\u2019s back stimulates her spinal cord, overriding her body\u2019s pain signals to give her some relief from the back pain that has plagued her for years.\nBut she shares a similarity with those characters: Her all-too-human body has been upgraded with a machine.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "With relaxation of the muscles, the distance between the vertebrae returns,\" Dr. Napoli explained.\nNinety percent of the patients were able to avoid surgical treatment.\nOf the 80 patients treated, 81 percent were pain free one year after a single 10-minute treatment session.\nDr. Napoli said no patients experienced side effects after receiving the minimally invasive outpatient treatment.\n\"There's a big gap between conservative treatments for disc compression and herniation and surgical repair, which can lead to infection, bleeding and a long recovery period,\" Dr. Napoli said.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "At one point, the lead investigator Alessandro Napoli, says, \u201cThe results have been extraordinary. Patients have been relieved of pain and resumed their normal activities within a day.\u201d Can we really call these results extraordinary? As noted above, we are talking about results in just 65 patients over just one year.\nThere are a long list of treatments for low back disorders that initially reported results that sounded too good to be true, but weren\u2019t.  ", "answer": 0}, {"article": "He is a professor in the School of Health and Biomedical Sciences at RMIT University in Melbourne, Australia.\nThe study results suggest acupuncture would be especially beneficial for patients who can't use standard pain-relieving drugs because of other medical conditions, Cohen added.\n\"While acupuncture is widely used by practitioners in community settings for treating pain, it is rarely used in hospital emergency departments,\" said study lead investigator Marc Cohen.\nMore than 80 percent still had a pain rating of at least 4, the findings showed.\nOne hour after treatment, less than 40 percent of all patients had significant pain reduction, meaning at least a 2-point decline on the 10-point scale.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The two quoted statements in this story are identical to those in the university\u2019s news release. The story appears to rely heavily on that news release.\nFor example, this quote appears in both the news story and the news release:\n\u201cWhile acupuncture is widely used by practitioners in community settings for treating pain, it is rarely used in hospital emergency departments,\u201d said study lead investigator Marc Cohen. He is a professor in the School of Health and Biomedical Sciences at RMIT University in Melbourne, Australia.", "answer": 0}, {"article": "As they age, people with elevated diastolic blood pressure are at a higher-than-average risk of developing elevated systolic blood pressure.\nThis collaborative research began in 2010.\n\"Heart disease and strokes are a leading cause of death in the United States.\nThese evidence-based data demonstrate the effect of diet on cardiovascular disease outcomes, particularly diastolic blood pressure.\"\nAt the beginning and end of each diet period, participants spent three days undergoing metabolic testing in a clinical research setting.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "No unjustifiable language here.", "answer": 1}, {"article": "Dr. Steve Hicks, senior author of the study and an assistant professor of pediatrics at Penn State College of Medicine, said the \"five microRNAs in saliva could predict with approximately 85% accuracy which concussed children would have symptoms one month later.\nHe added that creating an actual test for use by doctors will require collaboration on the part of researchers.\nDr. Jeffrey Kutcher, a neurologist and National Director of The Sports Neurology Clinic at The CORE Institute, said that \"work like this is important because it does provide potential for tests that can be helpful in the clinical setting.\"\nThe study was funded in part by Quadrant Biosciences, a biotech company that hopes to bring a saliva test for concussion to market in the next 12 to 24 months, Hicks said.\nIn addition, some scientists are exploring functional MRI techniques to look at the metabolic function of different areas of the brain to gain insight into concussion, he said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes a substantial amount of information not included in the Penn State Health news release about the study.", "answer": 1}, {"article": "Other ways women can protect their bones as they age include weight-bearing exercise, and osteoporosis drugs for women at high risk for fractures.\nIt's important to note that calcium intakes on food labels are based on adult requirements of 1,000 milligrams per day.\nRemember, Senay urged: Most people can achieve the recommended calcium intake by eating three or four servings of dairy products and other foods that contain calcium per day.\nCalcium recommendations vary according to age.\nSupplements are an additional tool to be used when needed.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if the story relied solely or largely on a news release. ", "answer": 2}, {"article": "\"What we've had available the last 16, 17 years has made a big difference,\" Richert says, \"and what we have coming onboard now, these are going to make even a larger difference.\nThe main benefit of the pills will be that they are easier to take.\nThese dangers are nothing new \u2014 the MS drug Tysabri was pulled from the market after some patients came down with rare brain infections.\nThose painful welts are something he would happily do without \u2014 and the new pills could be the answer.\nBut soon, it seems, they will have an alternative to this painful regimen: drugs that can be taken by mouth.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story clearly did not rely on a news release. ", "answer": 1}, {"article": "They found that rats with strokes who received DBS had more proteins in the brain that are associated with brain plasticity\u2014and twice as many synapses or connections between nerve cells compared to rats with strokes who did not undergo DBS.\nThat\u2019s why doctors at the Cleveland Clinic will test deep brain stimulation (DBS)\u2014a procedure in which electrodes are implanted in the brain to provide small electric pulses as a way to help people recover control of their movements.\nThe stimulation will hopefully jump-start the brain\u2019s recovery process and help them gain more control while undergoing standard therapy.\nSince the procedure is experimental, there may be some unknown risks as well.\nIf ultimately successful, DBS could become a treatment used in tandem with physical rehabilitation.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no indication\u00a0that this story relied on a news release.\u00a0 A quick check of the Cleveland Clinic\u2019s website shows no release touting this research project.", "answer": 1}, {"article": "Melanoma is the most serious, and often deadly, form of skin cancer.\nBy targeting different points in the same growth-factor pathway, the kinase inhibitor drugs dabrafenib and trametinib postponed the development of drug resistance in patients with BRAF-positive metastatic melanoma, the study authors said.\n\"We investigated this (drug) combination because of research we and others have conducted into the molecular underpinnings of resistance to BRAF inhibitor therapy,\" study lead author Dr. Keith Flaherty, of the Massachusetts General Hospital Cancer Center, said in a hospital news release.\nBut the response is temporary in most cases, and tumor growth resumes in six or seven months, the researchers explained.\nThis study combined dabrafenib [a selective BRAF inhibitor] and trametinib, [a selective MAPK kinase (MEK) inhibitor].\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Although the story features an independent take on the results, it\u00a0uses a quote from a hospital press release and makes liberal use of the copy/paste functions.\u00a0Example:\nPress release:\u00a0\u00a0\u201cIn recent years, drugs that inhibit BRAF activity have rapidly halted and reversed tumor growth in about 90 percent of treated patients, but most patients\u2019 response is temporary, with tumor growth resuming in six or seven months. Investigations into how this resistance emerges have suggested that the MAPK pathway gets turned back on through activation of MEK, another protein further down the pathway.\u201d\nStory: \u201cDrugs that inhibit BRAF activity can rapidly stop and reverse tumor growth in about 90 percent of patients. But the response is temporary in most cases, and tumor growth resumes in six or seven months, the researchers explained. Previous research suggested that this drug resistance develops because the MAPK pathway gets turned back on through activation of MEK, another protein that is part off the MAPK pathway.\u201d\nWe\u2019re concerned that the story is\u00a0regurgitating\u00a0content without sufficient evaluation and analysis.", "answer": 0}, {"article": "Older adults with mild cognitive impairment have less severe memory loss than those with Alzheimer's but often go on to develop the disease.\nThe team cautioned that while eating baked and broiled fish appears to exert some cognitive benefit, other lifestyle and socioeconomic factors may play a role.\nBut fish and chips lovers, take note: No cranial benefit was evident with respect to consumption of fried fish.\nTo assess the impact of fish on cognitive health, the authors focused on 260 mentally healthy elderly individuals drawn from the Cardiovascular Health Study, sponsored by the U.S. National Heart, Lung, and Blood Institute.\nDr. Richard Lipton, vice chair of neurology at the Albert Einstein College of Medicine in New York City, reiterated the point.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We have no evidence that the story relied on a news release.\n ", "answer": 1}, {"article": "Observers measured the symmetry of their smiles, checked for drool and listened to them read sentences.\nDr. Papas, an adviser to Novalar and an investigator in its clinical trials, said she thought the drug would appeal especially to those receiving cosmetic dentistry \u201cwho like to look good when they leave the dentist\u2019s office.\u201d\n\nNovalar said its surveys showed great interest in the product among consumers and among dentists, some of whom said they would mark up the price of the drug as a source of profit.\nIn two trials of 484 patients in total, people were given either OraVerse or a sham injection.\nNovalar also said patients did not have pain because the anesthesia wore off more quickly, except for a little extra pain at the injection site.\nAbout 59 percent of those who got OraVerse had normal sensation in the upper lip after one hour, compared to 12 percent in the control group.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The drugmaker issued a press release on the same day the story appeared in the newspaper.\nThere is one place where the story and press release track fairly closely, raising questions about the reporter\u2019s independence from this source: \nPress release Within one hour after administration of OraVerse, 41% of patients reported normal lower lip sensation as compared to 7% in the control group, and 59% of patients in the OraVerse group reported normal upper lip sensation as compared to 12% in the control group.\nTimes report About 41 percent of patients who got OraVerse reported normal lower lip sensation one hour after getting the drug, compared with 7 percent of those getting the sham injection. About 59 percent of those who got OraVerse had normal sensation in the upper lip after one hour, compared to 12 percent in the control group.\nThat, coupled with the fact that only company executives and dentists who consult with the company were quoted leads us to give an unsatisfactory score on this criterion. \u00a0", "answer": 0}, {"article": "It's a barrier between enamel and the soft tissue that contains all the blood vessels and cells,\" Celiz explained.\n\"We're trying to provide an alternative material, an alternative therapy,\" he said, because the current method involves the dentist removing all of the infected pulp tissue, \"scraping it out, and it can be very painful.\"\n\"We're hoping this approach can bring regenerative medicine into the dentistry field,\" said Celiz.\nInstead of the current dental materials used on fillings, which are toxic to cells, the new approach harnesses stem cells instead.\nThough the work is still in its early stages, and has not yet been tested in people, the scientists won an award from the Royal Society of Chemistry for their idea: regenerative dental fillings.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story used some statements from\u00a0the\u00a0news release\u00a0without attribution, although they were slightly altered.\nExample, from the story:\nWhen dental pulp disease and injury happen, a root canal is typically performed to remove the infected tissues, explained Dr. Adam Celiz, Marie Curie Research Fellow at the University of Nottingham.\u00a0Instead of the current dental materials used on fillings, which are toxic to cells, the new approach harnesses stem cells instead.\nAnd how it appeared in the news release:\n\u201cExisting dental fillings are toxic to cells and are therefore incompatible with pulp tissue inside the tooth. In cases of dental pulp disease and injury a root canal is typically performed to remove the infected tissues.\u201d", "answer": 0}, {"article": "For more information on breast cancer, visit the American Cancer Society.\nEating bitter melon could also have a beneficial effect, Ray said.\nThe next step is to see if the team can repeat these findings in animals, Ray said.\nThe extract slowed the growth of these breast cancer cells and even killed them, the researchers found.\nMarji McCullough, strategic director of nutritional epidemiology at the American Cancer Society, expressed interest in the findings.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did include a comment from an American Cancer Society expert, so it doesn\u2019t appear to rely solely on a news release. ", "answer": 1}, {"article": "\u2022 None New guidelines outline how to handle back pain \n\n\n\nIn the study, 320 adults with moderate to severe back pain received one of three approaches over 12 weeks:\n\u2022 Education about how to cope with back pain\n\n\n\nYoga was just as effective as physical therapy -- and both groups were about 20 percent less likely to use pain medication than patients receiving education alone.\nDr. Robert Saper at Boston Medical Center is one of the authors.\n\"Yoga was as effective as physical therapy for reducing pain intensity,\" Saper said.\nOne person who might agree is 74-year-old Judith Zaborowski, who took up yoga more than 10 years ago to help with her aching back.\nHe explained the results.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We did not find a news release for this study, so we\u2019ll rate this N/A.", "answer": 2}, {"article": "In a statement, Dr. Lesley Russell, Cephalon's chief medical officer, said:\n\nThe most common side effects for Nuvigil, include diarrhea, headache, insomnia and nausea, according to Cephalon.\nBut the regulators weren't buying the evidence put forward by the company to prove the medicine's benefits in treating travelers' \"excessive sleepiness\" outweighed its risks.\nThe regulators just gave a second thumbs down to drugmaker Cephalon's application to sell Nuvigil as a remedy for jet lag.\nFinally, it should be said that the Drug Enforcement Administration has made Nuvigil a federally controlled substance because it has the potential for abuse and dependence.\nCephalon soldiered on, giving FDA more data.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story didn\u2019t rely solely on a news release, but, rather, demonstrated a grasp of the history of this product and its regulatory review.", "answer": 1}, {"article": "\"Although we do not know why the men who took saunas more frequently had greater longevity (whether it is the time spent in the hot room, the relaxation time, the leisure of a life that allows for more relaxation time, or the camaraderie of the sauna), clearly time spent in the sauna is time well spent,\" Redberg wrote.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story may have relied to some extent on a news release, but it clearly wasn\u2019t the only source material.\u00a0The quote from Dr. Redberg appears in the release as well as in an online editor\u2019s note. Other comments and data come from the published study and weren\u2019t in the news release. Although no interviews appear to have been done \u2014 something which would have eliminated any doubt \u2014 it seems clear enough to us that the story went beyond the release.", "answer": 1}, {"article": "Meningitis is a condition \u2014 inflammation of the membranes that surround the brain and the spinal cord \u2014 that can be triggered by some viruses and several types of bacteria.\nThat may explain why the B vaccine appears to offer some protection against Neisseria gonorrhea.\nBut confirmation would be good news for the prevention and control of gonorrhea.\n\u201cWhile it is still very early days, these findings represent a positive step in the search for a vaccine against this common and distressing disease that is increasingly resistant to antibiotic treatment,\u201d said Robin Gaitens, a spokeswoman for GSK, which owns the product that contains this meningitis component.\n\u201cA lot of these vaccines have been used widely globally,\u201d Petousis-Harris said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on the news release from\u00a0The Lancet.", "answer": 1}, {"article": "CRISPR stands for \"clustered regularly interspaced short palindromic repeats.\"\nDr. Kmiec said the lung cancer work reflects an approach adopted by the Gene Editing Institute to move cautiously in developing medical applications of gene editing.\nHe said using CRISPR to do things like improving drug response represents the \"low-hanging fruit\" of CRISPR patient applications.\nDr. Kmiec said there are chemotherapies that have helped patients achieve remission or at least live longer and enjoy a better quality of life by significantly slowing the progress of the disease.\nThat was the conclusion of a new study published today in the journal Molecular Therapy Oncolytics by scientists from The Gene Editing Institute of the Helen F. Graham Cancer Center & Research Institute at Christiana Care Health System.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release uses cautious language. However, the headline overreaches in declaring that \u201cCRISPR restores effectiveness of lung cancer treatment.\u201d", "answer": 0}, {"article": "When Finnish researchers randomly assigned 230 babies at high risk of type 1 diabetes to receive either a regular infant formula, or one that was extensively hydrolyzed -- which means the proteins in the formula are already partially broken down and more readily available for digestion -- they found that the extensively hydrolyzed formula cut the rate of developing diabetes-linked antibodies in the blood by about half.\nHow the highly hydrolyzed formula might reduce the risk of developing diabetes-predictive antibodies is unknown, but the researchers speculated that it might contribute to reduced gut permeability or changes in gut microflora, among other things.\nPeople who have two or more type 1 antibodies have between a 50 and 100 percent risk of developing type 1 diabetes, according to background information in the study.\nThe results of the study were published in the Nov. 11 issue of the New England Journal of Medicine.\n\"I think this is an important study because we need to understand what causes type 1 diabetes,\" said Harlan, who added the caveat: \"In this study, while there is an apparent signal, there are also some causes for withholding complete faith in the conclusion that the formula caused diabetes.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is some thoughtful independent reporting and the story does not appear to rely on a news release.", "answer": 1}, {"article": "Some prostate cancers evolve to use energy from lipids (fat).\n\u201cThis finding may have a huge impact on patients with CRPC that had very few options before,\u201d says Schlaepfer.\n\u201cThere is a critical need for improved therapies for this specific cancer type.\u201d\n\nMost cells use the energy of glucose (sugar).\nPrevious work shows that metabolizing lipids helps prostate cancer escape anti-androgen therapy.\n\u201cSince the drugs are clinically safe, a clinical trial can be designed in patients for whom enzalutamide is prescribed.\u201d\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "This news release is almost a poster child for unjustifiable language including use of the word, \u201cbreakthrough\u201d in the title. Then there is the suggestion that \u201cThis is a huge development for men with CRPC that previously did not have many options.\u201d\nThis might be a huge breakthrough for mice with a certain type of cancer but that hardly justifies the use of the term \u201cbreakthough\u201d in applying the study\u2019s finding to human men. ", "answer": 0}, {"article": "Elective Caesarean-section deliveries can increase problems for a newborn if done too early -- even when the baby has technically reached full term, according to a large new study.\n\nThe findings could help diminish a widely popular practice -- now about one in every 14 births -- in which mothers choose to schedule c-sections, or surgical removal of the baby. The study, published in the New England Journal of Medicine, found that about a third of elective c-sections are done too early -- before 39 weeks. Although a fetus is considered...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if the story relied solely or largely on a news release.\u00a0 Only an author and an editorial writer were quoted. ", "answer": 2}, {"article": "In people with atrial fibrillation, disorganized electrical activity causes ineffective contraction of the upper chambers of the heart.\n\"This analysis provides further support for the benefit of apixaban, but given the very low risk of bleeding with apixaban, it also suggests that the current stroke and bleeding risk scores may not be sensitive enough to tease out those patients with the very lowest risk of stroke who might benefit from apixaban therapy,\" said Ansell, who is chairman of the department of medicine at Lenox Hill Hospital in New York City and a consultant to Bristol-Myers Squibb and Pfizer, the companies that are marketing the drug as Eliquis.\nMONDAY, Oct. 1, 2012 (HealthDay News) -- A new anti-clotting drug called apixaban was better than warfarin at preventing stroke in patients with the heart rhythm disorder atrial fibrillation, a new study found.\nCurrent practice guidelines permit the use of either anti-clotting therapy with aspirin or warfarin.\n\"With new oral anticoagulants, such as apixaban, we might not need risk scores to guide treatment decisions for stroke prevention in patients with atrial fibrillation.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The first quote in the story comes from the press release. Normally, this wouldn\u2019t disqualify a story in this category, but the story did not provide any outside perspective to counter the overall feel of the piece, which comes across like a press release or advertisement.", "answer": 0}, {"article": "In the United States, the Affordable Care Act designates HIV testing as a preventive service, meaning that all insurers must cover it without charging a co-pay.\nA sizable fraction of the undiagnosed may be people who have been tested, just not recently enough.\nAnd because the incidence of other sexually transmitted infections declined for these men, after the diagnosis, the scientists had reason to believe the self-reports of condom usage were accurate.\nThe Home Access HIV-1 Test System lets patients collect blood at home, but it must then be sent to a clinic for testing.\nThat suggests that both countries still face serious gaps in diagnosis.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes information from a variety of online sources, so it does not appears to rely on just a news release.", "answer": 1}, {"article": "This, too, is suggested by sense and common experience, as it is affirmed by the science reported here,\" Katz said.\nLower stress by itself predicted more weight loss during the first phase of the trial, they added.\nThose in the second phase of the trial continued their diet and exercise program.\nThese factors may also have a biological impact, he added.\nThe important message is that weight loss should not be looked at with tunnel vision, Katz said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely solely on a news release.", "answer": 1}, {"article": "An estimated 50,000 people a year experience end-stage ankle arthritis, in which the ankle cartilage has worn away completely, causing painful bone-on-bone contact and some level of disability.\nEach year about two million Americans visit the doctor for ankle pain from arthritis or fracture.\nAnkle replacement has been around for three decades, but it has been slow to catch on.\nThe procedure is among the most difficult that foot and ankle surgeons perform, and one of the biggest challenges is getting proper alignment of the replacement joint.\nThe operation is complex, and many foot and ankle surgeons lack experience.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does not appear that the article is based on a press release.", "answer": 1}, {"article": "The American Cancer Society has more on lymphoma.\nThat finding comes from a new study by Mayo Clinic researchers of nearly 4,100 people with lymphoma, a cancer that starts in the white blood cells that normally help fight infection.\n\"Our findings show that physical activity can have a positive impact on survival in lymphoma patients,\" she said in a Mayo news release.\nBut the study couldn't prove that more exercise actually caused death risk to drop.\nThe study was presented Monday at the annual meeting of the American Society of Hematology in Atlanta.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story heavily relies on a news release issued by the Mayo Clinic.", "answer": 0}, {"article": "Type 2 diabetes, which is often tied to obesity, affects about 8 percent of the U.S. population, according to the U.S. National Institute of Diabetes and Digestive and Kidney Diseases.\nIt\u2019s also not possible to say from the current evidence that heavy coffee drinkers (and tea and decaf drinkers) don\u2019t have other characteristics that might protect them against developing diabetes, they add, such as eating a healthier diet.\nIn the years since then, they add, the amount of research on coffee and diabetes risk \u201chas more than doubled,\u201d while other studies have suggested that tea and decaf coffee may also be preventive.\nThe current analysis could have overestimated the effect of these beverages on diabetes risk due to statistical issues with the smaller studies, Huxley and her colleagues note.\nClinical trials are needed to investigate whether these beverages do indeed help prevent diabetes, the researchers say.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no evidence that the story relied solely or largely on a news release.\u00a0", "answer": 1}, {"article": "They were then randomized to receive either Forteo or a placebo.\n\"There was a significant improvement in clinical measures of gum and bone,\" McCauley stated.\nAfter eight weeks of treatment with Forteo, though, the pain went away and the osteonecrosis resolved, reported the authors, from Austin Health in Melbourne, Australia.\nBut the two papers in the Oct. 16 online issue of the New England Journal of Medicine report success with teriparatide (Forteo) in rebuilding bone.\nAfter six weeks of therapy, patients in the Forteo arm saw greater healing of their jawbone and this continued throughout one year of follow-up.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to have relied on a press release.\u00a0", "answer": 1}, {"article": "Jason Dragoo\u2019s Stanford University research team gets 100 to 200 inquiries every day from people interested in joining its clinical trial studying the use of stem cells to treat knee injuries.\n\nThe interest highlights a growing demand for the use of stem cells derived from a person\u2019s own bone marrow or fat to treat orthopedic injuries. Osteoarthritis, a degenerative joint disease where the protective tissue or cartilage around a joint wears down, is a particular focus of inquiry.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story does not appear to rely upon a news release.", "answer": 1}, {"article": "But plasma insulin response was sharply lower in fructose drinkers, which may affect what we eat, according to the senior author, Dr. Kathleen A.\nThe volunteers drank a 10-ounce glass of cherry-flavored liquid that contained two and a half ounces of fructose or glucose.\nBefore having their drinks, the participants rated their desire to eat on a one-to-10 scale from \u201cnot at all\u201d to \u201cvery much.\u201d Then they drank the liquids and had functional magnetic resonance imaging brain scans while looking at images of food and of neutral objects like buildings or baskets.\n\u201cInsulin is released when we consume glucose,\u201d she said.\nBut it also sends a signal to the brain that says \u2018you\u2019ve eaten.\u2019 Fructose doesn\u2019t stimulate insulin secretion, and if there\u2019s no insulin, you don\u2019t get the information that you\u2019re full.\u201d\n\nDoes this mean that it is a good idea to avoid fruit, because it contains fructose?\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not draw from any news release that we could find. It appears to include original reporting from an interview with one of the study authors.", "answer": 1}, {"article": "In a study published last month in Nature, 80 percent of infants diagnosed with autism as toddlers had an increased rate of growth in the surface area of their brains in their first year, compared to toddlers who were not diagnosed with autism.\nExcess brain fluid may be more than an early marker for autism, Di Martino said.\nAdditional studies are needed to confirm the finding, he said.\nCompletely different mechanisms may be at work for kids without an older sibling with autism, said Shen and Dimartino.\nHe and his colleagues are working on improving accuracy by combining their brain fluid findings with other recent research.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "But none of these works for everybody, and the immune suppressant drugs can raise the risk of cancers such as lymphoma.\nDupixent is for the hard-core cases that aren\u2019t helped by anything else.\n\u201cOf the adults with uncontrolled moderate to severe atopic dermatitis in the United States, it is estimated that 300,000 are most in need of new treatment options,\u201d Regeneron said.\nIt can be very unpleasant.\nPatients can do it at home.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This is barely passing: The story relies heavily on a news release but also contains material that isn\u2019t from the\u00a0news release.", "answer": 1}, {"article": "...\nUnder the best of circumstances, that's not a strong result, says anesthesiologist Kimball Atwood of Newton-Wellesley Hospital in Massachusetts, who has followed the study from its beginning.\nStephen Kopecky, a Mayo Clinic cardiologist who participated in the trial, says he's also concerned about the reliability of its findings.\nNational Institutes of Health officials say they launched the study because there has never been any evidence that the practice is effective or safe.\nThat could lead to a bias in favor of chelation, Atwood says.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is enough original reporting for us to be sure this story wasn\u2019t based on a press release.\n\u00a0", "answer": 1}, {"article": "The study described in the article \"Effect of Foeniculum vulgare Mill.\nIn the end, fennel was concluded to be a safe and effective treatment to reduce menopause symptoms without serious side effects.\nThe study outcomes are published online today in Menopause, the journal of The North American Menopause Society (NAMS).\n\"A larger, longer, randomized study is still needed to help determine its long-term benefits and side effect profile.\"\nThe study was completed in Tehran, Iran, where the average age of women at menopause is younger than in the United States: 48.2 years versus 51 years, respectively.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t employ sensational language. However, we do have concerns with the headline, as noted above, since it overstates the findings.", "answer": 1}, {"article": "Load up on berries.\nBut he says it's important to point out that the women in this study weren't prime candidates for heart attacks anyway.\nAnd if they're out of season, like now, studies show frozen berries have similar levels of beneficial compounds.\nAll of these effects could be beneficial, explains Robert Eckel, a preventive cardiologist at the University of Colorado.\nAnd when you eat a steady diet of them, they seem to have a number of positive health effects.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The NPR story does not seem to rely solely on a press release, and there is evidence of original reporting with the independent comment from cardiologist Dr. Robert Eckel.", "answer": 1}, {"article": "This enzyme in humans has many important functions, including its involvement in wound healing.\nThe author of the study believes that the effectiveness of curcumin gel on the skin - or topical curcumin - is related to its potent anti-inflammatory activity.\nDr. Heng uses curcumin gel for burns, scalds and other skin conditions as complementary treatment, in addition to standard treatment usually recommended for such conditions.\nThis study published reports that topical curcumin gel applied soon after mild to moderate burns and scalds appears to be remarkably effective in relieving symptoms and improved healing of the affected skin.\nIn this report, use of curcumin after burns and scalds were found to reduce the severity of the injury, lessen pain and inflammation, and improve healing with less than expected scarring, or even no scarring, of the affected skin.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release does not include unjustifiable, sensational language.", "answer": 1}, {"article": "Dr. Adolfo Llanos, a neonatologist at Nicklaus Children's Hospital in Miami, who was not involved with the new study, said the \"quality of this analysis is very good.\nWhen they do, the screening and treatments are not as good, Chen said, so blindness may be more likely.\nThe antioxidants in human milk may help, Chen said.\nHuman milk also has immune-protective properties, the researchers said.\nAnd the risk of severe ROP seemed to be reduced by 90 percent, the researchers added.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can be fairly confident that the article\u00a0did not rely solely on a news release, especially since it has an independent source.", "answer": 1}, {"article": "Researchers told the American Diabetes Association\u2019s (ADA) annual meeting that 13.0 percent of patients on Victoza died from cardiovascular causes or suffered non-fatal heart attacks or strokes, against 14.9 percent of those on placebo.\nThe Victoza trial, known as Leader, had been designed to show Novo\u2019s drug did not increase heart risk, so its superiority is welcome news for the company, especially as Sanofi\u2019s (SASY.PA) rival Lyxumia failed to show heart benefits in an earlier test.\nMads Krogsgaard Thomsen, Novo\u2019s chief science officer, said the results should encourage doctors to use Victoza earlier, since they could now see it offered \u201clife-expanding\u201d treatment.\nJefferies analyst Jeffrey Holford said market expectations had been for a mid-to-high teens percent reduction in complications.\nThere was also concern that Victoza did not appear to lower heart risks in American patients monitored in the study, despite doing so in other parts of the world and producing a solid result globally.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story is not based solely on Novo Nordisk\u2019s news\u00a0release. As mentioned, some of the relative risk figures which the story leans on, as well as two\u00a0sources who are quoted, are found in the\u00a0news release. But\u00a0the writer clearly conducted independent interviews and sourced information elsewhere.", "answer": 1}, {"article": "Chronic idiopathic constipation is a diagnosis given to those who experience persistent constipation and for whom there is no structural or biochemical explanation.\nTrulance should be avoided in patients six years of age to 18 years of age.\nThe safety and effectiveness of Trulance have not been established in patients less than 18 years of age.\nTrulance should not be used in patients with known or suspected mechanical gastrointestinal obstruction.\nTrulance should not be used in children less than six years of age due to the risk of serious dehydration.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t contain any unjustifiable language.", "answer": 1}, {"article": "Both studies, which appear today in the New England Journal of Medicine, find these kids get over painful ear infections faster, and have less severe symptoms, if they get prompt treatment with Augmentin, an inexpensive antibiotic often used to treat respiratory infections.\nBut here's the rub \u2013 diagnosing ear infections in very young children, who tend to squirm, is not easy.\nMuch of the confusion, experts say, has been caused by studies that weren't careful enough about the diagnosis.\nAnd, he notes, they shouldn't be afraid to press their pediatrician.\nIf the eardrum is red and bulging outward, that's a strong sign of a middle-ear infection.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a news release.", "answer": 1}, {"article": "However, \"I don't want women who chose mastectomy to think they did the wrong thing,\" Hwang said.\nHwang believes the study does arm women with valuable information.\nThe findings may reverse the mastectomy trend, said Dr. Laura Kruper, co-director of the breast oncology program at the City of Hope Comprehensive Cancer Center in Duarte, Calif., who was not involved in the study.\nThe study is scientifically sound in many ways, Kruper said.\nHwang and others suspect that women told they could safely opt for lumpectomy were still afraid to try it.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes several independent sources.", "answer": 1}, {"article": "\u201cIt\u2019s time for her to be a kid again and get her childhood back,\u201d Mr. Whitehead said.\nDr. June knew that a drug could lower IL-6 \u2014 his daughter takes it for .\nBut Mr. Hoppenot said Novartis was taking a different path with cancer drugs, looking for treatments that would have a big, unmistakable impact on a small number of patients.\nBut such drugs tend to be extremely expensive.\nSome patients have had the cells for years.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There\u00a0is enough original reporting that we can be sure the story didn\u2019t rely on\u00a0press release.", "answer": 1}, {"article": "Traditionally patients begin treatment with one drug at a very low dose, which is increased over time with additional drugs added and increased in dosage to try to reach target.\nWith high blood pressure the leading cause of disease burden worldwide, it's expected the findings published in JAMA will change guidelines globally.\nDr Ruth Webster, of The George Institute for Global Health, said this was a major advance by showing that the Triple Pill was not only more effective than standard care, it was also safe.\nThe George Institute is now looking at strategies to maximise uptake of the study results.\nA new low dose three in one pill to treat hypertension could transform the way high blood pressure is treated around the world.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "This framing is premature, not supported by the study, and therefore unjustified:\nCould transform the way high blood pressure is treated around the world \u2026 expected the findings will change guidelines globally \u2026 a major advance.", "answer": 0}, {"article": "The Society works closely with many other sports medicine specialists, including athletic trainers, physical therapists, family physicians, and others to improve the identification, prevention, treatment, and rehabilitation of sports injuries.\n\u201cWhile young athletes and parents may be wary of surgery, our study shows the advantages of this treatment approach,\u201d commented Marshall.\n\u201cHowever, this study shows a substantial benefit for athletes undergoing surgery to prevent recurrent instability down the road.\u201d\n\nThe research data was collected between 2003 and 2013 from eight fellowship trained surgical practices, with patient ages ranging from 16 to 30 years old.\n\u201cDeciding between a non-operative program or going forward with surgery can be a challenging decision for medical professionals treating shoulder injuries in young athletes,\u201d noted the study\u2019s lead author Tyler J. Marshall, MD, from Alabama Ortho Spine and Sports in Birmingham, AL.\nSurveys given to patients during follow-ups asked for information such as test for shoulder functionality, whether patients returned to sport, postoperative instability events, and if further surgery was required on the shoulder.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t rely on sensational language or make overtly unjustified claims. However, as noted above under the summary and evidence headings, we have some concerns about the way the study findings were presented in the release.\nThe news release says that the research \u201cdemonstrated that surgery after a first-time shoulder dislocation lowered the re-injury risks and need for follow-up surgery when compared to those who were initially treated non-operatively and experienced a repeat dislocation prior to surgery.\u201d\nBut the study abstract itself does not justify going that far. Instead, it says simply that \u201cfirst time dislocators had lower postoperative instability rates and reoperation rates when compared to patients with recurrent dislocations prior to surgical intervention.\u201d\nAssociation v. Causation 101.\nAnd a quote from the lead author offers a curious view of the role of the physician:\u00a0\u201cDeciding between a non-operative program or going forward with surgery can be a challenging decision for medical professionals treating shoulder injuries in young athletes,\u201d says Dr. Marshall.\nThat statement implies that treatment decisions are made by medical professionals alone. But the agenda paper offers a more inclusive take: \u201cYoung, athletic patients with shoulder instability should be offered early surgical intervention to lower the risk of postoperative instability and reoperation,\u201d it says.", "answer": 1}, {"article": "T. Kondo, R. Goto, K. Ono, S. Kitano, M. A. Suico, M. Sato, M. Igata, J. Kawashima, H. Motoshima, T. Matsumura, H. Kai, and E. Araki, \"Activation of heat shock response to treat obese subjects with type 2 diabetes: a prospective, frequency-escalating, randomized, open-label, triple-arm trial,\" Scientific Reports, vol.\nThis determined the most effective treatment frequency.\nThe current study reports clinical trial results for optimal use frequency.\nThe first trial showed that activation of the HSR produced a large therapeutic effect.\nA new wearable medical device developed by Kumamoto University has been found to effect visceral fat loss and improve blood glucose (sugar).\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release doesn\u2019t employ sensational language.", "answer": 1}, {"article": "Alzheimer's disease is the most common age-associated neurodegenerative disorder that has no cure.\nAn early online version of this paper detailing the findings has been published and is scheduled for publication in the July 7 issue of the Journal of Alzheimer's Disease.\nSince the people involved in the study mostly come from Texas, the researchers further compared their over 65 years old group with the prevalence of Alzheimer's in the general population of the state and got similar results.\nTo bypass this issue, the UTMB team analyzed data from the medical records of 2,644 patients who received organ transplants and must take calcineurin inhibitor-based medications, such as Tacrolimus or cyclosporine, for the rest of their lives to prevent rejection of the transplanted organ.\nUsing a mouse model of Alzheimer's, the researchers earlier showed that blocking calcineurin restored memory function.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release is a bit too enthusiastic about the results of this retrospective observational study. One of the authors says the data \u201csupport, for the first time in human subjects, our notion that calcineurin inhibition has a protective effect on the development and possible progression and even reversal of Alzheimer\u2019s disease.\u201d Certainly \u201creversal\u201d is beyond the pale. The release\u2019s repeated claims that these drugs \u201cprotect\u201d against Alzheimer\u2019s is also not justified based on the evidence.", "answer": 0}, {"article": "\u2022 Prostate cancer mainly occurs in older men; about 6 in 10 cases are diagnosed in men aged 65 or older.\nThe researchers said the analysis in their study is better at forecasting how prostate cancer will advance compared to the current diagnostic tests being used for prostate cancer such as the prostate specific antigen test and the Gleason score.\nWhile the findings need further research, larger clinical trials could give better information on individualized treatment for each prostate cancer type.\nThis could lead to a better quality of life and more effective treatment based on which prostate cancer a man is diagnosed with.\nThey concluded that five different types of prostate cancer were found based on 100 genes.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release makes several leaps intended to drive readers to think there\u2019s something notable being offered, but there\u2019s little hard evidence provided to back up the claims.\nOne example: \u201cIf five types of the disease exist, how does this change popular medical opinion on prostate cancer screening? This may mean that each type of the disease needs its own approach to screening, diagnosis, treatment and even recurrence,\u201d noted Dr. Samadi.\nThis is misleading, since the test has no effect on screening and cannot be used to diagnose cancer (you still need a biopsy); it might lead to different treatment and surveillance strategies.", "answer": 0}, {"article": "Elevated sweat chloride confirms that an infant actually has CF.\nThe findings, published in the journal ACS Central Science, shed new light on the underlying mechanisms of CF and could lead to improved prognosis and better therapies for a disease which is quite variable, affecting different children in different ways, say researchers.\nThe biomarkers also point to other underlying mechanisms that contribute to the progression of CF and could lead to better therapeutic interventions earlier in life.\nBut there are some obstacles that complicate clinical decision-making, explains Britz-McKibbin, because sweat chloride can result in ambiguous diagnoses in some borderline cases and does not reveal how the disease might progress for individual patients.\n\"CF Canada invests heavily in research that aims to improve the lives of people living with CF, and findings such as those from Dr. Britz-McKibbin are crucial to our understanding of the disease.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Here\u2019s the news release headline: \u201cScientists discover biomarkers which could lead to better treatments for CF patients\u201d (emphasis added). Treatments are mentioned only twice in the text of the release. Here, in the second paragraph: \u201cThe findings\u2026shed new light on the underlying mechanisms of CF and could lead to improved prognosis and better therapies for a disease which is quite variable, affecting different children in different ways, say researchers.\u201d And here, in the ninth paragraph: \u201cThe biomarkers also point to other underlying mechanisms that contribute to the progression of CF and could lead to better therapeutic interventions earlier in life.\u201d In short, the release offers very little to support the idea of better treatments for CF patients. How does the study improve our understanding of the underlying mechanisms of CF? And how could that potentially lead to improved treatments? The release doesn\u2019t tell us. One could see how it may lead to earlier treatment, if diagnoses are improved, but the release doesn\u2019t address how earlier treatment could improve patient outcomes. So, while one can say that these biomarkers \u201ccould\u201d lead to better treatments, one could just as easily say that these biomarkers \u201cmay not\u201d lead to better treatments. The release would have been on much firmer ground if it had either fleshed out how the findings may inform future treatment research or had focused on the value of the study\u2019s findings in regard to diagnostics.", "answer": 0}, {"article": "To test this theory, the Italian researchers compared 25 healthy infants who were randomly assigned to receive drops of Lactobacillus reuteri to 21 healthy infants randomly assigned to receive placebo drops.\nSome researchers question whether symptoms could be alleviated using probiotic therapy, or \"healthy\" bacteria to restore bacterial balance in the gut.\nColic affects up to 28% of infants and has no known cause or cure.\nResearchers from the University of Turin, Italy, found that a few daily drops of Lactobacillus reuteri, a bacterium that can help improve digestion, significantly reduced crying among infants with colic.\nThe infants' mothers were also advised to avoid cow's milk in their own diets during the study period.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We couldn\u2019t find any evidence that this story relied\u00a0on a news release.\u00a0Considering that\u00a0nobody was interviewed,\u00a0however, the best we can do is\u00a0call it not applicable.", "answer": 2}, {"article": "A moderate dose of MDMA was found to significantly increase feelings of loving, friendliness and playfulness, the researchers said, whereas the low dose of MDMA boosted feelings of loneliness.\nThis effect, the Bedi and his team suggested, could help people improve their social skills by shielding them from the negative emotions of others.\n\"More controlled research is needed to establish whether MDMA can safely and effectively add to psychotherapy for some conditions and, if so, what the mechanisms of these effects are,\" Bedi said.\nAll said they had taken MDMA for recreational purposes at least twice in their lives.\nEach session lasted at least 4.5 hours, or until all effects of the drug had worn off.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure of the extent to which this story may have been influenced by a news release.", "answer": 2}, {"article": "Phentermine quickly suppresses appetite, while the controlled-release topiramate decreases appetite and increases satiety throughout the day.\nThe people who took the lowest dose of the drug dropped about 5.1% of body weight at six months, and, on average, gained some back by one year.\nOverall, people who took the combination pill lost more weight than their counterparts who were given a placebo.\nTopiramate also has blood pressure-lowering effects, she says.\nThose who took the medium dose of the pill lost 8% of their body weight at six months and 8.2% by one year.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does not appear that the story relied solely or largely on a news release. ", "answer": 1}, {"article": "...\nThe U.S. Food and Drug Administration has not approved pharmacologic treatments for BED, according to background information in the study.\nSimilarly, BE episodes decreased in the 50- and 70-mg/d treatment groups.\nConfirmation of these findings in ongoing clinical trials may results in improved pharmacologic treatment for moderate to severe BED,\" the study concludes.\nThis study was supported by Shire Development, LLC, including funding to Scientific Communications & Information and Complete Healthcare Communications, Inc., for support in writing and editing the manuscript.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Contrary to sensationalizing this study,\u00a0the news release offers\u00a0a rather cautious summary of the research. Unfortunately, this caution seems to have come at the expense of readability. The release quotes extensively from the original study, with language that\u2019s quite technical.", "answer": 1}, {"article": "More than 2.2 million men in the U.S. are living with prostate cancer.\nAnother potential source of the associated reduction was reduced inflammation due to a lower circulation of interleukin-6, high levels of which \u201cpredicted a 73% increased risk of dying from prostate cancer among normal-weight men,\u201d the researchers wrote.\nThe findings are in line with previous research suggesting that physical activity may help reduce the risk of disease-related death in certain cases of prostate cancer.\nMen who took acetaminophen for less than five years saw no protective benefit.\nResearchers from the University of California, San Francisco (UCSF), and Harvard School of Public Health followed the men from 2004 to 2009 and found that those who engaged in regular brisk walking after diagnosis were significantly less likely to see their disease progress.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Not applicable because no one was directly interviewed and quoted.\u00a0 The story did draw from another news source \u2013 MedPage Today \u2013 but we don\u2019t know if any original reporting was done.", "answer": 2}, {"article": "Autologous CD34?\nEncouraging early clinical trials suggest that cell therapy is an attractive treatment option for these patients, especially trials in which subjects were transplanted with autologous (self-donated) CD34+ cells.\"\nThe researchers concluded that for \"no option\" patients with class III/IV angina refractory that was unresponsive to conventional medical therapy and who were not candidates for revascularization, injection of CD34+ cells resulted in persistent improvement in angina at two years post-treatment.\nThe patients, who were unresponsive to other treatments, were considered to have no other options (refractory).\n\"Recent reports suggest that in patients with recurring symptoms, repeated cell administration may replicate the initial positive results.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "This is satisfactory, but barely. The release headline tells readers that this treatment reduces angina frequency for \u201cno option\u201d patients. But it doesn\u2019t clearly describe the treatment, the condition or the extent to which frequency is reduced \u2014 and it\u2019s a little unclear as to why these are \u201cno option\u201d patients. The body of the release says that some patients have \u201climited\u201d options, but not that they have no options. And it doesn\u2019t articulate what those limited options might be. However, the last sentence of the release provides some needed clarity: \u201cThe researchers concluded that for \u2018no option\u2019 patients with class III/IV angina refractory that was unresponsive to conventional medical therapy and who were not candidates for revascularization, injection of CD34+ cells resulted in persistent improvement in angina at two years post-treatment.\u201d", "answer": 1}, {"article": "Minimally invasive procedures increased to 31 percent of all radical prostatectomies in 2005 from 12.2 percent in 2003.\nBut the surgery increases the chance for longer term problems that require further therapy, the research says.\nThe widely advertised procedure is becoming more popular, said Dr. Jim C. Hu, the lead author of the study and an instructor in surgery at Harvard.\nThe study, published on May 10 in The Journal of Clinical Oncology, examined a sample of 2,702 Medicare patients undergoing radical prostatectomy, the complete removal of the prostate, from 2003 to 2005.\n\u201cThis paper,\u201d Dr. Hu said, \u201cdemonstrates that there are hidden risks for patients who opt for laparoscopic or robotic surgery.\u201d\n\nIn laparoscopy, a surgeon inserts instruments through small cuts in the skin instead of making large incisions to expose the organs.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does not appear that a press release is associated with this journal article. ", "answer": 2}, {"article": "Or eat turkey or bananas, both of which contain tryptophan, which is believed to trigger sleepiness.\n-- Practice good sleep hygiene.\nThat means turning off all electronics, including the TV, and creating as quiet a sleep space as you can.\nIf your teen has to get up at, say, 6:30 to be at school by 7:30, that means bedtime's at 9:15 or 9:30 p.m.)\n\nVorona says he'd like to delve deeper into the sleep-obesity question.\n-- Avoid caffeinated coffee, tea and soda.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article does not appear to rely on a news release.", "answer": 1}, {"article": "Cortisol is known as the \u201cstress hormone\u201d because it is released in response to acute stress to help the body react and cope.\nThe greater number of traumatic events a child had experienced, such as divorce, injury, moving house, severe illness or the death of a family member, the higher the hair cortisol concentrations were, the researchers found.\nBut it did reveal it was important to further study hormones and the body\u2019s endocrine system, and how they relate to mental illnesses like anxiety and depression, he said.\n\u201cHowever, hair samples are not only easier to obtain, but provide us with a picture of total cortisol throughout the system across many months rather than just at a point in time,\u201d Simmons said.\n\u201cWhat\u2019s less commonly understood is that beyond poor mental health, it can also be associated with the development of other illnesses such as diabetes, obesity and cholesterol issues, because cortisol is also central to glucose availability, blood pressure and immune function, so identifying these children is important.\u201d\n\nWhile blood or saliva tests could be used to detect cortisol levels, these methods were sometimes problematic, especially in children, Simmons said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We couldn\u2019t find any evidence of any news release about this study. However, because there are no independent sources quoted, we can\u2019t be sure that the story didn\u2019t rely on such a news release that we weren\u2019t able to find (e.g. one that may have been emailed to reporters). The best the story can score here is Not Applicable.", "answer": 2}, {"article": "For example, blood pressure (BP), not only tends to increase but as well become more irregular.\nNone of these effects was found in 34 placebo treated seniors, thus ruling out the possibility that rhythms could be improved just because of regular schedule and presence of medical personal who took measurements.\nThe present study was aimed to investigate whether such changes can be reversed by daily melatonin ingestion.\nThe hypotensive effect was dependent on time.\nLuckily, as we show in our research, melatonin helps to ameliorate both trends.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release concludes with cheerleading on behalf of melatonin use. The claim that \u201cmelatonin can be of great value\u201d for older folks with hypertension is more than a stretch based on the limited evidence.", "answer": 0}, {"article": "\"Six-month IOP Reduction with a Topical Bimatoprost Ocular Insert: Results of a Phase 2 Randomized Controlled Study,\" Brandt, et al.\nThe ring became dislodged in 15 patients but was replaced each time, allowing therapy to continue.\nThe ring is designed to be replaced by an ophthalmologist every six months.\nThe authors noted the device could also be used for non-glaucoma medications, with potential applications for dry eye, allergies and inflammation.\nOphthalmologists at 10 sites nationwide tested the ring in a phase 2 clinical trial on patients with glaucoma or ocular hypertension.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release states that the device \u201cmay one day be a promising option\u201d for glaucoma patients who struggle with eye drops without mentioning the obvious corollary that it may not do that. However, the article otherwise does not engage in sensational language.", "answer": 1}, {"article": "High cholesterol levels can increase the risk of heart attack.\n\"Overall, the evidence is inadequate to establish a protective role of selenium in cardiovascular disease or to recommend selenium supplementation to improve cardiovascular health,\" he said.\nThe finding comes from a six-month examination of the impact of various dosages of the supplement on the cholesterol levels of healthy people in England.\n\"And so I would caution against anybody in the U.S. increasing their selenium intake based on what we found, because we also know there's an increased risk for type 2 diabetes when you increase selenium intake if you are already at a high level of blood selenium levels.\"\nHowever, the safety of selenium has not been studied, and the authors said the findings weren't significant enough to recommend supplementation of the trace mineral.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We couldn\u2019t find a news release that was issued for this particular study.\u00a0But by including an independent expert source, the story assures us that it didn\u2019t rely exclusively on PR materials.", "answer": 1}, {"article": "A complex and expensive pacemaker-defibrillator can significantly improve the chance for survival among the tens of thousands of heart-failure patients with only mild symptoms, according to a major, multiyear clinical study.\n\nThe research, regarded as likely to change medical practice, showed that the device to \"resynchronize\" the hearts of such patients lowered the death rate by 29% in such patients over 40 months, compared to those who had a standard defibrillator implanted.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a news release.", "answer": 1}, {"article": "Women who carry a defective gene on one X chromosome can compensate with the good copy on their other X chromosome, but they bequeath the defective copy to half their children.\nTwenty more patients will be treated to assess the best dose of the virus, the goal being the highest dose that does not set off an immune system attack, Dr. Tuddenham said.\nThe patients had been recruited and treated with the virus in England by a team led by Dr. Amit C. Nathwani of University College London; researchers at the Children\u2019s Hospital of Philadelphia monitored their immune reactions.\nDr. Nathwani and his team reported that they treated the patients by infusing the delivery virus into their veins.\nThe virus has a propensity for making liver cells its target, which is good for the therapy because these cells are the natural producers of Factor IX.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that this story did not rely on a news release.", "answer": 1}, {"article": "Some years ago, Italy instituted a countrywide rule requiring competitive athletes to undergo an electrocardiogram, a test that records the electrical activity of the heart.\nCurrently, an EKG and echocardiogram would cost parents a minimum of $2,500, Anderson says.\nSince the study began about a year ago, 500 local teens have been screened and 26 diagnosed with heart abnormalities.\nIf an ongoing program of testing happens, the hospital would try to tap into third-party funding, donations and grants, Towbin says.\nBut the Children's Hospital study is showing more than twice that rate and a higher rate for more minor abnormalities as well, perhaps because of better technology, Grenier says.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It appears that the reporter spoke to researchers and parents and did not rely only on a news release. However, it is not clear whether the reporter gathered any information independently or merely relied on information provided by the researchers or their institution.", "answer": 1}, {"article": "About the Society of Breast Imaging\n\nThe Society of Breast Imaging (SBI), established in 1985, is a professional medical organization dedicated to improving the practice of breast imaging and the quality of medical education in breast imaging.\nWASHINGTON, Sept. 29, 2015 /PRNewswire/ -- The American College of Radiology (ACR), Society of Breast Imaging (SBI) and major medical organizations experienced in breast cancer care continue to recommend that women start getting annual mammograms at age 40.\nSeventy-five percent of women diagnosed with breast cancer have no family history or other factors that place them at high risk for the disease.\nTo mark National Breast Cancer Awareness Month, women are encouraged to ask their health care providers about scheduling an annual mammogram.\nThe SBI also provides a medium for the exchange of ideas among those involved in breast imaging.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "A statement from Dr. Debra Monticciolov raised our eyebrows, especially given the surge in recent, high-quality evidence questioning the value of mammograms for some women: \u201cAll women age 40 and over can benefit from annual mammography.\u201d In fact, it seems not every woman does benefit \u2014 for every woman whose life is saved, many more are overdiagnosed and overtreated. We think women should be encouraged to make an informed personal decision about screening mammography based on a clear understanding of the benefits and risks.\u00a0This could include, in partnership with her doctor, a look at all known risk factors, including gender, age, race, family history, reproductive history, pregnancies, radiation exposure, previous abnormal breast biopsies, DES, HRT, alcohol use, obesity, physical activity, known genetic abnormalities, prior cancer classification, and other factors. Mammograms do not eliminate these risks.", "answer": 0}, {"article": "Find out more about brain health at the Alzheimer's Association.\nA clinical trial comparing high and low intake of omega-3s in relation to brain imaging would help answer those questions, he said.\nThis suggests they may play a role in promoting general vascular, or blood vessel, health in the brain, similar to how they are thought to help heart health, rather than acting on just one brain area, Tan said.\nThe decrease in brain volume was enough to make their brains appear two years older than those of people in the top three-quarters for fatty-acid levels.\nTan added, however, that it remains possible that factors they did not control for, such as fruit and vegetable consumption, are really responsible for the brain benefits.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story was not based on a press release.", "answer": 1}, {"article": "ASTRO publishes three medical journals, International Journal of Radiation Oncology\n\u2022 Biology\n\u2022 Physics (www.redjournal.org), Practical Radiation Oncology (www.practicalradonc.org) and Advances in Radiation Oncology (www.advancesradonc.org); developed and maintains an extensive patient website, RT Answers (www.rtanswers.org); and created the Radiation Oncology Institute (www.roinstitute.org), a nonprofit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment.\nThe advanced form of radiation therapy (RT) was well tolerated among this relatively understudied elderly population, indicating that SBRT is a viable option for patients who may otherwise be offered no curative treatment.\n\u201cElderly patients, who are otherwise doing well, should not have treatment withheld based solely on concerns about side effects and age.\u201d\n\nThe abstract, \u201cStereotactic body radiotherapy for early stage non-small cell lung cancer in patients 80 years and older: A multi-center analysis,\u201d will be presented in detail during the poster session at the 2017 Multidisciplinary Thoracic Cancers Symposium in San Francisco (full details below).\n\u201cThe low rates of side effects from SBRT for this elderly population in our study indicate that these concerns should not prevent physicians from considering definitive treatment for their inoperable octogenarian and nonagenarian patients with early stage lung cancer.\u201d\n\nFindings are based on a retrospective analysis of 58 consecutive patients who received definitive lung SBRT across four academic sites within Emory between 2010 and 2015.\nOS rates were higher for patients with higher Karnofsky Performance Status (KPS), which measures a patient\u2019s functional ability to perform ordinary tasks, such as work and self-care (HR = 0.91; p < 0.01).\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The use of \u201ccurative\u201d in the headline and the suggestion that SBRT is a \u201ccurative treatment\u201d is misleading. The release doesn\u2019t say whether the tumors treated originated in the lung or if they metastasized from some other part of the body. Particularly in the case of metastasized tumors, the treatment would be \u201cpalliative,\u201d but not curative.\nThe claims of treatment effectiveness and added survival are not supported by this study. What\u2019s more, evidence from other studies is weaker than the release implies. It is not justifiable for a researcher to plainly state the \u201cSBRT can effectively and safely add years to the lives of elderly patients\u201d when the study did not compare treatments. It would have been better for the release to limit itself to the actual results of the study; that is, that this group of elderly patients appeared to do as well as their doctors expected, and so age itself should not be used to disqualify patients from considering SBRT.", "answer": 0}, {"article": "Some 68% of the country is either overweight or obese, but there\u2019s not much clinical evidence on the best way to lose weight, outside of research on bariatric surgery. (True, \u201cEat less and exercise more\u201d is great advice if you can manage to follow it, but public-health authorities have repeated that line until they\u2019re blue in the face and as a population we\u2019ve only gotten fatter.)\n\nResearch presented over the weekend at the annual meeting of the Obesity Society and published online in the Journal of the American Medical Association suggests a few specific strategies that may help \u2026", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story does not rely on a news release.", "answer": 1}, {"article": "GAITHERSBURG, Md.\nThe therapy is exciting, AIDS specialists say, even though it is at least three years from market, because it could offer a completely new tool to combat a 25-year-old foe.\nBevirimat is being developed as physicians begin to use drugs from different classes in combination to fight the virus at different steps in its life cycle.\nNow its derivative is being tapped to fight HIV by a small Watertown-based biotechnology company.\nIf approved by the Food and Drug Administration, bevirimat, developed by Panacos Pharmaceuticals Inc., would represent the first in a new class of drugs that uses an unusual approach to block maturation of the virus that causes AIDS.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a press release as the only source of information. ", "answer": 1}, {"article": "Read all the details of this study, the full list of contributors and their financial support in Clinical Cancer Research.\nFurthermore, these tumor cells were sensitive to an experimental drug, neratinib.\n\"A circulating tumor DNA-based blood test also could therefore be potentially used to monitor tumor progression and to determine whether patients are responding or not to treatment after just one month of therapy,\" Ellis said.\n\"This is the first time we had a reasonable number of patients treated for HER2 mutations in whom we could estimate the response rate.\"\nThis task turned out to be a major challenge because for 20 to 30 percent of the patients the researchers did not have sufficient material to make the diagnosis.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "No sensational language here. But with only five patients (out of 16) showing a response to neratinib, the release seems to inflate the study results.", "answer": 0}, {"article": "\"Our meta-analysis of RCTs characterizes how cocoa flavanols affect cardiometabolic biomarkers, providing guidance in designing large, definitive prevention trials against diabetes and cardiovascular disease in future work,\" said corresponding author Dr. Simin Liu, professor and director of the Center for Global Cardiometabolic Health at Brown University who worked with epidemiology graduate student and lead author Xiaochen Lin.\nAll studies were small and of short duration, not all of the biomarkers tracked in these studies changed for the better, and none of the studies were designed to test directly whether cocoa flavanol consumption leads to reduced cases of heart attacks or type 2 diabetes.\nBut taking into account some of these heterogeneities across studies, the team's meta-analysis summarizing data from 19 trials found potential beneficial effects of flavanol-rich cocoa on cardiometabolic health.\nThere were small-to-modest but statistically significant improvements among those who ate flavanol-rich cocoa product vs. those who did not.\n\"We found that cocoa flavanol intake may reduce dyslipidemia (elevated triglycerides), insulin resistance and systemic inflammation, which are all major subclinical risk factors for cardiometabolic diseases.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There was no unjustifiable language in the piece. In fact, we thought it did a pretty good job bringing in the appropriate caveats and using language like: \u201cThere were small-to-modest but statistically significant improvements among those who ate flavanol-rich cocoa product vs. those who did not.\u201d\nThe release was very measured and like the scientific review, did not overstate the findings.", "answer": 1}, {"article": "Oxytocin,which is produced in abundance when a mother is breast-feeding her baby, is known as the \"bonding\" hormone.\nAlso, scientists would need to come up with a different method of delivery, Young said.\nThere were, however, wide variations in individual responses, the team noted.\nWhile there are drugs for the secondary symptoms of autism, such as irritability and aggression, doctors have nothing yet for the core symptoms in the areas of language, social interaction and intellectual deficits.\n\"It's not clear whether this would be effective at all in children or in young adults who had intellectual problems,\" warned Young.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "Learn about diagnosis and treatment of prostate cancer from the U.S. National Cancer Institute.\nThe Hopkins work was described as \"outstanding\" by Dr. William J. Catalona, director of the prostate cancer program at Northwestern Memorial Hospital's Robert H. Lurie Comprehensive Cancer Center, who pioneered the use of the standard PSA test and helped develop the new version of the test.\nIt is the pro-PSA level that is most valuable as a predictor, Veltri said, but it is only one part of the study.\nThe regimen found unfavorable indications for 39 of the cancers -- meaning progression of cancer grade or tumor size -- and favorable for the 32 others, Veltri said.\nThe Hopkins group is trying to identify other biomarkers that would improve the program's predictive value, he said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does not appear that the story relied solely on a news release. ", "answer": 1}, {"article": "They identified a total of 24 breasts reconstructed by DTI in 19 patients, all with at least 30 days' follow-up and most with one year of follow-up\n\nPatient characteristics and outcomes were compared to those of 109 breasts with TEI reconstruction in 98 patients.\nDr. Moreira and colleagues write, \"These reported cases include our learning curve patients as we familiarized ourselves with appropriate patient selection and surgical technique.\"\nPlastic and Reconstructive Surgery\u00ae is published by Wolters Kluwer.\nThe authors note some important limitations of their study--particularly the fact that it was a review study of one hospital's experience with a relatively new procedure.\nThe researchers identified women over age 65 who underwent DTI reconstruction at the Cleveland Clinic between 2012 and 2015.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "No major issues noted here.", "answer": 1}, {"article": "The researchers, Drs.\nAlso, he said, erectile dysfunction can also be a factor of aging and can be treated in most cases.\nBut the findings are not likely to be practice-changing, said Dr. Richard E. Greenberg, chief of urologic oncology at Fox Chase Cancer Center in Philadelphia, who was not involved with the study.\nThere was also a benefit in men whose tumors had low-risk characteristics.\nAlso, the men in this study were diagnosed only after they had symptoms, unlike the majority of men in the United States, Greenberg said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not rely on a news release.", "answer": 1}, {"article": "Tactics being tested include renal nerve ablation, a procedure that emits low-power radiofrequency along the nerves next to the kidneys, interrupting signals that trigger high blood pressure.\nIn the case study, a 55-year-old man was implanted with a deep brain stimulator to treat severe pain stemming from a stroke.\nThe finding introduces the possibility that deep brain stimulation -- a surgical implant that delivers electrical pulses to the brain -- might one day become a treatment for drug-resistant hypertension or lead to clues about the brain's role in regulating blood pressure.\nAbout 10 percent of high blood pressure cases either can't be controlled with medication or patients cannot tolerate them, study author Dr. Nikunj K. Patel, a neurosurgeon at Frenchay Hospital in Bristol, England, said in a journal news release.\nThe study adds to other recent research focused on neuromodulation, which harnesses the power of electrical impulses in the body for therapeutic benefit.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes interviews with two independent experts, so we can be sure it wasn\u2019t based on a news release.", "answer": 1}, {"article": "Neurosurgeons performing EDAS reroute arteries from the scalp and the membranes that cover the brain and place these arteries under the skull near areas of the brain at risk of stroke.\nTwo of the EDAS patients had small wound openings that required additional surgical interventions, but there were no intracranial hemorrhages or other serious adverse events, the researchers reported.\nThe trial, led by Nestor R. Gonzalez, MD, professor of Neurosurgery and director of the Neurovascular Laboratory at Cedars-Sinai, enrolled 52 patients with severe brain atherosclerosis, also known as intracranial atherosclerotic disease, or ICAD, who showed symptoms of either a recent stroke or a mini-stroke, called a transient ischemic attack.\nThese patients received EDAS surgery, along with intensive medical management, which included diet and lifestyle changes, blood thinners and other medications to control blood pressure, cholesterol and blood sugar levels.\nGonzalez said his team is working with the stroke prevention working group of the National Institutes of Health to develop a proposal for a Phase III randomized clinical trial across multiple institutions to further test the effectiveness of EDAS as compared with intensive medical management.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release claims that the described procedure \u201csignificantly decreases the rate of stroke recurrence and death for patients with severe atherosclerosis of the brain arteries\u201d but as noted under the Evidence criteria, the results did not demonstrate statistical significance.", "answer": 0}, {"article": "\u201cThere is a larger program we are putting into place.\u201d\nOther drugmakers including Roche have seen similar investigational medicines stumble, making Novartis\u2019s progress here hopeful news, doctors involved in the trial said.\n\u201cThese data have the potential to allow physicians to address an unmet need in this patient population by using a biomarker-driven treatment to inform their sequencing decisions,\u201d Andre added.\nBut this specific benefit data is being released on Saturday at the European Society for Medical Oncology\u2019s annual conference in Munich.\nBYL719 plus fulvestrant cut risk of death or progression in those patients by an estimated 35 percent, Novartis said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The reporter appears to have interviewed one source directly. However, one source\u2019s quote is taken directly from the drug company\u2019s news release, and is not attributed to the release. This statement appears in both the news story and the news release:\n\u201cThese data have the potential to allow physicians to address an unmet need in this patient population by using a biomarker-driven treatment to inform their sequencing decisions,\u201d Andre added.\nFor this reason, the story scores not satisfactory on this criterion.", "answer": 0}, {"article": "Omega-3 fatty acids are unsaturated fats found in most fish, but especially in fatty fish that live in cold seawater, such as salmon and herring.\nThe research described in Quick Study comes from credible, peer-reviewed journals.\nCAVEATS Most participants were white.\nTesting and measurements were done once, providing no data for comparison over time or to determine any link to dementia.\nWHO MAY BE AFFECTED?\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t tell to what extent this story may have relied on a press release, so we\u2019ll call it not applicable.", "answer": 2}, {"article": "In undeveloped countries, 75,000 women die from pre-eclampsia each year.\nThe cost of treating mothers with pre-eclampsia is $45 billion a year in the United States, Europe, Asia, Australia and New Zealand, the researchers said.\nSuch a \u201cmetabolic fingerprint\u201d test could save the lives of thousands of women, Philip Baker of the University of Alberta in Canada, who helped lead the study, said in a statement.\n\u201cIt would also ensure that those women are educated about the warning signs of pre-eclampsia.\n\u201cWe identified 40 organic molecules to be significantly elevated and 5 that were reduced in plasma at 14 to 16 weeks\u2019 gestation,\u201d they wrote.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\u00a0The article appeared to draw from the journal\u2019s press release and on the press release from the University of Alberta. But\u00a0there is enough original reporting here to make it squeak by.\u00a0", "answer": 0}, {"article": "An estimated 5 million people in the world have an eye disease called trachoma that affects the cornea, and another 1.5 million to 2 million are thought to have developed cornea-related blindness through other diseases or trauma.\nThe next step in research, Griffith said, is to create a \"new generation\" of cornea implants and test them on a wider variety of patients.\nGriffith said a German study recently found that donated corneas cost about $2,500.\nThe study appears in the Aug. 25 issue of Science Translational Medicine.\n\"We were pleasantly surprised that in six patients, vision improved from about 20/400 to 20/100, meaning that these patients could see objects four times farther away than before the operation,\" said Griffith, director of the Integrative Regenerative Medicine Center at Linkoping University in Sweden.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story goes beyond the news release, but, like the Reuters story, does not actually present the evidence with the same caveats and caution that come through in the news release and in the WebMD story.", "answer": 1}, {"article": "LONDON -- AstraZeneca PLC said Monday its experimental heart pill Brilinta was more effective at preventing heart attacks and strokes in a large clinical trial than the blockbuster pill Plavix, boosting commercial prospects for the U.K. drug maker's still unmarketed treatment.\n\nPlavix, which is marketed by Sanofi-Aventis SA and Bristol-Myers Squibb Co., was the second-biggest-selling drug in the world last year, with global revenue of $8.6 billion, according to IMS Health. Any competitor to it could have a shot at big sales.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure of the source of the information.\u00a0 No independent source is quoted.\u00a0 There are only brief references to what analysts say.\u00a0 ", "answer": 2}, {"article": "Spinal cord stimulation works by implanting an electrode near the spinal cord, inserted through the same place where epidural pain relief is injected for women in labor.\nDoctors say simple adjustments to the device may solve that problem.\nAnother concern is that patients who require high doses of stimulation drain the battery quickly, requiring surgery to replace the device.\n\u201cIt quickly becomes clear that \u2018weird\u2019 is going to be just fine if it replaces the pain.\u201d\n\nChronic pain is a particularly difficult problem to understand and solve.\nNot every patient feels that way.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story turned to several different sources, making it unlikely that it relied solely or largely on a press release.", "answer": 1}, {"article": "Of these, 85 percent were mild or moderate.\nBut no problems were seen with lower doses.\nBecause this study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\nSalloway's study looked at the drug's safety in 194 Alzheimer's patients, most of whom had mild- to-moderate Alzheimer's and participated in a long-term (78 weeks or longer) study.\nThe edema was symptomless in most cases, he said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story did not rely solely on a news release.", "answer": 1}, {"article": "All rights reserved.\nAdditionally, the support from the medical community builds on a previously important review article about the use of peppermint oil in IBS.\nAn international scientific and medical review team reported that there are a range of agents available to treat IBS and physicians should be knowledgeable about the efficacy and risk profile of any option they are about to prescribe.\n\"IBS considerably affects quality of life and places an enormous burden on patients, physicians and the health-care system,\" said Brooks D. Cash, M.D., A.G.A.F., F.A.C.G., F.A.C.P., F.A.S.G.E., Professor of Medicine in the Gastroenterology Division at the University of South Alabama in Mobile, Ala. \"The results of these studies add to the growing body of medical evidence supporting the utility of IBgard\u00ae, a novel formulation of peppermint oil, in improving the symptoms, patient satisfaction and quality of life of patients with IBS.\nIn the section of the article discussing management options for IBS, Dr. Enck and the accompanying panel of researchers stated \"peppermint oil\u2026is beneficial in reducing IBS symptoms.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release improperly portrays citations of a single, company-sponsored trial as the \u201cLatest in growing scientific and medical recognition of IBgard as an effective, safe, and well-tolerated option in the management of IBS.\u201d\nThis bullet point at the top of the release also goes overboard in suggesting that peppermint oil is the best treatment for IBS: \u201cBuilds on a previous review article where the lead author cited peppermint oil as the most effective option in management of IBS.\u201d\nThere is growing appreciation of the potential benefits of peppermint oil, but not of IBgard per se.", "answer": 0}, {"article": ".\nThe researchers investigated patients enrolled in the randomized, double-blind, comparative, multicenter international phase 3 ACTIVE trial to evaluate the efficacy and safety of 80 micrograms of abaloparatide-SC in preventing fractures in otherwise healthy, ambulatory, postmenopausal women with osteoporosis.\nThe results of the pre-specified subgroup analysis within the ACTIVE clinical trial will be presented Friday, April 1, at ENDO 2016, the annual meeting of the Endocrine Society, in Boston.\nThe Society, which is celebrating its centennial in 2016, has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries.\nOverall, 2,463 patients between 49 and 86 years of age were randomized to one of three treatment arms for 18 months: double-blind 80 micrograms of abaloparatide-SC, blind-matched placebo, or open-label 20 micrograms of subcutaneous teriparatide (an FDA-approved prescription drug known to increase bone density and strength).\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There\u2019s no unjustifiable language in use here.", "answer": 1}, {"article": "People taking resveratrol also showed suppression of the inflammatory protein tumor necrosis factor, or TNF, and other compounds that increase blood vessel inflammation and interfere with insulin action, causing insulin resistance and the risk of developing diabetes.\nNow, Ghanim and colleagues say they have found that resveratrol reduces inflammation in humans that could lead to heart disease, stroke, and type 2 diabetes.\nBlood samples from those on placebo showed no significant change in pro-inflammatory markers.\nResults showed that resveratrol suppressed the generation of \u201cfree radicals\u201d -- unstable molecules known to cause oxidative stress and release pro-inflammatory substances into the blood, resulting in damage to the blood vessel lining.\nThe volunteers took pills once a day for six weeks.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Not applicable because we can\u2019t be sure of the extent to which the story was influenced by a news release.\u00a0 We do know that no truly independent source was quoted in the story. ", "answer": 2}, {"article": "Adding small amounts of powdered ginger to food may help take the edge off seasonal allergy symptoms, according to an animal study published online in the Journal of Nutritional Biochemistry. Daily intake of dried ginger significantly reduced sneezing and other signs of allergy in rodents with induced allergic rhinitis, or hay fever.\n\nA major component in ginger, 6-gingerol, suppresses the activation of T lymphocytes, or T cells, a type of white blood cell that plays an important role in sensitizing people to specific allergens,...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We couldn\u2019t find any news release related to this study. And since the story doesn\u2019t include any independent perspective \u2014 which would indicate that it went beyond any such news release \u2014 we can\u2019t be sure whether the story meets our standard here or not. We\u2019ll rate it Not Applicable.", "answer": 1}, {"article": "May 23, 2011 -- Researchers in Europe say a fermented dairy product containing a specific bacterium known as a probiotic did not relieve constipation in children more than a dairy product without a probiotic.\nBut in a new study the kids who consumed the fermented dairy product did no better, based on number of stools produced, than youngsters in a comparison group.\nThe finding is significant, the researchers say, because probiotics have helped some adults with constipation.\nThe study examined 159 children with constipation for at least two months with a defecation rate of less than three times per week.\nIt seemed logical that probiotics, live microorganisms that are often called \u201cfriendly\u201d or \u201cgood\u201d bacteria, might work for children.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because an independent expert was interviewed, it\u2019s clear the story didn\u2019t rely solely on a news release.", "answer": 1}, {"article": "About 23 percent of the women reported taking a low-dose aspirin (81 milligrams), 18 percent took ibuprofen, 11 percent took full-strength aspirin (325 mg) and about 10 percent took a COX-2 inhibitor or another nonsteroidal anti-inflammatory drug (NSAID).\n[Certain adults should take a daily baby aspirin, expert panel says]\n\nWho may be affected?\nData on aspirin and other NSAID usage came from the women\u2019s responses on questionnaires.\nThe research described in Quick Study comes from credible, peer-reviewed journals.\nMillions of people take a low-dose aspirin daily in hopes of reducing their chances of having a heart attack.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story contained information about the harms of aspirin, which was not in the news release, which we reviewed. This is a barely passing satisfactory since the story mostly otherwise uses information from the release, but at least not verbatim.", "answer": 1}, {"article": "Though these children are larger, they do not have increased rates of obesity,\" Wu added.\nBut Rabin, who was not involved in the study, did add a few caveats about the findings.\nAccording to Dr. Jill Rabin, co-chief of the division of ambulatory care, Women's Health Programs-PCAP Services at Northwell Health, in New Hyde Park, N.Y., \"In pregnancy and beyond, adequate intake of fish is important for normal human development, and this paper certainly adds to the literature.\"\nThe report by Bisgaard and colleagues was published online Sept. 4 in the BMJ.\n\"For the past decade, the importance of fish oil and the omega-3 fatty acids have been stressed to patients,\" explained Wu, who was not involved in the study.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story doesn\u2019t appear to rely on a news release.", "answer": 1}, {"article": "Welch, author of a book, Should I Be Tested for Cancer?\nBoth Kopans and Dr. Otis W. Brawley, the American Cancer Society's chief medical officer, criticized the research team's short follow-up period -- just 2.2 years of observation, on average.\n\"Mammography is not perfect; no one has claimed that it is,\" said Kopans, a member of the ACR Commission on Breast Imaging.\nThe analysis, published in the Sept. 23 issue of the New England Journal of Medicine, raises new questions about the benefits versus risks of screening mammography and is already reigniting tensions over its frequency of use in the United States.\nBut Kopans noted that mammography is still the only test that has been proven to reduce the death rate from breast cancer and that this study should not divert attention away from that fact.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not rely on a news release.", "answer": 1}, {"article": "We can't find the page you're looking for. Try one of these options.\n\nAre you sure this is the right web address? Let us know.", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Overall, the news release uses neutral, appropriate language and does not sensationalize the device.\nThe following phrase did raise a red flag, though. \u201cThe risk of the chemotherapy drug missing an isolated grouping of the breast cancer cells in the scalp because of the cold cap is extremely rare.\u201d The small trial size and brief followup timeline don\u2019t warrant such a definitive statement. It would have been more justifiable to state that this is a theoretical risk that is likely rare but conceivable based upon the purported action of the device.", "answer": 1}, {"article": "Briakinumab works by dampening the immune system response that causes psoriasis, said Bruce Bebo, director of research and medical programs for the National Psoriasis Foundation, based in Portland, Ore.\n\nMore serious infections were seen in people taking briakinumab (2.6 percent) vs. those taking methotrexate (1.8 percent).\nThe current study included 317 people with moderate to severe psoriasis.\nThe study was funded by the drug's manufacturer, Abbott Laboratories.\nAt the time, Abbott withdrew its application for approval from the U.S. Food and Drug Administration pending further research.\n\"Very high levels of response\" were observed and maintained throughout the study period, said lead researcher Dr. Kristian Reich, a professor of dermatology at the University of Gottingen and a managing partner at Dermatologikum Hamburg, both in Germany.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely solely on a news release.", "answer": 1}, {"article": "\"Doctors are already doing these [glucose and HbA1c] tests together -- if a patient is obese, for example, and has other risk factors for diabetes, the physician is likely to order tests for both glucose and HbA1c from a single blood sample.\nBut taking the test twice takes up time and money and could still result in missed diagnoses, said a team from the Johns Hopkins Bloomberg School of Public Health in Baltimore.\n\"The CDC reports that greater than 52 percent of the U.S. population has either clinical diabetes or prediabetes,\" Bernstein noted.\n\"Given these numbers, any abnormality of glucose should be regarded as sufficient reason to start preventative treatment with an education program, lifestyle change and first-line medication such as metformin.\"\nHe agreed that quicker diagnosis could mean better treatment and outcomes for patients.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story drew heavily from a Johns Hopkins news release but also used other sources.", "answer": 1}, {"article": "Coleman RE, Hall A, Albanell J, Hanby A, Bell R, Cameron D, Dodwell D, Marshall H, Jean-Mairet J, Tercero JC, Rojo F, Gregory W, and Gomis RR.\nThe new study, which is published in the journal Lancet Oncology, was part of an international phase 3 clinical trial involving 3,360 women with stage II or III breast cancer.\nWomen who do not carry the gene - approximately 80 per cent of women with breast cancer - were found to benefit from the bone strengthening treatment.\nThe results need to be confirmed in a second trial, currently underway in the United States, before the test is likely to receive approval for wider use in patients.\n\u201cThe difficulty is identifying which patients will benefit from these drugs,\u201d said Professor Robert Coleman, emeritus professor of medical oncology who led the new study.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There is no unjustifiable language.", "answer": 1}, {"article": "The other is that, for tens of thousands of years, parasites and other infections unusual in modern society were a major problem in humans. The body developed a defense mechanism - inflammation - to fight them. Now, there aren't as many of these infectious diseases for our bodies to deal with, but we still have this defense mechanism. It has begun to target other things, such as allergens in the environment. Immunotherapy helps teach the body to better tolerate these harmless parts of our environment.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The feature was not based on a release as far as we can tell from the university\u2019s news release site.", "answer": 1}, {"article": "\"At the end of the day, our findings might modestly over - or under-estimate the health burdens,\" he told us.\nBut, here's the flip side: The researchers also found there's a significant risk in eating too little of certain healthy foods.\nScientists at Tufts University identified the foods that seem to contribute the most to the risk.\nNow, the task of estimating death or disease linked to diet is tricky.\nAnd eating more \u2014 or less \u2014 of just 10 types of food can help raise or lower the risk of death from these causes, the researchers found.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes original reporting and doesn\u2019t rely too heavily on this news release.", "answer": 1}, {"article": "\"We're always searching for simpler things to do,\" Brooks said.\nBrooks said it would be nice to have a very simple, accurate screening test -- whether that means a breath test or blood or urine tests.\nIt's all based on studies showing that breath samples from cancer patients tend to have a distinguishing pattern of so-called volatile organic compounds (VOCs).\nAnother big question, he added, is whether breath analysis could pinpoint people with colon polyps.\nBut, Brooks pointed out, that also means the breath test was wrong about one-quarter of the time.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It doesn\u2019t appear that the story relied inappropriately on this press release.", "answer": 1}, {"article": "\"Doing that could be a lot easier than nudging children about going to bed,\" Raine said.\nThe researchers also want to add to this current observational study to establish, through randomized controlled trials, that eating fish can lead to better sleep, better school performance and other real-life, practical outcomes.\nGiven the young age of this study group, Liu and colleagues chose not to analyze the details participants reported about the types of fish consumed, though they plan to do so for work on an older cohort in the future.\n\"We have found that omega-3 supplements reduce antisocial behavior, so it's not too surprising that fish is behind this.\"\nFor the work, a cohort of 541 9- to 11-year-olds in China, 54 percent boys and 46 percent girls, completed a questionnaire about how often they consumed fish in the past month, with options ranging from \"never\" to \"at least once per week.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Generally the language was satisfactory, but based on the observational nature of the research alone it seems the concluding advice may be premature:\n\u201cThe researchers recommend incrementally incorporating additional fish into a diet; consumption even once a week moves a family into the \u201chigh\u201d fish-eating group as defined in the study.\u201d\nCurrent US dietary guidelines already recommend at least 8 ounces of fish and shellfish at least once a week. The release could have clarified this.  ", "answer": 1}, {"article": "Overweight people on low-carbohydrate and Mediterranean diets lost more weight and got greater cardiovascular benefits than people on a conventional low-fat diet, according to a study that endorses alternative diets published in a major medical journal.\n\nThe study, which tracked 322 Israelis for two years, surprisingly found that a low-carb diet, often associated in the U.S. with high levels of meat consumption -- was better than a low-fat diet in boosting blood levels of \"good\" cholesterol, or high-density lipoproteins...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because of the number of sources and perspectives represented, it\u2019s safe to assume this story did not rely solely or largely on a news release. ", "answer": 1}, {"article": "Research in the Journal of the American College of Nutrition suggests that eating a hearty portion of instant oatmeal for breakfast -- versus a popular oat-based cold cereal -- leads to lower calorie intake at lunch\n\nCHICAGO, IL, August 19, 2015 - A new study revealed that your cereal choice at breakfast might have an impact on how much you eat for lunch.\n\"The fact that choosing instant oatmeal over a cold cereal may also help Americans curb their intake at lunch is especially encouraging.\"\nNewly published research in the Journal of the American College of Nutrition showed that a hearty bowl of instant oatmeal helped curb food intake at lunch better than a leading oat-based, cold cereal -- even when each bowl provided the same number of calories.\nThe Quaker Oats Center of Excellence is focused on elevating the relevance and benefits of oats through science, agriculture and innovation.\nThe lunches offered ranged from 2,600 to 2,800 calories and participants were told to \"eat to satisfaction.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There was nothing out of bounds about the language used in the release.", "answer": 1}, {"article": "Because obesity is linked to poor outcomes for expectant mothers and babies -- including birth defects, gestational diabetes, high blood pressure, premature birth and even childhood obesity -- efforts to lose weight before pregnancy are important, said Dr. Aaron Caughey, chair of the department of obstetrics and gynecology at Oregon Health and Science University's School of Medicine.\nThe investigators didn't examine what might have caused smaller babies among bariatric surgery recipients, or higher stillbirths.\nThe surgical group was also much less likely to give birth to larger-than-normal babies.\nCaughey agreed with the researchers that any pregnancy occurring after weight-loss surgery merits a higher level of monitoring and should be considered high-risk.\nBut Caughey, who wrote an editorial accompanying the new research, said women considering weight-loss surgery should make the decision based on the long-term health benefits of the procedure -- not on potential pregnancy-related benefits.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article goes beyond any press release.", "answer": 1}, {"article": "In the United States study, 80% of the children on antibiotics felt better on the seventh day of treatment; 74% of the children taking a placebo also felt better on the seventh day.\nRosenfeld says it's never wrong to prescribe an antibiotic for a well-diagnosed ear infection.\nOne of the strengths of both studies, Rosenfeld said, is that the researchers took the time to make a solid diagnosis.\nIn treatment outcomes for pain, there was no difference, he notes.\nAccording to one of the studies, ear infection, or acute otitis media, is the most frequently diagnosed illness in children in the United States, and most children with these ear infections are routinely given antibiotics.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story features comments from two independent experts, so we can be sure it\u2019s not based on a news release.", "answer": 1}, {"article": "In Rothwell\u2019s study, published in The Lancet, researchers found the 20-year risk of death was reduced by about 10 percent for prostate cancer, 30 percent for lung cancer, 40 percent for colorectal or bowel cancer and 60 percent for oesophageal cancer in those taking aspirin.\nPeter Elwood, an expert on aspirin from Cardiff University\u2019s medical school who was not involved in this study, described aspirin as \u201ca remarkable drug.\u201d\n\n\u201cThis risk of a bleed is so small compared to the benefits,\u201d he told reporters.\nAlastair Watson, professor of translational medicine at the University of East Anglia, said the study was an important step in scientists\u2019 understanding of how to prevent cancer.\nThe findings will fuel an already intense debate about the merits of taking aspirin, which increases the risk of bleeding in the stomach to around one patient in every thousand per year.\nThe researchers added, however, that treatment with aspirin during the trials lasted for only for between four and eight years on average, so the effects on risk of deaths due to cancer may underestimate possible results of longer-term treatment.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\nThe story does not appear to rely on a news release.", "answer": 1}, {"article": "Read more: Trump Health Exam: President Still Taking Hair Loss Drug Even After Research Revealed Link to Erectile Dysfunction and Depression\n\nIn the U.S., the National Institute of Mental Health estimates 16.2 million adults experienced at least one major depressive episode in 2016.\nIn the U.K, where a number of the study authors are based, at least one million more people could benefit from drugs or psychotherapy, senior author John Geddes said.\nJames Warner, an Imperial College London psychiatrist, added: \u201cDepression causes misery to countless thousands every year and this study adds to the existing evidence that effective treatments are available.\u201d\nApproximately 37 percent of these people received no treatment.\nHelen Stokes-Lampard, chair of the U.K.\u2019s Royal College of GPs, expressed concern about the stigma surrounding antidepressant use.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story quotes a news release from the Royal College of General Practitioners and pulls two other quotes from a list of \u201creactions\u201d to the study put together by the Science Media Centre, which it does not attribute. Quotes from the study author were attributed to a press briefing.\nWhile the story doesn\u2019t technically rely on a news release, it doesn\u2019t appear to include any original reporting.", "answer": 1}, {"article": "\"But at the same time it's something we'll continue to look at, and hopefully confirm absence of risk.\"\nThat means many doctors are likely to charge more than $300 retail, putting the Merck product in league with Prevnar, an expensive Wyeth vaccine that has been widely used in the United States for five years.\nThe federal Centers for Disease Control and Prevention and the manufacturer, Merck & Co. Inc. of Whitehouse Station, N.J., have promised elaborate studies to catch any safety problems.\nThe vaccine won approval from the Food and Drug Administration on Feb. 3, and some doctors have received supplies of it.\nThe decision means that pediatricians are likely to recommend three doses of the oral vaccine for nearly every child at age 2 months, 4 months and 6 months, beginning almost immediately.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no evidence that this story relied solely or largely on a news release.", "answer": 1}, {"article": "In a study by researchers from the Hospital Clinic of Barcelona and Loma Linda University, more than 700 older, healthy adults were asked to add either a handful of walnuts to their daily diets or to follow their normal diet without eating nuts.\nWalnuts have long been touted as a healthy, whole food, but new research just upped the homely nut's reputation another notch.\nThe research shows the well-known cholesterol-lowering effect of eating walnuts works equally well in the elderly, even in the long term, the authors reported at the Experimental Biology conference in San Diego.\nIt's still important to remember portion control, especially for people on weight loss programs, warned Politi.\nWalnut oil can be a good alternative too, in dressings and for light basting, Politi said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is a news release that was obviously used in this story, but there was also an outside source, which is just enough to rate as Satisfactory.", "answer": 1}, {"article": "The researchers found that 10.2 percent of the patients who received zotarolimus-coated stents suffered a major adverse cardiac event, compared with 8.3 percent of the patients who received sirolimus-coated stents and 14.1 percent of those with paclitaxel-coated stents.\nFor the study, a team led by Dr. Duk-Woo Park from the University of Ulsan College of Medicine and Asan Medical Center in Seoul randomly assigned 2,645 patients undergoing angioplasty, a procedure to restore blood flow through the artery, to one of the three stents.\nIn preventing major cardiac events, the researchers found that zotarolimus-coated stents, the new entry in the field, were less effective than the sirolimus-eluting stents, but better than stents coated with paclitaxel.\nFonarow said the study results can help cardiologists arrive at treatment decisions.\nThe number of heart attacks and deaths was about the same in each group, but the rate of blood clots in the stents was significantly lower with sirolimus-eluting stents, Park's team also found.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We didn\u2019t find evidence that this article relied on a news release.", "answer": 1}, {"article": "The world\u2019s biggest maker of cancer drugs is counting on growing sales of Tecentriq, which notched 487 million Swiss francs in 2017, to help offset falling revenue from its older cancer medicines Avastin, Rituxan and Herceptin whose patent expirations are exposing them to rivals\u2019 cheaper copies.\nWhile Roche did not provide specific overall survival data, the headline result helps its bid to catch up to better-established immunotherapies from Merck and Bristol-Myers Squibb and its shares rose about 1 percent in early trading.\n\u201cWe continue to see Roche efficacy more than sufficiently competitive to grant a 43 percent market share in the indication, translating in 4.9 billion francs Tecentriq peak sales and 1.2 billion francs in 2018,\u201d Baader\u2019s Bruno Bulic said.\nAnalysts from Baader Helvea said its announcement completes an \u201calready robust\u201d set of data for regulators who now must sign off on Tecentriq\u2019s use as an initial treatment of lung cancer.\nMixing Tecentriq with Avastin and carboplatin and paclitaxel boosted overall survival in first-line treatment of non-squamous non-small cell lung cancer, Roche said on Monday, compared to patients who received only Avastin plus the two chemotherapies.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story used a quote from a Roche news release, but did not attribute it to the release:\nWe are pleased that the IMpower150 study demonstrated a clinically meaningful survival benefit for people receiving their initial treatment for this type of advanced lung cancer,\u201d said Sandra Horning, MD, Roche\u2019s Chief Medical Officer and Head of Global Product Development.\u201d\nBut since it discussed the profit motives at play, which Roche didn\u2019t disclose, it just barely offsets the reliance on the news release and earns a satisfactory score.", "answer": 1}, {"article": "Knee replacements were first offered in the 1960s, and hip replacements began in the 1940s, so many boomers are facing the same surgeries their fathers and mothers underwent.\nBut having had the procedures, many say they wish they\u2019d done it sooner.\nBut he has already resumed golfing \u2014 on a March trip to visit his son and his family in Atlanta.\nWhile physical activity obviously plays a role in joint deterioration, genetics may be the biggest factor in determining who needs a replacement and when, he said.\nAnd, he promised, \u201cI will get on the skates again.\u201d\n\nLike Smith, many boomers endured months or years of pain before surgery, pain caused by \u201cbone-on-bone\u201d friction when cartilage deterioration eroded their bone cushioning.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not appear to rely on a news release.", "answer": 1}, {"article": "Iowa Democrats may have saved the caucuses\n\nIf the proposed Democratic plan is adopted, the Iowa Democratic caucuses will be both familiar and new and may well endure as first in the nation.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no evidence that this story relied solely or largely on a news release.", "answer": 1}, {"article": "For the really Type A personality, here's a chance to measure how well you are relaxing. Makers of home biofeedback devices that monitor your heart rhythms say the devices teach you to combat emotional stress. Psychologists and psychiatrists say the gadgets appear to help their stressed-out patients but warn that there isn't yet strong scientific evidence that they work.\n\nBiofeedback has long been used to treat stress in psychologists' offices -- with an expert who leads the patient in relaxing breathing exercises and...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if the story relied solely or largely on a news release. ", "answer": 2}, {"article": "The difference could mean 50,000 to 70,000 fewer deaths and 100,000 fewer cases of kidney failure each year in the U.S., researchers estimate.\nIVs are one of the most common things in health care.\nThe fluids cost about the same \u2014 a dollar or two per IV \u2014 and many suppliers make both types, so switching should not be hard or expensive, doctors said.\nThey\u2019re widely used in Europe and Australia.\nKellum had no role in the two studies, which were discussed Tuesday at a critical care conference in San Antonio and published by the New England Journal of Medicine.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This article does not appear to rely solely upon a news release.", "answer": 1}, {"article": "Dr.\nDr. Ahlquist said he was very pleased with the new results, especially the 64 percent detection rate for precancerous polyps, since these are best targets for intervention.\nThe specificity of the Exact Sciences test is 88 percent, meaning that 12 percent of the time the patient will be given a false alarm.\nBoth tests would be less expensive than colonoscopy, and potentially more effective.\n\u201cWith stool tests, you need a 90 percent specificity,\u201d said Dr. Bert Vogelstein, a cancer expert at Johns Hopkins University who is also an adviser to the company.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story did not rely on a news release.", "answer": 1}, {"article": "\u201cBut I wasn\u2019t really doing well,\u201d said Ms. Schomaker, 73.\n\u201cI had many interests.\u201d She traveled and even tried dating again.\n\u201cI had terrible pangs of sadness and despondency.\n\u201cThe pain just didn\u2019t go away,\u201d she said.\nFriends thought Anne Schomaker was coping well with her loss, she recalled.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story goes beyond any news release to include independent reporting.", "answer": 1}, {"article": "No serious adverse events were reported.\nLarger and longer studies are now needed to prove that the twice-daily pill can also reduce severe asthma attacks, known as exacerbations.\nNovartis believes the medicine could be filed for regulatory approval in around 2019.\nPills for asthma used to be standard treatment 40 or 50 years ago, but those older products were often associated with worrying side effects.\nAt the same time, many drugmakers are developing improved asthma inhalers, including \u201csmart\u201d devices with sensors that monitor use.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely solely on the\u00a0news release, which we also reviewed.", "answer": 1}, {"article": "Because about one-half of the deaths in people with type 2 diabetes are caused by cardiovascular disease, reducing cardiovascular risk is considered essential to diabetes care.\nHe has not prescribed Jardiance and similar drugs as frequently as treatments like Januvia, but expects that may change based on the new data.\nThe benefits were especially impressive because they added to protection that patients received from taking cholesterol fighters and other life-saving heart drugs, Zinman said.\nThe vast majority of those patients could be candidates for Jardiance, which costs over $4,000 per year, Morningstar analyst Damien Conover said.\n\u201cIt is probably going to be a more popular drug because of that.\u201d\n\nSanford Bernstein analyst Tim Anderson more than tripled his annual sales forecast for Jardiance and combination drugs containing it to $2.7 billion by 2020.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes quotes from interview with Dr. Zinman, so we know that it went beyond the news release\u00a0issued for the study.\n\u00a0", "answer": 1}, {"article": "\"So before we activated the device, we have all sorts of problems\u2026 This is basically your brain saying, 'I'm not breathing.'\nFor Siravo, she said her memory is back to 100 percent.\nIt's only for moderate to severe cases, and like any surgery, there is risk of infection.\n\"And then that didn't work.\nExhausted, the 59-year-old could barely do her job as a nurse \u2013 and she knew something wasn't right.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story doesn\u2019t appear to rely on a news release. In fact, it\u2019s not clear why the story is running now at all. Inspire was approved by the FDA in 2014 and has been on the market for quite some time.", "answer": 1}, {"article": "The study was supported by the Andrew Sabin Family Fellowship Program; the American Association for Cancer Research \u2013 Stand Up to Cancer; the National Institutes of Health (CA219896-01A1, HL124112); the Cancer Prevention & Research Institute of Texas; and the Melanoma Moon Shot\u2122, part of MD Anderson\u2019s Moon Shots Program\u2122, a collaborative effort to accelerate the development of scientific discoveries into clinical advances that save patients\u2019 lives\n\nIn addition to Wang, other MD Anderson authors include: Diana Wiesnoski, Christopher Sanchez, and Chia-Chi Chang, Ph.D., all of Genomic Medicine; Beth Helmink, M.D., Ph.D., and Vancheswaran Gopalakrishnan, Ph.D., both of Surgical Oncology; Hamzah Abu-Sbeih, M.D., Gottumukkala Raju, M.D., and John Stroehlein, M.D., all of Gastroenterology, Hepatology & Nutrition; Edwin Parra, M.D., Ph.D., and Alejandro Francisco-Cruz, Ph.D., both of Translational Molecular Pathology; Matthew Campbell, M.D., Jianjun Gao, M.D., Ph.D., and Sumit Subudhi, M.D., Ph.D., all of Genitourinary Medical Oncology; Dipen Maru, M.D., of Pathology; Jorge Blando, DVM, and James Allison, Ph.D., both of Immunology; Padmanee Sharma, M.D., Ph.D., of Genitourinary Medical Oncology and Immunology; Michael Tetzlaff, M.D., Ph.D., of Translational Molecular Pathology and Pathology; Jennifer Wargo, M.D., of Genomic Medicine and Surgical Oncology; and Robert Jenq, M.D., of Genomic Medicine and Stem Cell Transplantation.\nBoth patients in the study had a complete resolution of their colitis following treatment with FMT.\nThe study from The University of Texas MD Anderson Cancer Center, which includes two patients, suggests fecal microbiota transplantation (FMT) is worth investigating in clinical trials as a therapy for this common side effect of immunotherapy.\nWith endoscopic evaluation before and after treatment, both patients displayed significant improvements in inflammation and ulcerations, including a reduction of inflammatory immune cells.\nAdditionally, distinct new populations of bacterial species were evident in these patients following FMT compared to pre-treatment samples, including several species known to be protective or reduce inflammation.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Although the text identifies the sample of only two patients as a design limitation, the first author of the study projects confidence that the procedure is \u201csafe, quick, and the effect is durable\u201d and recommends that others consider the procedure \u201cas a first-line therapy for ICI-associated colitis.\u201d Without appropriate clinical trials on a larger population, such confidence may not be warranted.", "answer": 0}, {"article": "About the University of Louisville Physicians Group and The James Graham Brown Cancer Center:\n\nThe James Graham Brown Cancer Center is a key component of the University of Louisville Health Sciences Center.\nIRE was successfully administered to all patients.\nThe data was presented at the American Surgical Association annual meeting in San Diego.\n\"This new analysis of IRE could help change the standard of care for Stage III pancreatic cancer patients whose only treatment options until now were chemotherapy or a combination of chemo-radiation therapy, which will only stabilize the disease and not destroy the tumor.\n\"The STAR data adds to the growing body of evidence that IRE ablation may represent a new treatment paradigm for patients with locally advanced pancreatic cancer,\" said Robert Martin, M.D., Ph.D., F.A.C.S., director of the Division of Surgical Oncology, and Professor, Department of Surgery, University of Louisville, James Graham Brown Cancer Center.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release\u00a0asserts the NanoKnife IRE treatment can\u00a0double the survival for pancreatic cancer patients, but it doesn\u2019t lay out\u00a0potential\u00a0caveats, nor how this only applies to the 1-year survival category (and not the 5-year survival category). However, since we\u2019ve already dinged them for that deficiency, and there are no other examples of hyperbole, we\u2019ll call this Satisfactory.", "answer": 1}, {"article": "Michael T. Lotze, a professor of surgery and bioengineering at the University of Pittsburgh, said that \"the work is heroic.\nResponse by others in the field was positive but not effusive.\nThe report, published online by the journal Science, is the latest result of a three-decade effort by surgeon Steven A. Rosenberg to find ways to manipulate the human immune system to fight cancer.\nAnd cancer sometimes returns even after that much time has elapsed.\nAt least five years would need to pass before such a declaration would be considered.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This article does not appear to rely exclusively on a press release as its sole source of information", "answer": 1}, {"article": "Statins reduce cardiovascular risk and scientists believe it is because they decrease low-density lipoprotein, or LDL, the so-called bad cholesterol.\nStill, the findings could help smooth the way for regulatory approval, wider use of the drugs by doctors and possibly reimbursement by insurers.\nBut merely looking at cholesterol levels can be misleading.\nAnalysts say the drugs will have billions of dollars in annual sales and will be taken by millions of people who cannot lower their cholesterol enough using statins alone or cannot tolerate statins.\nWhether the results from these two small studies will be persuasive enough remains to be seen.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article did not seem to be based on this press release\u00a0or this one. The critical perspectives given by the independent experts in this story are evidence of original reporting.", "answer": 1}, {"article": "She is 5-foot-7, and her starting weight was 165 to 170; after two months she had lost about 28 pounds.\nPart of the reason for the study, Dr. Ravussin said, was to find out whether people could stand calorie restriction.\nAnother group ate 75 percent of what members needed to keep their weight steady.\nThey had to take time off work for metabolism tests and also ate many meals at the clinic.\nHe wound up in the group assigned to cut calories by 25 percent.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t judge if the story relied solely or largely on a news release. ", "answer": 2}, {"article": "A little bit of current may calm the tremors of Parkinson\ufffds disease, ease depression and epilepsy, and awaken those with terrible injuries.\nA glimpse of Mom must first register on your occipital lobes as a pattern of light and shadow.\nIt's harder than you think to say hello to your mother--at least in terms of the work your brain has to do.\nFrom there it is relayed to your memory center, where it is identified by comparison with every other face you've ever seen.\nYou must then summon the speech centers in your frontal lobes, which recruit your breath and muscles and at last allow you to utter the words Hi, Mom.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not appear to rely on a published press release.", "answer": 1}, {"article": "Commenting, Professor Andreas Meyer-Lindenberg, Central Institute of Mental Health, Mannheim and member of the ECNP executive board, said: \"This work builds on previous studies that have shown a critical role of excessive activity of subregions of the temporal lobe in the generation of voice hallucinations in schizophrenia.\nFor the first time, scientists have precisely identified and targeted an area of the brain which is involved in \"hearing voices\", experienced by many patients with schizophrenia.\nThis is the first controlled trial to show an improvement in these patients by targeting a specific area of the brain and using high frequency TMS.\nTo move this into treatment, controlled trial such as the one by Dollfus and coworkers are important.\nThey have been able to show in a controlled trial that targeting this area with magnetic pulses can improve the condition in some patients.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "This is a close one. In its opening sentence, the release states that \u201cFor the first time, scientists have precisely identified and targeted an area of the brain which is involved in \u2018hearing voices\u2019, experienced by many patients with schizophrenia.\u201d But there have been previous studies that have tied areas of the brain to hallucinations (e.g., this 2015 Nature Communications paper). That initially gave us pause. However, we\u2019ll give the release the benefit of the doubt given that the opening sentence notes that this study \u201cprecisely\u201d identifies an area of the brain associated with AVHs specifically.\nIt\u2019s a minor point, but we don\u2019t think it was necessary to repeatedly put quotation marks around the phrase \u201chearing voices.\u201d People with this symptom of schizophrenia hear voices. Period. They\u2019re generated from within their brains, without the benefit of outside sensory input, but they hear them as if they were.", "answer": 1}, {"article": "The oldest cyclists had less muscular power and mass than those in their 50s and early 60s and considerably lower overall aerobic capacities.\nOn almost all measures, their physical functioning remained fairly stable across the decades and was much closer to that of young adults than of people their age.\nAge does seem to reduce our endurance and strength to some extent, Dr. Harridge said, even if we exercise.\nThe findings suggest that many of our expectations about the inevitability of physical decline with advancing years may be incorrect and that how we age is, to a large degree, up to us.\nBut even so, both of those measures were higher among the oldest cyclists than would be considered average among people aged 70 or above.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The quotes in the story are not the same as the ones in a news release issued by Kings College London, so it appears interviews were done. However, the news release was more cautious than this story about the results. For example, the story calls the results proof that \u201cmany of our expectations of the inevitability of physical decline with advancing years may be incorrect\u201d and \u201chow we age is, to a large degree, up to us.\u201d\nThe release does not extend to suggest that individuals can control the aging process, but just raises the possibility that there is a great degree of variability in how people age. Here is an excerpt from the release:\n\u201cOverall, the study concluded that ageing is likely to be a highly individualist phenomenon. As people are so different, the team concluded that more studies are needed which follow the same healthy and exercising individuals over time to better understand the effects of ageing the body.\u201d\nSee: http://www.kcl.ac.uk/newsevents/news/newsrecords/2015/January/Exercise-allows-you-to-age-optimally.aspx", "answer": 1}, {"article": "One group of researchers, for example, recently worked backward to take on the problematic overlap between depression and bipolar disorder\u2014many bipolar patients are initially and incorrectly diagnosed with depression.\nDespite these exciting preliminary findings, there aren\u2019t yet any biological tests for mental illness widely used in medical practice.\nA tumor seen on a scan, bacteria identified by a throat culture, a fracture captured on an X-ray: They\u2019re all clear signs something is wrong.\nIt took a few years to find the right \u2018formula\u2019 of meds.\u201d While the doctors recommended some medication that helped, it was a matter of trial and error, since Orlando still doesn\u2019t have a concrete diagnosis today.\nNext, she was told she had depression.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on any news releases, as far as we can tell.", "answer": 1}, {"article": "Sept. 17, 2010 -- The FDA has approved Krystexxa (pegloticase) for the treatment of gout.\nThe drug is administered to patients every two weeks as an intravenous infusion.\nThe drug is associated with some serious side effects.\nTwo six-month clinical trials of 212 total patients showed that the drug lowered uric acid levels and reduced deposits of uric acid crystals in joints and soft tissue.\nSavient expects Krystexxa to be available by prescription later this year.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Unsatisfactory.\u00a0 Both quotes \u2013 according to the story itself \u2013 came from a news release.\u00a0 Why not do independent reporting on this?\u00a0 ", "answer": 0}, {"article": "One patient with ovarian cancer had a complete response that lasted 89 weeks, one patient with gastroesophageal cancer had a partial response that lasted 16 weeks, and four patients (two with colon cancer, one with prostate cancer, and one with ovarian cancer) had stable disease.\nAccording to Berzofsky, the main scientific limitation of the study is that it is a relatively small, phase I clinical trial with no placebo control.\nAdverse reactions were predominantly injection-site reactions that did not require treatment.\nThis study was supported by intramural funds from the National Cancer Institute.\nPreclinical studies, which were previously published in the AACR journal Cancer Research, showed that this type of vaccine could eradicate large, established tumors as well as lung metastases in mice.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release does not rely on unjustifiable language.", "answer": 1}, {"article": "That number was the same in younger people who had large waistlines, and even lower in those with metabolic syndrome, a combination of risk factors including belly fat, high blood pressure and high blood sugar.\nAs a result, he said, it is hard to know whether removing polyps in younger people would in turn lower their risk of getting cancer.\nLeFevre, a member of the U.S. Preventive Services Task Force, a federally appointed expert panel, said the chances that a polyp turns into cancer is currently a matter of debate.\nColonoscopy, used in millions of Americans every year, is just one of many methods to detect abnormalities.\nIn younger people, it is unclear that the benefits of screening offset the risks.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story quotes several independent sources, the reader can assume that the story does not rely on a press release as the sole source of information.", "answer": 1}, {"article": "Larry Holzman \u2014 avid mountain-biker, skier and guitarist in a band \u2014 plays hard.\nHis physical therapist quickly diagnosed it as tennis elbow.\nIt usually happens when people grip things too hard or too long.\nAnd he didn't want to give it all up due to a \"spot of pain\" in his elbow.\nIn Larry's case, it was a combination of all his hobbies: from squeezing the handlebars on his bike, to lifting weights and playing in a band.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story wasn\u2019t based on a news release.", "answer": 1}, {"article": "Post-traumatic stress disorder (PTSD) is a term for a broad range of psychological symptoms that can develop after someone experiences or witnesses a traumatic event.\nA week later, under no medication, participants returned to repeat the experiment.\nThis is called 'reconsolidation', and we now plan to test the effect of doxycycline on reconsolidation of fear memories.\nThe screen would flash either blue or red, and one of the colours was associated with a 50% chance of receiving a painful electric shock.\nTo treat such diseases, we already have clinically approved drugs that block these enzymes, including the antibiotic doxycycline, so we wanted to see if they could help to prevent fear memories from forming in the brain.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t include any sensational, unjustifiable language.", "answer": 1}, {"article": "\"There is a fairly active and vocal group of families in Colorado who are using cannabidiol oils that are made artisanally,\" she said.\nIf CBD proves effective in controlled trials, it could be two to five years before the drug is approved by the U.S. Food and Drug Administration, Devinsky noted.\n\"We don't know the real effect of the cannabidiol, and we won't until we complete the studies that are ongoing that are placebo-controlled and blinded,\" added Brooks-Kayal, who is also a professor of pediatrics, neurology and pharmaceutical sciences at the University of Colorado School of Medicine.\nBut, researchers believe it may interact with a brain receptor that plays a role in the development of seizures, Devinsky said.\nCannabidiol is a major chemical component of marijuana, said Dr. Orrin Devinsky, a neurologist at NYU Langone Medical Center's Comprehensive Epilepsy Center in New York City and co-author of one of the studies.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story reflects some enterprise reporting independent of the news release from the American Epilepsy Society; for example, the reporter solicited information about the study\u2019s validity from an independent researcher.", "answer": 1}, {"article": "For example, a normal-weight woman should gain between 25 and 35 pounds, while an overweight woman should gain between 15 and 25 pounds.\nThe review incorporates dozens of new studies to update a previous review that did not find enough evidence to support the use of diet and exercise during pregnancy.\nWhile the new study generally did not show fewer complications in the diet and exercise group, Dr. Loralei Thornburg told Reuters Health that it\u2019s good that there was no increase in complications.\nFor the new review, the researchers examined data from 65 randomized controlled trials, which are considered the \u201cgold standard\u201d of medical research.\nAfter including the new studies, the new review found \u201chigh-quality evidence\u201d to show diet, exercise or both can reduce the risk of excessive weight gain during pregnancy, write the researchers in The Cochrane Library.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story cited at least one independent source and drew on material from the Institute of Medicine.", "answer": 1}, {"article": "A healthy cholesterol level is less than 200 mg/dL, according to the American Heart Association, while 200 to 239 mg/dL is considered \u201cborderline high.\u201d\n\nIn the groups taking 100 and 200 micrograms of selenium daily, total cholesterol dropped an average of 8.5 mg/dL and 9.7 mg/dL, respectively, compared to the group taking a placebo pill.\nThe picture of selenium\u2019s health benefits \u2014 or possible health risks \u2014 has been anything but clear.\nStill, the finding is \u201creassuring\u201d because previous research had linked high selenium with higher cholesterol levels, said study author Dr. Eliseo Guallar, from the Johns Hopkins Bloomberg School of Public Health in Baltimore.\nWhile Guallar said the results are \u201cgood news\u201d in showing that high selenium intake is probably not a risk for high cholesterol, he wanted to add a note of caution.\nThey recruited about 500 older adults in the UK to take one of three different doses of selenium daily \u2014 100, 200, or 300 micrograms \u2014 or a placebo pill with no selenium.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We couldn\u2019t find any press release that would have served as the basis for this story. Since the story quotes only one source who was affiliated with the study, however, we can\u2019t be certain to what extent this story may have relied on a press release. We\u2019ll call it not applicable.", "answer": 2}, {"article": "On the other hand, she says, \"people's dietary habits don't really change a lot.\nMaryam Farvid, a fellow at the Harvard School of Public Health who is lead author of the study, says the influence of fiber on cancer risk may be time-sensitive.\nShe says it can be hard to get the attention of teenagers about healthy eating.\nThis new study provides some evidence of yet another potential benefit.\nThis is a question Kristi King, a dietitian at Texas Children's Hospital, has thought about a lot.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story went well beyond a news release, incorporating significant additional information \u2014 particularly in regard to how to communicate the findings to adolescent and young adult women.", "answer": 1}, {"article": "Bisphosphonates include such common drugs as Fosamax (alendronate), Boniva (ibandronate), Actonel (risedronate) and Reclast (zoledronic acid).\nA randomized trial is need to prove that bisphosphonates are protective against colorectal cancer, Rennert said.\n\"The magnitude of the reduced risk is less important because this is an association study; however, it is very significant after controlling for a dozen other known risk factors,\" Rennert said.\nHowever, these results should be interpreted with caution and require confirmation by additional studies, he said.\n\"Results from the only other study of bisphosphonate use and colorectal cancer, a recent large study from the United Kingdom, do not support an important protective effect,\" Jacobs noted.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Neither story relied on a news release.", "answer": 1}, {"article": ".\nA new study shows that electro-acupuncture may be effective in providing some relief.\nAlthough electro-acupuncture produced significant sleep improvements, researchers noted that sleep quality for the participants was still not as good as it should be, implying that more research is necessary to explore possible combinations of pharmacologic and nonpharmacologic treatments.\n\"This study shows that, for women who need or choose to avoid medications, electro-acupuncture may be an option because it has minimal risks, but blinded controlled trials are needed,\" says Dr. JoAnn Pinkerton, NAMS executive director.\nIt is estimated that by the year 2020 there will be nearly six million breast cancer survivors in the United States.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "No unjustifiable language was used here.", "answer": 1}, {"article": "NASHVILLE -- Sick with depression, Harriet Bruce spent her days lying in bed for months at a time.\nThe NeuroStar system resembles a dentist's chair.\nThe devices cost around $100,000, Cochran said, who has treated 45 patients with the therapy.\nBut TMS is expensive.\nIt's an alternative to electroconvulsive therapy \u2014 shock treatments \u2014 for patients who have not responded to drugs or psychotherapy.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a press release", "answer": 1}, {"article": "Nuts, seeds, whole grains, legumes and even dark chocolate are high in fiber\u2014as are vegetables.\nSonnenburg was not involved with this study, but research from his lab also suggests that fiber plays a big role in promoting good bacteria.\n\u201cThat means if you\u2019re not eating dietary fiber, your immune system may be existing in kind of a simmering pro-inflammatory state,\u201d he says\u2014the very state that predisposes us to different Western diseases.\nScientists are hard at work trying to determine how and why that\u2019s that case, as well as which bacteria are beneficial\u2014and how to protect them.\nLoading up on fiber-fortified processed foods isn\u2019t likely a good way to increase the kind of fiber that benefits the gut.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story incorporates input from an independent source, references outside research, and does not appear to draw from a news release.", "answer": 1}, {"article": "The F.D.A.\nThe review for Medicare said there was insufficient evidence to judge whether Provenge would work if used off-label.\nThere is only \u201cmoderate\u2019\u2019 evidence that the newly approved prostate cancer drug Provenge helps patients, according to an analysis done for Medicare that was made public on Wednesday.\n\u201cHistorically, moderate means that CMS will reimburse the product for its on-label indication,\u2019\u2019 she wrote.\nDendreon\u2019s shares rose more than 5 percent in trading after the close of the market.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\nThe story does not rely on a news release.", "answer": 1}, {"article": "This level is equivalent to two to three 8-oz cups of coffee per day, five to six 8-oz cups of black tea, or seven to eight 12-ounce cans of cola.\nThe findings come from participants in the Women's Health Initiative Memory Study, which is funded by the National Heart, Lung, and Blood Institute.\nIntake was estimated from questions about coffee, tea, and cola beverage intake, including frequency and serving size.\nDriscoll and her research colleagues used data from 6,467 community-dwelling, postmenopausal women aged 65 and older who reported some level of caffeine consumption.\nIn 10 years or less of follow-up with annual assessments of cognitive function, 388 of these women received a diagnosis of probable dementia or some form of global cognitive impairment.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Beyond the inflated comments about novelty stated above, the release doesn\u2019t rely on sensational, unjustified language.", "answer": 1}, {"article": "Pfizer, the New York-based maker of Viagra, abandoned efforts to adapt its pill for women in 2004 and closed sex-health research at the end of last year.\nThe drug, which is being developed by the giant German drug maker Boehringer Ingelheim, could become the first treatment approved by U.S. regulators for women who suffer from hypoactive sexual desire disorder.\nIt could take two to three years to come to market in the United States, the company said.\nThe issue of a woman\u2019s libido is more complicated than the dysfunction treated by the well-known little blue pill, according to women\u2019s sexual health experts.\n\"I\u2019m hoping this will help the women who need it.\u2019\u2019\n\nOne expert, Andrew Goldstein who runs the Sexual Wellness Center in Annapolis, Md., described a \"huge\u2019\u2019 unmet need for a medical treatment.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t judge the extent to which the story may have been influenced by a news release.\u00a0", "answer": 2}, {"article": "LOS ANGELES (Reuters) - Scientists for the first time have used gene therapy to successfully destroy cancer tumors in patients with advanced disease \u2014 a goal that has taken 20 years to achieve.\nThe treatment appears safe, but researchers said more study was needed.\nThe results provide \u201ca tumor-attack roadmap for the treatment of other cancers,\u201d including those of the lung and ovaries as well as myeloma and melanoma, researchers said.\nThe research group plans to treat four more patients with CLL before moving into a larger Phase II trial.\nTo deliver the gene therapy, the researchers used a virus that can only infect cells once.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Neither story relied on this University of Pennsylvania news release.", "answer": 1}, {"article": ".\nA limitation of the study is that the motion sensor often slipped off the sleepers at night.\nCanha, who wasn\u2019t involved with this study, researches indoor air quality and sleep during different ventilation patterns.\n\u201cWe spend nearly a third of our life in the bedroom environment, but the air quality in our sleeping environment is often overlooked,\u201d said study author Dr. Asit Mishra of Eindhoven University of Technology.\nOpen windows and doors helped reduce carbon dioxide levels and improve ventilation and air flow, which was related to better sleep quality for the healthy young adults in the study.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely solely on a news release, and quotes a researcher who was not part of the project.", "answer": 1}, {"article": "Their overall risk of death was 30% lower than the sedentary adults, with the risk of cardiovascular and cancer deaths lower by 40% and 18% respectively.\nThe findings will reassure people who find it hard to make time for a daily exercise routine and opt instead to break a sweat once or twice a week in the hope of keeping fit.\nNearly 9,000 of the study participants died in the period.\nUlf Ekelund at the Norwegian School of Sport Sciences in Oslo said the study emphasised what researchers have found time and again: that even a small amount of regular exercise wards off death.\nBut the weekend warriors also saw substantial health benefits if they met the physical activity target too.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news\u00a0release.", "answer": 1}, {"article": "After all, our immune system evolved over millions of years to respond to infections of injured skin, not vaccines delivered by hypodermic syringe into muscle,\" he noted.\nNearly all modern vaccines are given via injection, according to background information in a news release about the study, which is published in the Jan. 17 issue of Nature Medicine.\n\"This research illustrates the remarkable capacity of the most superficial layer of skin to generate powerful protective immune responses after vaccination,\" study senior researcher Dr. Thomas Kupper, chairman of the dermatology department at the hospital, said in a news release from the hospital.\n\"We should also continue to explore the implications for developing powerful cancer vaccines, like the one demonstrated by melanoma vaccine results in this study.\"\nThey also found that a melanoma vaccine delivered by scarification was much more effective than injected vaccines in protecting animals against melanoma tumor growth.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story admits it was based on a news release.\u00a0 There was no sign of any independent reporting.\u00a0 So it gets an \"A\" for honesty but an \"Unsatisfactory\" for this criterion. ", "answer": 0}, {"article": "Neuroblastomas are cancers that start in early nerve cells and commonly form in the tissue of the adrenal glands, near the kidneys.\nThis research is an excellent example of the collaboration between Nemours Children's Hospital and the University of Central Florida.\nOverall, the nano-therapeutic treatments showed a more pronounced effect in MYCN-amplified cells, which are traditionally more resistant to drug therapies.\nThe study, conducted in partnership by researchers at Nemours Children's Hospital and the University of Central Florida, demonstrates a potentially novel treatment for neuroblastoma, the most common cancer in infants.\n\"High-risk neuroblastoma can be resistant to traditional therapy, and survival can be poor.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release does not include include unjustifiable, sensational language.", "answer": 1}, {"article": "Milo A. Puhan, MD, is director of the Epidemiology, Biostatistics and Prevention Institute and professor of epidemiology and public health at the University of Zurich.\nThat\u2019s ironic because aspirin is ubiquitous and most patients perceive it to be safe and harmless.\nThat means for some low-risk individuals, taking daily aspirin could do more harm than good.\nMany patients \u2014 and many health care providers \u2014 believe that the aspirin-for-primary-prevention issue is settled.\nThat\u2019s the final recommendation from the US Preventive Services Task Force (USPSTF) after more than a year of study and lively public comment.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "With a full slate of outside observers commenting on this study, it is unlikely to be overly reliant on any news release.", "answer": 1}, {"article": "When that occurs, the next step is to examine the suspicious area, with the physician ordering a biopsy or inserting a scope into the lungs to evaluate further.\nAccording to Dubinett, about one in 500 chest X-rays shows a lung nodule of ''indeterminant significance.\"\nIf perfected, the test could help spare patients the need to undergo invasive procedures such as biopsies when lung cancer is suspected, they predict.\nHe is the senior author on the study, presented at the American Association for Cancer Research-International Association for the Study of Lung Cancer's joint conference in Coronado, Calif.\n\nAbout 219,000 new cases of lung cancer were expected to be diagnosed in the U.S. in 2009, according to the American Cancer Society, and about 159,000 deaths were expected.\n''Currently, 20% to 25% of surgeries done for suspected lung cancer turn out to be benign diagnoses,\" says Steven Dubinett, MD, professor of medicine and pathology and director of the Lung Cancer Research Program at the Jonsson Comprehensive Cancer Center at the David Geffen School of Medicine, University of California, Los Angeles.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article does not appear to rely solely or largely on a news release.", "answer": 1}, {"article": "\u201cPatients readmitted after surgery almost always have a postoperative complication, either medical or surgical,\u201d Drs.\nDoctors who did not perform the surgery won\u2019t have that context, which may explain part of the survival benefit of returning to the original hospital, he said.\nPatients should try to stay in the immediate vicinity of their surgical hospital for at least a week, Brooke said.\nAmbulance drivers and emergency department doctors should make every effort to get a patient who has had major surgery back to their original hospital, he said.\n\u201cA lot of big Fortune 500 companies contract with bigger hospitals for patients undergoing major surgery,\u201d Brooke said, noting the Wal-Mart has contracted with the Cleveland Clinic.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes quotes from a telephone interview, so we can be sure it went beyond any news release.", "answer": 1}, {"article": "Suvorexant is part of a class of drugs called Dual Orexin Receptor Antagonists or DORAs, which work by blocking chemical messengers called orexins.\n\u201cThese treatments work by forcing the brain to go to sleep,\u201d said study leader Jason Uslaner of Merck in an interview on the website of Science Translational Medicine, which published the study.\nExperiments in animals suggest Merck\u2019s sleep drug Suvorexant, now before the U.S. Food and Drug Administration, may avoid these side effects, the company said.\nSo far, Merck has not seen any cases of narcolepsy, a sleep disorder marked by daytime sleepiness, in its late-stage clinical trials, Renger said.\nOrexins originate in a specific region of the hypothalamus, so targeting them may have less impact on other brain functions, Renger said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "Wolters Kluwer N.V. (AEX: WKL) is a global leader in information services and solutions for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors.\n\"The results also show that migraine surgery can lead to dramatic improvements in functioning and coping ability, even in patients who are very disabled before surgery.\"\nThe study included 90 patients who underwent migraine surgery, performed by Dr. Austen, between 2013 and 2015.\nBefore migraine surgery, the patients had \"extremely poor\" PSEQ scores, indicating a high level of disability.\nThe PSEQ has been used to study treatment outcomes in patients with a wide range of pain conditions.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The headline of the news release was taken from a quote from the lead author, who said that migraine surgery can lead to \u201cdramatic improvements\u201d in the daily functioning of migraine patients. Yet, as mentioned above, based on the quality of the evidence and benefits we have no idea just how big these improvements are. Is a patient that was formerly severely disabled now able to work and maintain a normal quality of life? All we know is that the patients improved in one self-reported measurement, but we don\u2019t know how much improvement should be considered \u201cdramatic.\u201d", "answer": 0}, {"article": "The National Cancer Institute has more on prostate cancer.\nA final study of almost 4,000 patients found that surgeons needed to perform 1,600 procedures known as robotic-assisted laparoscopic radical prostatectomies (RALP) to become adept at the procedure.\n\"We recommend that this operation should not be done by all urologists in small community hospitals but should be focused and concentrated on high volume centers of excellence... in order to achieve best possible results for patients,\" said study author Dr. Prasanna Sooriakumaran, a visiting fellow in urology at the Weill Cornell Medical College in New York.\nOne caution, though, is that the study only looked at three surgeons performing RALP.\n\"A low PSA, particularly those in men who have less than 1.0, and probably those less than 2.0, certainly could be considered for substantially longer intervals of PSA screening... Personalization of PSA screening is clearly underway.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story identified the teleconference that was the source of this story and it appears to be the only source of information used in this piece. At the time this story was published, the results of the studies described had not yet even been presented. So the teleconference, with only the authors presenting, is the equivalent of an audio news release.\u00a0 And it was the only source for this story.", "answer": 0}, {"article": "The fibers within the tendons fray.\nBut that cautionary experiment and others didn\u2019t slow the ascent of cortisone (also known as corticosteroids).\n\u201cThey change the pain biology in the short term.\u201d But, he said, cortisone shots do \u201cnot heal the structural damage\u201d underlying the pain.\nThe shots were quite effective, providing rapid relief of pain.\n\u201cIt\u2019s not insignificant, but it\u2019s not kidney stones.\u201d\n\nSo the question of whether cortisone shots still make sense as a treatment for tendinopathies, especially tennis elbow, depends, Dr. Khan said, on how you choose \u201cto balance short-term pain relief versus the likelihood\u201d of longer-term negative outcomes.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\nThis article did not rely on a press release.\n", "answer": 1}, {"article": "Tau has been tied to neurofibrillary tangles in the brain; researchers find that an increase in tau in cerebrospinal fluid is associated with Alzheimer's also.\nThe current thinking is that interventions will be most effective when given to a patient as early as possible, Brickman said.\nBut it's too early to use this as a diagnostic tool in clinical settings, says Brickman.\nKnowing which patient with mild cognitive impairment patients may go on to develop Alzheimer's is vital information for researchers, who are looking for treatments for the fatal brain disease.\nThat suggests that a five-year follow-up period is not long enough to determine how well biomarkers can predict which patients will develop Alzheimer's disease, researchers say.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely solely or largely on a news release.", "answer": 1}, {"article": "\"I'm not sure I'd want to sign up for that one before I had longer-term results,\" Califf said.\nUse as a single drug treatment for elevated cholesterol levels could follow, first in selected patients, then more widely, he said.\nBut he echoed the thought that a longer-term and larger test is needed to determine the incidence of some possible major side effects, such as impotence.\nIf eprotirome does pass all the anticipated tests successfully, its use at first probably would be in combination with a statin, Angelin said.\nThe trial's researchers were careful to list indications of possible harmful side effects, such as a reduction in levels of HDL (\"good\") cholesterol, Califf said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely solely on a news release. ", "answer": 1}, {"article": "Cabozantinib, also known as XL184, is an oral drug designed to limit blood supply to tumors and to block two segments of a pathway used by cancer cells to grow and spread.\nThe drug reduced by 87 percent the risk of disease progression or death.\nOther Phase 2 data presented over the weekend showed that treatment with cabozantinib led to significant tumor shrinkage in 24 percent of patients with metastatic ovarian cancer.\nThe study results were reported on Monday at the American Society of Clinical Oncology\u2019s annual meeting.\nThe disease remained stable in 23 other patients, or 21 percent, and worsened in three.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure of the extent to which the story relied on a news release.\u00a0 We do know it quoted only the company CEO.", "answer": 2}, {"article": "In February, the World Health Organization offers a prediction \u2014 based on surveillance and laboratory and clinical studies \u2014 and then each country uses that prediction to approve vaccines in its jurisdiction.\nThat seems to be the same conclusion that other studies have drawn \u2014 the flu vaccine is modestly helpful, and doesn't hurt.\nOn the other hand, the evidence suggests that there's no harm in getting a flu shot, either.\nAgain, though, this doesn't mean we should throw away the vaccine.\nBeyond public health measures (making sure you have good hand hygiene and avoiding the office when you're sick), the flu shot is the best medical intervention we have for preventing infection.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story shows no indications that it was based on a news release.", "answer": 1}, {"article": "\"Take some individual responsibility to stay healthy during the flu season,\" said Health and Human Services Secretary Kathleen Sebelius, who scheduled her own seasonal shot for Friday.\nThe report from the Centers for Disease Control and Prevention Friday also came with good news: Testing of vaccines for swine flu show that they work with a single dose and take effect rapidly.\nThe U.S. has ordered 195 million doses, based on the hope that 15 micrograms was indeed the right dose.\nAustralian and U.S. researchers said Thursday that one dose of the new swine flu vaccine looks strong enough to protect adults \u2013 and can begin protection within 10 days of the shot.\nOne dose means tight supplies of H1N1 vaccine won't be stretched so thin after all.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\nThe story does not appear to be based on a press release; but it does appear to be primarily a summary of news conferences and official statements.", "answer": 1}, {"article": "Soy has been touted as an alternative treatment to hormone replacement therapy after HRT was linked to an increased risk of breast cancer.\nNow, researchers who took another look at 19 published studies find that soy supplements may help, at least over time.\nThe study had no industry funding.\nTwo co-authors, not including Melby, have ties to the soy industry.\nAlthough all the studies looked at soy supplements, Melby says that getting soy from food is a better bet.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because two independent experts were quoted, we don\u2019t think there\u2019s any evidence that the story relied on a news release.", "answer": 1}, {"article": "Dozens of biotechnology and pharmaceutical companies including Alnylam, Merck, Pfizer, Novartis and Roche are looking for ways to manipulate RNA to block genes that make disease-causing proteins involved in cancer, blindness or AIDS.\nThe finding, reported in the journal Nature on Sunday, offers early proof that a new treatment approach called RNA interference or RNAi might work in people.\nDavis could not say whether the therapy helped shrink tumors in the patients, but one patient did get a second cycle of treatment, suggesting it might be.\nOther teams are using fats or lipids to deliver the therapy to the treatment target.\nTumor samples taken from three people with melanoma showed the nanoparticles found their way inside tumor cells.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story says it relied on a telephone interview, so that\u2019s not a news release. ", "answer": 1}, {"article": "The new research provides more evidence of the need for new regional centers of care, in order to minimize the time it takes to transport a patient to hospital capable of providing stent therapy, according to Dr. William J.\n\u201cThey are destined to be in a nursing home or to be dead and when we re-establish blood flow \u2014 often times right there on the table \u2014 they get better.\u201d\n\nStent retriever therapy is a new procedure experts call the most major advance in stroke treatment in two decades.\nRelated: New Recommendations Say More Americans Should Take Aspirin\n\nFor Reisch, the impact was almost immediate: he began to regain feeling while undergoing the procedure.\nFirst responders asked Reisch to smile and immediately recognized his drooping mouth as a sign of a stroke.\nAt the hospital, the first-line therapy, a powerful blood-thinning medication called tissue plasminogen activator or tPA could not dissolve the blood clots in Reisch\u2019s brain.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We\u2019re always happy to see a story go beyond a news release \u2014 which this story clearly does with its inclusion of several independent expert sources. We have to note, however, that the release in this case actually provided more and better information than the story.\n\u00a0", "answer": 1}, {"article": "In addition, BCG alters metabolism so cells consume higher levels of glucose, drawing more of it out of the blood, in a process called aerobic glycolysis.\nThe new paper and a presentation scheduled for a meeting of the American Diabetes Association this weekend focus on the patients who have been followed for more than five years.\nWhile the results, from only nine patients, must be replicated in a larger study, said Dr. Joseph Bellanti of Georgetown University Medical Center, \u201cif what they found is true, they really have something here.\u201d Bellanti, who was not involved in the research, said the study\u2019s eight-year follow-up and use of a placebo control arm made him \u201ccautiously optimistic\u201d that two doses of the BCG vaccine \u201ccan decrease levels of A1c,\u201d a measure of blood glucose that predicts the likelihood of serious complications such as stroke and kidney failure.\nA Phase 2 clinical trial of BCG is currently underway at Mass.\nAfter the vaccine showed signs of effectiveness, an additional six patients were vaccinated five years ago, and 111 more recently.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "One of the quotes included from a researcher not involved in the study does appear to have been taken from a Massachusetts General Hospital news release, and that is not noted in the story. We also reviewed the news release. If that connection had been disclosed, this would have been satisfactory.\n\u00a0", "answer": 0}, {"article": "Prostate cancer patients had a 28 percent higher relative chance of having a fatal heart attack and a 21 percent increased chance of dying from heart disease.\nStill, these risks were low in absolute terms: researchers estimated the hormone therapies would cause an extra 10 heart problems \u2013 like chest pain or a heart attack \u2013 a year for every 1,000 prostate cancer patients.\nHelen Rippon, head of research management at Britain's Prostate Cancer Charity, said the benefits of hormone therapy ultimately outweighed the increased risk of heart problems.\n\"What we can do with these results is to raise a flag with hormone treatments,\" said Mieke Van Hemelrijck, a cancer epidemiologist at King's College in London and the study's lead researcher.\n\"What patients should do is talk about this with their doctor,\" said Michael Thun, a vice president emeritus at the American Cancer Society, who was not connected to the research.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\nThe story does not appear to rely largely on a news release.", "answer": 1}, {"article": "More than 25 million people in the United States and about 2.5 million Canadians suffer from chronic rhinosinusitis, or sinus infection, and experience compromised quality of life.\nPatients who were instructed to use nasal irrigation showed improvement at 3 and 6 months, as measured by the Rhinosinusitis Disability Index.\nResearchers from the United Kingdom conducted a randomized controlled trial on the effectiveness of advice from primary care physicians to use nasal irrigation and/or steam inhalation for chronic sinusitis.\nSince the impact was less than in previous studies that had used more intensive coaching about nasal irrigation, the authors suggest that further research is needed to understand how much coaching of patients is required.\n\"Although there was no significant difference in either physician visits or antibiotic use, as might be expected over only a 6-month follow-up period, our findings concerning consultations are important in the longer term, given antibiotic use increases the risk of antimicrobial resistance.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There is no unjustifiable language. We would quibble with the use of the word \u201cprevention\u201d in the title, however. This research did nothing to study preventing sinus infections. It studied improving symptoms.", "answer": 1}, {"article": "For older people who fracture a hip, the prognosis is grim: a third or more die within a year and only about 1 in 5 return to their pre-injury level of function.\n\nA new approach to care could mean it doesn\u2019t have to be that way.\n\nMore hospitals are putting hip fracture patients on a fast track from the emergency room to the operating room,...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does not appear that there was a news release on this topic that instigated the story.", "answer": 1}, {"article": "Needle-phobia, or trypanophobia, is a recognized medical condition that causes sufferers to avoid medical care.\nThe microneedle technology may also be used for other vaccinations, such as polio and measles, said Prausnitz.\nIn a mouse study reported Sunday in the online edition of Nature Medicine, Prausnitz's team found the patch improved the immune system's antibody memory and was more efficient at clearing the lungs of the flu virus, compared to a placebo and hypodermic needle-delivered vaccine.\nThe muscle into which needles deliver vaccine is not nearly as active immunologically.\nThe patch, which is lined with microscopic needles that dissolve into the skin, could provide a painless alternative to hypodermic needles and make visits to the doctor's office or clinic for a traditional flu shot a thing of the past.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Although\u00a0several experts are\u00a0interviewed,\u00a0passages from this Georgia Tech\u00a0press release are reprinted nearly verbatim. Example:\nPress release: \"When infected with influenza virus 30 days later, both groups that had received the vaccine remained healthy while mice in the control group contracted the disease and died.\"\u00a0Chronicle: \"Infected with the influenza virus 30 days later, both groups that received the vaccine remained healthy while mice in the control group contracted the flu and died.\"\nIf an editor doesn\u2019t catch this and judge it to be unsatisfactory, we will.", "answer": 0}, {"article": "\"One day I turn to my wife and I'm like, 'I feel calm today.\nThe fear was \"overwhelming,\" he says.\nA month later, he was back at work.\nAnd he couldn't stop thinking about gruesome scenarios, like a murderer coming for his family.\nHe says his response was dramatic.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to be based on a news release.", "answer": 1}, {"article": "The results suggested that children who went through a year of sublingual therapy followed by one to two years of oral immunotherapy were less likely to have significant allergic reactions when undergoing the oral immunotherapy.\nSome participants have shown they can safely eat milk products up to a year after stopping the therapies, Wood said.\nThis is the first time the sublingual therapy has been studied in terms of its benefit as a precursor to the oral immunotherapy, Wood said.\nIt's not known yet whether children respond better to this kind of treatment than adults, since there have been so few participants in this research.\nStill, it did not eliminate all symptoms.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does not appear that the story relied solely on a news release.", "answer": 1}, {"article": "\"Started looking in the cupboard and I saw pie pans and I said, 'These are perfect.\nThe last thing John Kanzius thought he'd ever do was try to cure cancer.\nThat's what 60 Minutes wanted to know, so Stahl went to his garage laboratory to find out.\nWell it's true, and if you think it sounds improbable, consider this: he did it with his wife's pie pans and hot dogs.\nKanzius put his hand in the field to demonstrate that radio waves are harmless to humans.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if the segment relied solely or largely on a news release.\u00a0 We do know that the segment only discussed the perspectives of the inventor and three potentially self-interested supporters, one of whom is dead. ", "answer": 2}, {"article": "When Marin Mejia was pregnant with her son Owen, one such blood test that picks up DNA from mother and baby came back showing abnormal results.\nMore testing showed she had anal cancer.\nBut doctors told Mejia they needed to investigate what caused the irregular finding.\nFurther testing showed the baby was healthy.\nAt the time she was 39 and had experienced bleeding she blamed on hemorrhoids.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story may have been suggested by a release, but clearly focused almost entirely on interviews with a mother and the principal investigator.", "answer": 1}, {"article": "About Milken Institute School of Public Health at the George Washington University: Established in July 1997 as the School of Public Health and Health Services, Milken Institute School of Public Health is the only school of public health in the nation's capital.\nVery little help is provided to pregnant smokers who want to quit so the study's findings are important, especially if the strategy can be adjusted to be more effective, Abroms says.\nThe researchers recruited pregnant women who were already enrolled in an established text messaging program called Text4baby.\nThe more intensive intervention did seem to help two subgroups quit smoking at least in the short run, Abroms says.\nAbroms and her team wanted to find out if a more intensive mobile phone program called Quit4baby would be more effective.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The main message of the release is misleading if not deceptive. However, we\u2019ve already addressed that issue and see no other unjustified statements that would merit a Not Satisfactory rating here.", "answer": 1}, {"article": "Some critics say Medicare would not be doing a review of a drug already approved by the F.D.A.\nSo it cannot be completely ruled out that XL184 somehow stopped bone growth without killing the cancer.\nHowever, Dr. Smith said he doubted that was the case because there were signs the drug also controlled tumors outside the bones.\nThat could give Medicare grounds for denying payment when the drug is used off-label, as cancer drugs often are.\nAnother investigator in the trial, Dr. David C. Smith of the University of Michigan, said he could not believe it when the bone scan of one patient, who previously had widespread cancer in his bones, came back completely clean.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure of the extent to which the story relied on a news release.\u00a0 We know there was independent reporting because we know that several interviews were conducted.\u00a0 But if the study results had yet to be presented and have not been published, where did the information come from? There was a company press release (http://www.exelixis.com/investors-media/press-releases ) and/or review of a poster before it was presented and/or there were advance interviews with researchers promoting their work.", "answer": 2}, {"article": "He says he plays basketball with his granddaughter, works on his farm, and gets on the treadmill for 30 minutes three times a week.\nIt's the first time tissue-specific stem cells, other than bone-marrow cells, have been tested in humans, Hare says.\nIt's early -- results are in for only the first 16 patients -- but the results already are drawing praise from experts not easily impressed by first reports.\nHare was not involved in the study.\nThe breakthrough comes just as researchers were becoming discouraged by studies in which bone-marrow stem cells failed to heal damaged hearts.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a news release.", "answer": 1}, {"article": "Prediabetics are at increased risk for developing diabetes, which can damage the eyes, kidneys, nerves and blood vessels and often leads to cardiovascular disease.\nFor this study, the researchers recruited 39 middle-aged, overweight or obese volunteers with prediabetes and sleep apnea.\nAfter two weeks, blood sugar control, as measured by an oral glucose tolerance test, improved for those in the CPAP group compared to the oral placebo group.\n\"Our study showed that CPAP in patients with prediabetes can lower their risk of progressing to diabetes when CPAP is used for eight hours, a full night's sleep,\" said the study's lead author, Sushmita Pamidi, MD, a former fellow at the University of Chicago who is now on the faculty at McGill University in Montreal, Canada.\nBefore and after each treatment period, participants' glucose metabolism was assessed by oral and intravenous glucose-tolerance tests.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "If a release is going to include a headline that says, \u201cEffective sleep apnea treatment lowers diabetes risk,\u201d it should back that statement up with evidence. We\u00a0believe the benefits of this proof-of-concept study are exaggerated in the release headline. This was not a randomized controlled study comparing 8 hours of CPAP in prediabetes for several months with a sham CPAP treatment, then looking at incidence of progression to diabetes months or years later \u2014 THAT would have justified this headline.\u00a0 The right headline would be something like, \u201cCPAP can improve glucose metabolism.\u201d\u00a0 Whether that leads to a decreased risk of future diabetes was not established by this study.", "answer": 0}, {"article": "I will say it\u2019s an effective method of controlling pain.\u201d\n\nDr. Shmerling said that though tai chi is inexpensive compared with other treatments, some patients would reject such an alternative therapy.\nDr. Solomon and other experts cautioned that bigger studies with other masters and approaches were necessary.\n\u201cThe mind-body connections set it apart from other exercises,\u201d she said, adding that doctors are seeking \u201canything we can offer that will make patients say \u2018I can really do this.\u2019 \u201d\n\u201cFibromyalgia is so common, and we have such a difficult time treating it effectively.\n\u201cIt\u2019s hard for some patients\u2019 families and their doctors to get their head around what it is and whether it\u2019s real.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\u00a0The story is very well reported and goes well beyond the original study, the editorial and any supporting materials. We were unable to locate a press release about the study.", "answer": 1}, {"article": "A drug derived from this bushy sea creature showed modest, preliminary promise as an Alzheimer's treatment.\n\nIn small Alzheimer\u2019s study, hints of modest benefit from unusual drug\n\nA little-known drug company announced modestly encouraging results for its experimental Alzheimer\u2019s drug on Monday, a rare but still preliminary glimmer of hope in a field that has been battered by failure after failure.\n\nA mid-stage study by a tiny company wouldn\u2019t usually attract much attention, but the results unveiled by Neurotrope BioScience have been eagerly anticipated because its drug \u2014 derived from a bushy, hermaphroditic sea creature \u2014 takes a novel approach.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not overly rely on a news release.", "answer": 1}, {"article": "Cervical cancer is the fourth most common cancer in women, with more than 500,000 new cases occurring annually worldwide.\nThis work was supported by the National Institutes of Health (1R01CA195500, 1R01CA193380).\nThe device also includes a channel through which contrast agents used for the cervical cancer screening procedure can be applied.\nAsiedu is also working to automate the screening process.\nRamanujam believes she can replace at least two of these requirements.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "No unjustifiable language was noted.", "answer": 1}, {"article": "Kilmer McCully of the V.A.\nThe findings follow a number of disappointing studies testing vitamins and other dietary supplements for health reasons.\nThe new findings undermine a theory that taking B vitamins to reduce levels of an amino acid in the blood called homocysteine could protect against heart attacks and strokes.\nThe findings, released yesterday, are the latest in a series of recent studies that have found vitamins and other dietary supplements fail to have the health benefits they are touted for.\n\"These studies did not test whether B vitamins used by healthy people can help keep them healthy.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if the story relied solely or largely on a news release. ", "answer": 2}, {"article": "Of those, 2,148 had taken lithium, 1,670 had used valproate, 1,477 had been on olanzapine and 1,376 had taken quetiapine.\nThe lead author behind the research told the Guardian that widespread \u201clithium stigma\u201d among patients is leading to them receiving the wrong treatment and ending up admitted to hospital unnecessarily because their condition is not as well controlled as it could be.\nIt is seen by patients, and some psychiatrists, as a dangerous drug.\nThe researchers\u2019 analysis bore out one of the two main criticisms of lithium, but found the other to be baseless.\nResearchers claim that although the drug does carry some health risks, its overall effectiveness, especially its ability to reduce self-harm and suicide, mean it should be much more widely used.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news\u00a0release.", "answer": 1}, {"article": "People who experience them see or hear things that are not there (hallucinations) and/or have false beliefs (delusions).\nNo drug in this class is approved to treat patients with dementia-related psychosis.\nThe drug was also granted a priority review.\nThe U.S. Food and Drug Administration today approved Nuplazid (pimavanserin) tablets, the first drug approved to treat hallucinations and delusions associated with psychosis experienced by some people with Parkinson\u2019s disease.\nNuplazid was granted for the treatment of hallucinations and delusions associated with Parkinson\u2019s disease.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There is no evidence of unjustifiable language in the news release.", "answer": 1}, {"article": "HPV causes cervical cancer, which remains a significant health problem, particularly in less resource-rich areas of the world.\nThe HPV test should become the screening tool of choice for women 35 and older, the researchers said.\nNot all experts agree, though, that current practice would change based on the study's findings alone.\nIt could be done less frequently than the Pap test, which could be used only in women who have tested positive for HPV, they said.\nBy contrast, Pap smears have a callback rate of about 5 to 7 percent, he said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story quotes multiple experts, it does not appear to rely on a press release as the sole source of information.", "answer": 1}, {"article": "The first figure is systolic pressure, generated when the heart is pumping, and the second figure is diastolic pressure, created when the heart is relaxing and filling with blood.\nAs for the next step in confirming the relationship between beetroot juice and blood pressure, she says this was a small trial.\nThe trial was double-blind, which means neither the administering clinicians nor the patients knew whether the beetroot juice they were given was the placebo or the active supplement.\nThe 8/4-mmHg reduction brought the blood pressure of many participants back into the normal range.\nThey conducted a placebo-controlled trial with dozens of participants.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story relies heavily on a news release from the Queen Mary University of London but fails to attribute complete quotes and other information to that news release. In several instances, release quotes are verbatim; in others, release material is only slightly altered. Material taken from news releases should always be attributed to such releases to avoid the readers\u2019 assumption that the writer actually interviewed the sources involved. That wasn\u2019t done for this story.", "answer": 0}, {"article": "Knee surgery for a torn meniscus is done about half a million times each year in the U.S.\nThe therapy was nine sessions on average plus exercises to do at home, which experts say is key to success.\nThirty percent of patients assigned to physical therapy wound up having surgery before the six months was up, often because they felt therapy wasn't helping them.\n\"I felt better within two weeks\" on physical therapy, he said.\nSurgery costs about $5,000, compared with $1,000 to $2,000 for a typical course of physical therapy, Katz said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely on a news release.", "answer": 1}, {"article": "In 2016, he was ranked the No.\n\"The existing totality of evidence suggests an urgent need to increase the use of varenicline in the general population as well as in those with serious mental illness who on average die about 20 years earlier than the general population, in part, because their smoking rates may be as high as 75 percent,\" said Hennekens.\nIn a commentary published in the current issue of the American Journal of Medicine, researchers from the Charles E. Schmidt College of Medicine at Florida Atlantic University reassure clinicians and their patients that varenicline, whose brand name is Chantix, is a safe and effective way to achieve smoking cessation and that failure to use this drug has caused preventable heart attacks and deaths from cardiovascular disease.\nSuch a large randomized trial was recently completed that included both apparently healthy individuals as well as those with severe mental illness.\nIn 2006, varenicline was approved as a safe and effective means to quit smoking and achieved permanent quit rates of approximately 25 percent.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release states that \u201cfailure to use [Chantix] has caused preventable heart attacks and deaths from cardiovascular disease.\u201d But, and this is a key point, what is more accurate is that a failure to quit smoking is likely to have contributed to preventable heart attacks and deaths from cardiovascular disease. Could Chantix have helped people quit? That may well be. But this release makes a cause and effect connection that simply doesn\u2019t hold up. In short: a failure to take Chantix does not kill people.", "answer": 0}, {"article": "\"The first time those three letters were uttered in a group setting, everyone's like, 'Oooo, that's scary, do we want to do that?'\nThe results are often inaccurate.\nAnd that opens the door for insurance companies to pay for it.\n\"The qualities of a good video game, things that hook you, what makes the brain \u2014 snap \u2014 engage and go, could be a perfect vessel for actually delivering medicine,\" he says.\nRight now, screening for Alzheimer's is subjective.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The number and range of sources make it clear that the story does not rely on a news release.", "answer": 1}, {"article": "(PHILADELPHIA) -- When patients present with neurologic symptoms such as severe headaches or seizures, the symptoms could suggest anything from infection, cancer, or an autoimmune disease of the brain or spinal cord, leaving physicians scrambling to find the cause in a short amount of time.\n\u201cBeing able to rapidly identify a central nervous system disorder as infectious can be crucial in rapid response.\u201d\n\n\u201cIn addition, the test could distinguish viral from non-viral infections, a distinction that could spare a child with a viral infection from an unnecessary course of antibiotics, and tailor the care toward antiviral and supportive measures as needed,\u201d said Dr. Curtis.\nRather than testing for the presence of bacteria or virus, the researchers looked at the first tell-tale signs of infection: the cytokines produced by the patient\u2019s immune system in response to pathogens and other injury processes.\nThe diagnostic could prove particularly useful in infants and young children.\n\u201cInfants and young children have an especially high risk of meningitis and encephalitis and the related, often serious sequelae,\u201d said Dr. Curtis.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There was some dramatizing of the conditions and stakes of CNS problems, but nothing that struck us as unjustifiable.", "answer": 1}, {"article": "This can cause less blood to reach the brain and, in rare cases, may also trigger a stroke if plaque breaks off and becomes lodged in the small vessels in the brain.\nThose who would benefit from the ultrasound test are people with known carotid stenosis who are fit for surgery, Topakian said.\nMarquardt noted that the risks associated with the surgery are a lot higher than leaving the stenosis as it is and starting aggressive medical treatment.\nThe patients who are at high risk are candidates for surgery, he said.\nDr. Lars Marquardt,a professor of surgery at the University of Erlangen-Nuremberg in Germany and co-author of an accompanying journal editorial, said surgery for people with asymptomatic carotid steno sis is done too frequently.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story did not appear to rely on a news release.", "answer": 1}, {"article": "In the new trial, 614 patients with severe heart failure in the United States and Canada were randomly assigned to receive a MitraClip along with standard medical treatment or to continue with standard care alone.\nUntil today, researchers were not sure that fixing the mitral valve would do much to help these patients.\nThe result was to convert a valve that barely functioned into one able to regulate blood flow in and out of the heart.\nBut that research included many patients with less severe valve problems, the procedure was not performed as adeptly, and the patients\u2019 medications were not as well optimized as in the new study.\nA smaller study in France with similar patients failed to find a benefit for the MitraClip.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story doesn\u2019t rely on a news release.", "answer": 1}, {"article": "AMD, the No.\n\"In the end, L-DOPA may not be the drug that ends the disease but the pathway identified is likely to be a key observation as the search for a cure continues.\"\n\"Showing that L-DOPA causes this protective effect will require further investigation, but if confirmed, could lead to new drugs or combination therapies for AMD that target DOPA-responsive cells in the retina.\"\nThese provocative results were then confirmed in a much larger data set of 87 million patients where similar results were observed and the study expanded to include prevention and delay of \"wet\" AMD, the most devastating form of the disease.\nThis work grew out of research using albino mouse models.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We\u2019ll give the benefit of the doubt here because the release does not use overtly unjustifiable language. But the use of words such as \u201cprevention\u201d implies causation, which this study was incapable of showing. A better way to phrase this might be to say \u201cThere is an association between taking L-Dopa and having AMD start at a later age.\u201d", "answer": 1}, {"article": "\"Afrezza is an ultra-rapid-acting insulin, and clinical studies have shown us that it has the potential to change diabetes therapy, because in the body, Afrezza looks like the insulin that's normally in a person's body,\" said Andrea Leone-Bay, vice president of pharmaceutical development for MannKind Corp., manufacturer of Afreeza.\nIt will only replace meal-time insulin.\nWhile Afrezza looks promising, it can't replace all injections for people with diabetes.\nThe company is conducting clinical trials to assess Afrezza in people with asthma.\nThis finding came after Exubera had been pulled from the market, and the sample size wasn't large enough to draw a definitive link between the drug and the increased risk of lung cancer.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article does not appear to rely on any press release we can find.", "answer": 1}, {"article": "No doubt you have heard that yogurt is teeming with bacteria--and no doubt you try not to think about that as you dig into a cup of the stuff. Yes, they're supposed to be good bacteria, ones that not only don't make you sick but actually improve your health. Still, a spoonful of critters with unlovely names like Lactobacillus reuteri, Lactobacillus rhamnosus and Bifidus regularis will never sound like a palate pleaser to even the most dedicated health nut.\n\nWhether or not you've ever developed a taste--or even a tolerance--for living things in your lunch, more are on the way. Food...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if the column relied solely or largely on a news release.\u00a0 We can be sure that it seemed to rely almost exclusively on an interview with a book-promoting, probiotics-promoting physician. ", "answer": 2}, {"article": "\"We are not going to reverse any of the chronic diseases in this country by changing the composition of the diet,\" Dr. Howard said.\nThat could mean that fat in the diet may have a small effect, Dr. Rossouw said, perhaps in some subgroups of women or over a longer period of time.\nBut that belief was not supported by this study.\nDr. Rossouw said the observational studies that led to the hypothesis about colon cancer and dietary fat included men and women.\n\"The studies were well designed,\" Dr. Freedman said, \"and the investigators tried to confirm popular hypotheses about the protective effect of diet against three major diseases in women.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no evidence that this story relied solely or largely on a news release. ", "answer": 1}, {"article": "Dominic Gessler lifts two squirming mice from their cages.\nThe drug is the fruit of Gao\u2019s 23-year career in gene therapy.\nWhen Gessler returned to assess the results, he couldn\u2019t find the mouse.\nThe mouse was there, acting just as healthy as the control mice.\nHe worried he had mislabeled a cage.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story seems independent of news releases and appears to stem from a good bit of reporting work by the journalist.", "answer": 1}, {"article": "A new asthma drug being developed by Sanofi and Regeneron Pharmaceuticals may help patients whose condition is not well controlled by existing medicines, according to the results of a small clinical trial released Tuesday.\n\nIn the 12-week study, the number of asthma attacks or other outbreaks of symptoms decreased by 87 percent in those getting the drug, dupilumab, compared with those getting a placebo.\n\nOther measures of lung function and disease control also improved, according to the study results, which were published online Tuesday in The New England Journal of Medicine and presented at the annual meeting of the American Thoracic Society in Philadelphia.\n\nDupilumab blocks the action of interleukin-4 and interleukin-13, two inflammatory chemicals made by the body that are believed to contribute to asthma. Sanofi and Regeneron say there are also preliminary signs dupilumab works against the skin condition atopic dermatitis, suggesting it can be blocking a biological pathway that contributes to multiple allergic conditions.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a press release.", "answer": 1}, {"article": "Irritable bowel syndrome can be highly debilitating, if not virtually paralyzing, and affect work, sleep and personal and family relationships.\n\u201cThis is the only methodically rigorous clinical trial to show that diet-based therapy can not only improve symptoms, but also quality of life in patients with IBS,\u201d says U-M assistant clinical professor and gastroenterologist Shanti Eswaran, M.D., who researches the role of diet and food in functional bowel diseases such as IBS.\nThat\u2019s the result of research by the University of Michigan Health System, presented at Digestive DiseaseWeek, that studied for the first time in the United States the result of following a carefully controlled diet to improve the symptoms and quality of life for those with irritable bowel syndrome.\nBecause of the many unknowns about the chemical causes and triggers of IBS, the list of \u201cbad\u201d foods is exhaustive and elusive, and help from a dietician is highly recommended.\nWhile the results are highly encouraging for IBS sufferers, there are a few important caveats, Eswaran says.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release hypes the study\u2019s importance as the \u201cfirst of its kind study in the U.S.\u201d and quotes a researcher saying it\u2019s the \u201conly methodically rigorous clinical trial\u201d to show that dietary changes can improve not only symptoms but also quality of life for patients with IBS.\u201d These phrases might overstate the study\u2019s significance somewhat, since there\u2019s ample evidence supporting the efficacy of a low FODMAP diet for some IBS patients. But overall, the language is justifiable.", "answer": 1}, {"article": "THE AMERICAN SOCIETY OF ANESTHESIOLOGISTS\n\n\n\nFounded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific society with more than 52,000 members organized to raise and maintain the standards of the medical practice of anesthesiology.\nNone of the patients in the HF10 therapy group experienced paresthesia.\nHF10 therapy remained more effective than traditional SCS over the 12 month study period.\nSCS is reversible and is an important option for chronic pain sufferers who otherwise would rely on opioids or back surgery for relief.\nThe new treatment, called HF10\u2122 therapy, uses proprietary high frequency pulses of 10,000 Hz, compared to traditional SCS which uses frequencies of 40 to 60 Hz.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Nothing over-the-top here. We\u2019ve already commented on exaggeration in the Disease Mongering criterion above.\n\u00a0", "answer": 1}, {"article": "Male infertility has a range of root causes, from low or abnormal sperm production to blockages to illness.\n\u201cThe accuracy of this approach was very similar to that of computer-assisted laboratory analysis, even when it was performed by untrained users with no clinical background,\u201d they wrote in the study.\nThe researchers tested the device on 350 clinical semen specimens in Massachusetts, including both trained and untrained users in their trial.\nThat\u2019s the question researchers at Brigham and Women\u2019s Hospital and Massachusetts General Hospital tried to answer when they went about developing a smartphone-based test that men could use to test their semen in the comfort of their homes.\nThough the system is in the prototyping stage, it could eventually shake up the world of fertility testing by allowing men to evaluate their sperm in their own homes and helping health centers with fewer resources offer easy, cheap testing.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The talking points of this story and a news\u00a0release by Brigham and Women\u2019s Hospital match quite closely, but the story did include unique quotes not found in the news release, so this is a just-passing satisfactory.", "answer": 1}, {"article": "For more information, please see www.arthrokinex.com\nThis therapy has recently been highlighted by several professional football players traveling to Europe for treatment.\nThe cost of the USA-based IRAPjoint\u2122 treatment is $2,000 compared to the reported price of $10,000 for a foreign competitor.\nFinally, a U.S. based company has a solution for America's professional and weekend athletes as well as those struggling with aching or arthritic joints.\nThe European-based process was the inspiration for Dr. Barreto of Oklahoma City, Oklahoma to work on developing a stronger, more effective, and more cost-efficient version in the United States.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The sensational language here is subtle (no explicit talk of a \u201cbreakthrough\u201d), but still may lead a reader to be over-confident in the treatment and its abilities based on the quality of evidence. The news release emphasizes several times that the treatment is \u201cnatural\u201d since it is derived from the patient\u2019s own blood. And one of the last sentences of the news release stood out as particularly heavy-handed: \u201cFinally, a U.S. based company has a solution for America\u2019s professional and weekend athletes as well as those struggling with aching or arthritic joints.\u201d ", "answer": 0}, {"article": "Bone-marrow transplants, which infuse healthy blood cells taken from a donor, are used when chemotherapy and radiation fail to stop cancerous blood cells from taking over and ultimately destroying a person\u2019s immune system.\nBut she has been free of cancer for five years.\nThis expanded cord-blood technique has been a \u201chuge home run\u201d for patients, said Colleen Delaney of the Fred Hutchinson Cancer Research Center in Seattle, who helped create it.\nHis wife, Caryn, recalls how little they knew about his disease \u2014 acute myeloid leukemia \u2014 as doctors discussed treatment with them.\nNot everyone is as lucky.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a news release.", "answer": 1}, {"article": "A drug-coated stent made by Abbott Laboratories that is awaiting U.S. regulatory approval is as safe as, and potentially more effective than, the market-leading version of the heart device made by Boston Scientific Corp., according to findings presented Tuesday at the EuroPCR conference in Barcelona.\n\nClinical-trial data analyzed by Abbott two years after its Xience V stents were implanted in patients are likely to reassure investors and regulators about the product's long-term safety and could restore some investor confidence...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if the story relied solely or largely on a news release, but the quantitative information about the benefit of this product appears to rely on the company news release. If not, the story should have explained where it came from. We do know the story only included comments from the company and from someone involved in the study \u2013 no independent perspectives.\u00a0 ", "answer": 2}, {"article": "\"Like many things, the evidence changes over time,\" says Hensrud.\nBut he says that newer studies suggest that drinking coffee may actually be good for you.\nHowever, coffee alone may not be the answer according to some experts.\nBut he is concerned that the side effects of coffee are not addressed in this study.\nDr. Dong Shin, a head and neck specialist at Emory Winship Cancer Institute says this new study suggests \u201cthere is a hint of beneficial outcomes\" with coffee and oral cancer.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because of the number of sources cited, it\u2019s clear this did not rely on a news release. ", "answer": 1}, {"article": "For more about blood pressure drugs, visit the American Heart Association.\nAccording to the new analysis, published online Jan. 4 in the Mayo Clinic Proceedings, the only difference between the medications is that ARBs are more easily tolerated.\nAlthough ACE inhibitors were developed 10 years earlier, both types of drugs showed similar effects in the analysis, challenging previous findings that suggest ACE inhibitors have greater benefits.\nHowever, when trials were conducted at similar times, one drug was not more effective than the other, the findings showed.\nScientists at the NYU Langone Medical Center in New York City said their findings settle a longstanding debate about which of two types blood-pressure lowering medications studied are better.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Given that the quotes in this story closely mirror those in the NYU news release, and that no additional sources or material are provided to amplify the story, we believe the writer relied heavily, if not totally, on the prepared news release. We appreciate the fact that the story acknowledged the source of these quotes, but without additional reporting, we don\u2019t think this is sufficient to satisfy the intent or spirit of the criterion. The Washington Post story on the same research provided at lease a minimal additional amount of information, fleshing out the story.", "answer": 0}, {"article": "B vitamins, including B12 and folate, have been shown to help lower homocysteine levels, so high levels of the amino acid suggest low levels of B12.\nThe relationship between vitamin B12 and Alzheimer's risk is \"complex,\" says Dr. Sudha Seshadri, M.D., an associate professor of neurology at the Boston University School of Medicine and the author of an editorial accompanying the study.\n\"Lowering these in general is important for cardiovascular health, and this study strengthens our knowledge about its role in risk for Alzheimer's disease.\"\nDr. Sam Gandy, M.D., the associate director of the Alzheimer's Disease Research Center at the Mount Sinai School of Medicine, in New York City, says that it may make sense for people to get blood tests to measure their levels of B12 and folate.\nHealth.com: 9 foods that may help save your memory\n\nOver the next seven years, 17 study participants were diagnosed with Alzheimer's disease.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "", "answer": 1}, {"article": "Those most at risk of developing such cancers are of Eastern European Jewish descent.\nThe prescription-free test is the first to report on three specific BRCA1 and BRCA2 breast cancer gene mutations, according to the FDA.\n\u201cThe test should not be used as a substitute for seeing your doctor for cancer screenings or counseling on genetic and lifestyle factors that can increase or decrease cancer risk,\u201d he said.\nStill, the company, which already tests DNA for other health risks as well as ancestry, said this cancer test is \"a step in the right direction.\"\nThe test detects only three out of more than 1,000 known BRCA mutations.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "23andMe issued a release \u2014 and so did the FDA. As far as we can tell, all of the material in the story was drawn from these two releases.", "answer": 0}, {"article": "Xarelto already is approved for use by those with atrial fibrillation (irregular heartbeat) and by people who are having hip- or knee-replacement surgery.\n\"While it is true that these bleeding events typically do not lead to death or irreversible harm, these events may represent the biggest problem for both patients and health care providers if rivaroxaban is approved.\"\n\"However, what is not reflected in the sponsor's analysis are minor bleeding events,\" FDA reviewer Dr. Karen Hicks wrote in the briefing documents.\nIn the FDA briefing documents, an agency reviewer recommended approving the drug for treatment of acute coronary syndrome, mostly because trial data showed there was a reduction in cardiovascular death, even though there was also an increased risk of potentially fatal bleeding.\nOf those patients, 136 had bleeding in the brain.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story simply repeated what appeared in FDA briefing documents and in an earlier conference news release.\u00a0 Apparently no one was interviewed for this story.\u00a0 That\u2019s not ideal health care journalism.", "answer": 0}, {"article": "\"We do not want to give anyone false hopes that this is ready for the clinic yet.\nCarissa Cascio, an assistant professor of psychiatry from Vanderbilt University School of Medicine, who specializes in autism and neuro-imaging, believes these study results are important.\nStill he believes this is new study can help pinpoint the earliest markers of concern in developing brains.\nLange is quick to caution that this type of test is not yet ready for prime time.\nThe images of the brains helped researchers correctly identify those with autism with 94 percent accuracy, says Nicholas Lange, an associate professor of psychiatry at Harvard Medical School and one of the study authors.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a news release.", "answer": 1}, {"article": "Statin use may also lead to:\n\u2022 Decreased fibrosis (hardening or scarring of tissue),\n\u2022 Less development of fatty liver,\n\u2022 Slowed or halted spread of hepatitis C virus,\n\u2022 Improvement of portal hypertension (high blood pressure in the liver\u2019s blood vessels),\n\u2022 Destruction of existing liver tumor cells, and\n\u2022 Reduced risk of developing liver cancer.\nNOTE TO JOURNALISTS: To schedule an interview with a member of the research team, please contact the APS Communications Office or 301-634-7209.\nThe article is published ahead of print in the American Journal of Physiology\u2014Gastrointestinal and Liver Physiology.\nThe Society represents more than 10,500 members and publishes 15 peer-reviewed journals with a worldwide readership.\n(March 23, 2017)\u2014Statin drugs are widely used to manage high cholesterol and reduce the risk of cardiovascular disease.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There are no notable\u00a0examples of unjustifiable language here.", "answer": 1}, {"article": "\"The work by [first author] Price et al.\nWe should be very careful about claiming the importance of resveratrol for medical purposes.\nTesting the effect of resveratrol on SIRT1 in mice was difficult, Sinclair said.\nstrongly supports the basic rationale being pursued at Sirtris, which focuses on the development of small-molecule compounds that directly activate the enzymatic activity of SIRT1 as a new therapeutic approach to many diseases of aging,\" Vlasuk wrote in an email to the journal.\nThe study is in the May 1 issue of Cell Metabolism.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There\u2019s no evidence that the story relied solely on a news release.", "answer": 1}, {"article": "\"It's only been relatively recently that energy surplus has become a problem,\" Wu said.\nThe research was supported by the Human Frontier Science Program, Edward Mallinckrodt Jr. Foundation, National Institutes of Health and American Heart Association.\nResearchers in the lab of Jun Wu, research assistant professor at the LSI, wanted to better understand cinnamaldehyde's action and determine whether it might be protective in humans, too.\nAnd because it is already used widely in the food industry, it might be easier to convince patients to stick to a cinnamon-based treatment than to a traditional drug regimen.\nNow, before anyone goes dumping tons of extra cinnamon in their egg nog in hopes of keeping holiday-season pounds at bay, Wu cautioned that further study is needed to determine how best to harness cinnamaldehyde's metabolic benefits without causing adverse side effects.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "This news release does not use unjustifiable language. It clearly states that this is work that has been done in mice and now in human cells. It also issues a warning not to use cinnamon as a treatment as there might be side effects.", "answer": 1}, {"article": "About the UNM Comprehensive Cancer CenterThe University of New Mexico Comprehensive Cancer Center is the Official Cancer Center of New Mexico and the only National Cancer Institute-designated Cancer Center in a 500-mile radius.\nCosette Wheeler, PhD, at The University of New Mexico Comprehensive Cancer Center, was the lead author of the report.\nThe international study found that it protects against HPV infection in women older than 26 years.\nAnnual research funding of almost $60 million supports the UNM CCC\u2019s 130 cancer scientists.\nThese study results are essential to new approaches in cancer prevention, particularly those that are investigating combined approaches of cervical screening and vaccination in adult women.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release exhibits\u00a0balanced language throughout.", "answer": 1}, {"article": "Breathing problems -- already a high risk because labor helps clear the baby's lungs of fluid -- happened four times as often in babies born at 37 weeks than those born at 39 weeks.\nThe findings from the study sponsored by the National Institute of Child Health and Human Development's Maternal Fetal Medicine Units Network also underscore the importance of a woman seeking medical care as early into her pregnancy as possible, so that doctors can accurately gauge the gestational age with an ultrasound, Mercer said.\nThe tests the doctors perform to determine the extent of the fetus's development are often not sophisticated enough to determine subtle milestones for breathing and processing food independently, said Dr. John Thorp, a University of North Carolina-Chapel Hill obstetrician and one of the authors of the study.\nAll of the women had previously had C-sections.\nOf those, more than 13,000 had elective C-sections.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story quotes multiple experts, it is clear that the story does not rely on a press release as the sole source of information.", "answer": 1}, {"article": "Researchers said they had identified a family of retroviruses in patients with chronic fatigue syndrome, opening up a potentially promising new avenue of treatment for a debilitating disease that afflicts as many as four million Americans and 17 million people world-wide.\n\nThe finding will likely spur patients with the condition to seek treatment with drugs used to fight HIV, the virus that causes AIDS. Although HIV and the newly identified virus group are different, they are both retroviruses.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "", "answer": 1}, {"article": "And the warriors had a 40 percent lower risk of cardiovascular death and an 18 percent lower risk for cancer-related death.\nThis could be something as simple as a brisk walk or other low-impact options for vigorous exercise about 20 minutes a day.\nThe researchers then cross-referenced this information with health department death records.\nMore than 90 percent of the subjects were white.\nHowever, there are also some limitations to this study, the researchers say.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news\u00a0release.", "answer": 1}, {"article": "Thrombectomy involves a catheter placed in the femoral artery and snaked up the aorta and into the cerebral arteries where the clot that is blocking the artery, and causing the neurological symptoms, is retrieved.\nTo select patients for the trial, the researchers used a new approach which used brain imaging and clinical criteria as opposed to just time alone.\nHowever, a pre-planned interim review of the treatment effectiveness after 200 patients were enrolled in the trial led the independent Data Safety Monitoring Board overseeing the study to recommend early termination of the trial, based on pre-defined criteria demonstrating that clot removal provided significant clinical benefit in the studied patients.\nThe trial was sponsored by Stryker Corporation, a medical technology company that manufactures the clot removal devices used in the study.\nThe international multi-center clinical study, known as the DAWN trial, randomly assigned 206 stroke victims who arrived at the hospital within six to 24 hours to either endovascular clot removal therapy, known as thrombectomy, or to standard medical therapy.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Terms like \u201cbreakthrough\u201d and \u201cparadigm shift\u201d are over-the-top for these findings.\u00a0 While the release provides good supporting data, readers should remember that the study was a non-blinded, non-placebo controlled trial and given what we have learned from the ORBITA trial on cardiovascular stenting which has gained so much attention recently, even intervention therapies need a placebo control. ", "answer": 0}, {"article": "Of the men who had a raised platelet count of the same value or higher six months after being diagnosed with thrombocytosis, 18.1% developed cancer, while for women the figure was 10.1%.\nRichard Neal, professor of primary care oncology at the University of Leeds who was not involved in the research, welcomed the study.\n\u201cThis work should begin to change practice, so that GPs should be testing patients with raised platelet counts for cancer, especially those without other potential cancer symptoms,\u201d he added.\n\u201cThis is a clue which can be used in practice by GPs to help them select patients for further investigation \u2026 most excitingly in some patients who may not already have other symptoms of cancer to achieve earlier diagnosis,\u201d said Sarah Bailey, co-author of the research from the University of Exeter.\nDr Jasmine Just, Cancer Research UK\u2019s health information officer, said more research was need to confirm whether further tests following a high platelet count would save lives.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The University of Exeter published a news release on its website,\u00a0from which the story\u00a0drew substantially. But the story\u00a0also used outside sources.\n\u00a0", "answer": 1}, {"article": "Nerve cells that communicate and control the voluntary muscles of the body (such as those in the arms, legs and face) degenerate or die.\nUnfortunately, the procedure provided no benefit to patients, though it caused substantial pain to two of the study participants.\nNeither his primary care physician nor his neurologist could identify the cause of his deterioration.\n\"People who do these studies should be considered medical heroes,\" Goldstein said, adding, \"The selflessness of these people when they're told they're gonna die.\"\nIn Pharr's father's case, the progress of disease was rapid.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "Shares in Angle, which has a market cap of about 50 million pounds, rose 2.2 percent to 68 pence.\nHeadline results from a study of 400 patients in Europe and the United States showed the test to detect cancerous cells in the bloodstream correctly identified cancer in up to 95 percent of cases, the company said.\nThe performance of the test would now be validated in another study designed to meet European CE Mark and US FDA regulatory requirements, he said.\nThe test was nearly twice as successful in eliminating false-positives than current tests, he said.\nIt also had the potential to identify targets on the tumor that could be used to inform treatment strategies, he said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Parts of this story (a direct quote, for example) are independent of the company\u2019s news release.\n\u00a0", "answer": 1}, {"article": "\"One caveat is that other agents that have shown clear efficacy in this model of PD have subsequently failed to show benefit in clinical studies in PD (e.g.\nThe third in a series of studies from the Andersen lab involving PD and low-dose lithium, the results add to mounting evidence that low-doses of the psychotropic drug could benefit patients suffering from the incurable, degenerative condition.\n\"The treatment also protected the area of the brain that is normally damaged by Parkinson's.\"\nThe Buck Institute is the U.S.'s first independent research organization devoted to Geroscience - focused on the connection between normal aging and chronic disease.\n\"For patients these side effects are just as devastating as the freezing that is associated with PD.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The headline of the release cannot be justified on the basis of the information provided or by the results of the study itself.", "answer": 0}, {"article": "Italian researchers retrospectively studied 647 kidney transplants, grouping the donors according to whether they were in their 50s, 60s, 70s or 80s.\nA new study has found a kidney transplanted from a deceased 79-year-old can be as effective as one from a person 30 years younger.\nGenerally, guidelines classify donors older than 50 as \u201cextended criteria donors,\u201d but shortages have led to using these donors more frequently.\nThe study is in the Clinical Journal of the American Society of Nephrology.\nOld age is not necessarily a barrier to kidney donation.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The post does not appear to rely solely on the news\u00a0release\u00a0(because it has\u00a0unique quotes), but\u00a0it didn\u2019t provide anything beyond what the news release stated.", "answer": 1}, {"article": "WASHINGTON\u2014The Food and Drug Administration questioned the clinical benefit of using GlaxoSmithKline PLC's Avodart to cut the risk of prostate cancer.\n\nAvodart is currently approved to treat benign enlargement of the prostate. The company is seeking FDA approval to market the drug to certain men to reduce the risk of prostate cancer. The drug will be reviewed by an FDA advisory panel on Wednesday along with Merck & Co.'s Proscar, a drug similar to Avodart.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story quotes\u00a0an FDA document as well as an official from Glaxo. It doesn\u2019t appear to rely solely on any press release.", "answer": 1}, {"article": "Hernias occur when part of an internal organ, such as the intestines, bulges out through muscle.\nIt was developed in the 1990s, Brunt said.\nAlmost all the patients were men, and their average age was around 55.\nThe findings appear in the March issue of the Archives of Surgery.\n\"One repair isn't appropriate for all circumstances.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story wasn\u2019t based on a press release.", "answer": 1}, {"article": "\"Daniel's obstruction was both at the level of the soft palate and at the back of the tongue,\" Thaler says.\nBut Sheiner was extremely committed to trying it.\nAnd even then, success rates aren't high; they're effective only 20 to 30 percent of the time.\nA sleep study confirmed Sheiner had one of the worst cases of apnea his doctors had ever seen.\nSheiner is one of only about a half-dozen patients to have this robotic surgery for apnea.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely solely on a news release.", "answer": 1}, {"article": "\u201cWe do not know for sure, and we do not know which particular aspect of olive oil is the most relevant to stroke,\u201d he says.\n\u201cMaybe olive oil improves vascular risk factors such as hypertension, dyslipidemia, diabetes, heart disease, obesity, which may in turn reduce stroke risk, or it may be that olive oil is anti-inflammatory or an antioxidant.\u201d Scarmeas writes an accompanying editorial.\nShe calls the findings \u201cintriguing\u201d but says they \u201cdo not equate a randomized clinical trial and should be used with appropriate caution in making broad recommendations.\u201d\n\nSuzanne Steinbaum, MD, director of women and heart disease at Lenox Hill Hospital in New York, says moderate use of olive oil in cooking and on bread may help protect against stroke in people older than 65.\n\u201cOlive oil is a healthy fat and it can reduce cholesterol and inflammation, and has been shown to help reduce the incidence of heart disease,\u201d she says.\nShe agrees with the study authors and editorialist that it is too early to make any recommendations about olive oil intake and stroke risk.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely on a news release.", "answer": 1}, {"article": "Worldwide, more than 10 million people have impaired vision or blindness as a result of corneal damage, but only a small fraction ever receive transplants from cadaver donors.\nIn a newly released study, investigators from Canada and Sweden reported results from the first 10 people in the world treated with the biosynthetic corneas.\nNine of the 10 experienced cell and nerve regeneration, meaning that corneal cells and nerves grew into the implant.\nThe corneas were sensitive to touch and produced normal tears.\nThe research was primarily funded by grants from the Canadian Stem Cell Network, the Swedish Research Council, and the Marie Curie International Fellowship.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on the news release.", "answer": 1}, {"article": "Professor Peter Sadler, a medicinal chemist at the University of Warwick commented:\n\n\"Platinum compounds are the most widely used drugs for cancer chemotherapy, but we urgently need to respond to the challenges of circumventing resistance and side-effects.\nManipulating and applying well-established chemistry in a biological context provides a highly selective strategy for killing cancer cells.\nUniquely, this chemo-catalyst treatment can be recycled and reused within a cancer cell to attack it repeatedly.\nSince this new research functions in a totally new and unique way, it may overcome this acquired resistance and widen the spectrum of anticancer activity.\nChemo-catalysts, especially those with immunogenic properties, might provide a breakthrough.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The problems with this release lie in what it does not say. There is nothing wrong with the language used here. For example, the release states that \u201ccancer cells can be destroyed more effectively and selectively\u2026\u201d but it doesn\u2019t give readers crucial information. For example, the release says JPC11 is \u201cmore effective\u201d at destroying cancer cells. More effective than what? How much more effective? What sort of cancer cells were tested? Any time one says Thing A is \u201cmore effective\u201d or \u201cbetter\u201d or \u201csafer\u201d or whatever, there has to be a Thing B. This release doesn\u2019t do that. It\u2019s not that the release makes outrageous claims, there\u2019s just a complete lack of context for the information that\u2019s there. That makes the release virtually useless for readers.", "answer": 0}, {"article": "Lung cancer is the most common cause of cancer death in the U.S. for men and women.\nThe researchers say the framework of the new compound is different from that of other cancer drugs and acts against a protein that carries a structural defect, according to a news release.\nThe new compound seems promising in mouse models, the researchers say, adding they hope it proves effective in clinical trials and is better tolerated than drugs now used.\nThe researchers say their new compound shows how fast lung cancer research and development are moving forward.\nMuch work lies ahead in determining whether the compound and related ones will prove to be effective therapies, but the researchers say their discovery demonstrates the power of screening specially designed compounds against cancers \"with certain genetic quirks.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Besides the final paragraph on epidemiology, the article appears to rely entirely on the Dana Farber\u00a0press release. Much of the language was taken verbatim.\u00a0 One researcher\u2019s quote is identical to one in the news release, yet there is no attribution, making it appear as though WebMD interviewed the researcher. ", "answer": 0}, {"article": "If the child said a word, the parent repeated it and added something.\n\u201cThese results at follow-up are pretty consistent in showing the benefit of this early intervention for autism across a range of measures.\nNevertheless, for parents of children with autism, even a modest reduction would be worthwhile.\u201d\n\nDr Max Davie, of the Royal College of Paediatrics and Child Health, said it offered \u201ca hugely cheering message for families\u201d, while Uta Frith, emeritus professor of cognitive development at University College London, called it \u201ca remarkably positive story, because the intervention itself was neither intensive nor invasive\u201d.\nMy impression is that this is an intervention that reduces the severity of autistic symptoms, rather than curing autism.\nThe children in the intervention group, though, got better.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article appears to have involved interviews and original reporting of the research summary published in the Lancet.", "answer": 1}, {"article": "\"We have the side view and the back view,\" said Kaufman.\nThis new wave of radiology-based colonoscopy could improve those odds further.\nBoth have made early detection and treatment more precise.\nIt may need to be followed with the physical colonoscopy later, as well.\nHe added it could lead to better and earlier detection of colon polyps.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes an interview with Dr. Arie Kaufman, so it\u2019s safe to say that it went beyond any news release.", "answer": 1}, {"article": "Gastric bypass surgery involves making the stomach smaller, and attaching the lower part of the small intestine directly to the stomach, so much of the small intestine is bypassed.\nThe new study is notable because of the decade-long follow-up, said Maciejewski, who is also a research career scientist at Durham Veterans Affairs Medical Center.\nThe study helps address a knowledge gap about long-term outcomes of bariatric surgery, said Dr. Jon Gould, chief of general surgery at the Medical College of Wisconsin in Milwaukee.\nAt the study's one-year mark, those who had the bypass had lost 31 percent of their starting weight, but the non-surgical patients had lost just 1 percent.\nThe study \"shows that the gastric bypass procedure compared to sleeve gastrectomy or adjustable gastric banding produces more weight loss and it was sustained over the long term,\" Gould said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Duke Medicine issued a news\u00a0release, and the HealthDay story\u00a0does not rely solely on it.", "answer": 1}, {"article": "Cystic fibrosis (CF) is a genetic disorder that causes persistent lung infections.\nThe trials were short-term, finding that the drug combinations improved adult patients' lung function over four weeks.\nBoth new trials focused on those two groups of patients.\nThe other trial had nearly identical results.\nThe other trial used the same existing drugs, along with a similar new drug, dubbed VX-445.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not appear to rely on a news release.", "answer": 1}, {"article": "The Mediterranean diet can vary from country to country but the foods consumed from Greece to Spain tend to be high in fruits, vegetables, fish, legumes, nuts, bread, pasta, cereals, potatoes and unsaturated fats like olive oil.\nThey are the first studies to examine the association between the Mediterranean Diet and neurological diseases \u2013 specifically Alzheimer's.\nThis study, as well as another published earlier this year, were both conducted by Columbia University Medical Center and sponsored by the National Institution of Health (NIH).\nFor more further information, you can see the studies here and here.\n\"Those who moderately adhered to the diet had a 53 percent reduction in risk of developing Alzheimer's disease,\" The Early Show medical contributor Dr. Emily Senay.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story is based on a study appearing in the Journal of American Medical Association \u2013 for which there was a press release \u2013 but there is additional reporting and a caveat that further randomized controlled intervention studies are needed to more clearly define a link between diet and Alzheimer\u2019s. ", "answer": 1}, {"article": "When it comes to health, I\u2019m skeptical of willpower. Sure, I talk to my students about personal responsibility, but when it comes to the health of populations, I look for big fixes more than for small acts of will.\n\nThat\u2019s why my ears perked up when I heard that two old physician friends had decided to start taking, as a preventive measure, some of the medications often included in what the field has dubbed the \u201cpolypill.\u201d My friends are both top doctors in their 60s, with good diet and lifestyle, and this is now part of their...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story doesn\u2019t appear to rely on a news release, it appears to be original commentary.", "answer": 1}, {"article": "April 28, 2010 -- Federal researchers say a new treatment can reverse vision loss in many patients with diabetic macular edema, a leading cause of blindness in people with diabetes.\n\nIn a news conference yesterday, researchers announced findings from a government study comparing treatments for swelling of the retina caused by leaking blood vessels in the eye.\n\nNearly 50% of patients given eye injections of the drug Lucentis along with laser treatments showed improvement in vision after a year of treatment, compared to just over a fourth of patients treated with laser alone.\n\nFor several decades, laser has been the standard treatment for diabetic macular edema, or DME, in which fluid builds up near the center of the retina.\n\n\u201cFor the first time in 25 years we have definitive proof that a new treatment can lead to better results for the eye health of people with diabetes,\u201d said Neil M. Bressler, MD, who oversaw the study as chairman of the Diabetic Retinopathy Clinical Research Network.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear the story did not rely on a news release. ", "answer": 1}, {"article": "For more on stroke, visit the National Stroke Association.\nIn this study, patients were given the drugs within 4.5 hours after the onset of a stroke, Campbell said.\nBleeding into the brain, the most serious side effect of either drug, occurred in 1 percent of patients, regardless of which drug they received, Campbell said.\nAmong more than 200 stroke victims, TNKase (tenecteplase) was about twice as effective as alteplase in restoring blood flow to the brain, and it also resulted in less disability, the scientists found.\nArora explained that tenecteplase is not widely used in the United States for heart attack patients because these patients are typically treated with angioplasty or heart bypass surgery.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "Among the women who initially had no heart disease and did not take any dietary supplements, 3.4 percent had heart attacks, compared to 2.6 percent of the women who took multivitamins plus other supplements; this translated to a 27 percent lower heart attack risk with vitamins.\nBut vitamin pills seemed to have less of an effect in women with heart disease, Dr. Susanne Rautiainen of the Karolinska Institutet in Stockholm, Sweden, and her colleagues found.\nThe women ranged in age from 49 to 83 at the study\u2019s outset, and about 60 percent in each group used some type of dietary supplement.\nSimilar studies have been done in men, with some confirming the current findings and others contradicting them, Rautiainen said.\nThe results don\u2019t settle the question of whether it\u2019s actually the vitamin pills that are protective, Rautiainen told Reuters Health via e-mail.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes quotes from one of the researchers.", "answer": 1}, {"article": "The new research, reported Oct. 10 in the journal Nature Communications, was led by Charles Brenner, PhD, professor and Roy J.\nThe information from the mouse study subsequently helped Brenner's team design the formal clinical trial.\nThe experiments also revealed more detail about NAD+ metabolic pathways.\nMore than a decade of research on NR metabolic pathways and health effects in mice and rats had convinced him that NR supplementation had real promise to improve human health and wellness.\nBrenner notes this was a case of bidirectional translational science; having learned something from the initial human experiment, his team was able to return to laboratory mice to explore the unexpected NAAD finding in more detail.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release overall has a measured tone and avoids exaggeration and sensationalism, except for some troublesome phrases that have already been addressed under the Benefits criterion.\u00a0 In particular, the headline states that NR \u201csafely boosts levels of important cell metabolite linked to multiple health benefits.\u201d The lead echoes that NR \u201cincreases levels of a cell metabolite that is critical for cellular energy production and protection against stress and DNA damage.\u201d Those statements imply benefits that are not proven to exist.", "answer": 1}, {"article": "A lot changed in between the births of my second and third daughters. For one thing, this time around I really am getting no sleep; for another, the pediatrician recommended something for our 1-month-old that is different from what had been suggested for our other children. She said we needed to pick up a liquid multivitamin that contains 400 international units (IUs) of vitamin D. It was a little confusing, because with our first daughter, now almost 4, the doctor told us to simply get her out in the sun from time to time to let her body produce vitamin D,...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not appear to rely on a press release.", "answer": 1}, {"article": "Researchers used CAR-T to treat a man with brain cancer to some success\n\nGlioblastoma is one of the deadliest cancers \u2014 an illness that responds to few treatment options, and often poorly. But a single case study that uses an experimental immunotherapy to treat these brain tumors might give oncologists a new way to approach the disease.\n\nThe therapy, called CAR-T, is controversial and has faced hurdles in clinical trials. It has shown great promise in treating blood cancers like leukemia and lymphoma \u2014 but has proven challenging in treating other forms of the disease, including solid tumors.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story\u00a0possibly may have started with the\u00a0news release, but it reflects useful additional outside reporting. \u00a0\u00a0", "answer": 1}, {"article": "Thirty women each received real acupuncture that also included a bit of an electric buzz or the inactive placebo pill, 32 women got sham acupuncture, and 28 women received gabapentin (Neurontin).\nInterestingly, sham acupuncture came in second place for effectiveness, the researchers said.\n\"There is a component of behavior of doing a sham procedure, so it psychologically may trigger a different kind of reaction from patients versus taking the placebo pill.\"\n\"The so-called bedside manner or communication with patients -- all of these enhance the effect of the patients feeling they're getting something.\"\n\"The magnitude of the placebo effect for acupuncture is bigger than for the drug.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The presence of an outside observer\u2019s comments, and the lack of exaggeration of the findings, would suggest that this story goes beyond any news release.", "answer": 1}, {"article": "Mannitol pulls water out of the tightly packed cells lining the capillaries so that they shrink and pull away from one another, opening up gaps through which drug molecules can pass into the brain.\n\u201cNobody knows.\u201d\n\nIndeed, the death of the first patient was a reminder that glioblastoma can invade other parts of the brain and the spinal fluid and that the highly localized spray of Avastin might miss deadly seeds of cancer.\nBut a scan found a brain tumor nearly the size of a golf ball.\nThat means a lot to me.\u201d\n\nDr. Boockvar said: \u201cAvastin may not be the best drug for this delivery technique.\nMr. Sugrue said he was all for it, even though Dr. Boockvar warned him that the drug was no magic bullet.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no evidence that the story relied on a news release. ", "answer": 1}, {"article": "Silicone breast implants were pulled off the market in 1992 amid concerns that leaks from the implants could lead to cancer or autoimmune disease.\nMoreover, that data are limited to just the last two or three years \u2014 not enough, Wolf says, to make any real claims about the long-term safety of the implants.\nSo you have to at least expect that sometime in your life, you are going to need a reoperation.\nBut ultimately she decided she didn't want to go through more surgery.\nDoctors reassured her it wasn't her implants.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story didn\u2019t rely solely on a news release.", "answer": 1}, {"article": "The Web site naturalaugmentation.com lists several doctors, mostly ob-gyns and family medicine physicians, not plastic surgeons, who offer coupons for \u201cnatural augmentation\u201d and even something called \u201cstem-cell breast augmentation.\u201d\n\nA company called makes a machine used in that concentrates the cells within fat tissue that aren\u2019t strictly fat cells, including .\nThe pleased mother of three in the news clip said her breasts grew \u201covernight,\u201d which is misleading.\nThat hasn\u2019t stopped Dr. Todd Malan, a board-certified ob-gyn in , Ariz., who is the surgeon in the ABC news clip, from anointing himself the \u201cFirst in U.S. to perform Stem Cell Enhanced Breast Augmentation!\u201d on his Web site.\nNor has \u201cconcentrating\u201d cells in fat been proved to make a difference in controlled studies, said Dr. Karol A. Gutowski, chairman of the plastic-surgery society\u2019s task force.\n\u201cSuddenly everyone is claiming to have 10 years of experience,\u201d said Dr. Coleman, who is a paid adviser to Cytori.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story includes information from several sources and so does not appear to be based on a news release.", "answer": 1}, {"article": "In type 1 diabetes, the immune system attacks and destroys insulin-producing cells within the pancreas.\nThis is the latest of several stem cell studies to show promising results for the treatment of type 1 diabetes, Ratner notes.\nThe \"cocktail treatment\" combines stem cell therapy with drugs that suppress the body's immune system.\nThe study was very small, and the procedure is not ready for widespread use.\nFirst, patients are given drugs to stimulate production of blood stem cells.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does not appear that the story relied solely on a news release.", "answer": 1}, {"article": "Dec. 14, 2009 -- Every cup of coffee a person drinks per day may lower the risk of diabetes by 7%.\nThey say several studies have suggested that drinking coffee may lower the risk of developing type 2 diabetes and others have shown that decaffeinated coffee and tea may offer similar benefits, but there has not been a recent review of the research on the issue.\nWhen the information from the individual studies was combined, researchers found each additional cup of coffee drunk per day was associated with a 7% lower risk of diabetes.\nThe study also showed that people who drank more than three to four cups of decaffeinated coffee per day had about a one-third lower risk of developing type 2 diabetes than those who didn\u2019t drink any.\nThe results showed that people who drink more coffee, whether it\u2019s regular or decaffeinated, or tea appear to have a lower risk of developing type 2 diabetes.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story appears to draw entirely from a journal news release.\u00a0 The concluding quote in the story is exactly the same as the concluding quote from the news release. ", "answer": 0}, {"article": "Nov. 22, 2010 -- Exercising to piano music may help improve balance and prevent falls among the elderly.\n\nA new study shows older men and women who participated in a piano-music-based exercise program were less likely to suffer a fall than those who didn't. Those who exercised to piano music also showed improvements in balance and the manner or style of walking.\n\n\u201cEach year, one-third of the population 65 years and older experiences at least one fall, and half of those fall repeatedly,\u201d write researcher Andrea Trombetti, MD, of University Hospitals and Faculty of Medicine of Geneva, Switzerland, and colleagues in the Archives of Internal Medicine. \u201cExercise can counteract key risk factors for falls, such as poor balance, and consequently reduce risk of falling in elderly community-dwelling individuals.\u201d\n\nResearchers say a large proportion of falls in elderly people occur while walking, so improving gait and balance can have a major impact on fall prevention.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\nThis story appears to be based on a news release issued by the Archives of Internal Medicine. The only direct quote in the story is identical to one featured in the news release. The news release introduces the fundamental misunderstanding of the trial design that is repeated in the news report.\n\u00a0\nArchives of Internal Medicine News Release:\nExercising to Piano Music Appears to Help Reduce Falls Among Older Adults\nhttp://pubs.ama-assn.org/media/2010a/1122.dtl#5\n", "answer": 0}, {"article": "Fibromayalgia is a condition marked by fatigue, disturbed sleep, and pain.\nHowever, a rheumatologist not connected to the study does not expect the new drug to be a ''game-changer.\"\nCyclobenzaprine, marketed in higher doses by others as Amrix, Fexmid, and Flexeril, is already widely used ''off-label'' for patients with fibromyalgia, Lederman says.\nTONIX is developing a lower-dose version and improving the formula, Lederman says.\nThe results of the study are published online in The Journal of Rheumatology.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\nThe story does not appear to rely on a news release.", "answer": 1}, {"article": "As technologies and processes continue improve this is likely to be reduced,\" she continues.\nHe added, however, that the studies confirm the potential of cancer vaccines.\nBoth vaccines were deemed safe and are expected to be taken forward for further research.\nCornelius Melief, from the Leiden University Medical Center, Netherlands, said in an accompanying News & Views article that controlled, randomized Phase II clinical trials will be needed to work out if the vaccines are effective.\nIn two studies published in the journal Nature, researchers have shown promising results from Phase I clinical trials.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes independent sources and does not appear to be reliant on a news release.", "answer": 1}, {"article": "Back in April the WSJ wrote about the race to develop ways of detecting Alzheimer\u2019s disease using a brain scan. Currently only a post-mortem sampling of brain tissue can provide a definitive diagnosis. But the hope is that a technology that could be used in living patients could help rule out Alzheimer\u2019s in some patients and for those that have the disease, allow its \u2026", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\u00a0It is not clear whether this information comes directly from a news release and/or entirely from Bloomberg News. ", "answer": 2}, {"article": "A Harvard researcher hopes an old arthritis drug, which he read about in a 19th century German medical journal, could be a cheap new treatment for diabetes.\n\nIn the late 1990s, Steven Shoelson's research suggested that the drug, called salsalate, might also help diabetics. The idea sent him into the basement stacks of a Harvard library to see whether anyone else had pursued the notion.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Clear enterprise reporting. ", "answer": 1}, {"article": "When considering where to give birth, most parents-to-be and doctors in Western nations believe a hospital is the best place.\n\nNot so Jean Stevens, 32, who chose to deliver two children at home in the U.K. She says her two labors were nearly pain-free.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not seem to be tied a news release, and clearly draws from interviews with multiple sources.", "answer": 1}, {"article": "\"It can be extremely painful to pass these jagged little crystallized minerals and it's very common for sufferers to go to an emergency department for treatment.\nEMF Australasia Chair, Associate Professor Sally McCarthy said this research had the potential to help millions of Australians suffering with this extremely painful condition.\nEMF Australasia awarded more than $270,000 to support Dr Furyk's research, through its Queensland Research Program, which is funded by the Queensland Government Department of Health.\n\"This means patients with large stones might not need more complicated treatments including surgeries, and this has potential to improve care and reduce costs.\n\"It may also have implications for patients living in rural and regional areas, where access to urologists - the specialist doctors who treat this condition - can be limited.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Aside from an over-generalized headline, the release doesn\u2019t engage in unjustifiable language.", "answer": 1}, {"article": "Medical researchers are well aware that the dummy pills used in clinical trials often provide as much relief as the actual drugs being tested. This is what's known as the placebo effect, and it's quite common in people with Parkinson's, a movement disorder that causes tremors, stiffness and balance problems. A 2008 meta-analysis found that placebos used in clinical trials of Parkinson's treatments improved symptoms by an average of 16%.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story quotes from an accompanying editorial, so we can be sure that it went beyond this news release issued by the University of Cincinnati.", "answer": 1}, {"article": "Hialeah bucket list: All the things you need to do in Hialeah before you die\n\nYou can spend your whole life working on this list.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story is well-researched and uses input from many experts, which would not normally be contained within a press release.\u00a0 ", "answer": 1}, {"article": "Inflammation strips the myelin coating from nerve cell extensions, called axons, and connections at the ends of nerves, called synapses, are lost, together disrupting signaling and eventually causing permanent disability depending on where this occurs.\nWorking with a mouse model of MS, the research team assessed astrocytes in various regions of the brain and spinal cord known to be involved in walking, vision or cognition.\nGene expression in specific cells and in specific regions can provide a more precise, neuroprotective approach than traditional treatments for neurological diseases.\nThey treated MS mice with a drug that increased expression in cholesterol synthesis genes - and this resulted in improved walking ability.\nThe work was supported with funding from the Conrad N. Hilton Foundation, the National Institutes of Health, the California Community Foundation, the Tom Sherak MS Hope Foundation, the Rhoda Goetz Foundation for Multiple Sclerosis, and other partners of the UCLA Multiple Sclerosis Program.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The headline skirts the edges, by appearing to promise a way to repair nerves in humans when this study is only in mice. But the headline clings to accuracy by using the phrase \u201cpotential path.\u201d", "answer": 1}, {"article": "Attention, memory, and language improved.\n\"The most surprising result was that the positive effects were found in countries around the whole world.\nMoreover, the benefits to cognition afforded by the MedDiet were not exclusive to older individuals.\n\"I would therefore recommend people to try to adhere or switch to a MedDiet, even at an older age,\" Hardman added.\nThey envision that the utilization of a dietary pattern, such as the MedDiet, will be an essential tool to maintain quality of life and reduce the potential social and economic burdens of manifested cognitive declines like dementia.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The researcher quoted in the news release recommends that folks adopt\u00a0the Mediterranean Diet and testifies that he himself follows it. That is a fairly robust statement of\u00a0advocacy, but it is not overly sensational.", "answer": 1}, {"article": "For example, robots that provide sensory feedback could eventually help a disabled person cook a meal or clean up things at home.\nThat makes it very challenging to perform simple tasks like grasping a foam coffee cup without crushing it, McLoughlin says.\nOf course, mind-controlled robots are still years away from consumer applications, McLoughlin says.\nAnd there's no good way to control them without implanting electrodes in the brain.\nIt's a mind-controlled robotic arm that has pressure sensors in each fingertip that send signals directly to Copeland's brain.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story contains quotes that were not in the original news release.\n\u00a0", "answer": 1}, {"article": "Using the gentler technique, called laparoscopy, a surgeon makes small cuts in the abdomen before inserting a tiny camera inside, then performing the operation by watching a television monitor.\nYet again, the patients who had laparoscopy fared much better than those who had conventional surgery.\nThe new study, in the Annals of Surgery, doesn\u2019t settle that question.\nOn average, it cost $17,594, compared to $12,125 for the laparoscopic surgery.\n\u201cIn healthy individuals, the death rate is very (small) for all groups of patients.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story didn\u2019t rely on a news release.", "answer": 1}, {"article": "Unlike a heart attack, which happens when blood flow to a portion of the heart is blocked, cardiac arrest occurs when the heart\u2019s electrical system malfunctions, often due to irregular heart rhythms.\nThe study is observational and doesn\u2019t prove bystander CPR increases survival odds, the authors note in Circulation.\n\u201cEarly CPR saves lives, and the lack of CPR efforts from bystanders could result in significantly decreased chances of survival,\u201d said lead study author Dr. Shahzleen Rajan of Copenhagen University Hospital in Denmark.\nAfter 13 minutes, patients who got CPR at the scene continued to have better survival odds but the difference was no longer statistically meaningful.\n\u201cClearly, if someone has been motivated to learn and has been taught CPR, they will often assist,\u201d Pons, who wasn\u2019t involved in the study, said by email.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to be based solely on a press release. It quotes two experts who were not involved in the study.", "answer": 1}, {"article": "The requested URL /2011-08-30/business/29945941_1_mark-kris-cancer-cases-lung was not found on this server.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\nThis story appears to rely entirely on a conference call arranged and managed by Pfizer, in essence an audio news release.", "answer": 0}, {"article": "Personal sound amplification products (PSAPs) are less-expensive, over-the-counter devices not specifically labeled for hearing loss treatment, but some are technologically comparable with hearing aids and may be appropriate for mild to moderate hearing loss.\nA limitation of the study was the modest number of participants.\nNicholas S. Reed, Au.D., of the Johns Hopkins School of Medicine, Baltimore, and colleagues compared five of these devices (costs, approximately $350 to $30) with a conventional hearing aid (cost, $1,910) among 42 adults (average age, 72 years) with mild to moderate hearing loss.\nThe researchers found that the change in accuracy in speech understanding from unaided to aided varied by device.\nAccording to nationally representative estimates, less than 20 percent of adults with hearing loss report hearing aid use.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We didn\u2019t detect any words that hyped the results.", "answer": 1}, {"article": ".\nShah is familiar with such skepticism.\nRaybuck, who learned to perform the procedure in Quebec 12 years ago, estimates he uses it fewer than two dozen times annually, and only when circumstances require it.\nIt was removed after about eight hours and replaced by a simple bandage.\nThat is likely to change.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Clearly, the story did not rely on a news release.", "answer": 1}, {"article": "The findings, reported in the journal Diabetes Care, do not suggest that yoga should replace other forms of exercise for people with type 2 diabetes \u2014 a disease commonly associated with obesity.\nFurther, long-term studies are needed to see whether that is the case, the researchers say.\nMeanwhile, their average blood sugar levels held steady \u2014 in contrast to the non-yoga-practicing \u201ccontrol\u201d group, whose blood sugar levels rose.\nThey found that, on average, the yoga group\u2019s levels of the chemicals dipped by 20 percent.\nThe yoga used in this study was a gentle form, Hegde said, and parts of the practice were adapted for people who had additional health problems; certain poses were avoided in people who had heart disease, for example.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure of the extent to which the story relied on a news release.\u00a0 We do know that it quoted only a single source \u2013 the lead researcher.", "answer": 2}, {"article": "Stress tests measure the heart's response to exertion, letting doctors see or hear any disease.\nEven more surprising, the rate of bad outcomes among the heart patients studied were extremely low.\nBut \u2014 partly because his mother had died of coronary artery disease at age 49 \u2014 David remained unconvinced by those results.\nBut they had new symptoms that caused physicians to suspect heart disease \u2014 and nearly all had at least one risk factor like high blood pressure, diabetes or a history of smoking.\nThe first showdown pitting 3-D, heart-imaging exams against older stress tests atop treadmills or stationary bikes found that among 10,003 heart patients, their rates of eventually having serious heart events were the same \u2014 no matter which method doctors used to check their tickers, researchers said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story seems to have gone beyond the press release by interviewing the lead study author, gathering reactions from a researcher outside the project, and adding an anecdotal story to the text. \u00a0That anecdote, by the way, makes the main point of the story more murky rather than more clear.", "answer": 1}, {"article": "For a man in the U.S., the risk of dying of prostate cancer is about 2.5 percent.\nThe analysis, published Monday in Annals of Internal Medicine, drew wildly different reactions, as is often the case with research on PSA screenings.\nIf the new analysis is correct, one of the influential PSA studies, called PLCO, reduced deaths from prostate cancer by 27 percent to 32 percent, not the zero percent that PLCO researchers themselves found.\n\u201cNo matter how sophisticated, they shouldn\u2019t trump data from real people who participated in the randomized trials\u201d \u2014 which in PLCO found zero lives saved from PSA screening.\nThis is a screening test that saves lives.\u201d\n\nThose gains come at some cost to health, though: For every life saved, she estimated, five men will be told they have cancer when in fact their abnormal cells would never grow, spread, or harm them.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This article clearly goes beyond what would have likely been the contents of a news release, particularly in deeply re-examining the findings from multiple perspectives.", "answer": 1}, {"article": "According to Dr. Anthony L. Komaroff, a Harvard internist and epidemiologist who has written a commentary to accompany the study, \"For many years medical scientists have speculated that the symptoms of ME/CFS might be caused by cytokines, molecules that the immune system use to wage war against foreign invaders of the body.\nThis is significant because symptoms in these patients and findings from other studies also suggest that chronic inflammation plays a major role in the illness.\nWhat's more, the findings also point to possible treatment with immune-modifying or anti-inflammatory therapy.\nThat supports the theory that the cytokines are a cause of the symptoms.\"\nKomaroff also notes a recent increase in research funding by the National Institutes of Health, which has included a comprehensive in-house study aimed at unraveling the underlying causes of the condition.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes quotes that appear to be directly from interviews with an author and a reviewer of the study.", "answer": 1}, {"article": "In devising their models, the researchers updated assumptions that have cast doubt on the relevance of existing breast-cancer risk calculators, which relied on the experiences of women who got an earlier generation of screening mammograms and were more likely to die of breast cancer than is currently the case. Here, teams of modelers from Erasmus University in the Netherlands, Albert Einstein College of Medicine in New York and Harvard Pilgrim Healthcare assumed that women were getting digital mammograms, which offer improved cancer detection rates at lower radiation dosages than earlier mammographic methods. They took into account improved rates of breast cancer treatment effectiveness, and changing causes of mortality for women older than 50. They also took account of the fact that breast density decreases in older women.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "UCSF did issue a news release, and the LA Times story\u00a0quotes nearly word-for-word one of the paragraphs from the release, without attribution:\nLA Times:\u00a0\u201cSome lesions detected in screening will never grow to become clinically significant and will not impact a woman\u2019s life,\u201d Kerlikowske said.\nNews release:\u00a0\u201cSome lesions detected in screening will never grow to become clinically significant and will not impact a woman\u2019s life,\u201d Kerlikowske explained.\n\u00a0", "answer": 0}, {"article": "Aug. 17, 2011 -- German researchers say that highly trained dogs are able to reliably sniff out lung cancer in human breath.\nBut that test has caused controversy because it falsely detects cancer in about one out of four people, leading to further invasive procedures.\nHe was not involved in the research.\n\"The whole field is focused on using something that's readily available that does not involve an expensive surgery or scan that would allow us to find early cancers,\" says Ramalingam, who is developing technology that aims to replicate the ability of dogs to smell trace amount of chemicals produced by cancerous tumors.\n\"This is the holy grail,\" says Suresh S. Ramalingam, MD, associate professor and director of the lung program at Emory University's Winship Cancer Institute in Atlanta.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story shows reporting beyond a news release.", "answer": 1}, {"article": "Generalized anxiety disorder (GAD) is one of the most common anxiety disorders in older adults and is associated with poor quality of life, increased health care utilization and impaired memory.\nThese two trends are inextricably linked in the area of geriatric mental health and our search for better, more effective treatments with greater reach.\u201d\n\nThe author made conflict of interest disclosure.\nTelephone CBT consisted of up to 11 sessions (nine required) and focused on, among other things, anxiety symptom recognition, cognitive restructuring, relaxation, coping statements and problem solving.\nThis work was supported by grants from the National Institutes of Health and funding from the Taylor Family Institute for Innovative Psychiatric Research.\n\u201cTelephone-delivered psychotherapy is one way to overcome some barriers to mental health treatment that rural older adults face,\u201d the study concludes.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release does not appear to use any unjustifiable language.\nBut, on a side note about language, the release never defined \u201cnon directive supportive therapy,\u201d which is what the comparison group received. \u00a0Many journalists \u2013 and general public readers \u2013 might not know what that means and would benefit from a one line definition.", "answer": 1}, {"article": "Lobular breast cancer forms in the milk glands.\nExactly how fish oil may affect breast cancer risk is not fully understood, but it may be related to its strong anti-inflammatory properties.\nThe use of fish oil was linked to lower risk of invasive ductal breast cancer.\nOther supplements were not linked to breast cancer risk in the new study, including black cohosh, dong quai, soy, and St. John's wort, which are often taken to relieve some of the symptoms of menopause.\nThe new research is part of the Vitamins and Lifestyle (VITAL) study, which included data from women 50 to 76 years old from Washington state.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely solely on a news release.", "answer": 1}, {"article": "It appears that abiraterone is able to shut down androgen production not only in the testes, but also from the adrenal gland and from within prostate tumors themselves.\nThis study was presented at a medical conference.\nThe study was funded by Johnson & Johnson, which is developing the drug.\nThe treatment gave patients with metastatic, castration-resistant prostate cancer only an extra four months of life.\nThe findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Given that the one quote in the story is attributed to a news release (at least they admitted that), and that there is no independent perspective in the piece, it appears that the story did rely solely or largely on a news release. ", "answer": 0}, {"article": "The F.D.A.\nAnd the drug failed to do that by a statistically significant measure.\nDr. Gold said there were about 100,000 men who get such a diagnosis each year.\ninstead said it wanted more proof that the drug worked and would await results from a trial that was then under way.\nThe F.D.A.\u2019s decision two years ago ignited an outcry from some prostate cancer patients and from investors in Dendreon, who said the agency was being unreasonable and denying patients a treatment that might work.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story\u2019s tortured formulation suggesting that the goals the FDA had set for the drug had been met\u2013while avoiding plainly stating what the FDA had required and what the results showed\u2013first appears in the company\u2019s press release.\nDendreon Corporation (Nasdaq: DNDN) announced today that the pivotal Phase 3 IMPACT study of PROVENGE\u00ae (sipuleucel-T) in men with advanced prostate cancer met its primary endpoint of improving overall survival compared to a placebo control. The magnitude of the survival difference observed in the intent to treat population resulted in the study successfully achieving the pre-specified level of statistical significance defined by the study\u2019s design.\n\u00a0", "answer": 0}, {"article": "Repeated treatments also resulted in a higher likelihood of remission or a longer time to relapse, with an overall response and remission rate of 68.8 percent for the patients receiving ketamine treatment.\n\"Not only was ketamine well-tolerated by participants, with none experiencing severe or problematic side effects, but giving the treatment by a simple subcutaneous injection (a small injection under the skin) was also shown to be an acceptable method for administering the drug in a safe and effective way.\"\nAs part of the double-blind, placebo-controlled trial, an active control treatment which causes sedation similar to ketamine, was used to substitute for one of the treatment sessions.\nFollowing the RCT, participants also received 12 ketamine treatments in an open-label phase to investigate the effectiveness of multiple doses of ketamine.\nLed by a team of researchers from UNSW Sydney and Black Dog Institute, the trial tested different doses of ketamine amongst 16 older age participants (aged over 60 years) who had treatment-resistant depression, administered at Wesley Hospital.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t employ unjustifiable language.", "answer": 1}, {"article": "[3] Yokell et al.\nEVZIO is not a substitute for emergency medical care.\nEVZIO was the first naloxone product specifically designed, FDA approved and labeled for the emergency treatment of opioid overdose by individuals without medical training.\nEach kal\u00e9o product combines an established drug with an innovative delivery platform with the goal of achieving superiority and cost effectiveness.\nWithout rapid intervention, brain injury or death can occur in as little as 4 minutes.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release avoids the use of unjustifiable terms like \u201cbreakthrough\u201d and \u201cgame-changing\u201d so we rate this criteria as satisfactory, despite its heavy reliance on anecdotes.", "answer": 1}, {"article": "But in the U.S., most prostate cancers are identified by PSA screening, and less than half have palpable tumors.\nSo there's reason to think men followed with active surveillance and treated when necessary would fare better than the \"watchful waiting\" group in the newly published study.\nAlmost 90 percent had tumors their doctors could feel on digital rectal exams.\nSmith makes another point: Both surgical techniques and radiation therapy technology have improved since the Swedish study was done.\nIt's actually an update of a 2008 report, with an additional three years of data on the nearly 700 men who volunteered for the trial up to 15 years ago.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story did not rely solely on a press release.", "answer": 1}, {"article": "Dr Sheraz Markar, an NIHR Clinical Trials Fellow from Imperial College London, under the supervision of Professor George Hanna, told the Congress: \"At present the only way to diagnose oesophageal cancer or stomach cancer is with endoscopy.\nThe new research, involving more than 300 patients, showed that the test could diagnose cancer with an overall accuracy of 85%.\nThis study suggests that we may be able detect these differences and use a breath test to indicate which patients are likely to have cancer of the oesophagus and stomach, and which do not.\nThis will assess the ability of the test to pick up cases within a group that is likely to contain only a small percentage of cancers.\nOver the next three years, the researchers will continue with a larger trial, using the test with patients who are being given an endoscopy for gastrointestinal symptoms but not yet diagnosed with cancer.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "As noted above, most of the \u201cpromise\u201d of the breath test is based on hoped-for developments, not what was actually demonstrated in this trial. It is too early to say whether the ability to often distinguish between compounds in the breath of healthy people and those in the breath of people with established, often advanced, cancers means that it is at all likely that this test will someday be able to pick out important cancers in people in the general population.", "answer": 1}, {"article": "AstraZeneca PLC's cholesterol drug Crestor sharply lowered risk of heart attacks among apparently healthy patients in a major study that challenges longstanding heart-disease prevention strategies. The findings could substantially broaden the market for statins, the world's best-selling class of medicines.\n\nHeart experts said the findings, presented Sunday at the annual scientific meeting of the American Heart Association in New Orleans, could reshape cholesterol-treatment guidelines used for more than a decade to fight cardiovascular...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not rely exclusively on a press release.", "answer": 1}, {"article": "\"Everyone heals differently.\nThe goal of the home-exercise program was to improve movement in the neck area.\nThere also isn't a great deal of information on how effective medications or home exercise programs are for treating neck pain, the researchers noted.\nThere are different pathways to healing, and whether you feel you're better off with chiropractic, home exercises or medications, this study shows that all three are basically just as effective.\nAll three experts said anyone experiencing neck pain needs to have it evaluated to make sure there isn't a serious or correctable cause of the pain.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "BRCA mutations cause about 5 to 10 percent of breast cancers and 10 to 15 percent of ovarian cancers among white women in the United States.\nCancer experts said Tuesday that the actress and filmmaker Angelina Jolie Pitt was wise to have had her ovaries and fallopian tubes removed last week because she carries a genetic mutation, BRCA1, that significantly increases the risk of ovarian cancer, a disease so difficult to detect that it is often found only at an advanced, untreatable stage.\n\u201cProphylactic removal of ovaries and fallopian tubes is strongly recommended in women before age 40 in BRCA1 and BRCA2 mutation carriers,\u201d said Dr. Susan Domchek, executive director of the University of Pennsylvania\u2019s Basser Research Center, which specializes in BRCA mutations.\nIt is unclear how common the mutations are in other racial and ethnic groups.\nThey also said Ms. Jolie Pitt\u2019s decision to discuss her own choices so frankly will encourage women in similar situations to consider their own options.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The basis for the story is an Op-Ed in the NY times by Ms. Jolie Pitt. \u00a0The comments of the experts in the field provide additional information beyond the original story.", "answer": 1}, {"article": "Infants exposed to partial treatment in the womb healthier than those not exposed.\nThe new study, supported by NIH\u2019s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), provides strong evidence that even a partial course can have some benefit.\nInfants in the partial treatment group fared better than untreated infants.\nAdditional funding for the study was provided by NIH\u2019s National Center for Advancing Translational Sciences.\nInfants in the complete treatment group fared best.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release does not use unjustifiable, sensational language.", "answer": 1}, {"article": "So you do not get the impression that the world is moving or that you are moving, you actually do not feel anything,\u201d Bergquist explained.\nThe research was led by Associate Professor Filip Bergquist, who said the simple device was similar to the TENS (Transcutaneous Electrical Nerve Stimulation) therapy which is used for pain relief, for example in child birth.\nThe researchers have also tested the method on ten Swedish Parkinson\u2019s patients, in both medicated and unmedicated states.\nAccording to the research institute, the experiments showed that the active noise stimulation improved both the patients\u2019 balance and the combined symptoms.\nAccording to Sahlgrenska, on one day the patients received an active noise stimulation and on another day inactive treatment, not knowing which day the current was active.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does draw considerably from this news\u00a0release, as noted below:\nStory:\nThe researchers have also tested the method on ten Swedish Parkinson\u2019s patients, in both medicated and unmedicated states. According to Sahlgrenska, on one day the patients received an active noise stimulation and on another day inactive treatment, not knowing which day the current was active. According to the research institute, the experiments showed that the active noise stimulation improved both the patients\u2019 balance and the combined symptoms.\nNews Release:\nThe researchers have now tested the same method on ten Swedish Parkinson\u2019s patients.\nThe patients were studied in both medicated and unmedicated states. On one day, the patients received an active noise stimulation and on another day inactive treatment, blinded to which day the current was active. The experiments show that the active noise stimulation improved both the patients\u2019 balance and the combined symptoms.\nHowever, because the story includes quotes from the primary investigator and a study subject, we can be sure that the press release wasn\u2019t the only source of information.", "answer": 1}, {"article": "Excessive drinking alone is linked to 88,000 deaths each year.\nThat\u2019s long led researchers to suspect that alternative mutual help groups could work.\nThe good news is that the research suggests the spiritual aspect doesn\u2019t fully explain why the 12 steps are effective for some people.\nWhile alternatives like SMART or LifeRing do exist, they\u2019re not nearly as available as AA \u2014 and they certainly aren\u2019t built into professional treatment programs in the same way as the 12 steps.\nAnd since it\u2019s only one study, it\u2019s possible that the results were biased in some other way.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story clearly goes beyond any news release.", "answer": 1}, {"article": "Before the introduction of whooping cough vaccine in the 1940s, more than 200,000 cases a year were reported in the U.S. By 1965, that number plummeted to fewer than 10,000 a year. But the disease made a comeback in the 1990s, as the newer \"acellular\" vaccine \u2014 containing only cellular material but not whole cells \u2014 was phased in. While it is safer and has fewer side effects than the old version, studies have found that its protective effects wane more quickly than originally expected.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is a quote from a CDC news release, though it is clearly sourced. However, a hyperlink to the release itself would have benefitted readers.", "answer": 1}, {"article": "George Bray, an obesity researcher at Pennington Biomedical Research Center in Baton Rouge who has also studied this topic and who wrote the accompanying editorial in JAMA, says that other studies \"show that you can do well on any diet as long as you stick to it.\nMore research is needed to show that interesting results like these are applicable in real life, she says.\nA new study is raising questions about the age-old belief that a calorie is a calorie.\nOn a low-glycemic index diet, you would avoid highly processed carbs such as white bread, white rice, many snack foods, prepared breakfast cereals, sugary desserts and sugary beverages, she says.\nParticipants were fed food that was prepared for them by diet experts.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story is not based on a press release.", "answer": 1}, {"article": "That\u2019s because when you up one circuit in the brain, you\u2019re probably impairing another system.\u201d\n\nEarly studies attributed a lot of short-term benefits to nootropics \u2014 so much so that in 1983, Russian scientists turned to phenylpiracetam to boost the physical and mental performance of cosmonauts during space flight.\nBut self-experimenters such as Burke often don\u2019t restrict themselves to medication alone.\nPlease don\u2019t take it, people!\u201d\n\nFor Burke and other brain hackers, the evidence for nootropics is strong enough.\nIt\u2019s for when people have difficulty finishing that last connection in the brain\u201d).\nFounded by two Stanford University computer graduates, the company has initiated an international fasting group on Facebook; at last count, there were 3,500 members.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "[3] Quote direct from author and cannot be found in text of Article.\nWeak grip strength is linked with shorter survival and a greater risk of having a heart attack or stroke, according to an international study involving almost 140000 adults from 17 culturally and economically diverse countries [1].\nThe study, published in The Lancet, also found that grip strength is a stronger predictor of death than systolic blood pressure, and the authors suggest that it could be used as a quick, low-cost screening tool by doctors or other healthcare professionals to identify high-risk patients among people who develop major illnesses such as heart failure and stroke.\nBut until now, information on the prognostic value of grip strength was limited, and mainly obtained from select high-income countries.\nLoss of grip strength is unlikely to lie on a single final common pathway for the adverse effects of ageing, but it might be a particularly good marker of underlying ageing processes, perhaps because of the rarity of muscle-specific diseases contributing to change in muscle function.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "This is a close call. The tone of the release is generally measured. However, the release headline suggests that hand grip strength\u00a0is \u201csimple\u201d and \u201clow cost\u201d \u2014 neither of which have been proven in widespread clinical practice. It takes training to use this device and interpret the results correctly. And it\u2019s not clear how accurate this test is or if it\u2019ll lead to unnecessary tests or treatments. In other words, the release conveys a certainty about this test that just doesn\u2019t exist\u00a0\u2014 something we think is unjustified.", "answer": 0}, {"article": "It may actually help you live longer, according to new research from the Harvard T.H.\n\u201cIf you\u2019re more optimistic, you tend to have healthier behaviors.\n\u201cOne is called \u2018best possible self,\u2019\u201d Eric Kim, who also co-led the study, told CBS News.\n\u201cOptimism in prior research has been shown to be related to better health behaviors and better health outcomes, particularly in cardiovascular disease,\u201d postdoctoral research fellow Kaitlin Hagan, co-lead author of the study, told CBS News.\nWhile the study is observational and cannot prove a cause-and-effect relationship between optimism and a longer life, the researchers have some theories for what might be behind the connection.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The reporting here appears to be original, as we didn\u2019t detect any copy/pasted quotes.", "answer": 1}, {"article": "To make sure it works, though, the Centers for Disease Control and Prevention says doctors need to do a number of things:\n\u2022 Prescribe Truvada only for men at high risk of getting infected \u2013 that is, only for men who have sex with men, those who have multiple sex partners, and those who live in areas where there's a lot of HIV circulating.\nThe study makes that last point very clear.\nNow health officials are warning doctors that preventing the disease will take more than just writing a prescription.\nThe pill, called Truvada, is already on the market for treating HIV infections.\nThat'll help avoid creating viruses resistant to the drug when patients miss doses.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We\u00a0 have no evidence that the story relied on a news release.", "answer": 1}, {"article": "Some see Qnexa as a test of the FDA trying to recalibrate how it weighs risks and benefits for weight-loss drugs.\nBut some say the agency's aversion to accepting any risks is outdated.\nThe setbacks put a spotlight on how the FDA handles these drugs.\nThe company is submitting new data it says show that the risk is lower than had been feared.\nAs the FDA works through this, many are watching how the agency handles Qnexa.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that this story did not rely solely or largely on a news release.", "answer": 1}, {"article": "Those with the BRCA1 mutation also have a 36 to 63 percent higher risk of ovarian cancer and those with the BRCA2 mutation have a 10 to 27 percent higher risk of ovarian cancer.\n\u201cThis is the first study to prove women survive longer with these preventive surgeries and shows the importance of genetic testing when there is a family history of early breast or ovarian cancer,\u201d Dr. Virginia Kaklamani of Northwestern University in Chicago wrote in a commentary about the study published in the Journal of the American Medical Association.\n\u201cOur results confirm that risk-reducing mastectomy is associated with a significant reduction in breast cancer risk,\u201d Domchek and colleagues wrote.\nThe study shows the benefits of genetic tests that give women with a family history of cancer the chance to take steps to increase their chances of survival, they said.\n\u201cIt\u2019s not cookie-cutter medicine,\u201d Pruthi, who was not involved in the study, said in a telephone interview.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nAlthough several of the quotes in this story are taken from the journal articles, the reporter also interviewed at least one expert.", "answer": 1}, {"article": "Melanie Ashton continued, \"We found that people who had a better-quality diet, a diet with anti-inflammatory properties, or a lower BMI, showed better response to add-on nutraceutical treatment than did those who reported a low-quality diet, or a diet including foods that promote inflammation, or who were overweight.\nThis is a randomised, controlled trial, but what we found were exploratory outcomes; in other words, it wasn't the main result that we were testing.\nParticipants received the study medication in addition to any stable treatments they were already receiving.\nNow a group of Australian, German and American scientists have shown those who have a high quality diet, a less inflammatory diet, and/or a low BMI (Body Mass Index) may respond better to an add-on nutraceutical treatment provided as part of a clinical trial.\n\"If we can confirm these results, then it's good news for people with Bipolar Disorder, as there is a great need for better treatments for the depressive phase of Bipolar Disorder\" said lead researcher Melanie Ashton of Deakin University in Australia.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "A major strength of this news release is that it mentions the preliminary nature of the study results on three\u00a0 occasions, including once by an independent source NOT affiliated with the study (although his credentials should have been mentioned).", "answer": 1}, {"article": "Highlighting the significance of the findings, the study\u2019s senior author, George A. Macones, MD, the Mitchell and Elaine Yanow Professor and head of the Department of Obstetrics and Gynecology, said, \u201cThis study is a tremendous addition to the literature on preventing surgical-site infections after cesarean.\nBut according to Tuuli, the unique circumstances of a C-section \u2014 that bacteria come from both skin and vagina and that a woman\u2019s immune system is altered during pregnancy \u2014 mean the results of these studies may not apply.\nThe investigators pointed out that all other standard procedures for reducing the risk of infection after surgery, including giving preventive antibiotics beforehand, were the same in both groups.\nOf 575 patients who randomly received the iodine-alcohol combination, 42 developed a surgical-site infection.\nBut based on the biological plausibility and the striking reduction in surgical-site infections with chlorhexidine, this is one of those circumstances.\u201d\n\nThis work was supported by a Women\u2019s Reproductive Health Research Career Development grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, of the National Institutes of Health (NIH), grant number 1K12HD063086-01; and by the Department of Obstetrics and Gynecology at Washington University School of Medicine in St. Louis.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release does not resort to unjustifiable language. It uses a measured tone and acknowledged a potential weakness when pointing out that the study was limited to a single hospital.\nThe call for a change in practice, which in our opinion may be premature based on one single-site study, is offered as an opinion expressed by the senior author:\n\u201cThis study is a tremendous addition to the literature on preventing surgical-site infections after cesarean. There are few circumstances when a single study should change our practice. But based on the biological plausibility and the striking reduction in surgical-site infections with chlorhexidine, this is one of those circumstances.\u201d\nWe think experts can be given latitude to express a range of opinions in a news release.", "answer": 1}, {"article": "\u201cLet\u2019s talk about your test results,\u201d my neurologist said.\n\nShe looked as if she had good news. Instead, it was shocking.\n\nThe carotid artery on the left side of my neck, one of the brain\u2019s two main sources of blood and oxygen, was clogged with fatty plaque, the doctor said. The artery was almost completely blocked.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story is based on the reporter\u2019s personal experience.", "answer": 1}, {"article": "(Reuters) - The U.S. Food and Drug Administration (FDA) on Friday expanded the use of Novartis AG\u2019s relapsing multiple sclerosis (MS) drug Gilenya to treat children and adolescents.\n\nMS is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body and is among the most common causes of neurological disability in young adults.\n\nGilenya is the first FDA-approved drug to treat pediatric patients suffering from relapsing MS, the U.S. health regulator said.\n\nIn a clinical trial 86 percent of patients receiving Gilenya remained relapse-free after 24 months of treatment, compared to 46 percent of those who were administered another MS drug.\n\nGilenya was first approved by the FDA to treat adults with relapsing MS.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story appears to have relied solely on the\u00a0news release. But it was less informative and had fewer details than the news release.\n\u00a0", "answer": 0}, {"article": ".\nAfter 18 months, the women who received the placebo halted the injections.\nThe Endocrine Society is based in Washington, DC.\nThe study, \"Effect of Growth Hormone Treatment on Fractures and Quality of Life in Osteoporosis - A 10-year Follow-up,\" was published online at http://press.\nMore than half of the participants had fractured bones prior to the start of the study.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release is careful in its use of language. Any problems with the release revolve around what was left out, rather than on the language of the release.", "answer": 1}, {"article": "Co-authors are: Leslie Donato, Ph.D.; Sandra Bryant; Grant Spears; Peter Berger, M.D.\nThe present study is also the first to test its clinical utility in a U.S. population.\nPatients were grouped into four risk categories according to their ceramide levels: low (0\u20132), intermediate (3\u20136), moderate (7\u20139) and high (10\u201312).\nThe trial was funded by Mayo Clinic.\nOverall, 5.1 percent of patients had a major cardiovascular event each year.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "None of the language in the news release rises to the level of what we\u2019d flag here.", "answer": 1}, {"article": "Eli Lilly announced promising data on its efforts to have its Cymbalta depression treatment also used as pain medicine, saying a study showed the drug \"significantly\" reduced chronic lower-back pain.\n\nLilly has been looking at the potential of Cymbalta for relieving the discomfort of fibromyalgia and osteoarthritis pain as well as back pain. The company's results of late have been boosted by the antidepressant, whose second-quarter sales jumped 26% to $654.4 million.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This exact same quote appeared in the story and in the company news release:\u00a0 \"Chronic low back pain can have a significant impact on a person\u2019s ability to do the things they enjoy,\" said Vladimir Skljarevski, lead study author at Lilly Research Laboratories. \"This research may offer hope to those dealing with this debilitating condition.\"\u00a0 Did he say the same thing exactly the same way twice?\u00a0 Why didn\u2019t the story attribute the quote to the news story if it wasn\u2019t gathered independently? ", "answer": 0}, {"article": "Psilocybin acts on the serotonin system, suggesting it could be developed for treating depression.\nA small-scale pilot study of psilocybin\u2019s use in cases of treatment-resistant depression showed it was safe and effective, the British researchers said.\nRobin Carhart-Harris, who led the study at Imperial College London\u2019s department of medicine, said the results, published in the Lancet Psychiatry journal, were striking.\nThe trial involved six men and six women, aged between 30 and 64, all diagnosed with treatment-resistant depression.\nOf 12 patients given the drug, all showed some decrease in symptoms of depression for at least three weeks.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "While the story did not include outside voices, it did include unique quotes from the researchers that weren\u2019t in the news release, and this is enough to rate Satisfactory.", "answer": 1}, {"article": "Those in the lower group ate an average of 0.5 meals per week.\nDuring the course of the study, each person received annual, standardized testing for cognitive ability in five areas -- episodic memory, working memory, semantic memory, visuospatial ability and perceptual speed.\nThe results were the same after researchers adjusted for other factors that could affect memory and thinking skills, such as education, physical activity, smoking and participating in mentally stimulating activities.\nThe study group also completed annual food frequency questionnaires, allowing the researchers to compare participants' reported seafood intake with changes in their cognitive abilities as measured by the tests.\nThey also had slower rates of decline in a test of perceptual speed, or the ability to quickly compare letters, objects and patterns.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "This is a close one, but mainly because of the headline. Declines in semantic memory and perceptual speed weren\u2019t prevented, or even postponed, they were simply slowed down. That said, we\u2019ll give the release the benefit of the doubt. The body of the release used language that was measured and appropriate.", "answer": 1}, {"article": "Evolve recently completed a $40M Series C round of funding co-led by the Bill & Melinda Gates Foundation and Horizons Ventures, the venture division of the Li Ka Shing Foundation.\nIn a landmark clinical trial, Evivo produced rapid, substantial and persistent stabilization of the infant gut microbiome, to help set a foundation for life-long health.\n\"The ability to quickly measure levels of Bifidobacterium in a stool sample would enable pediatricians to identify babies with low levels of these beneficial bacteria and take appropriate action.\"\n\"With recent research indicating most babies born after 1980 do not acquire Bifidobacterium at birth, our ability to detect significant levels of Bifidobacterium gives pediatricians and parents an immediate indication of whether or not their baby has this beneficial gut bacteria that set them up for lifelong health.\"\nEvivo has commenced rigorous clinical trials with the prototype to demonstrate the results from infant stool samples.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We saw the words \u201cproven\u201d and \u201cproving\u201d in the release, which raised some red flags. The research appears too preliminary to prove anything, especially when both studies referenced by the release contain caveats saying as much.", "answer": 0}, {"article": "After five years, 74 percent of the angioplasty group and 72 percent of the medication group were free of chest pain \u2014 \"no significant difference,\" Boden said.\nAbout 40 percent had a prior heart attack.\nAlso, the clogs treated with angioplasty are not the really dangerous kind.\nNeither treatment proved better for any subgroups like smokers, diabetics, or older or sicker people.\nThose patients now should try drugs first, experts say.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not appear to rely solely or largely on a press release.", "answer": 1}, {"article": "For decades, researchers have searched unsuccessfully for ways to automatically coordinate insulin delivery with real-time changes in blood sugar to essentially create an artificial pancreas that maintains target blood sugar levels with minimal effort.\nNow new technology is making this possible, and new research shows that an experimental system can improve nighttime blood sugar control.\nThe system proved better than a conventional insulin pump for maintaining optimal blood sugar levels during the night in a study from the U.K.'s University of Cambridge.\nAaron J. Kowalski, PhD, of the Juvenile Diabetes Research Foundation, which was involved in funding the research, says the study represents an important step forward in the search for a clinically feasible artificial pancreas to improve outcomes and quality of life among insulin-dependent diabetes patients.\n\"Nighttime is the time of day that strikes fear into patients and parents of children with diabetes.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure of the extent to which this story ws influenced by a news release. ", "answer": 2}, {"article": "When treating a patient suffering from depression, Brent Forester considers which anti-depressant to prescribe\u2014ideally, one that will ease psychic pain without side effects.\n\nIt can be a tough call.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "As noted above, the article quotes outside sources.", "answer": 1}, {"article": "\u201cWhen people engage in risky behaviors like driving or smoking, they\u2019re encouraged to take measures that minimize their risk, like wearing a seatbelt or choosing cigarettes with filters.\n\u201cStatins are a vital medicine for people with \u2014 or at high risk of developing \u2014 heart disease,\u201d he said.\nIt\u2019s better to avoid fatty food altogether.\n\u201cStatins don\u2019t cut out all of the unhealthy effects of a burger and fries.\n\u201cAlthough no substitute for systematic lifestyle improvements, including healthy diet, regular exercise, weight loss, and smoking cessation, complimentary statin packets would add, at little cost, one positive choice to a panoply of negative ones,\u201d the scientists write in their paper.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story went well beyond the press release.", "answer": 1}, {"article": "The F.D.A.\nNovartis said that about 2.2 million Americans would be eligible for the drug, which was approved for patients with so-called Class II to Class IV chronic heart failure with so-called reduced ejection fraction.\nNovartis is sponsoring another study to see if the drug is effective for those with preserved ejection fraction, which accounts for half of heart failure cases.\nPatients in both groups of the study could also take other drugs, such as beta blockers, as their doctors saw fit.\nBlacks and those with a previous history of the condition were at increased risk, it said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story incorporates information not included in the news release.", "answer": 1}, {"article": "Instead, they recruited 20 volunteers who were overweight or obese and assigned them to a week of either egg breakfasts or ready-to-eat cereal breakfasts.\nBoth types of breakfasts had the same number of calories, but the egg breakfasts contained \u201chigher protein quality,\u201d according to an abstract for the study, posted online here.\nThat\u2019s right \u2013 the folks who sell eggs paid for a study that comes to the shocking conclusion that eggs are an ideal breakfast food.\nThe folks who carried out this egg industry-funded research were from the Pennington Biomedical Research Center in Baton Rouge, La.\nThis message was brought to you by the American Egg Board.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Since there are no independent sources cited, we cannot be sure to what extent this story may have relied on a news release. We\u2019ll rate it not applicable.", "answer": 2}, {"article": "According to the American Cancer Society, melanoma accounted for more than 68,000 cases of skin cancer in 2009, and 8,650 deaths.\nThe study is the first to test ipilimumab in patients whose skin cancer had spread to the brain, and the findings, released in an abstract or brief summary, support its potential use in these patients, the researchers said.\nIn the phase 2 trial, researchers said four out of 51 patients with at least one brain lesion had a partial response to the drug, and in 5 out of 51 patients, both brain and other tumors in the body stabilized after 12 weeks of treatment.\nResults of a late-stage study of the drug in melanoma patients will be detailed in a \u201clate-breaker\u201d session at ASCO\u2019s annual meeting in June.\nBristol-Myers Squibb\u2019s closely watched biotechnology drug ipilimumab, which enlists the help of the immune system to attack tumors, was found generally safe and showed signs that it was working on tumors in the brain, which are especially difficult to treat.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "1clip_filelist.xml\"/>\n\n\n\n \nThis story appears to be based entirely on abstracts posted on the asco.org web site. Although meeting abstracts are not the same as news releases, they do not provide details that are vital to providing readers with a clear understanding of both the benefits and harms of the treatment being studied.Abstract links:1clip_filelist.xml\"/>\n\n\n\n \nAbstract 1: \nPhase II trial of ipilimumab monotherapy in melanoma patients with brain metastases.\nhttp://abstract.asco.org/AbstView_74_50834.html \nAbstract 2: \nRe-induction with ipilimumab, gp100 peptide vaccine, or a combination of both from a phase III, randomized, double-blind, multicenter study of previously treated patients with unresectable stage III or IV melanoma.\nhttp://abstract.asco.org/AbstView_74_47740.html \n \n\u00a0\n", "answer": 2}, {"article": "The requested URL /usnews/health/articles/070513/21sunscreen.htm was not found on this server.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It is unclear\u00a0whether the article relied solely or largely on a press release.", "answer": 2}, {"article": "Fish oil also boosts levels of glutathione, an antioxidant that protects the brain against oxidative stress.\nSeventy-six of the 81 study participants, or 94 percent, completed the trial, Amminger noted, which underscores the safety and tolerability of fish oil.\n\u201cAt the moment there\u2019s no state-of-the-art guideline (on) how to treat those people.\u201d\n\nPrescribing antipsychotic medications may be helpful, Amminger added, but these medications have serious side effects, and can also be stigmatizing.\nThe effect of fish oil capsules, Amminger noted, was similar to that seen in two trials of antipsychotic drugs in at-risk individuals.\nThere\u2019s considerable evidence that abnormal fatty acid metabolism may contribute to the development of schizophrenia, Amminger and his team note in the Archives of General Psychiatry.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story does not rely on a press release.", "answer": 1}, {"article": "Trisha Bradbury was one of the participants allocated to the FIT study, and she explains: \"I lost my mum at 60, and being 59 myself with a variety of health problems, my motivation was to be there for my daughter.\n\"As well as being delighted by the success of the study in the short term, there are very few studies that document weight loss past the end of treatment, so to see that people continued to lose weight despite not having any support shows the sustainability and effectiveness of this intervention.\"\nFrom there we are able to encourage them to fully imagine and embrace their own goals.\nIn addition, users of FIT lost 4.3cm more around their waist circumference in six months - and continued to lose weight after the intervention had finished.\nFIT goes one step further than MI, as it makes use of multisensory imagery to explore these changes by teaching clients how to elicit and practice motivational imagery themselves.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release avoids unjustifiable language.", "answer": 1}, {"article": "Dr. Claudia Henschke of New York Presbyterian/Weill Cornell Hospital says CT scans offer hope to many people who are at-risk for the disease, including current smokers, former smokers, and in some cases people were never smokers but exposed to second-hand smoke.\nIf Lazarus hadn't had any studies, says Dr. Harvey Pass of the NYU Medical Center in New York, the tumor would have grown causing pain, cough bleeding and maybe not have been able to be surgically removed.\nThat's because standard chest X-rays too often can't spot it until it's too late, reports.\nA chest X-ray showed nothing suspicious.\nIt turned out to be cancer.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no way to know if the story relied on a press release as the sole source of information.", "answer": 2}, {"article": "In a new study, 49 people with knee OA aged 45 to 87 who wore a knee brace had less pain, stiffness, and disability after six months of use.\nNew research presented at a media briefing Tuesday in New York City suggests that Peterson is not the only one to find relief from knee bracing.\nThe study was also presented at the recent annual meeting of the American Academy of Orthopaedic Surgeons in New Orleans.\nThe brace used in the study was provided by Ossur, which also provided financial support to the study through a research grant and sponsored the media briefing.\n\"By wearing the brace, I could get back to sports and was able to call my physician and say 'why didn't we try this first?'\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Reporting from a company-hosted media briefing isn\u2019t much different than relying solely on a news release. ", "answer": 0}, {"article": "When a hip bone breaks because of osteoporosis, the fracture usually involves either the ball at the top of the femur or the narrow neck just below the ball.\nFor instance, they started out with a history of more fractures, so the comparison isn't valid.\nStill, the accumulating evidence that there is a risk of these serious, unusual fractures associated with bisphosphonates is getting a lot of attention in the medical community.\nThat's called the relative risk, and it seems alarming.\nThat's obviously a lot more benefit than risk.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely solely or largely on a news release.", "answer": 1}, {"article": "There were 812 deaths (32.2 percent) among heart failure patients not treated with Plavix and 709 deaths (28.1 percent) among heart failure patients treated with Plavix.\nA randomized study comparing conventional heart failure therapy with and without Plavix \"is needed urgently,\" the editorial writer concluded.\nThe study appears online March 23 and in the March 30 print issue of the Journal of the American College of Cardiology.\nMONDAY, March 22, 2010 (HealthDay News) -- The anti-clotting drug Plavix is of modest benefit in cutting the odds of death in patients with heart failure and heart attack who don't undergo angioplasty, a new study finds.\nHe said the benefit of the drug found in this study is \"of unquestionable practical importance,\" and added that the positive outcomes seen in a relatively short follow-up suggests potentially even better long-term survival.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story states that its sole source was a news release from the American College of Cardiology. ", "answer": 0}, {"article": "Ten years ago, scientists started looking at the hormones made in the pituitary gland to see how they act on certain targets.\nThey found some of these hormones had an effect on bone mass.\nBut it could also be a unique drug because it lowers body fat and makes bones stronger.\n\u201cIt could be a unique obesity drug.\nBut scientists also realized it could have other uses.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to be based on a news release.", "answer": 1}, {"article": "In a related editor's note, Mitchell H. Katz, M.D., a deputy editor of JAMA Internal Medicine, writes: \"Of course, no study is perfect.\nThe intervention paradigm implemented in the PREDIMED trial provides a useful scenario for breast cancer prevention because it is conducted in primary health care centers and also offers beneficial effects on a wide variety of health outcomes.\nMiguel A. Mart\u00ednez-Gonz\u00e1lez, M.D., of the University of Navarra in Pamplona and CIBEROBN in Madrid, Spain, and coauthors analyzed the effects of two interventions with the Mediterranean diet (supplemented with extra virgin olive oil [EVOO] or nuts) compared with advice to women to follow a low-fat diet.\nIt may also prevent breast cancer.\nPreventive strategies represent the most sensible approach against cancer.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There is no unjustifiable language in this release.", "answer": 1}, {"article": "At week 40, for example, 81 percent of patients taking a 200-mg dose of guselkumab had a score of 0 or 1, compared to 49 percent of patients taking adalimumab.\nAn ongoing phase III trial is continuing to test the safety and efficacy of guselkumab as a psoriasis treatment.\nThe disease affects nearly 3 percent of the world's population, according to the World Psoriasis Day consortium, but about half of all patients with psoriasis do not get any treatment, Dr. Gordon said.\n\"Research like this study is leading to a series of new medications that promise high levels of response for an increasing number of patients,\" said first author Kenneth Gordon, MD, professor in Dermatology.\nThis study was supported by Janssen Research and Development, the manufacturer of guselkumab.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release uses fairly cautious language throughout, as exemplified in the headline, which says only that\u00a0guselkumab is \u201cmore effective\u201d than adalimumab. However, readers have to be sophisticated enough to know that a phase II trial is merely an intermediate step in the clinical trial process. The release should have noted in the headline and lead paragraphs that further work is needed in order to reach firm conclusions about the effectiveness and potential side effects of this experimental treatment.", "answer": 1}, {"article": "Swaminath noted that one study published in 2012 found that \"colonoscopy reduced the risk of death from colon cancer by 53 percent, by removing polyps.\nFor now, he said, the data from this study is not strong enough to spur any changes in current screening recommendations.\nOne expert said more efforts are needed to get people to undergo colonoscopy, which is currently recommended once every 10 years beginning at age 50.\n\"A risk stratification tool is critical in helping physicians make appropriate screening recommendations for patients,\" Garbus said.\nImperiale's team noted that not all people deemed to be at \"average risk\" for colon cancer face the same risk of the disease, and so some might benefit more from invasive colonoscopy than others.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We could not find a news release related to this study. But in any case, the comments from two independent experts assure us that the story wasn\u2019t based on a news release.", "answer": 1}, {"article": "Since IVM results in lower fertilization rates, protocols that use IVM are more likely to also use intracytoplasmic sperm injection (ICSI), in which one sperm is injected into one egg.\nIVM has the potential to improve the chances for women to have babies without a long course of hormones.\nFor starters, since there is less time involved with IVM, women who are undergoing chemotherapy, radiation or plan to have surgery may be good candidates.\nYet most studies have found that IVF is superior to IVM.\nIVM can also help women who are adverse to injections or who have failed IVF, Luk said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Hard to say for sure, but it would appear that there was none, and the reporter did apparently interview two sources.", "answer": 1}, {"article": "\u201cMy nightmare was that nothing would be different from the placebo group, and there would be nothing of interest to talk about,\u201d he says.\nI think resveratrol is an engaging target that\u2019s very interesting and could be pharmacologically manipulated to develop a treatment.\u201d\n\nMORE: Red Wine Not That Healthy After All, Study Shows\n\nThe resveratrol group showed no change in the levels of a protein that builds up in the brains of Alzheimer\u2019s patients.\nWe need more studies to see if it really does have benefit and then it could be turned into more effective drugs that can better target Alzheimer\u2019s.\u201d\n\nCorrection: The original version of this story misstated that all the participants were men.\nThe amounts of resveratrol in the purified doses that the participants took were extremely high and beyond those found on the market currently \u2014 around what would be contained in about 1,000 bottles of red wine.\nIn what the authors describe as the largest and longest study of resveratrol in people with mild to moderate Alzheimer\u2019s disease, there\u2019s encouraging news that the component, which is found in red wine, grapes and dark chocolate, may keep the disease from progressing.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story technically meets our standard here since it includes quotes from an interview with the lead author \u2014 quotes that weren\u2019t included in a news release about the study and which indicate original reporting. But we\u2019d note that the news release on this study is actually much more careful in its presentation of the results than this more sensational news story. The news release is more accurate in claiming, \u201cResveratrol impacts Alzheimer\u2019s disease biomarker,\u201d and says nothing about \u201cslow[ing] Alzheimer\u2019s.\u201d The release also includes cautionary language sprinkled throughout the text, whereas the lone caveat in this story comes only at the very end.", "answer": 1}, {"article": "Ultraviolet light can alter chromophores so they no longer absorb color, but UV light can damage the retina.\nTo make cataract treatment available to more people around the world, a less-invasive, less-expensive technique is needed.\nThe laser treatment reduces the light absorption and also helps restore the lens proteins to their proper structure.\nIn their approach, described in the open-access journal PLoS ONE, they \u201cbleach\u201d the lens with a laser.\nLine Kessel, an ophthalmologist at Glostrup Hospital of the University of Copenhagen in Denmark, and colleagues have come up with what they say is a promising alternative to replacement surgery.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure. ", "answer": 2}, {"article": "A compound in raspberries is being touted as the next new fat burner. But people looking to lose a few pounds may not want to go running to the produce aisle just yet. Scientists say there are no major human studies to support the idea that a berry holds the secret to weight loss.\n\nRaspberry ketones, the organic compounds that give raspberries their aroma, raised hopes as a weight-loss aid after a 2005 study by Japanese researchers found the ketones boosted fat-burning processes in rat cells in a laboratory as long as those...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There\u2019s enough original reporting that we can be sure this story wasn\u2019t based on a press release.", "answer": 1}, {"article": "Bathing-suit season is here and with it, anxiety over cellulite. A new laser device that burrows under the skin is getting praise from some doctors who say it gives more dramatic and longer-lasting results than previous treatments, but others caution that more research is needed.\n\nCellulite is a dimpled, uneven appearance of skin caused by fat underneath. It affects some 85% of women and about 5% of men. Until recently, the main treatments to battle cellulite have been external treatments such as creams and radio-frequency and...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because two apparently independent experts were quoted, it does not appear that the story relied solely on a news release.", "answer": 1}, {"article": "Low sperm count, or oligospermia, is a main cause of male infertility.\nAs SpermCheck\u2019s website puts it, a \u201ctrip to a fertility clinic for a semen analysis is not for everyone.\nFor women who are having trouble getting pregnant, the test may very well be one they \u2014 and not their squeamish partners \u2014 snap up along with over-the-counter ovulation kits.\n\u201cMen don\u2019t say, \u2018Let me go to the urologist and give a semen sample.\u2019\u201d That reluctance has created a $440 million-a-year market for male fertility tests in the U.S., Lopez says.\nThese tests can be expensive (costing hundreds of dollars and not typically covered by insurance), inconvenient and are often embarrassing.\u201d\n\nMORE: \u2018Sonicated\u2019 Sperm: Could Ultrasound Be the Next Male Contraceptive?\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Some lines in the story are suspiciously similar to those in the company\u2019s news release (see \u201cBenefits\u201d criterion above).\nOne quote is lifted directly from the news release \u2013 the company chairman quote: \u201d\n\u201cThis at-home test was created to meet the needs of couples who are considering and just planning on starting a family, those currently having trouble conceiving and even those men who are just curious about their sperm count.\u201d", "answer": 0}, {"article": "Inflammation associated with dry eye may eventually lead to damage to the surface of the eye.\nThere are more than 30-plus new dry eye basic, translational and clinical studies being funded by the NEI/National Institutes of Health to further explore these lipids and proteins, with more than 50 papers being published monthly.\n\u201cFunding from NIH is helping the optometry world make significant strides in understanding the cause and treatment of dry eye,\u201d Nichols said.\nSpecialty testing for dry eye is performed at the Dry Eye Relief Clinic at UAB Eye Care, in the School of Optometry.\nNichols continues to push for funding and advancement for dry eye research and treatment.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release body does not engage in unjustifiable language. However, the headline says that a \u201cUAB Optometrist improves treatment and care for patients with dry eye.\u201d Though that may well be true, the news release does not offer evidence to support that assertion. We rate this a borderline satisfactory.", "answer": 1}, {"article": "\u2022 43% had at least 50% fewer arthritis symptoms, compared to 19% getting a placebo.\nNobody is exactly sure of the role Syk plays in rheumatoid arthritis.\nThe drug does have side effects.\nThere's at least one theoretical concern about R788.\nFor now, R788 looks very promising, the researchers report.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story reads a little like a news release, but we could not find a news release that contained this content.", "answer": 2}, {"article": "America\u2019s ongoing battle with weight-loss that has led to fad diets and invasive surgeries like gastric bypass and stomach stapling.\nDr. Prem Chattoo, a New York based gastroenterologist, told FoxNews.com that the balloon is placed it into the stomach through the mouth.\nChattoo said that even if the balloon were to pop, the saline would be absorbed and pose no harm to the patient.\nThe hope is that patients can train their body to eat in a much healthier fashion without feeling overly hungry.\nIn addition to eliminating the scarring and risks involved with more invasive options, Chattoo said that the recovery time is also much faster.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to be based on any specific news release that we could find.", "answer": 1}, {"article": "Shift workers with chronic sleep deprivation also face an increased risk of accidents.\n\u201cSleep deprivation makes this worse of course, and together with the clock, this conspires to impair our ability to sustain attention to task (e.g., driving), and avoid distraction, and react quickly to external stimuli like traffic lights, brake lights in front of you, road signs, etc,\u201d Mistlberger added by email.\nMore research is needed on the potential of bright light therapy to make exhausted drivers safer, said Dr. Donald Redelmeier, a researcher at the University of Toronto who wasn\u2019t involved in the study.\n\u201cThere is evidence that the use of bright light at the office (or even at home directly prior to beginning the work shift) may be beneficial in preventing sleep deprivation-related motor vehicle collisions,\u201d said Russell Griffin, a researcher at the University of Alabama at Birmingham who wasn\u2019t involved in the study.\nBeyond its small size, other limitations of the study include the reliance on lab conditions for sleep deprivation and light exposure, which may not match what shift workers would experience on the job, the authors note.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "A\u00a0release relevant to this story did not emerge from our search efforts. \u00a0The addition of independent sources bolsters the idea that enterprise reporting undergirds this text.", "answer": 1}, {"article": "Pulses become more intense when arteries near the heart are worn down -- usually by lifestyle factors such as poor diet and drug use -- and can no longer \"cushion\" the blood flow coming from the heart.\nThe test, which analyzes the pulse of blood vessels in the neck, could become part of routine testing for cognitive decline, according to the study by scientists at University College London (UCL), who presented their work Sunday at the American Heart Association's annual scientific conference.\nIf the findings are confirmed by larger studies, they could vastly improve the ability to detect dementia in middle age.\nThere is currently no cure for dementia, though medication can be used to temporarily treat its symptoms.\nThe study's findings have been met with cautious optimism by dementia organizations.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to be based on a news release.", "answer": 1}, {"article": "More than 20 percent of Americans have significant symptoms of depression or anxiety each year, but only around 20 percent of people with a mental health problem get adequate treatment.\nAlthough the apps are not validated, each one was designed by Northwestern clinicians and based on validated techniques used by therapists.\nBut Northwestern researchers hope participants will provide confidential feedback, via four weekly questions, that will be used to further develop the system.\nSome also will have access to an IntelliCare coach via text messaging and phone calls, who are available to support them in using the apps.\n\"There were many apps to try during the study, so there was a sense of novelty.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t rely on sensational language, although the sushi analogy was ill-advised.", "answer": 1}, {"article": "We share our bodies with trillions of microbes that live on our skin, in our noses, in the gut.\nGallo\u2019s team took a closer look at how microbes in healthy skin might be keeping that bad staph in check.\nIn one early test, those customized creams guarded five patients with a kind of itchy eczema against risky bacteria that were gathering on their cracked skin, researchers reported Wednesday.\n\u201cIt\u2019s boosting the body\u2019s overall immune defenses,\u201d said Dr. Richard Gallo, dermatology chairman at the University of California, San Diego, who is leading the work.\nThe study couldn\u2019t address the bigger question of whether exposure to the right mix of protective bacteria might improve atopic dermatitis itself, cautioned Mount Sinai\u2019s Guttman-Yassky.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story included an interview with an independent source, so it didn\u2019t seem to rely on the news release.", "answer": 1}, {"article": "Tissue that dies in the brain from stroke is absorbed, leaving a cavity, devoid of blood vessels, neurons or axons, the thin nerve fibers that project from neurons.\nThe mice with new neurons showed improved motor behavior, though the exact mechanism wasn't clear.\n\"This study indicated that new brain tissue can be regenerated in what was previously just an inactive brain scar after stroke.\"\nThe gel was eventually absorbed by the body, leaving behind only new tissue.\nThis research was designed to explore recovery in acute stroke, or the period immediately following stroke - in mice, that is five days; in humans, that is two months.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "With one glaring exception, this is a strong point of the news release.\nIt\u2019s made quite clear this is research in mice that is not currently applicable to humans. Unjustified cause-and-effect language is not used.\nThe exception? Use of the term \u201cstroke-healing gel.\u201d The gel would only be truly \u201cstroke-healing\u201d if it resulted in the damaged area fully reverting to it\u2019s original, pre-stroke level of functioning.", "answer": 1}, {"article": "Dr. Sonia Friedman is an associate professor of medicine at Harvard Medical School.\nForty percent of those taking a 10-mg dose of the drug had remission at a year.\nWhether Xeljanz should be used as a first treatment is still not clear, said Dr. Arun Swaminath, director of the inflammatory bowel disease program at Lenox Hill Hospital in New York City.\nThe study was funded by Pfizer, Inc., the maker of Xeljanz.\n\"Treatment with oral tofacitinib is potentially a new treatment option for patients with moderate to severe ulcerative colitis, pending review by the [U.S. Food and Drug Administration],\" Sandborn said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story clearly goes well beyond a news release.", "answer": 1}, {"article": "AURORA, Colo. (Nov. 16, 2016) - Researchers at the University of Colorado Anschutz Medical Campus have found that high doses of vitamin D reduce the incidence of acute respiratory illness (ARI) in older, long-term care residents.\nThe findings of the clinical trial, published today in the Journal of the American Geriatrics Society, could help reduce one of the leading causes of serious illness, debilitation and death among patients in nursing homes and other long-term care facilities.\nBut Ginde said the primary finding that vitamin D can reduce ARI is a major step forward in treating these dangerous infections.\nHe cautioned that the study is not definitive proof that vitamin D can prevent ARI but it suggests that it can and at little risk to the patient.\n\"This finding requires a confirmatory trial, including whether high daily doses of vitamin D, rather than high monthly doses, makes patients less likely to fall,\" Ginde said.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We never like to see terms like \u201clife saving\u201d even when the word \u201cpotentially\u201d is appended in the front. The headline on this release says, \u201cA potentially life-saving discovery in older patients at high risk for these illnesses.\u201d", "answer": 0}, {"article": "For example, a poor test grade or bad performance evaluation might lead to feelings of \"I'm not good enough,\" but the lessons encourage more positive thinking about \"how many exams have you passed, to put this failure in a more accurate light,\" Guille said.\nThe study involved interns at Yale University and the University of Southern California.\nThe online program included sessions about how to put feelings of stress or despair into perspective.\nSarah Dalechek, a first-year psychiatry resident at that university, said her program requires two month-long rotations of 16-hour overnight shifts in an emergency room.\nLuckily, her depression subsided when that rotation ended.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to be based on a news release.", "answer": 1}, {"article": "Allergy shots may be used for hay fever when antihistamines and other allergy medications do not control a person\u2019s symptoms adequately, or for people who want to reduce their reliance on medication.\nIn addition, the long-term effectiveness of the grass-pollen tablets is not yet fully clear.\nNo sublingual immunotherapy products have yet been approved in the United States, however.\nLike allergy shots, the oral immunotherapy takes time.\nDr. Harold Nelson, an allergist at National Jewish Health in Denver, said that the body of evidence indicates that sublingual immunotherapy beats antihistamines and other medications used to control hay fever symptoms.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "1clip_filelist.xml\"/>1clip_themedata.thmx\"/>1clip_colorschememapping.xml\"/>\n\n\n\n \nThis piece does not rely on a press release. \n", "answer": 1}, {"article": "NSAIDs - which include aspirin, naproxen (marketed as Aleve), and ibuprofen (Advil) \u2014 have side effects, she noted, such as stomach bleeding.\nAs a result, \u201cI wouldn\u2019t recommend (taking NSAIDs to reduce melanoma) just based on this\u201d new study, Asgari noted.\nThe findings are interesting, but should not lead people to conclude that popping a few painkillers will reduce their risk of skin cancer, cautioned Dr. Maryam Asgari of Kaiser Permanente Northern California and the University of California San Francisco, who co-authored the 2008 study.\nNow, a smaller study that asked people with melanoma and those without the disease to recall their use of NSAIDs has found that taking these drugs - particularly aspirin - at least once a week for more than 5 years may have offered some protection against the deadly disease.\nUnfortunately, the technique \u2014 comparing people with melanoma to those without - is fraught with potential problems, said Asgari.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely solely on a news release.", "answer": 1}, {"article": "A minimally invasive procedure designed to shrink prostate tissue with a series of nine-second blasts of steam offers men a new treatment for urinary symptoms commonly associated with enlarged prostates.\n\nThe procedure, called Rez\u016bm (pronounced \u201cresume\u201d) and developed by NxThera Inc. of Maple Grove, Minn., became widely available in the U.S. in the second half of 2016. Thermal energy in the form of steam is applied to the prostate with a needle. As it cools it releases heat energy into the tissue, killing cells and shrinking...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to be based on a news release.", "answer": 1}, {"article": "While some teenagers want to switch from insulin injections to pump therapy to gain more flexibility in their lives, doctors said device problems such as a blocked tube can lead quickly to dangerous episodes of high blood sugar.\nParents should be vigilant in watching their children\u2019s use of the pumps, researchers from the Food and Drug Administration wrote.\nBut they called for more study to address safety concerns in teens and even younger children who use the popular pumps.\nThe federal review of use by young people over a decade found 13 deaths and more than 1,500 injuries connected with the pumps.\nAnd they\u2019re a growing segment of diabetes care, with $1.3 billion in annual sales worldwide, said Kelly Close, a San Francisco-based editor of a patient newsletter.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no evidence that the AP story relied solely or largely on a news release. ", "answer": 1}, {"article": "FDA approves breakthrough cholesterol drug, but only for certain high-risk patients\n\nOvereating may be caused by a hormone deficiency, scientists say\n\nCDC report: Lyme disease is spreading to new territories\n\nResearchers retract study claiming marriages fail more often when wife falls ill\nBut a separate finding about the effect of the drug on death risk was a surprise.\nThe results were part of the Early Breast Cancer Trialists' Collaborative Group, a collaboration based at the University of Oxford, that collects and analyzes information about randomized clinical trials every few years.\nIf this had not happened, \"the benefit of aromatase inhibitors over tamoxifen would probably have been somewhat greater,\" they surmised.\nFirst marketed in the 1960s as a fertility drug, tamoxifen has been hailed as a miracle drug for its ability to prevent and treat breast cancer, and despite decades of research scientists have not been able to find anything comparable -- until now.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The Washington Post story relies on this news release a bit too much for our liking. The article\u2019s lead quote from Paul Workman comes right from the press statement. And while the story acknowledges the source for that quote, it doesn\u2019t alert readers that a second quote from\u00a0Richard Gray is also pulled from the same news release. We can\u2019t find evidence of any other original reporting, so we\u2019ll flag the story here as Not Satisfactory.", "answer": 0}, {"article": "Both show that antibiotics are more effective than placebos in relieving ear-infection symptoms such as fever, poor appetite, decreased activity and irritability and suggested that their benefits warrant their being administered early on, regardless of the seeming severity of a child's symptoms.\nNow two new studies (bolstered by an accompanying editorial) in the New England Journal of Medicine demonstrate what we parents have suspected for years: When it comes to ear infections, antibiotics are in order.\nStill, some of the placebo-group kids required \"rescue treatment\" when their symptoms grew markedly worse.\nInterestingly, antibiotics were no more effective at reducing pain, as reported by parents or children, than placebos.\nBut please give some to my kid anyway.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Since the story includes no outside perspective on the research, we can\u2019t be sure to what extent it may have relied on a press release. We\u2019ll call it not applicable.", "answer": 2}, {"article": "Feb. 22, 2012 -- When women in their 40s get breast cancer , their tumors need less intense treatment and recur less often if they were first detected during routine mammogram screening.\nEven the USPSTF accepts the fact that beginning breast cancer screening at age 40 saves lives.\nThese women will suffer the harms of early screening.\nThe women were carefully followed since their diagnosis in 1990 to 2008, says study co-leader Judith A. Malmgren, PhD, president of Seattle's HealthStat Consulting.\nBut the picture isn't so clear for women in their 40s.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does not appear that the story relied solely or largely on a news release.", "answer": 1}, {"article": "Why smokers are more susceptible is not known for sure, but some scientists believe it has to do with smoking-caused damage that allows the bacteria to more easily attach to the lungs and windpipe, said Dr. Pekka Nuorti, a medical epidemiologist with the Centers for Disease Control and Prevention.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There isn\u2019t any evidence that the story relied solely or largely on a news release. ", "answer": 1}, {"article": "PHILADELPHIA - Patients with atrial fibrillation (AF), a rapid irregular heartbeat caused by pooling blood in the heart which can lead to heart failure and stroke, are often treated with an ablation, a minimally invasive procedure used to remove the tissue which causes the pooled blood.\n\"These are patients who were actively seeking, preparing for and are committed to the alternate treatment method, and who are informed about how to diligently and effectively monitor their pulse throughout the day.\"\nWe call them \"highly motivated patients,\" said lead author Monica Pammer, PA-C, a physician assistant in Electrophysiology at the Hospital of the University of Pennsylvania.\nOf these patients, 84 had been ablated, sixteen were being treated with drug therapy, and three had implanted devices that served as a quality control check.\n\"It is extremely common for patients with AF to seek treatment that does not involve the use of chronic oral anticoagulants therapy, as there are other risks associated with their long term use,\" said co-author Francis E. Marchlinski, MD, FHRS, director of Electrophysiology for the University of Pennsylvania Health System and Richard T. and Angela Clark President's Distinguished Professor in the Perelman School of Medicine at the University of Pennsylvania.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There was no exaggerating language in the news release. However, the headline went overboard stating that the study proved that this therapy is safe or effective.", "answer": 1}, {"article": "Watch Sanjay Gupta MD Saturday at 4:30pm and Sunday at 7:30am ET.\n(Agatston does not make any money from the coronary calcium scan.)\nAgatston says relatively new imaging tests give real-time pictures showing whether plaque is building up in key blood vessels, alerting doctor and patient to an increased risk of a potentially deadly heart attack.\nA calcium score would answer that question, she says.\nThere's a third test Agatston likes: a $65 blood test that looks at a patient's LDL, or bad cholesterol.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\nThe story does not rely on a press release.", "answer": 1}, {"article": "Behind that common piece of advice is a complex series of physiological processes that calm the body, slow the heart and help control pain.\n\nBreathing and controlling your breath is one of the easiest ways to improve mental and physical health, doctors and psychologists say. Slow, deep and consistent breathing...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes quotes from a variety of experts. It seems clear it did not rely on a news release.", "answer": 1}, {"article": "The best moment in Rene\u00e9 Ford's life came the day her son Chase, then 2, tried to kick his doctor. It was July 2005, and that angry gesture marked the first time the boy had moved below the neck in more than a month.\n\nThese days when you look at Chase, you don't at first notice any sign of what happened to him that year--not the fall he took while jumping on the couch nor the paralyzing blow to the neck as he hit the wooden armrest. More and more, Chase can do the kinds of things any other 4-year-old can...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no way to know if the story relies on a press release as the sole source of information.", "answer": 2}, {"article": "If a robot is to be enlisted, he recommends asking how the procedure would be performed if the robot is not available or if it doesn\u2019t work.\nThe robotic equipment provides better three-dimensional vision, increased range of motion and intuitive, downscaled movements, while adding a few thousand more dollars to the procedure\u2019s price tag, the authors note.\n\u201cRobotics increases the chance that a hysterectomy can be done by laparoscopy,\u201d he added.\nThe researchers found that the two advanced minimally invasive techniques led to similar results, and both appeared to be generally superior to the traditional open procedure.\n\u201cRobotic-assisted surgery is in its infancy, and it definitely has a future,\u201d said Nezhat.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely solely on a news release, as it turned to two independent experts.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/12/national/a131601S24.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "No obvious use of text from the company\u2019s press release in the article.", "answer": 1}, {"article": "The researchers wanted to evaluate whether in a group of women suffering from severe menstrual pain, aged between 18 and 34, self-acupressure would be more effective at achieving a sustained reduction in menstrual pain than usual care alone (e.g.\nAdditionally, the app was used to collect all study-related data.\n\"We were surprised to see that, after six months, two thirds of participants continued to use self-acupressure.\nThe app helped participants to apply simple self-acupressure techniques to three different acupressure points.\nAcupressure-based features - with instructions on how to administer self-acupressure shortly before and during menstruation - were only made available to the intervention group.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t engage in unjustifiable language.", "answer": 1}, {"article": "\"The disc is made up of mostly water, and it get tears in it.\nHe says his intent was not to put some orthopedic surgeons out of business.\nBut no matter where you live, surgery is not necessarily the best or only option.\nIn fact, Dr. Weinstein's findings, released today in the Journal of the American Medical Association, conclude that surgery is only slightly more effective in some cases than a non-surgical approach.\nWhether you have surgery often depends on where you live and what doctor you see.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no way to know if the story relied on\u00a0a press release as the sole source of information, although it did only interview the study's lead author. ", "answer": 2}, {"article": "ORMD-0801 goes from the gut to the liver, while injected insulin circulates throughout the body before it gets there.\nThe 28-day study involved patients whose type 2 diabetes was not adequately controlled by metformin.\nBut the data from the Phase II, 180-patient trial represents a major milestone.\nThe positive results must be replicated in a larger Phase III trial before the drug, known as ORMD-0801, can be submitted for approval.\nA safe and effective oral insulin, if approved, is expected to become a multibillion-dollar product.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story contains original quotes not found in the news release, this squeaks by as\u00a0Satisfactory. It is clear, however, that this story is being published because of promotional outreach by the company, and the lack of outside perspective makes this feel more like a news release than a piece of journalism. (We also reviewed the news release.)", "answer": 1}, {"article": "The MEND protocol, outlined in a 2014 study in the journal Aging, calls for interventions to treat conditions that could be associated with Alzheimer's such as inflammation, stress and diabetes.\nBredesen said that to simplify the program, they are connecting patients with health coaches.\n\"Not all things from the approach have a lot of scientific support behind them,\" Galvin told CBS News.\nBredesen noted, too, that the MEND protocol was suitable for patients in the early stages of Alzheimer's.\nJames E. Galvin, M.D., M.P.H., a professor of clinical biomedical science at FAU's Charles E. Schmidt College of Medicine and a professor in the Christine E. Lynn College of Nursing, who was not involved in the study, agreed that personalized approaches such as the MEND protocol are the types of approaches needed for this disease going forward.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because an independent sources was included, the story does not appear to rely solely on a news release. However, it does cite the news release directly.", "answer": 1}, {"article": ".\n\"However, further research is needed to assess the benefits of using statins before surgical repair of other types of aneurysms.\"\nThe bottom line is that patients who used statins were more likely to survive during and after an elective endovascular procedure.\"\nOf those who do get to a health facility alive, only about 50 percent survive.\n\"Most patients with this disease are older and tend to have other health conditions such as high cholesterol.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The lead is unjustified and way over the top. We believe that a more temperate approach, especially for a summary of an epidemiological study, would have been appropriate here.", "answer": 0}, {"article": "Earlier studies have found that women taking bisphosphonates have a lower risk of breast cancer.\nIndeed, it found a higher risk of throat cancer in patients on the medication.\nHis team found that women who had been taking bisphosphonates \u2014 mainly the drug alendronate (Fosamax), which costs around $10 per month in the U.S. \u2014 for at least a year had a considerably lower risk of developing colon cancer later on.\n\u201cBased on current evidence, bisphosphonates should not be used for prevention of colorectal cancer,\u201d Jacobs said.\nAlso, not all patients asked to participate in the study agreed, which could limit the results further.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story didn\u2019t rely on a news release.", "answer": 1}, {"article": "Radiation oncologist Dr. Richard Stock, of Mt.\n\"With four treatments left, I have 98 percent of my vision left,\" Rianta said.\n\"There is no good evidence, medical evidence that it is better than the current state of the art intensity modular radiation therapy,\" Stock said.\nAt double the cost of standard treatments, many experts say it's being used without proof it's more effective.\nBut proton beam therapy is at the heart of the debate over rising health-care costs.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story quotes multiple experts, the reader can assume the story does not rely on a press release as the sole source of information.", "answer": 1}, {"article": "Although total sleep deprivation or partial sleep deprivation can produce clinical improvement in depression symptoms within 24 hours, antidepressants are the most common treatment for depression.\nThe results are published today in the Journal of Clinical Psychiatry.\nReviewing more than 2,000 studies, the team pulled data from a final group of 66 studies executed over a 36 year period to determine how response may be affected by the type and timing of sleep deprivation performed (total vs early or late partial sleep deprivation), the clinical sample (having depressive or manic episodes, or a combination of both), medication status, and age and gender of the sample.\nAlso, future studies are needed to include a more comprehensive assessment of potential predictors of treatment outcome to identify those patients most likely to benefit from sleep deprivation.\n\"Our analysis precisely reports how effective sleep deprivation is and in which populations it should be administered.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There was no unjustifiable language.", "answer": 1}, {"article": "\"You're going through all this suffering and stuff and you want to know, am I going to survive?\nGraham said there are maybe a dozen published human studies so far, most involving too few patients to draw a firm conclusion.\nBut the FLT PET scans offered an answer as soon as a day after treatment started.\nBut researchers are exploring a new use for medical imaging that could shorten the stay in purgatory, possibly revealing within a few days whether chemo is working.\nThe hope is that, over time, FLT PET would prove reliable for giving a faster answer on whether an experimental treatment is working.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if the story relied on a news release. ", "answer": 2}, {"article": "While some people are helped by over-the-counter medications like ibuprofen, others need prescription medications that may cause side effects, such as dizziness.\nFor 63-year-old Lynn Kaufman, the battle against migraines consumed her life.\nAnother advantage: it could lead to a decrease in the amount of medications used by patients to handle headaches acutely.\nThe aim of the medication is to stop a migraine before it even starts.\nMy entire head throbbed and stung.\u201d\n\nKaufman, who lives in Los Angeles, visited dozens of doctors, trying every option, including pain clinics, holistic remedies, Botox shots, and even hypnotherapy.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We could not locate a news release related to this topic, so we don\u2019t know to what extent the story may or may not have relied on a news release. Had the story included independent sources, we could have been confident that the story contained original reporting. We\u2019ll rate this N/A.", "answer": 2}, {"article": "\"This is outside the box. I've never used it this far out,\" Metz said. \"My radar is up if I see [such an injury] again. As we get more follow-up from David, it will be important to publish this case so people will be aware.\"", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does not appear this story relied on a news release.", "answer": 1}, {"article": "If an AAA is found, doctors sometimes use a stent to repair the aorta, but it doesn't always work since the aneurysms are often in places where a stent can\u2019t fit.\n\u201cAn aneurysm in no way means that you're going to die.\nA hidden, often deadly heart condition with no clear known cause nearly killed 54-year-old Gina Berg two years ago.\nThey are now training doctors nationally.\nUsing a minimally invasive endoscopic vascular surgical technique, patient recovery times are quicker.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to be based on a news release.", "answer": 1}, {"article": "\"It's like 'Star Trek.'\nAnd while some patients like Campbell do well with the implant, there are some who struggle.\nAnd just recently, during a vision test, Campbell was able to correctly identify a sequence of letters for the first time in decades.\nThen earlier this year, she went from coping with blindness to hoping she might see again.\nToday, the artificial retina is primarily for sufferers of retinitis pigmentosa, but it could expand to other diseases, like dry age-related macular degeneration, Mech said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not draw excessively from a press release. But it has an interesting provenance nonetheless.\nSecond Sight Medical Products Inc. issued a press release in May announcing new enrollments in the study featured in this report.\u00a0 Several stories in the popular press followed. \nThe New York Times article published on Sept. 26 bears similarities to the CNN story, including a focus on the same study subject, Barbara Campbell. ", "answer": 1}, {"article": "But, that's an entirely different problem, compared with atrial fibrillation,\" he said.\nWith apixaban, patients can use a standard dose that doesn't need monitoring and adjusting, Ansell said.\nThe study was funded by Bristol-Myers Squibb and Pfizer, the makers of apixaban.\nAlso, unlike warfarin, apixaban has few interactions with other drugs or foods, he added.\nCommenting on the latest study, Dr. Gregg C. Fonarow, a professor of cardiology at the University of California, Los Angeles agreed that \"atrial fibrillation substantially increases the risk of stroke and death.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "While the story referenced a news release, it does not appear to be its sole source of information.", "answer": 1}, {"article": "More: The hidden side of dementia: Families fight over care, end-of-life decisions, finances, estates\n\nDementia is a term used to broadly describe symptoms of cognitive decline; Alzheimer's disease is the most common cause of dementia.\nDoris Lambracht-Washington, a professor of neurology and neurotherapeutics at the University of Texas Southwestern Medical Center, said researchers believe the vaccine could extend lives by preventing the disease from developing.\nThe vaccine is one of several promising treatments aimed at reducing the buildup of those substances before they become deadly plaques and tangles in the brain.\nIf the vaccine proves safe and effective in humans, it could slice the number of dementia diagnoses in half, the study's senior author told USA TODAY.\nTesting in mice showed that the vaccine safely prevents the buildup of substances in the brain associated with the fatal disease, the team reported this week in the journal Alzheimer's Research & Therapy.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story barely goes beyond the contents of a UT Southwestern news release, which contains more guarded and accurate language than the story.", "answer": 1}, {"article": "Newsday's coverage of the Class of 2019, led by Mariano Rivera and Mike Mussina.\nHere\u2019s how he got out.\nAt 14, MS-13 was his family.\nA hijab, a turban, a beard: What aren\u2019t you seeing?\nFrom a Catholic school uniform to a hijab, LIers talk about their religious clothing.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if the story relied solely on a news release.", "answer": 2}, {"article": "Illinois is one of 21 states and the District of Columbia that have introduced legislation that would put HPV on the school shot sheet along with smallpox and measles shots.\nBut is it something that we are in position to sort of ramrod down people's throats?\nBut some worry that may sends a mixed signal by protecting girls against a sexually transmitted disease while at the same time telling them they shouldn't have sex.\nHe's not only a dad, he's an expert on pediatric infectious diseases at the University of Chicago.\nMillions of Americans have seen the ad blitz for Merck's new drug Gardasil.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can't be sure if the story relied on a press release as the sole source of information.", "answer": 2}, {"article": "But \"that trial is never getting done, nor should it be done,\" Golden said.\nAs to whether circumcision reduces sexual sensitivity, Perera said there's no evidence that it affects sensation when performed on adults.\nNot so, write the Australian researchers, who examined eight studies for a review in the latest issue of the Annals of Family Medicine.\nThe findings come as the American Academy of Pediatrics debates updating its recommendations regarding circumcision among newborns.\nThe highest-quality studies, known as randomized controlled trials, don't report whether infant circumcision affects sensation, she said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "", "answer": 1}, {"article": "LDL was 8.3 points lower on the moderate-fat diet without the avocado and 7.4 points less on the lower-fat diet.\n\u201cAll the foods were exactly the same, except the avocado versus oils that were high in monounsaturated fat on the moderate-fat diet.\nAnd it\u2019s one more piece of evidence in favor of adding good fats to the diet.\nThe two moderate-fat diets looked a lot like the average American diet, with about a third of calories coming from fat.\n\u201c\n\nAmericans may not be used to eating avocado but Kris-Etherton says it\u2019s easy to add.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story clearly went beyond the news release. It included an interview with the researcher and brought in a significant amount of additional context from other diet studies.", "answer": 1}, {"article": "There's no definitive answer to that just yet, Wang said.\nWhile larger studies are needed to confirm the findings, tai chi looks promising as an alternative treatment, Yeh said.\n\"This could represent an ideal exercise for fibromyalgia sufferers.\nDoctors will often suggest exercise, sleep hygiene techniques and medications to treat the condition, but often with limited success, said Dr. Gloria Yeh, an assistant professor of medicine at Harvard Medical School, who wrote an accompanying editorial in the journal.\nThe improvements were still evident at 24 weeks, according to the research reported in the Aug. 19 issue of the New England Journal of Medicine.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\u00a0The story is based on an study appearing in the New England Journal of Medicine. The writer did contact the lead author and another researcher for quotes.\u00a0", "answer": 1}, {"article": "Infection with H. pylori is associated with increased risks of stomach and throat cancers.\nImmunochemical FOBT is now largely replacing the older test.\nThe findings, reported in the Canadian Medical Association Journal, give some extra weight to fecal occult blood testing (FOBT) as a valid option for early detection of colon cancer.\nBut there\u2019s been surprisingly little evidence that it really is highly \u201cspecific\u201d to colon cancer, according to Dr. Yi-Chia Lee of National Taiwan University Hospital, one of the researchers on the new study.\nBut as far as cutting the risk of death from colon cancer, stool testing is similarly effective, according to the U.S. Preventive Services Task Force.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not rely solely on a news release.", "answer": 1}, {"article": "Who and When: 8,385 obese patients in Israel who underwent bariatric surgery (laparoscopic banding, Roux-en-Y gastric bypass, or laparoscopic sleeve gastrectomy) from 2005-2014; 25,155 obese patients who received nonsurgical care for obesity management from primary care physicians that may have included dietary counseling and behavior modification.\nWhy The Research Is Interesting: Much is known about the short-term outcomes of bariatric surgery for weight loss but relatively little is known about its long-term effects.\nThe study is observational.\nStudy Conclusions: The association between bariatric surgery and a lower rate of death from any cause adds to the limited literature describing the beneficial outcomes of these surgical procedures for obese patients.\nSome previous research has been limited by a number of factors, including the lack of a comparison group of obese patients who did not undergo bariatric surgery.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There is no unjustifiable language employed.", "answer": 1}, {"article": "Each person's genome, or complete set of DNA, is like a word that's the length of 3 billion characters; but spelled with only the letters A, T, C or G. Traditional DNA sequencing techniques decode sections of DNA 700 characters at a time, while NGS takes advantage of parallel computing capabilities, enabling scientists to decode millions of DNA fragments.\nIn fact, there is no national surveillance here, but the CDC estimates that 1 in 323 American children have the condition.\nThe earlier the diagnosis, the earlier we can direct therapies at the child.\n\"The evidence suggests that there is some epigenetic connection,\" said Crowgey.\nFunding from the Swank Foundation enabled Nemours to develop a cerebral palsy tissue bank that stores blood and tissue samples from hundreds of surgical patients at Nemours.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release is premature in claiming the test is a \u201cbreakthrough\u201d in the sub-headline and a \u201cgame changer\u201d in the lead researcher\u2019s quote.", "answer": 0}, {"article": "\"Our idea was to ask, 'What are the most important proteins we could find in Alzheimer's patients?'\nMore intriguing is a test that examined stored blood samples and predicted Alzheimer's disease in 20 of 22 patients who developed the disease 2 to 5 years later.\nMucke acknowledged that there are very few medical treatments for patients once they are diagnosed with Alzheimer's.\nThe test initially will be used in research labs, where scientists are trying to learn more about the memory-wasting disease that is one of the most feared consequences of aging.\nThe test has also shown promise in predicting which patients with mild memory loss are at high risk of developing the dreaded syndrome, which each year kills 66,000 Americans and inflicts incalculable heartache on the families of its victims.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not appear to rely exclusively on a press release.", "answer": 1}, {"article": "The Hass Avocado Board (HAB) is an agriculture promotion group established in 2002 to promote the consumption of Hass Avocados in the United States.\nClinical studies are currently underway to investigate the relationship between avocado consumption and risk factors for heart disease, diabetes, support of weight management and healthy living.\"\nIn 2010, HAB established a nutrition research program to increase awareness and improve understanding of the unique benefits of avocados to human health.\nHowever, the optimal amount of avocado and frequency of use needs further evaluation along with the nutritional similarities and differences between other different MUFA sources.\nOn the heels of this advice, a new meta-analysis (considered the best evidence and an unbiased overview of the body of knowledge on a specific topic), published in the Journal of Clinical Lipidology, adds to the growing body of research that supports the use of avocados in lieu of solid fats (and foods that have higher saturated fat content) to significantly change lipid profiles.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release misinforms when it claims that meta-analysis studies such as the one described here are \u201cconsidered the best evidence and an unbiased overview of the body of knowledge on a specific topic. \u201d In reality, a randomized, controlled, blinded clinical trial involving an adequate sample of participants would likely provide better evidence and less chance of bias than a retrospective review of hand-selected previously published research.\n\u00a0", "answer": 0}, {"article": "Several companies, including one owned by Koniver, make herbal combinations.\nGiven these two rejections, it could be a while before another pharmaceutical company decides to sink money into developing a new drug for women with sexual problems.\n(CNN) -- Losing interest in sex would be unfortunate for most people, but for Linda Poelzl it was a professional hazard.\nBut in the absence of a drug to help women with sexual problems, here's what's recommended by some practitioners.\nBlakeway says she often has success combining acupuncture with Chinese medicine.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure to what extent this story may have relied on a release, so we\u2019ll call it not applicable.", "answer": 2}, {"article": "\"I think this may be changing in health care,\" said Spears, \"but because migraine affects women more than men, there is a stigma around the stereotype of a patient who comes in with multiple complaints, calls frequently and wants to see the doctor frequently.\" Men, on the other hand, have been stereotyped as going to the doctor \"only when something he has is real.\"", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "\u201cAccording to NOAA\u2019s own statistics, per capita consumption of seafood has risen from 14.8 pounds in 2001 to 16.6 pounds in 2004.\u201d\n\nJane Houlihan, the research director of the Environmental Working Group, another advocacy group, said, \u201cThe Harvard study reads like an advertisement for the seafood industry.\u201d\n\nBoth studies reinforce advice from the Food and Drug Administration and the Environmental Protection Agency in 2004, to eat about six ounces of fish a week, preferably high in omega-3\u2019s, with a caveat for women of childbearing age and children under 12 not to eat swordfish, shark, tile fish or king mackerel and to limit their intake of albacore (white meat) tuna to six ounces a week to avoid mercury.\n\u201cThe high degree of certainty in one report and the extreme caution in the other,\u201d said Rebecca Goldberg, a senior scientist with Environmental Defense, an advocacy group, \u201cwill make people more confused than ever.\u201d\n\nTo the surprise of Institute of Medicine officials, NOAA sponsored the hastily called press conference at which the Harvard report was released, even though that study conflicted with the one prepared by the institute.\nThe two studies, which conflict in important aspects, seem unlikely to provide much clarity.\n\u201cFortunately, Environmental Defense and Monterey Bay Aquarium, who specialize in both health and environmental fish issues, provide advisory cards for choosing fish, and no one can manage this without one.\u201d\n\nThe Environmental Defense list is at oceansalive.org and the Monterey Bay Aquarium\u2019s is at mbayaq.org/cr/seafoodwatch.asp.\nDr. Malden C. Nesheim, chairman of the institute\u2019s committee and a provost emeritus at Cornell, said, \u201cWe are quite cautious because the studies we looked at are not controlled for all the variables, and we can\u2019t distinguish between the effects from omega-3\u2019s or replacement of other foods in the diet.\u201d\n\nThe National Oceanic & Atmospheric Administration had requested the institute\u2019s report because it said consumers were confused about how much and what kind of fish they should eat.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story relied on several different sources, it is appears safe to assume it did not rely solely or largely on a news release.", "answer": 1}, {"article": "Robotic surgery replaces a surgeon\u2019s hands with ultra-precise tools at the ends of mechanical arms, all operated by the surgeon from a console.\nThe trade-off was the cost, with robotic prostate removal costing about $10,000 on average, roughly $700 more than laparoscopic surgery and $1,100 more than open surgery.\nDavid Penson, a surgeon at Vanderbilt University Medical Center who was not part of the study, said more consideration should have been given to the state of patients afterwards.\nThe open-surgery group also stayed in the hospital about one day longer than the robotic group.\nHu and his team analyzed surgery data from a national government database to see if the costlier robotic surgeries were cost effective with extra benefits over older techniques.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does not appear that the story relied on a news release.", "answer": 1}, {"article": "For the study, the researchers followed 57,872 women in B.C.\nThey used maternity, medical billing and demographic data to investigate the odds of small-for-gestational age birth, pre-term birth and low birth weight for low-income women receiving care from a midwife, GP, or OB.\nMcRae said the findings add new evidence in support of midwifery care, and support the development of policies to ensure midwives are available and accessible, especially for low-income women.\nThe study was co-authored by Patricia Janssen, Saraswathi Vedam, Maureen Mayhew at the University of British Columbia, and Deborah Mpofu and Ulrich Teucher at the University of Saskatchewan.\nThe study, published today in the British Medical Journal Open, found that low-income pregnant women who receive care from a midwife compared to a physician are less likely to go into early labour, to have a baby with a low birth weight, or to have a small-for-gestational age birth, meaning a fetus or infant that is smaller or less developed than normal for the number of weeks in pregnancy.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release did not use unjustifiable language.", "answer": 1}, {"article": "In a transvaginal ultrasound (TVU), sound waves emitted from a probe placed in vagina help a physician check if Essure has been placed properly.\nAll physicians who offer Essure are expected to be trained to perform the TVU confirmation test by mid-2016, the company said.\nBut since its approval in 2002, women using the device have sent the FDA more than 5,000 complaints, ranging from pain and menstrual problems to pregnancies and even deaths.\nA woman using Essure must do a test to confirm that the device is properly placed within three months of the procedure and until she receives a confirmation from her doctor, she must use alternate birth control methods, Bayer said in a statement on Wednesday.\nThis test is an alternative to the generally-prescribed modified hysterosalpingogram (HSG) test in which an x-ray of the uterus and fallopian tubes is used to check for proper device placement.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story is an example of one that relies excessively on a news release. There are no sources named other than the device maker, no interviews and no effort to show the test benefit or how an alternative test might improve outcomes. Sections of the story have only been marginally rewritten from the news release. For example:\nStory:\u00a0All physicians who offer Essure are expected to be trained to perform the TVU confirmation test by mid-2016, the company said.\nNews release:\u00a0All physicians who offer Essure are expected to be trained and certified on the TVU confirmation test by mid-2016.", "answer": 0}, {"article": "In Japan, \u201cfood and health care companies have found cosmetic applications for their ingredients, so they are creating skin care brands.\u201d\n\nFor example, Frutarom, a flavor-ingredient house based in Israel, makes Alguard, a purified polysaccharide shield from a red microalgae that it says protects skin from daily assaults and reduces roughness as well as the look of fine lines.\nThere are more than 100 algae-derived ingredients used in cosmetics worldwide, Mrs. Lewis said.\nThe patent-pending alguronic acid in Algenist is a \u201csingle, purified, highly bioactive compound,\u201d said Tony Day, the vice president for research and development at Solazyme, and therefore delivers \u201cmuch higher activity to the skin\u201d than products using only a microalgae extract.\nDr. Dana Sachs, an associate professor of dermatology at the University of Michigan, Ann Arbor, wrote in an e-mail after looking at Algenist\u2019s dossier that \u201cthe claims on cell regeneration and elastin synthesis are based on in vitro models, which is hard to extrapolate to in vivo, and again no statistical significance is presented, so this is a weak claim.\u201d\n\nDr. Day, who has a doctorate in biochemistry, said that statistical significance was found but not included in press materials.\nIt may seem novel for a nonbeauty company to get into skin care, but these days, it really isn\u2019t, Mrs. Lewis said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story goes well beyond any news release.", "answer": 1}, {"article": "At 12 months in patients receiving torcetrapib, there was a 72 percent increased in good cholesterol and a 24.9 percent decrease in bad cholesterol.\nThe study said there were still many unanswered questions about Pfizer's pill, torcetrapib, the first in a new class of heart medicines known as a CETP inhibitors, which raise HDL, or good cholesterol, and lower LDL, or bad cholesterol.\nIt was unclear what the mixed bag of data presented at the American Heart Association's Scientific Session in Orlando would mean for CETP drugs under development by Merck and Roche, and another candidate in early-stage development by Pfizer.\nCardiologists had hoped it would reduce the buildup of plaque in blood vessels that can cause heart attacks.\nA long-awaited postmortem released this morning of Pfizer's (NYSE: PFE) failed heart drug held out hope for the discovery of a safe version of the revolutionary heart pill.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no way to know if the story relied on a press release as the sole source of information.", "answer": 2}, {"article": "At the annual Alzheimer\u2019s Association International Conference, researchers say they have found a series of substances in saliva that can distinguish between people who experience normal aging, those with mild cognitive dementia (MCI, which in some cases can lead to Alzheimer\u2019s and in other cases not), and Alzheimer\u2019s disease.\nThe results aren\u2019t conclusive enough yet for doctors to start using them to distinguish people who are more likely to develop Alzheimer\u2019s, but that\u2019s the goal, says Sapkota.\nBy comparing their saliva components, the scientists found that each of the three groups showed slightly different patterns of compounds, which could form the basis of a relatively easy and non-invasive way to determine which people are at higher risk of developing more serious degenerative brain conditions.\nExperts now believe that the biological processes behind the neurodegenerative condition begin years, if not decades, before memory problems and confusion become noticeable.\nSome had been diagnosed with Alzheimer\u2019s and some with MCI, while others did not have any neurological conditions.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We didn\u2019t see evidence that the story relied on this news release about the presentation. However, since it contains such limited information, it\u2019s hard to determine how it was produced. We\u2019ll rule it Not Applicable.", "answer": 2}, {"article": "An Online Program May Help Prevent Depression In Some People\n\nWorking through a self-help program online can prevent or delay major depression disorder in people who are vulnerable, a study finds.\nLead author Claudia Buntrock, a PhD candidate in clinical psychology at Leuphana, says that because the study only tracked participants' mental health over the course of 12 months, the long-term effectiveness of the intervention is unknown.\nIt's also not clear if this kind of program could be scaled up.\nSimilar programs have been used to treat depression, but this may be the first one tested to prevent it, the researchers say.\nOf the 406 participants that began the study, 335 completed the telephone follow-up at the end of 12 months.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story appears to go beyond any news release on the work.", "answer": 1}, {"article": "ASTHMA According to conventional wisdom, asthma and other allergic diseases like hay fever are made worse by dirty environments. Recent evidence has suggested, however, that children exposed to dirt and germs early in life may have a lower risk of developing asthma and other allergies. Studies have found that the children of farmers -- who presumably are exposed to a ... (Full article: 838 words)", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not appear to rely on the press release from AstraZeneca distributed when the study was presented at the American College of Cardiology meeting.", "answer": 1}, {"article": "When skin is exposed to sun, it makes vitamin D.\n\nStill, the doctor wanted to run a blood test to see if Rebecca Rosen had adequate vitamin D.\n\n\"So my wife said, 'Well, why do I need to have a vitamin D [test]?'\nThe evidence is strongest for colorectal cancer, she says.\nNeither study subjects nor investigators will know until the end which regimen they are on.\nThe recommendations may change soon.\nAn Institute of Medicine panel is working on a vitamin D update, which may come out this summer.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\u00a0Does not appear to rely on a press release.", "answer": 1}, {"article": "Learn more at: www.DecipherTest.com and follow Decipher on Twitter @DecipherTest and on Facebook.\nUse of this test therefore has the potential to assist clinicians to better direct utilization of secondary therapy after surgery.\nThe test provided a more accurate and precise estimate of a patient's risk of recurrence.\nDecipher was developed in partnership with the Mayo Clinic.\nAdding truly unique information to the treatment decision-making process, Decipher generates a risk result that is completely independent and distinct from PSA, Gleason score and other clinical risk factors.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We found no charged or dramatic language. On the contrary, the entire release is pretty staid.", "answer": 1}, {"article": "Drinks such as POM have become increasingly popular with consumers in recent years, thanks in part to public health campaigns against soda that have been prompted by the obesity epidemic.\nThe bottom line is that consumers shouldn't believe everything they read on labels.\nThey also earned the disapproval of the Federal Trade Commission (FTC).\nProbably not,\" says Dr. Lenard Lesser, M.D., one of the co-authors of that study and a researcher at UCLA.\nThat's the paradox of products such as POM, Silverglade says: The health claims on these products strain the imagination, yet studies have repeatedly shown that health claims sell food.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story was clearly not based on a news release.", "answer": 1}, {"article": "The requested document is forbidden. Please try your operation again .", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not appear to rely on a press release.", "answer": 1}, {"article": "Eventually, the overwhelmed system leaves these sugars, in the form of glucose, to build up in the blood, which can lead to obesity, damage the heart, and cause other metabolic problems.\nThat\u2019s because experts believed that once the pancreatic islet cells, the body\u2019s insulin-making factories, were compromised, they couldn\u2019t be made to work again.\nMore work will be needed to confirm what benefit betatrophin might have on diabetic patients before that might be possible, however.\n\u201cThat\u2019s a huge difference.\u201d\n\nWhat\u2019s more, it appears the cells are relatively long-lasting, which could indicate they are robust enough to bring glucose levels in diabetics under control.\nWhat\u2019s more, they also surmised that only a specialized set of beta cells were equipped to make insulin, and that once diabetes set in, too few of these cells remained to pump out the critical hormone.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story doesn\u2019t seem to have relied excessively on this press release\u00a0about the study.", "answer": 1}, {"article": "But in either case, \"Something is better than nothing,\" Sayre said.\nBut less than a third of victims get this essential help.\nGoodall, a 49-year-old construction contractor, said he had been healthy and fit before the collapse, and there'd been no hint that he had clogged heart arteries.\nThe CPR guidelines had been inching toward compression-only.\nSayre said the association took the unusual step of making the changes now - the next update wasn't due until 2010 - because three studies last year showed hands-only was as good as traditional CPR.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if the story relied solely or largely on a news release.\u00a0 No expert is interviewed.\u00a0 And no direct reference was made to the research published in the AHA journal Circulation. So the story may have relied largely on a news release.\u00a0 Or it may not.\u00a0 We can\u2019t judge. ", "answer": 2}, {"article": "scans on 991 people ages 50 to 90.\nThe question, though, was whether it helped the patients and their doctors to know what the M.R.I.\u2019s had found.\nHe told her bluntly that her pain was caused by arthritis, not the torn cartilage.\nAnd the answer, Dr. Modic reported, is that it did not.\nBut that leaves patients and doctors in an untenable situation.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story quotes multiple experts, the reader can assume the story did not rely on a press release as the sole source of information.", "answer": 1}, {"article": "It needs to be tested in large trials,\" he said.\nIn this latest trial, researchers found that routinely removing clots was not beneficial, Jolly said.\nAnother trial in 2013, however, suggested that removing clots was not beneficial, he added.\nA number of studies have suggested a benefit from manually removing clots during an angioplasty, but this trial found no clinical benefits for doing so, he said.\nJolly said there are mechanical methods of removing clots, which were not tested in this study.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "While there is a press release on this study produced by the conference, the expert interviews are evidence that the story did not rely on them excessively. We\u2019d note that there is some information in the press release that would have made the story better.", "answer": 1}, {"article": "The median age was 70, with a range of 50 to 88.\nThe study is titled \u201cQuality of Life in Patients Undergoing Pleurectomy and Decortication for Malignant Pleural Mesothelioma.\u201d The surgeries were performed by Dr. Vigneswaran at University of Chicago Medicine, where he practiced before recently joining Loyola.\nQuality of life was not adversely affected by surgery at any time in patients who, prior to surgery, had performance status of 1 or 2; a tumor volume greater than 600 ml.\nDr. Vigneswaran and colleagues administered a cancer quality-of-life survey known as the EORTC QLQ-C30 to 114 mesothelioma patients who underwent PD surgery.\nWickii Vigneswaran, MD, presented the study during the 2016 annual meeting of the American Society of Clinical Oncology.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "While not explicit, the news release veers toward absolute and ambiguous language at times. For example, it states that quality of life improved in all patients, which is not true, since some patients\u2019 conditions remained unchanged. In others, quality of life was \u201cnot significantly better\u201d or \u201cadversely affected\u201d by the surgery.\nIn addition, the sole quote from the researcher is limited in our opinion, since it only talks about the net benefits of the surgery without any mention of its potential risks. The researcher also concludes the procedure is \u201cjustified\u201d in a majority of patients. But as we had mentioned previously in the benefits section, it\u2019s hard to make such sweeping statements on a small study with no control group. These comments should be compared to an earlier study by the same researcher who concluded: \u201dExtended pleurectomy and decortication did not improve overall HRQoL and had a negative impact in pulmonary function in minimally symptomatic patients.\u201d", "answer": 1}, {"article": "The American Academy of Family Physicians outlines medicines used to treat patients with acute coronary syndrome.\nA study author agreed that for most patients, using the drug with a lower dose of aspirin is usually warranted.\nThe panel's recommendation was based in part on prior findings from this study, called the Platelet Inhibition and Patient Outcomes (PLATO) trial.\n\"A higher aspirin dose (325 mg versus 81 mg) increases the risk of bleeding without increasing the efficacy of the drug.\"\nThe findings were reported Monday in an American Heart Association online conference.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article has several differences from the news release, and on that we pass it on this criteria. They do have a similar tone, and neither addresses the investigators\u2019 recommendation for cautionary interpretation of this exploratory study, which \u00a0they conclude may be reporting the effects of chance. Although the release does mention that AstraZeneca funded the study.", "answer": 1}, {"article": "GHRH, a hormone produced by the hypothalamus in the brain, is linked to the insulin system, but also has a host of other effects.\n\u201cOn self-report, many of the folks in the active group reported they felt better,\u201d Baker, who led the study, told Reuters Health.\n\u201cWe recommend commonly that people start exercising when they are having mild cognitive impairment,\u201d Baker said.\nAt the end, those who got the drug did better on psychological tests of executive function - whether or not they had mild cognitive impairment.\nBaker said researchers have failed so far to come up with effective drugs to treat mild cognitive impairment, just as there is no known treatment to stave off the normal memory decline that comes with age.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not rely on a news release.", "answer": 1}, {"article": "Then in 2002, the results of the largest randomized clinical trial of hormone replacement, the Women\u2019s Health Initiative (W.H.I.\nstudy actually had nothing to do with menopausal symptoms.\nDr. Manson is distressed about the large number of women \u2014 about a third of those now on hormone replacement \u2014 who are relying on \u201ccustom-compounded\u201d products that have not been reviewed for safety and effectiveness by the Food and Drug Administration.\nAmong these older women, it found no such effect.\nMost of the 27,347 women entering the study were already in their 60s and 70s, already a decade or more past menopause.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not rely on a news release.", "answer": 1}, {"article": "He walks about 50,000 steps a week, golfs, works out and tap dances and consumes about 1,800 daily calories.\nThe study, known as DPPOS, puts science behind Mr. Held's success.\nHis results do not surprise researchers.\nThat's to say, he's delayed the onset of type 2 diabetes and potentially can prevent the onset for the rest of his life.\nThe study is published online today in the The Lancet, a medical journal.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no evidence the reporter drew inappropriately from the press release. ", "answer": 1}, {"article": "But when the Toronto-based artist and mother puts on a new kind of camera-equipped headgear, she looks at me like no one has before.\nThe visor that allows legally blind people to see is no longer Star Trek fiction.\nGeoffrey A. Fowler discusses the headset with Yvonne Felix, a blind artist and supporter of the technology.\nPhoto/Video: Emily Prapuolenis/The Wall Street Journal\n\nYvonne Felix\u2019s eyes don\u2019t work well enough on their own for her to read, recognize faces or cross the street without help.\nLeaps in augmented-reality technology are being used to help people with severely low vision gain back enough sight to function, and then some.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We didn\u2019t see any copy/pasted quotes or other material lifted from a news release. Dozens of outlets have covered the company and its devices over the years, and it seems many of them jumped on the story again due to an in-person press event and demo for eSight\u2019s latest model.\n\u00a0", "answer": 1}, {"article": "With the new antibiotic treatment, Pimentel tells WebMD, many participants ''say they are 80% improved, 90% improved, that kind of results.\nThat can translate to big changes in the lives of those with IBS, estimated to affect about 15% of adult Americans.\nWith the drug treatment, Pimentel says, those with the IBS ''can enjoy social outings without the worry of having to run to the bathroom and having diarrhea.\"\nThe study looked only at those IBS patients with the non-constipation form, he tells WebMD.\nExisting treatment options -- diet and lifestyle modification, psychological therapy, and other drugs -- do not help all people with the condition.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not rely on a news release.", "answer": 1}, {"article": "For more on aspirin, visit the National Institutes of Health.\n\"These findings provide the first proof in man that aspirin reduces deaths due to several common cancers,\" the study team noted in a news release.\nThe current observations follow prior research conducted by the same study team, which reported in October that a long-term regimen of low-dose aspirin appears to shave the risk of dying from colorectal cancer by a third.\nBut the study's lead author, Prof. Peter Rothwell from John Radcliffe Hospital and the University of Oxford, stressed that \"these results do not mean that all adults should immediately start taking aspirin.\"\nThe potential impact of aspirin on pancreatic, stomach and brain cancer death rates was more problematic to gauge, the authors noted, due to the relative paucity of deaths from those specific diseases.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story acknowledges taking\u00a0some quotes directly from a news release about the study, and a number of passages bear a resemblance to the text of the\u00a0release. However, the story\u00a0does also solicit feedback from an independent expert not affiliated with the study. Borderline, but enough for a satisfactory.", "answer": 1}, {"article": "Wu says in a news release: \u201cThe system we have is portable and as soon as you lie down you can get a scan -- it\u2019s real-time.\nThe real-time imaging minimizes the chance of missing a breast tumor during scanning.\u201d Wu says it will even work through a bra.\n\u201cAlthough there is still research to be done, the system has great potential to bring a new way for breast cancer diagnosis.\u201d\n\nCarolyn Rogers, clinical nurse specialist at Breast Cancer Care in the U.K., says in an emailed statement: \u201cEvidence is needed to demonstrate the accuracy and uses of this device.\nThe scanner is based on radiofrequency technology, which is able to quickly show malignant and benign tumors when linked to a computer.\nCosts are reduced and the electronics fit into a case the size of a lunchbox.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It seems that, save the email from Carolyn Rogers, the article is based entirely on the press release from the University of Manchester. The content and tone are very similar, and every rating we\u2019ve given the story applies to the press release.", "answer": 0}, {"article": "Sitting has been identified as a risk factor for early mortality, independent of the presence of a disease, such as cancer or diabetes.\nParticipants in the study familiarized themselves with the workstations during one visit.\n\u201cThese results suggest that non-exercise active thermogenesis, which we call NEAT, can increase movement and calorie burning, and may have the potential to impact health,\u201d said Horswill, the senior author on the study.\n\u201cThis is more evidence that NEAT, something everyone can do throughout the day, may be an important strategy for improving health, and even reducing early death,\u201d said Horswill.\nHaley Scott and Danel Voorhees are co-authors on the paper.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "No unjustifiable or sensational language.", "answer": 1}, {"article": "A rare form of blindness inched closer to a cure, after two groups published preliminary studies on replacing the bad gene that causes the condition. The results are likely to boost the prospects of gene therapy, a technique that shows promise but has yet to prove it can be used to cure many diseases.\n\nAbout 2,000 people in the U.S. have Leber's congenital amaurosis No. 2, caused when a child inherits a certain flawed gene from both parents. Patients with the bad gene can't make a protein that is supposed to nourish the eye's...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if the story relied solely or largely on a news release.\u00a0 We can be sure that it quoted only the doctor who led the US study. ", "answer": 2}, {"article": "The requested URL /usnews/health/articles/070408/16healy.htm was not found on this server.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story clearly relies both on a recent journal article as well as many years of clinical research. ", "answer": 1}, {"article": "Matthews: \u2018It\u2019s only going to get better\u2019\n\nIn his first game with the Pacers, he only made two shots but they came in the fourth quarter to pull out the victory vs. the Hornets.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not appear to rely on a press release, although it reads like a marketing piece.", "answer": 1}, {"article": "An estimated 5.4 million Americans have Alzheimer's disease, the most common form of dementia, according to the Alzheimer's Association.\nHis test is one of numerous such tests under study, says Heather Snyder, PhD, a spokesperson for the Alzheimer's Association, who reviewed the research results.\nThe research results on the new test are published online in PLoS ONE.\nHe is also founder of Durin Technologies Inc., the company that is developing the test.\nNone are highly accurate, and some are costly and not practical to use on a widespread basis, experts say.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\nThe story includes interview quotes and does not appear to rely on a news release.", "answer": 1}, {"article": "In their study, published in the Feb. 23 issue of the Journal of the American Medical Association, Miglioretti and her colleagues found that false positives and interval cancers were both higher in women with a history of breast cancer than in those without such history.\nDr. William Audeh, medical director of the Samuel Oschin Cancer Center and the Wasserman Breast Cancer Risk Reduction Program at Cedars-Sinai Medical Center in Los Angeles, described the findings as \"not at all surprising.\"\nIt points to the need, she said, for women to remain vigilant about screening after their breast cancer treatment -- and to report any symptoms to their doctor immediately.\nThe interval cancer rate was 3.6 per 1,000 screenings in those with a history and 1.4 per 1,000 in those without, the investigators found.\nAnd though mammography did not catch all cancers in the women with a breast cancer history, the study still points out the value of the test, he said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The\u00a0article does not rely solely on a news release.\u00a0 It includes several explanatory quotes from Dr. Diana Miglioretti, one of the co-authors of the study as well as quotes from two doctors not connected with the study.", "answer": 1}, {"article": "Breast MRI currently is used to screen women at high risk of breast cancer and as a diagnostic adjunct to mammography.\nThe new approach is not intended to replace current contrast-enhanced breast MRI protocols in general, Dr. Bickelhaupt emphasized, but to expand the spectrum of options available for answering specific clinical questions.\nThe examination relies on gadolinium-based contrast agents that need to be injected intravenously.\nThe software algorithm makes the assessment reader-independent, ensuring that its accuracy is maintained across different imaging facilities.\nShould the results hold in larger trials, the model has potential advantages in the clinic beyond its ability to reduce unnecessary biopsies in women with BI-RADS 4 lesions.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "No \u00a0unjustifiable language was observed in this news release.", "answer": 1}, {"article": "\u2022 Try to stay indoors, and avoid mowing lawns or raking leaves.\nBut you can also tell by the ads: TV spots selling remedies for drippy, congested noses, itchy eyes and other symptoms are in heavy rotation.\nPeople with mild to moderate symptoms have the best chance of full relief, he says.\nYou can tell by the sniffles and sneezes of the afflicted.\nHere's what some top allergists say you need to know about these non-prescription options.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes enough original reporting that we can be sure it\u2019s not based on a press release.\n\u00a0", "answer": 1}, {"article": "Dr Francoise Soussaline, PhD, DSc, IMSTAR's president said: \"To bring a universal 'liquid biopsy' blood test for cancer to market, it must achieve a number of criteria, including high sensitivity and specificity and be fully automated with high throughput for a medical routine use.\nThe research team believes that the test could be the first screening tool to 'rule in, or rule out' cancer in patients under suspicion of the disease, alongside other traditional diagnostics methods.\nThese findings are published in FASEB BioAdvances journal.\nUK researchers behind a potential 'universal' liquid biopsy blood test for cancer detection have licensed the technology to an industrial partner to take it to market.\nThe test was developed at the University of Bradford, UK.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The text exercises appropriate caution, describing the blood test as a \u201cpotential\u201d tool.", "answer": 1}, {"article": "Testing cholesterol in toddlers and babies?\nThe study also revealed parents who had the condition but didn\u2019t know it, and had passed it on to their children.\nNinety percent of them started taking preventive medicines after finding out.\nThe study was led by Dr. David Wald at Queen Mary University of London.\nBut many parents balk at the idea of testing children for a disorder associated with middle age, experts say.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There are two sources who do not appear to be associated with the study.", "answer": 1}, {"article": "But the F.D.A.\nSo injecting it is an off-label use.\nShe said veins as large as a Sharpie marker can be tackled with foam sclerotherapy.\n\u201cOtherwise they\u2019ll just come back.\u201d\n\nToday, sluggish underlying veins are best addressed with radio-frequency or laser treatment, said Dr. Min, who developed such a laser.\nA series of sessions is usually required for a large area.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that this story isn\u2019t based on a news release.", "answer": 1}, {"article": "Both Prozac and Celexa belong to a class of antidepressants known as selective serotonin reuptake inhibitors, or SSRIs.\n\u201cIt takes the edge off,\u201d Hollander explains, noting that the findings were statistically significant and clinically meaningful.\nThe study was published in the American Journal of Psychiatry.\nTaking Prozac (fluoxetine) doubled the chances that a patient would show overall improvement, measured by their clinicians.\nWhen taking Prozac, Hollander says, \u201cPatients acknowledge experiencing less discomfort.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a press release.\n\u00a0\n\u00a0", "answer": 1}, {"article": "Dr. Carroll's co-authors are Eric C. Larsen at Maine Children's Cancer Program, Scarborough, ME; Meenakshi Devidas and Si Chen at the University of Florida; Wanda L. Salzer at the U.S. Army Medical Research and Materiel Command, Fort Detrick, MD; James B. Nachman at the University of Chicago; Elizabeth A. Raetz at the University of Utah; Mignon L. Loh at the Benioff Children's Hospital and the University of California, San Francisco; Leonard A. Mattano Jr. at HARP Pharma Consulting; Catherine Cole at Princess Margaret Hospital for Children and University of Western Australia; Alisa Eicher at Doernbecher Children's Hospital, Portland, OR; Maureen Haugan at Ann and Robert H. Lurie Children's Hospital of Chicago; Mark Sorenson at University of Iowa Hospitals and Clinics; Nyla A. Heerema and Julie M. Gastier-Foster at The Ohio State University School of Medicine; Andrew A. Carroll at the University of Alabama at Birmingham; Michael J. Borowitz at Johns Hopkins Medical Institutions; Brent L. Wood at University of Washington; Cheryl L. Willman at University of New Mexico; Naomi J. Winick at University of Texas Southwestern Medical Center, Dallas; and Stephen P. Hunger at Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania.\nThe clinical protocol also examined how to best use a steroid formulation called decadron to treat high-risk ALL patients.\nThat could change with the results from a clinical trial co-led by investigators from NYU Langone Medical Center, which shows giving high doses of a commonly-used chemotherapy drug increases the survival rate for these patients.\nThis was a large-scale study involving pediatric cancer centers across the country.\nPrior to the release of the initial study results, which were first presented last year at the annual meeting of the American Society of Clinical Oncology (ASCO), the standard of care for high-risk ALL patients in North America was escalating methotrexate.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There is no use of unjustifiable language in this release. However, the tone may be a bit overly optimistic given the study findings.", "answer": 1}, {"article": "\u201cBut we do expect the patients to have significant improvements in mobility.\u201d\n\nNearly 30,000 Asterias\u2019s shares were traded by 12:30 p.m.\nLichtinger said he was confident the data would be positive but was not expecting miracles.\nMenlo Park, California-based Asterias expects to release complete safety data from the first half of the study later in the year.\nThe therapy, AST OPC-1, is the first product derived from human embryos to be tested on humans.\nData showed that the severity of the spinal injury was reduced in the first patient and two other patients were able to resume their rehabilitation programs soon after being injected with the stem cells.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Although the article refers to the company\u2019s news release, the comments from CEO Lichtinger are original. But one-source stories are not ideal: We would have liked to have seen comments from other researchers, especially one who was not involved in the trial.\nSince the Reuters story made an effort to go beyond the news release, we give it a Satisfactory rating here.", "answer": 1}, {"article": "\"What we found is that kids get home from school around 4 p.m.\nParticipants in the study were part of a larger longitudinal study on a school-based obesity intervention program.\nFollowing the 12-week intervention, students spent 12 more weeks maintaining the healthy snacking habit.\nThe researchers conclude that afterschool programs and schools can replace energy dense, unhealthy snacks with peanuts to provide a healthier alternative for children (researchers in the study ensured students did not suffer from nut allergies).\nThe 12-week study was conducted by researchers at the University of Houston Department of Health and Human Performance (HHP), Baylor College of Medicine and Texas Woman's University.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release doesn\u2019t cross the line it its claims. However, the selected quotes used in the release make broad statements that appear to make more judgments about the study population than about the data gathered in the study.", "answer": 1}, {"article": "Necator americanus, the New World hookworm, is as long and thin as a vermicelli noodle.\nThe doctor wanted to know whether there might be a connection between the dramatic success of deworming programs around the world and the rise of immune system problems like asthma and celiac disease.\nThe study is the latest from a surprising field of research into the potentially positive sides of parasites, one of the most maligned groups in the animal kingdom.\nIt was important that the participants be adults, because even relatively benign parasites can cause serious problems for children, pregnant women and others.\nAnd because of the risks associated with parasites, going around infecting people isn't a viable treatment option.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story appears to include novel quotes from the researchers that were not taken from the news release.", "answer": 1}, {"article": "For men with advanced prostate cancer, the news for decades has been mostly bleak. Until recently, only two treatments had been shown to prolong survival.\n\nResearchers reported Monday that the drug abiraterone, being developed by Johnson & Johnson, extended survival by an average of 3.9 months among men with cancer that has spread beyond the prostate and for whom other treatments have failed. Among men, prostate cancer is the second-leading cancer killer, behind only lung cancer.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\nThe story does not appear to be based on a news release.", "answer": 1}, {"article": "A new study finds that supplementing the Mediterranean diet with more olive oil or more nuts helps diminish age-related decline in cognitive function. Photo: Getty Images\n\nThe Mediterranean diet, supplemented with a handful of nuts or a few tablespoons of olive oil a day, can counteract the effects of aging on the brain\u2019s ability to function, a new clinical study suggests.\n\nThe study, published online Monday in JAMA Internal Medicine, was unusual in that it employed rigorous scientific practices to test the effect of the diet on health. Most previous evidence showing benefits from the Mediterranean diet was gathered through observational studies, a less conclusive research technique.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Since it includes a comment from an independent expert, we can be certain that this story didn\u2019t rely excessively on any news release.", "answer": 1}, {"article": "\"It's a very fragile organ to begin with,\" Kavaler said, \"and if you start to do all these things to it you can disfigure it...\nDr. Elizabeth Kavaler, a urologist at Lenox Hill Hospital in New York City, said functional issues resulting from conditions such as birth defects or prostate cancer surgery may warrant penile surgery, but such cases are unusual.\nLong-term vacuum treatments did not appear effective, producing no significant physical changes after six months, Gontero said, but did provide a degree of psychological satisfaction.\n\"No study has, however, specifically addressed the extent and type of sexual bother in this patient category.\"\nHe and his colleagues found no scientific evidence to support penile-lengthening exercises.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a news release.", "answer": 1}, {"article": ".\nThis suggests that the blood test could be used by clinicians for up to a week after injury to detect brain injury.\nThe results showed that the blood test was able to detect brain injuries with 94 percent accuracy, nearly as effective as state-of-the art CT scans.\nThe discovery could greatly expand the window for diagnosing concussions, especially in patients who experience a delayed onset of symptoms.\nWhen cross-checked with scans, the blood test was able to detect mild to moderate traumatic brain lesions with up to 97 percent accuracy in patients 18 years and older.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "This release includes some unjustified language. For starters, there is no such thing as a \u201csimple blood test,\u201d particularly one that tries to diagnose a brain injury based on a blood sample. We\u2019ve addressed this in a previous review of an Orlando Health news release. We also have concerns about the use of the term \u201ccan\u201d in the headline. This is still preliminary research and more studies are required to prove its usefulness.", "answer": 0}, {"article": "So, for example, a person who is actively using opioids and can't manage the withdrawals may be better suited for buprenorphine, while someone coming from a facility where he or she has detoxed and who doesn't want to use opioids may be better suited for naltrexone.\nWhat was important, Lee said, was for opioid addicts as well as treatment providers to understand that addiction isn't one-size-fits-all.\nOnce on either of the medications, people fared equally well.\nWithout the opioids, people can go into withdrawal, all contributing to a cycle of dependency.\nPublic health experts consider medicated-assisted treatment the gold standard of opioid addiction treatment.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes reporting that\u2019s independent from The Lancet\u2019s news release. It is interesting to see the different framing\u00a0of the study from the drug company that makes Vivitrol.", "answer": 1}, {"article": "It also includes UCSF Health, which comprises top-ranked hospitals, UCSF Medical Center and UCSF Benioff Children's Hospitals in San Francisco and Oakland -- and other partner and affiliated hospitals and healthcare providers throughout the Bay Area.\nThe fMRI method and analysis developed for the study highlighted abnormal patterns of brain activity that pointed to a higher risk for long-term, post-concussive symptoms, even among the 44 study participants who had no evidence of bleeding or bruising in the brain in the immediate aftermath of brain trauma on computed tomography (CT) or ordinary MRI scans.\nSeveral of these differences were associated with worse performance months later in cognitive and behavioral tests.\nThe research was funded through project grants from the National Institutes of Health and the Department of Defense.\nIn the new study, the researchers focused on well-known networks of activity that are observed when the brain is in a resting state.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release does not include unjustifiable, sensational language.", "answer": 1}, {"article": "About half of breast cancers develop in the upper-outer quadrant of the breast, which is largely inaccessible to mammography scanners.\nThe preferred method, known as the vertical strip, three-pressure test, has proved the most sensitive and least likely to produce false alarms, Steiner said.\nShe stopped routinely teaching self-exams to patients after the large trials in China and Russia showed no benefit.\nBut finding a lump also is no reason to panic, given the limited accuracy of the self-test.\nShe encourages women to schedule an appointment devoted to learning the technique, which should take at least a half-hour.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes several independent sources and references to published studies. The story does not appear to rely solely or largely on a news release.", "answer": 1}, {"article": "Flublok is an exact copy of the influenza virus coat protein and is not subject to the egg-adapted mutations associated with low vaccine effectiveness (see Skowronski et al.\nThis data satisfies both pre-specified criteria for non-inferiority and superiority of Flublok over the traditional egg-based quadrivalent inactivated vaccine.\nFlublok contains three times more active ingredients than traditional vaccines and produced significantly higher immune responses to the A strains of influenza (especially H3N2) in the Flublok Quadrivalent study.\nFurthermore, Flublok Quadrivalent is the first and only high antigen-content quadrivalent flu vaccine that with its high efficacy makes it ideal for older adults and those with a compromised immune system.\n\"We demonstrated statistically significantly better protection by Flublok based on considerably fewer people contracting the flu after vaccination with Flublok Quadrivalent.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "In addition to the findings that inflated the relative risk reduction from 30 to 40 percent (described under benefits), the chief medical officer\u2019s statement includes the following: \u201cClearly, Flublok represents a major step forward in combating influenza on a global scale.\u201d Stating the the findings are \u201ca major step forward\u201d and \u201con a global scale\u201d are broad, unjustified claims. This is an incremental improvement, not a major step forward.", "answer": 0}, {"article": "\"My impression is, even with the newer band, the results are not significantly better,\" he says.\nBut a spokesman for the company that manufactures Lap-Band says the study is flawed.\nThe critics also point out that both the device itself and the expertise of surgeons placing it have improved greatly since the patients in the study had their bands placed, in the years 1994 through 1997.\nBut some, including the manufacturer of the Lap-Band -- used in a technique called laparoscopic adjustable gastric banding -- take exception to the study, criticizing the small sample size and the number of patients lost to follow-up.\nEven so, a majority of the patients in their small study said they were satisfied with the procedure.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story does not appear to be based exclusively on a news release.", "answer": 1}, {"article": "Learn more about alcoholism and how it is treated at the U.S. National Institute on Alcohol Abuse and Alcoholism.\nExactly how this drug curbs drinking is not fully understood, but its use may increase blood pressure, heart rate and feelings of sadness and nausea, thereby blunting the pleasurable effects of alcohol, the researchers said.\nThe study was funded by the U.S. National Institute on Drug Abuse and the U.S. National Institute on Alcohol Abuse and Alcoholism.\nMore research is needed, he noted, but \"this medication may be helpful for people with a drinking problem who are also smokers.\"\nWhether the drug might someday be approved to help problem drinkers cut back remains to be seen, said the researchers, who acknowledged that the study's small size is a limitation.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "\u201cA lot of preparations have added so many things that they aren\u2019t releasing zinc properly,\u201d said Dr. Ananda Prasad, professor in the department of oncology at Wayne State University School of Medicine in Detroit and an early pioneer of research into zinc as an essential mineral.\nIn some of the cited studies, the benefits of zinc were significant.\nA sweeping new review of the medical research on zinc shows that sniffing, sneezing, coughing and stuffy-headed cold sufferers finally have a better option than just tissue and chicken soup.\nAlthough a majority of trials have shown some benefit from zinc, many of them have been criticized for failing to \u201cmask\u201d the treatment, meaning the participants most likely knew they were using zinc, which may have skewed the results.\nEven so, the new report gives credence to the long-debated theory that zinc can be an effective treatment for colds.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story does not appear to rely on a news release. \u00a0\u00a0\n", "answer": 1}, {"article": "BOSTON -- In 2006, the FDA warned the public that the use of common antidepressants, like Prozac and Paxil, late in pregnancy could put a baby at risk for respiratory failure.\nBut now a new, large-scale study finds that the risk is negligible -- much lower than previously believed, reports CBS Boston's Dr. Mallika Marshall.\n\"So for women with severe debilitating depression that is not responsive to other non-pharmacological treatments, this should be reassuring information.\"\nIt's certainly reassuring news for Dr. Katherine Economy, a maternal fetal medicine specialist at the Brigham who cares for many pregnant women on antidepressants.\n\"The risk increase of taking antidepressants late in pregnancy, if present, is much more modest than previous studies have found,\" says Krista Huybrechts, Ph.D., an epidemiologist at Brigham and Women's Hospital.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear some original reporting was done and that the story did not rely excessively on a JAMA news release. That release did have some useful information (e.g. roughly how many pregnant women take SSRIs, the\u00a0mortality rate of PPHN, confounding factors, etc.).", "answer": 1}, {"article": "Although the company selling Xiaflex will be Auxilium Pharmaceuticals of Malvern, Pa., the F.D.A.\napproval was a belated triumph for the drug\u2019s original developer, BioSpecifics Technologies of Lynbrook, N.Y., on Long Island.\nWith Dr. Korn\u2019s help, BioSpecifics licensed the drug to Auxilium in a matter of weeks, receiving $5 million initially.\nIt now has only five employees and a business of collecting a roughly 11 to 12 percent royalty on sales of Xiaflex.\nAuxilium and BioSpecifics hope that the half-century-old collagenase might eventually become as versatile as Botox, another bacterial product.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The depth and sourcing of this story precludes the possibility that it was based on a press release.", "answer": 1}, {"article": "\"We think it will be a very important tool in the toolbag of surgeons and physicians treating obesity and its co-morbidities,\" said Gregory S. Lea, senior vice president and chief financial officer of EnteroMedics. \"When patients leave the diet, counseling and drug world and have nothing more, they turn to surgical procedures, and only 1% to 2% of patients who might be eligible for bariatric surgery are getting it.\"", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Since the story includes comments from expert interviews, we can be sure it wasn\u2019t based entirely on a press release.", "answer": 1}, {"article": "In the Swiss research, animals took a drug that dissolved a barrier around the part of the brain where mammals store their fear memories. Afterward, they stopped being afraid of noises that were linked to electric shocks, which meant their bad memories had been erased, according to the Mail. Human brains, explains NYU neuroscience Prof. Joseph LeDoux, could actually \"overwrite\" memories with happier thoughts if the medication is developed for people, according to the Daily Mail.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story does not rely on a press release, but it is largely based on a piece in the London Daily Mail. We can\u2019t be sure of the extent to which the original story may have relied on a news release. ", "answer": 2}, {"article": "Uterine fibroids are benign tumors that grow in and around the uterus.\nPatients with the condition say it\u2019s time for better treatments.\nThe drugs, experts say, would provide a new treatment option for a condition most commonly treated with a hysterectomy, or removal of the uterus.\nIf a woman has no symptoms, treatment of fibroids isn\u2019t necessary, experts say.\nWomen often must take it with hormone replacement therapy.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes comments from two experts and it appears as though the second one had no involvement with the study. ", "answer": 1}, {"article": "So, indeed, there has been a strong interest in giving the best additional therapy possible,\" Choti added.\nAnd even for those, unfortunately 75 to 80 percent of those will go on to recur even after the surgery appears to be successful.\nAfter nearly three years of treatment, the researchers found almost no difference between survival rates in the two groups.\nDr. Michael Choti, a professor of surgery and oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Baltimore, described the study as \"important,\" but he does not believe it will alter the current approach to post-surgical chemotherapy.\n\"Really in the scope of things following major surgery, both are fairly tolerable regimens, and this study doesn't necessarily change the pattern of use in terms of choosing post-operative therapy,\" Choti said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "A JAMA press release seems to be the primary source, but an independent expert gets enough air time that we give the author the benefit of the doubt.\u00a0", "answer": 1}, {"article": "At Cooper, cardiologist Phillip Koren said he and colleagues have used the Lariat on the left atrial appendage of about 10 patients in the last six months. The closure was unsuccessful in a few of those cases, but in those, there have been no strokes, said Koren, deputy director of the Cooper Heart Institute. None of the 10 patients suffered adverse events from the device.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story was not based on a news release and showed evidence of independent reporting.", "answer": 1}, {"article": "Antidepressants frequently prescribed to help treat bipolar depression do little to help patients recover, according to a new study that adds fuel to a long-running debate over how to best treat an affliction that affects an estimated eight million Americans.\n\nBipolar disorder, also known as manic depression, is a serious mental illness that involves dramatic swings in mood, including frequent and lengthy periods of depression. Along with mood-stabilizing drugs like lithium, many physicians also treat the disorder with common...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There was independent reporting and no evidence the information in this story is taken directly from a press release.", "answer": 1}, {"article": "Bright-colored berries have long been a part of any healthy diet, owing mainly to the anthocyanins that give them their vibrant color and act as antioxidants to fight off damage to cells.\n\u201cAlthough we know about the effects of antioxidants and flavonoids, and their effects in wine and chocolate, it is interesting to look at their effects in such a large group of women over a long period of time,\u201d says Dr. Suzanne Steinbaum, director of women and heart disease at Lenox Hill Hospital in New York City, who was not involved in the study.\nThe benefits for the heart of eating strawberries and blueberries can build up over a lifetime, according to the latest research.\nThe researchers focused on blueberries and strawberries because these are the most widely consumed varieties in the U.S.\nThat means that regular consumption of berries might be a relatively easy way to lower a woman\u2019s risk of having a heart attack later in life, possibly even insulating her from heart problems.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The Time story does not seem to rely solely on a press release, and there is evidence of original reporting with the independent comment from Dr. Suzanne Steinbaum.", "answer": 1}, {"article": "The investigators found that the less salt people ate, the more likely they were to die of heart disease \u2014 50 people in the lowest third of salt consumption (2.5 grams of sodium per day) died during the study as compared with 24 in the medium group (3.9 grams of sodium per day) and 10 in the highest salt consumption group (6.0 grams of sodium per day).\nBut, Dr. Alderman said, the new study is not the only one to find adverse effects of low-sodium diets.\nLowering salt consumption, Dr. Alderman said, has consequences beyond blood pressure.\n\u201cThey do not tell you what will happen if you change peoples\u2019 sodium intake.\u201d\n\nWhat is needed, Dr. Alderman said, is a large study in which people are randomly assigned to follow a low-sodium diet or not and followed for years to see if eating less salt improves health and reduces the death rate from cardiovascular disease.\n\u201cThe low-salt advocates suggest that all 300 million Americans be subjected to a low-salt diet.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "", "answer": 1}, {"article": "Nerve cells in the brain die, and in a few short years, children lose the ability to walk or talk.\nThey usually die within five years of diagnosis.\nOne of medicine\u2019s greatest villains: HIV.\nFor the first time, doctors have used gene therapy to stave off a fatal degenerative brain disease, an achievement that some experts had thought impossible.\nThe key to making the therapy work?\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story goes well beyond a news release.", "answer": 1}, {"article": "The website for LipoFuze says that the supplement \"increases the metabolic mechanism in your body.\" The site also says the green tea and caffeine will \"rev up your metabolism\" and \"increase energy, focus and physical performance.\" The site features testimonials it says are from users who claim they have lost huge amounts of weight with the help of LipoFuze. One man says he dropped more than 100 pounds, although it's unclear how long that took. A woman says she lost 40 pounds in less than a year, including 20 pounds in her first month.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the column did not rely solely or largely on a news release.", "answer": 1}, {"article": "That muddies the picture because men may see a benefit in the form of fewer heart attacks, whereas aspirin appears to lower the risk of stroke in women.\n\u201cI don\u2019t think this paper is inconsistent with previous work.\u201d\n\nNichols, who was not involved in the study, said aspirin is clearly beneficial for people who\u2019ve already had heart disease, and that it also seems to help those at high risk.\n\u201cIt refines our knowledge of how beneficial aspirin is,\u201d Dr. Graham Nichol, an expert in emergency care at the University of Washington in Seattle, said about the study.\nBut the blood-thinning drug doesn\u2019t appear to cut the chances of dying from the disease, at least not enough that researchers can say for certain.\nThe task force advises that men age 45 to 79 take aspirin to stave off heart attacks, as long as the benefit outweighs the risk of bleeding.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely solely on a news release.", "answer": 1}, {"article": "In early September, the FDA held scientific meetings to clarify how to regulate such practices.\nGiven that the stem cell-treated knee was no better than the control-treated knee \u2014 both were significantly better than before the study began \u2014 the researchers say the stem cells\u2019 effectiveness remains somewhat uninterpretable.\nThe researchers say such testing is needed because there are at least 600 stem cell clinics in the U.S. offering one form of stem cell therapy or another to an estimated 100,000-plus patients, who pay thousands of dollars, out of pocket, for the treatment, which has not undergone demanding clinical study.\nHe adds that these findings are important because while use of a patient\u2019s own stem cells for regenerative therapy is extraordinarily popular, the treatments may be untested and are often poorly regulated.\nEach of the 25 patients enrolled in the study had two bad knees, but did not know which knee received the stem cells.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release in too many places hedges on affirmative conclusions and as such may leave the impression that there is evidence from this study to encourage patients to keep spending thousands on BMAC. The possibility that there was systemic spread of the BMAC to the saline-injected knee is speculative and remains a hypothesis.\nThis study showed no benefit. Indeed the knee that received the placebo treatment appeared to fare better, according to the study.", "answer": 0}, {"article": "And for the test to be useful, \"you've got to find cancer that's going to otherwise be lethal, and not cancer that would otherwise be destined to do nothing,\" Prasad says.\nOf course, the ultimate goal of this test is to find cancer in people who haven't already been diagnosed.\nThen the researchers will need to show that the rate of false alarms remains very low, otherwise people will be sent on needless and expensive medical odysseys.\nBut these methods alone don't give reliable results.\nAn effective screening test would hold lots of potential for cancer patients, Prasad says.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story does not appear to rely upon a news release.", "answer": 1}, {"article": "\"We want to take the focus off pain and put it onto functioning, and finding pleasurable ways to spend time,\" Ilgen says.\nAnd the study's authors note that the ImPAT approach has the potential to be easily and inexpensively adopted by addiction treatment centers and groups worldwide, through team members trained in standard psychological techniques.\nANN ARBOR, Mich. -- It's a Catch-22 with potentially deadly consequences: People trying to overcome addiction can't get treatment for their pain, because the most powerful pain medicines also carry an addiction risk.\nAddiction treatment programs often have patients who suffer from chronic pain, but offer few options to treat them, Ilgen says.\nIn an editorial accompanying the new paper, another addiction and pain specialist, William C. Becker, Ph.D. of Yale University and the Connecticut VA, notes that the new results are even more impressive because ImPAT was compared with another psychosocial approach.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Here\u2019s the opening sentence: \u201cIt\u2019s a Catch-22 with potentially deadly consequences: People trying to overcome addiction can\u2019t get treatment for their pain, because the most powerful pain medicines also carry an addiction risk.\u201d\nWe get that it\u2019s a Catch-22. But what are the \u201cpotentially deadly consequences?\u201d Failure to seek addiction treatment? Suicide? The release doesn\u2019t tell us. It never explains what those \u201cpotentially deadly consequences\u201d are. To be clear, it\u2019s not that we doubt whether there might be deadly consequences\u2013but if you\u2019re going to spring a line like that on readers, you need to articulate exactly what you mean.", "answer": 0}, {"article": "The Pear Bureau Northwest was established in 1931 as a nonprofit marketing organization to promote the fresh pears grown in Oregon and Washington.\nIf that isn't reason enough to fill your shopping basket, there's another reason to add this fruit to your grocery list.\nThe USA Pear Bureau continues to collaborate with researchers to commission additional studies that show the relationship between pears and positive health outcomes.\nThe epidemiologic study, led by Carol O'Neil of the Louisiana State University Agricultural Center, used a nationally representative analytic sample to examine the association of fresh pear consumption with nutrient intake, nutrient adequacy, diet quality, and cardiovascular risk factors in adults.\nA new study, 'Fresh Pear Consumption is Associated with Better Nutrient Intake, Diet Quality, and Weight Parameters in Adults: National Health and Nutrition Examination Survey 2001-2010,' published in Nutrition and Food Science, revealed new information regarding the health benefits of pear consumption.1 Of particular interest given the high rates of obesity in the United States, the study found that adult pear consumers had a lower body weight than non-pear consumers and they were 35 percent less likely to be obese.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The quoted lines from the lead investigator are carefully phrased, but the overall release is misleading to suggest pears alone are a solution to the obesity problem. But since we\u2019ve already raised that concern elsewhere in the release we\u2019ll give the benefit of the doubt here. ", "answer": 1}, {"article": "That's the tantalizing premise behind Deplin, a prescription form of the B-vitamin folate. Although it has been on the market since 2006, Deplin is generating growing buzz at psychiatric conferences and among clinicians and patients, particularly those who haven't responded to antidepressants or did for a while only to have their depression return.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story was not based on a press release.", "answer": 1}, {"article": "What's more, \"people tended to measure the outcomes very differently,\" Matthews says.\nAnd there wasn't much hard data on psychological, social or economic outcomes, according to the report.\nBut Matthews says reviewers found few high-quality studies about any treatment.\nAnd here's a biggie: There wasn't much information about adverse effects on women and babies, something everyone would certainly want to know.\nBut Matthews says the evidence isn't strong enough to make a recommendation.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes an interview with one of the authors of the study and doesn\u2019t include any direct duplication of text from this press release.\u00a0So we feel\u00a0pretty confident that it didn\u2019t rely exclusively on a release\u00a0for its content. \u00a0", "answer": 1}, {"article": "Medical-device makers, venture capitalists and surgeons are racing to turn a once-controversial weight-loss procedure into the next big thing in elective surgery.\n\nOnce dismissed by some surgeons as a gimmick, gastric banding -- in which a silicone band is wrapped around the upper stomach to restrict food intake -- is now the focus of a fierce competition pitting consumer-products giant Johnson & Johnson against Botox maker Allergan Inc. Venture-capital-backed outpatient centers are popping up to implant the bands. Growing...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not rely on a press release", "answer": 1}, {"article": "A common heart drug called a beta blocker was associated with a striking increase in survival for women with ovarian cancer in a study that suggests a possible new strategy for treating a variety of tumors.\n\nResearchers analyzing a database of 1,425 women with the tough-to-treat cancer found those who had taken a certain type of beta blocker lived more than four years longer on average than those who hadn\u2019t been prescribed the drug. The women were taking the medicine to treat high blood pressure or another heart problem, not...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the article quotes an independent, unaffiliated cancer expert, we are confident the article doesn\u2019t rely solely on a press release.", "answer": 1}, {"article": "N-acetylcysteine reduced PTSD symptoms, cravings, and depression in veterans with PTSD and substance use disorder in a randomized controlled pilot trial conducted at the Medical University of South Carolina and the Ralph H. Johnson VA Medical Center\n\nN-acetylcysteine, when combined with group cognitive behavioral therapy (CBT), reduced symptoms of posttraumatic stress disorder (PTSD), cravings, and depression significantly more than CBT alone in veterans with co-occurring PTSD and substance use disorder, a particularly difficult-to-treat population, according to the findings of a randomized controlled pilot trial conducted by researchers at the Medical University of South Carolina (MUSC) and the Ralph H. Johnson VA Medical Center.\nThis trial is the first to use NAC as a pharmacotherapy for PTSD and a broad range of SUDs.\nThe threshold CAPS score for diagnosis of PTSD is 50.\nOf the veterans enrolled in the trial, 83% completed it, a very high rate for this difficult-to-treat population.\nCurrently, there are no well-explored pharmacological treatments for patients with co-occurring PTSD/SUD.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There is no use of unjustifiable language. In fact, we were pleased to see the consistent use of \u201csubstance use disorder\u201d or SUD to describe the inappropriate use of illegal and legal drugs. Our recent post on ways to put people first when talking about addiction shows how careful terminology improves accuracy and reduces stigma.", "answer": 1}, {"article": "CT scans became popular because they offer a quick, relatively cheap and painless way to get 3D pictures so detailed they give an almost surgical view into the body.\nThat puts them at risk of developing radiation-induced cancer, Brenner and Hall said.\nIt's also a good idea to keep a diary of X-ray exposure, especially for children.\nBut CT use continued to soar.\nThe radiation and risk from one CT scan is low, but it carries a dose 50 to 100 times greater than a traditional X-ray, reports LaPook.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not appear to rely solely or largely on a press release. ", "answer": 1}, {"article": "Inflammation can make urination difficult.\nSymptom scores on the IPSS test also showed improvement.\nThose with the highest levels of inflammation benefited the most from the periodontal treatment.\nBissada is now conducting follow-up research to support the first study's findings.\nCase Western Reserve dental researchers Nishant Joshi, Catherine Demko and Robert Skillicorn; and University Hospitals Case Medical Center researchers Donald Bodner, Lee Ponsky, Sanjay Gupta and Gregory T. MacLennan contributed to the study.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The study that\u2019s the basis for this news release clearly states that no cause and effect relationship can be inferred from this very limited data. And yet the news release leads with a statement that \u201cTreating gum disease reduced symptoms of prostate inflammation.\u201d That\u2019s simply not justifiable.", "answer": 0}, {"article": "\"We compare the colored glasses to being like a brace or cast but for the brain,\" he says.\nPhotophobia is so common that many neurosurgical intensive care units consider it standard operating procedure to keep lights dimmed in rooms containing TBI patients says Clark.\nWe believe the use of the colored glasses that provide photophobia mitigation has added benefits superior to dark sunglasses, especially for indoor lighting.\"\n\"We believe that an athletic trainer, in consultation with team physicians, may find it useful to apply this photophobia assessment and recommend colored glasses to his or her athlete,\" Clark says.\nThe goal is to help the concussion patient feel better as the brain heals.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We find the language largely descriptive and not overly effusive beyond what appears to be supported by the study, however limited in scope it is.", "answer": 1}, {"article": "For more information on statins, visit the U.S. National Library of Medicine.\nA previous study on the same group indicated that persistent use of statins was associated with substantially lower all-cause mortality, which could not be explained only by the prevention of cardiovascular disease, he said.\nThis work received no outside or corporate finding, the researchers noted.\n\"Although the study does not have immediate clinical implications, our findings may suggest that patients who were prescribed statins and take it persistently may benefit from the many effects of statins, which go far beyond cholesterol reduction, including the reduction of rheumatoid arthritis risk,\" Chodick said.\n\"Patients who were covered for more than 80 percent of the time, had a 40 percent lower risk of developing rheumatoid arthritis,\" Chodick said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\nThe story does not appear to rely on a news release.", "answer": 1}, {"article": "We keep them at that temperature for the first 24 hours, at which time we re-warm them,\" Likosky explains.\nIt's called induced hypothermia.\nIt requires training and a lot of coordination.\nThanks to CPR and defibrillators, that's happening more often \u2014 and Dean Cowles is living proof.\n\"It should be more widely used.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not appear to rely on a press release. ", "answer": 1}, {"article": "\"Nicotine replacement therapies ... do not show any long-term effect on quitting even when combined with counseling,\" says researcher Gregory Connolly, DMD, director of the Center for Global Tobacco Control and professor of public health at the Harvard School of Public Health.\nThe findings are at odds with clinical trials, Connolly says.\nBetter strategies are needed to prevent relapse, he tells WebMD.\nSmoking cessation experts and a maker of nicotine replacement therapies took issue with the findings.\nThe results of the new study are published online in Tobacco Control.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not rely on any press release.", "answer": 1}, {"article": "The data indicate that for every 10,000 women in their 50s, those using estrogen would experience 12 fewer heart attacks, 13 fewer deaths and 18 fewer adverse events like blood clots or stroke in a given year, compared with those taking a placebo.\nThe research, part of the landmark Women\u2019s Health Initiative study, is likely to surprise women and their doctors, who for years have heard frightening news about the risks of hormone therapy.\nThe new findings, reported Tuesday in The Journal of the American Medical Association, come from 10,739 women in the Women\u2019s Health Initiative study who had previously had a hysterectomy, the surgical removal of the uterus.\nDr. Rowan Chlebowski, another author of the study and a medical oncologist at Los Angeles Biomedical Research Institute, said the findings underscored the fact that the risks and benefits of menopause hormones change depending on a woman\u2019s health status, her age and the type of hormone used.\nNobody is suggesting that women start using estrogen to prevent breast cancer, but the finding opens a potentially new avenue of research in the prevention of the disease.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes independent reporting, so it\u2019s clear it didn\u2019t rely on a news release.", "answer": 1}, {"article": "\"It is not going to be reimbursed by insurance, at least for the first generation and certainly for the foreseeable future,\" he said.\nThe device doesn't change the stomach's natural anatomy, according to the FDA.\nPatients who did not receive the device lost about half that amount of weight -- just over 3 percent of their total body weight, the FDA said.\nThat clinical trial was funded by the company that makes the ReShape system, according to a presentation from the Obesity Society annual meeting in Boston.\nBut the device can only be used for six months at a time, and it is not likely to be an alternative for people who require lap-band surgery, stomach stapling or other forms of bariatric surgery, said Dr. Mitchell Roslin, chief of obesity surgery for Lenox Hill Hospital in New York City.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely solely on the release, but shows independent reporting.\n[http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm456296.htm]\n\u00a0", "answer": 1}, {"article": "It also triggers the release of the stress hormone norepinephrine, as well as the mood regulator serotonin.\nThose in the acupuncture group also seemed to have a generally higher overall quality of life in terms of both physical and mental health, with no serious side effects, the study authors said.\n\"Acupuncture together with enhanced self-care for three months is effective in reducing hot flashes in women with breast cancer,\" said study author Giorgia Razzini, a clinical trial project manager in the oncology unit of Ospedale di Carpi (Carpi Hospital), in Bologna, Italy.\nThe second group, of 85, was offered the same advice in the same time frame along with 10 half-hour weekly sessions of \"traditional\" acupuncture.\nRazzini and colleagues published their findings online March 28 in the Journal of Clinical Oncology.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to be based on a news release, and clearly involves some original reporting.", "answer": 1}, {"article": "Those who reported longer fast durations also indicated they consumed fewer calories per day, ate fewer calories after 10 p.m. and had fewer eating episodes.\n\u201cNew evidence suggests that when and how often people eat can also play a role in cancer risk.\u201d\n\nWomen in the study reported eating five times per day with a mean nighttime fasting of 12 hours.\n\u201cIncreasing the duration of overnight fasting could be a novel strategy to reduce the risk of developing breast cancer,\u201d said Catherine Marinac, UC San Diego doctoral candidate and first author on the paper.\n\u201cThe dietary advice for cancer prevention usually focuses on limiting consumption of red meat, alcohol and refined grains while increasing plant-based foods,\u201d said co-author Ruth Patterson, PhD, UC San Diego Moores Cancer Center associate director for population sciences and program leader of the cancer prevention program.\nThe findings were presented at the American Association of Cancer Research\u2019s annual meeting in Philadelphia.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The\u00a0headline \u2013 by stating that fasting may be associated with breast cancer risk reduction \u2013 implies that the release\u00a0is going to show evidence to support this statement. It didn\u2019t.", "answer": 0}, {"article": "Gestational diabetes increases the mother\u2019s chances for high blood pressure disorders of pregnancy and the need for cesarean delivery, and the risk for cardiovascular disease and type 2 diabetes later in life.\nSimilarly, research is needed to determine whether lowering HbA1c with lifestyle changes, either in early pregnancy or before pregnancy, could reduce the risk for the condition.\nThe test is not currently recommended to diagnose gestational diabetes at any point in pregnancy.\nThe authors noted that further studies are needed to confirm whether measuring HbA1c levels in early pregnancy could determine a woman\u2019s later risk for gestational diabetes.\nThe study appears in Scientific Reports.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "None here.", "answer": 1}, {"article": "How miserable is combing a child's hair, lock by lock, to pick off head lice? So miserable that some parents are buying $30 shampoos and other washes that promise to ward off the tiny, grayish bugs.\n\nThe parents get peace of mind that they are doing something. Conveniently for the product makers, there's no way to tell if they kept lice at bay, or if children wouldn't have gotten lice anyway. Makers say sales are growing fast.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that this story involved independent enterprise reporting.", "answer": 1}, {"article": "Followers of the popular regime eat during an eight-hour window, in this case between 10 a.m. and 6 p.m. And for the 16 hours in between, they consume only calorie-free drinks, such as water.\nThe researchers compared the results to existing data from a separate weight loss trial carried out between 2011 and 2015.\nWe observed that fewer participants dropped out of this study when compared to studies on other fasting diets,\u201d said Varady.\nThe authors noted that the results mirror those from previous studies of other forms of intermittent fasting, including alternate day fasting, where an individual eats normally every other day.\nCommenting broadly on fast-style diets, James Catterson of the Institute of Healthy Ageing at University College London, who was not involved in the study, previously told Newsweek the jury is still out on fasting diets.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story drew exclusively from a news release.\u00a0 It only added some previously reported comments from an independent source.", "answer": 0}, {"article": "Dr Davide Pellacani, who began these studies in York, before moving to the University of British Columbia, said: \"Using this computer analysis, not only could we see which tissue samples had cancer and which didn't, but also which cancers were dangerous and which ones less so.\nThe team needed to eliminate the 'noise' of the genetic patterns that make individuals unique, to leave them with the patterns that indicate cancer.\n\"Out of almost a million markers studied, we were able to use our new tools to single out differences in cancer potency.\"\nThe research, published in the British Journal of Cancer, was funded by The Freemasons of the Province of Yorkshire (North and East Ridings) and The Masonic Samaritan Fund.\nIt is now understood that to find the different levels of cancer, scientists have to identify genes that have been altered in different cancer types.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "No sensational or unjustifiable language.", "answer": 1}, {"article": "About the Journal of the American Osteopathic Association\n\nThe Journal of the American Osteopathic Association (JAOA) is the official scientific publication of the American Osteopathic Association.\nDifferences between treatment groups were evaluated for subgroups of participants based on their age, Pneumonia Severity Index and type of pneumonia.\nThe study analyzed 375 patients ages 50 or older who were randomly assigned to three groups, either receiving OMT, a light touch or conventional care only.\nDisclosures: The basis for this analysis, The Multicenter Osteopathic Pneumonia Study in the Elderly (MOPSE) clinical trial, was funded by a consortium of foundations including the Foundation for Osteopathic Health Services.\nBy intention-to-treat analysis of the older subgroup, in-hospital mortality rates were 11 percent lower to the conventional-care only group.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release really needed a quote or other statements qualifying the call for essentially immediate and wide use of manipulation in elderly patients with pneumonia. The statement related to the benefits needed some moderation. In a randomized controlled trial, only intention-to-treat analyses of the primary outcomes really count. It doesn\u2019t appear that this study found any significant analyses in primary, ITT analyses. As such, all these subgroup analyses are hypothesis generating and would require confirmation in a new trial focused on the subgroups demonstrating OMT benefit.", "answer": 0}, {"article": "That doesn\u2019t mean you should extend your own use of the contraceptives without talking to your doctor.\nThe study is still ongoing, and the researchers plan to recruit up to 800 women and ultimately test whether the IUDs and implants were effective for up to three years after their current FDA-approved duration.\nBy the end of the trial period, none of the women using the implant were pregnant and there was one pregnancy among the women using the IUD.\nThe women were informed of the pregnancy risk associated with using their device longer than recommended, and the researchers called them for followup every 6 months for 36 months or until the women had their device removed.\nThe implants are currently approved for three years, and the hormonal IUD used in the study is approved for five.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story appears to draw exclusively from this university press release. No independent sources are quoted, and there are substantial similarities between text in the story and the news release.\nHere is a side-by-side comparison:\nNews release: \u201cStudy participants were 18 to 45 years old, and their contraceptives had to be within six months of expiring when they enrolled. The women were informed of a possible risk of pregnancy if the devices were used beyond the time periods approved by the FDA.\u201d\nStory: \u201cAll the women were between the ages of 18 and 45 and their contraceptives were within six months of expiring before they enrolled in the study. The women were informed of the pregnancy risk associated with using their device longer than recommended\u2026\u201d\nConducting just one interview would have removed any doubt as to whether the story relied excessively on the news release.", "answer": 0}, {"article": "\"We don't yet have a full understanding--nobody does--of how the bile acid actually does what it does in heart cells,\" explains Michalak.\nThe study discovered the specific triggers activating the development of fibrosis which accelerates heart failure.\n\"Prevention of fibrosis will extend the ability of the heart to function, even if at a reduced capacity.\nThe team is now pushing forward with additional studies to see if the same therapeutic effect can be achieved in humans.\nThe bottom line is that this shows for the first time that cardiac fibrosis is preventable.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "As we have pointed out on other occasions, the use of \u201cgroundbreaking\u201d in a release is by and large unjustified but is becoming more commonplace across many platforms. (According to the Google Ngram Viewer,  an online search engine that charts frequencies on the use of specific terms, the use of \u201cgroundbreaking\u201d in books increased 175% from 1998 to 2007.)\nAdditional language in the release, including the statements below, belie the fact that the study was conducted in transgenic mice.\n\u201cThe bottom line is that this shows for the first time that cardiac fibrosis is preventable.\u201d\n\u201cIt offers hope to those who are living with heart failure,\u201d\nThe study is important and may lead to new options for treatment or prevention. The use of \u201cgroundbreaking\u201d in its description takes away from the scientific significance of the work.", "answer": 0}, {"article": "Although the precise estimate is still uncertain, researchers found that people who started taking zinc-loaded lozenges or syrups within 24 hours of showing symptoms \u2014 a sore throat, say, or runny nose \u2014 shortened their cold by one day.\nThe bottom line: After seven days of treatment, those taking the supplements had less than half the chance of still being sick.\n\u201cI think one can give it a try,\u201d said Dr. Meenu Singh, a pediatrician at the Post Graduate Institute of Medical Education and Research in Chandigarh, India, who led the new work.\nStill, with an infection that currently has no good treatment and leads to an estimated 275 million lost work days a year in the U.S., well, what a difference a day makes.\n\u201cBut giving zinc over a long period of time for prevention should be done very carefully,\u201d she told Reuters Health.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story didn\u2019t rely solely or largely on a news release.", "answer": 1}, {"article": "Forty-one percent of the meditation group took aspirin, as did 31 percent of the health education group; 38 percent of the meditation group and 43 percent of the health education group smoked, the researchers noted.\nEven though the findings in this study were statistically significant, the new study was too small to be conclusive, Fonarow said.\nAn outside expert, however, said the study is too limited in size and scope to allow conclusions as to whether meditation really reduces risk of death or disease.\nThe goal was to rest while remaining alert.\nThe new study focused on Transcendental Meditation.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story has enough original reporting that we can be sure it wasn\u2019t based on a\u00a0press release.", "answer": 1}, {"article": "Injections of botulinum toxin, best known as a wrinkle treatment, are now being used increasingly to prevent chronic migraine sufferers. Scientific data are mixed, but two large recent studies show Botox can reduce the number of headache days in chronic sufferers.\n\nMigraine headache is a debilitating neurological condition that manifests itself as an intense throbbing pain on one or both sides of the head, according to the Migraine Research Foundation, a New York nonprofit. Some 14 million people experience migraine attacks...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article did not appear to rely on a news release.", "answer": 1}, {"article": "Newly postmenopausal women who received estrogen via a skin patch had reduced beta-amyloid deposits, the sticky plaques found in the brains of people with Alzheimer\u2019s disease, a Mayo Clinic study published this month in the Journal of Alzheimer\u2019s Disease found.\n\u201cThis study showed, for the first time, that the brain amyloid deposition \u2500 a hallmark of Alzheimer\u2019s disease \u2500 is reduced in newly postmenopausal women who received 17beta-Estradiol patch form of hormone therapy,\u201d says lead author Kejal Kantarci, M.D., a Mayo Clinic radiologist.\nThe oral treatment was not associated with lower amyloid deposition.\nThe researchers used positron emission tomography, also known as a PET scan, to look for the brain amyloid deposits three years after the trial ended.\n\u201cIt also may have a significant impact on women making the decision to use hormone therapy in the early postmenopausal years.\u201d\n\nStudy co-authors are Val Lowe, M.D.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Words employed by both the text and the researchers, the latter via quotes, are straightforward.", "answer": 1}, {"article": "\"But it's a slippery slope to saying 'OK, maybe two is better.'\nStudies will continue, and not everyone has given up the idea that moderate drinking \u2014 up to two drinks a day for men and one day for women \u2014 might have some cardiovascular benefits.\nBut that's not the only reason, says Lori Mosca, a professor of medicine at Columbia University Medical Center and a spokesperson for the American Heart Association.\nThere's no evidence drinking in your 20s or 30s has any health benefits.\nBut those studies do not prove alcohol is the reason for the differences.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The USA Today report was not based on this\u00a0press release\u00a0about the study.", "answer": 1}, {"article": "People with painfully damaged knees and hips have increasingly turned to \"minimally invasive\" joint-replacement surgery. But these relatively new procedures, though they promise shorter recuperation times, are raising concerns about potential complications.\n\nMany surgeons in recent years have performed joint replacements with ever smaller incisions. In minimally invasive surgery, the incision is typically about three to four inches long, roughly half that of traditional surgery. By cutting less of the surrounding tissue...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\nThere is no obvious use of text from the press release.", "answer": 1}, {"article": "\"It's an outpatient procedure, and no physical therapy is required before or after this procedure,\" he said.\nThe microparticles are inserted using a catheter run through a pinhole-sized incision, in a procedure that lasts between 45 and 90 minutes, Bagla said.\nDr. Suresh Vedantham, president of the Society of Interventional Radiology, called the new procedure \"very promising,\" given that it focuses on the inflamed knee lining that causes the pain.\n\"Patients overall were able to improve their physical function in the knee after the procedure, and there were no adverse events related to this treatment,\" said lead researcher Dr. Sandeep Bagla.\nBagla said no side effects are expected because the procedure only blocks additional blood flow to the knee, rather than cutting it off altogether.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "A healthy intake of vitamin D in the first year of life appears to set children up to have more muscle mass and less body fat as toddlers, according to a new study published in the journal Pediatric Obesity.\nThe researchers found that higher doses did not provide any additional benefit -- at least not in terms of bone development.\nThe new study confirmed the importance for the development of strong bones of a vitamin D supplement of 400 IU/day during a baby's first year.\nThe findings emerged from research initially aimed at confirming the importance of vitamin D for bone density.\nThis amount is in line with current Canadian health guidelines.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The claims in the headline and lead paragraphs that the study found supplementation reduced body fat and improved muscle-mass development in toddlers are unjustified, because they are simply wrong.", "answer": 0}, {"article": "About the University of Maryland School of Medicine\n\nThe University of Maryland School of Medicine was chartered in 1807 and is the first public medical school in the United States and continues today as an innovative leader in accelerating innovation and discovery in medicine.\nWhile most cancer patients are well served with today's state-of-the-art radiation therapy technology, up to 30 percent are expected to have a greater benefit from the new form of targeted proton beam therapy.\nThis technique can precisely direct radiation to the most difficult-to-reach tumors.\nProton therapy is just one of several new methods for treating cancer.\nThe center will provide one of the newest and highly precise forms of radiation therapy available, pencil beam scanning (PBS), which targets tumors while significantly decreasing radiation doses to healthy tissue.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "This is a close call. While he release does avoid the type of dramatic language (e.g., \u201cBreakthrough!\u201d) that we typically associate with unjustifiable language, we think the cumulative effect of so much positive/promotional language in this release (e.g. \u201cinnovative, precise approach,\u201d \u00a0\u201cnewest and highly precise,\u201d \u201cprecisely direct[s] radiation to the most difficult-to-reach tumors,\u201d \u201ccan really make a difference in cancer patients\u2019 lives\u201d), totally detached from any consideration of evidence, rises to the level of unjustified.\n\u00a0", "answer": 0}, {"article": "Scientists have slowed down the ageing process by implanting stem cells into the brains of animals, raising hopes for new strategies to combat age-related diseases and extend the human lifespan.\nThe work, described as a tour de force and a breakthrough by one leading expert, suggests that ageing across the body is controlled by stem cells that are found in the hypothalamus region of the brain in youth, but which steadily die off until they are almost completely absent in middle age.\nThe animals died months earlier than healthy control animals.\nHaving proved that it was neural stem cells that were important for ageing, the scientists ran further tests to work out what the cells were doing.\nThe latest investigation from the US team pinpoints which cells are important and how they might work.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.\n\u00a0", "answer": 1}, {"article": "Traditionally, highly sensitized patients in need of a kidney have languished on waiting lists because it's so hard to find a compatible donor.\nBut the findings mark another step forward for patients like these, according to Jordan, who is medical director of the kidney transplant program at Cedars-Sinai, in Los Angeles.\nLead researcher Dr. Stanley Jordan agreed that more work is necessary.\nThose patients were all successfully treated with standard anti-rejection drugs, according to the researchers.\nFunding for the study came from the company developing IdeS -- Hansa Medical.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Hansa Medical issued a news release pursuant to publication of the study results in the New England Journal of Medicine, but the story clearly goes beyond the release.\n\u00a0", "answer": 1}, {"article": "Given in the abdomen, AMG145 reduced low-density lipoprotein (LDL) cholesterol levels among a group of healthy volunteers.\nFormer AHA President Dr. Ralph Sacco said that it is too early to make any predictions about what role, if any, this therapy will have in lowering cholesterol levels, but it could one day fill an important void.\nCardiologists were cautiously optimistic about the novel therapy.\nThe new drug did hit its target, PCSK9, and decreased levels of LDL cholesterol by up to 64 percent.\nAn LDL of less than 100 mg/dL of blood is considered optimal.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes comments from experts not involved with the study, so we can be sure it wasn\u2019t based on a news release.", "answer": 1}, {"article": "About 94 percent were free of any invasive cancer, including new cancers at other sites or in the opposite breast.\n\u2018\u2018These patients who had low risk scores by Oncotype did extraordinarily well at five years,\u2019\u2019 said Dr. Hope Rugo, a breast cancer specialist at the University of California, San Francisco, with no role in the study.\nBut independent monitors recommended the results on the low-risk group be released, because it was clear that adding chemo would not improve their fate.\nMary Lou Smith, a breast cancer survivor and advocate who helped design the trial for ECOG, the Eastern Cooperative Oncology Group, which ran it, said she thought women \u2018\u2018would be thrilled\u2019\u2019 to skip chemo.\n\u2018\u2018Patients love the idea of a test\u2019\u2019 to help reduce uncertainty about treatment, she said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The Associated Press article does not seem to be based on any news releases we found online. In addition, the story demonstrates original reporting with its four independent sources and comment from the lead author.", "answer": 1}, {"article": "\"Regorafenib has shown it can improve survival in patients with advanced hepatocellular carcinoma progressing on sorafenib.\nThis trial provides evidence that regorafenib is the first systemic treatment for patients whose HCC progressed during treatment with sorafenib, the only other drug with proven clinical benefit.\nThe success of this trial opens the field for testing drugs in third-line treatment of HCC and provides a rationale to test regorafenib as a first-line treatment or in combination with therapies administered directly into the tumor or diseased liver in patients in an earlier stage of HCC, according to Dr. Llovet.\n(New York, NY - January 18, 2017) An international phase 3 trial has found that the drug regorafenib improved survival in patients with advanced hepatocellular carcinoma (HCC), a form of liver cancer, giving people who previously had no other options a better chance at survival.\nResults from the study, which included researchers at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, were recently published online in The Lancet.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There are two issues here. First, as noted above under \u201cWhy This Matters,\u201d writers need to be cautious when throwing around terms like \u201csuccessful\u201d \u2014 because they can mean different things to different people. When a headline trumpets a \u201csuccessful\u201d cancer drug, many readers may assume that the drug does more than extend life for 2.8 months. The fact that the release makes clear, in the third paragraph, that we\u2019re talking about an extra couple of months (rather than remission) doesn\u2019t forgive the headline. It would have been much better to have a headline that focuses on specifics, such as \u201cextends life by 2.8 months,\u201d rather than vague terms that can be easily misunderstood. Second, while the clinical trial\u2019s findings are certainly worth reporting, we are rarely pleased to see a news release use vague, over-hyped (and overused) terms like \u201cbreakthrough,\u201d as was done here.", "answer": 0}, {"article": "People with Type 2 diabetes get an earful of grim lectures about their health prospects and endure much hardship to manage their condition well. But new research offers those who do so a rare reward. A glass of wine every day not only won't hurt, says a new study: It can actually improve cardiac health, help manage cholesterol and foster better sleep.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The lack of any direct quotes and the absence of any comments from independent sources make it difficult to determine whether or not this story relies largely on a news release. But since we didn\u2019t see any obvious similarities between the story and two news releases that were issued about the findings (see here and here), we\u2019ll give the benefit of the doubt on the rating.", "answer": 1}, {"article": "All rights reserved.\nHe said a gene test may have made him more comfortable with that decision.\n\"You can shop for a toaster\" better than for prostate treatment, he said.\nOnly 10 percent who are candidates for monitoring choose it now.\nYet it has a track record from its breast cancer test.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Lots of independent reporting so it\u2019s clear this story didn\u2019t rely on a news release.", "answer": 1}, {"article": "Drawing on a huge sample of nearly 320,000 patients who were continuously enrolled in private health insurance plans from 2001 and 2013, researchers compared those who were prescribed just opioids versus those who were prescribed both, and what their additional risk of an emergency room visit or inpatient admission was in the period they were prescribed both.\nAnd since the research relied on patients who were continuously insured throughout the study period, it\u2019s possible the findings don\u2019t exactly apply to people with spottier coverage.\nStill, it\u2019s well established that benzodiazepine and opioids compound each other\u2019s overdose risk.\nFor some patients, eliminating these co-prescriptions could involve some tough trade-offs.\nKeith Humphreys, a drug policy expert at Stanford University and one of the authors of the study, said this reveals an underappreciated policy lever for reducing drug overdoses: making sure patients prescribed to opioids aren\u2019t also prescribed to benzodiazepines, and vice versa.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "One therapy at M.D.\nThe treatment \u2014 shots that grab the immune system and jolt it to fight against rebel tumor cells \u2014 has been a dream for more than a century.\nSuch research already is under way \u2014 a potential antidote for people whose genetics seemingly fate them for cancer.\nNow, because drugs are mostly tested on patients whose cancer has resisted previous treatment, it's usually used on tumors advanced to often fatal stages.\nThe challenge was getting the immune system to recognize the enemy.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no way to know whether the story relied on a press release as the sole source of information.", "answer": 2}, {"article": "For example, before adjusting for these kinds of differences between the groups, the researchers found that light drinking was connected with 33% lower rates of overall behavior problems in boys \u2014 after the adjustment, that effect fell to 23%.\nA glass of wine or two a week \u2014 and not more than one large glass on any occasion \u2014 may be safe during pregnancy, according to a large study just published in the Journal of Epidemiology and Community Health.\nThis data is notoriously hard to interpret, however, in part because it is based on women\u2019s self-reports: the public health message against drinking during pregnancy has been so widely adopted that women who do drink may significantly underreport their consumption to researchers.\nThe research included 11,513 children participating in a large U.K. study.\n(But see here for coverage of a study that found even heavy drinkers beat abstainers when it comes to mortality in mid- to late life.)\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a news release.", "answer": 1}]